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Abstract 
Cyclin-dependent kinase 2 (CDK2) and Nek2 (Never-In-Mitosis A related kinases) are 
cell-cycle associated serine-threonine kinases that play an important role in the regulation 
of cellular proliferation and mitosis. Aberrant CDK2 and Nek2 activity are strongly 
associated with cancer, and inhibitors of these protein kinases are of potential therapeutic 
use as antitumour agents.  
Inhibitors of Nek2 –Previous studies identified a series of 2-aminoaryl-6-ethynylpurines 
(e.g. 42), as potent and selective irreversible Nek2 inhibitors with good antitumour 
activity in vitro and in vivo. 6-Ethynylpurine 42 binds within the ATP domain of Nek2 
via a triplet of hydrogen bond interactions with the hinge region, enabling a covalent 
reaction between Cys-22 and the 6-ethynyl substituent. However, subsequent SAR 
studies indicated possible off-target activity for this series, which has been investigated 
through the synthesis and evaluation of control compounds engineered to be inactive 
against Nek2. With a view to abolishing Nek2-inhibitory activity without imposing 
dramatic structural changes, the effect of methylation at the purine N-7 (64) and N-9 (63) 
positions was studied. The corresponding isosteric 6-cyanopurine derivatives (65, 66, and 
67) were also synthesised, which were expected to resemble closely 6-ethynylpurines 
without the capacity to react covalently. Evaluation of these derivatives in cell-based 
assays confirmed the presence of a growth-inhibitory activity unrelated to Nek2 
inhibition. Regioselective N-7 methylation of 65 proved challenging, and a novel 
approach was developed whereby initial N-9 protection enabled selective methylation at 
the purine N-7 position, with concomitant loss of the N-9 protecting group giving the 
target purine 67. Kinetic studies have also been conducted with 42, 63 and 64 to assess 
the impact of N-7/N-9 methylation on the chemical reactivity of the 6-ethynyl ‘warhead’. 
A model system was developed to investigate a possible correlation between the chemical 
and biological reactivity of the 6-ethynyl group of the purine derivatives with thiols.  
 
Inhibitors of CDK2 –Previous studies have resulted in the identification of the purine 
CDK2 inhibitor 60, found to inhibit CDK2 in a time-dependent manner (IC50 = 63 nM) 
via conjugate addition of a lysine residue (Lys89), located in the ‘hinge region’ of the 
v 
ATP-binding domain, to the vinyl sulfone functionality of 60. This is thought to represent 
the first example of irreversible CDK2 inhibition, and prompted more detailed 
investigations with 60.  
 
Compound 60 exhibited a short half-life in both plasma (44 min) and medium (19 min), 
ascribed to hydration of the vinyl sulfone. Therefore, a priority was to improve the 
chemical stability of 60 without compromising inhibitory potency and time-dependent 
inhibition. Using the crystal structure of 60 in complex with CDK2 to guide inhibitor 
design, a range of derivatives (162-168) have been synthesised bearing α-substituents (R) 
on the vinyl sulfone group. In addition, synthetic methodology was developed for the 
synthesis of the corresponding 2-hydroxyalkyl products which are putative ATP-
competitive inhibitors. From the biological studies conducted on purine derivatives 162-
168, only the α-chlorovinyl sulfone compound 167 (IC50 (4 h) = 14 nM) has emerged as 
of particular interest, whereas others have shown competitive CDK2 inhibition, 
confirmed by X-ray crystallography. The β-position of the vinyl sulfone moiety has been 
briefly explored with purines (323, 333 and 339). In this series, one inhibitor (323) has 
been shown to bind covalently to CDK2 by structural biology studies. Alternative 
‘warheads’ to the vinyl sulfone group have been investigated and exhibited competitive 
CDK2 inhibitory activity in a time-dependent inhibition assay. Finally, insertion of the 
vinyl sulfone warhead into known CDK2 inhibitors was investigated in preliminary 
studies. 
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Chapter 1. Targeted Cancer Therapy and the Cell Cycle 
1.1 Cancer evolution towards a targeted therapy 
Cancer has always been present, throughout centuries,
1
 but in former times never 
represented a major cause of death due to short life expectancy. In the medical archives, 
breast cancer was first mentioned around 3000-2500 BC in The Edwin Smith Surgical 
Papyrus.
1
 Major understanding and progress in cancer research were made during the 
20
th
 century with the introduction of chemotherapy.
1
 Discovered during the First World 
War and known to attack bone marrow and lymphoid tissues, mustard gas was first used 
as a chemotherapeutic agent in 1942 for human lymphoma.
2
 From this molecule, research 
focussed on developing other anti-cancer drugs such as topoisomerase inhibitors,
3
 
antimetabolite agents
3
 and microtubule inhibitors.
3
 The most important discovery, leading 
to a better understanding of cancer at a molecular level, was the human DNA structure 
decoded in 1953 by Francis Crick and James Watson,
4
 aided by X-ray images of DNA 
provided by Rosalind Franklin. Discoveries through the centuries contributed to the 
understanding of cancer, a term that embraces not one but over one hundred diseases. 
1.1.1 Causes of cancer 
In 40% of all cases, cancer can be avoided through changes in lifestyle.
5
 One of the major 
risk factors is tobacco smoke and tar, which contribute to carcinogenesis, owing to the 
presence of numerous mutagenic compounds.
6
 Tobacco smoking and chewing can cause 
lung, oesophagus, stomach, pancreas, liver, bladder, kidney and cervical cancers,
5
 all 
having poor diagnosis and making tobacco a major death risk.
5
 Alcohol consumption is 
another lifestyle factor, with ethanol considered a co-carcinogen and thought to facilitate 
cell division and proliferation.
7
 By liberating mutagenic free radicals, alcohol could also 
potentially be a cancer initiator.
8
 In addition, oxidative metabolism of ethanol generates 
acetaldehyde, known to be a genotoxic compound causing mutations and chromosomal 
aberrations in cells, and is classified as a possible carcinogen to humans.
9
 Acetaldehyde is 
present is tobacco, vehicle emissions but, more importantly, is found in several fruits, 
vegetables and cooked meats.
9
 Diet represents another risk factor due to a general 
tendency to eat food rich in calories and animal fat and low in fiber, resulting in 
acceleration of the risk of developing cancer.
10
 Mutagenic free radicals are generated 
from polyunsaturated fatty acids contained in animal fat.
11
 By contrast, the anti-oxidant 
properties of fruits and vegetables can help in protection against free-radical damage.
5
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Obesity is a concern in cancer development even though no direct evidence has been 
demonstrated.
5
 Carcinogens can accumulate in adipose tissue, increasing the risk of 
cancer.
12
 Being overweight also increases the risk of diabetes and cardiovascular diseases, 
contributing to mortality.
5
 It is worth noting that some chemotherapeutic agents elicit 
cardiovascular toxicity, which may cause problems when treating obese patients for 
cancer.
5
 
The environment represents another risk. Viruses can induce cancer, with the most 
common being Human Papilloma Virus and Hepatitis B, responsible for cervical and 
liver cancer, respectively.
13, 14
 Radiation arising from human nuclear activities, X-rays in 
medicine for diagnosis or treatment purposes, or UV-rays from the sun can induce skin 
cancer.
15
 Exposure to air pollution, in which mutagens such as benzene and buta-1,3-
diene are found, from vehicle exhausts and factory smoke can be responsible for inducing 
cancer.
5
 
Cosmetics and medicines are factors to consider. Cosmetics can contain carcinogens such 
as paraben, suspected to be a risk factor for breast cancer.
16
 Pesticides used in intensive 
farming are generally classified as potential carcinogens,
5
 as they enter the body through 
ingestion, inhalation and skin contact.
17
 They are found in water and in fruits and 
vegetables.
5
 Also, contraceptives have been shown to increase slightly the risk of breast 
cancer.
5
All these factors constitute minor risks taken individually, but all together they 
can have a major impact on health. 
1.1.2 Hallmarks of cancer – Towards targeted chemotherapy 
Understanding the hallmarks of cancer is crucial for developing safer therapies for 
patients as the previous generation of chemotherapeutic agents caused too many 
undesired effects. In the process of tumourigenesis, tumour cells acquire properties, 
progressively through different mechanisms, allowing them to survive, proliferate and 
metastasise.
18
 These capabilities are known as the hallmarks of cancer (Figure 1).
18
 
Douglas Hanahan and Robert A Weinberg have described the main hallmarks of cancer 
from the results and observations obtained in cancer research over the last ten years. 
Understanding the biology of cancer and the role of tumour environment is essential to 
improve cancer research.
18
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Figure 1 - The Hallmarks of cancer
18 
(from D. Hanahan and R. A. Weinberg, 2011) – Description 
of the properties acquired by tumour cells to divide indefinitely and invade tissues, and the class 
of inhibitors developed for each hallmark. 
One of the main properties acquired by tumour cells is indefinite division.
18
 Contrary to 
normal cells, which control their production of growth-promoting signals to enter cell-
cycle and division, tumour cells can proliferate without restraint by deregulating these 
growth factors.
18
 By binding to receptors on the cell-surface, the growth signals send a 
message regulating the cell cycle and cell growth, therefore influencing cell survival and 
energy metabolism. However, a high level of proliferative signaling has been 
demonstrated in cell culture to drive the tumour cell into a non-proliferative-state, called 
senescence.
19
 This phenomenon may constitute a limit to tumour cell proliferation, but 
some cancer cells can adapt and interfere with this senescence state, by evading the 
negative pathways, depending mostly on tumour suppressor genes that regulate cell 
division.
18
 Defects in the retinoblastoma-associated (Rb) pathway, which regulates the 
growth-and-division cycle of the cell, may lead to uncontrolled cell proliferation.
20
 In 
addition, tumour protein p53 can transiently stop the cell cycle or trigger apoptosis by 
responding to an excess of stress and abnormal signals from the cell. Defects in the p53 
pathway may thus result in persistent cell proliferation.
18
 Another factor known to stop 
cell proliferation is cell-to-cell contact, when a population of normal cells becomes too 
dense; most cancer cells have lost such contact inhibition.
18
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On their way to unlimited proliferation, tumour cells have to develop the ability to resist 
cell death. Apoptosis represents a natural barrier to cancer development in response to 
high levels of oncogene signals and DNA damage.
21
 Apoptosis is controlled by pro-
apoptotic proteins (e.g. Bax and Bak) and anti-apoptotic proteins (e.g. Bcl-2).
21
 When the 
apoptotic pathway is triggered, the cell is disassembled and consumed by surrounding 
cells and phagocytes.
18
 Apoptosis may be attenuated in tumour cells by several strategies 
such as the loss of p53,
22
 an increase of anti-apoptotic proteins and survival signals, and a 
decrease in pro-apoptotic proteins.
18
 In tumourigenesis, necrosis appears to be an 
important factor. By lysing, necrotic cells release pro-inflammatory signals causing the 
recruitment of immune inflammatory cells to clear the residues,
23
 whereas apoptotic cells 
are consumed by neighbours. Necrotic cells are known to enable angiogenesis, cancer 
cell proliferation and invasiness.
18
  
As mentioned previously, one of the main properties of tumour cells is unlimited 
proliferation that allows the formation of a macroscopic tumour. To acquire this 
capability, tumour cells must counteract the limitations of excessive growth and division 
imposed on healthy cells.
18
 This limited number of divisions is dictated by the length of 
telomeric DNA present in the cell.
24
 Telomeres protect the end of chromosomes and each 
division shortens their length. After several generations of cells, telomeres are eroded, 
triggering a crisis mode, causing apoptosis. To prevent this, tumour cells overexpress 
telomerase, an enzyme responsible for extending telomeric DNA, to allow further 
divisions. This overexpression creates resistance to both senescence and apoptosis, and 
generates immortalised cells.
18
 
To proliferate, tumour cells require nutrients and oxygen, and need to release their waste 
products and carbon dioxide.
18
 In response to their needs, tumour cells stimulate the 
formation of new blood vessels.
25
 Existing vessels exit their quiescent state to expand the 
vessel network under stimulation from angiogenic inducers such as VEGF or FGF.
26, 27
 
Some cells from the bone marrow appear to play a role in angiogenesis by facilitating 
tumour growth and local invasion.
28
 
Alterations in shape, cell to cell adhesion and cell to extracellular matrix adhesion are 
characteristics allowing tumour cells to invade surrounding tissue.
18
 Local invasion and 
metastasis arise from a multi-step process as tumour cells will first invade local tissues, 
close to blood and lymphatic vessels. They will move through the latter to invade distant 
tissues
29
 and form micrometastases, and then grow into macroscopic tumours, in a 
process known as colonisation.
18
 In this process of growing and metastasing, tumour cells 
 5 
have support from neighbouring cells.
30
 Macrophages and inflammatory cells, for 
example, can provide matrix-degrading enzymes, which help tumour cell growth.
30
 
Tumourigenesis cannot be studied by considering not only the tumour cells, but also the 
tumour and its environment. When tumour cells colonise a tissue, they need time to adapt 
to their new environment.
18
 They are in a dormant state, finding a way to acquire the 
properties required to grow into macrometastases.
31
 This dormant state explains why, 
after having their primary tumour removed, patients can develop a secondary tumour 
several years following surgery. 
In addition to these hallmarks, the ability of cancer cells to reprogram energy metabolism 
and evade immune destruction has been recognised in the last ten years. Growing and 
dividing requires energy from the cell.
18
 Under aerobic conditions, normal cells process 
glucose into pyruvate by glycolysis in the cytosol and pyruvate into carbon dioxide in the 
mitochondria.
32
 Under anaerobic conditions, the main pathway to energy is glycolysis. It 
has been noticed that in tumour cells, glycolysis is the main route of energy metabolism, 
probably due to the diversity of glycolytic intermediates arising from this process, which 
trigger the biosynthesis of elements needed in the recruitment of new cells.
18
 
Another defence mechanism along with apoptosis would be the immune system resisting 
tumour formation and progression.
18
 The invasive growth of a tumour would imply that 
somehow the tumour manages to escape this immune surveillance.
33
 An observation 
supporting the role of the immune system is the development of tumours in patients after 
an organ transplant. Tumour cells in a dormant state, and tightly controlled by the donor’s 
immune system, grew freely after a patient had been immunosuppressed.
34
 
The hallmarks acquired by tumour cells arise through genomic instability and immune 
system defects. In contradiction, the immune system helps to resist tumour growth but 
some cells are involved in tumour progression.
18
 These cells can supply growth factors 
for cell proliferation, survival factors to resist apoptosis, and pro-angiogenic signals to 
facilitate angiogenesis.
35
 However, the acquisition of hallmarks is mainly caused by DNA 
alterations which lead to genome instability.
18
 The inhibition of pathways involved in one 
or several hallmarks of cancer, by single or combined chemotherapy, represents a 
strategic and targeted method for cancer therapy, as shown in Figure 1. 
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1.2 Protein kinases and the cell cycle 
Uncontrolled cellular proliferation represents one of the hallmarks of cancer. Targeting 
components of the cell cycle to induce apoptosis is thus one possible strategy to stop 
tumour growth. 
1.2.1 The cell cycle 
The cell cycle is a vital and complex process for all living organisms (Figure 2). Errors 
could cause aneuploidy or genetic instability, which may lead to cell death or 
abnormalities such as malignancy.
36
 The mitotic cell cycle comprises four main phases 
(G1, S, G2, M) leading to the generation of two daughter cells having a full set of 
chromosomes, one centrosome and the appropriate levels of cytoplasm and organelles. 
For this process to occur correctly, protein kinases involved in cell cycle regulation have 
to be coordinated. In case of an eventual error, checkpoints are present throughout the 
cell cycle either to arrest the process until repair occurs or to induce apoptosis if too much 
damage has been caused.
36
  
 
Figure 2 – The cell and centrosome cycle37(adapted from A. R. Barr and F. Gergely, 2007) – 
Illustration of the different phases of the cell cycle (G1, S, G2, M) including details of mitosis, 
and the centrosome cycle showing the different steps in centrosome duplication and separation. 
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In G1 phase, chromatin condenses in the cell. Meanwhile, centrioles, components of the 
centrosome, undergo dissolution of their link.
37
 During S phase, the link between the two 
centrioles is weakened which allows duplication of the centrosome. This phenomenon 
occurs at the same time as DNA replication. The bond between the old centriole and the 
new one is then reinforced to prevent further replication.
37
 Before migrating apart to 
opposite poles, centrosomes recruit an additional pericentriolar matrix in late G2. The 
separation of centrosomes occurs simultaneously with the nuclear envelope breaking 
down. After this event, centrosomes start nucleating microtubules. Once microtubules 
have been generated, kinetochores of mitotic chromosomes attach to them during 
prometaphase, and form a bipolar spindle structure.
37
 When all of the chromosomes are 
attached to microtubules and form an equatorial plane (metaphase), sister chromatids and 
centrosomes undergo segregation to opposite poles (anaphase). Once sister chromatids 
and centrosomes are located at each pole, the nuclear envelope is formed around them 
(telophase), and the chromatids disintegrate. Finally, two new cells are formed, in a 
process known as cytokinesis.
37
  
1.2.2 The cyclin-dependent kinase (CDK) family 
To date, thirteen CDKs have been identified in humans (CDK1 to CDK13).
38
 They have 
been shown to be activated by binding to cyclin-related proteins and cyclins, which are 
regulated throughout the cell cycle. Proteins possessing a cyclin-binding element have 
also been identified in addition to the thirteen CDKs (Figure 3).
38
 They do not have a 
CDK name as they have not been shown to bind to a cyclin partner, but the similarities 
between them and CDKs 1-13 make them members of the CDK family. CDKs can be 
separated into two mains groups, those involved in the cell cycle and others having a 
different function.  
 
Figure 3 - Evolution of CDKs
38
 (from M. Malumbres et al, 2009) 
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 CDKs governing the cell cycle 
The best-characterised members of the CDK family are those highly involved in the cell 
cycle.
39
 Each CDK member will have a preference for binding to a specific cyclin (CYC) 
partner, which will direct cell cycle progression (Figure 4).
39
 
 
Figure 4 - Presence of CDK-cyclin (CYC) complexes during the cell cycle
40
 (from S. Lapenna 
and A. Giordano, 2009) 
Progression from G0 to G1 involves three CDKs: CDK4, 6 and 2, and their regulators. 
Mitogen signals stimulate the synthesis of cyclin D, while CDK4 and CDK6 are 
transported to the nucleus.
41
 Activation of CDK4 has been studied, revealing its 
instability when alone. Thus, Hsp90 and p50
Cdc37
 assemble with CDK4, representing a 
chaperone complex essential for CDK4 stability (Figure 5).
41
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Figure 5 - CDK4 transport and activation
41
 (from J. W. Harper and P.D. Adams, 2001) 
CDK4 is released from its chaperone complex when in the presence of cyclin D. CIP/KIP 
proteins facilitate the binding, and thus the assembly, of CDK4 and cyclin D.
41
 These two 
proteins are either freshly synthesised or released from the CDK2/cyclin E inhibition 
complex. Indeed, the CIP/KIP complex plays a role of inhibitor for the CDK2/cyclin E 
complex, but acts as an activator for the CDK4/cyclin D complex.
41
 CDK4/cyclin D and 
CDK6/cyclin D complexes accumulate in G1 and phosphorylate members of the 
retinoblastoma (Rb) protein family. Phosphorylation of the Rb protein activates the 
synthesis of cyclin E which binds to CDK2. However, the CDK2/cyclin E complex is 
silenced by p27
KIP1
, a cyclin-dependent kinase inhibitor (CKI).
41
 In order to activate the 
CDK2/cyclin E complex, CDK4/cyclin D sequesters p27
KIP1
 releasing activated 
CDK2/cyclin E. The activation of the CDK4/cyclin D/p27
KIP1
 complex is a two step 
process where p27
KIP1
 has to be phosphorylated first to allow phosphorylation of CDK4 
by the CAK complex.
42
 The phosphorylation of p27
KIP1
 promotes the assembly and 
activation of the CDK4/cyclin D/p27
KIP1
 complex, reducing the inhibitory effect of 
p27
KIP1
 towards CDK2/cyclin E.
43
 This last complex phosphorylates pRb inducing a 
positive feedback until reaching a level of activated CDK2/cyclin E complex sufficient to 
phosphorylate p27
KIP1
, leading to its degradation by proteasomes.
41
 At this point, pRb is 
irreversibly inactivated. The cell is now independent of mitogenic signals, and this is 
termed the restriction point (R) (Figure 6).
41
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Figure 6 - Hyperphosphorylation of pRb triggering G1/S transition
44
 (from G. K. Schwartz and 
M. A. Shah, 2005) 
In parallel to pRb and p27
KIP1
 inhibition for activation of S-phase kinases, pre-RC 
complexes, required for DNA replication in S-phase, are synthesised.
41
 Thus, during G1, 
Anaphase Promoting Complex (APC), an E3  ubiquitin ligase, demonstrates high activity 
and as a consequence CDK/cyclin activity is low. At the restriction point, the activity is 
reversed, leading to inactivation of the APC complex (Figure 7).
41
  
 
Figure 7 - APC activity versus CDK/cyclin activity throughout the cell cycle
41
 (from J. W. 
Harper and P. D. Adams, 2001) 
In S-phase, DNA replication starts as well as histone synthesis, where the CDK2/cyclin E 
complex is involved.
39
 New DNA binds to histones and assembles into chromatin. To 
ensure only one replication, the CDK2/cyclin E complex is silenced by degradation of 
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cyclin E by Skp1/Cdc53/F-box (SCF) ubiquitin ligase.
39
 Inhibition of pRb in late G1 
leads to the synthesis of cyclin A and B during S phase. Once the CDK2/cyclin E 
complex has dissociated, CDK2 binds to the splice variants cyclin A1 and A2. The new 
CDK2/cyclin A complex is responsible for phosphorylation of several proteins essential 
for S phase exit.
39
 At the end of S phase, cyclin A binds preferentially to CDK1 over 
CDK2 forming the CDK1/cyclin A complex. During G2, cyclin A is degraded by 
ubiquitin-mediated proteolysis while cyclin B is synthesised.
39
 With degradation of cyclin 
A, CDK1 binds to cyclin B to form CDK1/cyclin B, essential for the mitosis trigger. This 
complex is responsible for the phosphorylation of more than 70 proteins involved in G2-
M transition and through mitosis. To exit mitosis, cyclin B is degraded via ubiquitination 
by the APC complex.
39
  
As explained by CDK orchestration of the cell cycle, CDK activity is tightly controlled 
by its regulators, cyclins and cyclin-dependent inhibitors (CKIs). In order to be active, the 
CDK/cyclin complex needs to be phosphorylated in its conserved T-loop.
39
 This 
phosphorylation is catalysed by the CDK-Activating Kinase (CAK) complex, comprised 
of CDK7, cyclin H and Mat-1, which can be found mostly alone or with the core TFIIH, 
a multi protein complex with dual roles in transcription and DNA repair.
45
 The 
phosphorylated CDK/cyclin complex can be inhibited by CKIs (CIP/KIP).
39
 In addition, 
CDK can be inactivated in its monomeric form by direct binding with CKIs (INK4).
39
 
Eventually, when CDK binds to cyclin to form a complex not yet active, this complex can 
be phosphorylated by Wee1 and Myt1 kinases. This negative process is reversible thanks 
to the activity of Cdc25 phosphatases (Figure 8).
39
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Figure 8 - Activation/inactivation of CDKs
39
 (from M. Malumbres and M. Barbacid, 2005) 
 CDK activation 
CDKs are inactive in their monomeric form. For full activation, CDKs require binding to 
a cyclin and phosphorylation of their activation loop. However, the order of these two 
events differs among the CDKs, and it is likely that each CDK complex is regulated in its 
own way in vivo.
46
  CDK2 comprises an N-terminal lobe (β-sheets), a C-terminal lobe (α-
helix) and an ATP-binding site, that are common to other protein kinases, located at the 
interface of the two lobes.
47
 For CDK2, the unique features are its PSTAIRE sequence (in 
red, Figure 9) and the regulatory loop (in yellow, Figure 9).  
 
Figure 9 - Structures of CDK2 alone and in complex with cyclin A
47
 (from N. P. Pavletich, 1999) 
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The CDK catalytic subunit is constituted of 298 amino acids in length.
47
 In its inactive 
form, the T-loop blocks access to the substrate binding site and the conformation of the 
ATP pocket limits interactions with the phosphate group of ATP.
48
 Binding of cyclin A to 
the PSTAIRE helix of CDK2 induces conformational changes including a repositioning 
of the PSTAIRE helix into the ATP-binding site and a realignment of the T-loop, 
enabling entry to the ATP-binding pocket.
47
 These changes constitute the first step of the 
activation, and at this stage, the CDK2/cyclin complex possesses little enzymatic activity. 
The second activation step is phosphorylation of the T-loop by the CAK complex, 
accompanied by conformational changes,
47
 which increase the reactivity of the complex 
by 1000-fold (Figure 10).
49
 More recently, studies in vivo showed that CDK2 was likely 
to be phosphorylated in its monomeric form, and then to bind to its cyclin partner. 
Interestingly, these studies revealed that for CDK1, phosphorylation and cyclin-binding 
are mutually dependent in vivo and need to occur simultaneously.
46
 The kinetic difference, 
observed in vivo, of CDK phosphorylation by the CAK complex and assembly with 
cyclin partners is likely to rule the selectivity and timing of CDK/cyclin complex 
formation during the cell cycle.  
 
Figure 10 - Structure of the activated CDK2/cyclin A complex showing CDK2 in blue, cyclin A 
in purple, the activation loop in yellow and ATP binding to CDK2
47
 (from N. P. Pavletich, 1999) 
 Cyclin-dependent kinase inhibitors (CKIs) 
As explained previously, CDKs can either be inactivated in their monomeric form or 
when in complex with a cyclin, by the binding of a CKI or by phosphorylation as 
reversible processes. Two types of cyclin-dependent kinase inhibitor exist: p21/27 and 
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INK4, which differ in structure, mechanism of inhibition and specificity.
50
 Their mode of 
action is shown in Figure 11. 
 
Figure 11 - CKI mode of action
47
 (from N. P. Pavletich, 1999) 
p21-27 family members possess a conserved amino-terminal domain of 60 residues 
responsible for binding and inhibition of CDKs. These inhibitors target CDKs especially 
at the G1/S phase.
50
 The protein p21 preferentially inhibits cyclin E and D dependent 
kinases.
51
 The level of p21 is controlled by p53. In the event of DNA damage, p53 
stimulates the synthesis of p21 which will bind to and inhibit CDK/cyclin complexes, 
leading to cell cycle arrest during DNA repair (Figure 12).
51
  
 
Figure 12 - Role of p21 in cell cycle arrest
51
 (from C. J. Sherr and J. M. Roberts) 
Protein p27 preferentially inhibits cyclin D, E, A and B dependent kinases.
51
 The 
interaction between p27 and the CDK2/cyclin A complex has been studied.
47
 Thus, p27 
blocks the ATP-binding site, acting as a competitive inhibitor, by mimicking the 
interactions (hydrogen bonds and Van der Waals interactions) between the ATP molecule 
and the ATP-binding pocket of CDK2, through the insertion of an α-helix.47 This binding 
invokes conformational changes preventing phosphorylation by the CAK complex 
(Figure 13).
51
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Figure 13 - p27 binding to the CDK2/cyclin A complex showing CDK2 in blue, Cyclin A in 
purple and p27 in yellow
47
 (from N. P. Pavletich, 1999) 
The INK4 family comprises p15, p16, p18 and p19, and is selective for CDK4 and 6.
50
 
These proteins will directly bind to CDK4 and 6 preventing assembly with cyclin D. A 
high level of p16
INK-4a
 causes G1 arrest when CDK4/cyclin D and CDK6/cyclin D levels 
are too low to phosphorylate pRb.
50
 After the restriction point, p16 as well as other 
members of this family downregulate cyclin D-dependent kinase activity.
51
 The assembly 
of p16
INK-4a
 and CDK6 has also been studied.
47
 p16 interacts with both N- and C-lobes 
leading to allosteric changes, which further block cyclin binding. The interaction is 
responsible for misalignment of the N- and C-lobes, and the PSTAIRE helix (Figure 
14),
47
 causing a distortion in the ATP site reducing its ATP-binding efficiency.
47
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Figure 14 – Structure of p16 (in yellow) binding to CDK6 (in blue) and a schematic 
representation of p16 (in orange) interacting with the N- and C- lobes of CDK2 preventing the 
assembly with cyclin A (in pink)
47
 (from N. P. Pavletich, 1999) 
 Other endogenous cyclin-dependent kinase inhibitors 
The dual-specificity kinases, Wee1 and Myt1, can phosphorylate CDK/cyclin 
complexes.
48
 They have been shown to phosphorylate CDK1 on Thr14 (Myt1) and CDK2 
on Tyr15 (Wee1),
48
 and their phosphorylation affects kinase activity without blocking the 
ATP-binding site. CDK1/cyclin B is phosphorylated and remains inactive until the end of 
G2. Dephosphorylation by Cdc25 phosphatases leads to activation of the CDK1/cyclin B 
complex.
48
  
1.2.3 Never-In-Mitosis A related kinases (Nek kinases) 
Nek kinases are mammalian homologues of the Never In Mitosis A (NIMA A) protein in 
Aspergillus nidulous and Fin1 in fission yeast (Table 1).
52
 NIMA is a serine-threonine 
kinase, first isolated in 1975,
53
 and found to be essential for mitotic entry.
54
 NIMA is 
implicated in the localisation of the CDK1/cyclin B complex to the nucleus to trigger 
chromatin condensation as well as spindle formation. Fin1 and NIMA have also been 
shown to play a role in cytokinesis.
55
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Table 1 - Nek2 members (adapted from Fry, 2002)
55
 
Kinase Species 
Accession 
number 
Percent identity 
to Human Nek2 
in catalytic 
domain 
Proposed functions 
Nek2 
Human P51955 100 
Centrosome separation 
Centrosome organisation 
Mouse O35942 93 Chromatin condensation 
NIMA Aspergillus P11837 44 
Mitotic entry          
Chromatin condensation 
Localisation of cyclin B 
Replication checkpoint 
Fin1p 
Schizosaccha- 
romyces pombe 
CAB11653 41 
Mitotic spindle formation 
SPB organisation      
Mitotic entry           
Nuclear envelope integrity 
 
The first members of the mammalian Nek family to be characterised were Nek1, 2 and 3 
by Pawson and Nigg in the early 1990s.
56
 Since then, eight other members have been 
identified.
57
 In the early 1990s, Nurse and Hunter demonstrated that kinases related to 
NIMA might be mitotic regulators of the cell cycle, as they played an important role in 
mitosis.
58
 The Nek family, with eleven members, represents 2% of the entire kinome. 
They share 40% of their N-terminal catalytic domain with NIMA, but differ from the C-
terminal domain, which confers their own specificities.
59
 From the eleven members, four 
have been shown to be involved in mitotic progression: Nek2, 6, 7 and 9 (Figure 15).
52
  
 
Figure 15 – Comparison of structures of Nek members52 (from L. O’Regan et al, 2007) 
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 Nek2 
Nek2 is the closest member to NIMA and Fin1 in terms of homology of the catalytic 
domain.
55
 The kinase exists as three splice variants: Nek2A, 2B and 2C.
60, 61
 The last of 
these, however, has not been widely studied or compared to Nek2A and 2B whose 
structures are shown in Figure 16. Nek2B possesses the same catalytic domain and 
leucine zipper (LZ) as Nek2A but differences lie in their C-terminal domain. Nek2A 
possesses a coiled-coil (CC) domain, a PP1c binding site and a KEN-box, not present in 
Nek2B.
55
  
 
Figure 16 - Nek2A and 2B kinase domains
55
 (from A. M. Fry, 2002) 
Nek2 is found at the centrosomes and mitotic spindle poles throughout the cell cycle.
55
 
However, its concentration varies. During G1 phase, Nek2A and 2B are expressed at a 
low level, but at the G1/S transition, their concentrations increase until reaching a 
constant concentration that is maintained throughout S and G2 phases.
55
 At the onset of 
mitosis, Nek2A disappears, being degraded by the APC/C protein complex, leaving 
Nek2B intact but decreasing the overall Nek2 concentration.
55
  
The main role of Nek2 is to trigger centrosome separation at the G2/M transition (Figure 
17).
52
 Nek2 phosphorylates the C-Nap1/rootletin complex, two major components of the 
intercentriolar linkage maintaining the two centrosomes close to each other.
62, 63
 This 
phosphorylation induces dissociation of the C-Nap1-rootletin complex and therefore 
breaks the link between the two centrosomes.
52
 Until the onset of mitosis, Nek2 is 
inactivated by PP1 which binds through the KVHF motif in the C-terminal region.
64
 At 
the G2/M transition, CDK1 stimulates binding between PP1 and Inh-2 (Inhibitor-2 
protein) resulting in the activation of Nek2.
52
 Nek2 can bind to and inhibit PP1, allowing 
auto-phosphorylation and activation.
65
  
 19 
 
Figure 17 - Nek2 role in the G2/M phase
52
 (from L. O’Regan et al, 2007) – CDK1 promotes the 
binding between Inh2 and PP1, activating Nek2. Phosphoylation of the C-Nap1/rootletin complex 
(in red) by Nek2 induces centrosome separation. 
Nek2 has also been shown to be involved in microtubule organisation through the 
activation of Nlp ((Nep1)-like protein) and centrobin, both implicated in microtubule 
anchoring.
52
 Plk1 (Polo-like kinase 1) was also suggested to be a substrate of Nek2 as 
Nlp is a substrate of Plk1.
52, 66
 Nek2 could play an additional role in late 
mitosis/cytokinesis because depletion of Nek2B results in a delay in mitotic exit.
55
  
Nek2 may also be directly involved in the mitotic checkpoint (Figure 18). Nek2 was 
shown to phosphorylate the Mad2/Cdc20 protein complex and also to interact with Hec1 
(Highly expressed in cancer 1) and Mad1 (Mitotic arrest deficient-like 1).
67
 When 
kinetochores are not properly attached to microtubules, Mad2 adopts a conformation 
allowing binding to Cdc20, leading to its inhibition.
67
 Cdc20 normally activates the 
APC/C complex which in turn degrades securin, a protease separase inhibitor, resulting in 
chromosome segregation. By binding to Cdc20, Mad2 stops the segregation.
67
 Therefore, 
by associating with the Mad2/Cdc20 complex, Nek2 might interfere with the mitotic 
checkpoint leading to aneuploidy and tumourigenesis.
67
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Figure 18 - Nek2 and the mitotic checkpoint – At the spindle checkpoint, the APC/C complex, 
activated by Cdc20, triggers the ubiquitination of securin leading to chromosome segregation. 
Progression to chromosome segregation can be stopped by association of Mad2 with Cdc20, a 
complex which can be phosphorylated by Nek2. 
 Other Nek members involved in mitosis 
Nek6 and 7 share 87% sequence identity in their kinase domains and differ only within 
the N-terminal domain.
59
 Nek7 levels are constant during the cell cycle and are 
concentrated at centrosomes during interphase and mitosis, suggesting a role in recruiting 
γ-tubulin and homologues.68 By contrast, Nek6 appears to be highly expressed during 
mitosis.
69
 Both Nek6 and 7 may be substrates of Nek9 and activated through 
phosphorylation. To date, no substrates of Nek6 and 7 have been identified, and further 
investigations of these two members are needed to understand whether they have the 
same role.
52
  
Nek9 is expressed at a constant level throughout the cell cycle but its kinase activity 
reaches a peak on spindle poles in mitosis.
70
 Two regions of Nek9 seem important for its 
function: RCC1 is responsible for auto-inhibition of Nek9, permitting reasonable Nek9 
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concentration, and the coiled-coil domain is essential for its kinase activity, as depletion 
leads to a drop of activity.
52
 Nek9 is involved in spindle organisation by regulating the 
anchoring of centrosomal microtubules by recruitment of γ-tubulin,52 and has been shown 
to be essential in chromosome segregation but not for mitotic entry.
52
  
1.2.4 Other cell cycle-associated kinases 
Polo-like kinases (Plks) are serine-threonine kinases, with the first Plk being discovered 
in Drosophila melanogaster.
71
 Four members have been identified to date: (i) Plk1 is 
present in late G2 and M phase and regulates mitosis,
72
 (ii) Plk2, found in early G1, 
controls entry into S phase,
72
 (iii) Plk3 is present at a constant concentration during the 
cell cycle and may have a function at the G2/M transition,
72
 (iv) Plk4 is involved in 
mitotic exit.
72
 Although the Plk family has several members, only Plk1 has been widely 
investigated, with the role of Plk2, 3 and 4 remaining unclear. 
The first Aurora kinase was identified in D. melanogaster mutants having spindle-pole 
defects.
73
 In mammals, three serine-threonine kinases have been identified, known as 
Aurora A, B and C.
74
 Aurora A and B have been demonstrated to be closely involved in 
cell division, whereas less is known about Aurora C, which is mainly present in testis.
75
  
1.3 Protein kinases as drug targets 
1.3.1 Protein kinases in drug discovery 
Protein kinases (PKs) catalyse the transfer of a phosphate group from adenosine-5'-
triphosphate (ATP) to an amino-acid substrate, releasing adenosine diphosphate (ADP) in 
the process
76
 (Figure 19). Protein phosphorylation controls a range of biological 
mechanisms, such as signal transduction, metabolism, transcription, cell cycle 
progression, cytoskeletal rearrangement, cell movement, apoptosis and differentiation.
77
 
Phosphorylation can be reversed by phosphatases.  
 
Figure 19 – Protein phosphorylation and dephosphorylation40 (from S. Lapenna and A. Giordano, 
2009) 
As protein phosphorylation is essential for various biological mechanisms, disruption of 
this process can lead to diseases such as arthritis, diabetes, inflammation, and 
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immunological, neurological and metabolic disorders as well as cancer.
78, 79
 In 1978, 
Erikson showed the oncogene potential of a protein kinase and, in 1981 Castagna 
demonstrated the activation of protein kinase C (PKC) by tumour promoting phorbol 
esters
80
 (Figure 20). In the late 1980s, after the discovery of the activity of staurosporine 
against PKC, the pharmaceutical industry started to investigate protein kinase inhibitors 
as possible drugs.
80
 But it was not until the late 1990s that the first protein kinase 
inhibitor, fasudil, reached the Japanese market for the treatment of cerebral vasospasm.
80
 
However, the myth that no potent and selective PK inhibitor was possible ended with 
imatinib, the most famous example of a successful PK inhibitor.
80
 Selective inhibition of 
PKs was shown to be feasible and well tolerated by normal cells in comparison to tumour 
cells.
79
 Since the discovery of Imatinib, PKs represent attractive targets as they are 
involved in every phosphotransfer cascade controlling signal transduction. Environmental 
and genetic alterations are the main causes of deregulation of kinase function, one of the 
hallmarks of many pathological conditions.
81
 Approximately 180 kinases were shown to 
be deregulated in cancers, the immune system and infections.
81
  
 
Figure 20 - Timeline of kinase inhibitor drug discovery during the 20
th
 century
80
 (from P. Cohen, 
2002) 
1.3.2 Protein kinase classification 
The human kinome comprises 518 protein kinases, representing 1.7% of all the human 
genes, and 106 kinase pseudogenes that are non-functional copies of kinase genes.
77
 The 
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human kinome is one of the largest families of genes in eukaryotes. Among the 518 
kinases, 478 have been identified with a common domain called the eukaryotic protein 
kinase (ePK) catalytic domain.
77
 The remaining 40 kinases show similar activity to the 
other kinases but lack the ePK domain.
77
 Kinases are classified into groups, families and 
subfamilies according to their catalytic domain similarities, their biological functions and 
their similarities outside of the catalytic domain.
77
 Kinases belonging to the same family 
have similar structure. There are seven main families, which are the AGC family named 
after the protein kinase A, G and C, the CAMK family with Ca
2+
/CAM-dependent PK, 
the CK1 (casein kinase 1) family, the CMGC family named after the CDK, MAPK 
(mitogen-activated protein kinases), GSK (glycogen synthase kinases) and CDK-like 
kinases, the STE family, the TK (tyrosine kinase) family and the TK-like family.
82
  
Another method of classification of kinases is by the amino acids that they 
phosphorylate.
82
 Protein kinases can either transfer a phosphate group to a tyrosine 
residue or a serine or threonine residue, or both. They are thus separated into two main 
classes: tyrosine kinases and serine-threonine kinases.
82
 The human kinome includes 420 
serine-threonine kinases and 94 tyrosine kinases.
81
  
1.3.3 Kinase structure 
Protein kinases have a common general structure. They are constituted of two lobes 
connected by a hinge region.
78
 The N-terminal lobe is formed by β sheets and one α helix, 
and the C-terminal lobe is mostly α helical domain with a segment called the activation 
loop (T-loop), a phosphorylation site to trigger kinase activity, and limited by the 
gatekeeper residue (Figure 21).  
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Figure 21 – Structure of CDK2 illustrating the general structure of kinases with the N-lobe 
containing the C-helix and the C-lobe including the T-loop – CDK2 inactive conformation in blue 
and CDK2 active conformation in orange
83
 (from M. D’Abramo et al, 2014) 
Understanding how ATP binds to the kinase is helpful in the design of inhibitors. The 
triphosphate group of ATP interacts with a group of conserved kinase residues.
76
 More 
particularly, the triphosphate moiety and the basic side chains of these residues showed 
some affinity. These interactions are well conserved throughout the kinome, in contrast to 
the adenosine moiety binding which is less conserved.
76
 N-1 of ATP is engaged in an 
interaction with hydrogen bond-donor localised within the hinge region.
76
 In addition, N-
7 of ATP interacts with hydrogen bond-acceptor carbonyl also situated in the hinge 
region.
76
 These hydrogen bond interactions are often mimicked by small-molecule 
inhibitors (Figure 22). 
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Figure 22 - ATP in complex with the CDK2 ATP-binding site
84
 (from P. G. Wyatt et al, 2008) – 
the key regions are highlighted: Phosphate pocket, ribose pocket, DFG region, gatekeeper, 
solvent exposed area and the hinge. (Drawn from PDB code 1HCL) 
In the protein phosphorylation process, the limiting step is ADP release. ATP and ADP 
have similar structures, so if ATP binds to the kinase, ADP is most likely to have affinity 
for the kinase too. However, to catalyse another phosphorylation, the kinase must release 
ADP to allow another ATP molecule to bind. Specific polar sites are present in the ATP 
binding site to facilitate ADP release by reducing the affinity of ADP for the kinase.
76
 
Other regions of the kinase around the ATP pocket can be exploited in the design of 
selective inhibitors, such as the hydrophobic pocket, adjacent to N-6 of adenosine, the 
hydrophobic channel, next to the ribose flank and the gatekeeper residues.
76
 These 
pockets differ within the kinome and allow inhibitor selectivity. 
1.3.4 Active/Inactive conformation of kinases 
A kinase can be found either in its active or inactive conformation.
82
 Serine/threonine and 
tyrosine kinases possess a conserved catalytic domain but also a conserved active 
conformation, rendering selective inhibition challenging.
77
 For this reason, the inactive 
conformation appears more attractive as ‘all active kinases are alike but an inactive 
kinase is inactive after its own fashion’.78 The first inactive conformation to be identified 
was in CDK2
85
 and Src
86
 kinases. Since the discovery of these two inactive 
conformations, others have been described including those in Abl,
87
 Wnk
88
 and Nek2.
89
 
Key structural features of the active form of the kinase were found to be essential in the 
catalysis of phosphate transfer.
90, 91
 The importance of the activation loop, in particular 
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the DFG-motif (Asp-Phe-Gly) in the N-terminal region, the position of the helix αC and 
interactions formed by the HRD motif and glycine-rich P-loop was revealed.  
 
Figure 23 - Highlights of the key structural features of the active conformation of protein kinase 
A (PKA)
92
 (from N. Jura et al, 2011) – activation loop, helix αC, P-loop, ATP, magnesium ion. 
The key catalytic residues are shown – DFG aspartate (D184), HRD aspartate (D166), catalytic 
lysine (K72), catalytic glutamate (E91) and the autophosphorylation site (T197).The PDB entry is 
1ATP. 
The side chain of the aspartate residue of the DFG-motif was shown to coordinate with 
Mg
2+
 and interact with the phosphate groups of ATP (Figure 23). In addition, the open 
conformation of the C-terminal region of the activation loop was highlighted, 
representing a platform for docking substrates.
92
 A conserved glutamate residue (Glu91) 
in the helix α-C in the N-lobe of the kinase was demonstrated to be crucial for the active 
conformation as a salt bridge is formed between Glu91 and a conserved Lys72 (Figure 
23). Both residues are important for the active conformation as mutations of Lys72 lead 
to the inactive conformation of the kinase.
93
 The conserved HRD-motif (His-Arg-Asp) 
and the glycine-rich P-loop, both located in the active site, are key features of the active 
conformation. The glycine-rich P-loop was shown to interact with the phosphates of ATP 
(β and ɤ) when Asp166 of the HRD motif acts as a catalytic base with the substrate 
(Figure 23).
92
  
In addition to the key structural features in the active conformation, the 
assembly/disassembly of hydrophobic residues forming intramolecular networks between 
N- and C- lobes correlates with the active/inactive conformation of the kinase
94, 95
 
(Figure 24). The first network, called the ‘regulatory spine’, is constituted of four 
residues, Leu106, Leu95 (from helix α-C), Phe185 (from the DFG-motif) and Tyr164 
(from the HRD-motif) and is involved in substrate binding.
92
 The assembly of the 
regulatory spine is dependent on the change of orientation of helix α-C and the HRD-
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motif, caused by displacement of the activation loop upon activation.
94
 The second 
network, known as the ‘catalytic spine’, possesses residues in the C-lobe, more 
specifically in helix α-F and α-D, and in the N-lobe (Ile174, Leu173, Val57, Ala70).92, 95 
Following ATP binding, the adenine ring is located in the catalytic spine and the network 
establishes a connection between the N- and C-lobes. Both regulatory and catalytic spines 
are linked by the helix α-F, which binds to the catalytic network by Met231 and Leu227, 
and to the regulatory network by Asp220.
92
  
 
Figure 24 - Structural differences between the active and inactive conformation of a protein 
kinase (Abl kinase) illustrating the catalytic and regulatory spines and key residues, DFG-
phenylalanine, catalytic lysine (K) and catalytic glutamate (E)
92
 (from N. Jura et al, 2011) The 
PDB entries are 1OPJ and 2G2I. 
Several active and inactive conformations of kinases were studied, highlighting 
differences with the activation loop being found to block binding of substrates.
96
 This 
same activation segment also interfered with the ATP-binding pocket resulting in its 
blockade.
96
 The glycine rich loop was also found to be distorted.
96
 Finally, in some cases, 
a salt bridge exists between a Glu residue situated at the centre of the α-C helix and a Lys 
residue which binds to the triphosphate of ATP. This was shown to be disrupted because 
of the misalignment of the α-C helix in the N-terminal lobe due to the change of 
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conformation.
96
 In all inactive conformations of kinases, at least two of the disruptions 
described above were found, with 60% involving the ATP-binding site blockade.
96
  
1.3.5 Protein kinase inhibition by small molecules 
Targeting protein kinases selectively remains challenging as they represent one of the 
largest gene families, and the ATP-binding site is well conserved among the kinome.
81
 To 
date, only a small number of kinases are inhibited by kinase inhibitors approved by the 
FDA, while around 180 kinases have been identified as attractive targets.
81
  
Table 2 - Kinase inhibitors in oncology accepted by the FDA from 2001 to 2014
97
 (from T. Barf 
and A. Kaptein, 2012) 
Generic name Year of approval Indication Target kinase 
Imatinib 2001 CML Abl, c-Kit, PDGFRα/β 
Gefitinib 2003 NSCLC EGFR 
Erlotinib 2004 
NSCLC, pancreatic 
cancer 
EGFR 
Sorafenib 2005 
Hepatocellular 
carcinoma, RCC 
Raf, VEGFR2/3, c-Kit, 
PDGFRβ 
Sunitinib 2006 GIST, RCC 
C-Kit, VEGFR, PDGFR, 
FLT3 
Dasatinib 2006 CML Abl, c-Kit, PDGFR, Src 
Nilotinib 2007 CML 
Abl, c-Kit, PDGFR, Src, 
ephrin 
Lapatinib 2007 Breast cancer EGFR, ErbB2 
Pazopanib 2009 RCC VEGFR, PDGFRα/β, c-Kit 
Vandetanib 2011 Thyroid cancer VEGFR, EGFR, RET 
Vemurafenib 2011 CML 
Abl, c-Kit, PDGFR, Src, 
ephrin 
Crizotinib 2011 NSCLC (ALK +ve) ALK, MET 
Ruxolitinib 2011 Myelofibrosis JAK1/2 
Axitinib 2012 RCC VEGFR, PDGFRα/β, c-Kit 
Bosutinib 2012 CML Bcr Abl/SRC 
Afatinib 2013 NSCLC EGFR/ErbB2 
Ibrutinib 2014 MCL, CLL BTK 
 
Drug discovery projects based on kinase inhibition represent some 30% of projects 
conducted by the pharmaceutical industry, making kinases the second most exploited 
target after G-protein coupled receptors (GPCRs).
98
 Two classes of inhibitors exist: 
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covalent (or irreversible) inhibitors and non-covalent (or ATP-competitive) inhibitors, 
with the latter having received the most attention. From 2001 to 2014, of 17 approved 
kinase inhibitors, only two irreversible inactivators (afatinib (6) and ibrutinib (8)) have 
been approved by the FDA in oncology (Table 2). 
 Reversible inhibitors 
Most kinase inhibitors are ATP-competitive inhibitors making one to three hydrogen 
bonds with amino acids within the kinase hinge region, thereby mimicking interactions 
between the hinge region and the adenine ring of ATP.
79
 Most of the inhibitors being 
developed do not exploit the ribose or the triphosphate bonding site.
79
 Reversible 
inhibitors targeting the active conformation of the kinase, by binding to the ATP-pocket, 
are known as Type 1 inhibitors. Most of them possess a heterocycle localised in the 
adenine-binding region of the ATP pocket. Functional groups are added to the 
heterocyclic core to occupy regions not exploited by ATP, such as hydrophobic pockets, 
to improve selectivity and potency.
81
 Vemurafenib (1) is a selective inhibitor of the most 
common mutant form of the oncogenic B-Raf tyrosine kinase, 
V600E
B-Raf.
99
 This 
compound exploits structural differences between the mutant and wild-type forms of B-
Raf, and was shown to cause melanoma tumour growth regression in patients having the 
V600E
B-Raf mutation by inhibiting the MAPK signalling pathway. In patients not bearing 
this mutation, vemurafenib seemed to enhance tumour growth.
99
 Another example is 
vandetanib (2), originally investigated in clinical trials in combination therapies for 
patients with advanced stage NSCLC or with metastases. As no benefits were observed, 
this drug was withdrawn from clinical trials in 2009.
100
 However, two years later, 
vandetanib was the first drug approved by the FDA for the treatment of metastatic 
medullary thyroid cancer, and was given to patients ineligible for surgery.
100
  
 
Reversible inhibitors targeting the inactive conformation of a kinase are called Type 2 
inhibitors. As explained previously (Chapter 1, section 1.3.4.), by moving from its active 
to inactive conformation, the enzyme creates a new environment for inhibitors to exploit 
for selectivity purposes. In the inactive conformation of Abl-1, the activation loop forms 
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a new hydrophobic pocket next to the ATP-binding site, which is non-existent in the 
active form. Imatinib exploits this new pocket (Figure 25).
79
  
 
Figure 25 - Imatinib in complex with the inactive conformation of ABL1
79
 (from J. Zhang et al, 
2009) - The interactions between Imatinib and the protein are illustrated in the cartoon. The PDB 
entry is 1IEP. 
The ATP-binding site is a well conserved site among kinases, rendering selectivity 
challenging. In addition, when designing ATP-competitive inhibitors, potency needs to be 
high for the inhibitors to compete with ATP in the cell ([ATP] = 5-15 mM).
40
 Some 
reversible inhibitors are designed to bind to allosteric sites situated outside of the ATP 
pocket, and are known as allosteric inhibitors.
79
 As allosteric sites are more specific to an 
individual kinase, these inhibitors tend to be highly selective. 
 Covalent inhibitors 
Irreversible inhibitors have been avoided in drug discovery programs because of the 
perceived safety and toxicity problems associated with them.
97
 Compounds metabolised 
to highly reactive intermediates were studied in the 1970s, showing that covalent binding 
between these metabolites and liver proteins caused hepatotoxicity.
101
 Non-selective 
irreversible inhibitors can bind to proteins, DNA and glutathione.
102
 Drugs that are either 
non-selective or metabolised into active metabolites may be responsible for direct tissue 
damage or haptenisation of proteins, triggering an immune response (Figure 26).
101
 In 
addition, with covalent inhibitors, a risk for idiosyncratic toxicity is to be considered even 
when no particular toxicological problems are encountered in preclinical models.
102
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Figure 26 - Possible effects arising from covalent drugs
102
 (from M. H. Potashman and M. E. 
Duggan, 2009) 
Even though the physiological response to formation of a drug-protein complex is 
difficult to predict, several covalent drugs have been accepted by the FDA, with 20% in 
cancer therapy.
101, 102
 Among these drugs, lansoprazole, clopidogrel (5) and esomeprazol 
(9) are examples of successful and effective marketed covalent drugs, as in 2009, they 
were classified as blockbusters in the top 10 selling drugs in the USA.
101
  
 
Figure 27 - Progress of covalent drugs from the 19
th
 to the 21
th
 century
101
 (from J. Singh et al, 
2011) 
Covalent binding is not a new concept in drug discovery as the most widely consumed 
drug in the world is a covalent inhibitor (Figure 27). Thus, aspirin (3) is responsible for 
acetylation of a serine residue of cyclooxygenase 1, near the active site. Its mechanism of 
action was determined long after aspirin was licenced for pharmaceutical use.
103
 
Esomeprazole (9), the (S)-enantiomer of omeprazole (7) approved in the 1980s, is a 
proton pump inhibitor (PPI) use for gastrointestinal reflux disease. This drug is converted 
 32 
into a covalent modifier of the proton pump by acid in the gastric environment (Figure 
28).
104
 Clopidogrel (5) is an anti-clotting agent used for treating vascular disease that was 
approved in the 1990s. The drug’s effect is due to covalent binding to P2Y, a G-protein 
complex receptor.
105
 Covalent drugs in oncology have been developed following a new 
strategy of ‘targeted covalent inhibitor’ (TCI), where the covalent drug targets a non-
catalytic nucleophile, unique or poorly conserved among the kinome.
101
 Neratinib, an 
irreversible pan-inhibitor of HER kinases, showed substantial activity in phase II clinical 
trials for the treatment of metastatic breast cancer as a monotherapy.
106
 Another example 
is afatinib (6), a third generation inhibitor of EGFR which binds covalently to Cys797. 
This drug was approved by the FDA in 2013 for the treatment of metastatic NSCLC.
107
 
More recently, ibrutinib (8), a covalent inhibitor of BTK (Bruton’s tyrosine kinase), has 
been approved by the FDA for the treatment of mantle cell lymphoma (MCL) and 
chronic lymphocytic leukaemia (CLL).
108
 Ibrutinib was shown to react covalently with 
Cys481 through its acrylamide warhead.
109
 
 
Figure 28 – Mechanism of action of esomeprazole (9) 
In the concern of safety related to covalent drugs, the difference between highly reactive 
compounds and the TCI approach has to be emphasised. Highly reactive compounds are 
extremely electrophilic intermediates by comparison with the warheads of a TCI,
101
 
which are specific to one target, decreasing the risk of toxicity. However, the risk of 
haptenisation is still present but no current technology allows a useful risk assessment.
101
 
It is worth mentioning that to date, TCIs are considered for life threatening diseases 
where no effective therapies are available, and the benefits can therefore overcome 
potential immunotoxicity.
101
 In the near future, more data will be available on the safety 
profile of TCIs thanks to current drugs in clinical trials. Until then, a compilation of 
toxicophores is available for medicinal chemists, listing pre-existing reactive electrophilic 
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functions and compounds likely to undergo metabolism. Another parameter to consider 
for safety purposes is the dose of drug administered to the patient. Most of the drugs 
withdrawn from the market were given at doses higher than 100 mg/day compared with 
less than 10 mg/day for drugs still on the market.
110
 With covalent drugs, the dose can be 
lowered because target inhibition still persists after drug clearance. The enzyme’s 
function is restored only after protein resynthesis thus differentiating pharmacokinetic 
from pharmacodynamic effects, therefore, giving more flexibility over the clearance of 
the drug.
111
 This mechanism of action is a real advantage in drug resistance cases. 
Reversible inhibitors have to be administered more often because of their short half-life, 
which can lead to the development of resistance, in contrast to irreversible inhibitors that 
have a longer therapeutic effect.
101
  
To understand better the advantages offered by covalent binding over non-covalent 
binding, the mechanism of action of irreversible inhibitors needs to be highlighted.
112
 A 
covalent drug first binds in a non-covalent manner, by affinity for the protein, positioning 
its electrophile moiety near the specific nucleophile to be targeted (Ki). The drug then 
undergoes nucleophilic attack creating a covalent bond between the protein and the drug 
(k2). In the case of an irreversible inhibitor, the covalent bond cannot normally be cleaved 
(k-2 = 0).
101
 The covalent binding is dependent on the kinetics of each step (Figure 29). 
The non-covalent binding (Ki) needs to be long enough to allow nucleophilic attack (k2) 
to take place. In addition, nucleophilic attack (k2) needs to be fast enough to occur while 
the drug is binding non-covalently to the protein (Ki).
101
  
 
Figure 29 – Kinetics of binding of covalent drugs101 (from J. Singh et al, 2011) 
The formation of a covalent bond is an energetically favoured process offering high 
potency and good ligand efficiency.
113
 Therefore, modulation and optimisation of 
parameters such as potency, selectivity or ADME properties are facilitated by the 
flexibility of structural modifications of irreversible inhibitors.
113
 Possible off-target 
activity of covalent drugs appears to be the main concern of medicinal chemists as it is 
generally associated with toxicity, as explained above. Non-covalent drugs are rarely 
specific to only one target and are often shown to be weak inhibitors of other targets. 
Covalent inhibitors may offer a solution to minimise the off-target effect by giving the 
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opportunity to have a rapidly cleared drug after irreversible binding to the target of 
interest.
101
 Studies have shown that the orientation of the electrophilic warhead is key for 
the reaction with a desired nucleophilic residue, allowing selectivity.
111
 The real threat is 
when a protein, other than the one targeted, offers enough affinity for the drug to bind 
non-covalently and possesses a nucleophile allowing covalent binding.
101
 Drug resistance 
can be limited with irreversible inhibitors as mentioned previously, and covalent binding 
offers a dual inhibition mechanism allowing drug resistance to be overcome. Mutations of 
the binding site, which dramatically affect the binding of a non-covalent drug, only affect 
the rate of the binding of the covalent drug.
101
 Mutations of the nucleophile of interest 
may prevent covalent binding, but the inhibitor can still bind in a non-covalent manner.
101
 
Even after such mutations, irreversible inhibitors often still retain activity compared with 
ATP-competitive inhibitors.
114
  
As the covalent drug mechanism is becoming better understood and thanks to their 
progress through clinical trials, then safety and efficacy information should encourage the 
development of this class of drugs.
101
 From the mechanism of action, selectivity is a key 
parameter to limit off-target activity and, as a consequence, toxicity. Targeting a unique 
or poorly conserved nucleophile among the kinome is crucial for selectivity.
101
 To date, 
only lysine and cysteine have been reported to react with kinase inhibitors thus creating a 
covalent bond,
97
 and there is no report yet about nucleophilic attack from a serine or 
threonine residue on a kinase inhibitor. Targeting a lysine residue conserved among the 
kinome, such as the one located in the phosphate transfer region, would not be a good 
strategy for selectivity. The ideal lysine residue to target would be one located around the 
ATP pocket but uniquely positioned among the kinome. Reactions with lysine depend on 
a small equilibrium concentration of the free amino form as lysine residues are found 
largely in the protonated form (pKa ~ 11). 5’-Fluorosulfonylbenzoyl adenosine (FSBA, 
10) is a compound used as an affinity label for kinases, and binds covalently to Lys56 of 
the non-phosphorylated and active form of p38ɣ.97  
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Cysteines are the most commonly targeted residues by covalent inhibitors. The thiol of 
cysteine has a pKa of 8.5 but this value can decrease by up to 5 log units in a polar and 
positively charged environment.
97
 Cysteine residues have been classified into four groups 
according to their positions in the kinase, plus another category corresponding to 
cysteines in the activation loop (Figure 30). 
 
Figure 30 - Location of the cysteine residues in kinases
97
 (from T. Barf and A. Kaptein, 2012) – 
The cysteine residues are classified into 5 groups depending on their location in the kinase. The 
gatekeeper residue and the activation loop are represented. The PDB entry is 1SM2. 
One example of an inhibitor targeting cysteines positioned in the P-loop (Group 1) was 
reported. FIN-1 (11), a pan-inhibitor of FGFR 1, 2, 3 and 4, covalently binds to Cys486 
by a Michael addition on its acrylamide moiety.
97, 115
 Cysteines situated on the ‘roof’ of 
the ATP-binding site represent Group 2. Fluoromethylketone (FMK, 12) is a small 
molecule covalent inhibitor of RSK1 and 2, binding by attack of Cys463 on its acyl 
fluoride motif.
116
 Only nine other kinases have a cysteine located in subgroup 2B, 
offering an opportunity for selectivity. Among them are Nek2, Plk1-3, MSK1 and 2, 
MEKK1 and RSK3 and 4.
97
 With the cysteines of Group 3 located in the hinge region 
and at the front of the ATP pocket, those belonging to subgroup 3F are of interest.
97
 They 
are highly nucleophilic (low pKa) compared with the other cysteines because of their 
position at the end of the αC helix. Only ten kinases are in this subgroup, offering also the 
possibility for selectivity.
97
 PD168393 (13) is an inhibitor of EGFR (IC50 = 2 nM) and 
Her2 (IC50 = 114 nM). This compound was shown to bind covalently by reaction of 
Cys797 situated in the hinge region of EGFR on its acrylamide group.
117
 Further 
development of this compound led to the synthesis of dacomitinib (14), currently in 
clinical trials for patients with advanced NSCLC.
118
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One particular cysteine residue, adjacent to the DFG-motif, is common to almost 10% of 
all kinases and forms Group 4.
97
 A quinone derivative (15) was shown to bind covalently 
to Cys1045 of VEGFR-2 and exhibited a good selectivity profile despite the presence of 
the residue in other kinases.
119
 The last group of cysteine residues (Group 5) is located 
outside of the ATP pocket within the activation loop. However, predictions as to the 
exact position of these cysteines are difficult because of the flexibility of the activation 
loop.
97
 Frenoline B (16) is another quinonoid irreversible inhibitor of Akt-1 that binds to 
both Cys296 and Cys310 in the activation loop.
120
 Recently, targeting a cysteine residue 
positioned outside the kinase domain has been achieved with the CDK7 inhibitor THZ1 
(17).
121
 This compound binds to CDK7 in a unique manner, combining interactions with 
the ATP-site and allosteric covalent binding to Cys312, found to be unique to CDK7 
within the CDK family. 
Each irreversible inhibitor possesses an electrophilic warhead allowing attack of a 
cysteine or lysine to form a covalent bond. Several motifs are found in these inhibitors 
such as Michael acceptors, epoxides or acetylenes (Figure 31).  
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Figure 31 - Examples of electrophilic warheads
81
 (from I. Shchemelinin et al, 2006) 
Even though the kinome is composed of more than 500 kinases, only 20 of them have 
been targeted by irreversible inhibitors, predominantly directed at cysteine residues.
81
 
Until recently, only one example of an irreversible inhibitor of Nek2 has been reported 
(see Chapter 2, section 2.2.2.), but none for CDK2.  
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Chapter 2. Inhibiting the Cell Cycle Kinases, CDK2 and Nek2, in 
Cancer Therapy 
2.1 Purines in drug discovery 
Purine is the trivial name given to imidazo[4,5-d]pyrimidine in 1884 by Emil Fischer, 
who synthesised the molecule for the first time. He won the Nobel Price in 1902 for his 
research on sugars and purines. As shown in Figure 32, chemistry around the purine 
scaffold has been widely studied for the last 100 years, leading to the discovery of many 
drugs targeting numerous diseases.
122
 
 
Figure 32 - Purines in drug discovery
122
 (from M. Legraverend and D. S. Grierson, 2006) 
Among promising drugs are 6-thio-N
9
-substituted purines and agelasine (18) isolated 
from marine sponges of the Agelas sp. One of the components of the bone matrix is the 
Type I collagen whose degradation is catalysed by cathepsin K, a cysteine protease. This 
degradation is responsible for bone and cartilage breakdown. Targeting and inhibiting 
cathepsin K represents a promising strategy to treat osteoporosis. Novartis identified the 
interesting purine 19 via high-throughput screening, with the compound showing good 
inhibitory activity against cathepsin K (IC50 = 7 nM). Abnormal expression of 
corticotropin-releasing factor (CRF), a natural human response to stress, has been found 
in several neuropsychiatric diseases such as Parkinson’s disease, Alzheimer’s disease and 
depression. 2,6,9-Trisubstituted purines (e.g. 20) have been identified as CRF1 
antagonists and could thus be effective anxiolytic and antidepressant drugs. Another 
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example is the inhibition of the chaperone protein Hsp-90, a common target for all cancer 
types. For this reason, research has been focused on developing Hsp-90 inhibitors. An 
extensive SAR study on 2,8,9-trisubstituted-6-aminopurines led to the identification of 
compound 21.
122
 
 
Designing potential drugs around the purine scaffold appears to be difficult, as according 
to the substituent pattern such compounds can target a variety of receptors and have 
completely different effects, as shown by the examples cited above. Selectivity towards 
one target over others requires studying carefully the unique features and differences of 
the targets. As shown in Figure 33, purvalanol B (22) and AP23137 (23) possess the 
same hydrogen bond interactions due to their purine scaffold, but thanks to their 
substituents they are highly selective to their kinase targets, CDK2 and Scr (proto-
oncogene tyrosine-protein kinase), respectively. The isopropyl group on the 8-position of 
purvalanol B (22) interacts perfectly with a small hydrophobic pocket of CDK2. In 
contrast the 8-substituent on AP23137 (23) fits into a larger hydrophobic pocket of Scr 
and reaches two amino acids forming additional hydrogen bonds, which is not possible in 
the small hydrophobic site of CDK2.
122
 
 
Figure 33 - Importance of substituents for selectivity
122
 (from M. Legraverend and D. S. Grierson, 
2006). Variations of substituents on the purine scaffold modify the binding mode of the inhibitors, 
creating the opportunity for selectivity. 
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2.2 Nek2: a valid target in cancer research 
2.2.1 Nek2 and cancer 
As described previously, defects in the Nek2 pathway lead commonly to aneuploidy and 
chromosomal instability, key features in tumourigenesis. Nek2 has been shown to be 
abnormally expressed (2- to 5-fold higher than in normal cells) in several human cancers 
especially breast, cervical and prostate cancer, and in lymphomas.
123
 Overexpression of 
Nek2 can be explained by different mechanisms. One explanation would be the presence, 
more often, of the Nek2 locus 1q32.1 resulting in gene amplification.
124
 Another 
possibility would be sequestration of p107/p130, proteins of Rb, by E7 protein from 
human papillomavirus (HPV).
124
 Nek2 expression is regulated by the E2F4 transcription 
factor via p107/p130. By sequestering p107/p130, E7 protein allows the expression of 
Nek2.
124
 Finally, any defects in Nek2 degradation or ubiquitylation by APC/C
Cdc20/Cdh1
 
would also lead to an overexpression of Nek2.
124
 
To improve therapies available for patients, a specific molecular target, essential for the 
development of a particular tumour, should be identified. A research group in Japan 
studied the expression of Nek2 in several tumour types such as breast, cervical and 
colorectal cancer.
123, 125
 Colorectal cancer represents the second most common cancer 
type in Japan with poor outcomes for late stage diseases.
125
 Breast cancer is one of the 
most common cancers in Asia as well as worldwide.
123
 Two main types of breast cancer 
arise: receptor positive to estrogen, progesterone and ErbB2 (ER-positive) and receptor 
negative (ER-negative).
123
 The latter shows resistance to existing therapies, and there is a 
need for an effective drug.
123
 Finally, cholangiocarcinoma, the most common form of 
liver cancer in Southeast Asia, shows poor prognosis for patients.
126
 In these three types 
of cancer, Nek2 was shown to be overexpressed. 
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HUCCT1, TFK1, HuH28 and CCKS1 are cholangiocarcinoma cell lines.
126
 Nek2 was 
found to be overexpressed in these four tumour cell lines by comparison with the normal 
fibroblast cell line HFF, representing the control (Figure 34).
126
 Nek2 expression was 
also demonstrated to be high in both ER-positive and ER-negative breast cancer cell lines 
compared to HFF cells (Figure 34).
123
 Finally, Nek2 was elevated in HCT-15, DLD-1, 
Colo320 and Colo205, four colorectal tumour cell lines (Figure 34).
125
  
 
Figure 34 - Nek2 expression in colorectal, cholangiocarcinoma and breast cancer cell lines
123, 125, 
126
 (from N. Tsunoda et al, 2009, K. Suzuki et al, 2010 and T. Kokuryo et al, 2007). Western blot 
analyses showing the expression of Nek2 and its splice variants, Nek2A and Nek2B, in several 
cell lines of colorectal cancer (A), cholangiocarcinoma (B) and breast cancer (C). Β-Actin and α-
tubulin are used as loading controls. 
The effect of Nek2 on tumour growth and survival was examined in either the HUCCT1,
1
 
DLD-1
2
 or MCF-7
3
 xenograft nude mouse model.
123, 125, 126
 After a period of inoculation 
(variable according to the cell line), nude mice were treated either with Nek2 siRNA or 
control siRNA. Tumour sizes in mice treated with Nek2 siRNA were clearly reduced 
compared with control siRNA or control. Suppression of Nek2 using Nek2 siRNA led to 
arrest of tumour growth and increased survival in each tumour type (Figure 35).
123, 125, 126
  
 
                                                 
1
 Cholangiocarcinoma cell line 
2
 Colorectal tumour cell line 
3
 Breast cancer cell line 
A B 
C 
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Figure 35 - Effect of Nek2 suppression on tumour growth in nude mice
123, 125, 126
 (from K. Suzuki 
et al, 2010 and T. Kokuryo et al, 2007). In HUCCT1 and DLD-1 cell lines, Nek2 suppression by 
siRNA was shown to reduce the tumour size by comparison to the control experiments (control, 
PBS and control siRNA). The visualisation of tumour regression is imaged for both cell lines. 
Following these results, DLD-1 xenograft nude mice were treated with Nek2 siRNA in 
combination with cisplatin (CDDP).
125
 Combination treatment was shown to be more 
effective on tumour proliferation than Nek2 siRNA alone or control siRNA with 
CDDP.
125
 The tumour size was also reduced significantly, using the combination 
treatment (Figure 36).
125
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Figure 36 - Effect of Nek2 siRNA in combination with CDDP on tumour growth
125
 (from K. 
Suzuki et al, 2010). Using colorectal tumour cell line (DLD-1) in nude mice, the combination of 
Nek2 suppression with treatment of cisplatin (Nek2 siRNA + CDDP) was shown to reduce the 
tumour size more efficiently than cisplatin alone (control siRNA + CDDP) and Nek2 suppression 
alone (Nek2 siRNA). Images illustrate the tumour size depending on the treatment. 
Studies using Nek2 siRNA treatment of a breast tumour cell line showed a regression in 
colony formation and invasion of surrounding tissues.
123
 Nek2 siRNA treatment of breast 
carcinoma cells reduced by 4-fold the number of cell colonies formed compared with the 
control experiment.
123
 This study was carried out on both MCF-7 (ER-positive) and 
Hs578T (ER-negative) cell lines (Figure 37). In both cell lines, Nek2 siRNA was shown 
to be efficient in reducing colony formation.
123
 This observation demonstrated the 
dependence of these cell lines on Nek2 for tumourigenic growth. Nek2 siRNA treatment 
was also demonstrated to be efficient in the reduction of invasiness in both MCF-7 and 
Hs578T cell lines (Figure 37).
123
 This assay supported the role of Nek2 in tumour 
invasion. 
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Figure 37 - Effect of Nek2 depletion on colony formation and invasiveness of breast cancer cell 
lines, MCF7 (ER-positive) and Hs578T (ER-negative)
123
 (from N. Tsunoda et al, 2009) – number 
of colonies counted for the control and each siNek2 treatments (on the left) and number of cells 
that penetrated the membrane in the assay using the modified Boyden chamber method (on the 
right).  
Others studies have been conducted to understand better the modulation of Nek2 activity. 
In the first example, HeLa cells
4
 treated with Nek2 siRNA were studied.
127
 Days after 
transfection (from one to six), centrosome separation, cell number and apoptotic cell 
number were evaluated (Figure 38). Depletion of Nek2 by Nek2 siRNA had a crucial 
impact on centrosome separation,
127
 and three days after cell transfection, suppression of 
Nek2 decreased centrosome separation by two-fold. In addition, Nek2 siRNA stopped 
cell growth with obtention of a flat growth curve. Nek2 siRNA was shown to induce cell 
growth arrest resulting in a high level of apoptotic cells.
127
 
  
                                                 
4
 Immortal cell line derived from cervical cancer 
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Figure 38 - Effect of Nek2 suppression on cell growth and centrosome separation
127
 (from L. 
Fletcher et al, 2004). Nek2 suppression using Nek2 siRNA in HeLa cells was shown to decrease 
centrosome separation (by comparison with the control experiment GL3 siRNA), stop cell growth 
(by comparison with control experiments GL2 siRNA and GL3 siRNA) and promote apoptosis 
(by comparison with the control experiment GL3 siRNA). 
Another experiment was conducted on mouse blastomeres to study Nek2-suppressed 
embryos.
128
 For fragments 1 and 2 (Figure 39), both Nek2A and Nek2B were blocked, 
resulting in no embryonic development. The same observation was made when Nek2A 
was blocked (Fragment 3, Figure 39). In fragment 4 (Figure 39), the blockade of Nek2B 
did not affect embryonic development. These results underlined the critical role of 
Nek2A in mouse early embryogenesis.
128
 
 
Figure 39 - Effect of Nek2 suppression in mouse embryonic development
128
 (from S. Sonn et al, 
2004). In experiments 1 and 2, both Nek2A and Nek2B were blocked using Nek2 dsRNA, 
causing no embryonic development. In experiment 3, only Nek2A was blocked resulting in no 
embryonic development. In experiment 4, only Nek2B was blocked which had no effect on the 
embryonic development. Control experiments were performed for comparison (un-injected and 
GFP siRNA). 
Depletion of Nek2 in mouse blastomeres had an effect on the morphology of ova.
128
 
Nek2 suppression caused abnormalities such as dumbbell-like nuclei, nuclear bridges and 
micro-nuclei (Figure 40).
128
 Incomplete chromosome segregation, lack of MTOC 
structure and abnormal spindle structures were suggested to be responsible for these 
 46 
abnormalities, which would cause a delay for the progression into M phase.
128
 Nek2 was 
shown to be critical for embryonic mitosis and chromosome segregation but was not 
proved essential for mitotic entry.
128
 
 
Figure 40 - Effect of Nek2 depletion on morphology of mouse embryos
128
 (from S. Sonn et al, 
2004) – formation of dumbbell-like nuclei (empty head arrows), nuclear bridges (arrows) and 
micro nuclei (full head arrows). 
Another experiment, studying the possible interaction between Nek2A and Mitotic Arrest 
Deficiency (MAD) enzymes, components of the spindle checkpoint, was conducted.
129
 
MAD1 was shown to interact with Nek2A, with formation of a complex by co-
precipitation.
129
 This observation combined with the localisation of Nek2A at the 
kinetochores of mitotic cells, suggested that Nek2A interactions with MAD1 occurred at 
the kinetochores.
129
 However, Nek2A was shown not to be responsible for the 
localisation of MAD1 at the kinetochores.
129
 Nek2A interaction with MAD2 was also 
studied. Depletion of Nek2 provoked premature anaphase with errors during chromosome 
segregation.
129
 Nek2A was shown to retain MAD2 at the kinetochores until the separation 
of all sister chromatids. This action allowed efficient chromosome segregation before the 
beginning of anaphase.
129
 
Nek2 was found to be involved in tumourigenesis not only by promoting chromosomal 
instability but also by activating several tumour enabling pathways, such as the Akt 
pathway, known to promote growth and survival.
130
 The phosphatase PP1 regulates the 
activation of both Nek2 and Akt by dephosphorylation. When Nek2 is overexpressed, 
PP1 is overcome by the level of activated Nek2 and cannot regulate the activation of Akt, 
the level of which becomes aberrant and leads to an up-regulation of ABC transporter 
family members, including the multi-drug resistance protein ABCC1 and the breast 
cancer resistant protein ABCG2 (Figure 41).
131
 Nek2 was found to influence the efflux 
pumps and the mitotic checkpoint protein MAD2 by up-regulation, two mechanisms 
related to drug resistance (Figure 41).
131
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Figure 41 – Consequences of Nek2 overexpression on protein levels131 (from W. Zhou et al, 
2013). Western blot experiments showing the effects of Nek2 overexpression (Nek2 OE) on 
protein levels by comparison to the control experiment with normal Nek2 expression (EV), in two 
cell lines, ARP1 (multiple myeloma cell line) and H1299 (non-small cell ling carcinoma cell line). 
Another crucial downstream effect of Nek2 overexpression is activation of the Wnt 
pathway, implicated in cancer cell survival and drug resistance. Wnt signalling depends 
mainly on the nuclear accumulation of β-catenin, stimulated by Nek2.131 Nek2 was found 
to have a multifaceted role in tumour biology by inducing cell proliferation, chromosomal 
instability and drug resistance (Figure 42).
131
 
 
Figure 42 – Central role of Nek2 in tumour biology131 (from W. Zhou et al, 2013). Interactions of 
Nek2 with binding partners have a crucial impact on chromosomal instability (CIN), cell 
proliferation and drug resistance. 
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2.2.2 Nek2 in drug discovery 
A number of Nek2 inhibitors have been investigated, but so far none have entered clinical 
trials. The crystal structure of Nek2 has been solved which provides the opportunity for 
rational inhibitor design.
130
 Nek2 possesses a characteristic ATP-binding site with the 
Phe147 at the base of the ATP pocket only being present in 39 human kinases (usually 
Leu is present at this site), and a large gate-keeper, which allows inhibitor selectivity over 
other kinases. However, selectivity over Plk1, which shares similarities with Nek2, 
appears to be more challenging. The presence of Arg136 in Plk1 does provide an 
opportunity for selectivity as this residue is not present in Nek2 (Figure 43).
130
 An SAR 
study from a hit compound (24) identified by high-throughput screening led to the 
identification of the pyrazine derivative 25 (Figure 44). In parallel, a benzimidazole 
scaffold was developed, inspired by GSK461364A (26), a Plk1 inhibitor developed by 
GlaxoSmithKline. This study resulted in compound 27, which demonstrated 100-fold 
selectivity over Plk1.
132
 
 
Figure 43 – Structure differences between Nek2 (orange) and Plk1 (blue)130 (from B. Frett et al, 
2014). Both structures show similarities in the covalent region, hinge region and the position of 
the gatekeeper residue with the exception of the selectivity region with the presence of Arg136 in 
Plk1. The PDB entries are 2XNP and 4J52. 
The most promising features of the scaffolds were combined to generate a hybrid series, 
exemplified by compound 28 (Figure 44). This inhibitor exhibits good potency, 
selectivity and growth inhibition profile, and therefore proves to be an excellent tool 
compound to investigate further the role of Nek2 in tumour biology.
130
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Figure 44 – Strategy used for the discovery of Nek2 inhibitors130 
Another study was published describing the design of an irreversible inhibitor of Nek2.
133
 
The authors started from the crystal structure of SU11652 (29), an oxindole-pyrrole 
derivative, bound to Nek2 by forming, among other interactions, key hydrogen bonds 
(Figure 45). Inhibitors were rationally designed by changing the 5-position group where 
Cys22 can be reached, and also modifying the 3’, 4’ and 5’ positions to confer more 
selectivity for Nek2. The most potent compounds were shown to interact with Cys22. To 
confirm this interaction, the most promising compounds were tested against Nek2, and a 
Nek2 mutant kinase where Cys22 was replaced by valine. A significant drop in activity 
was noticed, suggesting that these compounds act via alkylation of Cys22. After further 
modifications, propynamide compound 30 was obtained (Figure 45) and found to be 
selective over CDK1 (~30 fold), Rsk2 (5 fold) and Plk1 (>30 fold). However, compound 
30 was only evaluated against a small number of kinases. Inhibition of Nek2 by 30 did 
not abolish mitotic entry, mitotic checkpoint, bipolar spindle assembly or chromosome 
segregation, suggesting that the other mitotic kinases were still fully functional.
133
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Figure 45 - Crystal structure of SU11652 (29) in complex with Nek2 showing a triplet of H-
bonds with the hinge region and the presence of Cys22; structure of the most promising 
compound of the series, 30, shown for comparison
133
 (from J. C. Henise and J. Taunton, 2011) 
The PDB entry is 2JAV. 
Another example of covalent inhibition of Nek2 was reported in the literature. The series 
started with the non-covalent inhibitor HCI-2388 (31), which demonstrated good activity 
against Nek2 (IC50 = 34 nM). Introduction of an acrylamide moiety (HCI-2389, 32) led to 
a 2-fold increase in potency and time-dependent Nek2 inhibition (Figure 46).
134
 
Phosphorylation of PP1-α was studied and shown to decrease in both Nek2 
overexpressing Hela cells and GFP controls after treatment with 32 (Figure 46). 
134
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Figure 46 – A. Structures of HCI-2388 (31) and HCI-2389 (32), inhibitors of Nek2; B. Nek2 
activity assay in vitro; C. Level of phosphorylated PP1-α in Nek2 overexpressed Hela cells (HeLa 
+ Nek2) and GFP controls (HeLa GFP)
134
 (from J. Flory et al, 2013). 
2.2.3. Development of selective irreversible inhibitors of Nek2 
From a high-throughput screen of approximately 73,000 compounds,
135
 A number of 6-
alkoxypurines and 4-alkoxypyrimidines, available from a previous project at Newcastle 
University on CDK2 inhibitors, showed modest activity against Nek2. The O
6
-
alkylguanine class (33), active against CDK2, did not express any activity against Nek2 
unless substituted by an aryl group at the 2-position (34, 35). 
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Further analogues were synthesised, guided by the crystal structure of 35 with Nek2. A 
triplet of donor/acceptor/donor hydrogen bonds from the purine scaffold with the hinge 
region of Nek2 was highlighted (Figure 47). This observation was rationalised from the 
X-ray crystal structure of SU11652 (29) in complex with Nek2, previously reported by 
Smerdon et al.
89
  
        
Figure 47 - Analogy of interactions between SU11652 (29) and purine 35 within the ATP-
binding site of Nek2 
The first SARs carried out suggested that the 6-cyclohexylmethoxy group, essential for 
CDK2 inhibition, was not a prerequisite for activity against Nek2. Substituents on the 2-
arylamino group were tolerated and required a hydrogen bond donor/acceptor such as a 
sulfonamide (36), urea (37) or amide. 8-Substitution was tolerated, but suggested another 
binding mode. Knowing the essential features to inhibit Nek2, selectivity over CDK2 had 
to be improved. 
 
Modifications of the 6-position have been explored. Firstly, 6-unsubstituted analogues 
(38, 39) were synthesised and showed good selectivity for Nek2 over CDK2. These 
examples indicated that the ribose binding pockets of Nek2 and CDK2 were different and 
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that these differences could be used to rationally design Nek2 selective inhibitors. 
Introduction of functional groups at the 6-position was investigated. The 6-ethynylpurine 
40 showed a time-dependent inhibition profile against Nek2 suggesting that 40 was 
binding covalently to Nek2 according to the mechanism in Figure 48.  
 
 
Figure 48 - Irreversible inhibition of Nek2 by compound 40 
Compound 40 was the first of the series showing high potency against Nek2 and good 
selectivity over CDK2, other Nek members (Nek1, 3, 6, 7 and 11) and a range of kinases. 
The selectivity resulted from the Cys22 residue, commonly replaced by a valine or 
alanine in other kinases. Only seven kinases among the kinome possess this Cys22, 
namely Plk 1, 2 and 3, MSK1 and 2, and MEKK1.
79
 
Work on improving cell permeability and kinase selectivity led to the initial hit 
compound of the project (41). The 2-position was further explored as the 2-amino group 
was positioned in the specificity pocket of Nek2. This work led to the identification of the 
early lead compound 42.  
 
Compound 42 was more potent and selective than its analogue 41. 6-Ethynylpurines were 
confirmed to be covalent inhibitors as potency was observed to increase in a time-
dependent manner, one of the hallmarks of irreversible inhibitors. X-ray crystallography 
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confirmed this hypothesis, with the crystal structure of the Nek2-inhibitor complex 
showing a covalent bond between Cys22 and the 6-ethynyl group (Figure 49). 
 
Figure 49 - Crystal structure of compound 42 in complex with Nek2 showing covalent binding 
between the inhibitor and Cys22
136
 (from C. J. Matheson, 2012) 
Compound 42 was tested against a C22A mutant kinase to confirm that covalent binding 
contributed to potency. After incubation for one hour, 42 was less potent against Nek2 
C22A (IC50 = 3.5 µM) than the Nek2 wild type (IC50 = 0.046 µM).
131
 Compound 42 was 
also tested in a cellular assay in different tumour cell lines and showed reasonable 
cellular activity (GI50 = 18 µM (HCT116
5
); 32 µM (HeLa
6
); 6.6 µM (MCF7
7
); 1.6 µM 
(REC1
8
); 5.8 µM (RIVA
9
); 2.2 µM (SKBR3
10
); 3.6 µM (T47D
11
); 3.7 µM (ZR75
12
)).
131
 
As 6-ethynylpurines are irreversible inhibitors, compound 41 was also tested in a Comet 
Assay, also known as single-cell gel electrophoresis, to detect potential DNA damage. 
After the cells were treated with 41, the comet tails (yellow, green and blue, Figure 50) 
were found to be similar to the comet tail of the untreated cells (red, Figure 50), 
demonstrating that 41 did not cause any DNA damage. For the control experiment, cells 
were exposed to ionising radiation and showed a high level of DNA breaks by comparing 
the comet tail to the comet head (black, Figure 50). This assay confirmed that 41 was not 
a DNA alkylating agent. 
                                                 
5
 Colon cancer cell line 
6
 Immortal cell line derived from cervical cancer 
7
 Breast cancer cell line 
8
 β cell non-Hodgkin’s lymphoma 
9
 Diffuse large β cell lymphoma 
10
 Breast adenocarcinoma cell 
11
 Ductal breast epithelial cell 
12
 Breast carcinoma cell 
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Figure 50 – Investigation of compound 41 in a Comet Assay to assess DNA damage131 (from C. J. 
Matheson, 2012). Cells were treated with compound 41 at two concentrations. No DNA damage 
was observed after 24 h at 1 μM (yellow) and at 10 μM (green), or after 96 h at 1 μM (blue). The 
results obtained for the cells treated with 41 were comparable to the results observed with the 
untreated cells (red). As control experiments, cells expressed DNA damage after exposition to 
ionising irradiation (IR, black). 
Compound 42 was shown to inhibit Nek2 in the enzymatic assay but studying the effect 
of Nek2 inhibition by 42 on downsteam substrates was also important. Therefore, U2OS 
cells
13
 were treated with 42 at different concentrations and phosphorylation of C-Nap-1, a 
downstream substrate of Nek2, was measured. As predicted, C-Nap1 phosphorylation 
was shown to decrease with an increase of concentration of 42 (Figure 51).  
 
Figure 51 – Investigation of compound 42 on downstream substrates with the phospho C-Nap1 
cell assay
131 
(from C. J. Matheson, 2012). Phosphorylation of C-Nap1, a downstream substrate of 
Nek2 was shown inhibited by compound 42 at different concentrations (1, 5 and 10 μM). 
A second SAR study was conducted around the lead compound 42 (Figure 52). The 
ethynyl group at the 6-position was replaced by an enamine moiety to give a competitive 
inhibitor, less potent than the corresponding ethynyl compound.
131
 Substitution on the 
ethynyl group by a methyl or phenyl function reduced activity considerably, whilst a 
                                                 
13
 Osteosarcoma cell line 
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vinyl group abolished activity.
131
 Modification of the imidazole ring of the purine 
scaffold was investigated by its replacement with a pyrrole and N
7
-methylpyrazole, both 
changes leading to inactive compounds. However, pyrazole in place of imidazole showed 
poor activity by contrast to triazole which retained activity.
137
 Concerning the pyrimidine 
ring, N-1 appeared to be essential for activity as its removal abolished potency.
132
 
Changing substituents on the 2-arylamino group was tolerated.
131
 Several analogues were 
synthesised showing activity against Nek2, with the carboxamide moiety of 42 being the 
best group. All compounds prepared in this project were assessed in both enzymatic and 
cellular assays. Surprisingly, enzymatic (IC50) and cellular (GI50) results were poorly 
correlated, suggesting a possible off-target effect of these inhbitors. 
 
Figure 52 – SAR study in the Nek2 project based on results obtained from inhibitors 41 (green) 
and 42 (purple) 
2.3. CDK2 as a potential drug target 
2.3.1. CDK2 and cancer 
CDK2 has been shown to be overexpressed in a number of tumours. Deregulation of 
cyclin E, one partner of CDK2, is often observed in cancer.
138
 One disorder is the 
generation of a low-molecular-weight (LMW) isoform of cyclin E, a shorter version of 
the full-length cyclin E. LMW cyclin E is associated with an increase of mammary 
tumours and increased metastasis.
138
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Figure 53 - Effects of CDK2 suppression on breast tumour formation in nude mice
138
 (from S. 
Alki et al, 2011). A. CDK2 suppression was studied with a p53+/+ background. Partial 
suppression (CDK2 +/-) was shown to delay slightly the tumour formation by comparison to the 
control experiment when CDK2 is fully expressed (CDK2 +/+). Complete suppression (CDK2 -/-) 
was shown to prevent tumour formation. B. CDK2 suppression was studied with a p53-/- 
background. Partial suppression (CDK2 +/-) had no effect on tumour formation by comparison to 
the control experiment (CDK2 +/+). Complete suppression (CDK2 -/-) was shown to prevent 
tumour formation. 
CDK2 binds to LMW cyclin E causing an augmentation of its activity. LMW cyclin E is 
critical in tumourigenesis, especially as cells expressing LMW-cyclin E appear to be 
resistant to existing therapies such as anti-oestrogens and aromatase inhibitors.
138
 Studies 
showed that suppressing CDK2 in mice with either p53+/+ or p53+/- background 
prevents the formation of breast tumours induced by LMW cyclin E (Figure 53). This 
suggests the critical role, not only of LMW cyclin E, but of the complex CDK2/LMW 
cyclin E.
138
 As a consequence, CDK2 was inhibited by meriolin (43) and roscovitine (44), 
two known non-selective CDK2 inhibitors. LMW cyclin E p53+/- double transgenic mice 
were treated twice daily for seven days. Tumour development was delayed, probably due 
to a decrease in proliferation and apoptosis (Figure 54).
138
 Therefore, specific CDK2 
inhibitors could be one possible efficient therapy for LMW cyclin E induced tumours. 
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Figure 54 - Effects of CDK2 inhibitors (43 and 44) on tumour development in p53+/- double 
transgenic mice
138
 (from S. Alki et al, 2011). Treatment with meriolin (A) and (R)-roscovitine (B) 
was shown to delay the tumour formation by comparison to the control experiment (Vehicle), 
thus, improving survival. 
The critical role of the cyclin E/Cdk2 complex was also shown in amplified 19q12 
incorporating cyclin E1 (CCNE1) cell lines. CCNE1 genomic amplification was observed 
in high-grade serous ovarian cancer (HGSC), the most common type of epithelial ovarian 
cancer, which is often associated with poor overall survival, and where primary treatment 
often fails.
139
 CDK2 knockdown (Figure 55 - A) or inhibition by a small molecule CDK 
inhibitor (dinaciclib (45), Figure 55 - B) was shown to have a dramatic effect on the 
formation of colonies in cell lines with amplified CCNE1 compared with normal cell 
lines.
139
 These experiments validated the therapeutic role of CDK2 inhibitors in HGSC 
with amplified CCNE1. 
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Figure 55 – Effects of CDK2 knockdown (A) or inhibition by dinaciclib (44) (B) on colony 
formation in different cell lines (SK-OV-3 (CCNE1 unamplified), OVCAR-4 (CCNE1 gained), 
OVCAR-3 (CCNE1 amplified))
139
 (from D. Etemadmoghadam et al, 2013). A. CDK2 
knockdown was shown to decrease colony formation in cells with amplified cyclin E1. CCNE1 
knockdown also affected the colony formation in OVCAR-4 and OVCAR-3 cell lines, in the 
same range as CDK2 knockdown. The control experiment was conducted with normal expression 
of CDK2 and CCNE1 (NS). B. CDK2 inhibition by dinaciclib was shown to reduce colony 
formation in OVCAR-4 and OVCAR-3 cell lines. 
Anti-oestrogen resistance is highly dependent on CDK activity, and so CDK inhibition 
would be a strategy to address this resistance.
140
 The role of CDK1 and CDK2 in both 
anti-oestrogen resistant (LCC9) and sensitive (MCF7) cell lines was investigated. CDK2 
knockdown caused a G1 accumulation of cells in both cell lines. CDK1 knockdown 
provoked a G2/M accumulation in all cell lines. Combined CDK1/CDK2 silencing had 
the most important impact, with a high G2/M accumulation of cells and diminution of 
colony formation with partial apoptosis (Figure 56).
140
 A high reduction of colony 
formation was noticed when CDK1 was knocked down, compared to CDK2.
140
 This 
observation might be related to the ability of CDK1 to replace CDK2 in its absence, a 
property that CDK2 does not possess. From these results, two dual inhibitors of CDK1 
and 2, NU2058 and NU6102, were tested. These two drugs induced cell cycle arrest and 
apoptosis.
140
 
CDK2 activity was shown to be crucial not only in breast cancer but also in colorectal 
carcinoma.
141
 Normal and tumour tissues from patients suffering from primary colorectal 
cancer were investigated. CDK2 and 1 activity were found to be higher in 8/8 cancer 
tissues and 7/8 patients in healthy tissues.
141
 In cancer tissues, CDK2 expression was 
found to be 40-fold higher than in adjacent tissues. These data indicated a possible role of 
CDK2 in colorectal carcinoma.
141
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Figure 56 - Effects of CDK1/2 knockdown on colony formation in different cell lines
140
 (from N. 
Johnson et al, 2009). CDK1 knockdown alone (black) was shown to prevent colony formation in 
all cell lines more efficiently than CDK2 knockdown alone (white). Dual CDK1 and CDK2 
knockdown (grey) considerably reduced colony formation.
14
 
2.3.2 CDK2, a viable cancer therapeutic target? 
CDK2 activity has been studied closely in several tumour cell lines. To understand its 
role, CDK2 expression was suppressed (Figure 57).
142
 CDK2 was first inhibited by 
p27
KIP1
, released from CDK4 in UO126 cell lines. CDK2 was also inhibited by 
sequestration of cyclin E using ectopic dominant-negative (DN) CDK2. Eventually, 
CDK2 was suppressed through antisense oligonucleotides.
142
 Inhibition of CDK2 by 
these methods did not cause growth arrest in colon cancer cells.
142
 CDK2 activity was 
found to be dispensable for G1/S transition in colon carcinoma and no cell accumulation 
was noticed in G0/G1.
142
 From these observations, CDK2 did not appear to be essential 
in cell cycle progression. 
 
                                                 
14
 MCF7 (breast cancer cell line), MMU2 and LCC9 (resistant MCF7 cell line), T47D (ductal breast 
epithelial cell), MDA-MB-231 (breast adenocarcinoma cell line) and HCC1937 (breast carcinoma cell line). 
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Figure 57 - CDK2 does not block cancer cell proliferation
142
 (from O. Tetsu and F. McCormick, 
2003). CDK2 expression was suppressed through antisense oligonucleotides in four different 
colon cancer cell lines. No change in the cell cycle distribution was observed when CDK2 
expression was suppressed (-) by comparison to a normal CDK2 activity (+). 
CDK2 inhibition was also studied using small molecules in direct comparison with 
CDK2 knockdown. CDK2 was genetically modified to form a CDK2 analogue-sensitive 
(AS) version selectively inhibited by 1-NM-PP1 (46). Inhibition of CDK2
AS
 by 46 
showed a decrease in MCF proliferation (Figure 58 - A), whereas CDK2 knockdown by 
siRNA resulted in an increase of proliferation (Figure 58 - B).
143
 
   
Figure 58 - Cell proliferation profile after small molecule (46) inhibition (A) or genetic loss 
(B)
143
 (from D. Horiuchi et al, 2012). A. CDK2 inhibtion using 46 had no effect on cell 
proliferation in the wild-type cells (WT-PP1 versus WT-DMSO) but was shown to decrease 
considerably cell proliferation in the CDK2
AS
 cells (AS-PP1 versus AS-DMSO). B. CDK2 
knockdown (CDK2 siRNA) was shown to promote cell proliferation by comparison to the control 
experiment (Cont. siRNA). 
With genetic loss, cyclin E binds to CDK1 as its CDK2 partner is absent. However, when 
CDK2 is inhibited, cyclin E does not switch partner and as a result does not bind to 
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CDK1.
143
 Observations on MCF proliferation were also applicable to the HCT116
15
 cell 
line where proliferation decreased when inhibition was carried out using the small 
molecule 1NM-PP1 (46).
143
 CDK2 was also shown to be required for 3D-anchorage 
independent growth of cells overexpressing oncogenes (MYC, Ras or v-ABL) on soft 
agar (Figure 59).
143
 These results emphasise the difference between genetic loss and 
inhibition by a small molecule inhibitor.  
 
Figure 59 - Effect of small molecule inhibition on colony formation on soft agar
143
 (from D. 
Horiuchi et al, 2012). CDK2 inhibition by small molecule (PP1) was shown to reduce colony 
formation in CDK2
AS
 cells (CDK2
AS
+PP1) overexpressing different oncogenes (MYC, Ras, v-
ABL) by comparison to the control experiment (CDK2
AS
+DMSO). In the wild-type cells, CDK2 
inhibition by small molecule (CDK2
WT
+PP1) had no effect on colony formation by comparison to 
the control experiment (CDK2
WT
+DMSO). 
Other studies, conducted on CDK2-/- mice, confirmed the non-central role of CDK2.
144
 
CDK2 knockdown in mice induced prenatal lethality but survivors did not suffer from 
any malformations, although they were smaller than the CDK2+/+ mice. The expression 
of the other crucial cell cycle regulators was monitored with no observation of any 
change in expression of CDK4, 6 and 1 or of cyclin E1 and A2.
144
 In addition, the 
expression of p27
T187
 was similar in both CDK2+/+ and CDK2-/- mice suggesting 
phosphorylation by other kinases.
144
 However, loss of CDK2 in mouse embryonic 
fibroblasts (MEFs) revealed a delay in S-phase entry. CDK2 seems to be important in 
timing for entry into S-phase (Figure 60) but is replaceable by other kinases, such as 
CDK4, for p27 phosphorylation, for example.
144
 
                                                 
15
 Colon cancer cell line 
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Figure 60 - CDK2 influence on S-phase entry
144
 (from C. Berthet et al, 2003). A delay in S-phase 
was observed in mouse embryonic fibroblasts (MEFs) when CDK2 was knocked down(CDK2-/-, 
black) by comparison to normal CDK2 expression (CDK2+/+, grey). 
CDK4 was suggested as a substitute for CDK2 for the phosphorylation of p27. As such, 
CDK4-/-, CDK2-/- mice were studied.
145
 These mice were normal at birth but died after 
24 h due to heart tissue problems. Expression of cell cycle regulators was monitored in 
these mice, revealing no change in activity compared with normal mice (Figure 61 - 
A).
145
 An augmentation of CDK6/cyclin D2 and CDK1/cyclin E1 was observed (Figure 
61 - B) and pRb was still present (Figure 61 - C), suggesting phosphorylation by another 
CDK/cyclin complex.
145
 
 
Figure 61 - Expression of cell cycle regulators in both CDK4-/-, CDK2-/- and CDK4 +/+, 
CDK2+/+ mice
145
 (from C. Barriere et al, 2007). Western blot analyses show the level of 
expression of cell cycle regulators in CDK4+/+, CDK2+/+ and in CDK4-/-, CDK2-/- mice. β-
actin is used as a loading control. 
In higher eukaryotes, several CDKs are expressed, by comparison with unicellular 
organisms possessing a single CDK, for a more precise control of cell cycle events.
146
 
The loss of one or several CDKs seems to be compensated by other CDKs. The 
expression of cell cycle regulators in CDK4-/-, CDK2-/-, CDK6-/- mice was studied and 
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found to be unchanged.
146
 Rb was still phosphorylated at sites thought to be CDK2 
specific. When CDK1, cyclin A2 and cyclin B1 were lacking, problems of cell division 
appeared.
146
 CDK1 was shown to interact with all the cyclins involved in the cell cycle in 
the absence of interphase CDKs. The cell cycle can be represented as shown in Figure 62, 
with CDK1 as the master of the cell cycle interacting with different cyclins.
146
 
 
Figure 62 - CDK1 as the only essential CDK for the cell cycle
146
 (from D. Santamaria et al, 
2007). 
These observations have to be interpreted carefully as genetic background was revealed 
to be extremely important.
147
 CDK2 was found to be overexpressed in MYCN-amplified 
neuroblastoma, leading to poor prognosis.
147
 Suppression of CDK2 by shRNA caused 
apoptosis. On the contrary, silencing CDK2 in MYCN single copy neuroblastoma cell 
lines resulted in an increase or no visible change in fibroblast growth (Figure 63).
147
 
These results differed from previously reported observations suggesting the relation 
between genetic background and efficiency of silencing CDK2 in cancer therapy. 
  
 65 
 
Figure 63 - Effect of CDK2 silencing on the IMR32 (neuroblastoma) cell line with MYCN 
amplification
147
 (from J. J. Molenaar et al, 2009). Overexpression of CDK2 (CDK2 on) was 
observed in MYCN-amplified neuroblastoma (MYCN on) by comparison to MYCN single copy 
neuroblastoma (MYCN off). Suppression of CDK2 (CDK2 off) using CDK2 shRNA in MYCN-
amplified neuroblastoma (MYCN on) caused apoptosis. Suppression of CDK2 (CDK2 off) using 
CDK2 shRNA in MYCN single copy neuroblastoma (MYCN off) had no effect on cell growth. 
CDK2 appears to be a controversial target with results questioning its importance in 
cancer therapy but recent results are re-positioning CDK2 as a crucial regulator of the cell 
cycle. Combination therapy would represent an effective and viable strategy. Inhibition 
studies have been conducted on CDK1/2 and PI3K, a lipid kinase.
148
 The results showed 
apoptosis when inhibition of the three kinases was combined. This observation was 
confirmed by R-roscovitine (44), a dual CDK1 and 2 inhibitor, combined with PIK-90, a 
PI3K inhibitor, on nude mice implanted with GBM43 cells.
148
 The combined therapy 
showed promising results after 12 days of treatment, with significant tumour regression 
observed compared to monotherapies (Figure 64). Dual PI3K and CDK1/2 inhibition 
seems to induce synthetic lethality in PTEN
WT
 glioma xenografts in vivo.
148
 These 
observations supported the therapeutic viability of CDK2 inhibition alone or in 
combination. 
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Figure 64 - Effects of roscovitine and PIK-90 on tumour size in PTEN
WT
 glioma xenografts
148
 
(from C. K. Cheng et al, 2012). Inhibition of PI3K with PIK-90 (brown) or inhibition of CDK1/2 
with roscovitine (red) had similar effects on the tumour size, with a delay in tumour formation by 
comparison to the control experiment (blue). Dual inhibition of PI3K and CDK1/2 (green) 
induced synthetic lethality. 
2.3.3. CDK2 inhibitors 
 Purine-based inhibitors 
6-Dimethylaminopurine (47) was the first CDK inhibitor reported in the literature.
149
 Its 
activity was first noticed in sea urchin oocytes where mitosis, but not protein biosynthesis, 
was blocked. Inhibition of CDK1 (IC50 = 120 µM) was shown to be responsible for this 
activity.
149
 Further purine derivatives were examined, leading to more potent compounds 
such as isopentenyladenine (48) and olomoucine (49), moderately potent against CDK1 
(IC50 = 7 µM), CDK2 (IC50 = 7 µM) and CDK5 (IC50 = 3 µM) but selective over a 
number of other kinases.
150
 From the discovery of olomoucine, efforts were made in the 
synthesis of 2,6,9-trisubstituted purines leading to R-roscovitine (44), a structural 
analogue of 49.
149
 This compound, acting as a suppressor of gene transcription, was 
shown to be 10-fold more potent than 49 (IC50 (CDK1) = 0.45 µM, IC50 (CDK2) = 0.70 
µM, IC50 (CDK5) = 0.16 µM)
149
 and was found to inhibit proliferation of colon, NSCL, 
breast and prostate human cancer xenografts.
151
 R-Roscovitine (44) underwent clinical 
investigation where its efficiency as single agent was demonstrated in several tumour 
types.
44
 The compound was investigated in phase II clinical trials in leukaemias as 
monotherapy, and in NSCL and metastatic breast cancer in combinatorial trials.
44
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Further analogues of 44 were synthesised such as purvalanol A (50) and B (22). 
Purvalanol A (50) was shown to be selective for CDK2, 4 and 5.
150
 Studies on the 
mechanism of action of 50 revealed inhibition of CDK partners (e.g. protein Rb, cyclin A 
and cyclin E).
152
 This molecule appeared to cause reversible G2 arrest, characteristic of 
CDK2 inhibition in living cells, without affecting S-phase. Cell death and inhibition of 
cell proliferation were also noticed on proliferating cells treated with 50.
152
 Purvalanol B 
(22) was shown to act in a similar manner but appeared to be more potent against 
CDK2/cyclin A complex (IC50 (22) = 6 nM versus IC50 (50) = 70 nM).
149
  
 
R-Roscovitine (44), purvalanol A (50) and purvalanol B (22) are structural analogues and 
were shown to share the same binding mode to CDK2. Contrary to ATP, which binds to 
CDK2 via one H-bond each to Glu81 and Leu83, these compounds interact primarily 
with Leu83. The N-7 of the purine scaffold acts as a H-bond acceptor, instead of N-1 with 
ATP, for NH of Leu83 (red in Figure 65), while NH at the 6-position plays the role of the 
H-bond donor with the carbonyl of Leu83 (blue in Figure 65). 
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Figure 65 - Binding mode of purvalanol B (22) with CDK2 showing interactions with key 
residues
149
 (from A. Huwe et al, 2003). 
Another purine, NU2058 (51), was shown to be moderately potent against CDK2 (IC50 = 
12 µM) and CDK1 (IC50 = 5 µM).
153
 Interestingly, this compound demonstrated a 
different binding mode from ATP or the 2,6,9-trisubstituted purines (see Chapter 2, 
section 2.3.4.).  
 Other classes of inhibitors 
Flavopiridol (52) is a semisynthetic flavonoid, isolated from the leaves and stems of 
Amora rohituka, an Indian plant (Figure 66).
151
 This drug was initially developed as an 
EGFR inhibitor, but was later shown to bind to CDK2, 7 and 9.
154
 Flavopiridol was found 
to induce apoptotic cell death by activating the MAPK pathway, as well as inhibiting the 
production of anti-apoptotic molecules such as p21, bcl-2 or cyclin D1, and transcription, 
as a result of CDK9 inhibition.
44
 Indeed, CDK9 plays an important role in the initiation 
and elongation of mRNA, essential in protein synthesis.
155
 Compound 52 was shown to 
induce cell cycle arrest and apoptosis in squamous head and neck cell lines
44
 and to have 
a growth inhibition effect on breast and lung cancer cell lines and prostate and head and 
neck tumour xenografts.
150
 Even though the effects of this drug were significant, results 
of clinical trials using flavopiridol as a single agent on solid tumours were disappointing 
because of a poor response.
156-158
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Figure 66 - Structure of flavopiridol (52) and effects on the cell cycle
44
 (from G. K. Schwartz and 
M. A. Shah, 2005). Flavoripidol inhibits cdc2 (CDK1) in complex with cyclin A or with cyclin B. 
Flavoripidol also inhibits CDK2/cyclin E as well as CDK4 and 6. 
AT7519 (53), developed by Astex, is a multi-CDK inhibitor active against CDK5 and 9, 
but with a preference for CDK2.
40
 This compound showed antiproliferative activity in 
different human tumour cell lines and evoked tumour regression in colon cancer 
xenograft models.
40
 Compound 53 has been investigated in phase I clinical trials.
40
 
NU6027 (54), a pyrimidine analogue of the CDK2 purine inhibitor NU2058 (51), was 
shown to bind to CDK2.
149
 This compound is an ATP-competitive inhibitor which 
inhibits both CDK1 and CDK2 (IC50 (CDK1) = 2.5 µM, IC50 (CDK2) = 1.3 µM).
153
 
Compound 54 was found to be more potent in cellular tests (10 µM) than its purine 
analogue 51.
153
 NU6027 (54) binds in a similar manner to NU2058 (51) with a triplet of 
H-bonds (Figure 67).
149
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Figure 67 - Binding mode of 54 in the ATP pocket of CDK2 showing key H-bond interactions 
with the hinge region
149
 (from A. Huwe et al, 2003). 
BMS-387032 (55) (or SNS-032) is an aminothiazole analogue that selectively inhibits 
CDK2, 7 and 9.
44
 This drug was shown to induce cell cycle arrest and apoptosis in 
several tumour cell lines such as ovarian carcinoma.
44
 The in vivo activity was confirmed 
in animal models including ovarian and colon cancer.
154
 This compound is currently 
being investigated in phase I clinical trials, in several refractory solid tumours and B-
lymphoid malignancies.
154
  
Another class of CDK inhibitor is based on the imidazopyridine pharmacophore. An 
example of this type is AZ703 (56), a selective inhibitor of CDK1/cyclin B (IC50 = 6 nM), 
CDK2/cyclin E (IC50 = 4 nM) and CDK2/ cyclin A (IC50 = 3 nM).
159
 Compound 56 was 
shown to induce G1/S and G2/M phase arrest, and had an antiproliferative effect on 
several tumour cell lines in vitro such as breast, lung and colorectal cancer.
159
 Inhibition 
of phosphorylation of p27 on Thr187 and pRb on Thr821 was observed after exposure to 
56.
159
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Oxindoles were also investigated and several were shown to be 10-fold more potent for 
CDK2 over CDK1.
160
 These compounds inhibit tumour cell proliferation with an 8-fold 
selectivity for tumour cells over normal cells and block cell progression into S-phase.
160
 
An example of this series is indirubin-5-sulfate (57), which interacts with Glu81 and 
Leu83 residues of CDK2, in a similar manner to ATP (Figure 68).
149
 
 
Figure 68 - Binding mode of indirubin-5-sulfate (57) with CDK2 highlighting interactions with 
key residues, mainly from the hinge region
149
 (from A. Huwe et al, 2003). 
By comparison with first generation CDK inhibitors, discontinued in clinical trials due to 
selectivity problems, dinaciclib (45) was shown to be strongly selective for the CDK 
family, exhibiting activity against CDK2, 5, 1 and 9 (IC50 = 1, 1, 3 and 4 nM, 
respectively).
161
 After treatment of several human tumour cell lines with 45, cell cycle 
arrest was observed, demonstrating antiproliferative activity regardless of the tumour type 
or genetic background.
161
 Dinaciclib (45), developed by Merck, has progressed to phase 
III clinical trials for refractory chronic leukemia.
162
 The crystal structure of 45 with 
CDK2 revealed binding within the ATP-binding pocket, and interesting interactions such 
as the hydrogen bond between Lys89 and the N-oxide moiety (Chapter 9, section 9.2.).
162
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2.3.4 Covalent CDK2 inhibitors 
Abnormalities in genes encoding proteins involved in CDK pathways such as p16, cyclin 
D (direct interaction), p53 (indirect interaction) or pRb (substrate), have often been 
observed in human tumours.
153
 These results underline the need for the identification of 
CDK inhibitors more specific to one particular CDK, but still retaining cellular 
potency.
153
 This area might be wide as tumour cells express different sensitivity towards 
CDK inhibitors according to the tumour type studied.
40
 First and second generation CDK 
inhibitors were invariably ATP-competitive with poor selectivity. The third generation of 
CDK inhibitors
163
 would ideally target the cell cycle in a reversible manner for normal 
cells but would have a lethal effect on tumour cells.
159
 Design is a key feature in the 
synthesis of selective inhibitors, where the crystal structure of the enzyme is essential for 
guidance. Several X-ray structures of inhibitors in complex with CDK2 have been solved, 
as cited previously, guiding the synthesis of further inhibitors.
159
 
As mentioned above, NU2058 (51) is an ATP-competitive purine-based inhibitor with an 
IC50 of 5 µM for CDK1 and 12 µM for CDK2.
164
 Compound 51 was shown to bind to the 
Thr160 phosphorylated CDK2-cyclin A complex, via a triplet of hydrogen bonds 
between the purine core and the residues Leu83 and Glu81 within the hinge region (blue 
circle, Figure 69). The O
6
-cyclohexylmethyl moiety was shown to interact with the 
ribose site whereas the imidazole ring of the purine core is engaged in an aromatic-
aromatic contact with Phe80. SAR studies showed that a cyclohexylmethyl group at the 
O
6
-position was optimal for activity.
164
 Compound 51 emerged as a structural lead for the 
design of further CDK2 inhibitors. 
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Figure 69 - Crystal structure of 51 in complex with CDK2 highlighting the triplet of H-bonds 
with the hinge region
153
 (from C. E. Arris et al, 2000). The PDB entry is 1E1V. 
Further optimisations employing a structure-based approach led to the synthesis of 58, a 
potent CDK2 inhibitor (IC50 = 5.4 nM).
164
 The crystal structure of 58 in complex with 
CDK2 showed the same interactions as for 51. However, the introduction of a 
sulfonamide moiety allowed additional interactions. One oxygen of the sulfonamide 
moiety is involved in hydrogen-bonding with the NH of the backbone Asp86 residue 
(rNH-O = 3.1Å) while the NH2 of the sulfonamide moiety is involved in hydrogen-bonding 
with the carbonyl of the same Asp86 residue (rNH2-O = 2.9Å) (Figure 70).
165
  
 
Figure 70 - Crystal structure of 58 with CDK2 showing the triplet of H-bonds of the 2-
aminopurine scaffold with the hinge region and the H-bond interaction between the sulfonamide 
group and Asp86
164
 (from T. G. Davies et al, 2002). The PDB entry is 1H1S. 
To enhance the cellular activity of 58 found in the range 1-10 μM,165 isosteric 
replacement of the sulfonamide moiety of 58 was investigated with a series of 
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carboxamide- and urea-based purine derivatives. This strategy was unsuccessful with the 
sulfonamide being the best group for CDK2 activity. The high potency of 58 was due to 
its interactions with Asp86, and so to maintain this crucial interaction, sulfone-based 
inhibitors were synthesised. 
166
 Despite an overall reduction of activity against CDK2 
with these inhibitors, this series identified a vinyl sulfone (60), shown to inhibit CDK2 in 
a time-dependent manner. To confirm the covalent binding between 60 and CDK2, a 
mass spectrometric analysis was performed. Affinity labelling experiments were carried 
out with 60 and 59, a control compound with an ethyl group instead of the vinyl 
substituent. The mass spectrometric profile of 59 was similar to the blank experiment, 
with no change in mass observed (Figure 71). However, when the experiment was 
conducted with 60, an increase of 414 Da was observed, which corresponded to the 
molecular weight of 60 (Figure 71).
167
 This observation suggested that 60 was covalently 
bound to CDK2. 
 
Figure 71 – Mass spectrometric analysis of 59 and 60 with CDK2/cyclin A167 (from E. Meschini, 
2011). The experiment with compound 59 showed the same mass spectrometry profile as the 
control experiment (DMSO). The experiment with compound 60 showed an increase of 413 by 
comparison to the control experiment (DMSO) which corresponds to the molecular weight of 
compound 60, indicating covalent binding. 
Two residues, Lys88 and Lys89, were potentially sufficiently reactive and close enough 
to the vinyl sulfone moiety of 60 to form a covalent bond. To confirm this hypothesis, a 
mass spectrometric experiment was conducted on 60 with a mutant CDK2, 
Lys88E/Lys89V, where Lys88 was replaced by a glutamic acid and Lys89 by a valine. 
No difference in mass was observed between the blank experiment and that performed 
with 60, suggesting that 60 did not bind to the mutant form of CDK2 (Figure 72).
167
 The 
hypothesis that either Ly88 or Lys89 reacted covalently with 60 was, therefore, 
confirmed. 
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Figure 72 - Mass spectrometric analysis of 60 with mutant CDK2(Lys88E/Lys89V)/cyclin A 
167
 
(from E. Meschini, 2011). The mass spectrometry profiles of the protein with compound 60 and 
the control experiement (DMSO) are identical. No covalent binding occurs. 
The crystal structure of compound 60 in complex with CDK2 was solved. This inhibitor 
was shown to bind to the hinge region of the kinase via a triplet of hydrogen bonds, 
identical to 58, and an interaction through the sulfone moiety with the backbone residue 
Asp86 was also present. Crucially, a covalent bond between the vinyl sulfone moiety and 
the backbone residue Lys89 was observed (Figure 73).
167
 Compound 60 is the first 
irreversible CDK2 inhibitor described to date in the literature.
165
 
 
Figure 73 – Co-crystal structure of 60 with CDK2167 showing the H-bond interactions with the 
hinge region, the interaction with the sulfone group and Asp86, and the covalent binding between 
Lys89 and the vinyl sulfone warhead (from E. Meschini, 2011). 
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The probable mechanism by which Lys89 reacts with the vinyl sulfone moiety of 60 is 
shown below (Scheme 1), and involves a Michael addition reaction leading to the 
formation of a covalent bond between Lys89 and 60.
167
 The high reactivity of 60 caused 
stability and selectivity issues, and the results obtained from a time-dependent assay 
against were probably representative of both the potency of 60 (IC50 = 63 nM
165
) and its 
decomposition. 
 
Scheme 1 – Possible mechanism for the covalent reaction of 60 with Lys89 of CDK2. 
2.4. Objectives of the thesis 
The thesis is divided into two parts with the work carried out within the Nek2 project 
described first (Chapters 3 and 4) followed by the work done within the CDK2 projects 
(Chapters 5, 6, 7, 8 and 9). 
The objectives of the first project were the design and synthesis of control compounds to 
assess the potential off-target effect of the 2-aryl-6-ethynylpurine inhibitors of Nek2 by 
perturbing their main interactions with Nek2, the covalent binding with Cys-22 and the 
triplet of H-bonds with the hinge region. This work confirmed the presence of the off-
target activity of the 2-aryl-6-ethynylpurine series leading to the closure of the project. N-
7 methylation of purines was shown to abolish Nek2 inhibitory activity but retained the 
cellular potency. Based on this result, a series of N-7 methylated purines was developed 
with the objective to discriminate the off-target activity over Nek2 inhibition but the 
strategy was unsuccesful. Kinetic studies have also been conducted on selected 6-
ethynylpurines to assess the impact of N-7/N-9 methylation on the chemical reactivity of 
the 6-ethynyl ‘warhead’. A model system was developed to investigate a possible 
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correlation between the chemical and biological reactivity of the 6-ethynyl group of the 
purine derivatives with thiols. 
The objective of the second project was to improve the chemical stability of a covalent 
inhibitor of CDK2, the first to be described in the literature, through modifications of its 
vinyl sulfone warhead that reacts with Lys89, while retaining the covalent binding with 
CDK2. Substitutions of the vinyl sulfone at the α- and β- positions were investigated as 
well as the replacement of the vinyl sulfone group by other electrophilic warheads. This 
work led to the discovery of an α-chloro derivative showing the best time-dependent 
inhibition profile against CDK2 so far within the project.  To explore further the potential 
of the vinyl sulfone as a reactive warhead, this group was introduced into known CDK2 
inhibitors. 
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Chapter 3. Assessment of Potential Off-target Biological Activity of 6-
Ethynylpurine Nek2 Inhibitors 
A disparity was observed between the enzyme inhibitory activity and growth inhibition of 
the 6-ethynylpurine Nek2 inhibitors. Therefore, control compounds were required to 
assess the possibility of an off-target activity from the 6-ethynylpurine series. In this 
chapter, the synthesis of such compounds is described as well as their Nek2 inhibitory 
activities and cellular potencies (section 3.1). As the off-target activity was confirmed, a 
series of N-7 methylated purines was synthesised with the aim of discriminating the off-
target effect from the Nek2 inihibition. The biological results of this series are discussed 
(section 3.2). 
Methylation at the N-7 and N-9 position of compounds 41 and 42 was expected to perturb 
the triplet of donor/acceptor/donor hydrogen bonds (see Chapter 2) responsible for 
binding to the hinge region of Nek2 (61-64). 
 
The introduction of a 6-cyano group, bioisosteric with 6-ethynyl, was expected to block 
the addition of Cys22. The 6-cyano derivative 65 was synthesised along with the 6-
cyanopurines having a methyl group at the N-9 and N-7 positions (66 and 67, 
respectively), intended to abolish both covalent binding and interactions with the hinge 
region. 
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3.1. Synthesis of control compounds 61-64 
3.1.1. Synthesis of N
9
- and N
7
-methyl purines 
 
Scheme 2 - Reagents and conditions: (i) HBF4, NaNO2, r.t., 18 h, 50%;(ii) MeI, K2CO3 in DMF, 
r.t., 18h, 92%; (iii) triisopropylsilylacetylene, CuI, Pd(PPh3)2Cl2, Et3N in THF, r.t., 18 h, 49% 
(72), 22% (74); (iv) TFA, aniline in TFE, 140 °C, 15 min, MW, 34% (73), 62% (75); (v) TBAF in 
THF, r.t., 10 min, 56% (61), 47% (62). 
The synthetic scheme for the synthesis of the N
9
- and N
7
-methylpurine derivatives (61 
and 62, respectively) started with the commercially available 2-amino-6-chloropurine 68, 
which was subjected to a Balz-Schiemann reaction
168
 to insert a fluoro group at the 2-
position (69) (Scheme 2). Methylation of compound 69 was performed using MeI and 
K2CO3 in DMF.
153
 The isomers 70 and 71 were obtained as an inseparable mixture (ratio 
7:3 of N
9
- (70) and N
7
-methylpurines (71), respectively). The Sonogashira reaction
169
 was 
conducted on the mixture of isomers. At this stage, the two isomers were separable, 
leading to 49% of the N
9
-methyl isomer 72 and 22% of the N
7
-methyl compound 74. An 
NMR method based on the shift of the C8H of the purine was used to identify the two 
isomers, using the knowledge that the more deshielded C8H signal corresponds to the N-7 
isomer (Figure 74).
170
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Figure 74 – Identification of N7- (74) and N9-methyl (72) isomers by 1H NMR 
Aromatic substitution under microwave heating was performed at the purine 2-position 
on each of the two isomers, leading to N
9
-methyl isomer 73 in 34% and N
7
-methyl isomer 
75 in 62% yield.
171
 TFA catalysed the reaction by protonation of N-1, which facilitated 
nucleophilic attack by aniline to form the Meisenheimer-Jackson intermediate.
171
 Loss of 
fluoride from this intermediate afforded the target compounds (Scheme 3). Deprotection 
of the TIPS group using TBAF was performed using a calcium sulfonate scavenger resin 
to complex the tetrabutylammonium species remaining in the reaction mixture.
172
 
Compounds 61 and 62 were obtained in 56% and 47% yield, respectively.  
 
Scheme 3 - SNAr mechanism under TFA-TFE conditions 
A similar synthetic route was followed for the preparation of the control compounds 63 
and 64 having the substituted 2-arylamino group at the 2-position. The diversity was 
introduced during the nucleophilic aromatic substitution using the TFA/TFE method 
(Scheme 4). 
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Scheme 4 - Reagents and conditions: (i) TFA and 79 in TFE, 140 °C, 15 min, MW, 43% (76), 52% 
(77); (v) TBAF in THF, r.t., 10 min then scavenger beads, r.t., 18 h, 56% (63), 21% (64). 
As 2-(3-aminophenyl)acetamide 79 was not commercially available, the aniline was 
prepared from 3-aminophenylacetic acid 78 in two steps in a one-pot procedure.
136
 Firstly 
the methyl ester of carboxylic acid 78 was formed, and then ammonia was used to obtain 
the desired carboxamide 79 (Scheme 5). 
 
Scheme 5 - Reagents and conditions: (i) SOCl2 in MeOH then aq. NH3, 41%. 
3.1.2. Synthesis of 6-cyanopurine control compounds 
 Synthesis of 6-cyanopurine derivative 65 
 
Scheme 6 - Reagents and conditions: (i) PMBCl, Cs2CO3 in DMF, 60 °C, 18 h; (ii) DABCO, 
Et4NCN in MeCN, r.t., 18h; (iii) neat TFA, 70 °C, 5 h; (iv) HBF4, NaNO2, r.t., 18 h; (v) TFA, 
TFE, 140 °C, 30 min, MW. 
The previous method used within the group (Scheme 6) showed some weaknesses such as 
a poor yield of the fluorination step as well as in the nucleophilic aromatic substitution. 
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To improve the overall yield of the synthesis, iodination of the protected 2-amino-6-
cyano purine 81, instead of the traditional fluorination, was considered. From the iodo 
derivative 84, a Buchwald reaction was investigated (Scheme 7). 
 
Scheme 7 - Reagents and conditions: (i) PMBCl, Cs2CO3 in DMF, 60 °C, 18 h, 60%; (ii) 
DABCO, Et4NCN in MeCN, r.t., 18h, 62%; (iii) isoamyl nitrite, CH2I2, CuI in THF, 70 °C, 2 h, 
62%; (iv) Brettphos, K2CO3, 79, Pd(OAc)2 in DME, 120 °C, 20 min, MW, 43%; (v) TFA, 70 °C, 
5 h, 47%. 
In terms of N-9 protecting group choice, THP was previously employed within the group 
but was cleaved under the cyanation conditions. Benzyl was also used previously but 
found to be impossible to remove. The PMB group was chosen as orthogonal to 
cyanation conditions. 2,4-Dimethoxybenzyl was also considered as it would have been 
easier to remove than PMB. However, attempts to synthesise the reagent 2,4-
dimethoxybenzyl chloride were unsuccessful,
173
 the compound being extremely unstable. 
Regioselectivity was observed for PMB protection as only the N
9
-PMB compound 80 
was isolated in a satisfactory yield. The cyanation step was performed using DABCO and 
Et4NCN leading to compound 81 in 60% yield.
136
 This reaction involves the formation of 
an intermediate where DABCO acts as nucleophile and displaces the chloro group to 
form a better leaving group. This intermediate underwent a nucleophilic attack by 
Et4NCN to form the desired compound 81. Iodination
174
 was then carried out with some 
difficulties as the iodo derivative 84 appeared to be light-sensitive. In order to minimise 
degradation, the reaction mixture was protected from light and stored in the freezer under 
nitrogen. The yields for this reaction were approximately 50% and poorly reproducible. 
Buchwald reaction was tried initially on compound 84 under microwave heating using 
Xantphos as ligand, Pd(OAc)2 as catalyst, and Cs2CO3 as base in dioxane. However, the 
yield was relatively low (34%). From these results and based on the user’s guide for 
Buchwald reactions,
175
 DMA was used as solvent, K2CO3 as base, Pd(OAc)2 as palladium 
source and Brettphos as ligand. Using these conditions, the yield was improved to 43%. 
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PMB deprotection was performed in neat TFA under reflux.
136
 Compound 65 was 
obtained in six steps with an overall yield of 4%.  
 Synthesis of N9- and N7-methyl derivatives of 6-cyanopurine (66 and 67) 
For this synthesis, a similar route to that described in the section above was first 
considered (Scheme 8), but with methylation replacing the PMB protection to allow for 
the cyanation. Methylation using methyl iodide led to a mixture of N
9
- and N
7
-
methylpurines (86/87) in a ratio of 4:1, respectively. No purification was performed on 
this mixture of isomers as they were insoluble in common solvents, and the insolubility of 
this mixture (86/87) proved to be an important problem for the following step. The 
cyanation reaction was tried in different solvents such as MeCN, NMP and DMPU but no 
reaction occurred. When the temperature was slightly increased to 50 °C, degradation of 
the starting material (86/87) was noticed and no target compound (88/89) was formed. 
 
Scheme 8 - Reagents and conditions: (i) MeI, K2CO3 in DMF, r.t., 18 h, 89%; (ii) DABCO, 
Et4NCN in MeCN, r.t., 18 h, 62%. 
As a result, another strategy was considered (Scheme 9), where halogenation was 
performed first, followed by cyanation and coupling. The iodination performed on the 
mixture of 86/87 led to one desired intermediate, the N
9
-Me isomer 90, in 30% yield. A 
Buchwald reaction was carried out on compound 90 under the conditions detailed in 
section 3.1.2. Unfortunately, although the reaction mixture was clean, the cross-coupling 
took place at the unwanted 6-position (91) (observed by LC-MS, product not isolated). 
As the Buchwald reaction did not give the result expected, cyanation was attempted on 
compound 90 but only degradation was observed. 
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Scheme 9 - Reagents and conditions: (i) isoamyl nitrite, CH2I2, CuI in THF, 70 °C, 2 h, 30%; (ii) 
Brettphos, K2CO3, aniline, Pd(OAc)2 in DME, 120 °C, 20 min, MW; (iii) DABCO, Et4NCN in 
MeCN, r.t., 18 h. 
As the first attempts led to no satisfactory results, fluorination of the mixture of isomers 
86/87 was attempted (Scheme 10). The same observation as for the iodination was made: 
only the N
9
-Me isomer 70 was retrieved after purification, suggesting the minor 
formation of N
7
-methyl isomer. Cyanation and nucleophilic aromatic substitution 
reactions were attempted on compound 70, but the cyanation reaction was unsuccessful 
with degradation again being observed. When nucleophilic aromatic substitution reaction 
at the 2-position was attempted, the unwanted regioisomer 94 was obtained, with 
substitution occurring exclusively at the 6-position, as observed by LC-MS.  
 
Scheme 10 - Reagents and conditions: (i) HBF4, NaNO2, r.t., 18 h, 50%; (ii) DABCO, Et4NCN in 
MeCN, r.t., 18 h; (iii) TFA, aniline in TFE, 140 °C, 15 min, MW; (iv) aniline in TFE, 140 °C, 15 
min, MW. 
For both iodination and fluorination of compounds 86/87, the yields were modest, 
probably explained by the quality of the starting material, which had not been purified. 
From all of these results, the useful observation made was that the 6-position of the 
purine scaffold was the most reactive. Indeed, in the case of the nucleophilic aromatic 
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substitution, although fluoro is generally a better leaving group than chloro, substitution 
with the 2-fluoro-6-chloropurine 70 occurred exclusively at the 6-position (Scheme 10). 
Another strategy was considered (Scheme 11), which was similar to an approach 
previously used within the group. Thus, isolation of the unprotected purine 82, following 
PMB deprotection, was achieved by recrystallisation from MeOH: NH3 (3:1).  
 
Scheme 11 - Reagents and conditions: (i) PMBCl, Cs2CO3 in DMF, 60 °C, 18 h, 60%; (ii) 
DABCO, Et4NCN in MeCN, r.t., 18 h, 62%; (iii) neat TFA, 70 °C, 5 h, 74%. 
From the intermediate 82, direct methylation using MeI with either K2CO3 or Cs2CO3 
was conducted. The base was changed to study any differences in reaction rate and 
regioselectivity between the formation of N
9
- and N
7
-methyl compounds, 88 and 89, 
respectively. In both cases, methylation was complete after one hour and led almost 
exclusively to the N
9
-Me isomer 88, as the N
7
-Me isomer 89 represented less than 1% 
(Scheme 12) (ratio determined by 
1
H NMR). This result was interesting as it suggested 
that the 6-cyano group directed the methylation preferentially at the N-9 position 
compared with the 6-chloro group, where a mixture of N
7
- and N
9
-methylpurines was 
obtained. As the objective was to synthesise both isomers, this approach was stopped. 
The iodination reaction on compound 82 failed, suggesting that the N
9
H of the purine 
should be protected (Scheme 12). No further investigations were conducted on this 
scheme as the methylation gave selectively one isomer (88) and the iodination reaction 
failed. 
 
Scheme 12 - Reagents and conditions: (i) MeI, K2CO3 in DMF, r.t., 18 h, 59% (88), <1% (89); (ii) 
isoamyl nitrite, CH2I2, CuI in THF, 70 °C, 2 h. 
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Solubility of the compounds was a major concern. The phenylthiomethyl group was 
considered to confer better solubility (Scheme 13). This group was chosen to act as a 
protecting group which should cleave under hydrogenation conditions using Raney nickel 
to give the desired N-methylpurines. Phenylthiomethyl was introduced using 
chloromethylphenyl sulfide under the same conditions as for the PMB group.
176
 
Surprisingly, the two isomers, 96 and 97, obtained were separable by recrystallisation 
thanks to differences in polarity. After work-up, N
7
-protected isomer 97 was partially 
recrystallised from MeOH, whereas the N
9
-protected isomer 96 was soluble. After 
confirmation of structure by 
1
H NMR, compound 97 was isolated pure in 20% yield, and 
isomer 96 was obtained in 64% yield with residual isomer 97 (4:1 of 96: 97). At this 
stage, an attempt at deprotection was made on compound 97, the less soluble isomer, 
under hydrogenation conditions using Raney nickel. No deprotection occurred at r.t., but 
started slowly at 40 °C, and at 100 °C, the deprotection step was complete after 20 
minutes. Although the result was encouraging, the question of the cyano group stability 
under these rigorous conditions remained uncertain. 
 
Scheme 13 - Reagents and conditions: (i) PhSCH2Cl, Cs2CO3 in DMF, 60 °C, 18 h, 67% (96), 19% 
(97); (ii) DABCO, Et4NCN in MeCN, r.t., 18 h, 61%; (iii) Ra-Ni, H-cube in DMF, r.t. 
Cyanation was carried out on both isomers, 96 and 97, with the reaction occurring when 
the methylphenyl sulfide group was at the N-9 position but not at the N-7 position. This 
result could be explained by steric hindrance imposed by the phenylthiomethyl group. As 
discussed previously, the cyanation reaction proceeded through an intermediate formed 
by DABCO (Scheme 14). This group might not be compatible with another bulky group 
located nearby, at the N-7 position, resulting in no reaction. In the case of the N
9
-
protected isomer 96, cyanation was successful with a yield of 61%. Unfortunately, 
deprotection of compound 98 by hydrogenation with Ra-Ni, resulted in concomitant 
reduction of the cyano group to the corresponding amine, and this approach was 
abandoned. 
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Scheme 14 – Displacement of the 6-chloro group of 96 and 97 by DABCO  
Another idea to obtain the N
7
-methyl intermediate 89, the most difficult to synthesise 
according to the studies detailed above, was derived from knowledge of the N-7 
methylation of guanine residues in DNA by methylating agents (see chapter 3, section 
3.1.3). A new strategy for the synthesis of both N-methyl isomers was established 
(Scheme 15). The N
7
-methyl derivative 67 was obtained from direct methylation of the 
PMB protected precursor 85 with a yield of 56%, using the one-pot procedure developed 
(see chapter 3, section 3.1.3.).
177
 The N
9
-methyl isomer 66 was obtained by direct 
methylation of compound 65 in 40% yield. 
 
Scheme 15 - Reagents and conditions: (i) Me3OBF4 in TFE, r.t.; (ii) 100 °C, 20 min, MW, 56%, 
(iii) neat TFA, 70 °C, 5 h, 47%; (iv) MeI, K2CO3 in DMF, r.t., 18 h, 40%.  
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3.1.3. One-pot process for the selective N-7 methylation of purines 
 Mimicking a biological mechanism 
Commonly, methyl iodide in the presence of potassium carbonate or
153
 sodium hydride
178
, 
or diazomethane
179
 are reagents used to methylate purines. The regioselectivity of these 
two reagents favours methylation at the N-9 position as the N-7 isomer represents only 20% 
of the mixture of both isomers. Only a few examples were found in the literature for the 
selective N-7 alkylation of purines. The method used by Kotek et al
180
 consisted of 
protecting the N-9 position, reducing the imidazole ring of the purine, and then alkylating 
at N-7. Finally, they deprotected at N-9 and reoxidised the imidazole ring. Even if this 
method was effective with reported overall yields of between 55 and 87%, this five-step 
procedure showed some disadvantages such as stability problems arising from the 
formation of dihydropurines. This scaffold appeared unstable to electron-donating groups 
resulting in diversity limitations at the 2- and 6-positions. Khoda et al
181
 used another 
approach by methylating the N-7 position with methyl iodide while N-9 was protected by 
a ribose. The protecting group was subsequently hydrolysed under acidic conditions. 
Unfortunately, only one example was given and the use of acidic conditions might be 
incompatible with other groups on the molecule. Dalby et al
182
 developed another 
approach using methyl(aquo)cobaloxime to coordinate to purine N-3. A hydrogen bond 
was formed between the N-9 and the dimethylglyoximato oxyanion, preventing alkylation 
on N-9 and orientating it to N-7. However, this method was successful only on 6-
chloropurine and 2,6-dichloropurine, and failed when attempted on 2-amino-6-
chloropurine because of solubility problems. 
  
Scheme 16 - Mechanism of depurination by DNA glycosylases
183
 
To date, no mild and general method exists to selectively alkylate N-7 over N-9 on 
purines. A new approach was designed, inspired by the N-7 alkylation of guanine 
residues in DNA, a common DNA damaging process (Scheme 16).
184
 Alkylation of 
guanine residues arises from exposure to methylating agents, forming N
7
-methylguanine 
(7-mG).
185
 Nitrosamines are an example of alkylating agents, which form, via metabolic 
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activation by cytochrome P450 enzymes, highly reactive diazonium ions.
185
 4-
(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is a nitrosamine found especially 
in tobacco and has been associated with lung cancer.
186
 In the same family of compounds, 
dimethylnitrosamine (DMN) was studied as inducer of liver, kidney and lung tumours.
185
 
The damaged DNA is repaired by DNA glycosylases, enzymes responsible for the 
removal of alkylated purine nucleobases by depurination.
183, 187
  
If DNA is not repaired, depurination occurs spontaneously because of the positive charge 
on N-7; generating mutagenic abasic sites (Scheme 17),
188
 which are in equilibrium with 
the ring-opened aldehyde form. Loss of a proton at the α-position of the aldehyde moiety 
leads to a DNA strand break.
188
 To mimic chemically the natural methylation occurring 
on guanine residues, dimethyl sulfate is commonly used as in the Maxam-Gilbert 
procedure for DNA sequencing.
189
 
 
Scheme 17 - Depurination mechanism
188
 
To perform the selective N-7 methylation on the target purines, trimethyloxonium 
tetrafluoroborate was preferred as methylating agent for its ease of handling compared 
with the traditional Me2SO4 or MeI. PMB was selected as protecting group and TFE
190
 
was chosen as reaction solvent for its good solubilisation of trimethyloxonium 
tetrafluoroborate and the purine, its non-nucleophilic character, and for its slightly acidic 
nature (pKa ~ 12)
191
. Studies on the depurination of 7-mG showed that this process was 
accelerated under acidic conditions and by heating.
188
 Accordingly, the slightly acidic 
character of TFE can be used to trigger PMB deprotection after the N-7 methylation by 
heating under microwave conditions. 
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 Reaction optimisation 
Trimethyloxonium tetrafluoroborate was used as the methylating agent for the reaction, 
which was complete after 2 hours at room temperature. Different conditions were studied 
for the deprotection (Table 3) as heating overnight at 70 
o
C did not trigger PMB removal. 
Table 3 - Conditions investigated for the PMB deprotection 
% of TFA Conditions Results 
0 
70 °C overnight, heating 
120 °C, 5 min, MW 
100 °C, 20 min, MW 
No deprotection 
Deprotection (impure) 
Deprotection (complete) 
10 
r.t. overnight 
70 °C, 4 h 
No deprotection 
Deprotection (impure) 
20 
r.t. overnight 
70 °C, 4 h 
No deprotection 
Deprotection (impure) 
30 
r.t. overnight 
70 °C, 4 h, 
No deprotection 
Deprotection (impure) 
50 
r.t. overnight 
70 °C, 2.5 h 
No deprotection 
Deprotection (complete) 
100 r.t. overnight Deprotection (complete) 
 
From the results listed in Table 3, the best conditions were heating under microwave 
irradiation at 100 °C as this led to a complete and clean reaction in 65% yield. The 
weakly acidic character of TFE was enough to trigger PMB deprotection on heating 
(Scheme 18). 
 
Scheme 18 - Proposed mechanism for the selective N
7
-methylation of purine 
 Application of the method 
Conditions used to synthesise compound 67 were applied as a one-pot process to a range 
of 9-(4-methoxybenzyl)-purine substrates. The results are reported in Table 4.  
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Table 4 - Results of N-7 methylation on diverse 9-(4-methoxybenzyl)purine-based substrates  
 
X Y 
Time for 
deprotection 
Compound 
Isolated 
yield (%) 
CN NH2 20 min 89 65 
CN I 10 min 99 66 
CN 
 
10 min
1 67 56 
Cl NH2 10 min
1 872 68 
 
NH2 10 min 100 60 
 
I 20 min 101 45 
 
CN 20 min 102 70 
OEt NH2 10 min 103 66 
OEt I 10 min 104 73 
 NH2 20 min 105 40 
 I 10 min 106 58 
 F 10 min 74 42 
1
TFA was added to give a final concentration of 50%; 
2
TFA salt was obtained. 
The method offered acceptable yields ranging from 43% to 73%. This process showed 
good tolerance towards steric hindrance, as the reaction proceeded in good yield with 
TIPS and cyclohexylmethyl groups at the 6-position (entries 105, 106, 74 and 100-102, 
respectively). In addition, the reaction was tolerant to the groups at the 2-position as the 
yields were not affected. In the case of the reaction of 2-amino-6-cyanopurine 89, with 
methyl iodide, the N-9 isomer was obtained almost exclusively (see section 3.1.2.). This 
method appeared to be a viable alternative approach to prepare selectively the N-7 over 
the N-9 methylpurine, and is also a method to provide the N
7
-methyl isomer when only 
the N
9
-methyl isomer was obtained by traditional methylating agents. These conditions 
were also applied to 9-tetrahydropyranylpurine compounds (Table 5). In this case, room 
temperature was enough to trigger the THP deprotection during the reaction, although the 
reaction mixtures were less clean and more difficult to purify than for the corresponding 
PMB protected compounds. 
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Table 5 - Results of N-7 methylation on 9-tetrahydropyranylpurine compounds 
 
R X Y Compound 
Isolated 
yield (%) 
THP H F 107 57 
THP  F 74 41 
 
To confirm that methylation had occurred at the N-7 position, a crystal structure of 
compound 101 was determined. The methyl group on N-7 (N-1 on Figure 75) is on the 
same side of the molecule as the cyclohexylmethoxy group at the 6-position (C-5 on 
Figure 75) of the purine. From the crystal structure, it is evident that the methyl group is 
at the expected position, on the N-7 of the purine. 
       
Figure 75 - Crystal structure of 101 
To investigate whether these conditions could be applied to other alkyl groups, 
trimethyloxonium tetrafluoroborate was replaced by triethyloxonium tetrafluoroborate. 
Selective N-7 ethylation was again observed, demonstrating that this method can indeed 
be extended to larger alkyl groups (Table 6).  
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Table 6 - Results of N-7 ethylation using the one-pot process 
 
X Y 
Time for 
deprotection 
Compound 
Isolated 
yield (%) 
 
NH2 10 min 108 40 
OEt NH2 10 min 109 58 
 NH2 No reaction 110 - 
CN NH2 10 min 111 28 
 
Selective N-7 ethylation offered the same satisfactory results as the corresponding 
methylation when carried out on 6-alkoxypurines (Table 6, entries 108 and 109). By 
comparison with methylation, ethylation appears to be more difficult with a cyano group 
at the 6-position (Table 6, entry 111 compared with Table 4, entry 89). This reaction is 
moderately tolerant to steric hindrance though as the 6-triisopropylsilylethynyl group 
appeared to be too large for ethylation to occur (Table 6, entry 110). 
3.1.4. Biological results for the control compounds 
The four control compounds in the 6-ethynyl series (61-64) were assessed in an 
enzymatic (IC50) and cellular assay (GI50). The N
7
-methyl derivatives, 62 and 64, were 
essentially inactive against Nek2 in the enzymatic assay (IC50 = 15% @ 50 μM and 50% 
@ 100 μM, respectively), but the N9-methyl isomers, 61 and 63, retained low potency 
(IC50 = 28 μM and 4.0 μM, respectively). The N
7
-methyl isomers, 62 and 64, although 
inactive against Nek2, showed growth inhibition in a tumour cell line (SKBR3) (GI50 = 
0.3 μM and 2.9 μM, respectively). Taken together, the enzymatic and cellular results 
suggested that the activity of these compounds was, at least in part, the result of an off-
target Nek2-independent effect. 
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A ‘Dundee’ kinase screen was also performed against 121 different kinases for each 
compound at 1 µM. From these results, the inhibitors seemed highly selective, as activity 
only against Bruton’s tyrosine kinase (BTK) and aurora kinases A (AK-A) and B (AK-B) 
was observed (Table 7). These results suggested that the off-target activity was unlikely 
to arise from kinase inhibition, although it is recognised that this is only a proportion of 
the entire kinome.  
Table 7 - Kinase screening results
1
 
Compound
2
 Nek2 inhibition Other kinase inhibition 
 
(61) 64% BTK : 36% 
 
(62) 29% 
BTK : 84% 
AK-A : 34% 
 
(63) 29% 
AK-B : 51% 
AK-A : 4% 
 
(64) 6% AK-A : 37% 
1
 See Appendix for the complete results of the Dundee kinase screen. 
2
 Evaluated at 1.0 μM. 
A crystal structure of compound 63 in complex with Nek2 was determined to understand 
the binding mode of the molecule (Figure 76). Purine 63 bound in the same orientation as 
the other 6-ethynylpurines, and reaction with Cys22 on the ethynyl group still occurred, 
explaining the retention of Nek2 inhibitory activity. Perturbing the donor/acceptor/donor 
motif in this case was shown to modulate but not abolish the Nek2 inhibitory activity. 
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Figure 76 – Co-crystal structure of compound 63 in complex with Nek2. 
The three control compounds in the 6-cyano series (65, 66 and 67) were evaluated in both 
the enzymatic and cellular assays. As expected, these purines were less active against 
Nek2 than their corresponding 6-ethynyl bioisosteres (42, 63 and 64, respectively). 
However, they still showed the same relative potency with the parent compound 65 being 
the most potent (IC50 = 2.9 μM). Having a methyl substituent at the N-9 position (66) was 
shown to retain potency (IC50 = 38 μM), whereas a methyl group at the N-7 position (67) 
essentially abolished activity against Nek2 and cellular potency (IC50 = 20% @ 100 μM; 
(GI50 = >100 μM). These compounds did not show any sign of off-target activity from 
their enzymatic and cellular results. 
 
Compounds synthesised in section 3.1 of this chapter were tested for their Nek2 
inhibitory activity by Kathy Boxall, Sam Burns, Yvette Newblatt and Maura Westlake 
under the supervision of Dr Wynne Aherne in the Analytical Screening and Technology 
Laboratory of the CR UK Centre for Cancer Therapeutics, The Institute of Cancer 
Therapeutics, Sutton, Surrey, UK, SM2 5NG. 
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3.2. Attempted discrimination of off-target activity from Nek2 inhibition - Synthesis 
of a focused library of N
7
-methylpurines  
Purine-based control compounds have been synthesised and as suggested from their 
biological activity, the cellular growth inhibition seemed to arise from an off-target effect 
rather than as a result of Nek2 inhibition. N-7 Methylation abolished activity against 
Nek2 (IC50 results) but did not affect potency in the SKBR3 tumour cell line. From these 
results, the proposed strategy was to separate Nek2 inhibition from off-target activity. 
Nek2 potency could easily be abolished by N-7 methylation, but nothing was known 
about the nature of the off-target activity, apart from that it was unlikely to be related 
kinase according to the Dundee screen. The work described in this section consisted in 
finding compounds that did not affect the off-target activity. For that purpose, compounds 
having different potency against Nek2, and with structurally different anilines at the 2-
position, were methylated at the N-7 position. The strategy was to obtain a GI50 value 
related only to the off-target growth inhibition. If a compound possessed a modest or 
weak GI50, then the off-target locus would not be affected and the parent N
9
H analogue of 
this compound would potentially be Nek2 selective (Figure 77). 
 
Figure 77 - Strategy to identify a selective Nek2 inhibitor 
Eleven anilines were chosen (Figure 78) to be inserted at the 2-position of the purine for 
this small library of purine-based inhibitors, with only six being commercially available 
(112-117). The five remaining (118-122) had to be synthesised. 
Potentially selective Nek2 inhibitor 
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Figure 78 – Anilines used for the library of N7-methylpurines 
3.2.1. Synthesis of the inhibitors 
The best route to synthesise the eleven compounds was to have a common intermediate 
and introduce diversity at the final step. Thus, the first purine intermediate to be 
synthesised was the 2-fluoro compound 74 (Scheme 19). 
 
Scheme 19 - Reagents and conditions: (i) HBF4, NaNO2, r.t., 18 h, 50%; (ii) PMBCl, Cs2CO3 in 
DMF, 60 °C, 18 h, 38%; (iii) triisopropylsilylacetylene, CuI, Pd(PPh3)2Cl2, Et3N in THF, r.t., 18 h, 
40% (125) and 21% (126); (iv) OMe3BF4 in TFE, r.t.; (v) 100 °C, 20 min, MW, 52% (72) and 42% 
(74). 
The synthesis of the 2-fluoro intermediate 74 started with the Balz-Schiemann reaction 
followed by PMB protection. Unfortunately, a mixture of isomers (123/124) was obtained. 
A Sonogashira reaction was performed, followed by methylation using trimethyloxonium 
tetrafluoroborate. This route was not ideal as it offered a poor overall yield, mainly 
because of the mixture of isomers that required separation. From intermediate 74 only 
four compounds were prepared using TFA/TFE conditions for coupling, followed by 
TBAF deprotection (Table 8).  
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Table 8 – Summary of yields for the synthesis of the target N7-methylpurines 131-134.  
 
Reagents and conditions: (i) TFA in TFE, 140 
o
C, 30 min, MW; (ii) TBAF in 
THF, r.t., 5 min. 
R group Compound – yield for step (i) Compound – yield for step (ii) 
 
127 – 52% 131 – 45% 
 
128 – 43% 132 – 40% 
 
129 – 62% 133 – 41% 
 
130 – 66% 134 – 43% 
 
As the synthesis of the 2-fluoro intermediate 74 was not ideal, in particular working with 
a mixture of isomers, efforts were focused on synthesising the intermediate bearing an 
iodo group at the 2-position (106), as the synthetic scheme was better defined (Scheme 
20). 
 
Scheme 20 - Reagents and conditions: (i) PMBCl, Cs2CO3 in DMF, 60 °C, 18 h, 60%; (ii) 
triisopropylsilylacetylene, CuI, Pd(PPh3)2Cl2, Et3N in THF, r.t., 18 h, 65%; (iii) isoamyl nitrite, 
CH2I2, CuI in THF, 70 °C, 2 h, 30%; (iv) OMe3BF4 in TFE, r.t.; (v) 100 °C, 20 min, MW, 58%. 
The synthesis of the 2-iodo intermediate 106 started with PMB protection of the 
commercially available 2-amino-6-chloropurine 68, which occurred selectively at the 
purine N-9 position. A Sonogashira reaction was performed, followed by iodination to 
afford compound 136 in good yield. The last step was the one pot selective N
7
-
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methylation using trimethyloxonium tetrafluoroborate. This route offered a four-step 
selective synthesis of the intermediate 106.  
Amides 118 and 121 were obtained from the corresponding carboxylic acid using thionyl 
chloride in methanol to form the methyl ester, which was then treated with ammonia to 
afford the corresponding amide in good yield (Scheme 21).
136
  
 
Scheme 21 - Reagents and conditions: (i) SOCl2 in MeOH, r.t., 3 h; (ii) NH3 aq, r.t., 18 h, 48% 
(118) and 72% (121) over 2 steps. 
The three other aniline reagents were synthesised from 3-nitrophenylacetic acid 139. 
Compound 119 was obtained by amide coupling using dimethylamine in the presence of 
EDCI, followed by zinc reduction. Amide 120 was synthesised using a different method 
from peptide coupling conditions. 3-Nitrophenylacetic acid 139 was first converted into 
the acyl chloride with phosphorus trichloride and reacted directly with the amine present 
in the mixture.
192
 The isolated intermediate 141 was reduced with zinc (Scheme 22). 
 
Scheme 22 - Reagents and conditions: (i) EDCI, HOBt, NMe2, DIPEA in MeCN, r.t., 18 h, 82%; 
(ii) Zn, AcOH in MeOH, 50 °C, 2 h, 94% (119) and 93% (120); (iii) POCl3, 2,2,2-trifluoro-1-
ethanamine in MeCN, 140 °C, 5 min, MW, 80%. 
The last aniline 122 was more difficult to synthesise as the two previous methods 
described above, either with phosphorus trichloride or with EDCI, failed when attempted 
with N-acetylethylenediamine. Surprisingly, when another coupling agent, CDI, was used, 
the desired intermediate 142 was obtained in 41% yield. The amide 142 was reduced 
using zinc to give compound 122 in 88% yield (Scheme 23). 
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Scheme 23 - Reagents and conditions: (i) EDCI, HOBt, N-acetylethylenediamine, DIPEA in 
MeCN, r.t., 18 h; (ii) POCl3, N-acetylethylenediamine in MeCN, 140 °C, 5 min, MW; (iii) CDI, 
DIPEA, r.t. 2 h then N-acetylethylenediamine, r.t., 2 h, 41%; (iv) Zn, AcOH in MeOH, 50 °C, 2 h, 
88%. 
Buchwald couplings were performed between the 2-iodo intermediate 106 and the seven 
aniline reagents, followed by TIPS deprotection using TBAF (Table 9).  
Table 9 – Summary of yields for the synthesis of the target N7-methylpurines 150-156.  
 
Reagents and conditions: (i) Amine, K2CO3, Pd2(dba)3, XPhos in THF, 80 
o
C, 18 h; (ii) 
TBAF in THF, r.t., 5 min. 
R group Compound – yield for step (i) Compound – yield for step (ii) 
 
143 – 43% 150 – 47% 
 
144 – 45% 151 – 31% 
 
145 – 49% 152 – 73% 
 
146 – 73% 153 – 28% 
 
147 – 47% 154 – 64% 
 
148 – 35% 155 – degradation 
 
149 – 43% 156 - degradation 
 
The conventional conditions to deprotect the TIPS group using TBAF at room 
temperature failed with the 2-amino(benzenesulfonamide) or the 2-pyridyl group (155 
and 156, respectively). As this reaction was usually fast at r.t., the temperature was 
lowered to -78 
0
C to control the reaction. This was successful for the 2-pyridyl compound 
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149, giving a yield of 45% compared to degradation at r.t. (Scheme 24). Unfortunately, 
with the 2-amino(benzenesulfonamide) 148, the target product 155 was observed by LC-
MS but proved impossible to isolate. Various methods were tried including reverse phase, 
alumina or silica chromatography and preparative TLC. Eventually, TIPS deprotection 
was tried using fluoride on polymer support (Scheme 24). These conditions offered a 
clean reaction with sole formation of the target compound 155. As the compound was 
suspected to be unstable, no further purification was attempted, other than trituration in 
DCM. The desired product was obtained 97% pure by HPLC analysis. 
 
Scheme 24 - Reagents and conditions  (i) Fluoride on polymer support in MeOH, r.t., 2 h, 37%; 
(ii) TBAF in THF, -78 
0
C, 5 min, 45%. 
3.2.2. Biological results 
As mentioned previously, the major problem with the Nek2 inhibitors designed to date 
was their off-target activity in cells. N
7
-methylpurines, compared to their N
9
-methyl 
counterparts, which retained some potency against Nek2, were completely inactive in the 
Nek2 assay, but as active as the corresponding parent NH purines in cells. Finding an N
7
-
methyl compound with modest cellular activity might lead to a selective Nek2 inhibitor, 
which would be the corresponding parent NH compound. The results of the designed 
library are shown in Table 10. Unfortunately, all GI50 values were comparable. Only 
compound 154 showed no potency in cells, likely because of poor cell permeability. By 
comparison with the 6-cyano series, all of the 6-ethynylpurines had similar GI50 values, 
suggesting that off-target activity probably arises from the 6-ethynyl moiety and not from 
the groups at the 2-position. 
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Table 10 - Biological results of N
7
-methylated purines  
Compound GI50
1
 ClogP (tPSA) 
Nek2 inhibitory 
activity (IC50)of 
parent (N
9
H) 
compound 
 
(132) 1.0 µM 3.40 (52.4) 160 nM 
 
(132) 0.7 µM 4.11 (52.4) 400 nM 
 
(133) 1.2 µM 3.40 (52.4) 210 nM 
 
(134) 0.7 µM 2.60 (61.6) 94 nM 
 
(150) 3.2 µM 0.99 (95.4) 93 nM 
 
(151) 1.3 µM 1.50 (72.7) 90 nM 
 
(152) 1.2 µM 2.00 (81.5) 78 nM 
 
(153) 2.1 µM 1.52 (95.4) 79 nM 
 
(154) 68.9 µM 0.81 (110.6) 190 nM 
 
(155) 4.3 µM 0.85 (112.5) 140 nM 
 
(156) 0.39 µM 1.24 (64.7) 2.04 µM 
1
 Evaluated in SKBR3 cell line. 
These biological results are in accordance with the results of the N
7
-methyl-6-
ethynylpurine kinetic studies (Chapter 4, section 4.7.). In these studies, compounds 62 
and 64 have been shown to be far more reactive than their NH parents. Having a methyl 
group at the N-7 position increased the reactivity of the 6-ethynyl substituent towards 
nucleophilic attack. The compounds synthesised for this library did not represent control 
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compounds but highly reactive species. Finding a selective Nek2 inhibitor might be more 
challenging, and identification of the off-target(s) is essential if the biological results 
described are to be explained. 
Compounds synthesised in section 3.2 of this chapter were tested for their Nek2 
inhibitory activity by Kathy Boxall, Sam Burns, Yvette Newblatt and Maura Westlake 
under the supervision of Dr Wynne Aherne in the Analytical Screening and Technology 
Laboratory of the CR UK Centre for Cancer Therapeutics, The Institute of Cancer 
Therapeutics, Sutton, Surrey, UK, SM2 5NG. 
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Chapter 4. Kinetic Studies of Nek2 Inhibitors by Quantitative 
1
H NMR 
6-Ethynylpurines have been shown to bind covalently to the cysteine residue (Cys22) in 
the ATP binding site of the Nek2 kinase.
193
 In this chapter, kinetic studies using the 
quantitative 
1
H NMR (qNMR) method were conducted employing a model system 
previously optimised within the group,
194
 in order to help quantify the reactivity of 6-
ethynylpurines towards Cys22. The thiol of Cys22 reacts through a Michael-type addition 
at the 6-ethynyl moiety of the purine. Alkynes attached to a carbonyl, nitro or cyano 
group or suitable heterocycle
195-197
 are known to undergo 1,4-addition reactions, 
especially with soft nucleophiles such as thiols.
198
 6-Ethynylpurines are thus time-
dependent inhibitors of the Nek2 kinase. 
4.1. Applications of qNMR 
Nuclear Magnetic Resonance (NMR) is a technique most generally used for the structure 
determination of small molecules.
199
 Its use can be extended to quantitative studies, as 
first reported by Jungnickel and Forbes in 1963.
200
 Quantitative NMR (qNMR) is mainly 
accomplished with 
1
H because of its high sensitivity and abundance in the environment 
compared with other nuclei such as 
31
P and 
13
C.
199
 qNMR represents an especially useful 
analytical tool for pharmaceutical companies,
199
 as the purity of a drug and quantification 
of active drug and excipients in a drug formulation can be determined.
201
 In natural 
products research, qNMR gives valuable information on the structure of the molecule and 
an estimate of the purity of bioactive agents in the sample studied.
202
 The technique can 
help in the determination of the presence of possible tautomeric forms of a molecule,
202
 
and is also used in metabolomics in combination with mass spectrometry.
203
 In 
combinatorial chemistry, purification is often not required before analysis of the sample 
by qNMR.
199
 The rate of a reaction and the rate of product formation or consumption can 
be determined by qNMR.
204
 At the same time, indications of the structure of the 
product(s) can be obtained.
204
  
4.2. Optimisation of qNMR parameters 
From the examples given above, qNMR has been shown to be a very powerful and useful 
technique, widely used in diverse fields of chemistry and biochemistry.
199
 However, a 
number of parameters need to be optimised before and after the experiment. The 
1
H NMR 
experiment is composed of a relaxation time delay followed by a 90
o
 pulse, and ends with 
the acquisition of the signal (Figure 79).
205
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Figure 79 - 
1
H NMR components 
The repetition time (TR) represents the time required by the NMR instrument to acquire a 
single-scan spectrum,
199
 and depends directly on the relaxation delay (RD) and the 
acquisition time.
199
 The optimum RD is, by convention, 5 times the longitudinal 
relaxation (T1).
206
 When the nucleus is relaxing to return to its equilibrium state, the 
position of its spin can be followed in an (x,y,z) landmark, where the z component is the 
longitudinal relaxation T1, and the (x, y) component is the transverse relaxation T2 
(Figure 80).
207
  
 
Figure 80 - Characterisation of a spin in three-dimensions 
To obtain the highest signal and good accuracy of the results, the spin needs to recover 
fully from its 90° pulse before the next one. Just after the 90° pulse, the spin is only in the 
(x,y) plane. Before the next pulse, the spin needs to be re-aligned with the z axis and only 
possesses a longitudinal component of magnetisation. The time for the spin to acquire 99% 
of longitudinal magnetisation (maximum signal) is RD,
206
 which is calculated through T1, 
and determined experimentally (see Chapter 4, section 4.3.). The other variable that TR 
depends on is the acquisition time which needs to be long enough to recover FID signals 
fully without truncating any.
199
 Signal loss will affect the quality of the spectrum.
199
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Other parameters that could affect the accuracy are the signal-to-noise ratio (S/N) and 
temperature.
199
 Ideally, the S/N should be 250:1,
208
 and if too low, the resolution of the 
spectrum also becomes low. The S/N can be improved by increasing the number of scans 
or the concentration of the sample studied.
208
 In the 6-ethynylpurine studies, 4 to 8 scans 
per spectrum and a standard concentration of 6 mM of starting material was shown to 
give the optimum results. Temperature can affect the relaxation properties of the nuclei in 
a molecule, and it is therefore important to keep this constant during the entire 
experiment, which is of course also essential in kinetic studies.
205
 In the 6-ethynylpurine 
studies described below, the temperature was maintained at 24 ± 0.01 °C. 
After acquisition of the spectrum, a technique called ‘windowing’ is used to improve S/N. 
This consists of applying a filter to the data before Fourier transformation of the FID 
spectrum to enhance the FID signal.
199
 When analysing the spectrum, phase and baseline 
corrections are required to minimise inaccuracies when measuring the integration of the 
peaks.
199
 These two corrections were applied using Topspin 
TM
.  
qNMR is an accurate method when all the parameters are correctly optimised. However, 
to determine precisely the concentration of the molecule of interest, a reference is 
required.
199
 The latter is introduced at a known concentration which will allow a 
calculation of the concentration of any known species in the studied sample. The 
reference must be available in a highly pure form, be soluble in the NMR solvent and be 
inert to the reaction environment. The signal from the reference in the 
1
H NMR 
experiment must be in a region where no overlapping with other signals arises, in order to 
provide the most accurate signal integration, and a singlet is preferred for ease of data 
analysis.
199
 Finally, T1 of the reference must be close to T1 of the studied molecule for 
the reasons explained above. As a consequence, DMF, with its aldehydic resonance at δ 
7.9, was chosen for the 6-ethynylpurine qNMR studies. 
4.3. Optimisation of T1 
As explained previously, the relaxation time T1 needs to be optimised to afford the 
strongest signal possible. T1 can be measured experimentally using the inversion 
recovery method (Figure 81).
205
  
 107 
 
Figure 81 – The inversion recovery concept 
When the sample is in the NMR instrument, the nuclei align with the magnetic field 𝐵0⃗⃗⃗⃗  ⃗. 
With this method, a pulse is applied causing a 180° rotation of the nuclei, placing them 
anti-parallel to 𝐵0⃗⃗⃗⃗  ⃗. After this pulse, the nuclei then relax to return to their initial position, 
parallel to 𝐵0⃗⃗⃗⃗  ⃗. During their relaxation, a 90° pulse is applied. If by the time this second 
pulse is applied, the nuclei have had time to relax, the 90° pulse propels the nuclei 
directly perpendicular to 𝐵0⃗⃗⃗⃗  ⃗ along the (x,y) axis, giving a positive signal in the 1H NMR 
spectrum. However, if the nuclei did not have sufficient time to relax before the second 
pulse, the signal appears as negative in the 
1
H NMR spectrum and the nuclei are found 
along the –(x,y) axis. To have a zero net signal in the 1H NMR and determine D7, the 
nuclei need just enough time to relax until crossing the (x,y) axis (Figure 82).
207
  
 
Figure 82 - Relationship between the positions of the nuclei and the signals recovered 
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The time given for the nuclei to relax between the two pulses is the time delay (D7) and 
is directly linked to T1 by the relationship D7 = ln2 x T1.
207
 T1 is determined when D7 
has been optimised to obtain a zero net signal. The optimum relaxation delay can be 
calculated from T1 (RD = 5 x T1). This optimisation was carried out on the 6-
ethynylpurine 42 (Figure 83). The difference in relaxation between all the nuclei was 
observed, and the slowest proton to relax was the 6-ethynyl CH moiety. Ideally, D7 was 
found to be 5.0 seconds with a T1 value of 7.2 seconds. The optimum relaxation delay 
was therefore set as 36.0 seconds. 
 
Figure 83 - Inversion recovery experiment on 6-ethynylpurine 42 
4.4. 
1
H qNMR applied to 6-ethynylpurines 
The kinetic study of the reaction between the 6-ethynylpurines and the thiol of Cys22 
would assess the reactivity of the 6-ethynyl group towards Cys22. A model study was 
previously optimised within the group to mimic the Michael addition occurring within 
Nek2 kinase, using the time-resolved qNMR technique to monitor the reaction (Scheme 
25). N-Acetylcysteine methyl ester 157 was used as nucleophile to mimic the Cys22 
residue. However, because the reaction with this thiol was too slow, a base (DABCO) 
was added in catalytic quantity to generate the thiolate, which is much more reactive and 
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facilitates monitoring of the reaction. Ideally, the solvent for the reaction should be D2O 
to mimic as closely as possible biological conditions, but for solubility reasons DMSO-d6 
was chosen.  
 
Scheme 25 - Reaction of 6-ethynylpurine 42 with reagent 157 in the presence of DABCO 
The same conditions were used to study the reactivity of selected 6-ethynylpurines, and 
all of the reactions were carried out in a 5 mm NMR tube at a constant temperature (T = 
24 ± 0.01 °C). The reactions were monitored every 10 minutes using a customised 
1
H 
NMR experiment with the optimum relaxation delay determined experimentally (see 
Chapter 4, section 4.3.). The reactivity of 6-ethynylpurine 42, a lead compound of the 
project, was initially studied. Methylation at the N-7 and N-9 positions of the purine has 
been shown to affect the reactivity of 6-ethynylpurines with Nek2 by perturbing their 
binding. Studies of the N
7
- and N
9
-methyl isomers of both compounds 41 and 42 were 
performed to assess the effect of the methyl group on the reactivity of the 6-ethynyl group. 
4.5. Determination of E/Z isomer ratios 
The Michael type addition reaction (Scheme 25) was carried out on a larger scale to 
characterise fully the two isomers formed during the kinetic studies. The conditions were 
adapted by changing the reaction solvent to DMF rather than DMSO for ease of isolation. 
The 
1
H NMR spectrum revealed the formation of one main isomer, and to determine 
which isomer (E or Z) was formed, the products were isolated. The E isomer 158 was 
isolated pure but, surprisingly, the Z isomer 159 was obtained as an inseparable mixture 
with the product 160, arising from a double addition of reagent 157. 
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By comparison of the spectra of the isolated compounds, the major product (158) 
obtained was determined as the E isomer. The alkene resonances were not readily visible 
in the 
1
H qNMR spectrum, as the signal at δ 6.88 was overlapped with one aromatic 
resonance, while the other alkene resonance was under the NH signal of reagent 157. By 
carefully studying the 
1
H qNMR spectrum, a small signal corresponding to the NH acetyl 
of compound 159 was visible at approximately δ 8.55, suggesting the formation of the Z 
isomer. The ratio between the E and Z isomers could be determined by comparison of 
their NH acetyl resonances, which were very well defined (Figure 84). The ratio of 
compounds 158/159 was found to be 9:1 (E: Z isomers). It has been reported that thiolate 
attack on an ethynyl-ketone affords mainly the Z-isomer.
209
 
A comparison of the first qNMR spectrum obtained with the final one, showed the 
presence of unknown signals, which were present at the same concentration throughout 
the reaction (Figure 85). These signals did not arise from the starting materials, and a 
control experiment, repeating the kinetic experiment conditions without the purine, was 
conducted (Figure 85). The same signals were visible, indicating dimerisation of reagent 
157 in low concentration (10%) with oxidation by DMSO and oxygen seeming to be the 
likely explanation.
210
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Figure 84 - 
1
H NMR spectra illustrating the acetamido NH signals of compounds 158 and 159 
 
Figure 85 – 1H NMR spectra indicating the signals from the dimerisation of reagent 157 
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From a consideration of the reaction between compounds 42 and 157, it may be 
postulated that formation of allene intermediate 161 is followed by proton transfer from 
protonated DABCO to give the thioethenyl product (Scheme 26). If the proton approaches 
from the opposite side of the thioether group, then the Z-isomer 159 will be formed. 
However, this reaction pathway ‘pushes’ the thioether group toward the purine, which 
may render preferable the alternative mode of protonation leading to the 
thermodynamically stable E-isomer 158. A further possibility is that the Z-isomer 159 is 
the kinetic product, but undergoes rapid isomerisation to E-isomer 158 (Scheme 27). 
 
Scheme 26 – Mechanism of formation of the E (158) and Z (159) isomers from a common allene 
intermediate 
 
Scheme 27 - Postulated mechanism for the isomerisation of the product 159 
This stereochemical outcome differs from that observed for the irreversible inhibition of 
Nek2 by compound 42. In the enzyme ATP-binding site, the stereochemistry may be 
determined by the positioning of Cys22 and a proton source relative to the 6-ethynyl 
group of compound 42. For both the enzymatic and model systems, the direction of attack 
of the thiolate on the ethynyl group is presumably governed by the need to adopt a Bürgi-
Dunitz approach.
211
 It is widely known that a nucleophile approaches a carbonyl group at 
an angle of 107
o
 which maximises overlap with the π* orbital and minimises repulsion 
from the filled π orbital. The Bürgi-Dunitz approach can be extended to the Michael type 
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addition reaction observed between a 6-ethynylpurine and the Cys22 of Nek2 or N-
acetylcysteine methyl ester 157 (Scheme 28). 
 
Scheme 28 – The Bürgi-Dunitz approach on 6-ethynylpurines. 
4.6. Determination of the rate constant (k) 
The reaction between a 6-ethynylpurine and the thiolate 157
-
 formed from reagent 157 
and DABCO, gave a mixture of E/Z thioenol ethers (158/159). As a mixture of isomers 
was obtained, the rate of the reaction was more easily determined by following the 
consumption of the 6-ethynylpurine rather than product formation. The rate of the 
reaction will be dependent on the concentrations of 6-ethynylpurine, reagent 157 and 
DABCO. However, compound 157 was introduced in a 10-fold excess over the 6-
ethynylpurine rendering its concentration essentially constant throughout the reaction,
212
 
while the concentration of DABCO was considered constant. The reactions involved in 
the kinetic experiments can thus be expressed as follows: 
 
The reaction between thiol 157 and DABCO rapidly achieves equilibrium compared with 
the attack of thiolate 157
-
 on the 6-ethynylpurine (substrate). The equilibrium equation 
for the reaction between DABCO and thiolate 157
-
 can be written as follows: 
 K =
[157-]
e
[DABCO+]
e
 
[157]
e
[DABCO]
e
=
k
k'
     (1) 
After a short time, the initial concentration of thiol 157 can be written as: 
[157]0 = [157]𝑒 + [157
-]𝑒     (2) 
The rate of disappearance of the 6-ethynylpurine (substrate) can be expressed as: 
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−
d[sm]
dt
=k''[sm][157-]
e
= k''[sm]K[157]
e
 [DABCO]
e
[DABCO+]
e
 
      (3) 
By replacing [157
-
]e from Equation 1 in Equation 2, the following equation was obtained: 
[157]0 = [157]𝑒 + K[157]e
 [DABCO]
e
[DABCO+]
e
 
     (4) 
Therefore, [157]𝑒 can be expressed as: 
[157]𝑒 =
 [157]
0
1+K
 [DABCO]e
[DABCO+]e 
 
     (5) 
By substituting [157]𝑒 in Equation 3 by its expression from Equation 5, the final equation 
is: 
d[product]
dt
=k''[sm]K[157]
0
 [DABCO]
e
[DABCO+]
e
 + K[DABCO]
e
 
= k𝑎𝑝𝑝[sm]      (6) 
Knowing that the peak area of an NMR signal is directly related to the number of 
resonances contributing to the signal, the concentration of 6-ethynylpurine remaining was 
determined using Equation 7.  
[ethynylpurine] = [DMF] x 
ethynyl proton
peak area
aldehydic proton
peak area
   (7) 
For each reaction, the ethynyl proton CH was chosen to represent the quantity of 6-
ethynylpurine remaining, as this peak did not overlap with any other signal in the 
spectrum. The area of the signals of the ethynyl proton and the aldehydic proton from the 
DMF were carefully measured using Topspin
TM
. The two peaks of interest were always 
integrated between the same intervals for reproducibility. The data obtained from 
Topspin
TM 
were then manipulated with Microsoft Excel
TM
 to determine the apparent rate 
constant kapp of each reaction, kapp being the slope of the linear graph (Equation 6). 
Finally, the half-life (t1/2) of each reaction was calculated from the pseudo first order rate 
constant kapp (Equation 8). 
t1/2 = 
ln(2)
kapp
   (8) 
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4.7. Results of the kinetic studies 
The reaction between 6-ethynylpurine 42 and thiol 157 was monitored every 10 minutes 
by 
1
H qNMR, using 8 scans per spectrum, and disappearance of the 6-ethynyl proton was 
time-dependent (Figure 86). To calculate the kapp constant of the reaction, a logarithm 
function (ln) was applied to the concentration of compound 42 and plotted against time 
(Figure 87) to give a linear relationship. 
 
Figure 86 – Time-dependent consumption of compound 42 by thiol 157 in presence of DABCO 
 
Figure 87 – Linear relationship between time of reaction and concentration of compound 42 
The same reaction was conducted in triplicate and the values obtained from each 
experiment were similar. The slope of the linear graph obtained from the plot ln(42) 
against time gave the pseudo first order rate constant of the reaction (kapp) (Table 11). 
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Table 11 - kapp, R
2
, k and t1/2 values from the kinetic experiments with compound 42 
Experiment kapp (10
-4
 s
-1
) R
2
 value t1/2 (s) 
1 2.50 1.00 2773 
2 2.43 0.99 2852 
3 2.40 0.99 2888 
Average kapp = 2.44 10
-4
 s
-1
 
Average t1/2 = 2838 s 
The N
7
- and N
9
-methyl derivatives of compounds 42 and 41 (61-64) were also studied 
using the established 
1
H qNMR technique. The N
7
-methyl derivatives, 62 and 64, 
appeared to react faster than their NH analogues, 41 and 42, so the acquisitions were 
recorded every 3 minutes using only 4 scans. Data processing gave the following results 
(Table 12):  
Table 12 - kapp, R
2
, k and t1/2 values from the kinetic experiments 
 
Experiment kapp (10
-4
 s
-1
) R
2
 value t1/2 (s) 
1 3.87 1.00 1829 
2 3.86 0.99 1773 
3 3.01 0.99 2303 
Average kapp = 3.58 10
-4
 s
-1
 
Average t1/2 = 1968 s 
 
Experiment kapp (10
-4
 s
-1
) R
2
 value t1/2 (s) 
1 28.57 1.00 243 
2 27.77 0.99 250 
3 27.77 0.99 250 
Average kapp = 28.04 10
-4
 s
-1
 
Average t1/2 = 248 s 
 
Experiment kapp (10
-4
 s
-1
) R
2
 value t1/2 (s) 
1 2.87 0.99 2415 
2 3.11 0.99 2229 
3 3.01 0.99 2303 
Average kapp = 3.00 10
-4
 s
-1
 
Average t1/2 = 2316 s 
 
Experiment kapp (10
-4
 s
-1
) R
2
 value t1/2 (s) 
1 14.62 0.99 474 
2 15.19 1.00 468 
3 14.83 1.00 467 
Average kapp = 14.88 10
-4
 s
-1
 
Average t1/2 = 470 s 
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The experiments for each compound were repeated three times for accuracy of the results 
and as shown in Table 2, the results were consistent. The reactivity of the N
9
-methyl 
compounds, 61 and 63, was demonstrated to be close to the reactivity of the NH parents, 
41 and 42. However, the N
7
-methyl compounds, 62 and 64, were found to react 5 to 7 
times faster than their NH or N
9
-methyl analogues. Differences in reactivity were 
noticeable from the rate constant kapp values and the half-life values. The compounds 
bearing a simple aniline substituent at the 2-position showed a slightly higher reactivity 
than the ones having an amide substituent of the aniline ring (61 vs 63 and 62 vs 64). The 
amide function on the 2-aminoaryl group might be a weak electron-donor (because of the 
CH2 group) which would reduce the electrophilicity of the ethynyl moiety, affecting the 
rate of addition. 
4.8. Reactivity of N
7
-methyl purine 
One of the first observations about the reactivity of the N
7
-methyl compounds was their 
instability during the TIPS deprotection, under TBAF conditions. A second observation 
was easily made from the first one, which was the contribution of the groups at the 2-
position to the reactivity of the molecule, highly noticeable during TIPS deprotection (see 
Chapter 3, section 3.2.1.). Among the same library of compounds with only the 2-
substituents varying, yields were very diverse. As well, within the group, TIPS 
deprotection was carried out on a bioisostere of compound 42 having a CH2 group at the 
2-position instead of the NH group. In this case, the deprotection was much slower and 
complete after two hours
137
 compared to 5 minutes when having the NH group. These 
examples showed the influence of the groups at the 2-position on the stability of the 
ethynyl moiety. Another observation was the NMR shifts of the 6-ethynyl proton. The 
methyl group at the N-9 position had a slight effect on the ethynyl proton shift compared 
to the NH parent. The methyl group at the N-7 position, on the contrary, had a large effect 
on the shift of the ethynyl proton with almost 0.2 ppm of difference (Table 13). This 
observation correlated with the reactivity of the three compounds studied in kinetics. By 
comparison to the ethynyl proton shift, the carbon shift only changed slightly (Table 13). 
The last observation in NMR was the shifts of the methyl group. The resonance of the 
methyl group at the N-7 position was found to be downfield (δ 4.01) compared with the 
methyl group at the N-9 position (δ 3.76). As well, a significant change in 13C NMR shift 
was noticed when the methyl substituent was at the N-7 (δ 32.8) or at the N-9 position (δ 
29.3). This might be due to an interaction of the methyl group at the N-7 position with the 
ethynyl group.  
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Table 13 - 
1
H NMR shifts of compounds 42, 63 and 64. 
Compound 
1
H NMR shift of 
6-ethynyl proton 
13
C NMR shift of 
6-ethynyl proton 
1
H NMR shift of 
methyl protons 
13
C NMR shift of 
CH3 
42 4.82 86.9 - - 
63 4.84 87.1 3.76 29.3 
64 4.99 87.5 4.01 32.8 
 
From an assessment of these chemical observations in comparison with the biological 
results obtained for the N
7
-methyl derivatives, it was clear that a methyl group at the 
purine N-7 position activated the 6-ethynyl substituent to conjugate addition. The main 
reason for such activation was postulated to be a ‘buttressing’ effect, shown to influence 
the rate of racemisation of optically active derivatives of biphenyls.
213
  
The methyl group at the N-7 position of a purine scaffold was postulated to buttress the 
ethynyl group. As proposed from Adams’ work, the N7-methyl group should have a direct 
effect on bond angles.
214
 Small-molecule crystal structures obtained for the two N-methyl 
isomers, 63 and 64, showed a difference of 4° for the angle formed by the 6-ethynyl 
moiety and the purine core between the N
9
-methylpurine 63 and the N
7
-methylpurine 64 
(Figure 88). This observation confirmed the ‘repulsive’ effect of the methyl function, 
when situated at the N-7 position, on the ethynyl group. 
  
Figure 88 - X-Ray crystal structures of compounds 63 and 64. 
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This observation supported the hypothesis of a buttressing effect between the N
7
-methyl 
group and the 6-ethynyl moiety. This effect appeared to increase the rate of nucleophilic 
attack on the 6-ethynyl group during the Michael addition, and can be explained by the 
steric strain relief phenomenon.
215
 After attack of the nucleophile, the product formed is 
relieved from steric strain and is, therefore, under a more favoured state. The buttressing 
effect of the N-7 methyl group on the 6-ethynyl group imposed a steric strain in the 
molecule which accordingly became more reactive towards nucleophilic attack to be 
relieved from this unfavorable state. 
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Chapter 5. Substitution on the Vinyl Sulfone of 6-(Cyclohexylmethoxy)-
N-(4-(vinylsulfonyl)phenyl)-9H-purin-2-amine: Effects on Covalent 
Inhibition of CDK2 
The stability of vinyl sulfone 60 was shown to be compromised in plasma and cell culture 
medium (Figure 89). The main source of degradation was found to be hydration of 60, 
owing to the instability of the vinyl sulfone group in the presence of water. With the 
objective of improving chemical stability while retaining the biological activity of 60, 
analogues were synthesised and tested against CDK2. To fully understand the biological 
results of this new series, the 2-hydroxyalkyl compound derived from each vinyl sulfone 
was also prepared.  
 
 
Figure 89 - Stability of 60 in plasma, cell culture medium and acetonitrile
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In this chapter, the synthesis of selected α- and β-substituted vinyl sulfones is described. 
Such compounds, especially with electron-withdrawing substituents, have been rarely 
described in the literature. It was necessary to develop new routes to these target 
compounds, for which considerable experimentation was required that was partly 
frustrated by their reactivity and lability. 
5.1. Introduction of α-alkyl/aryl groups on the vinyl sulfone of 60 
In the crystal structure of vinyl sulfone 60 bound to CDK2, the vinyl sulfone group is 
orientated towards the solvent region, offering possibilities for structural modifications. 
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The α-position was first modified to investigate the influence of alkyl, aryl and electron-
withdrawing groups on the chemical reactivity of the vinyl sulfone warhead. The strategy 
towards the synthesis of these targets consisted of preparing an aniline derivative, which 
was reacted with 2-iodopurine 171 (Scheme 29). The aniline functional groups (FG) 
enabled formation of the desired vinyl sulfone moiety at the final stage of the synthesis. 
 
Scheme 29 – Synthetic strategy for the preparation of the α-substituted vinyl sulfones 162-170 
The common purine intermediate 171 was synthesised in three steps starting with 
protection of the purine N-9 of compound 68 with a PMB group, followed by 
nucleophilic aromatic substitution at the purine 6-position and, finally, iodination at the 
2-position of the purine (Scheme 30). 
 
Scheme 30 - Reagents and conditions: (i) Cs2CO3, 4-methoxybenzyl chloride in DMF, 60 
o
C, 18 
h, 60%; (ii) NaH, cyclohexylmethanol, r.t., 18 h, 70%; (iii) CH2I2, CuI, isoamyl nitrite in THF,  
65 
o
C, 2 h, 67%. 
5.1.1. α-Methyl analogue of vinyl sulfone 60 
Alkylation of thiophenol 173 with reagent 174 was performed in quantitative yield. The 
aldehyde 178 was obtained by consecutive hydrolysis of ester 175, followed by reduction 
of the resultant carboxylic acid 176 with borane, both steps occurring in high yields. The 
alcohol 177 was oxidised with the Dess-Martin periodinane to furnish aldehyde 178 in 
quantitative yield. Reductive amination of aldehyde 178 was carried out using sodium 
trimethoxyborohydride to give the tertiary amine 179. Finally, the nitro group of 
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compound 179 was reduced to the aniline 180 in the presence of zinc and acetic acid in 
excellent yield (Scheme 31).  
 
Scheme 31 - Reagents and conditions: (i) Et3N in DCM, r.t., 3 h, 94%; (ii) LiOH in THF, 50 °C, 
2 h, 88%; (iii) 1M borane in THF, r.t., 2 h, 76%; (iv) DMP in DCM, r.t., 3 h, 89%; (v) pyrrolidine, 
AcOH in toluene, r.t., 1 h; (vi) NaBH(OMe)3, r.t., 2 h, 85%; (vii) Zn, AcOH in MeOH, 50 °C, 1 h, 
98%. 
The aniline 180 was reacted with the intermediate 171 in a Buchwald coupling, followed 
by PMB deprotection in TFA to afford the intermediate 181 in 52% overall yield (Scheme 
32). The last step of the scheme was a one-pot procedure involving oxidation of sulfide 
181 with m-CPBA followed by a Cope type-elimination.
166
 For the parent compound 60, 
N-oxidation was sufficient to trigger the Cope type-elimination with formation of the 
vinyl sulfone and release of N-hydroxypyrrolidine. However, when a methyl group was 
present, a base was required for elimination, as the methyl substituent may have been too 
bulky and prevented the intermediate N-oxide from deprotonating at the α-position of the 
sulfone group. A weakly nucleophilic base (Cs2CO3) was chosen to prevent any reaction 
with the highly reactive vinyl sulfone moiety formed. 
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Scheme 32 - Reagents and conditions: (i) K2CO3, XPhos, Pd(dba)2 in MeCN, 80 °C, 18 h; (ii) 
TFA, 70 °C, 2 h, 62%; (iii) m-CPBA, Cs2CO3 in DCM, 0 °C, 0.5 h, 33%. 
The synthesis of the corresponding 2-hydroxyalkyl derivative of 162 started with the 
previously prepared aniline 177. Sulfide 177 was oxidised to the sulfone and the nitro 
group of compound 182 was reduced to the corresponding aniline 183, both steps 
proceeding in high yields. The aniline 183 was reacted with intermediate 171 to afford 
the 2-hydroxyalkyl derivative 184 after a Buchwald coupling and PMB deprotection 
(Scheme 33). 
 
Scheme 33 - Reagents and conditions : (i) m-CPBA in DCM, 0 
o
C, 0.5 h, 72%; (ii) Zn, AcOH in 
MeOH, 50 °C, 1 h, 91%; (iii) K2CO3, XPhos, Pd(dba)2 in MeCN, 80 °C, 18 h; (iv) TFA, 70 °C,   
2 h, 44%. 
5.1.2. α-Ethyl, isopropyl and phenyl derivatives of vinylsulfone 60 
With the objective of probing the space available at the α-position of the vinyl sulfone 
warhead of 60, larger groups were introduced. A common scheme was developed to 
introduce an ethyl, isopropyl and phenyl group, respectively. The same strategy as for the 
methyl derivative 162 was first considered, having a pyrrolidine moiety as precursor to 
the vinyl sulfone. Alkylation of thiophenol 173 with reagents 185, 186 and 187, 
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respectively, followed by hydrolysis and reduction with borane afforded the 
corresponding alcohols 194-196. However, oxidation with DMP led to extensive 
degradation when a phenyl (196) or ethyl group (194) was present and only a 20% yield 
was obtained when an isopropyl group (198) was in place (Table 14).  
Table 14 – Summary of yields for the synthesis of aldehydes 197-199.  
 
Reagents and conditions: (i) Et3N in DCM, r.t., 3 h; (ii) LiOH in THF, 50 °C, 2 h; (iii) 1M borane 
in THF, r.t., 2 h; (iv) DMP in DCM, r.t., 3 h. 
R group Yield for step (i) Yield for step (ii) Yield for step (iii) Yield for step (iv) 
Et 188 – 90% 191 – 89% 194 – 74% 197 – degradation 
i
Pr 189 – 46% 192 – 93% 195 – 84% 198 – 20%ddddd 
Ph 190 – 66% 193 – 96% 196 – 62% 199 - degradation 
 
Other oxidative methods were investigated including the Pfitzner-Moffatt procedure,
216
 
but no reaction was observed. Swern conditions were attempted but led to complete 
degradation when ethyl (194) and phenyl (196) groups were present, with a similar LC-
MS profile to the Dess-Martin periodinane procedure being observed, suggesting 
reactivity problems associated with the presence of the sulfide group. With an isopropyl 
group, the aldehyde 198 was obtained in 66% yield (Scheme 34). As a general method 
was preferred, this approached was discontinued. 
 
Scheme 34 - Reagents and conditions: (i) DCC, Et3N, TFA in DMSO/toluene, r.t., 18 h; (ii) 
DMSO, oxalyl chloride, Et3N in DCM, - 78 °C, 2 h, 0% (Et, 197), 66% (
i
Pr, 198), 0% (Ph, 199). 
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The strategy of utilising a leaving group to introduce the pyrrolidine moiety was then 
investigated. A mesyl group was first considered but attempts to mesylate the alcohol 194 
led only to a mixture of chloro compounds (200 and 201) (Scheme 35). Indeed, the lone 
pair of the sulfur displaced the mesyl group presumably leading to the formation of an 
episulfonium ion. The chloride counterion can then attack on either face (red or blue), the 
‘red’ being favoured by stabilisation of positive charge present in the transition state and 
the ‘blue’ being favoured by steric considerations (Scheme 35). 
 
Scheme 35 – Mechanism for the mesylation reaction on alcohol 194 
The chloro compounds (200 and 201) were isolated as 1:1 ratio of the isomers. An excess 
of pyrrolidine was added to 200/201, but no substitution was observed either at room 
temperature or by heating at reflux. Microwave heating was also tried but elimination 
was observed leading to an inseparable mixture of alkenes 204-206 (Scheme 36). Thus, 
although the chloro compounds (200 and 201) were stable to nucleophilic attack, under 
microwave heating, elimination reactions were observed and led to alkenes 204-206. 
 
Scheme 36 - Reagents and conditions: (i) pyrrolidine, r.t., 18 h, no reaction; (ii) pyrrolidine in 
MeCN, reflux, 2 h, no reaction; (iii) pyrrolidine in MeCN, MW, 150 °C, 4 bar, 30 min. 
The 2-hydroxyalkyl derivatives of vinylsulfones 163-165 were required and so the 
synthesis of these compounds was performed (Table 15) with the idea of using the 
leaving group strategy on these compounds (213-215) to obtain the desired vinyl sulfones 
163-165.  
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Table 15 – Summary of yields for the synthesis of 2-hydroxyalkyl derivatives 213-215. 
 
Reagents and conditions: (i) Zn, AcOH in MeOH, 70 °C, 2 h; (ii) K2CO3, XPhos, Pd(dba)2 in 
MeCN, 80 °C, 18 h; (iii) TFA, 70 °C, 2 h; (iv) m-CPBA, Cs2CO3 in DCM, 0 °C, 30 min; (v) 
MsCl, Et3N in DCM, r.t., 1 h then pyrrolidine. 
R group Yield for step (i) Yield for steps (ii) and (iii) Yield for step (iv) 
Et 207 – 77% 210 – 63% 213 – 28% 
i
Pr 208 – 79% 211 – 28% 214 – 36% 
Ph 209 – 85% 212 – 26% 215 – 56% 
 
The nitro group of compounds 194-196 was reduced to the corresponding aniline (207-
209). The anilines 207-209 were reacted with intermediate 171 in a Buchwald cross-
coupling reaction, followed by PMB deprotection as a one-pot procedure, affording the 
purine intermediates 210-212 in moderate yields. Oxidation of sulfides 210-212 to the 
required sulfones was achieved with m-CPBA. From the 2-hydroxyalkyl derivatives 213-
215, the corresponding mesylates were formed using methanesulfonyl chloride and an 
excess of triethylamine, but not isolated (confirmed by LC-MS). Pyrrolidine was used in 
an attempt to displace the mesyl group, but only the parent alcohols 213-215 were 
retrieved. A possible mechanism to explain this observation is shown in Scheme 37, and 
was supported by the isolation and characterisation of the pyrrolidine by-product (216) 
formed. 
 
Scheme 37 – Side-reaction observed during the attempted displacement of the mesyl group by 
pyrrolidine leading to the formation of 216 
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In the light of these results, tosylate, a larger group than mesylate, was considered. The 
tosylate intermediate was observed by LC-MS. Elimination was attempted by heating but 
no reaction was observed. Pyrrolidine was then used to displace the tosylate group but 
only the parent alcohol was obtained. Isolation and characterisation of the by-product 
formed during this reaction suggested a similar mechanism to that seen for the mesyl 
displacement reaction (Scheme 37). A last attempt was made from alcohol 213, using a 
thermal rearrangement with an acetate group, as reported in the literature.
217
 The acetate 
217 was readily synthesised from alcohol 213 using acetic anhydride. After isolation, 
acetate 217 was heated under microwave irradiation at 170 °C for 1 hour but no reaction 
was observed. Caesium carbonate was added to trap the acetic acid that would form but 
instead, triggered deacetylation to give the alcohol 213. This strategy (Scheme 38) was 
discontinued. 
 
Scheme 38 - Reagents and conditions: (i) Ac2O, Et3N, DMAP in DCM, r.t., 2 h, 60%; (ii) MeCN, 
MW 170 °C, 1 h; (iii) Cs2CO3 in MeCN, MW 100 °C, 15 min. 
From the attempts made previously, key information was obtained. Oxidation of the 
sulfides 194-196 was required, and the leaving group had to be chosen carefully to avoid 
regeneration of starting material as seen with mesylate and tosylate groups. After 
considering these results, the benzenesulfonyl group was selected (Table 16). 
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Table 16 – Summary of yields for the synthesis of the anilines 224-226.  
 
Reagents and conditions: (i) m-CPBA in DCM, 0 °C, 15 min; (ii) PhSO2Cl, Et3N in DCM, 
r.t., 18 h; (iii) pyrrolidine, r.t., 1 h; (iv) Zn, AcOH in MeOH, 50 °C, 1 h. 
R group Yield for step (i) Yield for steps (ii) and (iii) Yield for step (iv) 
Et 218 – 97% 221 – 75% 224 – 75% 
i
Pr 219 – 68% 222 – 65% 225 – 76% 
Ph 220 – 66% 223 – 61% 226 – 90% 
 
Compounds 194-196 were first oxidised with m-CPBA to give the corresponding 
sulfones 218-220 in high yields, which were reacted with benzenesulfonyl chloride and 
then pyrrolidine, in a one-pot procedure, to form the target tertiary amines 221-223. This 
step was further investigated to gain an understanding of the possible mechanism. 
Interestingly, the pyrrolidine did not directly substitute for the benzenesulfonyl group. 
Pyrrolidine first acted as a base to deprotonate at the α-position of the sulfone, which 
triggered elimination of the benzenesulfonate. The vinyl sulfone moiety thus formed 
reacted directly with pyrrolidine to give the tertiary amines 221-223 (Scheme 39). This 
step was high yielding for the three compounds studied. The last step was reduction of 
the nitro group to the corresponding amine to afford anilines 224-226 in good yields. This 
method allowed the synthesis of all three desired anilines, compared with the other 
approaches attempted that either failed or were only applicable to one analogue. 
 
Scheme 39 – Postulated mechanism of the one-pot reaction to convert the protected alcohol 227 
to the corresponding amine 
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When the one-pot procedure using benzenesulfonyl chloride was applied to alcohol 196, 
the alkene 229 was formed. In this case, pyrrolidine acted as a base effecting an 
elimination (Scheme 40). The resulting alkene is not electron-deficient and therefore, 
does not undergo nucleophilic attack by pyrrolidine, in contrast to the vinyl sulfone 228 
above (Scheme 39). 
 
Scheme 40 - Reagents and conditions: (i) benzenesulfonyl chloride, Et3N in DCM, r.t., 18 h; (ii) 
pyrrolidine, r.t., 1 h, 74%. 
The anilines 224-226 were reacted with intermediate 171 in the Buchwald reaction, 
followed by PMB deprotection. The corresponding N-oxide derivatives of amines 230-
232 were formed using m-CPBA and in the presence of caesium carbonate, the desired 
vinyl sulfone targets 163-165 were obtained. The yields were rather low, reflecting the 
reactivity issues with these compounds (Table 17). 
Table 17 – Summary of yields for the synthesis of the α-substituted vinyl sulfones 163-165.  
 
Reagents and conditions: (i) K2CO3, XPhos, Pd(dba)2 in MeCN, 80 °C, 18 h; (ii) TFA, 
70 °C, 2 h; (iii) m-CPBA, Cs2CO3 in DCM, r.t., 15 min, 23%. 
R group Yield for steps (i) and (ii) Yield for step (iii) 
Et 230 – 35% 163 – 23% 
i
Pr 231 – 18% 164 – 23% 
Ph 232 – 47% 165 – 29% 
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5.1.3. α-t-Butyl analogue of vinylsulfone 60 
The last target purine in the α-alkyl series was the t-butyl compound 166 for which 
several synthetic approaches were attempted. The first strategy entailed formation of a 
silyl enol ether 234, to be used subsequently in a Mukaiyama reaction (Scheme 41). 
 
Scheme 41 – First retrosynthetic approach for the synthesis of aniline 233. 
Various conditions were used for the synthesis of the silyl enol ether 234 from the ester 
237, obtained in two steps from thiophenol 175 (Scheme 42). The base, solvent and TMS 
source were varied (Table 18). The use of TMSCl and LDA in THF afforded 20% 
conversion according to 
1
H NMR analysis but was not reproducible. No literature 
precedent was found for the formation of a silyl enol ether on such a substrate (237), 
which raised the question of stability of the desired product. 
 
Scheme 42 - Reagents and conditions: (i) ethyl chloroacetate, Et3N in DCM, r.t., 1 h, 95%; (ii) m-
CPBA in DCM, r.t., 30 min, 86%; (iii) see Table 18. 
Table 18– Conditions studied for the formation of silyl enol ether 234 
 TMS source 
TMS-Cl TMS-Tf 
Base 
Et3N No reaction in toluene No reaction in THF 
NaH No reaction in toluene No reaction in THF 
LDA 
20% conversion in THF 
– not reproducible 
- 
 
Another approach required formation of the sulfur-carbon bond of compound 238 with an 
electrophilic source of sulfur (Scheme 43). Thus, either 4-nitrobenzenesulfenyl chloride 
(240) or 4-nitrobenzenesulfonyl chloride (242) was reacted with ethyl 3,3-
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dimethylbutyrate (239), previously treated with LDA (Scheme 44). These reactions led 
only to a complex mixture with no evidence of formation of the desired products, 238 and 
241. 
 
Scheme 43 – Second retrosynthetic approach to the synthesis of aniline 233. 
 
Scheme 44 - Reagents and conditions: (i) LDA in THF, -78 
o
C; (ii) LDA in THF, -78 
o
C. 
As the previous approaches were inconclusive, the synthesis of the thiol 244, from ketone 
246, was explored prior to reaction with 1-fluoro-4-nitrobenzene (245) (Scheme 45).  
 
Scheme 45 – Third retrosynthetic approach for the synthesis of aniline 233. 
The first step attempted was displacement of the chloro group from 1-chloropinacolone 
(247) by an alkoxide to form compound 246 (Scheme 46). Several conditions were tried 
using NaH and benzyl alcohol, and different solvents (THF, MeCN and DMF) in the 
absence or presence of potassium iodide. KHMDS was also used as an alternative to 
sodium hydride but under all conditions, no reaction was observed. 
 
Scheme 46 - Reagents and conditions: (i) NaH or KHMDS in THF or MeCN or DMF. 
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As displacement of the chloro group by an alkoxide proved unsuccessful, this reaction 
was conducted with a carboxylate following conditions found in the literature,
218
 and 
surprisingly, proceeded to give the ester 246b in quantitative yield (Scheme 47). The 
second step was the transformation of ketone 246b into thioketone 248. Achieving 
selectivity over the ester function was uncertain but two conditions were tried, namely 
Lawesson’s reagent and hexamethyldisilathiane with TMS-Tf, for which no reaction was 
observed in either case. This was probably due to the steric bulk imposed by the t-butyl 
group of compound 246b preventing the approach of reagents onto the ketone. 
 
Scheme 47 - Reagents and conditions: (i) benzoic acid, DIPEA in DMF, r.t., 2 h, 67%; (ii) 
Lawesson’s reagent in toluene, 110 oC, 18 h; (iii) hexamethyldisilathiane, TMSTf in MeCN, r.t., 
18 h. 
 
Scheme 48 – Fourth retrosynthetic approach for the synthesis of aniline 233. 
From the outset it was recognised that access to aniline 233 would be challenging. 
Although the retrosynthetic analysis of this last approach was obvious (Scheme 48), this 
method was tried last as concerns were raised as to an SN2 reaction on a sterically 
hindered electrophile, known to be disfavoured. Encouragingly, the reaction between 
thiophenol 173 and 1-iodo-2,2-dimethylpropane (251) was achieved (Scheme 49). 
Oxidation of sulfide 252 led to intermediate 250. Hydrocarbonylation was performed 
using LHMDS and solid CO2, affording 45% conversion to carboxylic acid 249. No 
higher yield was obtained but sulfone 250 was recovered and re-used. Consecutive 
reduction of the carboxylic acid and nitro groups gave the desired aniline 233. The 
successful route (Scheme 49) profited from the relatively high nucleophilicity of the 
thiolate of 173, which enabled SN2 displacement on the sterically hindered reagent 251, 
as well as the ability of the relatively small electrophile CO2 to capture the anion from 
250. 
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Scheme 49 - Reagents and conditions: (i) K2CO3 in DMF, r.t., 18 h, 68%; (ii) m-CPBA in DCM, 
r.t., 1 h, 86%; (iii) LHMDS in THF, -78 
o
C for 1 h then CO2, r.t., 1 h, 49%; (iv) 1M borane in 
THF, 50 
o
C, 18 h, 73%; (v) Zn, AcOH in MeOH, r.t., 1 h, 84%. 
Aniline 233 was reacted with intermediate 171 under Buchwald conditions followed by 
PMB deprotection to afford the desired 2-hydroxyalkyl derivative 254 (Scheme 50). The 
latter was converted into the corresponding target vinyl sulfone 166 by forming a 
mesylate which was then eliminated by DBU. From the same scheme, both 2-
hydroxyalkyl derivative 254 and vinyl sulfone compound 166 were obtained. 
 
Scheme 50 - Reagents and conditions: (i) K2CO3, XPhos, Pd(dba)2 in MeCN, 80 °C, 18 h; (ii) 
TFA, 70 °C, 2 h, 55%; (iii) MsCl, Et3N in DCM, r.t., 1 h then DBU, r.t., 0.5 h, 69%. 
5.2. Introduction of α-electron-withdrawing groups on the vinyl sulfone of 60 
To explore further the α-position of the vinyl sulfone warhead of 60, electron-
withdrawing groups were introduced. Having such a group at this position has been 
described in the literature, endowing a reversible covalent character to the inhibitor 
(Scheme 51).
219
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Scheme 51 – Mechanism for reversible covalent inhibition (adapted from Lee, 2012)219 
Inspired by this idea, chloro, fluoro and trifluoromethyl groups, electron-withdrawing by 
the inductive effect, were first investigated at the α-position of the vinyl sulfone warhead 
of compound 60. The cyano group, electron-withdrawing by virtue of inductive and 
mesomeric effects, was also considered. 
5.2.1. α-Chloro analogue of vinylsulfone 60 
Chlorination at a methylene group between a sulfone and ester moiety has previously 
been reported.
220
 This type of reaction was initially attempted on substrate 257 bearing 
only a sulfone group (Scheme 52), but no target compound was obtained. 
 
Scheme 52 - Reagents and conditions: (i) 2-chloroethanol, KOH in EtOH, reflux, 18 h, 96%; (ii) 
m-CPBA in DCM, 0 °C, 30 min, 84%; (iii) benzenesulfonyl chloride, Et3N in DCM, r.t., 18 h; (iii) 
pyrrolidine, r.t., 1 h, 67%; (iv) NaH, NCS in THF, r.t., 18 h. 
The reaction was incomplete and heating led to an intractable mixture. One main product 
was isolated from the reaction carried out at room temperature, for which LC-MS and 
1
H 
NMR analysis indicated formation of the elimination product 259, which could have been 
formed through loss of HCl from the dichlorinated product (Scheme 53). 
 
Scheme 53 - Possible mechanism for the formation of the elimination product 259. 
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To repeat more closely the literature conditions, chlorination was performed on substrate 
261, which was obtained by the following route (Scheme 54): 
 
Scheme 54 - Reagents and conditions: (i) tert-butyl chloroacetate, Et3N in DCM, r.t., 1 h, 90%; 
(ii) m-CPBA in DCM, r.t., 30 min, 95%; (iii) NaH, NCS in THF, r.t., 18 h, 78%; (iv) 10% TFA in 
DCM, r.t., 18 h. 
Monochlorination at the methylene group between the sulfone and the t-butyl ester, by 
controlling the stoichiometry, afforded the chlorinated compound 262 in good yield. The 
t-butyl ester was chosen for its easy cleavage under acidic conditions, but in the presence 
of TFA, decarboxylation of ester 262 was observed leading to the β-chloromethyl sulfone 
264. Hydrolysis of ester 262 under basic conditions gave only a mixture of compounds, 
and to avoid the hydrolysis step, reduction of the ester was considered. As ethyl esters are 
preferred for reduction, the synthesis was repeated using ethyl ester 237 instead of the t-
butyl ester 261 (Scheme 55). DIBAL was preferred for the reduction of ester 265 to 
minimise dehalogenation. However, although the desired alcohol 266 was obtained under 
these conditions, dehalogenation was also observed (LC-MS analysis), explaining the 
moderate yield of 56%.  
 
Scheme 55 - Reagents and conditions: (i) NaH, NCS in THF, r.t., 18 h, 66%; (ii) DIBAL in THF, 
0 
o
C, 2 h, 66%; (iii) Zn, AcOH in MeOH, r.t., 1 h, 84%. 
Reduction of the nitro group of compound 266 gave the aniline 267, which was coupled 
to intermediate 171, in the one-pot process comprising Buchwald coupling and PMB 
deprotection. By this route, the two target compounds, vinyl sulfone 167 and 2-
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hydroxyalkyl derivative 268, were synthesised. The vinyl sulfone 167 was obtained as 
described previously from alcohol 268, via an intermediate mesylate (Scheme 56). 
 
Scheme 56 - Reagents and conditions: (i) K2CO3, XPhos, Pd(dba)2 in MeCN, 80 °C, 18 h; (ii) 
TFA, 70 °C, 2 h, 33%; (iii) MsCl, Et3N in DCM, r.t., 22%. 
5.2.2. α-Fluoro derivative of vinylsulfone 60 
The fluoro compounds 168 and 272 were obtained in a similar manner to that employed 
for the α-chlorovinyl sulfone target 167. The only difference in the synthetic scheme was 
the step utilised for introduction of the fluoro group (Scheme 57). This was attempted 
following literature conditions, using Selectfluor,
221
 and led to a 64% yield of the 
fluorinated compound 269. 
 
Scheme 57 - Reagents and conditions: (i) NaH, Selectfluor in THF, r.t., 18 h, 62%; (ii) DIBAL in 
THF, 0 
o
C, 2 h, 68%; (iii) Zn, AcOH in MeOH, r.t., 1 h, 62%. 
The aniline 271 was coupled to intermediate 171 in the one-pot process described 
previously (Scheme 58). The vinyl sulfone 168 was obtained from the 2-hydroxyalkyl 
derivative 272 via a mesylate intermediate. 
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Scheme 58 - Reagents and conditions: (i) K2CO3, XPhos, Pd(dba)2 in MeCN, 80 °C, 18 h; (ii) 
TFA, 70 °C, 2 h, 33%; (iii) MsCl, Et3N in DCM, r.t., 10%. 
5.2.3. α-Cyano analogue of vinylsulfone 60 
Insertion of a cyano group at the α-position of the vinyl sulfone warhead proved to be 
difficult and remains to be achieved. The first approach for the synthesis of this target 
involved nucleophilic displacement of the chloro group from compound 274 to give the 
cyano derivative 273 (Scheme 59).  
 
Scheme 59 – First retrosynthetic approach for the introduction of an α-cyano group 
This reaction was first tried on the chloro compound 265 obtained previously, but no 
reaction was observed (Scheme 60). The same conditions were applied to substrate 276, 
synthesised from alcohol 266 and protected with a TBDMS group (Scheme 61). However, 
no product (277) was isolated. 
 
Scheme 60 - Reagents and conditions: (i) Et4NCN in MeCN, 18 h. 
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Scheme 61 - Reagents and conditions: (i) TBDMSCl, imidazole in DCM, 0 
o
C, 18 h, 85%; (ii) 
Et4NCN in MeCN, 18 h. 
Another strategy required formation of epoxide 278, followed by ring opening by attack 
of cyanide (Scheme 62).  
 
Scheme 62 – Second retrosynthetic approach for the introduction of an α-cyano group 
Epoxide 278 was prepared from alcohol 266 under basic conditions but only isolated in 
low yield because of loss in the work-up of the reaction owing to the polarity of 
compound 278 (Scheme 63). A one-pot process was considered with epoxide formation 
being followed by ring opening. Different conditions were investigated to favour attack 
on the internal carbon of the epoxide (Scheme 63). Indeed, in the literature, some 
examples reported nucleophilic attack at the most substituted carbon via coordination of 
the epoxide oxygen to a metal centre.
222
 This approach was attempted on epoxide 278 
using both copper cyanide and zinc cyanide.  
 
Scheme 63 - Reagents and conditions: (i) Cs2CO3 in MeCN, r.t., 25%; (ii) Et4NCN in MeCN, r.t.; 
(iii) Cu(CN) in MeCN, r.t.; (iv) Zn(CN)2 in MeCN, r.t. 
Under the three reaction conditions attempted, the same compound (280) was formed, 
arising from nucleophilic attack at the terminal carbon of the epoxide 278, leading to 
formation of the sulfinic acid 280 (LC-MS and 
1
H NMR analysis) and presumably 2-
cyanoethanal (281) (Scheme 64). 
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Scheme 64 - Mechanism of epoxide ring opening of compound 278 
Another strategy considered was cyanation with an electrophilic source of cyanide 
(Scheme 65).
223
 
 
Scheme 65 – Third retrosynthetic approach for the introduction of an α-cyano group 
A literature precedent was found reporting the use of tosyl cyanide.
224
 This reaction was 
attempted on substrate 282, obtained from ester 237 via reduction to the alcohol and 
protection with a benzyl group. These conditions for the cyanation were unsuccessful as 
no reaction to give compound 283 was observed (Scheme 66). 
 
Scheme 66 - Reagents and conditions: (i) DIBAL in THF, 0 
o
C, 2 h, 62%; (ii) NaH, BnBr in 
DMF, r.t., 3 h, 59%; (iii) LDA, TsCN in THF, -78 
o
C to 0 
o
C. 
The fourth attempt required the use of methyl cyanoacetate (285). Deprotonation of 
methyl cyanoacetate (pKa ~ 13 in DMSO
225
) can be easily achieved using a base such as 
caesium carbonate (Scheme 67). 
 
Scheme 67 – Fourth retrosynthetic approach for the introduction of an α-cyano group 
Two reagents were tried as electrophiles, 4-nitrobenzenesulfenyl chloride (240) and 4-
nitrobenzenesulfonyl chloride (242). Reaction with compound 240 was not conclusive 
(Scheme 68). However, the reaction with compound 242 was successful, and the use of 
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molecular sieves was found to be crucial to prevent formation of the sulfonic acid 
(Scheme 69). 
 
Scheme 68 - Reagents and conditions: (i) 285, Cs2CO3 in DCM, r.t.. 
 
Scheme 69 - Reagents and conditions: (i) 285, Cs2CO3, molecular sieves, in DCM, 0 
o
C, 51%. 
By 
1
H NMR analysis, the ester moiety of compound 284 was found to exist primarily in 
its enolic form, with a mixture of both E and Z isomers (284a and 284b) being observed. 
The next step was reduction of the ester 284 into the corresponding alcohol 279. To 
reduce selectively the ester moiety in the presence of the cyano group, lithium 
pyrrolidinoborohydride was first employed but no reaction was observed, and sodium 
borohydride was also unsuccessful (Scheme 70). As reduction of the ester group of 
compound 284 proved unsuccessful, hydrolysis was attempted but no reaction was 
observed (Scheme 70). Probably, the ester moiety, in its enolic form, was unreactive. As a 
consequence, this route was discontinued. 
 
Scheme 70 - Reagents and conditions: (i) Lithium pyrrolidinoborohydride in THF, r.t., 18 h; (ii) 
NaBH4 in MeOH, r.t., 2 h; (iii) 2M LiOH in THF, 50 
o
C, 5 h. 
Another approach involved the formation of β-cyanomethyl sulfone 288, prior to the 
introduction of an alkyl group (Scheme 71).  
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Scheme 71 – Fifth retrosynthetic approach for the introduction of an α-cyano group 
Formation of intermediate 288 was achieved in high yield (Scheme 72). To facilitate 
deprotonation at the α-position of the cyano group, the sulfide 290 was converted into the 
corresponding sulfone 288 (pKa ~ 21 in DMSO for the sulfide and 12 in DMSO for the 
sulfone
225
). Introduction of an alkyl group using a chloromethyl ether reagent (289) was 
attempted to obtain the protected hydroxyl group at the desired position. Two reagents 
were tried, chloromethyl methyl ether (289, R = Me) and benzyl chloromethyl ether (289, 
R = Bn), both commercially available at low technical grade purity. Reactions with these 
two reagents led to the formation of the same unidentified by-product (Scheme 72). This 
route may have been successful if the reagents would have been available at higher purity. 
Purification of the reagents was not attempted due to their toxicity. 
 
Scheme 72 - Reagents and conditions: (i) iodoacetonitrile, Et3N in DCM, r.t., 1 h, 87%; (ii) m-
CPBA in DCM, r.t., 1 h, 33%; (iii) NaH, 289 in THF, r.t. 
In summary, several strategies were investigated for the synthesis of the desired aniline 
273. This unsuccessful work emphasised the challenges of introducing several polar 
functional groups on a small labile molecule, and further efforts on this target were 
discontinued for the time being. 
5.2.4. α-Trifluoromethyl derivative of vinylsulfone 60 
To form the desired aniline 293, the approach considered was disconnection at the sulfur 
as shown in Scheme 73. 
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Scheme 73 – First retrosynthetic approach for the introduction of an α-trifluoromethyl group 
3,3,3-Trifluoropropane-1,2-diol (296) was a key intermediate obtained by reduction of 
ester 295.
226
 The secondary alcohol was selectively protected in good yield with a 
TBDPS group (297) (Scheme 74). 
 
Scheme 74 - Reagents and conditions: (i) LiAlH4 in THF, reflux, 2h, 82%;.(ii) TBDPSCl, 
imidazole in DCM, 0 °C, 1h, 75%. 
Formation of a leaving group from the tertiary alcohol 297 was investigated. Attempted 
preparation of the triflate 298, using several conditions, or the mesylate 299 failed. 
However, tosylate and benzenesulfonyl intermediates, 300 and 301, respectively, were 
obtained, and both intermediates were reacted with thiophenol 173 (Scheme 75).  
 
Scheme 75 - Reagents and conditions: (i) Tf2O, Et3N in DCM, 0 °C, 2 h or NaH, in THF then 
Tf2O, or NaH in THF then N-phenyltriflimide, 2 h, or MsCl, Et3N in DCM, 2 h; (ii) TsCl, Et3N in 
DCM, r.t., 2 h, or benzenesulfonyl chloride, Et3N in DCM, 5 h; (iii) 173, Et3N in DCM, r.t. 
A new product slowly appeared in both reactions (after 4 days of heating), and after 
isolation proved to be a by-product (303) arising from attack of the thiolate on the silicon 
of the TBDPS protecting group (Scheme 76). Attack on a carbon at the α-position of a 
CF3 group is known to be challenging.
227
 
  
 143 
 
Scheme 76 – Putative mechanism for formation of by-product 303 
Another protecting group was chosen because of this side reaction. Benzylation was 
attempted on the diol 296 using two different conditions, but no reaction was observed 
(Scheme 80). However, the protected alcohol 304 was obtained from the reaction between 
epoxide 306 and alcohol 305 (Scheme 77). 
 
 
Scheme 77 - Reagents and conditions: (i) BnBr, DIPEA in MeCN, r.t.; (ii) BnBr, K2CO3, KI in 
MeCN, r.t.; (iii) BF3.Et2O, 40 °C, 18 h, 85%. 
Formation of triflate 307 and tosylate 308 from the alcohol 304 was observed and these 
were treated directly with the thiolate 173
-
 but no reaction was observed (Scheme 78). 
 
Scheme 78 - Reagents and conditions: (i) Tf2O, Et3N in DCM, 0 °C or TsCl, Et3N in DCM, r.t.; 
(ii) 173, Et3N in DCM, r.t. 
Another approach was considered for the synthesis of aniline 293 using a reagent (310) 
providing an electrophilic source of CF3 (Scheme 79).
228
 
 
Scheme 79 – Second retrosynthetic approach for the introduction of an α-trifluoromethyl group 
Several conditions were studied on two different substrates using the reagent 5-
(trifluoromethyl)dibenzothiophenium trifluoromethanesulfonate (310). In each case, the 
 144 
same LC-MS profile was obtained indicating the presence of starting material and 
unidentified by-products (Scheme 80).  
 
Scheme 80 - Reagents and conditions: (i) 310, NaH in THF, r.t.; (ii) 310, NaH in MeCN, MW, 
110 °C, 30 min; (iii) 310, LDA in THF, -78 °C. 
As an alternative, the synthesis of a trifluoromethylalkyl derivative 313 was attempted, 
which would then be functionalised as an ester or carboxylic acid (Scheme 81).  
 
Scheme 81 – Third retrosynthetic approach for the introduction of an α-trifluoromethyl group 
The first step of the synthetic route was successful, in satisfying yield, and this was 
followed by oxidation of sulfide 314 to sulfone 313 (Scheme 82). Insertion of the ethyl 
ester moiety at the α-position of the sulfone group of 313 was attempted (Table 19). 
Several conditions were tried, varying the base and the temperature, but no desired 
product (311) was formed. 
 
Scheme 82 - Reagents and conditions: (i) ICH2CF3, Rongalit, K2CO3 in DMF, r.t., 18 h, 62%; (ii) 
m-CPBA in DCM, 1 h, 63%; (iii) diethyl carbonate in THF, see Table 19 for conditions 
investigated. 
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Table 19 – Conditions tried for the functionalisation of sulfone 313 
 Temperature 
r.t. 70 
o
C 
Base 
LHMDS 
Unknown compound 
isolated.  
LC-MS indicated 
impurities  
KHMDS 
LC-MS indicated impurities - 
After purification, no target 
compound obtained. 
LC-MS indicated 
impurities 
NaH No reaction - 
 
As the introduction of an ester group onto sulfone 313 was unsuccessful, the insertion of 
a carboxylic acid was investigated, using LHMDS and solid CO2 (Scheme 83). The LC-
MS of the crude mixture showed formation of both the carboxylic acid 315 and an 
unknown compound, with the latter being the major product. After a study of the 
1
H 
NMR spectrum and LC-MS analysis, formation of the corresponding acyl fluoride 316 
was suggested, arising from the mechanism shown in Scheme 84.  
 
Scheme 83 - Reagents and conditions: (i) LHMDS, CO2 in THF, -78 
o
C to r.t., 1 h. 
 
Scheme 84– Mechanism for the formation of acyl fluoride 316 
Several strategies were attempted for the synthesis of the desired aniline 293 but none 
were successful. Despite the results, interesting chemistry was highlighted along with the 
difficulties of synthesising these highly functionalised intermediates. 
5.3. Introduction of a β-methyl group on the vinyl sulfone warhead of 60 
In parallel with modifications at the α-position of the vinyl sulfone warhead of compound 
60 (Chapter 5, sections 5.1 and 5.2), the β-position was also investigated. From 
examining the crystal structure of vinyl sulfone 60 bound to CDK2, space was perceived 
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to be available at this position to accommodate groups, as the vinyl sulfone pointed 
towards the solvent. However, it was recognised that substitution at the β-position could 
render attack from Lys89 more difficult because of steric hindrance. 
5.3.1. β-methyl analogue of vinylsulfone 60 
Nucleophilic attack by thiophenol 173 on the chloroketone 317 proceeded in quantitative 
yield to give compound 318. Reductive amination of ketone 318 afforded amine 319. The 
nitro function of intermediate 319 was reduced to give the desired aniline 320 in good 
overall yield (Scheme 85). 
 
Scheme 85 - Reagents and conditions: (i) Et3N in DCM, r.t., 3 h, 98%; (ii) pyrrolidine, AcOH in 
toluene, r.t., 1 h; (iii) NaBH(OMe)3, r.t., 2 h, 57%; (iv) Zn, AcOH in MeOH, 50 °C, 1 h, 64%. 
As previously described, Buchwald reaction and PMB deprotection were carried out as a 
one-pot procedure leading to the intermediate 321 in 50% yield. However, oxidation of 
sulfide 321 with m-CPBA, followed by addition of caesium carbonate led only to 
degradation. Conversion of the sulfide 321 to the sulfone 322 was performed using oxone, 
which enabled better control over the oxidation step.
229
 The sulfone intermediate 322 
underwent Cope elimination using m-CPBA and caesium carbonate, leading to the target 
compound 323, albeit in low yield, as exclusively the E-isomer (determined by 
1
H NMR 
analysis) (Scheme 86).  
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Scheme 86 - Reagents and conditions: (i) K2CO3, XPhos, Pd(dba)2 in MeCN, 80 °C, 18 h; (ii) 
TFA, 70 °C, 2 h, 50%; (iii) oxone, H2O in MeOH, r.t., 1 h, 38%; (iv) m-CPBA, Cs2CO3 in DCM, 
0 °C, 30 min, 15%. 
The 2-hydroxyalkyl derivative 327 was synthesised directly from compound 318 in four 
steps (Scheme 87). The aniline 326 was reacted with intermediate 171 as before to afford 
the target compound 327. 
 
Scheme 87 - Reagents and conditions: (i) m-CPBA in DCM, 0 
o
C, 1 h, 73%; (ii) Dibal in THF, 0 
o
C, 3 h, 92%, (iii) Zn, AcOH in MeOH, 50 °C, 1 h, 84% (iv) K2CO3, XPhos, Pd(dba)2 in MeCN, 
80 °C, 18 h; (v) TFA, 70 °C, 2 h, 31%. 
5.3.2. α,β-Dimethyl analogue of vinylsulfone 60 
To complete the series of methyl derivatives of vinyl sulfone 60, the α,β-dimethyl 
compounds, 332 and 333, were prepared to enable evaluation of the combined effect of 
the two methyl groups. The synthetic scheme was similar to those discribed previously, 
starting from the thiophenol 173. The desired aniline 331 was formed in four steps in 
good overall yield, and was obtained as a mixture of diastereoisomers (4: 1) (Scheme 88).  
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Scheme 88 - Reagents and conditions: (i) 3-chloro-2-butanone, Et3N in DCM, r.t., 1 h, 89%; (ii) 
m-CPBA in DCM, 0 
o
C, 1 h, 92%; (iii) Dibal in THF, 0 
o
C, 3 h, 99%, (iv) Zn, AcOH in MeOH, 
50 °C, 1 h, 78%. 
A Buchwald coupling reaction between aniline 331 and the intermediate 171, followed by 
PMB deprotection, afforded the 2-hydroxyalkyl derivative 332 as a mixture of 
diastereoisomers (9:1) (Scheme 89). To obtain the corresponding vinyl sulfone 333, the 
mesylate was prepared from the alcohol 332 and elimination was performed using DBU. 
After addition of DBU, both vinyl sulfone 333 and 2-hydroxyalkyl compound 332 were 
visible. Competition was observed between deprotonation of the hydrogen at the α-
position of the sulfone group leading to elimination of the mesylate, and deprotonation of 
the methyl group of the mesylate to regenerate compound 332. This observation 
presumably accounted for the low yield of this last step in the synthesis of target 333. The 
vinyl sulfone compound 333 was obtained as a mixture of E and Z isomers (2:1 E:Z, ratio 
determined by 
1
H NMR analysis).  
 
Scheme 89 - Reagents and conditions: (i) K2CO3, XPhos, Pd(dba)2 in MeCN, 80 °C, 18 h; (ii) 
TFA, 70 °C, 2 h, 46%, (iii) MsCl, Et3N in DCM, r.t., 1 h; (iv) DBU, 17%. 
  
 149 
5.3.3. α-Chloro-β-methyl analogue of vinylsulfone 60 
From the biological activity observed for the α-chlorovinyl sulfone 167 (see Chapter 8) 
and the crystal structure of the β-methylvinyl sulfone 323 in complex with CDK2, the α-
chloro-β-methyl analogue of 60 was deemed to be an interesting target to assess the 
combined effects of the α-chloro and β-methyl groups on the vinyl sulfone. To synthesise 
the aniline 337, an analogous strategy to that used for the α-chloro target 167 was 
followed. Chlorination of compound 324 was then attempted under the conditions 
established previously but dichlorination (335) with loss of the acetyl group was observed. 
Other conditions were tried such as hydrogen peroxide and potassium chloride,
230
 but a 
similar observation was made (Scheme 90). The protons are relatively acidic in 
compounds 324-334 (pKa of 324 ~ 12 in DMSO
225
), evidently favouring further 
chlorination. The chlorination was performed on the sulfide 318 (pKa ~ 19 in DMSO
225
), 
but again, formation of the dichloro compound 335 was observed. 
 
Scheme 90 - Reagents and conditions: (i) m-CPBA in DCM, 0 
o
C, 1 h, 73%; (ii) NaH, NCS in 
THF, r.t. or KCl, H2O2 in AcOH, r.t. 
Owing to the difficulties encountered with direct chlorination, another strategy had to be 
considered. The new approach entailed introduction of the methyl ketone on the chloro 
alkyl intermediate 264, obtained by hydrolysis with in situ decarboxylation of the ester 
265. Several bases and alkylating agents were investigated at -78 
o
C in THF to determine 
the best combination, which proved to be LHMDS and EtOAc (Scheme 91, Table 20). 
 
Scheme 91 - Reagents and conditions: (i) LiOH in THF, 70 
o
C, 2 h, 88 %; (ii) see Tables 4 and 5; 
(iii) Zn(BH4)2 in Et2O/THF, r.t., 0.5 h, 73% over 2 steps; (iv) Zn, AcOH in MeOH, r.t., 1 h, 71%. 
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Table 20 – Conditions studied for the acetyl group introduction onto 264 
 Acetyl source 
 Acetaldehyde Acetyl chloride Ethyl Acetate 
Base 
n-BuLi 10% conversion
a
 No conversion
a
 No conversion
a
 
KHMDS - - 10% conversion
a
 
LHMDS - - 50% conversion
a
 
a.
 Conversion estimated by LC-MS 
Following this study, optimisations were carried out by varying the amount of LHMDS, 
EtOAc and reaction time. Varying the amount of EtOAc (Table 21, Exp2 and 4) or the 
reaction time (Table 21, Exp3) had little effect on the reaction outcome. However, 
increasing slightly the amount of LHMDS (Table 21, Exp5) improved the product 
formation up to 80%. The best conditions were found to be LHMDS (1.5 eq) and EtOAc 
(2.5 eq) for 1 h.  
Table 21 – Effect of reaction parameters on the conversion of 264 into 334 
 Exp1 Exp2 Exp3 Exp4 Exp5 
EtOAc 1.2 equiv. 2.5 equiv. 2.5 equiv. 10 equiv. 2.5 equiv. 
LHMDS 1.2 equiv. 1.2 equiv. 1.2 equiv. 1.2 equiv. 1.5 equiv. 
Time of 
reaction 
30 min 30 min 1 h 1 h 1 h 
Conversion
a
 50% 55% 60% 60% 80% 
a.
 Conversion estimated by LC-MS 
Reduction of ketone 334 was attempted with DIBAL but led to a mixture of products, 
none of which was the desired alcohol 336. A milder, less basic reducing agent, 
Zn(BH4)2
231
 was used (Scheme 96) and successfully gave the intermediate 336, which 
was further reduced to the aniline 337, obtained as a mixture of diastereoisomers 
(2:1).The 2-hydroxyalkyl derivative 338 and the vinylsulfone 339 were synthesised 
following the synthetic scheme previously described (Scheme 92). The 2-hydroxyalkyl 
derivative 338 was obtained as a mixture of diastereoisomers (2: 1) and the vinyl sulfone 
339 as a single isomer (determined by NMR analysis).  
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Scheme 92 - Reagents and conditions: (i) K2CO3, XPhos, Pd(dba)2 in MeCN, 80 °C, 18 h; (ii) 
TFA, 70 °C, 2 h, 17%; (iii) MsCl, Et3N in DCM, r.t., then DBU, r.t., 0.5 h, 50%. 
5.4. Synthesis of a cyclic analogue of 60 
Another interesting target was compound 349 where the vinyl function is constrained 
within a six-membered ring. A similar route to that used previously was first investigated 
(Scheme 93). Thiophenol 173 was reacted with cyclohexene oxide 340 to give a 1:1 
mixture of enantiomers 341. The sulfide 341 was oxidised to the corresponding sulfone 
342 using m-CPBA. The strategy using benzenesulfonyl chloride to introduce the 
pyrrolidine moiety was, in this case, unsuccessful, with only starting material 342 being 
isolated (Scheme 93). 
 
Scheme 93 - Reagents and conditions: (i) DIPEA in DCM, r.t., 18 h, 60%; (ii) m-CPBA in DCM, 
r.t., 1 h, 92%; (iii) benzenesulfonyl chloride, Et3N in DCM, r.t., 18 h; (iv) pyrrolidine, r.t., 1 h. 
 
Scheme 94 - Reagents and conditions: (i) MsCl, Et3N in DCM, r.t., 1 h; (ii) DBU, r.t., 1 h, 56%. 
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Formation of the mesylate 344 was carried out as detailed previously and DBU was 
added to trigger the elimination (Scheme 94).
232
 As these conditions proved successful, 
they were applied to the synthesis of the target vinyl sulfone 345 (Scheme 95). Thus, 
compound 342 was reduced to the aniline 346, which was subjected to Buchwald 
coupling and PMB deprotection to afford the 2-hydroxyalkyl compound 347 as a mixture 
of enantiomers. The purine derivative 347 was transformed into the corresponding 
mesylate and elimination was accomplished using DBU. However, the compound 
obtained (by LC-MS) was the N
9
-mesyl derivative 348 rather than the required vinyl 
sulfone 349. To deprotect the N
9
-H of the purine, an excess of DBU was introduced 
leading to the target vinyl sulfone 349.  
 
Scheme 95 - Reagents and conditions: (i) Zn, AcOH in MeOH, 50 °C, 1 h, 92%; (ii) K2CO3, 
XPhos, Pd(dba)2 in MeCN, 80 °C, 18 h; (iii) TFA, 70 °C, 2 h, 57%; (iv) MsCl, Et3N in DCM, r.t., 
1 h; (v) DBU (excess), r.t., 1 h, 23%. 
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Chapter 6. Structural Biology on Selected Purine Inhibitors in Complex 
with CDK2/cyclin A 
In the CDK2 project, central to this thesis, inhibitors were designed and synthesised using 
a structure-based approach employing the crystal structure of the lead compound (60) in 
complex with CDK2/cyclin A. In this chapter, the co-crystal structures of selected purine 
inhibitors in complex with CDK2/cyclin A are discussed, from protein expression to the 
interpretation of the results with the objective to understand how modifications of the 
vinyl sulfone warhead of compound 60 influenced the binding mode of new compounds. 
X-ray crystallography emerged as a valuable tool in drug discovery in the 1980s.
233
 High 
throughput screening (HTS) has been used for approximately two decades to identify hits 
against specific targets. Once identified, a detailed analysis of a crystal structure of a 
protein-ligand complex is now routinely used to highlight specific interactions between 
the ligand and the protein at an atomic level.
234
 Drug design can be guided by the 
structure of the protein in complex with the ligand. Another approach to hit identification 
is fragment-based design, which has emerged in the last decade, and where small 
fragments are identified as hits using high throughput X-ray crystallography.
235
 An 
extensive design protocol starts to optimise interactions with the protein, with only a few 
compounds being synthesised.
235
 X-ray crystallography is an essential technique in drug 
discovery whatever the approach chosen, and constitutes the basis for almost every 
contemporary drug development program today. 
6.1. CDK2/cyclin A complex as a structural target 
CDK2 was expressed in its full length, which corresponded to 298 amino acids (~34 kDa), 
whereas only a truncated version of cyclin A was expressed (between amino acids 173 
and 432, ~30kDa), comprising the CDK2 binding domain and the two cyclin box folds 
(Figure 90).
49
 
 
Figure 90 – A. Schematic representation of CDK2; B. Schematic representation of cyclin A 
(adapted from Noble, 1997)
49
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6.2. Expression of GST-tagged CDK2 and CIV1 constructs in E. coli 
The protein of interest was the protein cyclin A/CDK2
Thr160
 and therefore expression of 
cyclin A and CDK2
Thr160
 was required. To express CDK2 in its phosphorylated form, 
CIV1, the equivalent of the human CAK complex, was also expressed using the modified 
pGEX6P-1 vector and the construct, which was transformed into the E. coli expression 
host strain BL21(DE3)pLys/S. The vector contained genes encoding for a replication 
origin, an antibiotic resistance (for ampicillin), a lac operon and a GST-tag with 3C- and 
thrombin-protease cleavage site for CDK2 and CIV1, respectively.
236
 Protein expression 
was induced by the addition of IPTG (Figure 91). 
 
Figure 91 – pGEX6P-1 expression vector containing the lac operon (lac I), the ampicillin 
resistance gene (Amp) and the GST-tag with 3C-protease cleavage sequence (PreScission 
Protease)
236
 
6.3. Expression of the cyclin A construct in E. coli 
The pET vector, modified to express cyclin A, was transformed into BL21(DE3)pLys/S 
competent E. coli cells. The vector contained genes encoding for the lac operon, a T7 
promoter specific to T7 RNA polymerase, and an ampicillin resistance gene. The pET 
vector, unlike the pGEX vector, offers an indirect regulation where the gene of interest is 
not transcribed unless T7 RNA polymerase is present.
237
 Addition of IPTG activates the 
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lac operator on the gene encoding for T7 polymerase, which in this case triggers the 
expression of cyclin A (Figure 92).
237
 
 
Figure 92 – The pET system with the production of T7 RNA polymerase following IPTG 
induction, which is key for the generation of the target gene cyclin A.
237
 
6.4. Purification of the CDK2/cyclin A complex 
The bacterial cells were lysed and the supernatant fluid containing GST-tagged 
CDK2
Thr160
 was mixed with the supernatant containing cyclin A to form the target 
CDK2
Thr160
/cyclin A complex as a GST-tagged protein. This complex was purified by 
affinity chromatography and eluting with glutathione. The GST-tag was cleaved with 3C-
protease, used as a GST fusion protein itself for purification purposes. 3C-Protease 
recognises the sequence LeuGluValLeuPheGln/GlyPro and cleaves between the Gln and 
Gly residues (Figure 91).
236
 The resulting mixture was purified by size exclusion 
chromatography (Figure 93). 
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Figure 93 – Size exclusion chromatogram using a HiLoad 26/60 Superdex 75 column 
After purification, the CDK2
Thr160
/cyclin A complex (~64 kDa) was found to be 
contaminated with GST dimer (~52 kDa), which co-eluted during the size exclusion 
chromatography. The fractions containing the CDK2
Thr160
/cyclin A complex were 
combined and loaded onto a fresh glutathione column to remove the GST dimer 
contaminant by affinity chromatography (Figure 94). 
 
Figure 94 - Electrophoresis showing the different steps of the purification of the CDK2/cyclin A 
complex (A. After first glutathione column; B. After size exclusion chromatography using 
Superdex 75 column; C. Pure CDK2
Thr160
/cyclin A complex obtained after the second affinity 
chromatography purification step). 
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6.5. Crystal formation and data collection 
The purified CDK2
Thr160
/cyclin A complex was obtained in good yield (~11 mg/mL) and 
was mixed with the appropriate inhibitors. Crystallisation conditions for CDK2 were 
already established (0.8 M KCl, 1.1 M ammonium sulfate, 0.1 M Hepes pH 7.0), but a 
small matrix screen around the known conditions was set up to further optimise the 
crystallisation. Usually, several parameters can be optimised such as protein 
concentration, pH, the precipitant, precipitant concentration, the buffer type and the 
temperature.
238
 In this study, only the concentrations of ammonium sulfate (0.8 to 1.3 M, 
0.1 increment) and salt (KCl, 0.6 to 0.95 M, 0.05 increment) were modified. Screens were 
performed in 2-subwell 96 well plates. The protein mixture and crystallisation solution 
were mixed in the subwells, in 100 nL drops, using a ‘Mosquito’ robot. Crystallisation 
trays were stored at 4 
o
C in a Rokagu Minstrel incubator, for up to two weeks and crystal 
formation was monitored through automated imaging of the drops recorded at a set time 
point. Crystals were grown using the sitting drop vapour diffusion method where the 
protein became supersaturated and was driven out of the solution in the form of crystals. 
Crystallisation was helped by the precipitant, which caused proteins to adhere to each 
other by competing for solvent (Figure 95).  
   
Figure 95 - Principles of the sitting drop vapour diffusion crystallisation and protein solubility 
phases
238
 
After ten days, crystals appeared under the conditions containing 1.2 or 1.3 M ammonium 
sulfate and 0.75 or 0.8 M KCl (Figure 96). Once crystals were formed, they were 
harvested at 4 °C by the ‘loop mount’ method.238 They were then soaked into a cryogenic 
solution containing 30% of saturated ammonium sulfate or sodium sulfate before being 
flash frozen in liquid nitrogen. The use of a cryoprotectant has the advantage of 
protecting the crystals from radiation damage caused by X-ray analysis, and avoiding the 
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formation of hexagonal ice, known to diffract X-rays, in contrast to water glass. The 
crystals were stored in liquid nitrogen until studied by X-ray crystallography. 
 
Figure 96 – A drop containing crystals formed under the conditions of 1.3 M ammonium sulfate 
and 0.8 M KCl 
The protein expression, purification, and crystallisation were carried out with the help of 
Professor Jane Endicott, Dr Martyna Pastok and Stephen Hallett. The crystal harvesting 
and data collection was performed with the help of Dr Arnaud Basle. 
6.6. Highlights of the X-ray crystal structure determinations 
The resolution obtained from X-ray analysis of the crystals was in the range of 3.1 to 
2.1Å. Data analysis was performed only on one crystal per inhibitor (4 crystals were sent 
for each inhibitor in complex with CDK2 to the Diamond Light Source in Oxford, UK) 
having a resolution of 2.1 – 2.0 Å. Data were processed using XDS239 and Aimless240. 
The molecular replacement was applied using MOLREP
241
 and a CDK2/cyclin A 
structure. Rigid-body and restrained refinement was performed using REFMAC5.
242
 
Inhibitor models were positioned into the electron density in the active site using JLigand 
in COOT.
243
 Finally, the structures were further refined by Professor Martin Noble to 
assess the presence of covalent binding between the inhibitors and CDK2. 
For modulating the reactivity of the vinyl sulfone warhead of compound 60, the α-
position was more thoroughly investigated (see Chapter 5). Understanding the binding 
mode of inhibitors bearing α-substituents was important to interpret the biological results 
obtained from the time-dependent assays. The X-ray crystal structure of the compound 
bearing a methyl group at the α-position of the vinyl sulfone moiety (162) was obtained 
at 2.1 Å resolution (Figure 97). The inhibitor 162 was shown to bind in a similar manner 
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to compound 60 with the purine interacting with the hinge region, the cyclohexyl 
substituent positioned in the ribose pocket and the vinyl sulfone directed towards the 
solvent. The X-ray crystal structure of the ethyl analogue 163 was also determined at 2.1 
Å resolution (Figure 98). A similar binding mode was observed as for compound 162. No 
interaction with Lys89 was present in both X-ray crystal structures, demonstrating that α-
alkyl substituents hindered the attack from Lys89 onto the vinyl sulfone.  
    
Figure 97 - Purine 162 in complex with CDK2/cyclin A. The structure was determined at 2.1 Å 
resolution. 
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Figure 98 – Purine 163 in complex with CDK2/cyclin A. The structure was determined at 2.1 Å 
resolution. 
Both analogues retained potency in the time-dependent assay against CDK2, which can 
be attributed to the binding mode of the compound, consistent throughout this series, and 
showing that the triplet of H-bonds with the hinge region and the interaction of the purine 
6-cyclohexylmethyl group with the ribose pocket are crucial for activity. 
In the biological assay to determine the activity of the inhibitors against CDK2, the 2-
hydroxyalkyl compounds showed activity similar to their vinyl sulfone parents. To 
rationalise this observation, the X-ray crystal structure of the 2-hydroxyalkyl analogue 
184 was obtained at 2.0 Å resolution (Figure 99). The hydroxyl group did not make any 
new interactions with the protein and the activity of this compound against CDK2 was 
attributed to its binding mode, with crucial interactions arising within the hinge region 
and the ribose pocket. 
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Figure 99 – Purine 184 in complex with CDK2/cyclin A. The structure was determined at 2.0 Å 
resolution. 
The inhibitor bearing a methyl group at the β-position of the vinyl sulfone warhead (323) 
had a similar time-dependent inhibition profile to the α-methyl analogue (162) (see 
Chapter 8). The X-ray crystal structure of inhibitor 323 was obtained at 2.1 Å resolution 
(Figure 100) and showed the same interactions within the hinge region and the ribose 
pocket. However, with the methyl group at the β-position, Lys89 was able to attack the 
vinyl sulfone to make a covalent interaction. The mobility of Lys89 was noteworthy as its 
position in this X-ray crystal structure (Figure 100) was different from that observed for 
the previous crystal structures described (Figures 97-99). 
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Figure 100 – Purine 323 in complex with CDK2/cyclin A. The structure was determined at 2.1 Å 
resolution. 
The difference in reactivity between compounds 162 and 323 may be rationalised by two 
explanations. When a nucleophile reacts with a carbonyl group, the nucleophile 
approaches from an angle of 107
o
, termed the Bürgi-Dunitz angle (see Chapter 4, section 
4.5.).
211
 Assuming that this concept can be extended to Michael additions
244
 and to 
electron-deficient double bonds, then it is important to consider this reaction in the 
context of the protein environment. From the crystal structures (Figures 97 and 98), the 
orientation of Lys89 appears to be sub-optimal for attack onto the vinyl sulfone group via 
a Bürgi-Dunitz angle. Having a group at the α-position may provoke a twist in the 
conformation of the vinyl sulfone warhead. In addition to the Bürgi-Dunitz angle itself, 
the Bürgi-Dunitz trajectory also has to be considered. If approach of the nucleophile 
along the preferred trajectory is impeded, e.g. by a substituent in the molecule undergoing 
attack, then the rate of reaction may be considerably reduced. In this respect, the β-methyl 
group may cause greater difficulties as such a group is more likely to interfere with the 
nucleophile’s trajectory than a group in the α-position. However, since the structural 
biology results indicated a covalent interaction only with a group at the β-position, this 
suggests that other factors may be involved. 
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Another explanation for the observations made from the binding mode of these inhibitors 
is the stability of the intermediate formed during the Michael addition. When the 
nucleophile attacks the vinyl sulfone warhead, an intermediate is formed leading to a 
negative charge adjacent to a methyl group (162) or a hydrogen atom (323). A methyl 
group, being electron-donating, would destabilise the negative charge by comparison 
with hydrogen, rendering the intermediate less stable and therefore, product formation 
less favoured (Figure 101). This explanation rationalises the difference in reactivity 
observed between the inhibitors 162 and 323, although the Bürgi-Dunitz concept is still 
relevant for the type of reaction discussed. 
 
Figure 101 - A possible explanation for the difference of reactivity between inhibitors 162 and 
323. 
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Chapter 7. Investigation of New Electrophilic Warheads for Covalent 
Inhibition of CDK2 
Following the discovery of the vinyl sulfone purine 60, the first reported covalent 
inhibitor of CDK2, initially only analogues of the vinyl sulfone were synthesised 
(Chapter 5). In this chapter, the design and synthesis of analogues of purine 60 bearing a 
different electrophilic warhead are discussed with the objective of investigating the 
possibility of an alternative group at this position on the purine. 
7.1. Acrylamide analogue of 60 
The acrylamide group is a widely used electrophilic substituent for covalent binding in 
kinase inhibitors.
81, 106, 107, 118
 To maintain the interaction between the sulfone and Asp86 
of CDK2, compound 353 was designed. Buchwald coupling with purine 171 to afford the 
intermediate 351, followed by reaction with acryloyl chloride, gave a di-acrylamide 
compound 352, even though the stoichiometry was controlled. Compound 352 underwent 
PMB deprotection using TFA to give the acrylamide 353, with adventitious loss of one 
acrylamide group (Scheme 96). 
 
Scheme 96 - Reagents and conditions: (i) K2CO3, XPhos, Pd(dba) in MeCN, 80 °C, 18 h, 21%; 
(ii) acryloyl chloride, Et3N in DCM, r.t., 2 h, 29%; (iii) TFA, 70 °C, 2 h, 53%. 
7.2. Vinyl sulfonamide analogue of 60 
Because acrylamide was a popular electrophilic warhead and the lead compound 60 of 
the CDK2 project contained a vinyl sulfone group, the vinyl sulfonamide 362 was of 
interest. The aniline 359 was constructed in a similar way to the previous targets. 4-
Nitroaniline 354 failed to react with 2-chloroethanesulfonyl chloride, presumably because 
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the amino group was not sufficiently nucleophilic. p-Phenylenediamine 356 was mono-
protected to give aniline 357, which reacted with 2-chloroethanesulfonyl chloride to yield 
the sulfonamide 358. Addition of pyrrolidine to the vinyl sulfonamide 358 afforded the 
aniline 359 (Scheme 97). 
 
Scheme 97 - Reagents and conditions: (i) Cl(CH2)2SO2Cl, DIPEA in DCM, r.t, 2 h; (ii) Et3N, 
Boc2O in DMF, r.t., 3 h, 84%; (iii) Cl(CH2)2SO2Cl, DIPEA in DCM, r.t, 2 h, 36%; (iv) 
benzenesulfonyl chloride, Et3N in DCM, r.t., o/n; (v) pyrrolidine, r. t., 60%. 
An Ullmann-type reaction between the aniline 359 and intermediate 171 was performed, 
followed by Boc and PMB deprotection to give the intermediate 360 (Scheme 98). As the 
PMB group proved difficult to remove, microwave heating was required, which led, 
according to LC-MS analysis, to the trifluoroacetamide 360. The trifluoroacetamide 
group was easily cleaved with sodium borohydride to afford intermediate 361. When    
m-CPBA was used for the Cope elimination step, the compound 362 could not be directly 
isolated in a pure state.  
 
Scheme 98 - Reagents and conditions: (i) CuI, 2-thiophenecarboxylic acid in DMSO, 60 °C, 5 h; 
(ii) TFA, 110 °C, MW, 45 min; (iii) NaBH4 in MeOH, r.t., 15 min, 34% (over 3 steps); (iv) m-
CPBA in DCM, r.t., 30 min. 
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Another synthetic route was considered that avoided the use of m-CPBA (Scheme 99). 
The first step was Buchwald coupling between intermediate 171 and aniline 354, 
followed by PMB deprotection to afford intermediate 363. Reduction of the nitro group 
gave aniline 364. However, after several attempts at purification, no product was obtained. 
Hydrogenation with Pd/C under H2 was performed as alternative conditions for the 
reduction giving a clean reaction and the subsequent step was carried out on the crude 
compound 364. The final step showed complete reaction with formation of the vinyl 
sulfonamide 362 but, purification by column chromatography, either on silica or alumina, 
did not provide pure enough compound. 
1
H NMR analysis showed the presence of the 
desired target and minor impurities. The stability of the compound was assessed in acidic, 
basic and neutral aqueous environment, with no visible degradation by LC-MS. The 
isolation of compound 362 in a pure state was eventually achieved by semi-prep HPLC. 
 
Scheme 99 - Reagents and conditions: (i) K2CO3, XPhos, Pd(dba)2 in MeCN, 80 °C, 18 h; (ii) 
TFA, reflux, 5 h, 42%; (iii) Pd/C, H2 in MeOH, 40 °C, 2 h, 97%; (iv) Cl(CH2)2SO2Cl, DIPEA in 
DCM, r.t, 2 h, 3%. 
7.3. β-Ketosulfone analogue of 60 
As discussed previously, hydrolysis of the vinyl sulfone warhead of 60 was a major 
problem (see Chapter 5). An attractive inhibitor would be a compound with the potential 
for irreversible binding, but reacting preferentially with an amino group (from Lys89) 
compared with water. The β-ketosulfone could offer this selectivity via a mechanism 
comparable to a reductive amination. The iminium ion formed from the reaction of the 
ketone with Lys89 could lead to a resonance-stabilised ene-sulfonamide (Scheme 100).  
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Scheme 100 - Possible reaction between Lys89 of CDK2 and the β-ketosulfone moiety 
The β-ketosulfone intermediate 324, available from one of the syntheses described 
previously, underwent nitro reduction to form the aniline 365. The optimised one-pot 
process, Buchwald reaction followed by PMB deprotection, was then performed to 
provide the target compound 366 (Scheme 101). 
 
Scheme 101 - Reagents and conditions: (i) Zn, AcOH in MeOH, r.t., 1h, 77%; (ii) K2CO3, XPhos, 
Pd(dba)2 in MeCN, 80 °C, 18 h; (iii) TFA, reflux, 5 h, 45%. 
7.4. α-Halosulfone derivatives of compound 60 
During the preparation of the α-chlorovinyl sulfone derivative 167, the chloromethyl 
sulfone intermediate 264 was obtained. This substance was of interest because of its 
potential reactivity towards Lys89 of CDK2 (Scheme 102) by analogy with the known 
reactivity of α-chloroketones.  
 
Scheme 102 - Possible reaction between Lys89 and the α-haloalkyl derivative 
Intermediate 264 was reduced to the corresponding aniline 367, which was reacted with 
intermediate 171 under the standard conditions, to afford the α-chloromethyl sulfone 368 
(Scheme 103). 
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Scheme 103 - Reagents and conditions: (i) Zn, AcOH in MeOH, r.t., 1h, 70%; (ii) K2CO3, XPhos, 
Pd(dba)2 in MeCN, MW, 100 °C, 30 min; (iii) TFA, reflux, 5 h, 47%. 
Although fluoride is a poor leaving group in SN2 reactions, the α-fluoromethyl derivative 
372 was of interest because the synthesis of the α-fluoromethyl sulfone compound 370 
from an ester had no literature precedent. Hydrolysis was performed on ester 269, but 
decarboxylation did not occur readily by comparison with the chloro compound 265 (see 
Chapter 5, section 5.2.1.). The carboxylic acid 369 was therefore heated by microwave 
irradiation to trigger decarboxylation. Reduction of the nitro group afforded the aniline 
371, which was then reacted with intermediate 171 to give the target compound 372 
(Scheme 104). 
 
Scheme 104 - Reagents and conditions: (i) LiOH in THF, 50 °C, 2 h; (ii) in MeCN, MW, 180 
o
C, 
1 h, 79% over 2 steps; (iii) Zn, AcOH in MeOH, r.t., 1 h, 78%; (iv) K2CO3, XPhos, Pd(dba)2 in 
MeCN, MW, 100 °C, 30 min; (v) TFA, reflux, 5 h, 23%. 
7.5. α-Trifluoromethylsulfone derivative of 60 
From the results obtained previously (Chapter 5, section 5.2.4.), the α-trifluoromethyl 
sulfone group was interesting as it could react with Lys89 according to two mechanisms. 
The protons on a methylene flanked by a sulfone and a trifluoromethyl group are 
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relatively acidic (estimated pKa ~ 12 in DMSO
225
). Removal of such a proton could be 
followed by fluoride elimination to give an extremely reactive difluorovinyl sulfone for 
reaction with Lys89 (Scheme 105, Mechanism 1). Furthermore, this species in the 
presence of water may lead to an acyl fluoride, which could also react with Lys89 
(Scheme 105, Mechanism 2). 
 
Scheme 105 - Possible reactions between Lys89 and the α-trifluoromethylsufone derivative. 
The synthesis of this purine derivative (375) was straightforward with reduction of 
intermediate 314 to the aniline 373, which was reacted with intermediate 171. The final 
oxidation step provided the desired product 375 (Scheme 106). Oxidation was performed 
at the final step to avoid working with a reactive functionality throughout the synthesis, 
which could have led to side reactions. 
 
Scheme 106 - Reagents and conditions: (i) Zn, AcOH in MeOH, r.t., 1h, 85%; (ii) K2CO3, XPhos, 
Pd(dba)2 in MeCN, MW, 100 °C, 30 min; (iii) TFA, reflux, 5 h, 43%; (iv) m-CPBA in DCM, r.t., 
2 h, 40%. 
  
 170 
7.6. Vinyl ketone analogue of 60 
The effect of several substituents on the vinyl moiety was assessed, but the importance of 
the sulfone group still remained to be determined. The corresponding vinyl ketone 389 
was therefore of interest. The synthesis of the appropriate aniline was attempted 
following two different routes. The first scheme considered (Scheme 107) was lengthy 
with reduction of both ketone and ester groups of compound 376 required to give the diol 
378, followed by selective protection of the alcohol 378 and oxidation of the alcohol 379, 
with a difficult final deprotection step (Scheme 107). Other protecting groups than 
TBDPS could have been explored but a shorter route was clearly more desirable. 
 
Scheme 107 - Reagents and conditions: (i) NaBH4 in MeOH, r.t., 1 h, 64%; (ii) Dibal in THF, 0 
o
C, 1 h, 78%; (iii) imidazole, TBDPSCl in DCM, 0 
o
C, 1 h, 44%; (iv) DMP in DCM, r.t., 2 h, 
85%; (v) TBAF in THF, 0 
o
C, 1 h, degradation; (v) or fluoride on polymer support in THF, r.t., 18 
h, no reaction observed. 
A Stille reaction on the acyl chloride 382 gave the desired vinyl ketone 383 (Scheme 108). 
Completing the synthesis with this reactive group in place would have been challenging, 
and hence a masking approach was necessary. Addition of pyrrolidine to the vinyl ketone 
led to intermediate 384. With this group in place, Cope elimination would have enabled 
formation of the vinyl ketone at the final step of the synthesis. However, nitro reduction 
under the usual conditions led to degradation. Hydrogenation could have been attempted 
as an alternative but, in parallel, a more promising route was also investigated. 
 
Scheme 108 - Reagents and conditions: (i) tributyl(vinyl)tin, Pd(PPh3)4 in THF, 65 
o
C, 1 h, 35%; 
(ii) pyrrolidine in DCM, r.t., 2 h, 51%; (iii) Zn, AcOH in MeOH, r.t., 1h, degradation observed.  
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To synthesise the majority of the previous target compounds, an aniline intermediate was 
first formed and then coupled with the 2-iodopurine intermediate 171. Another strategy 
was considered starting with a Buchwald reaction between aniline 386 and intermediate 
171 (Scheme 109). A Weinreb amide 388 was prepared from the corresponding ester 387 
in good yield, and addition of vinylmagnesium chloride to the amide afforded the desired 
vinyl ketone 389. From the Weinreb amide 388, another target (390) was also synthesised 
by the addition of ethynylmagnesium bromide (Scheme 110). From this approach, from 
the common intermediate 388, two new warheads were introduced onto the purine. 
 
Scheme 109 - Reagents and conditions: (i) K2CO3, XPhos, Pd(dba)2 in MeCN, MW, 100 °C, 30 
min; (ii) TFA, reflux, 5 h, 55%; (iii) isopropylmagnesium chloride, N,O-dimethylhydroxylamine 
in THF, 0 
o
C, 2 h, 97%; (iv) vinylmagnesium chloride in THF, 0 
o
C, 2 h, 36%. 
 
Scheme 110 - Reagents and conditions: (i) ethynylmagnesium bromide in THF, r.t., 18 h, 25%. 
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Chapter 8. Biological Evaluation of the CDK2 Inhibitors 
In this chapter, the biological results of the inhibitors synthesised as described in 
Chapters 5 and 7 are presented and discussed. Each inhibitor was tested in an enzyme 
kinetic experiment which determined an inhibition profile of the studied compound over 
time. The kinetic assays were run up to 4 hours as results after this period were found not 
to be useful. Vinyl sulfones were shown to exhibit stability issues (see Chapter 5) and if 
the studied vinyl sulfone did not react with the enzyme during the 4 hours of the assay, it 
is possible that the inhibitor had degraded, partially or completely, into its 2-hydroxyalkyl 
derivative. Covalent inhibitors are known to react with the target enzyme gradually with 
time at a rate depending on the reactivity of the inhibitor.
101
 Therefore, if the experiment 
illustrates an increase of activity with time, this observation can be interpreted as covalent 
binding occurring between the studied inhibitor and enzyme. However, as the 
experiments were conducted only once (n = 1), and the inhibitors were incubated with the 
enzyme for 30 min prior to the first measurement, covalent inhibition, if suspected by the 
time-dependent inhibition profile of the inhibitor, had to be confirmed by structural 
biology studies. Indeed, some covalent inhibitors can react so quickly with the enzyme 
(e.g. during the incubation time) and therefore demonstrate a profile with activities within 
the same range throughout the experiment. Thus, the kinetic measurements could only 
provide an indication of the possibility of covalent binding and always required 
confirmatory structural biology studies. 
8.1. The α-substituted vinyl sulfone series 
Each vinyl sulfone derivative was assessed in a time-dependent assay against CDK2 (n = 
1). The graphs illustrating CDK2 inhibition versus the concentration of the studied 
inhibitor are shown below (Figure 102). In the alkyl/aryl series (162-166), the crucial 
observation was that there was no clear case of time-dependent inhibition compared to 
compound 60, indicating a lack of covalent binding between the inhibitors and CDK2. In 
addition, a loss of potency was noticed for groups larger than methyl (IC50 > 500 nM for 
164-166 and IC50 > 200 nM for 163), but no correlation was found between the potencies 
and the size of the groups at the α-position. 
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Figure 102– Biological results for compounds 162-166 and 60 in the time-dependent assay 
against CDK2 
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The 2-hydroxyalkyl derivatives corresponding to each vinyl sulfone were also evaluated 
against CDK2. The activities observed for these compounds were found to be within the 
same range exhibited for the parent vinyl sulfones (or they were less active) (Table 22). 
Moreover, the similar potencies exhibited by the pairs of inhibitors (vinyl sulfone and its 
corresponding 2-hydroxyalkyl analogue) needed to be investigated, and structural biology 
studies were carried out on selected purines (see Chapter 7). 
Table 22 – Activity (IC50 values) of the 2-hydroxyalkyl compounds against CDK2 and initial 
activity of the corresponding vinyl sulfone inhibitors against CDK2 for comparison 
 R group Me (184) Et (213) 
i
Pr (214) 
t
Bu (254) Ph (215) 
 
CDK2 
inhibitory 
activity  
(IC50 μM) 
0.08 0.13 0.37 2.20 2.00 
 
Initial CDK2 
inhibitory 
activity  
(IC50 μM) 
>100 0.29 1.70 0.71 0.62 
 
For vinyl sulfones bearing electron-withdrawing groups at the α-position, the derivative 
bearing a chloro group (167) demonstrated an excellent time-dependent inhibition profile 
compared with 60, with an initial potency of 361 nM that changed to 14 nM after 4 h 
(Figure 103). A crystal structure of compound 167 in complex with CDK2 would be 
required to confirm unambiguously the presence of a covalent interaction. The 
corresponding 2-hydroxyalkyl derivative 268 also exhibited evidence of a time-dependent 
inhibition (Figure 103), possibly due to conversion of the compound 268 into its vinyl 
sulfone parent 167. This explanation needs validation through an investigation of the 
stability of compound 167 under various conditions. 
 175 
 
Figure 103 - Biological results for compounds 167 and 268 in the CDK2 kinetic assay  
The fluoro derivative 168 did not exhibit a time-dependent inhibition profile compared 
with the chloro analogue 167, but behaved as an ATP-competitive inhibitor (Figure 104). 
However, its 2-hydroxyalkyl derivative 272 proved unexpectedly potent after 30 min 
(IC50 = 67 nM), raising doubts as to its stability, and the activity observed could be 
arising from a by-product generated during degradation. A mechanism was postulated 
requiring the generation of two by-products. The potential by-product 372 was 
synthesised and tested against CDK2 but was found to be only moderately potent 
(Chapter 8, section 8.3.). Therefore, the possibility that inhibitory activity may arise from 
the formaldehyde generated was suggested (Scheme 111). 
 
Figure 104 – CDK2-inhibitory activity of compounds 168 and 272 in the time-dependent assay 
against CDK2 
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Scheme 111 – Proposed mechanism for the formation of 372 from 272 
From the biological results for this series, taken in combination with those of the 
structural biology (Chapter 6), the loss of covalent binding, when the vinyl sulfone 
warhead was functionalised with an α-alkyl, aryl or fluoro group, could be explained by 
the stability of the intermediate formed (Chapter 6, Section 6.6). Notably, the first 
explanation that a small twist of the vinyl sulfone warhead conformation, induced by a 
group at the α-position, did not correlate with the biological activity observed for the α-
chloro derivative 167. However, the stability of the intermediate formed during the 
Michael addition may explain the results observed across both the alkyl/aryl (162-166) 
and electron-withdrawing (167, 168) series. When an alkyl group is positioned in the α-
position of the carbanion, the latter is destabilised by an inductive effect (+I) imparted by 
those groups, which can be quantified by Hammett σp values (-0.17 (Me), -0.15 (Et, 
i
Pr) 
and -0.20 (
t
Bu)
245
). Inhibitors 162-166 exhibited ATP-competitive behaviour in the time-
dependent assay against CDK2. On the contrary, the carbanion should have been 
stabilised by the inductive electron-withdrawing (-I) groups, F and Cl (σp values 0.06 and 
0.23,
245
 respectively), but only the chloro derivative 167 showed a time-dependent 
inhibition profile against CDK2. This observation may be explained by postulating that 
the lone pair of the carbanion interacts unfavourably with the lone pairs of the fluoro 
group, to a greater extent than with the lone pairs of the chloro group (Figure 105). This 
overlap is favoured by the similar sizes of F (50 pm
246
) and C (70 pm
246
) atoms and the 
length of the F-C bond (1.35 Å
247
) compared with the Cl-C bond (1.76 Å
248
). The lone 
pairs of the F atom tend to destabilise adjacent carbanion centres, and may explain 
therefore, the ATP-competitive behaviour of compound 168 in the time-dependent assay 
against CDK2. From a theoretical viewpoint, only the Cl group of compound 167 has a 
significant stabilising effect on the carbanion intermediate of the Michael addition, and 
accordingly only the vinyl sulfone purine bearing this group was shown to behave as a 
time-dependent CDK2 inhibitor. 
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Figure 105 – Lone pair effect in the destabilisation of a carbanion 
8.2. The β-substituted vinyl sulfone series 
Each vinyl sulfone (323, 333, 339 and 349) was evaluated in the time-dependent assay 
against CDK2 (n = 1). From the graphs obtained, none of the inhibitors exhibited a time-
dependent inhibition profile and a loss of potency was observed compared with 
compound 60 (Figure 106). The only modification tolerated was the insertion of a methyl 
group at the β-position (323). A crystal structure of compound 323 in complex with 
CDK2 was determined, which confirmed covalent binding to CDK2 (Chapter 6, section 
6.6.). This result was rather unexpected given the time-dependent inhibition profile of 
vinyl sulfone 323, which indicated only modest irreversible inhibition. Indeed, the α-
methyl (162) and the β-methyl (323) compounds exhibited a similar profile in the time-
dependent assay, but only vinyl sulfone 323 was found to be a covalent inhibitor of 
CDK2. Moreover, the initial time zero set-point was actually recorded after 30 min 
incubation of the inhibitor with the protein during which covalent binding could have 
occurred but was not recorded. Therefore, the time-dependent assay gives a good first 
estimation of the behaviour of the inhibitor, but crystallographic studies are invaluable to 
confirm the presence of a covalent interaction with CDK2. 
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Figure 106 – Time-dependent inhibition profile of compounds 323, 333, 339 and 349 against 
CDK2 
Compound 339 was designed with the idea of combining the effect of the α-chloro and β-
methyl groups which gave excellent results, best time-dependent inhibition in the assay 
and covalent inhibition shown by structural biology, respectively. The results obtained for 
inhibitor 339 were rather disappointing with loss of time-dependent inhibition and loss of 
potency. Having an α,β-disubstituted vinyl sulfone (333, 339 and 349) did not seem to be 
tolerated. As discussed in Chapter 6, having a group at the α-position must twist slightly 
the vinylsulfone group rendering the attack from Lys89 along the Burgi-Dunitz trajectory 
difficult. Moreover, the group positioned in β-position of the α-substituted vinyl sulfone 
imposes steric hindrance along the Burgi-Dunitz trajectory, perturbing attack from Lys89. 
These two major arguments may explain the biological results observed for these α,β-
disubstituted vinyl sulfones. 
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The 2-hydroxyalkyl analogues (327, 332, 338 and 347) were also assessed and were 
found to exhibit moderate CDK2-inhibitory activity (Table 23). The results were 
consistent with these compounds acting as ATP-competitive inhibitors. Compound 338 
was assessed in the enzyme kinetic assay (Figure 107) as the α-chloro analogue 268 
showed a slight time-dependent inhibition profile. Compound 338 exhibited an ATP-
competitive inhibition profile with activity within the same range of its vinyl sulfone 
parent 339. 
 
Figure 107 - Time-dependent inhibition profile of compound 338 against CDK2  
Table 23 – Activity (IC50 values) of the 2-hydroxyalkyl compounds against CDK2 
Compound  Activity against CDK2 (IC50 values) 
  
R = H (327) 0.16 μM 
R = Me (332) 0.64 μM 
  
(347) 0.50 μM 
 
8.3. New warheads 
As a general observation from the results for this series, none of the inhibitors exhibited a 
time-dependent inhibition profile and activity against CDK2 was found to vary for each 
inhibitor (Figure 108). Adding an acrylamide moiety adjacent to a sulfone group (353) 
essentially abolished potency against CDK2 (IC50 (4 h) = 4.9 μM). This result highlighted 
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the importance of the size of the warhead group. In this case, the extra atoms added to the 
sulfone substituent increased the length of the group, presumably rendering attack from 
Lys89 unfavourable. The vinyl sulfonamide 362 showed a loss of potency (IC50 (4 h) = 
0.51 μM) by comparison with compound 60, suggesting that the interaction between the 
sulfone and Asp86, lost on introduction of the NH group, was crucial for activity. The β-
ketosulfone derivative 366 showed interesting activity with acceptable potency against 
CDK2 (IC50 (4 h) = 117 nM). From previous results with compound 323, which did not 
appear to exhibit time-dependent inhibition in the biological assay, but showed covalent 
binding to CDK2 in the structural biology study, the β-ketosulfone 366 would be a good 
candidate for further analysis to determine its binding mode. This compound would be 
particularly interesting as it should react specifically with amines (e. g. Lys89) over water 
and would, therefore, solve the problem of stability of the vinyl sulfone warhead towards 
hydration.  
 
 181 
 
Figure 108 - Time-dependent inhibition profile of compounds 353, 362, 366, 368, 372, 375, 389 
and 390 against CDK2 
The α-halosulfone compounds, 368 and 372, were found to be moderate inhibitors of 
CDK2 with an ATP-competitive inhibition profile (IC50 (4 h) = 177 nM and IC50 (4 h) = 
305 nM, respectively). These compounds may not be sufficiently reactive for 
nucleophilic attack from Lys89, or, alternatively, Lys89 is positioned too far from the 
electrophile. The trifluoromethyl analogue 375 did not exhibit good CDK2-inhibitory 
activity (IC50 (4 h) = 705 nM), presumably reflecting the poor reactivity of this 
electrophilic group. Vinyl ketone 389 was designed to assess the importance of the 
sulfone group in the vinyl sulfone warhead of compound 60. Surprisingly, compound 389 
was found to be only weakly potent against CDK2 with a ~55-fold drop in potency (IC50 
(4 h) = 3.5 μM) by comparison with compound 60. Results obtained for vinyl ketone 389 
showed the importance of the sulfone group and its interaction with Asp86. The sulfone 
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group can be postulated to orientate the vinyl moiety in the right position for attack from 
Lys89. Compound 390 was synthesised as an analogue of compound 389. A loss of 
potency was observed by comparison with compound 60 (IC50 (4 h) = 0.89 μM), which 
can be attributed to the loss of interaction with Asp86 of CDK2. However, activities were 
shown to decrease with time with an initial potency of 2.80 μM that changed to 0.89 μM 
after 4 h. This observation suggests that compound 390 may have reacted covalently with 
CDK2, but slowly due to the reactivity of its electrophilic warhead (i.e. ethynyl ketone). 
This observation needs, however, to be considered carefully as the experiment was 
conducted only once and therefore, only structural biology studies could give further 
details on the binding mode of compound 390.  
Compounds synthesised in Chapters 5 and 7 were tested for their CDK2 inhibitory 
activity by Lan-Zhen Wang under the supervision of Professor Herbie Newell in the 
Biology Laboratory of the Northern Institute for Cancer Research, Newcastle upon Tyne, 
UK.   
 183 
Chapter 9. Covalent Inhibition of CDK2: Beyond Purines 
In this chapter, with the irreversible inhibition of CDK2 being at an early stage, 
modifications of known CDK2 inhibitors were investigated, by introducing appropriately 
positioned electrophilic warheads, such as a vinyl sulfone, to target Lys89. To achieve 
such modifications, the selected CDK2 inhibitors required a position on the molecule 
suitable for functionalisation, which would enable a potential interaction with Lys89. 
Non-covalent inhibition of CDK2 has been extensively studied over the past two decades 
(see Chapter 2, section 2.3.3.) but only one covalent inhibitor of CDK2 (60) has been 
reported to date. Modification of the electrophilic vinyl sulfone warhead of 60 has been 
investigated (see Chapters 5, 6 and 8). The vinyl sulfone warhead was found to be 
common feature of protease inhibitors
249-251
 but quite rare in kinase inhibitors,
252
 
rendering this group attractive in the design of new covalent CDK2 inhibitors.  
9.1. Modification of the potent pyrazole inhibitor 391 
The sulfonamide 391 is a potent CDK2 inhibitor (0.3 nM), whereas its piperidine 
analogue 392 demonstrated only modest activity by comparison (0.14 μM),253,84 
emphasing the importance of the sulfonamide group. Interactions between the pyrazole 
ring of compound 392 and the hinge region of CDK2 were highlighted in the crystal 
structure (Figure 109), with the piperidine ring pointing towards the specificity pocket 
where Lys89 is positioned. The difference in potency between inhibitors 391 and 392 was 
attributed to additional interactions between the sulfone of compound 391 and a 
neighbouring residue (Asp86), and to the substituents on the aromatic ring (Cl (391) vs F 
(392)) interacting with the ribose pocket.  
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Figure 109- Co-crystal structure of inhibitor 392 within the ATP-binding pocket of CDK2.
84
 The 
PDB entry is 2VTQ. 
Insertion of a vinyl sulfone group on the N-piperidine of 391 was the obvious 
modification to generate a potential covalent inhibitor. As only the crystal structure of 
compound 392 in complex with CDK2 was available, two models were created with 
Discovery Studio Visualizer
254
 (Accelrys) where the N-piperidine of pyrazole 392 was 
functionalised with either a vinyl sulfone (393) (Figure 110) or a vinyl ketone (394) 
group (Figure 111).  
 
Figure 110 - Model structure of compound 393 with CDK2 created with Discovery Studio 
Visualizer showing the distance between Lys89 and the vinyl sulfonamide warhead 
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Figure 111 - Model structure of compound 394 with CDK2 created with Discovery Studio 
Visualizer showing the distance between Lys89 and the acrylamide warhead. 
Both models suggested that the Lys89 was too far from the electrophilic site (~ 5.7 Å). 
However, it is important to note that the flexibility of Lys89 (highlighted in Chapter 6) 
may facilitate proximation of the two groups for covalent modification to occur. The 
models supported the potential for introducing an electrophile on the N-piperidino motif, 
and therefore, both the vinyl sulfone (395) and vinyl ketone (396) groups were added to 
the inhibitor 391, which showed higher potency than compound 392 against CDK2. 
 
9.1.1. Covalent analogues of the pyrazole CDK2 inhibitor 391 
The common intermediate 401 for the generation of 395 and 396 was synthesised in four 
steps following a literature procedure
84
 (Scheme 112), including two amide couplings. 
Pyrazole 401 was then reacted with either 2-chloroethanesulfonyl chloride or acryloyl 
chloride to give the vinyl sulfonamide 395 and the acrylamide derivative 396, 
respectively (Scheme 113). 
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Scheme 112 - Reagents and conditions: (i) 4-amino-1-boc-piperidine, HOAt, EDCI.HCl in DMF, 
r.t., 18 h; (ii) Pd/C, H2 in MeOH/DMF (5:1), 40 °C, 18 h, 36% (over 2 steps); (iii) 2,6-
dichlorobenzoic acid, HOAt, EDCI.HCl in DMF, r.t., 18 h, 62%; (iv) in TFE, MW, 160 °C, 4 h, 
61%. 
 
Scheme 113 - Reagents and conditions: (i) 2-chloroethanesulfonyl chloride, DIPEA in DCM, r.t., 
15 min, 34%; (ii) acryloyl chloride, DIPEA in THF, 0 °C, 1 h, 53%. 
9.1.2. Biological results of the new covalent CDK2 inhibitors, 395 and 396 
Compounds 395 and 396 were designed from the highly potent CDK2 inhibitor 391, with 
the objective of achieving covalent inhibition of CDK2. Both inhibitors were assessed in 
the kinetic assay against CDK2. The vinyl sulfonamide 395 showed extremely good 
activity against CDK2 and was found to be equipotent with compound 391 (Figure 112). 
Activities were found to increase with time, from 0.44 nM at 0 h to 0.20 nM at 4 h. These 
results suggest that compound 395 might react covalently with CDK2 but very rapidly. 
Further investigations, including structural biology, would be required on compound 395 
as it could be a selective, potent and covalent inhibitor of CDK2. 
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Compound 396 exhibited an ATP-competitive behavior with good potency but with a 30-
fold drop in activity compared to compound 391 (Figure 112). This decrease of activity 
could be attributed to a loss of interaction with Asp86, possible when a sulfone group is 
present on the molecule (e.g. compound 395). 
 
Figure 112 – Results of the kinetic assay against CDK2 for compounds 395 and 396 
Both compounds 395 and 396 were tested for their CDK2 inhibitory activity by Lan-Zhen 
Wang under the supervision of Professor Herbie Newell in the Biology Laboratory of the 
Northern Institute for Cancer Research, Newcastle upon Tyne, UK. 
9.2. Modification of the CDK2 inhibitor dinaciclib (45) 
Dinaciclib (45) is a potent inhibitor of CDKs 1, 2, 5 and 9 (IC50 = 3, 1, 1 and 4 nM, 
respectively –Chapter 2). The compound has been shown to interact with the hinge region 
of CDK2 via two H-bonds with Leu83 (Figure 113). The piperidine moiety occupies the 
ribose pocket and the pyridine N-oxide is orientated towards the solvent region, 
interacting with Lys89 in its protonated form to create a salt interaction.
162
 It was 
interesting to note the interaction with the protonated form of Lys89, as the neutral form 
of the same residue reacts covalently with the vinyl sulfone purine 60.  
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Figure 113 – Interactions between dinaclib (45) and the ATP-binding domain of CDK2.162 The 
PDB entry is 3QXP. 
The example of dinaciclib taken with the results obtained through modifications of 60, 
highlighted the versatility of Lys89, a mobile residue that can interact with inhibitors as a 
nucleophile (Michael addition on 60) or as a H-bond donor (dinaciclib). Lys89 was a 
residue offering flexibility in the design of CDK2 inhibitors and selectivity over CDK4 
and 6, which have a Thr residue at this position. From the crystal structure of dinaciclib 
(45) in complex with CDK2, a vinyl sulfone was modelled at the pyridine N-oxide 
position using Discovery Studio Visualizer (Accelrys). From the model (Figure 114), 
Lys89 would be ~4.0Å from the electrophilic vinyl group of 402, but would be closer to 
the sulfone group, suggesting that a H-bond interaction could be preferred over Michael 
addition. 
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Figure 114 –Model structure of 402, having a meta-vinyl sulfone group, showing possible 
interactions with CDK2 
The vinyl sulfone warhead was also modelled at the ortho-position of the phenyl ring of 
dinaciclib (Figure 115). From the model, Lys89 would be situated ~0.7Å from the vinyl 
group and the sulfone of the warhead would interact with Asp86. Both models offered 
two attractive targets but in the interests of time, a synthetic route was developed only for 
target 403. 
 
Figure 115 - Model structure of 403, having an ortho-vinyl sulfone group, illustrating the 
possible interaction with CDK2 
A similar synthetic route to dinaciclib (45) was considered for the synthesis of 403, with 
initial preparation of the heterocyclic core 414, which could then be functionalised by the 
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benzylamine 409 and the piperidine moiety. The synthesis of the benzylamine 409 started 
with the formation of the methyl ester 405 from the benzoic acid 404 (Scheme 114). The 
ester was converted into the corresponding amide 406,
255
 which was alkylated at the thiol 
group of 406. A low yield was obtained for these two steps, probably due to the 
instability of intermediate 406 to oxidation. Oxidation of sulfide 407 gave compound 408. 
Simultaneous reductions of the methyl ester and the amide moieties of intermediate 408 
were attempted using LiAlH4 but led to the isolation of an unknown compound in poor 
yield. The selective reduction of the ester into the alcohol should be first investigated 
followed by the reduction of the amide group to obtain the desired benzylamine 409. 
 
Scheme 114 - Reagents and conditions: (i) H2SO4 in MeOH, reflux, 48 h, 89%; (ii) formamide, 
25% wt/wt NaOMe in MeOH in DMF, 70 
o
C then 110 
o
C, 2 h; (iii) ethyl chloroacetate, Et3N in 
DCM, 13% over 2 steps; (iv) m-CPBA in DCM, r.t., 3 h, 73%; (v) LiAlH4 in THF, r.t., 16 h. 
The synthesis of the heterocyclic core started with the formation of the 3-aminopyrazole 
412. Deprotonation of butyronitrile 410 for reaction with ethyl formate was performed 
successfully with LiHMDS, as with potassium t-butoxide no reaction was observed 
(Scheme 115), to afford 3-aminopyrazole 412 in good yield. This intermediate was then 
reacted with dimethyl malonate to give compound 413. The next step would be 
aromatisation and chlorination of compound 413 to give intermediate 414. Consecutive 
nucleophilic aromatic substitutions on 414 would offer the intermediate 416. Mesylation 
followed by elimination would give the target vinyl sulfone 403. However, owing to time 
limitations, further work on this target was not undertaken. 
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Scheme 115 - Reagents and conditions: (i) LiHMDS, ethyl formate in THF, -78 
o
C, 30 min; (ii) 
N2H4.H2O, AcOH in EtOH, 80 
o
C, 40 h, 54%; (iii) dimethyl malonate, NaOH in MeOH, 65 
o
C, 16 
h, 74%; (iv) POCl3, N,N-dimethylaniline, reflux; (v) K3PO4.H2O, 409 in water/MeCN, reflux; (vi) 
Na2CO3, (S)-piperidine-2-ethanol in water/NMP, 150 
o
C; (vii) MsCl, Et3N in DCM, r.t. then DBU. 
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Chapter 10. Conclusions and Future Work 
Interest in covalent inhibitors has emerged in the past few years and therefore, tool 
compounds are required to contribute to the understanding of the value of covalent 
binding in drug discovery. This thesis has been dedicated to the design and synthesis of 
purine-based covalent inhibitors of the mitotic kinases, Nek2 and CDK2. 
In the Nek2 project, the synthesis of control compounds was described aiming to confirm 
the presence of an off-target activity of the 6-ethylnylpurine series by perturbing the main 
interactions with Nek2, namely the covalent binding between Cys-22 and the 6-ethynyl 
group, and the triplet of H-bonds with the hinge region. With the 6-cyanopurine 65, the 
possibility of Michael addition was removed, thus diminishing activity against Nek2. 
Perturbing both the covalent binding and the triplet of H-bonds with 66 and 67 abolished 
the Nek2 inhibitory activity. To synthesise the N
7
-methyl-6-cyanopurine derivative (67), 
a selective and high yielding one-pot procedure was developed which allowed for the 
selective N-7 methylation of various purines and represented an improvement to existing 
methods. The covalent binding of the inhibitors was shown to be essential for activity 
against Nek2 as illustrated by the N
9
-methyl-6-ethynyl derivative 63 which retained 
activity. The N
7
-methyl derivative 64, while inactive against Nek2 in the enzymatic assay, 
was found to be potent in the cellular assay. Disconnections between the enzymatic and 
cellular results of the 6-ethynylpurine series were established and confirmed the presence 
of an off-target activity. 
 
A small library of N
7
-methyl-6-ethynylpurines was synthesised with the objective of 
abolishing cellular activity (i.e. off-target activity) by modifying the 2-aryl group. The 
NH parent of such compounds would potentially be selective inhibitors of Nek2. All the 
compounds prepared in this series demonstrated activity in cells, suggesting that the off-
target activity was still present. 
The reactivity of 6-ethynylpurines was further investigated by 
1
H qNMR using a model 
reaction mimicking the addition of Cys-22 to the 6-ethynyl group. These studies 
highlighted the high reactivity of N
7
-methyl-6-ethynylpurines (62 and 64) by comparison 
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with their N
9
-methyl and NH analogues, which was attributed to a buttressing effect of 
the N
7
-methyl group on the 6-ethynyl moiety and a steric strain relief phenomenon. 
Efforts in the CDK2 project were focussed on modulating the chemical reactivity of the 
vinyl sulfone warhead without affecting the potency or the covalent binding mode of the 
inhibitor 60, the first irreversible inhibitor of CDK2. Insertion of substituents on the vinyl 
sulfone was aimed at improving the chemical stability of compound 60 towards hydration. 
Several α-substituted vinyl sulfone analogues (162-168) were prepared and assessed in a 
time-dependent assay against CDK2. The corresponding 2-hydroxyalkyl derivatives were 
synthesised for screening for CDK2 inhibitory activity and as reference standards for 
future HPLC stability studies on the vinyl sulfone inhibitors. Compounds bearing an α-
alkyl/aryl group (162-166) demonstrated ATP-competitive behaviour in the enzymatic 
kinetic assay. In this series, only the α-methyl group (162) was tolerated from the activity 
obtained against CDK2. α-Electron-withdrawing groups (167, 168) were investigated but 
the chemistry in this series was challenging, highlighting the difficulties of synthesising 
highly functionalised molecules of this type. The compound bearing an α-fluoro group 
(168) showed ATP-competitive behaviour while the best time-dependent inhibition 
profile was obtained for the inhibitor bearing an α-chloro group (167). At the α-position 
of the vinyl, only a chloro group seemed to maintain the time-dependent inhibition of 
CDK2, suggesting potential covalent binding, while other groups have shown loss of 
time-dependent inhibition. The chloro derivative 167 should be co-crystallised with 
CDK2 to confirm the presence of the covalent bond as an α-chloro vinyl sulfone would 
represent a novel electrophilic warhead. 
 
The β-position of the vinyl moiety was briefly explored by insertion of a methyl group 
alone (323) and in combination with other groups at the α-position (333, 339 and 349). 
All the compounds in this series showed ATP-competitive behaviour in the kinetic assay. 
Interestingly, disubstitution of the vinyl function was not tolerated, as exemplified by 
compound 339, bearing an α-chloro and a β-methyl group, which lost the excellent time-
dependent inhibition profile and potency exhibited by the α-chloro vinyl sulfone 
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compound 167. The corresponding 2-hydroxyalkyl derivatives were also assessed against 
CDK2 and revealed similar potency to their corresponding vinyl sulfone analogues. 
Structural biology studies were performed on selected vinyl sulfone inhibitors (162, 163 
and 323) with the objective of understanding their binding mode with CDK2. Substitution 
at the α-position was not tolerated for covalent binding, while insertion of a β-methyl 
group (323) was shown to be tolerated with the presence of a covalent bond between 
Lys89 and the modified vinyl sulfone group. Following these results, further investigation 
of the β-position should be carried out. These results highlighted the limits of the 
biological assay, which can only be used for the identification of potential covalent 
inhibitors for structural biology studies. Crystal structure of the 2-hydroxyalkyl derivative 
184 with CDK2 revealed a similar binding mode to the corresponding vinyl sulfone 
analogue, explaining the similar activity observed for the pair of inhibitors. 
 
The vinyl sulfone group of compound 60 was replaced by other potential electrophilic 
warheads to assess the importance of both the vinyl and sulfone groups. All the inhibitors 
prepared in this series demonstrated ATP-competitive inhibitory activity in the kinetic 
assay with the exception of the ethynyl ketone 390, which showed modest activity against 
CDK2 but with evidence for time-dependent inhibition. In addition, the β-ketosulfone 
366 seemed to retain activity against CDK2. Further analyses of compounds 366 and 390 
by structural biology to elucidate their binding mode would be interesting. Another 
interesting observation from this series of compounds was the 55-fold reduction in 
activity observed when the sulfone group was replaced by a ketone (compound 389), 
demonstrating the crucial importance of the sulfone for activity. The sulfone presumably 
interacts with Asp86 placing the vinyl group in the perfect position for attack of Lys89, 
crucial for covalent binding. To date, the best replacement of the vinyl sulfone warhead 
of 60 is the α-chlorovinyl sulfone group (167) which showed a remarkable time-
dependent inhibition profile with a potency relatively modest at time zero, suggesting 
improved chemical stability. However, each inhibitor has only been tested once, so 
biological evaluation should be repeated to confirm the observations made so far. To 
investigate further the potential of the vinyl sulfone group as an electrophilic warhead and 
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its use on other scaffolds and in other projects, chemical stability studies of the most 
promising compounds (167 and 323) would need to be assessed.  
With the objective of expanding the investigation of covalent inhibition of CDK2 and the 
use of the vinyl sulfone warhead, a potent ATP-competitive CDK2 inhibitor (391), 
developed by Astex Pharmaceuticals, was modified with the aim of inhibiting CDK2 
covalently. The vinyl sulfonamide 395 was found to be equipotent with the parent 
compound 391 and possibly exhibited a modest time-dependent inhibition profile. Further 
analysis by structural biology is required as this compound could potentially represent a 
selective and extremely potent covalent inhibitor of CDK2. 
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Chapter 11. Experimental 
11.1 Synthesis 
Chemicals and Solvents 
All commercial reagents were purchased from Aldrich Chemical Company, Alfa Aesar, 
or Lancaster Synthesis Ltd. The chemicals were of the highest available purity. Unless 
otherwise stated, chemicals were used as supplied without any further purification. 
Anhydrous solvents were obtained from AcroSealTM or Aldrich (SureSealTM bottles) 
and were stored under nitrogen. Petrol refers to the fraction with a boiling range between 
40 and 60 °C. 
Chromatography 
Thin layer chromatography utilised to monitor reaction progress was conducted on plates 
pre-coated with Si F254, NH2 F254s or RP-18 F254s. The eluent was as stated (where this 
consisted of more than one solvent, the ratio is stated as volume: volume) and 
visualisation was either by ultraviolet light. ‘Flash’ column chromatography was carried 
out at medium pressure using a Varian automated purification system with pre-packed 
silica cartridges or Biotage KP-NH cartridges. When stated, compounds were purified via 
semi-preparative HPLC on an Agilent 1200 Modular Preparative HPLC system using an 
ACE 5 Phenyl 150 x 21.2 mm column. 
Analytical techniques 
Melting points were determined using a VWR Stuart SMP40 apparatus and are 
uncorrected. 
1
H, 
19
F and 
13
C nuclear magnetic resonance (NMR) spectra were obtained as 
either CDCl3 or MeOD or DMSO-d6 solutions and recorded at 500 MHz, 470 MHz and 
125 MHz, respectively, on a Bruker Avance III 500 spectrometer. Chemical shifts are 
reported in parts per million (δ) referenced to the appropriate deuterated solvent 
employed and relative to tetramethylsilane. Multiplicities are indicated by s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet), b (broad) or combinations thereof. Liquid 
Chromatography – Mass Spectrometry (LC-MS) was carried out on a Waters Acquity 
UPLC system, with a Waters SQD ESCi source using an Acquity UPLC BEH C18 1.7 
μm, 2.1 x 50 mm column with a flow rate of 0.6 mL/min. The mobile phase used was 0.1% 
aq. formic acid in MeCN. Fourier Transform Infrared (FTIR) spectra were recorded on a 
Bio-Rad FTS 3000MX diamond ATR as a neat sample. Ultraviolet (UV) absorption data 
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were obtained using a U-2001 Hitachi Spectrophotometer with the sample dissolved in 
ethanol. High resolution mass spectrometry was performed by the EPSRC National Mass 
Spectrometry Service, University of Wales, Swansea, Singleton Park, Swansea, SA2 8PP. 
Microwave Assisted Synthesis 
Reactions were heated under microwave irradiation in sealed vessels using the Biotage 
Initiator Sixty with robotic sample bed. Reactions were irradiated at 2.45 GHz to reach 
temperatures up to 250 
o
C at a rate of 2-5 
o
C/sec and pressures up to 20 bars. 
11.2 Biological Evaluation 
Compounds subjected to biological evaluation were obtained with a purity higher than 
95%, determined by HPLC, using a Waters XSELECT CSH C18 3.5um 100 x 4.6 mm 
column, in basic (0.1% aq. ammonia in MeCN) and acidic (0.1% aq. formic acid in 
MeCN) conditions. 
Compounds synthesised within the Nek2 project were tested for their Nek2 inhibitory 
activity by Kathy Boxall, Sam Burns, Yvette Newblatt and Maura Westlake under the 
supervision of Dr Wynne Aherne in the Analytical Screening and Technology Laboratory 
of the CR UK Centre for Cancer Therapeutics, The Institute of Cancer Therapeutics, 
Sutton, Surrey, UK, SM2 5NG. Inhibitory potencies are reported as half maximal 
inhibitory concentrations (IC50) or percentage of inhibition. Assays were performed in the 
presence of 30 μM ATP, 1 μM ‘peptide 11’ substrate (5-FAM-KKLNRTLSVA-COOH) 
and 4 nM Nek2, using a microfluidic Caliper methodology. 
Compounds synthesised within the CDK2 project were tested for their CDK2 inhibitory 
activity by Lan-Zhen Wang under the supervision of Professor Herbie Newell in the 
Biology Laboratory of the Northern Institute for Cancer Research, Newcastle upon Tyne, 
UK. The kinase assay was started with addition of the inhibitor (3 µL of a 10 mM diluted 
solution from a 100 mM stock solution) to the reaction mix, prepared by mixing 
CDK2/cyclin A (10 µL, 1 mg/mL) and histone H1 (150 µL, 5 mg/mL solution) in buffer 
(500 µL containing Tris (50 mM) and MgCl2 (5 mM)). After incubation for 30 min at 0 
o
C, ATP (5 µL from a solution containing [
32
P] ATP and cold ATP at a final 
concentration of 12.5 µM) was added. The reaction mixture was spotted on an 
appropriate filter. After stirring in 1% phosphoric acid solution, the filtrates were washed 
and transferred to scintillation vials containing 5 mL of scintillation liquid. Radioactivity 
was measured in a scintillation counter.  
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11.3 Structural Biology Experimental 
Protein Expression and Purification 
The pre-prepared pGEX-6P-1 vector (containing GST-CDK2 and GST-CIV1 coding 
sequences) and pET plasmids (containing cyclin A or CDK2) were transformed into E. 
coli strain B834/Lys-S (Novagen). CDK2 and cyclin A were grown separately in BL21 
star (DE3) chemically competent cells (Invitrogen), in 500 mL cultures of Luria Broth 
(LB) media containing 50 μg/mL ampicillin. Cells expressing CDK2/CIV1 were grown 
at 37 
o
C until an optical density at 600 nm (OD600) of 0.8-0.9 was reached. The 
temperature of the culture was then dropped to 20 
o
C as rapidly as possible and the cells 
were left for a further 50 min to equilibrate. Expression of CDK2 and CIV1 as GST 
fusion proteins was induced by the addition of 0.1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and cells were then grown for 20-24 h at 20 
o
C, to ensure 
complete phosphorylation of CDK2 by CIV1.  
The culture containing bacteria for the expression of cyclin A was grown at 37 
o
C to an 
OD600 of 0.5-0.6. The temperature was then reduced to 25-30 
o
C and the cells were left 
for a further 30 min to equilibrate. Cyclin A was expressed following induction with 0.1 
mM IPTG and grown for another 20-24 h at 20 
o
C.  
Cells were harvested by centrifugation (4 
o
C, 20 min, 4000 x g, Beckman JLA8.1 rotor) 
and the pellet was resuspended in 20 mL of ice-cold modified HBS with one protease 
inhibitor tablet (Rochecor), fast frozen in dry ice and stored at – 80 oC until further use. 
As soon as thawing was apparent, RNase A (200 μL of 100 mg/mL stock), lysozyme 
(400 μL of 25 mg/mL stock), DNAase I (200 μL of 2 mg/mL stock) and 1M MgCl2 (200 
μL) were added. Once the pellets started to defreeze, they were sonicated at 0 oC (30% 
amplitude, 15 s on, 45 s off for 3.2 min total sonication time). The suspension was 
centrifuged (4 
o
C, 1 h, 25,000 g, Beckman JA25.50 rotor) and the supernatant obtained 
was removed from the pellet and stored on ice. Supernatant from CDK2/CIV1 culture 
was gently mixed with supernatant from cyclin A culture (ratio of 0.5: 1 CDK2: cyclin A). 
The mixed supernatant was purified on pre-equilibrated glutathione affinity column 
(glutathione Sepharose 4B, bed volume 2 mL). Proteins were cleaved from GST using 3C 
protease (50: 1 protein: 3C by weight) overnight at 4 
o
C, and purified using size-
exclusion chromatography (GE Healthcare HiLoad 26/60 Superdex 75 column). The 
collected fractions containing the fusion protein CDK2/cyclin A were analysed by SDS-
PAGE, combined and loaded onto a fresh pre-equilibrated glutathione affinity column 
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(glutathione Sepharose 4B, bed volume 2 mL) to remove any GST dimer left. The pure 
fusion protein was concentrated to 11 mg/mL and fast frozen in dry ice. 
Polyacrylamide Gel Electrophoresis 
SDS-PAGE was used for protein identification and semi-quantitative analysis. Pre-cast 
12 well, 16% acrylamide gels (RunBlue) were used with SDS run buffer (RunBlue). 
Samples were mixed with SDS loading buffer (RunBlue) and denatured at 100 
o
C for 5 
min before being loaded onto the gel. PageRuler pre-stained protein ladder (170-10 kDa, 
Thermo Scientific) was used as molecular weight marker. Electrophoresis was run at 175 
V and gels were stained with Coomassie quick stain. 
Protein concentrations were determined using UV absorbance at 280 nm using Nanodrop 
2000 (Thermo Scientific). Extinction coefficients were calculated based upon amino acid 
content using Protparam.
256
 
Protein Preparation for Crystallography 
Purified CDK2-cyclin A protein (11 mg/mL) was incubated with the appropriate inhibitor 
(1 mM in DMSO) for 1 h before crystallisation trays were set up in 2-subwell 96 well 
plates using the sitting drop vapour diffusion method. Protein mixture and reservoir were 
pipetted into the subwells in a 1:1 and 1:2 protein: reservoir ratio using a Mosquito robot 
(100 nL drops). Plates were sealed and stored in the Rigaku Minstrel tray hotel at 4 
o
C 
until crystal formation (up to 4 weeks). Crystals were transferred into a solution of 70% 
crystallant and 30% cryoprotectant (ammonium sulfate or sodium sulfate), stored in 
liquid nitrogen and shipped to the Diamond Light Source, Oxford, UK. 
11.4. General Procedures 
General procedure A: Removal of TIPS protecting group from 6-triisopropylsilyl 
ethynylpurines 
The desired 6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (0.90 mmol) was dissolved 
in THF (10 mL) and TBAF (1M in THF, 1.10 mmol) was added. The solution was stirred 
at r.t. for 5 min and scavenger beads were added. The magnetic stirrer was removed and 
the reaction transferred into a conical flask. The reaction was then agitated with a shaker 
overnight. The solvent was removed in vacuo and the crude mixture was purified as 
indicated.   
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General procedure B: N-9 methylation of purines 
The desired 9H-purine (5.80 mmol) and K2CO3 (11.60 mmol) were suspended in 
anhydrous DMF (15 mL) under N2. Methyl iodide (7.00 mmol) was added and the 
resulting solution was stirred at r.t. overnight. The solvent was removed in vacuo and the 
crude product was purified as indicated. 
General procedure C: Selective N-7 methylation of N
9
-PMB protected purines 
The desired 9H-purine-6-carbonitrile (0.16 mmol) and trimethyloxonium 
tetrafluoroborate (0.16 mmol) were solubilised in TFE (2 mL) under N2. The resulting 
solution was stirred at r.t. for 2 h. The reaction was purged with nitrogen, sealed and 
heated (microwave irradiation) at 100 °C. The solvent was removed in vacuo and the 
crude product was purified as indicated. 
General procedure D: Sonogashira coupling on 6-chloropurines 
The desired 6-chloropurine (5.80 mmol), Pd(PPh3)2Cl2 (0.10 mmol) and Cu(I)I (0.10 
mmol) were solubilised in anhydrous THF (30 mL) under N2. Triisopropylsilyl acetylene 
(6.40 mmol) and Et3N (14.50 mmol) were added. The resulting suspension was purged 
with N2 during 15 min. The reaction was stirred at r.t. overnight resulting in a colour 
change from yellow to dark brown. The suspension was filtered through Celite and the 
solvent was removed in vacuo. The crude product was purified as indicated. 
General procedure E: Nucleophilic aromatic substitution of 2-fluoropurines using 
TFA in TFE 
2-Fluoro-6-((triisopropylsilyl)ethynyl)-9H-purine (1.90 mmol) was dissolved in TFE (12 
mL). The appropriate aniline (3.80 mmol) and TFA (0.7 mL) were added. The reaction 
was purged with N2 and sealed. The solution was heated at 140 °C for 30 min in the 
microwave reactor. The solvent was removed in vacuo. The residue obtained was 
resuspended in EtOAc (10 mL) and extracted with sodium carbonate (10 mL), brine (10 
mL) and water (10 mL). The organic layers were combined, dried over MgSO4, and the 
solvent was removed in vacuo. The crude mixture was purified as indicated. 
General procedure F: Amide formation from the corresponding carboxylic acid 
Thionyl chloride (23.80 mmol) was added dropwise to a stirred solution of the desired 
phenylacetic acid (19.90 mmol) in anhydrous MeOH (60 mL) under N2. The solution was 
stirred at r.t. for 2 h. The solvent was removed in vacuo and aqueous ammonia (10 mL) 
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was added to the residue obtained. The resulting solution was stirred at r.t. for 1 h. The 
reaction was quenched with 4M HCl until a neutral pH was reached. Water was removed 
in vacuo and the product was purified as indicated. 
General procedure G: Iodination of 2-aminopurines 
Isoamyl nitrite (12.60 mmol) was added to a suspension of the desired 2-amino-9H-
purine-6-carbonitrile (4.00 mmol), diiodomethane (12.60 mmol) and Cu(I)I (4.00 mmol) 
in anhydrous THF (50mL) under N2. The reaction was stirred at reflux for 4 h and filtered 
through Celite. The solvent was removed in vacuo and the crude product was purified as 
indicated.  
General procedure H: Zinc reduction of nitro groups to amines 
The compound (2.26 mmol) was solubilised in MeOH (10 mL) and acetic acid (10 mL). 
Zinc powder (22.60 mmol) was added and the reaction was stirred at 50 °C for 2 h. The 
mixture was filtered through Celite and the solvent was removed in vacuo. The crude 
mixture was purified as indicated. 
General procedure I: Buchwald cross coupling reaction on a 2-iodopurine 
The appropriate 2-iodopurine (0.45 mmol) was dissolved in anhydrous MeCN (15 mL) 
under N2. The desired compound (0.68 mmol), K2CO3 (0.91 mmol), Pd(dba)2 (0.01 mmol) 
and XPhos (0.01 mmol)) were added. The solution was heated at 80 °C for 18 h. The 
solution was filtered through Celite and the solvent was removed in vacuo. The crude 
mixture was purified as indicated. 
General procedure J: SN2 reaction with 4-nitrothiophenol 
The desired electrophile (21.3 mmol) was added to a stirred solution of 4-nitrothiophenol 
(19.4 mmol) and Et3N (21.3 mmol) in anhydrous DCM (50 mL ) at 0
 
°C, under N2. The 
resulting solution was stirred for 1 h. After completion, the solution was diluted with 
DCM (50 mL) and washed with brine (3 x 50 mL). The organic layer was dried over 
MgSO4 and the solvent was removed in vacuo. The crude product was purified as 
indicated. 
General procedure K: Hydrolysis of esters under basic conditions 
LiOH (2M in THF, 26.6 mL) was added to the solution of the appropriate ester (4.82 
mmol) in THF (9.5 mL). The reaction was stirred for 2 h at 70 
o
C. After completion, the 
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reaction mixture was quenched with 4M HCl solution until a pH of 4 was reached. The 
resulting mixture was extracted with EtOAc (3 x 50 mL). The organic layers were 
combined and dried over MgSO4. The solvent was removed in vacuo to afford the desired 
acid. 
General procedure L: Reduction of acids using borane 
1M Borane in complex with THF (13.1 mmol) was added dropwise to a stirred solution 
of the appropriate acid (2.61 mmol) in dry THF (30 mL) under N2. The reaction was 
heated at 50 °C overnight. A saturated aqueous solution of NaHCO3 (20 mL) was added 
dropwise at 0 °C. The mixture was extracted with EtOAc (3 x 30 mL). The organic layers 
were combined and dried over MgSO4. The solvent was removed in vacuo. The crude 
product was purified as indicated. 
General procedure M: Oxidation of sulfides with m-CPBA 
The appropriate sulfide (4.41 mmol) was solubilised in DCM (50 mL). m-CPBA (9.25 
mmol) was added at 0 °C and the resulting solution was stirred at 0 °C for 1 h. A 
saturated aqueous solution of Na2CO3 (50 mL) was added and the reaction was extracted 
with DCM (3 x 50 mL). The organic layers were combined and dried over MgSO4. The 
solvent was removed in vacuo. The crude product was purified as indicated. 
General procedure N: Cope elimination 
The appropriate β-pyrrolidine sulfone (0.13 mmol) was solubilised in dry DCM (10 mL) 
under N2. m-CPBA (0.15 mmol) and Cs2CO3 (0.33 mmol) were added to the solution and 
the mixture was stirred at r.t. for 30 min. The solvent was removed in vacuo. The product 
was purified as indicated. 
General procedure O: Reduction of esters and ketones using DIBAL 
The appropriate ester or ketone (7.81 mmol) was solubilised in dry THF (15 mL) under 
N2 and cooled to 0 °C. A solution of DIBAL (1M in hexanes, 11.7 mL) was added slowly 
to the solution. The mixture was stirred at 0 °C for 2 h. After completion, MeOH (5 mL) 
was added dropwise followed by aqueous HCl (1M solution, 20 mL). The organic phase 
was extracted with EtOAc (3 x 30 mL) and the combined extracts were dried over 
MgSO4. The solvent was removed in vacuo. The crude product was purified as indicated.  
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General procedure P: Formation of a vinyl sulfone moiety using methanesulfonyl 
chloride 
The appropriate 2-hydroxyalkyl compound (0.60 mmol) was solubilised in dry DCM (6 
mL) under N2. Et3N (0.90 mmol) and MeSO2Cl (0.90 mmol) were added. The resulting 
solution was stirred at r.t. for 1 h. Brine (5 mL) was added and the organic phase was 
extracted with DCM (3 x 5 mL). The organic layers were combined, dried over MgSO4 
and the solvent was removed in vacuo. The product was purified as indicated. 
General procedure Q: One-pot reaction for the conversion of a 2-hydroxyalkyl 
compound to a β-pyrrolidino sulfone 
The appropriate 2-hydroxyalkyl compound (5.19 mmol) was solubilised in dry DCM (30 
mL) under N2. Et3N (7.79 mmol) and benzenesulfonyl chloride (7.79 mmol) were added 
to the solution. The reaction was stirred at r.t. for 18 h. Pyrrolidine (25.97 mmol) was 
added and the reaction was stirred for 1 h at r.t. The resulting mixture was washed with 
brine (3 x 50 mL). The combined organic layers were dried over MgSO4 and the solvent 
was removed in vacuo. The crude product was purified as indicated. 
General procedure R: 
1
H qNMR experiment 
N-Acetylcysteine methyl ester 157 (7.48 mg, 42 µmol) was added to a solution of the 
desired 6-ethynylpurine in DMSO-d6 (690 µL from a stock solution in DMSO-d6 
containing 4.2 µmol of purine). The temperature was maintained at approximatively 
24 °C using a water bath. A solution of DMSO-d6 (10 µL) containing DABCO (0.14 mg, 
1.26 µmol) and DMF (0.33 µL, 4.2 µmol) was added to afford a final 6-ethynylpurine 
concentration of 6 mM in a total volume of 700 µL. The NMR tube was inverted quickly 
to mix the reagents and inserted into the spectrometer cavity which was maintained at 
24.0 ± 0.1 
o
C. The acquisition of 
1
H qNMR data was immediately initiated. The time 
between the addition of the DABCO/DMF-solution and the completion of the first 
1
H 
qNMR experiment was monitored for accuracy. Subsequent time intervals between 
experiments were calculated based on the defined parameters. 
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6-Ethynyl-9-methyl-N-phenyl-9H-purin-2-amine (61)
137
 
 
The title compound was synthesised following general procedure A using 9-methyl-N-
phenyl-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine 73 (360 mg, 0.90 mmol) and 
TBAF (1M in THF, 1.10 mL, 1.10 mmol). The crude product was purified by MPC on 
silica (petrol: EtOAc 1: 1) to give the product 61 as a pale yellow solid (124 mg, 0.50 
mmol, 56 %). 
Rf 0.13 (petrol: EtOAc 1: 1); Mp = 246-248 °C; UV λmax (EtOH) 261 nm; IR (cm
-1
) 3300, 
3264, 3086, 3045, 2360, 1590, 1545, 1497, 1438; 
1
H NMR (500 MHz, DMSO-d6) (ppm) 
δ 3.76 (3H, s, NCH3), 4.85 (1H, s, H-2’), 6.96 (1H, t, J = 7.5 Hz, H-4’’), 7.30 (2H, dd, J = 
7.5 and 7.5 Hz, H-3’’), 7.85 (2H, d, J = 7.5 Hz, H-2’’), 8.26 (1H, s, H-8), 9.79 (1H, s, 
NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 29.3 (CH3), 78.9 (C-1’), 87.2 (C-2’), 
118.3 (C-2’’), 121.0 (C-4’’), 128.5 (C-3’’), 128.9 (Cq), 139.7 (Cq), 140.7 (Cq), 145.3 (C-
8), 153.4 (Cq), 156.1 (Cq); HRMS calcd for C14H12N5 [M+H]
+
 250.1087, found 250.1091.  
6-Ethynyl-7-methyl-N-phenyl-7H-purin-2-amine (62)
137
 
 
The title compound was synthesised following general procedure A using 7-methyl-N-
phenyl-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine 75 (300 mg, 0.70 mmol) and 
TBAF (1M in THF, 0.90 mL, 0.90 mmol). The crude product was purified by MPC on 
silica (petrol: EtOAc 2: 3) to give the product 62 as a pale yellow solid (88 mg, 0.40 
mmol, 47 %). 
Rf 0.10 (petrol: EtOAc 1: 1); Mp = 261-263 °C; UV λmax (EtOH) 271 nm; IR (cm
-1
) 3300, 
3280, 3190, 3130, 2360, 1590, 1560, 1494, 1439; 
1
H NMR (500 MHz, DMSO-d6) (ppm) 
δ 4.01 (3H, s, NCH3), 5.00 (1H, s, H-2’), 6.92 (1H, t, J = 7.5 Hz, H-4’’), 7.29 (2H, dd, J = 
7.5 and 7.5 Hz, H-3’’), 7.82 (2H, d, J = 7.5 Hz, H-2’’), 8.46 (1H, s, H-8), 9.61 (1H, s, 
NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 32.8 (CH3), 78.2 (C-1’), 87.5 (C-2’), 
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118.0 (C-2’’), 120.4 (Cq), 120.7 (C-4’’), 128.4 (C-3’’), 133.1 (Cq), 141.0 (Cq), 150.3 (C-
8), 156.4 (Cq), 162.5 (Cq); HRMS calcd for C14H12N5 [M+H]
+
 250.1087, found 250.1091. 
2-(3-((6-Ethynyl-9-methyl-9H-purin-2-yl)amino)phenyl)acetamide (63) 
 
The title compound was synthesised following general procedure A using 2-(3-((6-
ethynyl-9-methyl-9H-purin-2-yl)amino)phenyl)acetamide 76 (300 mg, 0.65 mmol) and 
TBAF (1M in THF, 0.80 mL, 0.80 mmol). The crude product was purified by MPC on 
silica (DCM: MeOH 19: 1) to give the product 63 as a pale yellow solid (124 mg, 0.50 
mmol, 56 %). 
Rf 0.63 (DCM: MeOH 9: 1); Mp = 233-235 °C; UV λmax (EtOH) 271 nm; IR (cm
-1
) 3410, 
3270, 3190, 2105, 1650, 1598, 1553, 1521, 1444; 
1
H NMR (500 MHz, DMSO-d6) (ppm) 
δ 3.36 (2H, s, H-7’’), 3.76 (3H, s, NCH3), 4.84 (1H, s, H-2’), 6.85 (1H, d, J = 7.8 Hz, H-
4’’), 6.90 (1H, br s, NH2), 7.21 (1H, dd, J = 7.8 and 7.8 Hz, H-5’’), 7.46 (1H, br s, NH2), 
7.65 (1H, d, J = 7.8 Hz, H-6’’), 7.82 (1H, s, H-2’’), 8.25 (1H, s, H-8), 9.77 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 29.3 (CH3), 42.2 (C-7’’), 78.9 (C-1’), 87.1 (C-
2’), 116.5 (C-6’’), 119.0 (C-2’’), 122.0 (C-4’’), 128.2 (Cq), 128.8 (C-5’’), 136.7 (Cq), 
139.8 (Cq), 140.6 (Cq), 145.2 (C-8), 153.3 (Cq), 156.1 (Cq), 172.2 (CO); HRMS calcd for 
C16H15N6O [M+H]
+
 307.1302, found 307.1308. 
2-(3-((6-Ethynyl-7-methyl-7H-purin-2-yl)amino)phenyl)acetamide (64) 
 
The title compound was synthesised following general procedure A using 2-(3-((6-
ethynyl-9-methyl-9H-purin-2-yl)amino)phenyl)acetamide 77 (290 mg, 0.63 mmol) and 
TBAF (1M in THF, 0.80 mL, 0.80 mmol). The crude product was purified by MPC on 
silica (DCM: MeOH 19: 1) to give the product 64 as a pale yellow solid (40 mg, 0.10 
mmol, 21 %). 
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Rf 0.65 (DCM: MeOH 9: 1); Mp = 216-218 °C; UV λmax (EtOH) 273 nm; IR (cm
-1
) 3299, 
3190, 2107, 1663, 1593, 1564, 1495, 1469; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.35 
(2H, s, H-7’’), 4.01 (3H, s, NCH3), 4.99 (1H,s, H-2’), 6.85 (1H, d, J = 7.8 Hz, H-4’’), 
6.87 (1H, br s, NH2), 7.21 (1H, dd, J = 7.8 and 7.8 Hz, H-5’’), 7.44 (1H, br s, NH2), 7.60 
(1H, s, H-2’’), 7.76 (1H, d, J = 7.8 Hz, H-6’’),8.45 (1H, s, H-8), 9.57 (1H, br s, NH); 13C 
NMR (125 MHz, DMSO-d6) (ppm) δ 32.8 (CH3), 48.6 (C-7’’), 78.2 (C-1’), 87.5 (C-2’), 
116.3 (C-6’’), 119.0 (C-2’’), 120.3 (Cq), 121.7 (C-4’’), 128.2 (C-5’’), 133.2 (Cq), 136.6 
(Cq), 140.8 (C-8), 150.2 (Cq), 156.5 (Cq), 162.5 (Cq), 172.2 (CO); HRMS calcd for 
C16H15N6O [M+H]
+
 307.1302, found 307.1307.  
2-(3-((6-Cyano-9H-purin-2-yl)amino)phenyl)acetamide (65) 
 
2-(3-((6-Cyano-9-(4-methoxybenzyl)-9H-purin-2-yl)amino)phenyl)acetamide 85 (110mg, 
0.27 mmol) was solubilised in TFA (5 mL). The resulting solution was heated at 70 °C 
for 5 h. Then the solvent was removed in vacuo. The product was purified by MPC on 
silica (DCM: MeOH 19: 1) to give the product 65 as a yellow oil (30 mg, 0.10 mmol, 
47%). 
Rf 0.28 (DCM: MeOH 9: 1); UV λmax (EtOH) 254 nm; IR (cm
-1
) 3430, 3122, 2340, 1664, 
1600, 1590, 1510, 1447; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.36 (2H, s, H-7’), 6.89 
(1H, br s, NH2), 6.91 (1H, d, J = 7.8 Hz, H-4’), 7.24 (1H, dd, J = 7.8 and 7.8 Hz, H-5’), 
7.45 (1H, br s, NH2), 7.52 (1H, s, H-2’), 7.71 (1H, d, J = 7.8 Hz, H-6’), 8.48 (1H, s, H-8), 
9.90 (1H, s, NH), 13.51 (1H, br s, N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 42.4 
(C-7’), 114.6 (Cq), 117.0 (C-6’), 119.8 (C-2’), 122.7 (C-4’), 126.7 (Cq),128.3 (C-5’), 
136.8 (Cq), 140.0 (C-8), 150.1(Cq), 146.6 (Cq), 156.3 (CN), 172.1 (CO); HRMS calcd for 
C14H12N7O [M+H]
+
 294.1098, found 294.1103. 
Note: One quaternary carbon was not visible on the 
13
C NMR spectrum. 
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2-(3-((6-Cyano-9-methyl-9H-purin-2-yl)amino)phenyl)acetamide (66) 
 
The title compound was synthesised following general procedure B using 2-(3-((6-
cyano-9H-purin-2-yl)amino)phenyl)acetamide 65 (106 mg, 0.36 mmol), K2CO3 (60 mg, 
0.43 mmol) and MeI (0.03 mL, 0.43 mmol). The crude product was purified by MPC on 
silica (DCM: MeOH 19: 1) to give the product 66 as a yellow solid (44 mg, 0.14 mmol, 
40%). 
Rf 0.55 (DCM: MeOH 9: 1); UV λmax (EtOH) 266 nm; Mp = 207-209 °C; IR (cm
-1
) 3430, 
3122, 2340, 1664, 1600, 1590, 1510, 1447; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.37 
(2H, s, H-7’), 3.79 (3H, s, NCH3), 6.90 (1H, br s, NH2), 6.91 (1H, d, J = 7.8 Hz, H-4’), 
7.25 (1H, dd, J = 7.8 and 7.8 Hz, H-5’), 7.47 (1H, br s, NH2), 7.62 (1H, d, J = 7.8 Hz, H-
6’), 7.78 (1H, s, H-2’), 8.48 (1H, s, H-8), 10.07 (1H, s, NH); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 29.6 (NCH3), 42.5 (C-7’), 114.3 (Cq), 117.0 (C-6’), 119.4 (C-2’), 
122.8 (C-4’), 128.3 (Cq), 129.1 (C-5’), 136.9 (Cq), 139.9 (Cq), 148.2 (Cq), 154.8 (Cq), 
156.2 (CN), 164.5 (Cq), 172.1 (CO); HRMS calcd for C15H14N7O [M+H]
+
 308.1254, 
found 308.1260. 
2-(3-((6-Cyano-7-methyl-7H-purin-2-yl)amino)phenyl)acetamide (67) 
 
The title compound was synthesised following general procedure C using 2-(3-((6-
cyano-9-(4-methoxybenzyl)-9H-purin-2-yl)amino)phenyl)acetamide 85 (67 mg, 0.16 
mmol) and OMe3BF4 (24 mg, 0.16 mmol). The reaction was heated for 20 min at 100 °C. 
The crude product was purified by MPC on silica (DCM: MeOH 19: 1) to give the 
product 67 as a yellow solid (28 mg, 0.09 mmol, 56%). 
Rf 0.55 (DCM: MeOH 9: 1); UV λmax (EtOH) 254 nm; Mp = 259-261 °C; IR (cm
-1
) 3390, 
3190, 2364, 1669, 1611, 1560, 1493, 1390; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.36 
(2H, s, H-7’), 4.01 (3H, s, NCH3), 6.89 (1H, br s, NH2), 6.90 (1H, d, J = 7.8 Hz, H-4’), 
7.24 (1H, dd, J = 7.8 and 7.8 Hz, H-5’), 7.46 (1H, br s, NH2), 7.57 (1H, s, H-2’), 7.71 (1H, 
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d, J = 7.8 Hz, H-6’), 8.66 (1H, s, H-8), 9.86 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) 
(ppm) δ 32.3 (NCH3), 42.4 (C-7’), 116.5 (C-6’), 119.2 (C-2’), 120.8 (Cq), 121.7 (Cq), 
122.2 (C-4’), 123.1 (Cq), 128.1 (C-5’), 136.6 (Cq), 140.0 (C-8), 152.4 (Cq), 156.4 (CN), 
163.9 (Cq), 171.9 (CO); HRMS calcd for C15H14N7O [M+H]
+
 308.1254, found 308.1259. 
6-Chloro-2-fluoro-9H-purine (69)
257
 
 
An aqueous solution of NaNO2 (7.00 g, 107.2 mmol) was added dropwise over 20 min to 
a stirred solution of 2-amino-6-chloropurine 68 (9.00 g, 52.9 mmol) in tetrafluoroboric 
acid (140 mL) at 0 °C. The resulting mixture was allowed to warn to r.t. and was stirred 
overnight. The reaction was then cooled to 0 °C and neutralised with a saturated aqueous 
solution of Na2CO3 until reaching a pH of 7-8. The resulting mixture was extracted with 
EtOAc (4 x 250 mL). The solvent was removed in vacuo and the crude solid was purified 
by MPC on silica (DCM: MeOH 9: 1) to give the product 69 as an off white solid (4.60 g, 
26.70 mmol, 50 %). 
Rf 0.55 (DCM: MeOH 9: 1); Mp = 169-171 °C (lit.,
257
 Mp = 161-162 °C); UV λmax 
(EtOH) 271 nm; IR (cm
-1
) 2900, 2780, 1580, 1480, 1250; 
1
H NMR (500 MHz, DMSO-d6) 
(ppm) δ 8.71 (1H, s, H-8), 14.10 (1H, s, N9H); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 
128.1 (Cq), 147.5 (C-8), 148.6 (Cq), 156.0 (d, J = 212.1 Hz, C-2), 162.3 (Cq); 
19
F NMR 
(470 MHz, DMSO-d6) (ppm) δ -52.8; HRMS calcd for C5H3ClFN4 [M
35
Cl+H]
+
 173.0025, 
found 173.0024, [M
37
Cl+H]
+
 175.0181, found 174.9994. 
Mixture of 6-chloro-2-fluoro-9-methyl-9H-purine (70) and 6-chloro-2-fluoro-7-
methyl-7H-purine (71)
137
 
 
The title compounds were synthesised following general procedure B using 2-fluoro-6-
chloropurine 69 (1.00 g, 5.80 mmol), K2CO3 (1.50 g, 11.6 mmol) and MeI (0.40 mL, 7.00 
mmol). The crude product was purified by MPC on amine silica (DCM: MeOH 49: 1) to 
give the products 70 and 71 as an off white solid (1.00 g, 5.40 mmol, 92 %). 
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Rf 0.80 (DCM: MeOH 9: 1);
 
IR (cm
-1
) 3080, 1550, 1390, 1260; 
19
F NMR (470 MHz, 
DMSO-d6) (ppm) δ -52.9, -52.4;  
6-Chloro-2-fluoro-9-methyl-9H-purine (70) 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.81 (3H, s, NCH3), 8.64 (1H, s, H-8); LRMS 
calcd for C6H5ClFN4 [M
35
Cl+H]
+
 187.0, found 187.1, [M
37
Cl+H]
+
 189.0, found 189.1. 
6-Chloro-2-fluoro-7-methyl-7H-purine (71) 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 4.07 (3H, s, NCH3), 8.79 (1H, s, H-8); LRMS 
calcd for C6H5ClFN4 [M
35
Cl+H]
+
 187.0, found 187.1, [M
37
Cl+H]
+
 189.0, found 189.1. 
Note: Not fully characterised as not pure. 
6-Chloro-2-fluoro-9-methyl-9H-purine (70) 
 
A mixture of 6-chloro-9-methyl-9H-purin-2-amine and 6-chloro-7-methyl-7H-purin-2-
amine (86/87) (400 mg, 2.20 mmol) was solubilised in tetrafluoroboric acid (5 mL). The 
solution was cooled to 0 °C. NaNO2 (300 mg, 4.36 mmol) in solution in water (2 mL) 
was added dropwise. The solution was then allowed to reach r.t. and was stirred for 1 h. 
After completion, the reaction mixture was cooled to 0°C and basified until reaching a 
neutral pH with a saturated aqueous solution of Na2CO3. The solution was extracted with 
EtOAc (3 x 10 mL). The organic layers were combined, dried over MgSO4 and the 
solvent was removed in vacuo. The product was purified by MPC on silica (DCM: 
MeOH 19: 1) to give the product 70 as a colourless oil (200 mg, 1.10 mmol, 50%). 
Rf 0.75 (DCM: MeOH 9: 1); UV λmax (EtOH) 250 nm; IR (cm
-1
) 3080, 1550, 1390, 1260; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.82 (3H, s, NCH3), 8.66 (1H, s, H-8); 
13
C NMR 
(125 MHz, DMSO-d6) (ppm) δ 30.2 (CH3), 140.0 (d, J = 3.1 Hz, Cq), 150.0 (d, J = 18.2 
Hz, Cq), 153.3 (C-8), 154 (d, J = 18.2 Hz, Cq), 156.0 (d, J = 213.7 Hz, C-2); 
19
F NMR 
(470 MHz, DMSO-d6) (ppm) δ -52.4; HRMS calcd for C6H5ClFN4 [M
35
Cl+H]
+
 187.0181, 
found 187.0181, [M
37
Cl+H]
+
 189.0337, found 189.0339.  
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2-Fluoro-9-methyl-6-((triisopropylsilyl)ethynyl)-9H-purine (72)
137
 
 
The title compound was synthesised following general procedure D using a mixture of 
6-chloro-2-fluoro-9-methyl-9H-purine 70 and 6-chloro-2-fluoro-7-methyl-7H-purine 71 
(1.00 g, 5.40 mmol), Pd(PPh3)2Cl2 (75 mg, 0.10 mmol), Cu(I)I (21 mg, 0.10 mmol), 
triisopropylsilyl acetylene (1.33 mL, 5.90 mmol) and Et3N (1.88 mL, 13.5 mmol). The 
crude product was purified by MPC on on silica (petrol: EtOAc 3: 2) to give the product 
72 as a yellow solid (880 mg, 2.70 mmol, 49 %). 
Rf 0.48 (petrol: EtOAc 3: 2); Mp = 114-116 °C; UV λmax (EtOH) 255 nm; IR (cm
-1
) 2940, 
2870, 1580, 1460, 1420, 1260; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.13-1.18 (21H, 
m, H-3’ and H-4’), 3.80 (3H, s, NCH3), 8.61 (1H, s, H-8); 
13
C NMR (125 MHz, DMSO-
d6) (ppm) δ 10.5 (C-3’), 18.3 (C-4’), 29.8 (CH3), 100.4 (C-1’), 102.2 (C-2’), 133.7 (d, J = 
4.2 Hz, Cq), 140.2 (d, J = 18.1 Hz, Cq), 149.3 (C-8), 154.8 (d, J = 18.1 Hz, Cq), 157.0 (d, 
J = 210.6 Hz, C-2); 
19
F NMR (470 MHz, DMSO-d6) (ppm) δ 52.4; HRMS calcd for 
C17H26FN4Si [M+H]
+
 333.1905, found 333.1910. 
9-Methyl-N-phenyl-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (73) 
 
The title compound was synthesised following general procedure E using 2-fluoro-9-
methyl-6-((triisopropylsilyl)ethynyl)-9H-purine 72 (880 mg, 2.60 mmol), aniline (0.70 
mL, 5.30 mmol) and TFA (1.0 mL). The crude product was purified by MPC on amine 
silica (petrol: EtOAc 7: 3) to give the product 73 as a yellow oil (360 mg, 0.90 mmol, 
34%). 
Rf 0.41 (DCM: MeOH 19: 1); UV λmax (EtOH) 275 nm; IR (cm
-1
) 3240, 2940, 2860, 1590, 
1580, 1540, 1440, 1390; 
1
H NMR (500 MHz, CDCl3) (ppm) δ 1.09-1.13 (21H, m, H-3’ 
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and H-4’), 3.80 (3H, s, NCH3), 7.03 (1H, t, J = 7.9 Hz, H-4’’), 7.34 (2H, dd, J = 7.9 and 
7.9 Hz, H-3’’), 7.71 (1H, br s, NH), 7.72 (2H, d, J = 7.9 Hz, H-2’’), 7.83 (1H, s, H-8); 13C 
NMR (125 MHz, CDCl3) (ppm) δ 11.2 (C-3’), 18.7 (C-4’), 29.6 (CH3), 99.8 (C-1’), 100.5 
(C-2’), 118.6 (C-2’’), 122.2 (C-4’’), 128.9 (C-3’’), 129.3 (Cq), 139.8 (Cq), 143.6 (C-8), 
153.6 (Cq), 156.2 (Cq); HRMS calcd for C23H32N5Si [M+H]
+
 406.2421, found 406.2420. 
Note: One quaternary carbon was not visible on the 
13
C NMR spectrum. 
2-Fluoro-7-methyl-6-((triisopropylsilyl)ethynyl)-7H-purine (74)
137
 
 
The title compound was synthesised following general procedure D using a mixture of 
6-chloro-2-fluoro-9-methyl-9H-purine 70 and 6-chloro-2-fluoro-7-methyl-7H-purine 71 
(1.00 g, 5.40 mmol), Pd(PPh3)2Cl2 (75 mg, 0.10 mmol), Cu(I)I (21 mg, 0.10 mmol), 
triisopropylsilyl acetylene (1.33 mL, 5.90 mmol) and Et3N (1.88 mL, 13.50 mmol). The 
crude product was purified by MPC on on silica (petrol: EtOAc 3: 2) to give the product 
74 as a yellow solid (390 mg, 1.20 mmol, 22 %). 
OR 
The title compound was synthesised following general procedure C using 2-fluoro-9-
(tetrahydro-2H-pyran-2-yl)-6-((triisopropylsilyl)ethynyl)-9H-purine (150 mg, 0.37 mmol) 
and OMe3BF4 (66 mg, 0.45 mmol). The crude product was purified by MPC on silica 
(petrol: EtOAc 3: 2) to give the product 74 as a yellow solid (51 mg, 0.15 mmol, 41%). 
OR 
The title compound was synthesised following general procedure C using 2-fluoro-9-(4-
methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purine 125 (110 mg, 0.25 mmol) and 
OMe3BF4 (45 mg, 0.30 mmol). The crude product was purified by MPC on silica (petrol: 
EtOAc 3: 2) to give the product 74 as a yellow solid (35 mg, 0.10 mmol, 42 %). 
Rf 0.18 (petrol: EtOAc 3: 2); Mp = 97-99 °C; UV λmax (EtOH) 310 nm; IR (cm
-1
) 2940, 
2870, 1560, 1460, 1430, 1295; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.13-1.18 (21H, 
m, H-3’ and H-4’), 4.11 (3H, s, NCH3), 8.79 (1H, s, H-8); 
13
C NMR (125 MHz, DMSO-
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d6) (ppm) δ 10.6 (C-3’), 18.3 (C-4’), 33.2 (CH3), 99.9 (C-1’), 102.4 (C-2’), 124.7 (d, J = 
4.4 Hz, Cq), 133.8 (d, J = 18.1 Hz, Cq), 153.4 (C-8), 157.0 (d, J = 207.5 Hz, C-2), 164.0 
(d, J = 18.1 Hz, Cq); 
19
F NMR (470 MHz, DMSO-d6) (ppm) δ -52.58; HRMS calcd for 
C17H26FN4Si [M+H]
+
 333.1905, found 333.1911. 
7-Methyl-N-phenyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-amine (75)
137
 
 
The title compound was synthesised following general procedure E using 2-fluoro-7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purine 74 (390 mg, 1.20 mmol), aniline (0.30 
mL, 2.40 mmol) and TFA (0.50 mL). The crude product was purified by prep-TLC 
(DCM: MeOH 19: 1) to give the product 75 as a yellow oil (300 mg, 0.70 mmol, 62%). 
Rf 0.46 (DCM: MeOH 19: 1); UV λmax (EtOH) 273 nm; IR (cm
-1
) 3050, 2945, 2870, 1590, 
1560, 1500, 1463, 1437; 
1
H NMR (500 MHz, CDCl3) (ppm) δ 1.10-1.14 (21H, m, H-3’ 
and H-4’), 4.02 (3H, s, NCH3), 6.93 (1H, t, J = 7.3 Hz, H-4’’), 7.18 (1H, s, NH), 7.25 (2H, 
dd, J = 7.9 and 7.3 Hz, H-3’’), 7.70 (2H, d, J = 7.9 Hz, H-2’’), 7.89 (1H, s, H-8); 13C 
NMR (125 MHz, CDCl3) (ppm) δ 11.3 (C-3’), 18.6 (C-4’), 33.3 (CH3), 100.6 (C-1’), 
101.0 (C-2’), 118.4 (C-2’’), 121.8 (C-4’’), 128.9 (C-3’’), 140.1 (C-8), 156.9 (Cq); HRMS 
calcd for C23H32N5Si [M+H]
+
 406.2421, found 406.2422. 
Note: Four quaternary carbons were not visible on the 
13
C NMR spectrum. 
2-(3-((9-Methyl-6-((triisopropylsilyl)ethynyl)-9H-purin-2-yl)amino)phenyl) 
acetamide (76) 
 
The title compound was synthesised following general procedure E using 2-fluoro-9-
methyl-6-((triisopropylsilyl)ethynyl)-9H-purine 72 (330 mg, 1.00 mmol), 2-(3-
aminophenyl)acetamide 79 (350 mg, 1.90 mmol) and TFA (0.40 mL). The crude product 
 213 
was purified by prep-TLC (DCM: MeOH 19: 1) to give the product 76 as a yellow solid 
(200 mg, 0.40 mmol, 43%). 
Rf 0.17 (DCM: MeOH 19: 1); Mp = 175-177 °C; UV λmax (EtOH) 276 nm; IR (cm
-1
) 
3300, 3180, 2944, 2865, 1660, 1595, 1553, 1516, 1442, 1393; 
1
H NMR (500 MHz, 
DMSO-d6) (ppm) δ 1.14-1.19 (21H, m, H-3’ and H-4’), 3.36 (2H, s, H-7’’), 3.77 (3H, s, 
NCH3), 6.85 (1H, d, J = 7.8 Hz, H-4’’), 6.90 (1H, br s, NH2), 7.20 (1H, dd, J = 7.8 and 
7.8 Hz, H-5’’), 7.45 (1H, br s, NH2), 7.62 (1H, d, J = 7.8 Hz, H-6’’), 7.91 (1H, s, H-2’’), 
8.24 (1H, s, H-8), 9.79 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 10.6 (C-
3’), 18.4 (C-4’), 29.3 (CH3), 42.6 (C-7’’), 98.1 (C-1’), 101.6 (C-2’), 116.5 (C-6’’), 118.9 
(C-2’’), 121.9 (C-4’’), 128.2 (Cq), 128.7 (C-5’’), 136.7 (Cq), 140.0 (Cq), 140.6 (Cq), 145.1 
(C-8), 153.3 (Cq), 156.0 (Cq), 172.2 (CO); HRMS calcd for C25H35N6OSi [M+H]
+
 
463.2636, found 463.2634. 
2-(3-((7-Methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-yl)amino)phenyl) 
acetamide (77) 
 
The title compound was synthesised following general procedure E using 2-fluoro-7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purine 74 (330 mg, 1.00 mmol), 2-(3-
aminophenyl)acetamide 79 (350 mg, 1.90 mmol) and TFA (0.40 mL). The crude product 
was purified by prep-TLC (DCM: MeOH 19: 1) to give the product 77 as a yellow oil 
(240 mg, 0.51 mmol, 52%). 
Rf 0.76 (DCM: MeOH 9: 1); UV λmax (EtOH) 276 nm; IR (cm
-1
) 3300, 3180, 2944, 2940, 
1672, 1605, 1567, 1497, 1464, 1389; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.14-1.19 
(21H, m, H-3’ and H-4’), 3.38 (2H, s, H-7’’), 4.03 (3H, s, NCH3), 6.84 (1H, d, J = 7.8 Hz, 
H-4’’), 6.87 (1H, br s, NH2), 7.19 (1H, dd, J = 7.8 and 7.8 Hz, H-5’’), 7.43 (1H, br s, 
NH2), 7.68 (1H, s, H-2’’), 7.74 (1H, d, J = 7.8 Hz, H-6’’), 8.44 (1H, s, H-8), 9.61 (1H, br 
s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 10.7 (C-3’), 18.4 (C-4’), 32.8 (CH3), 
42.1 (C-7’’), 98.6 (C-1’), 101.0 (C-2’), 116.2 (C-6’’), 119.0 (C-2’’), 120.0 (Cq), 121.6 (C-
4’’), 128.1 (C-5’’), 133.2 (Cq), 136.6 (Cq), 140.9 (Cq), 148.5 (Cq), 150.2 (C-8), 156.5 (Cq), 
172.2 (CO); HRMS calcd for C25H35N6OSi [M+H]
+
 463.2636, found 463.2633.  
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2-(3-Aminophenyl)acetamide (79)
258
 
 
The title compound was synthesised following general procedure F using 3-
aminophenylacetic acid 78 (3.00 g, 19.9 mmol) and SOCl2 (1.70 mL, 23.8 mmol). The 
crude product was purified by MPC on silica (DCM: MeOH 19: 1) to give the product 79 
as a pale yellow solid (1.23 g, 8.20 mmol, 41 %). 
Rf 0.48 (DCM: MeOH 9: 1); Mp = 156-158 °C; UV λmax (EtOH) 238 nm; IR (cm
-1
) 3410, 
3300, 3175, 1666, 1607, 1492, 1463, 1396; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.19 
(2H, s, H-7), 5.00 (2H, br s, NH2), 6.40-6.42 (2H, m, H-2 and H-4), 6.47 (1H, s, H-6), 
6.81 (1H, br s, NH2), 6.92 (1H, dd, J = 7.7 and 7.7 Hz, H-3), 7.34 (1H, br s, NH2); 
13
C 
NMR (125 MHz, DMSO-d6) (ppm) δ 42.6 (C-7), 112.0 (C-2), 114.6 (C-6), 116.6 (C-4), 
128.6 (C-3), 136.9 (Cq), 148.4 (Cq), 172.4 (CO); HRMS calcd for C8H11N2O [M+H]
+
 
151.0866, found 151.0863. 
6-Chloro-9-(4-methoxybenzyl)-9H-purin-2-amine (80)
259
 
 
2-Amino-6-chloropurine 68 (6.00 g, 35.5 mmol) and Cs2CO3 (13.80 g, 42.6 mmol) were 
dissolved in anhydrous DMF (80 mL) under N2. 4-Methoxybenzylchloride (6.00 mL, 
42.6 mmol) was then added and the reaction was stirred at 60 °C overnight. The solvent 
was removed in vacuo. The residue obtained was resuspended in EtOAc (50 mL) and 
washed with brine (50 mL) and water (50 mL). The organic layer was dried over MgSO4 
and the solvent was removed in vacuo. The product was purified by MPC on silica (DCM: 
MeOH 19: 1) to give 80 the product as an off-white solid (6.10 g, 21.00 mmol, 60%). 
Rf 0.64 (DCM: MeOH 9: 1); Mp = 176-178 °C; UV λmax (EtOH) 310 nm; IR (cm
-1
) 3440, 
3208, 2830, 1614, 1560, 1514, 1244; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.73 (3H, s, 
OCH3), 5.21 (2H, s, H-1’), 6.91 (2H, d, J = 8.7 Hz, H-3’), 6.94 (2H, s, NH2), 7.26 (2H, d, 
J = 8.7 Hz, H-4’), 8.21 (1H, s, H-8); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 45.5 (C-
1’), 54.9 (CH3), 114.1 (C-3’), 123.3 (Cq), 128.5 (Cq), 128.8 (C-4’), 143.0 (C-8), 149.4 
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(Cq), 153.9 (Cq), 158.9 (Cq), 159.9 (Cq); HRMS calcd for C13H13ClN5O [M
35
Cl+H]
+
 
290.0803, found 290.0808, [M
37
Cl+H]
+
 292.0960, found 292.0778. 
2-Amino-9-(4-methoxybenzyl)-9H-purine-6-carbonitrile (81)
136
 
 
6-Chloro-9-(4-methoxybenzyl)-9H-purin-2-amine 80 (2.00 g, 6.90 mmol) and Et4NCN 
(2.20 g, 13.8 mmol) were dissolved in dry MeCN (80 mL) under N2. DBU (1.50 mL, 13.8 
mmol) was then added and the reaction mixture was stirred at r.t. for 4 h. Aqueous 
ammonium hydroxide (50 mL) was added to the reaction and it was stirred for a further 1 
h. DCM (50 mL) was added and the organic layer was extracted, washed with brine (50 
mL) and water (50 mL). The organic layer was then dried over MgSO4 and the solvent 
was removed in vacuo. The product was purified by MPC on silica (DCM: MeOH 19: 1) 
to give the product 81 as pale yellow solid (1.20 g, 4.30 mmol, 62%). 
Rf 0.34 (petrol: EtOAc 1: 1); Mp = 172-174 °C; UV λmax (EtOH) 353 nm; IR (cm
-1
) 3471, 
3099, 2160, 1611, 1584, 1511, 1405, 1245; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.73 
(3H, s, OCH3), 5.24 (2H, s, H-1’), 6.91 (2H, d, J = 8.7 Hz, H-3’), 7.12 (2H, s, NH2), 7.27 
(2H, d, J = 8.7 Hz, H-4’), 8.44 (1H, s, H-8); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 
45.5 (C-1’), 55.1 (CH3), 114.1 (Cq), 114.5 (C-3’), 128.2 (Cq), 129.0 (Cq), 129.7 (C-4’), 
146.3 (C-8), 154.9 (Cq), 157.1 (Cq), 158.9 (Cq), 160.5 (CN); HRMS calcd for C14H13N6O 
[M+H]
+
 281.1145, found 281.1150. 
TFA salt of 2-amino-9H-purine-6-carbonitrile (82) 
 
2-Amino-9-(4-methoxybenzyl)-9H-purine-6-carbonitrile 81 (1.00 g, 3.60 mmol) was 
dissolved in TFA (50 mL) and heated at 70 °C for 4 h. TFA was removed in vacuo. The 
residue was suspended in MeOH and the resulting precipitate was filtrated to give the 
product 82 as a yellow solid (680 mg, 2.60 mmol, 74%). 
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Rf 0.38 (DCM: MeOH 9: 1); Mp = 239-241 °C; UV λmax (EtOH) 335 nm; IR (cm
-1
) 3448, 
3321, 2160, 1640, 1579, 1472, 1367; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 6.95 (2H, s, 
NH2), 8.34 (1H, s, H-8), 13.14 (1H, s, N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 
117.0 (q, J = 299.8 Hz, CF3), 144.8 (Cq), 152.0 (C-8), 158.0 (q, J = 30.2 Hz, CO), 158.5 
(Cq), 160.5 (Cq); 
19
F NMR (470 MHz, DMSO-d6) (ppm) δ -73.5; HRMS calcd for 
C6H5N6 [M+H]
+
 161.0570, found 161.0569. 
Note: One quaternary carbon was not visible on the 
13
C NMR spectrum. 
2-Iodo-9-(4-methoxybenzyl)-9H-purine-6-carbonitrile (84) 
 
The title compound was synthesised following general procedure G using 2-amino-9-
(4-methoxybenzyl)-9H-purine-6-carbonitrile 81 (1.12 g, 4.00 mmol), CH2I2 (1.70 mL, 
12.6 mmol), Cu(I)I (762 mg, 4.00 mmol) and isoamyl nitrite (1.70 mL, 12.6 mmol). The 
crude product was purified by MPC on silica (DCM: MeOH 9: 1) to give the product 84 
as pale yellow oil (1.20 g, 4.30 mmol, 62%). 
Rf 0.43 (petrol: EtOAc 1: 1); UV λmax (EtOH) 291 nm; IR (cm
-1
) 3115, 2160, 1590, 1564, 
1512, 1328, 1251; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.73 (3H, s, OCH3), 5.44 (2H, 
s, H-1’), 6.93 (2H, d, J = 8.4 Hz, H-3’), 7.34 (2H, d, J = 8.4 Hz, H-4’), 8.94 (1H, s, H-8); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 46.5 (C-1’), 55.1 (CH3), 113.4 (Cq), 114.2 (C-
3’), 119.2 (Cq), 127.3 (Cq), 129.4 (C-4’), 135.0 (Cq), 150.5 (C-8), 153.9 (Cq), 159.2 (CN), 
170.3 (Cq); HRMS calcd for C14H11IN5O [M+H]
+
 392.0003, found 392.0006. 
2-(3-((6-Cyano-9-(4-methoxybenzyl)-9H-purin-2-yl)amino)phenyl)acetamide (85) 
 
2-Iodo-9-(4-methoxybenzyl)-9H-purine-6-carbonitrile 84 (400 mg, 1.02 mmol), 2-(3-
aminophenyl)acetamide 79 (307 mg, 2.05 mmol), K2CO3 (282 mg, 2.05 mmol), 
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diacetoxypalladium (5 mg, 0.02 mmol) and Brettphos (11 mg, 0.02 mmol) were 
suspended in anhydrous DME (4 mL) under N2. The reaction was purged with N2, sealed 
and heated under microwaves for 20 min at 120 °C. The solution was filtered through 
Celite and the solvent was removed in vacuo. The product was purified by MPC on silica 
(DCM: MeOH 19: 1) to give the product 85 as a yellow solid (180 mg, 0.44 mmol, 43%). 
Rf 0.41 (DCM: MeOH 19: 1); Mp = 236-238 °C; UV λmax (EtOH) 253 nm; IR (cm
-1
) 
3446, 3250, 2160, 1683, 1615, 1521, 1458, 1405, 1245; 
1
H NMR (500 MHz, DMSO-d6) 
(ppm) δ 3.39 (2H, s, H-7’’), 3.72 (3H, s, OCH3), 5.37 (2H, s, H-1’), 6.90 (1H, br s, NH2), 
6.94 (3H, m, H-4’’ and H-3’), 7.26 (1H, dd, J = 7.8 and 7.8 Hz, H-5’’), 7.41 (2H, d, J = 
7.8 Hz, H-4’), 7.46 (1H, br s, NH2), 7.61 (1H, d, J = 7.8 Hz, H-6’’), 7.73 (1H, s, H-2’’), 
8.65 (1H, s, H-8), 10.09 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 42.4 (C-
7’’), 46.1 (C-1’), 55.1 (OCH3), 114.1 (C-3’), 114.2 (Cq), 117.0 (C-6’’), 119.6 (C-2’’), 
122.9 (C-4’’), 128.0 (Cq), 128.3 (Cq), 129.1 (C-5’’), 129.5 (C-4’), 129.7 (Cq), 136.8 (Cq), 
139.8 (Cq), 147.2 (C-8), 154.0 (Cq), 156.1 (Cq), 159.0 (CN), 172.1 (CO); HRMS calcd for 
C22H20N7O2 [M+H]
+
 414.1673, found 414.1675. 
Mixture of 6-chloro-9-methyl-9H-purin-2-amine (86) 
260
 and 6-chloro-7-methyl-7H-
purin-2-amine (87) 
 
The title compounds were synthesised following general procedure B using 2-amino-6-
chloropurine 68 (6.00 g, 35.5 mmol), K2CO3 (4.90 g, 35.50 mmol) and MeI (2.20 mL, 
35.50 mmol). The residue obtained was resuspended in MeOH and a precipitate appeared 
which was collected by filtration to give the products 86 and 87 as a pale yellow solid 
(5.80 g, 31.70 mmol, 89 %). 
Rf 0.33 (DCM: MeOH 9: 1); IR (cm
-1
) 3403, 3123, 1611, 1532, 1474;  
6-Chloro-9-methyl-9H-purin-2-amine (86) 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.64 (3H, s, CH3), 6.91 (2H, s, NH2), 8.08 (1H, 
s, H-8); MS [M
35
Cl+H]
+
 184.1, [M
37
Cl+H]
+
 186.1.  
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6-Chloro-7-methyl-7H-purin-2-amine (87) 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.91 (3H, s, CH3), 6.60 (2H, s, NH2), 8.30 (1H, 
s, H-8); MS [M
35
Cl+H]
+
 184.1, [M
37
Cl+H]
+
 186.1. 
Note: Not fully characterised as not pure 
TFA salt of 6-chloro-7-methyl-7H-purin-2-amine (87) 
 
The title compound was synthesised following general procedure C using 2-amino-9-(4-
methoxybenzyl)-9H-purine-6-carbonitrile 80 (100 mg, 0.34 mmol) and OMe3BF4 (61 mg, 
0.41 mmol). TFA (3 mL) was added after completion of the methylation to have a 50% 
TFA solution. The reaction was heated for 10 min at 100 °C. The crude product was 
recrystallised using petrol and DCM to afford the product 87 as a beige solid (70 mg, 
0.24 mmol, 68%). 
Rf 0.42 (DCM: MeOH 9: 1); Mp = 168-171 °C; UV λmax (EtOH) 302 nm; IR (cm
-1
) 2380, 
1630, 1583, 1391, 1030; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 4.00 (3H, s, NCH3), 
8.90 (1H, s, H-8); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 34.6 (CH3), 107.6 (Cq), 
114.2(CF3), 130.0 (Cq), 138.8 (Cq), 149.6 (C-8), 153.3 (Cq), 154.8 (CO); 
19
F NMR (470 
MHz, DMSO-d6) (ppm) δ -75.2; HRMS calcd for C6H7ClN5 [M
35
Cl+H]
+
 184.0384, 
found 184.0384, [M
37
Cl+H]
+
 186.0541, found 186.0353. 
2-Amino-9-methyl-9H-purine-6-carbonitrile (88) 
 
The title compound was synthesised following general procedure B using 2-amino-9H-
purine-6-carbonitrile 82 (150 mg, 0.58 mmol), K2CO3 (257 mg, 1.87 mmol) and MeI 
(0.06 mL, 0.93 mmol). The crude product was purified by MPC on silica (petrol: EtOAc 
1: 1) to give the product 88 as a yellow solid (60 mg, 0.34 mmol, 59%). 
Rf 0.14 (petrol: EtOAc 2: 3); Mp = 259-262 °C; UV λmax (EtOH) 335 nm; IR (cm
-1
) 3464, 
2361, 1634, 1608, 1579, 1468; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.66 (3H, s, 
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CH3), 7.09 (1H, br s, NH2), 8.31 (1H, s, H-8); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 
29.3 (CH3), 114.6 (Cq), 128.2 (Cq), 129.3 (Cq), 147.1 (C-8), 154.4 (Cq), 160.4 (CN); 
HRMS calcd for C7H7N6 [M+H]
+
 175.0727, found 175.0726. 
2-Amino-7-methyl-7H-purine-6-carbonitrile (89) 
 
The title compound was synthesised following general procedure C using 2-amino-9-(4-
methoxybenzyl)-9H-purine-6-carbonitrile 81 (100 mg, 0.36 mmol) and OMe3BF4 (54 mg, 
0.36 mmol). TFA (2 mL) was added and the reaction was heated for 20 min at 100 °C. 
The crude product was purified by MPC on silica (DCM: MeOH 19: 1) to give the 
product 89 as a beige solid (40 mg, 0.23 mmol, 65%). 
Rf 0.30 (DCM: MeOH 9: 1); Mp = 273-275 °C; UV λmax (EtOH) 254 nm; IR (cm
-1
) 3412, 
3185, 2360, 1610, 1501; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.94 (3H, s, NCH3), 
6.79 (2H, s, NH2), 8.51 (1H, s, H-8); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 32.2 
(CH3), 114.5 (Cq), 120.1 (Cq), 122.9 (Cq), 151.9 (C-8), 160.5 (Cq), 164.6 (CN); HRMS 
calcd for C7H7N6 [M+H]
+
 175.0727, found 175.0726. 
6-Chloro-2-iodo-9-methyl-9H-purine (90) 
 
The title compound was synthesised following general procedure G using a mixture of 
6-chloro-9-methyl-9H-purin-2-amine 86 and 6-chloro-7-methyl-7H-purin-2-amine 87 (50 
mg, 0.27 mmol), CH2I2 (0.11 mL, 1.35 mmol), Cu(I)I (52 mg, 0.81 mmol) and isoamyl 
nitrite (0.11 mL, 0.81 mmol). The crude product was purified by MPC on silica (DCM: 
MeOH 19: 1) to give the product 90 as pale yellow oil (24 mg, 0.08 mmol, 30%). 
Rf 0.59 (DCM: MeOH 9: 1); UV λmax (EtOH) 261 nm; IR (cm
-1
) 1586, 1328; 
1
H NMR 
(500 MHz, DMSO-d6) (ppm) δ 3.82 (3H, s, CH3), 8.56 (1H, s, H-8); 
13
C NMR (125 MHz, 
DMSO-d6) (ppm) δ 30.2 (CH3), 117.5 (Cq), 130.7 (Cq), 148.2 (C-8), 153.3 (Cq); HRMS 
calcd for C6H5ClIN4 [M
35
Cl+H]
+
 294.9242, found 294.9247, [M
37
Cl+H]
+
 296.9398, 
found 296.9401. 
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Note: One quaternary carbon was not visible on the 
13
C NMR spectrum. 
6-Chloro-9-((phenylthio)methyl)-9H-purin-2-amine (96) 
 
2-Amino-6-chloropurine 68 (1.00 g, 5.92 mmol) and Cs2CO3 (2.30 g, 7.10 mmol) were 
suspended in anhydrous DMF (50 mL) under N2. Chloromethyl phenyl sulfide (0.95 mL, 
7.10 mmol) was added slowly. The reaction was then heated at 40 °C for 24 h. The 
reaction mixture was filtered and the solvent was removed in vacuo. The residue was 
suspended in MeOH and the resulting precipitate was filtered. The filtrate was purified by 
MPC on silica (DCM: MeOH 19: 1) to give 96 as a yellow oil (1.16 g, 3.97 mmol, 67%). 
Rf 0.32 (DCM: MeOH 9: 1); 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 5.56 (2H, s, CH2), 
7.03 (2H, br s, NH2), 7.32-7.39 (5H, m, H-ar), 7.83 (1H, s, H-8); LRMS calcd for 
C12H11ClN5S [M
35
Cl+H]
+
 291.0, found 292.2, [M
37
Cl+H]
+
 292.0, found 294.3. 
Note: Not fully characterised as contaminated with compound 97. 
6-Chloro-7-((phenylthio)methyl)-7H-purin-2-amine (97) 
 
2-Amino-6-chloropurine 68 (1.00 g, 5.92 mmol) and Cs2CO3 (2.30 g, 7.10 mmol) were 
suspended in anhydrous DMF (50 mL) under N2. Chloromethyl phenyl sulphide (0.95 
mL, 7.10 mmol) was added slowly. The reaction was then heated at 40 °C for 24 h. The 
reaction mixture was filtered and the solvent was removed in vacuo. The residue was 
suspended in MeOH and the resulting precipitate was filtered to give 97 as a pale yellow 
solid (327 mg, 1.12 mmol, 19%). 
Rf 0.20 (DCM: MeOH 9: 1); Mp = 168-170 °C; UV λmax (EtOH) 304 nm; IR (cm
-1
) 3412, 
3174, 3070, 1629, 1545, 1496, 1299; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 5.75 (2H, s, 
CH2), 6.74 (2H, br s, NH2), 7.30-7.36 (5H, m, H-ar), 7.96 (1H, s, H-8); 
13
C NMR (125 
MHz, DMSO-d6) (ppm) δ 50.2 (CH2), 113.8 (Cq), 128.6 (C-ar), 129.4 (2 x C-ar), 131.0 
(Cq), 132.9 (2 x C-ar), 142.9 (Cq), 148.9(C-8), 160.3 (Cq), 164.6 (Cq); HRMS calcd for 
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C12H11ClN5S [M
35
Cl+H]
+
 292.0418, found 292.0423, [M
37
Cl+H]
+
 294.0575, found 
294.0393. 
2-Amino-9-((phenylthio)methyl)-9H-purine-6-carbonitrile (98) 
 
6-Chloro-9-((phenylthio)methyl)-9H-purin-2-amine 96 (1.1 g, 3.78 mmol) and Et4NCN 
(710 mg, 4.54 mmol) were dissolved in anhydrous MeCN (30 mL) under N2. DBU (0.80 
mL, 7.56 mmol) was then added and the reaction mixture was stirred at r.t. for 4 h. 
Aqueous ammonium hydroxide (30 mL) was added to the reaction and it was stirred for a 
further 1 h. DCM (30 mL) was added and the organic layer was extracted, washed with 
brine (30 mL) and water (30 mL). The organic layer was then dried over MgSO4 and the 
solvent was removed in vacuo. The product was purified by MPC on silica (petrol: 
EtOAc 2: 3) to give the product 98 as pale yellow solid (650 mg, 2.31 mmol, 61%). 
Rf 0.23 (petrol: EtOAc 3: 2); Mp = 185-187 °C; UV λmax (EtOH) 337 nm; IR (cm
-1
) 3465, 
3277, 3169, 2360, 1612, 1578, 1469, 1282; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 5.65 
(2H, s, CH2), 7.24 (2H, br s, NH2), 7.38-7.46 (5H, m, H-ar), 8.11 (1H, s, H-8); 
13
C NMR 
(125 MHz, DMSO-d6) (ppm) δ 46.0 (CH2), 114.3 (Cq), 127.2 (Cq), 128.2 (C-4’), 129.4 (2 
x C-ar), 129.9 (Cq), 131.6 (Cq), 131.9 (2 x C-ar), 145.4 (C-8), 154.5 (Cq), 160.4 (CN); 
HRMS calcd for C13H11N6S [M+H]
+
 283.0760, found 283.0765. 
2-Iodo-7-methyl-7H-purine-6-carbonitrile (99) 
 
The title compound was synthesised following general procedure C using 2-iodo-9-(4-
methoxybenzyl)-9H-purine-6-carbonitrile 84 (110 mg, 0.28 mmol) and OMe3BF4 (42 mg, 
0.28 mmol). The reaction was heated for 10 min at 100 °C. The crude product was 
purified by MPC on silica (petrol: EtOAc 2: 3) to give the product 99 as a colourless oil 
(53 mg, 0.19 mmol, 66%). 
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Rf 0.63 (DCM: MeOH 9: 1); UV λmax (EtOH) 302 nm; IR (cm
-1
) 2360, 1604, 1345; 
1
H 
NMR (500 MHz, DMSO-d6) (ppm) δ 4.07 (3H, s, NCH3), 8.91 (1H, s, H-8); 
13
C NMR 
(125 MHz, DMSO-d6) (ppm) δ 32.7 (CH3), 113.4 (Cq), 118.4 (Cq), 123.7 (Cq), 126.4 (Cq), 
153.9 (C-8), 163.4 (CN); HRMS calcd for C7H5IN5 [M+H]
+
 285.9584, found 285.9589. 
6-(Cyclohexylmethoxy)-7-methyl-7H-purin-2-amine (100) 
 
The title compound was synthesised following general procedure C using 6-
(cyclohexylmethoxy)-9-(4-methoxybenzyl)-9H-purin-2-amine 172 (100 mg, 0.27 mmol) 
and OMe3BF4 (45 mg, 0.30 mmol). The reaction was heated for 10 min at 100 °C. The 
crude product was purified by MPC on silica (DCM: MeOH 9: 1) to give the product 100 
as a white solid (43 mg, 0.11 mmol, 60%). 
Rf 0.46 (DCM: MeOH 9: 1); Mp = 167-169 °C; UV λmax (EtOH) 274 nm; IR (cm
-1
) 3162, 
2926, 2852, 1575, 1390, 1324, 1159; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.05-1.12 
(2H, m, H-3’ and H-7’), 1.17-1.30 (3H, m, H-5’, H-4’ and H-6’), 1.65-1.68 (1H, m, H-5’), 
1.72-1.75 (2H, m, H-4’ and H-6’), 1.79-1.82 (3H, m, H-2’, H-3’ and H-7’), 3.84 (3H, s, 
NCH3), 4.21 (2H, d, J = 6.2 Hz, H-1’), 6.07 (2H, s, NH2), 7.99 (1H, s, H-8); 
13
C NMR 
(125 MHz, DMSO-d6) (ppm) δ 25.3 (C-4’ and C-6’), 26.0 (C-5’), 29.2 (C-3’ and C-7’), 
33.4 (NCH3), 36.7 (C-2’), 70. (C-1’), 106.5 (Cq), 145.5 (C-8), 157.2 (Cq), 159.6 (Cq), 
163.6 (Cq); HRMS calcd for C13H20N5O [M+H]
+
 262.1662, found 262.1667. 
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6-(Cyclohexylmethoxy)-2-iodo-7-methyl-7H-purine (101) 
 
The title compound was synthesised following general procedure C using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (100 mg, 0.21 mmol) 
and OMe3BF4 (38 mg, 0.25 mmol). The reaction was heated for 20 min at 100 °C. The 
crude product was purified by MPC on silica (DCM: MeOH 9: 1) to give the product 101 
as a yellow solid (33 mg, 0.09 mmol, 45%). 
Rf 0.30 (DCM: MeOH 9: 1); Mp = 187-189 °C; UV λmax (EtOH) 248 nm; IR(cm
-1
) 2927, 
2851, 1536, 1415, 1332, 1123; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.10-1.15 (2H, m, 
H-3’ and H-7’), 1.17-1.31 (3H, m, H-5’, H-4’ and H-6’), 1.65-1.68 (1H, m, H-5’), 1.72-
1.74 (2H, m, H-4’ and H-6’), 1.81-1.83 (3H, m, H-2’, H-3’ and H-7’), 3.96 (3H, s, NCH3), 
4.28 (2H, d, J = 6.2 Hz, H-1’), 8.38 (1H, s, H-8); 13C NMR (125 MHz, DMSO-d6) (ppm) 
δ 25.2 (C-4’ and C-6’), 25.9 (C-5’), 29.0 (C-3’ and C-7’), 33.9 (NCH3), 36.6 (C-2’), 72.2 
(C-1’), 113.2 (Cq), 117.4 (Cq), 147.7 (C-8), 156.0 (Cq), 162.3 (Cq); HRMS calcd for 
C13H18IN4O [M+H]
+
 373.0520, found 373.0524. 
6-(Cyclohexylmethoxy)-7-methyl-7H-purine-2-carbonitrile (102) 
 
The title compound was synthesised following general procedure C using 6-
(cyclohexylmethoxy)-9-(4-methoxybenzyl)-9H-purine-2-carbonitrile (33 mg, 0.09 mmol) 
and OMe3BF4 (16 mg, 0.11 mmol). The reaction was heated for 20 min at 100 °C. The 
crude product was purified by MPC on silica (DCM: MeOH 19: 1) to give the product 
102 as a beige solid (17 mg, 0.06 mmol, 70%). 
Rf 0.65 (DCM: MeOH 9: 1); Mp = 168-170 °C; UV λmax (EtOH) 250 nm; IR (cm
-1
) 2927, 
2853, 2190, 1546, 1442, 1341, 1140; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.05-1.12 
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(2H, m, H-3’ and H-7’), 1.14-1.30 (3H, m, H-5’, H-4’ and H-6’), 1.64-1.66 (1H, m, H-5’), 
1.70-1.74 (2H, m, H-4’ and H-6’), 1.80-1.85 (3H, m, H-2’, H-3’ and H-7’), 4.03 (3H, s, 
NCH3), 4.38 (2H, d, J = 6.2 Hz, H-1’’), 8.67 (1H, s, H-8); 
13
C NMR (125 MHz, DMSO-
d6) (ppm) δ 25.2 (C-4’ and C-6’), 25.9 (C-5’), 29.0 (C-3’ and C-7’), 34.1 (NCH3), 36.6 
(C-2’), 72.6 (C-1’), 115.3 (Cq), 116.6 (Cq), 134.9 (Cq), 149.7 (C-8), 157.2 (Cq), 160.4 
(CN); HRMS calcd for C14H18N5O [M+H]
+
 272.1506, found 272.1511. 
6-Ethoxy-7-methyl-7H-purin-2-amine (103) 
 
The title compound was synthesised following general procedure C using 6-ethoxy-9-
(4-methoxybenzyl)-9H-purin-2-amine (100 mg, 0.28 mmol) and OMe3BF4 (50 mg, 0.33 
mmol). The reaction was heated for 10 min at 100 °C. The crude product was purified by 
MPC on silica (DCM: MeOH 19: 1) to give the product 103 as a colourless oil (35 mg, 
0.18 mmol, 66%). 
Rf 0.60 (DCM: MeOH 9: 1); UV λmax (EtOH) 275 nm; IR (cm
-1
) 3347, 3081, 2895, 1568, 
1385, 1290; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.38 (3H, t, J = 7.1 Hz, H-2’), 3.84 
(3H, s, NCH3), 4.45 (2H, q, J = 7.1 and 14.2 Hz, H-1’), 6.09 (2H, s, NH2), 8.00 (1H, s, H-
8); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 14.3 (C-2’), 33.3 (NCH3), 61.5 (C-1’), 114.3 
(Cq), 130.0 (Cq), 145.6 (C-8), 157.0 (Cq), 159.5 (Cq); HRMS calcd for C8H12N5O [M+H]
+
 
194.1036, found 194.1037. 
6-Ethoxy-2-iodo-7-methyl-7H-purine (104) 
 
The title compound was synthesised following general procedure C using 6-ethoxy-2-
iodo-9-(4-methoxybenzyl)-9H-purine (100 mg, 0.24 mmol) and OMe3BF4 (43 mg, 0.29 
mmol). The reaction was heated for 10 min at 100 °C. The crude product was purified by 
MPC on silica (DCM: MeOH 49: 1) to give the product 104 as a pale beige solid (55 mg, 
0.19 mmol, 73%). 
 225 
Rf 0.84 (DCM: MeOH 9: 1); Mp = 122-124 °C; UV λmax (EtOH) 266 nm; IR (cm
-1
) 2980, 
1610, 1484, 1331, 1128; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.41 (3H, t, J = 7.1 Hz, 
H-2’), 3.95 (3H, s, NCH3), 4.53 (2H, q, J = 7.1 and 14.2 Hz, H-1’), 8.38 (1H, s, H-8); 
13
C 
NMR (125 MHz, DMSO-d6) (ppm) δ 14.1 (C-2’), 33.8 (NCH3), 63.5 (C-1’), 117.4 (Cq), 
147.8 (C-8), 155.8 (Cq), 162.3 (Cq); HRMS calcd for C8H10IN4O [M+H]
+
 304.9894, 
found 304.9899. 
7-Methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-amine (105) 
 
The title compound was synthesised following general procedure C using 9-(4-
methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine 135 (100 mg, 0.23 
mmol) and OMe3BF4 (41 mg, 0.28 mmol). The reaction was heated for 20 min at 100 °C. 
The crude product was purified by MPC on silica (DCM: MeOH 9: 1) to give the product 
105 as a yellow oil (30 mg, 0.09 mmol, 40%). 
Rf 0.40 (DCM: MeOH 9: 1); UV λmax (EtOH) 337 nm; IR (cm
-1
) 3311, 2943, 2865, 1562, 
1295; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.12-1.15 (21H, m, H-3’ and H-4’), 3.96 
(3H, s, NCH3), 6.41 (2H, s, NH2), 8.30 (1H, s, H-8); 
13
C NMR (125 MHz, DMSO-d6) 
(ppm) δ 10.6 (C-3’), 18.4 (C-4’), 32.8 (CH3), 97.5 (C-1’), 101.6 (C-2’), 133.2 (Cq), 139.8 
(Cq), 141.7 (Cq), 150.0 (C-8), 160.3 (Cq); HRMS calcd for C17H28N5Si [M+H]
+
 330.2108, 
found 330.2114. 
2-Iodo-7-methyl-6-((triisopropylsilyl)ethynyl)-7H-purine (106) 
 
The title compound was synthesised following general procedure C using 2-iodo-9-(4-
methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purine 136 (65 mg, 0.12 mmol) and 
OMe3BF4 (22 mg, 0.14 mmol). The reaction was heated for 10 min at 100 °C. The crude 
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product was purified by MPC on silica (DCM: MeOH 49: 1) to give the product 106 as a 
colourless oil (30 mg, 0.07 mmol, 58%). 
Rf 0.63 (DCM: MeOH 9: 1); UV λmax (EtOH) 294 nm; IR (cm
-1
) 2943, 2864, 1590, 1470, 
1388, 1350; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.15-1.17 (21H, m, H-3’ and H-4’), 
4.08 (3H, s, NCH3), 8.68 (1H, s, H-8); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 10.5 (C-
3’), 18.4 (C-4’), 33.1 (NCH3), 99.8 (C-1’), 102.0 (C-2’), 119.2 (Cq), 125.7 (Cq), 133.6 
(Cq), 151.9 (C-8), 162.3 (Cq); HRMS calcd for C17H26IN4Si [M+H]
+
 441.0966, found 
441.0966. 
2-Fluoro-7-methyl-7H-purine (107) 
 
The title compound was synthesised following general procedure C using 2-fluoro-9-
(tetrahydro-2H-pyran-2-yl)-9H-purine (100 mg, 0.45 mmol) and OMe3BF4 (80 mg, 0.54 
mmol). The crude product was purified by MPC on silica (DCM: MeOH 49: 1) to give 
the product 107 as a colourless oil (39 mg, 0.26 mmol, 57%). 
Rf 0.41 (DCM: MeOH 9: 1); UV λmax (EtOH) 267 nm; IR (cm
-1
) 3091, 2945, 1606, 1399; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.81 (3H, s, NCH3), 8.59 (1H, s, H-8), 9.05 (1H, 
s, H-6); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 33.2 (NCH3), 143.5 (d, J = 16 Hz, C-6), 
148.7 (d, J = 3 Hz, C-5), 150.0 (d, J = 16 Hz, C-4), 152.1 (C-8), 158.0 (d, J = 206 Hz, C-
2); 
19
F NMR (470 MHz, DMSO-d6) (ppm) δ -53.1; HRMS calcd for C6H6FN4 [M+H]
+
 
153.0571, found 153.0568. 
6-(Cyclohexylmethoxy)-7-ethyl-7H-purin-2-amine (108) 
 
6-(Cyclohexylmethoxy)-9-(4-methoxybenzyl)-9H-purin-2-amine 172 (150 mg, 0.41 
mmol) and OEt3BF4 (93 mg, 0.49 mmol) were solubilised in TFE (5 mL) under N2. The 
resulting solution was stirred at r.t. for 2 h. The reaction was purged with nitrogen, sealed 
and heated under microwaves at 100 °C. The solvent was removed in vacuo and the crude 
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product was purified by MPC on silica (DCM: MeOH 9: 1) to give the product 108 as a 
colourless oil (45 mg, 0.16 mmol, 40%). 
Rf 0.45 (DCM: MeOH 9: 1); Mp = 73-76 °C; UV λmax (EtOH) 258 nm; IR (cm
-1
) 3101, 
2925, 2863, 1577, 1358, 1017; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.03-1.11 (2H, m, 
H-3’ and H-7’), 1.16-1.31 (3H, m, H-5’, H-4’ and H-6’), 1.38 (3H, t, J = 7.2 Hz, H-2’’), 
1.66-1.68 (1H, m, H-5’), 1.72-1.75 (2H, m, H-4’ and H-6’), 1.80-1.82 (3H, m, H-2’, H-3’ 
and H-7’), 4.20-4.24 (4H, m, H-1’ and H-1’’), 6.13 (2H, s, NH2), 8.09 (1H, s, H-8); 
13
C 
NMR (125 MHz, DMSO-d6) (ppm) δ 16.6 (C-2’’), 25.3 (C-4’ and C-6’), 26.0 (C-5’), 
29.2 (C-3’ and C-7’), 36.8 (C-2’), 41.8 (C-1’’), 70.7 (C-1’), 105.2 (Cq), 144.7 (C-8), 
156.8 (Cq), 159.5 (Cq), 163.5 (Cq); HRMS calcd for C14H22N5O [M+H]
+
 276.1819, found 
276.1820. 
6-Ethoxy-7-ethyl-7H-purin-2-amine (109) 
 
6-Ethoxy-9-(4-methoxybenzyl)-9H-purin-2-amine (90 mg, 0.30 mmol) and OEt3BF4 (69 
mg, 0.36 mmol) were solubilised in TFE (3.8 mL) under N2. The resulting solution was 
stirred at r.t. for 2 h. The reaction was purged with nitrogen, sealed and heated under 
microwaves at 100 °C. The solvent was removed in vacuo and the crude product was 
purified by MPC on silica (DCM: MeOH 9: 1) to give the product 109 as a colourless oil 
(36 mg, 0.17 mmol, 58%).  
Rf 0.43 (DCM: MeOH 9: 1); Mp = 158-161 °C; UV λmax (EtOH) 258 nm; IR (cm
-1
) 3451, 
3178, 2828, 1569, 1382, 1255; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.36-1.39 (6H, m, 
H-2’’ and H-2’), 4.20 (2H, q, J = 7.2 Hz, H-1’’), 4.46 (2H, q, J = 7.1 Hz, H-1’), 6.18 (2H, 
s, NH2), 8.11 (1H, s, C8H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 14.4 (C-2’), 16.4 
(C-2’’), 41.7 (C-1’’), 61.7 (C-1’), 105.6 (Cq), 144.7 (Cq), 156.7 (C-8), 159.4 (Cq), 
163.2(Cq); HRMS calcd for C9H14N5O [M+H]
+
 208.1193, found 208.1191. 
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2-Amino-7-ethyl-7H-purine-6-carbonitrile (111) 
 
2-Amino-9-(4-methoxybenzyl)-9H-purine-6-carbonitrile 81 (220 mg, 0.79 mmol) and 
OEt3BF4 (180 mg, 0.94 mmol) were solubilised in TFE (10 mL) under N2. The resulting 
solution was stirred at r.t. for 2 h. The reaction was purged with nitrogen, sealed and 
heated under microwaves at 100 °C. The solvent was removed in vacuo and the crude 
product was purified by MPC on silica (DCM: MeOH 19: 1) to give the product 111 as a 
pale yellow solid (41 mg, 0.22 mmol, 28%). 
Rf 0.43 (DCM: MeOH 9: 1); Mp = 270-273 °C; UV λmax (EtOH) 370 nm; IR (cm
-1
) 3416, 
3190, 2360, 1640, 1567, 1502, 1302; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.47 (3H, t, 
J = 7.3 Hz, C-2’), 4.34 (2H, q, J = 7.3 Hz, C-1’), 6.80 (2H, s, NH2), 8.59 (1H, s, H-8); 
13
C 
NMR (125 MHz, DMSO-d6) (ppm) δ 15.7 (C-2’), 40.7 (C-1’), 114.5 (Cq), 119.0 (Cq), 
122.7 (Cq), 151.0 (C-8), 160.5 (Cq), 164.9 (CN); HRMS calcd for C8H9N6 [M+H]
+
 
189.0883, found 189.0880. 
2-(4-Aminophenyl)acetamide (118)
136
 
 
The title compound was synthesised following general procedure F using 4-
aminophenylacetic acid 137 (500 mg, 3.31 mmol) and SOCl2 (0.30 mL, 3.97 mmol). The 
crude product was purified by MPC on silica (DCM: MeOH 9: 1) to give the product 118 
as a beige solid (240 mg, 1.60 mmol, 48%). 
Rf 0.45 (DCM: MeOH 9: 1); Mp = 151-153 °C; UV λmax (EtOH) 290 nm; IR (cm
-1
) 3345, 
3152, 1630, 1516, 1409; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.15 (2H, s, H-5’), 4.89 
(2H, br s, NH2), 6.49 (2H, d, J = 8.3 Hz, H-2’), 6.74 (1H, br s, CONH2), 6.90 (2H, d, J = 
8.3 Hz, H-3’), 7.25 (1H, br s, CONH2); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 41.5 
(C-5’), 113.5 (C-2’), 123.4 (C-4’), 129.4 (C-3’), 147.1 (C-1’), 172.9 (CO); HRMS calcd 
for C8H11N2O [M+H]
+
 151.0866, found 151.0864. 
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2-(3-Aminophenyl)-N,N-dimethylacetamide (119)
136
 
 
The title compound was synthesised following general procedure H using N,N-
dimethyl-2-(3-nitrophenyl)acetamide 140 (470 mg, 2.26 mmol) and zinc powder (1.50 g, 
22.6 mmol). The crude product was purified by MPC on silica (DCM: MeOH 9: 1) to 
give the product 119 as an off-white solid (380 mg, 2.13 mmol, 94%). 
Rf 0.53 (DCM: MeOH 9: 1); Mp = 50-53 °C; UV λmax (EtOH) 240 nm; IR (cm
-1
) 3425, 
3352, 3244, 1597, 1490, 1460, 1132; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 2.82 (3H, s, 
H-9’), 2.95 (3H, s, H-9’), 3.50 (2H, s, H-7’), 5.01 (2H, br s, NH2), 6.35 (1H, d, J = 7.7 Hz, 
H-4’), 6.41 (1H, d, J = 7.7 Hz, H-2’), 6.43 (1H, s, H-6’), 6.93 (1H, dd, J = 7.7 and 7.7 Hz, 
H-3’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 34.9 (C-9’), 37.2 (C-9’), 40.3 (C-7’), 
112.0 (C-4’), 114.0 (C-2’), 116.2 (C-6’), 128.8 (C-3’), 136.1 (C-5’), 148.7 (C-1’), 170.3 
(CO); HRMS calcd for C10H15N2O [M+H]
+
 179.1179, found 179.1179. 
2-(3-Aminophenyl)-N-(2,2,2-trifluoroethyl)acetamide (120)
136
 
 
The title compound was synthesised following general procedure H using 2-(3-
nitrophenyl)-N-(2,2,2-trifluoroethyl)acetamide 141 (280 mg, 1.07 mmol) and zinc 
powder (695 mg, 10.7 mmol). The crude product was purified by MPC on silica (DCM: 
MeOH 9: 1) to give the product 120 as a pale yellow oil (230 mg, 0.99 mmol, 93%). 
Rf 0.45 (DCM: MeOH 9: 1); UV λmax (EtOH) 239 nm; IR (cm
-1
) 3302, 3205, 3066, 1652, 
1560, 1396, 1148; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.33 (2H, s, H-7’), 3.86-3.93 
(2H, m, H-9’), 5.01 (2H, br s, NH2), 6.39 (1H, d, J = 7.6 Hz, H-4’), 6.41-6.43 (1H, m, H-
2’), 6.45 (1H, m, H-6’), 6.92 (1H, dd, J = 7.6 and 7.6 Hz, H-3’), 8.64 (1H, t, J = 6.2 Hz, 
NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 39.8 (q, J = 20.7 Hz, C-9’), 42.1 (C-7’), 
112.2 (C-2’), 114.5 (C-6’), 116.4 (C-4’), 124.0 (q, J = 279.2 Hz, CF3), 128.7 (C-3’), 
136.1 (C-5’), 148.5 (C-1’), 171.1 (CO); 19F NMR (470 MHz, DMSO-d6) (ppm) δ -70.7; 
HRMS calcd for C10H12F3N2O [M+H]
+
 233.0896, found 233.0898. 
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3-(3-Aminophenyl)propanamide (121)
261
 
 
The title compound was synthesised following general procedure F using 3-(3-
aminophenyl)propionic acid 138 (500 mg, 3.00 mmol) and SOCl2 (0.27 mL, 3.64 mmol). 
The crude product was purified by MPC on silica (DCM: MeOH 9: 1) to give the product 
121 as a white solid (360 mg, 2.20 mmol, 72%). 
Rf 0.43 (DCM: MeOH 9: 1); Mp = 78-80 °C; UV λmax (EtOH) 288 nm; IR (cm
-1
) 3335, 
3162, 1659, 1624, 1408; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 2.28 (2H, t, J = 7.6 Hz, 
H-7’), 2.63 (2H, t, J = 7.6 Hz, H-8’), 4.93 (2H, br s, NH2), 6.34-6.39 (3H, m, H-2’, H-6’ 
and H-4’), 6.74 (1H, br s, CONH2), 6.90 (1H, dd, J = 8.1 and 8.1 Hz, H-3’), 7.27 (1H, br 
s, CONH2); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 31.2 (C-7’), 36.8 (C-8’), 111.6 (C-
ar), 113.8 (C-ar), 115.7 (C-ar), 128.7 (C-3’), 142.0 (C-5’), 148.5 (C-1’), 173.4 (CO); 
HRMS calcd for C9H13N2O [M+H]
+
 165.1022, found 165.1020. 
N-(2-Acetamidoethyl)-2-(3-aminophenyl)acetamide (122)
136
 
 
The title compound was synthesised following general procedure H using N-(2-
acetamidoethyl)-2-(3-nitrophenyl)acetamide 142 (180 mg, 0.68 mmol) and zinc powder 
(440 mg, 6.80 mmol). The crude product was purified by MPC on silica (DCM: MeOH 9: 
1) to give the product 122 as a colourless oil (140 mg, 0.60 mmol, 88%). 
Rf 0.37 (DCM: MeOH 9: 1); UV λmax (EtOH) 239 nm; IR (cm
-1
) 3421, 3296, 1679, 1636, 
1549, 1493, 1438; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.79 (3H, s, H-12’), 3.07-
3.09 (4H, m, H-9’ and H-10’), 3.22 (2H, s, H-7’), 4.98 (2H, br s, NH2), 6.38-6.42 (2H, m, 
H-2’ and H-4’), 6.45 (1H, s, H-6’), 6.91 (1H, dd, J = 7.7 and 7.7 Hz, H-3’), 7.87 (1H, br s, 
NH), 7.98 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 22.6 (C-12’), 38.3 
(C-9’), 38.4 (C-10’), 42.7 (C-7’), 112.0 (C-2’), 114.5 (C-6’), 116.5 (C-4’), 128.6 (C-3’), 
136.7 (C-5’), 148.5 (C-1’), 169.3 (CO), 170.5 (CO); HRMS calcd for C12H18N3O2 
[M+H]
+
 236.1394, found 236.1396. 
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Mixture of 6-chloro-2-fluoro-9-(4-methoxybenzyl)-9H-purine (123) and 6-chloro-2-
fluoro-7-(4-methoxybenzyl)-7H-purine (124)  
 
2-Fluoro-6-chloropurine 69 (4.10 g, 23.80 mmol) and Cs2CO3 (11.6 g, 35.8 mmol) were 
dissolved in anhydrous DMF (80 mL) under N2. 4-Methoxybenzylchloride (3.90 mL, 
28.6 mmol) was then added and the reaction was stirred at 60 °C overnight. The solvent 
was removed in vacuo. The residue obtained was resuspended in EtOAc (50 mL) and 
washed with brine (50 mL) and water (50 mL). The organic layer was dried over MgSO4 
and the solvent was removed in vacuo. The product was purified by MPC on silica (DCM: 
MeOH 19: 1) to give the products 123/124 as a yellow oil (2.64 g, 9.05 mmol, 38%). 
Rf 0.80 (DCM: MeOH 9: 1); IR (cm
-1
) 2942, 2865, 1596, 1559, 1252, 1016; 
19
F NMR 
(470 MHz, DMSO-d6) (ppm) δ -52.9, -52.4. 
6-Chloro-2-fluoro-9-(4-methoxybenzyl)-9H-purine (123) 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.72 (3H, s, H-6’), 5.39 (2H, s, H-1’), 6.91 (2H, 
d, J = 8.7 Hz, H-4’), 7.35 (2H, d, J = 8.7 Hz, H-3’), 8.81 (1H, s, H-8); LRMS calcd for 
C13H11ClFN4O [M
35
Cl+H]
+
 293.1, found 293.2, [M
37
Cl+H]
+
 295.1, found 295.1. 
6-Chloro-2-fluoro-7-(4-methoxybenzyl)-7H-purine (124) 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.73 (3H, s, H-6’), 5.66 (2H, s, H-1’), 6.88 (2H, 
d, J = 8.7 Hz, H-4’), 7.22 (2H, d, J = 8.7 Hz, H-3’), 9.03 (1H, s, H-8); LRMS calcd for 
C13H11ClFN4O [M
35
Cl+H]
+
 293.1, found 293.4, [M
37
Cl+H]
+
 295.1, found 295.5. 
Note: Not fully characterised as not pure. 
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2-Fluoro-9-(4-methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purine (125)  
 
The title compound was synthesised following general procedure D using a mixture of 
6-chloro-9-(4-methoxybenzyl)-9H-purin-2-amine 123 and 6-chloro-7-(4-methoxybenzyl) 
-7H-purin-2-amine 124 (2.64 g, 9.00 mmol), Pd(PPh3)2Cl2 (127 mg, 0.18 mmol), Cu(I)I 
(34 mg, 0.18 mmol), triisopropylsilyl acetylene (2.23 mL, 9.90 mmol) and Et3N (3.15 mL, 
22.6 mmol). The crude product was purified by MPC on silica (petrol: EtOAc 1: 1) to 
give 125 was isolated as a brown solid (1.60 mg, 3.70 mmol, 40%)  
Rf 0.28 (petrol: EtOAc 9: 1); Mp = 107-110 °C; UV λmax (EtOH) 302 nm; IR (cm
-1
) 2947, 
2867, 1558, 1512, 1317, 1230; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.13-1.18 (21H, 
m, H-3’’ and H-4’’), 3.72 (3H, s, H-6’), 5.27 (2H, s, H-1’), 6.80 (2H, d, J = 8.7 Hz, H-4’), 
7.21 (2H, d, J = 8.7 Hz, H-3’), 8.77 (1H, s, H-8); 13C NMR (125 MHz, DMSO-d6) (ppm) 
δ 10.5 (C-3’’), 18.4 (C-4’’), 46.3 (C-1’), 55.1 (C-6’), 100.3 (C-1’’), 102.5 (C-2’’), 114.3 
(C-4’), 127.3 (Cq), 129.3 (C-3’), 133.8 (d, J = 4.1 Hz, Cq), 140.5 (d, J = 18.2 Hz, Cq), 
149.0 (C-8), 154.2 (d, J = 18.2 Hz, Cq), 157.0 (d, J = 210.5 Hz, C-2), 159.0 (Cq); 
19
F 
NMR (470 MHz, DMSO-d6) (ppm) δ -51.9; HRMS calcd for C24H32FN4OSi [M+H]
+
 
439.2324, found 439.2323. 
2-Fluoro-7-(4-methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-7H-purine (126) 
 
The title compound was synthesised following general procedure D using a mixture of 
6-chloro-9-(4-methoxybenzyl)-9H-purin-2-amine 123 and 6-chloro-7-(4-methoxybenzyl) 
-7H-purin-2-amine 124 (2.64 g, 9.00 mmol), Pd(PPh3)2Cl2 (127 mg, 0.18 mmol), Cu(I)I 
(34 mg, 0.18 mmol), triisopropylsilyl acetylene (2.23 mL, 9.90 mmol) and Et3N (3.15 mL, 
22.6 mmol). The crude product was purified by MPC on silica (petrol: EtOAc 1: 1) to 
give 126 was isolated as a brown solid (0.85 mg, 1.90 mmol, 21%)  
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Rf 0.28 (petrol: EtOAc 7: 3); Mp = 106-108 °C; UV λmax (EtOH) 274 nm; IR (cm
-1
) 2940, 
2870, 1580, 1460, 1420, 1260; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.04-1.09 (21H, 
m, H-3’’ and H-4’’), 3.72 (3H, s, H-6’), 5.75 (2H, s, H-1’), 6.90 (2H, d, J = 8.7 Hz, H-4’), 
7.19 (2H, d, J = 8.7 Hz, H-3’), 8.90 (1H, s, H-8); 13C NMR (125 MHz, DMSO-d6) (ppm) 
δ 10.6 (C-3’’), 18.2 (C-4’’), 48.1 (C-1’), 55.1 (C-6’), 99.8 (C-1’’), 103.5 (C-2’’), 114.2 
(C-4’), 123.8 (d, J = 4.1 Hz, Cq), 128.0 (Cq), 128.1 (C-3’), 133.8 (d, J = 18.3 Hz, Cq), 
152.8 (C-8), 157.0 (d, J = 210.6 Hz, C-2), 159.0 (Cq), 164.1 (d, J = 18.3 Hz, Cq); 
19
F 
NMR (470 MHz, DMSO-d6) (ppm) δ -52.4; HRMS calcd for C24H32FN4OSi [M+H]
+
 
439.2324, found 439.2324. 
N-(4-Chlorophenyl)-7-methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-amine (127) 
 
The title compound was synthesised following general procedure E using 2-fluoro-7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purine 74 (190 mg, 0.57 mmol), 4-chloroaniline 
113 (145 mg, 1.14 mmol) and TFA (0.22 mL). The crude product was purified by MPC 
on amine silica (petrol: EtOAc 1: 9) to give the product 127 as a yellow solid (130 mg, 
0.30 mmol, 52%). 
Rf 0.67 (DCM: MeOH 9: 1); Mp = 196-198 °C; UV λmax (EtOH) 278 nm; IR (cm
-1
) 3179, 
2941, 2864, 1563, 1462, 1321; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.14-1.21 (21H, 
m, H-3’ and H-4’), 4.04 (3H, s, NCH3), 7.32 (2H, d, J = 8.8 Hz, H-3’’), 7.89 (2H, d, J = 
8.8 Hz, H-2’’), 8.47 (1H, s, H-8), 9.83 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) 
(ppm) δ 10.6 (C-3’), 18.4 (C-4’), 32.9 (CH3), 98.9 (C-1’), 100.8 (C-2’), 119.3 (C-3’’), 
120.2 (Cq), 124.0 (Cq), 128.2 (C-2’’), 133.3 (Cq), 140.0 (Cq), 150.3 (C-8), 156.2 (Cq), 
162.4 (Cq); HRMS calcd for C23H31ClN5Si [M
35
Cl+H]
+
 440.2032, found 440.2032, 
[M
37
Cl+H]
+
 442.2003, found 442.2004. 
  
 234 
N-(4-Isopropylphenyl)-7-methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-amine 
(128) 
 
The title compound was synthesised following general procedure E using 2-fluoro-7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purine 74 (190 mg, 0.57 mmol), 4-
isopropylamine 114 (0.16 mL, 1.14 mmol) and TFA (0.22 mL). The crude product was 
purified by MPC on amine silica (petrol: EtOAc 1: 9) to give the product 128 as a yellow 
oil (110 mg, 0.25 mmol, 43%). 
Rf 0.83 (DCM: MeOH 9: 1); UV λmax (EtOH) 277 nm; IR (cm
-1
) 2951 , 2866, 1562, 1433, 
1390; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.14-1.17 (21H, m, H-3’ and H-4’), 1.19 
(6H, d, J = 7.0 Hz, H-6’’), 2.81-2.88 (1H, m, H-5’’), 4.03 (3H, s, NCH3), 7.17 (2H, d, J = 
8.6 Hz, H-3’’), 7.73 (2H, d, J = 8.6 Hz, H-2’’), 8.43 (1H, s, H-8), 9.53 (1H, s, NH); 13C 
NMR (125 MHz, DMSO-d6) (ppm) δ 10.7 (C-3’), 18.4 (C-4’), 24.1 (2 x C-6’’), 32.8 
(CH3), 32.9 (C-5’’), 98.5 (C-1’), 101.0 (C-2’), 118.3 (C-3’’), 120.2 (Cq), 126.1 (C-2’’), 
127.3 (Cq), 133.3 (Cq), 138.8 (Cq), 140.8 (C-8), 153.3 (Cq), 156.7 (Cq); HRMS calcd for 
C26H38N5Si [M+H]
+
 448.2891, found 448.2883. 
N-(3-Chlorophenyl)-7-methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-amine (129) 
 
The title compound was synthesised following general procedure E using 2-fluoro-7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purine 74 (220 mg, 0.65 mmol), 3-chloroaniline 
115 (0.14 mL, 1.30 mmol) and TFA (0.25 mL). The crude product was purified by MPC 
on amine silica (petrol: EtOAc 1: 9) to give the product 129 as a yellow solid (180 mg, 
0.41 mmol, 62%). 
Rf 0.45 (DCM: MeOH 9: 1); Mp = 196-200 °C; UV λmax (EtOH) 275 nm; IR (cm
-1
) 3322, 
2947, 2866, 1590, 1556, 1463; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.14-1.21 (21H, 
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m, H-3’ and H-4’), 4.04 (3H, s, NCH3), 6.94 (1H, d, J = 8.2 Hz, H-4’’), 7.29 (1H, dd, J = 
8.2 and 8.2 Hz, H-3’’), 7.66 (1H, d, J = 8.2 Hz, H-2’’), 8.17 (1H, s, H-6’’), 8.49 (1H, s, 
H-8), 9.90 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 10.6 (C-3’), 18.4 (C-4’), 
32.9 (CH3), 99.0 (C-1’), 100.9 (C-2’), 116.7 (C-2’’), 116.9 (C-6’’), 120.1 (Cq), 120.4 (C-
4’’), 130.0 (C-3’’), 133.0 (Cq), 133.1 (Cq), 142.6 (Cq), 150.5 (C-8), 156.0 (Cq), 162.4 (Cq); 
HRMS calcd for C23H31ClN5Si [M
35
Cl+H]
+
 440.2032, found 440.2030, [M
37
Cl+H]
+
 
442.2003, found 442.2001. 
N-(3-Methoxyphenyl)-7-methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-amine (130) 
 
The title compound was synthesised following general procedure E using 2-fluoro-7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purine 74 (220 mg, 0.65 mmol), m-anisidine 
116 (0.15 mL, 1.30 mmol) and TFA (0.25 mL). The crude product was purified by MPC 
on silica (petrol: EtOAc 1: 9) to give the product 130 as a yellow oil (190 mg, 0.44 mmol, 
66%). 
Rf 0.49 (DCM: MeOH 9: 1); UV λmax (EtOH) 223 nm; IR (cm
-1
) 3260, 2943, 2864, 1599, 
1542, 1494, 1387; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.14-1.21 (21H, m, H-3’ and 
H-4’), 3.74 (3H, s, H-7’’), 4.04 (3H, s, NCH3), 6.50 (1H, d, J = 8.2 Hz, H-4’’), 7.16 (1H, 
dd, J = 8.2 and 8.2 Hz, H-3’’), 7.36 (1H, d, J = 8.2 Hz, H-2’’), 7.66 (1H, s, H-6’’), 8.46 
(1H, s, H-8), 9.63 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 10.5 (C-3’), 
18.4 (C-4’), 32.9 (CH3), 54.6 (C-7’’), 98.7 (C-1’), 100.9 (C-2’), 104.1 (C-6’’), 105.7 (C-
4’’), 110.5 (C-2’’), 120.0 (Cq), 129.1 (C-3’’), 133.1 (Cq), 142.3 (Cq), 150.3 (C-8), 156.2 
(Cq), 159.7 (Cq), 162.4 (Cq); HRMS calcd for C24H34N5OSi [M+H]
+
 436.2527, found 
436.2522. 
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N-(4-Chlorophenyl)-6-ethynyl-7-methyl-7H-purin-2-amine (131) 
 
The title compound was synthesised following general procedure A using N-(4-
chlorophenyl)-7-methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-amine 127 (130 mg, 
0.30 mmol) and TBAF (1M in THF, 0.30 mL, 0.30 mmol). The crude product was 
purified by MPC on silica (DCM: MeOH 19: 1) to give the product 131 as yellow oil (38 
mg, 0.13 mmol, 45%). 
Rf 0.31 (DCM: MeOH 9: 1); UV λmax (EtOH) 275 nm; IR (cm
-1
) 3276, 3124, 2116, 1596, 
1540, 1489; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 4.01 (3H, s, NCH3), 5.02 (1H, s, H-
2’), 7.34 (2H, d, J = 8.9 Hz, H-3’’), 7.86 (2H, d, J = 8.9 Hz, H-2’’), 8.48 (1H, s, H-8), 
9.80 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 32.8 (CH3), 78.3 (C-1’), 87.7 
(C-2’), 119.4 (C-2’’), 120.5 (Cq), 124.0 (Cq), 128.3 (C-3’’), 133.1 (Cq), 140.1 (Cq), 150.6 
(C-8), 156.0 (Cq), 162.4 (Cq); HRMS calcd for C14H11ClN5 [M
35
Cl+H]
+
 284.0697, found 
284.0703, [M
37
Cl+H]
+
 286.0668, found 286.0672. 
6-Ethynyl-N-(4-isopropylphenyl)-7-methyl-7H-purin-2-amine (132) 
 
The title compound was synthesised following general procedure A using N-(4-
isopropylphenyl)-7-methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-amine 128 (110 mg, 
0.25 mmol) and TBAF (1M in THF, 0.25 mL, 0.25 mmol). The crude product was 
purified by MPC on silica (DCM: MeOH 19: 1) to give the product 132 as yellow solid 
(29 mg, 0.10 mmol, 40%). 
Rf 0.36 (DCM: MeOH 9: 1); Mp = no melt, degradation; UV λmax (EtOH) 274 nm; IR 
(cm
-1
) 3290, 2963, 2116, 1594, 1470, 1383; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.20 
(6H, d, J = 6.9 Hz, H-6’), 2.81-2.88 (1H, m, H-5’), 4.00 (3H, s, NCH3), 4.98 (1H, s, H-2’), 
7.16 (2H, d, J = 8.5 Hz, H-3’’), 7.70 (2H, d, J = 8.5 Hz, H-2’’), 8.43 (1H, s, H-8), 9.48 
(1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 24.1 (2 x C-6’), 32.8 (CH3), 32.9 
(C-5’), 78.2 (C-1’), 87.4 (C-2’), 118.4 (C-2’’), 120.1 (Cq), 126.1 (C-3’’), 133.2 (Cq), 
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138.7 (Cq), 140.9 (Cq), 150.2 (C-8), 156.6 (Cq), 162.5 (Cq); HRMS calcd for C17H18N5 
[M+H]
+
 292.1557, found 292.1559. 
N-(3-Chlorophenyl)-6-ethynyl-7-methyl-7H-purin-2-amine (133) 
 
The title compound was synthesised following general procedure A using N-(3-
chlorophenyl)-7-methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-amine 129 (180 mg, 
0.41 mmol) and TBAF (1M in THF, 0.41 mL, 0.41 mmol). The crude product was 
purified by MPC on silica (DCM: MeOH 19: 1) to give the product 133 as yellow oil (48 
mg, 0.17 mmol, 41%). 
Rf 0.40 (DCM: MeOH 9: 1); UV λmax (EtOH) 273 nm; IR (cm
-1
) 3306, 3069, 2116, 1591, 
1540, 1498, 1472; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 4.02 (3H, s, NCH3), 5.04 (1H, 
s, H-2’), 6.96 (1H, d, J = 8.1 Hz, H-4’’), 7.31 (1H, dd, J = 8.1 and 8.1 Hz, H-3’’), 7.70 
(1H, d, J = 8.1 Hz, H-2’’), 8.07 (1H, s, H-6’’), 8.50 (1H, s, H-8), 9.88 (1H, s, NH); 13C 
NMR (125 MHz, DMSO-d6) (ppm) δ 32.9 (CH3), 78.1 (C-1’), 87.9 (C-2’), 116.3 (C-2’’), 
116.9 (C-6’’), 120.2 (C-4’’), 120.7 (Cq), 130.1 (C-3’’), 133.0 (Cq), 133.2 (Cq), 142.6 (Cq), 
150.6 (C-8), 155.9 (Cq), 162.4 (Cq); HRMS calcd for C14H11ClN5 [M
35
Cl+H]
+
 284.0697, 
found 284.0703, [M
37
Cl+H]
+
 286.0668, found 286.0672. 
6-Ethynyl-N-(3-methoxyphenyl)-7-methyl-7H-purin-2-amine (134) 
 
The title compound was synthesised following general procedure A using N-(3-
methoxyphenyl)-7-methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-amine 130 (190 mg, 
0.44 mmol) and TBAF (1M in THF, 0.44 mL, 0.44 mmol). The crude product was 
purified by MPC on silica (DCM: MeOH 19: 1) to give the product 134 as yellow solid 
(52 mg, 0.18 mmol, 43%). 
Rf 0.47 (DCM: MeOH 9: 1); Mp = no melt, degradation; UV λmax (EtOH) 270 nm; IR 
(cm
-1
) 3090, 2937, 2117, 1598, 1497, 1461, 1281, 1164; 
1
H NMR (500 MHz, DMSO-d6) 
(ppm) δ 3.75 (3H, s, H-7’’), 4.01 (3H, s, NCH3), 5.00 (1H, s, H-2’), 6.51 (1H, d, J = 8.1 
 238 
Hz, H-4’’), 7.18 (1H, dd, J = 8.1 and 8.1 Hz, H-3’’), 7.36 (1H, d, J = 8.1 Hz, H-2’’), 7.58 
(1H, s, H-6’’), 8.46 (1H, s, H-8), 9.60 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) 
(ppm) δ 32.8 (CH3), 54.9 (C-7’’), 78.2 (C-1’), 87.5 (C-2’), 104.2 (C-6’’), 105.7 (C-4’’), 
110.7 (C-2’’), 120.4 (Cq), 129.1 (C-3’’), 133.1 (Cq), 142.1 (C-8), 150.3 (Cq), 156.3 (Cq), 
159.5 (Cq), 162.4 (Cq); HRMS calcd for C15H14N5O [M+H]
+
 280.1193, found 280.1197. 
9-(4-Methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine (135)
136
 
 
The title compound was synthesised following general procedure D using (6-chloro-9-
(4-methoxybenzyl)-9H-purin-2-amine 80 (1.00 g, 3.45 mmol), Pd(PPh3)2Cl2 (48 mg, 0.07 
mmol), Cu(I)I (13 mg, 0.07 mmol), triisopropylsilyl acetylene (0.85 mL, 3.80 mmol) and 
Et3N (1.18 mL, 8.61 mmol). The crude product was purified by MPC on silica (petrol: 
EtOAc 1: 1) to give the product 135 as a yellow oil (975 mg, 2.24 mmol, 65%). 
Rf 0.33 (petrol: EtOAc 7: 3); UV λmax (EtOH) 330 nm; IR (cm
-1
) 3297, 3179, 2867, 1594, 
1512, 1456, 1403, 1243; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.11-1.14 (21H, m, H-
3’’ and H-4’’), 3.72 (3H, s, H-6’), 5.21 (2H, s, H-1’), 6.68 (2H, s, NH2), 6.90 (2H, d, J = 
8.7 Hz, H-4’), 7.23 (2H, d, J = 8.7 Hz, H-3’), 8.19 (1H, s, H-8); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 10.5 (C-3’’), 18.5 (C-4’’), 45.2 (C-1’), 55.0 (C-6’), 97.2 (C-1’’), 
101.9 (C-2’’), 114.0 (C-4’), 128.7 (C-3’), 128.8 (Cq), 135.7 (Cq), 140.8 (Cq), 143.5 (C-8), 
153.7 (Cq), 158.7 (Cq), 160.4 (Cq); HRMS calcd for C24H34N5OSi [M+H]
+
 436.2527, 
found 436.2527. 
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2-Iodo-9-(4-methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purine (136)
136
 
 
The title compound was synthesised following general procedure G using 9-(4-
methoxybenzyl)-6-((triisopropylsilyl)ethynyl)-9H-purin-2-amine 135 (200 mg, 0.46 
mmol), CH2I2 (0.19 mL, 2.28 mmol), Cu(I)I (132 mg, 0.69 mmol) and isoamyl nitrite 
(0.19 mL, 1.38 mmol). The crude product was purified by MPC on silica (petrol: EtOAc 
4: 1) to give the product 136 as colourless oil (76 mg, 0.14 mmol, 30%). 
Rf 0.79 (DCM: MeOH 9: 1); UV λmax (EtOH) 311 nm; IR (cm
-1
) 2947, 2867, 1558, 1512, 
1317, 1230; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.12-1.15 (21H, m, H-3’’ and H-
4’’), 3.73 (3H, s, H-6’), 5.38 (2H, s, H-1’), 6.92 (2H, d, J = 8.7 Hz, H-4’), 7.30 (2H, d, J 
= 8.7 Hz, H-3’), 8.67 (1H, s, H-8); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 10.5 (C-3’’), 
18.4 (C-4’’), 46.2 (C-1’), 55.1 (C-6’), 100.2 (C-1’’), 102.2 (C-2’’), 114.1 (C-4’), 119.5 
(Cq), 127.8 (Cq), 129.1 (C-3’), 134.6 (Cq), 140.2 (Cq), 147.8 (C-8), 152.7 (Cq), 159.0 (Cq); 
HRMS calcd for C24H32IN4OSi [M+H]
+
 547.1385, found 547.1374. 
N,N-Dimethyl-2-(3-nitrophenyl)acetamide (140)
136
 
 
3-Nitrophenylacetic acid 139 (500 mg, 2.76 mmol), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (800 mg, 4.14 mmol), 1-hydroxybenzotriazole hydrate 
(485 mg, 3.59 mmol) and dimethylamine hydrochloride (270 mg, 3.31 mmol) were 
solubilised in anhydrous MeCN (12 mL) under N2. Then diisopropylethylamine (0.60 mL, 
3.31 mmol) was added and the reaction was stirred at r.t. overnight under N2. The solvent 
was removed in vacuo. The residue was resuspended in EtOAc (15 mL) and washed with 
NaHCO3. The organic layer was dried over MgSO4 and the solvent was removed in 
vacuo. The crude mixture was purified by MPC on silica (DCM: MeOH 19: 1) to give the 
product 140 as a pale yellow solid (470 mg, 2.26 mmol, 82%). 
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Rf 0.63 (DCM: MeOH 9: 1); Mp = 47-50 °C; UV λmax (EtOH) 263 nm; IR (cm
-1
) 1635, 
1522, 1342; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 2.86 (3H, s, H-9’), 3.06 (3H, s, H-
9’), 3.89 (2H, s, H-7’), 7.60 (1H, dd, J = 7.7 and 7.7 Hz, H-3’), 7.68 (1H, d, J = 7.7 Hz, 
H-4’), 8.10 (1H, d, J = 7.7 Hz, H-2’), 8.11 (1H, s, H-6’); 13C NMR (125 MHz, DMSO-d6) 
(ppm) δ 35.1 (C-9’), 36.9 (C-9’), 38.5 (C-7’), 121.3 (C-2’), 124.2 (C-6’), 129.4 (C-3’), 
136.5 (C-4’), 138.5 (Cq), 147.5 (Cq), 169.5 (CO); HRMS calcd for C10H13N2O3 [M+H]
+
 
209.0921, found 209.0921. 
2-(3-Nitrophenyl)-N-(2,2,2-trifluoroethyl)acetamide (141)
136
 
 
3-Nitrophenylacetic acid 139 (250 mg, 1.38 mmol) and 2,2,2-trifluoro-1-ethanamine 
hydrochloride (467 mg, 3.45 mmol) were solubilised in anhydrous MeCN (8 mL) under 
N2. Phosphorus trichloride (0.14 mL, 1.52 mmol) was added. The reaction was purged 
with N2, sealed and heated at 150 °C for 5 min under microwave heating. The solvent 
was removed in vacuo. The residue was resuspended in EtOAc (15 mL) and washed with 
NaHCO3. The organic layer was dried over MgSO4 and the solvent was removed in 
vacuo. The crude mixture was purified by MPC on silica (DCM: MeOH 19: 1) to give the 
product 141 as a white solid (291 mg, 1.11 mmol, 80%). 
Rf 0.67 (DCM: MeOH 9: 1); Mp= 130-132 
0
C; UV λmax (EtOH) 262 nm; IR (cm
-1
) 3287, 
1662, 1559, 1532, 1344, 1146; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.72 (2H, s, H-
7’), 3.91-3.98 (2H, m, H-9’), 7.63 (1H, dd, J = 7.9 and 7.9 Hz, H-3’), 7.71-7.73 (1H, m, 
H-4’), 8.13 (1H, ddd, J = 7.9, 2.3 and 1.0 Hz, H-2’), 8.17-8.18 (1H, m, H-6’), 8.88 (1H, t, 
J = 6.1 Hz, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 39.8 (q, J = 21.5 Hz, C-9’), 
40.9 (C-7’), 121.6 (C-2’), 123.7 (C-6’), 124.0 (q, J = 279.0 Hz, CF3), 129.7 (C-3’), 136.0 
(C-4’), 137.9 (C-5’), 147.6 (C-1’), 170.2 (CO); 19F NMR (470 MHz, DMSO-d6) (ppm) δ 
-70.8; HRMS calcd for C10H10F3N2O3 [M+H]
+
 263.0638, found 263.0643. 
N-(2-Acetamidoethyl)-2-(3-nitrophenyl)acetamide (142)
136
 
 
3-Nitrophenylacetic acid 139 (300 mg, 1.66 mmol) and CDI (270 mg, 1.65 mmol) were 
solubilised in anhydrous MeCN (15 mL) under N2. DIPEA (0.58 mL, 3.31 mmol) was 
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added and the reaction was stirred at r.t. for 2 h. N-Acetylethylenediamine (500 mg, 4.97 
mmol) was added and the solution was stirred at r.t. for 2 h. The solvent was removed in 
vacuo. The crude mixture was purified by MPC on silica (DCM: MeOH 9: 1) to give the 
product 142 as a white solid (180 mg, 0.68 mmol, 41%). 
Rf 0.75 (DCM: MeOH 9: 1); Mp = 108-110 °C; UV λmax (EtOH) 262 nm; IR (cm
-1
) 3263, 
3087, 1634, 1526 , 1346, 1446; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.78 (3H, s, H-
12’), 3.08-3.11 (4H, m, H-9’ and H-10’), 3.59 (2H, s, H-7’), 7.01 (1H, dd, J = 7.9 and 7.9 
Hz, H-3’), 7.21 (1H, d, J = 7.9 Hz, H-4’), 7.88 (1H, t, J = 4.6 Hz, NH), 8.11 (1H, d, J = 
7.9 Hz, H-2’), 8.16 (1H, s, H-6’), 8.20 (1H, t, J = 4.6 Hz, NH); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 22.6 (C-12’), 38.2 (C-10’), 38.5 (C-9’), 41.4 (C-7’), 121.4 (C-2’), 
123.8 (C-6’), 129.6 (C-3’), 136.0 (C-4’), 138.5 (C-5’), 147.6 (C-1’), 169.3 (CO), 169.4 
(CO); HRMS calcd for C12H16N3O4 [M+H]
+
 266.1135, found 266.1140. 
2-(4-((7-Methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-yl)amino)phenyl) 
acetamide (143) 
 
The title compound was synthesised following general procedure I using 2-iodo-7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purine 106 (200 mg, 0.45 mmol), 2-(4-
aminophenyl)acetamide 118 (75 mg, 0.50 mmol), K2CO3 (125 mg, 0.91 mmol), Pd(dba)2 
(10 mg, 0.01 mmol) and XPhos (5 mg, 0.01 mmol). The crude product was purified by 
MPC on silica (DCM: MeOH 19: 1) to give the product 143 as a yellow oil (90 mg, 0.19 
mmol, 43%). 
Rf 0.55 (DCM: MeOH 9: 1); UV λmax (EtOH) 278 nm; IR (cm
-1
) 3256, 3193, 2943, 2865, 
1645, 1563, 1496, 1302; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.14-1.20 (21H, m, H-
3’ and H-4’), 3.30 (2H, s, H-5’’), 4.03 (3H, s, NCH3), 6.82 (1H, br s, CONH2), 7.16 (2H, 
d, J = 8.6 Hz, H-3’’), 7.37 (1H, br s, CONH2), 7.75 (2H, d, J = 8.6 Hz, H-2’’), 8.43 (1H, s, 
H-8), 9.58 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 10.5 (C-3’), 18.4 (C-4’), 
32.8 (CH3), 41.7 (C-5’’), 98.5 (C-1’), 101.0 (C-2’), 117.9 (C-3’’), 119.8 (Cq), 128.7 (Cq), 
129.0 (C-2’’), 133.2 (Cq), 140.0 (Cq), 150.1 (C-8), 156.5 (Cq), 162.6 (Cq), 172.6 (CO); 
HRMS calcd for C25H35N6OSi [M+H]
+
 463.2636, found 463.2632. 
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N,N-dimethyl-2-(3-((7-methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-yl) 
amino)phenyl)acetamide (144) 
 
The title compound was synthesised following general procedure I using 2-iodo-7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purine 106 (200 mg, 0.45 mmol), 2-(3-
aminophenyl)-N,N-dimethylacetamide 119 (90 mg, 0.50 mmol), K2CO3 (125 mg, 0.91 
mmol), Pd(dba)2 (10 mg, 0.01 mmol) and XPhos (5 mg, 0.01 mmol). The crude product 
was purified by MPC on silica (EtOAc: MeOH 17: 3) to give the product 144 as a yellow 
oil (100 mg, 0.20 mmol, 45%). 
Rf 0.48 (DCM: MeOH 9: 1); UV λmax (EtOH) 276 nm; IR (cm
-1
) 3314, 3178, 1679, 1616, 
1496, 1306; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.14-1.20 (21H, m, H-3’ and H-4’), 
2.86 (3H, s, H-9’’), 3.04 (3H, s, H-9’’), 3.65 (2H, s, H-7’’), 4.03 (3H, s, NCH3), 6.76 (1H, 
d, J = 7.6 Hz, H-4’’), 7.20 (1H, dd, J = 7.6 and 7.6 Hz, H-3’’), 7.70 (1H, s, H-6’’), 7.71 
(1H, d, J = 7.6 Hz, H-2’’), 8.44 (1H, s, H-8), 9.61 (1H, s, NH); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 10.7 (C-3’), 18.4 (C-4’), 32.8 (CH3), 35.0 (C-9’’), 37.3 (C-9’’), 40.2 
(C-7’’), 98.6 (C-1’), 101.0 (C-2’), 116.2 (C-2’’), 118.6 (C-6’’), 120.0 (Cq), 121.4 (C-4’’), 
128.2 (C-3’’), 133.2 (Cq), 136.0 (Cq), 141.1 (Cq), 150.2 (C-8), 156.5 (Cq), 162.6 (Cq), 
170.1 (CO); HRMS calcd for C27H39N6OSi [M+H]
+
 491.2949, found 491.2939. 
2-(3-((7-Methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-yl)amino)phenyl)-N-(2,2,2-
trifluoroethyl)acetamide (145) 
 
The title compound was synthesised following general procedure I using 2-iodo-7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purine 106 (250 mg, 0.57 mmol), 2-(3-
aminophenyl)-N-(2,2,2-trifluoroethyl)acetamide 120 (145 mg, 0.63 mmol), K2CO3 (157 
mg, 1.14 mmol), Pd(dba)2 (10 mg, 0.01 mmol) and XPhos (6 mg, 0.01 mmol). The crude 
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product was purified by MPC on silica (DCM: MeOH 19: 1) to give the product 145 as a 
yellow oil (150 mg, 0.28 mmol, 49%). 
Rf 0.30 (DCM: MeOH 9: 1); UV λmax (EtOH) 276 nm; IR (cm
-1
) 3277, 2942, 2864, 1646, 
1537, 1494, 1296; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.14-1.21 (21H, m, H-3’ and 
H-4’), 3.48 (2H, s, H-7’’), 3.89-3.96 (2H, m, H-9’’), 4.03 (3H, s, NCH3), 6.82 (1H, d, J = 
7.8 Hz, H-4’’), 7.20 (1H, dd, J = 7.8 Hz, H-3’’), 7.71 (1H, s, H-6’’), 7.73 (1H, d, J = 7.8 
Hz, H-2’’), 8.44 (1H, s, H-8), 8.74 (1H, t, J = 6.1 Hz, NH), 9.63 (1H, s, NH); 13C NMR 
(125 MHz, DMSO-d6) (ppm) δ 10.6 (C-3’), 18.4 (C-4’), 32.8 (NCH3), 40.0 (q, J = 23.0 
Hz, C-9’’), 42.1 (C-7’’), 98.7 (C-1’), 101.0 (C-2’), 116.4 (C-2’’), 118.9 (C-6’’), 120.0 
(Cq), 121.3 (C-4’’), 126.0 (q, J = 279.2 Hz, CF3), 128.2 (C-3’’), 133.2 (Cq), 135.8 (Cq), 
141.0 (Cq), 150.2 (C-8), 156.5 (Cq), 162.5 (Cq), 170.9 (CO); 
19
F NMR (470 MHz, 
DMSO-d6) (ppm) δ -63.9; HRMS calcd for C27H36F3N6OSi [M+H]
+
 546.2666, found 
545.2647. 
3-(3-((7-Methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-yl)amino)phenyl) 
propanamide (146) 
 
The title compound was synthesised following general procedure I using 2-iodo-7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purine 106 (200 mg, 0.45 mmol), 3-(3-
aminophenyl)propanamide 121 (112 mg, 0.68 mmol), K2CO3 (125 mg, 0.91 mmol), 
Pd(dba)2 (10 mg, 0.01 mmol) and XPhos (5 mg, 0.01 mmol). The crude product was 
purified by MPC on silica (DCM: MeOH 9: 1) to give the product 146 as a yellow oil 
(157 mg, 0.33 mmol, 73%). 
Rf 0.32 (DCM: MeOH 9: 1); UV λmax (EtOH) 276 nm; IR (cm
-1
) 3331, 3201, 2943, 2864, 
1661, 1602, 1496, 1298; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.15-1.20 (21H, m, H-
3’ and H-4’), 2.36 (2H, t, J = 8.0 Hz, H-7’’), 2.77 (2H, t, J = 8.0 Hz, H-8’’), 4.03 (3H, s, 
NCH3), 6.75 (1H, br s, NH2), 6.77 (1H, d, J = 7.9 Hz, H-4’’), 7.17 (1H, dd, J = 7.9 and 
7.9 Hz, H-3’’), 7.26 (1H, br s, NH2), 7.66 (1H, d, J = 7.9 Hz, H-2’’), 7.69 (1H, s, H-6’’), 
8.44 (1H, s, H-8), 9.55 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 10.5 (C-3’), 
18.4 (C-4’), 31.4 (C-8’’), 32.8 (CH3), 36.9 (C-7’’), 98.6 (C-1’), 101.0 (C-2’), 115.8 (C-
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2’’), 117.9 (C-6’’), 120.0 (Cq), 120.6 (C-4’’), 128.3 (C-3’’), 133.1 (Cq), 141.0 (Cq), 141.6 
(Cq), 150.3 (C-8), 156.5 (Cq), 162.6 (Cq), 173.4 (CO); HRMS calcd for C26H37N6OSi 
[M+H]
+
 477.2793, found 477.2789. 
N-(2-Acetamidoethyl)-2-(3-((7-methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-
yl)amino)phenyl)acetamide (147) 
 
The title compound was synthesised following general procedure I using 2-iodo-7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purine 106 (170 mg, 0.39 mmol), N-(2-
acetamidoethyl)-2-(3-aminophenyl)acetamide 122 (100 mg, 0.43 mmol), K2CO3 (106 mg, 
0.91 mmol), Pd(dba)2 (8 mg, 0.01 mmol) and XPhos (4 mg, 0.01 mmol). The crude 
product was purified by MPC on silica (DCM: MeOH 9: 1) to give the product 147 as a 
yellow oil (100 mg, 0.18 mmol, 47%). 
Rf 0.31 (DCM: MeOH 9: 1); UV λmax (EtOH) 276 nm; IR (cm
-1
) 3271, 3075, 2944, 2865, 
1657, 1564, 1541, 1297; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.15-1.21 (21H, m, H-
3’ and H-4’), 1.79 (3H, s, H-12’’), 3.10 (4H, m, H-9’’ and H-10’’), 3.33 (2H, s, H-7’’), 
4.03 (3H, s, NCH3), 6.82 (1H, d, J = 7.8 Hz, H-4’’), 7.19 (1H, dd, J = 7.8 and 7.8 Hz, H-
3’’), 7.67 (1H, s, H-6’’), 7.74 (1H, d, J = 7.8 Hz, H-2’’), 7.89 (1H, br s, NH), 8.08 (1H, br 
s, NH), 8.44 (1H, s, H-8), 9.61 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 
10.7 (C-3’), 18.4 (C-4’), 22.6 (C-12’’), 32.8 (NCH3), 38.4 (C-9’’), 38.5 (C-10’’), 42.7 (C-
7’’), 98.6 (C-1’), 101.0 (C-2’), 116.3 (C-2’’), 118.8 (C-6’’), 120.0 (Cq), 121.5 (C-4’’), 
128.2 (C-3’’), 133.2 (Cq), 136.4 (Cq), 140.9 (Cq), 150.2 (C-8), 156.5 (Cq), 162.5 (Cq), 
169.3 (CO), 170.3 (CO); HRMS calcd for C29H42N7O2Si [M+H]
+
 548.3164, found 
548.3156. 
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4-((7-Methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-yl)amino)benzene 
sulfonamide (148) 
 
The title compound was synthesised following general procedure I using 2-iodo-7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purine 106 (500 mg, 1.17 mmol), 4-
aminobenzenesulfonamide 112 (215 mg, 1.25 mmol), K2CO3 (314 mg, 2.27 mmol), 
Pd(dba)2 (20 mg, 0.02 mmol) and XPhos (11 mg, 0.02 mmol). The crude product was 
purified by MPC on silica (DCM: MeOH 19: 1) to give the product 148 as a yellow oil 
(195 mg, 0.40 mmol, 35%). 
Rf 0.30 (DCM: MeOH 9: 1); UV λmax (EtOH) 276 nm; IR (cm
-1
) 3314, 3192, 2942, 2863, 
1600, 1544, 1465, 1306, 1155; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.14-1.24 (21H, 
m, H-3’ and H-4’), 4.05 (3H, s, NCH3), 7.16 (2H, s, NH2), 7.73 (2H, d, J = 8.9 Hz, H-2’’), 
8.00 (2H, d, J = 8.9 Hz, H-3’’), 8.51 (1H, s, H-8), 10.11 (1H, s, NH); 13C NMR (125 
MHz, DMSO-d6) (ppm) δ 10.5 (C-3’), 18.6 (C-4’), 32.8 (NCH3), 99.2 (C-1’), 100.9 (C-
2’), 116.7 (C-2’’), 120.5 (Cq), 126.4 (C-3’’), 133.4 (Cq), 135.3 (Cq), 144.1 (Cq), 150.6 (C-
8), 156.0 (Cq), 162.4 (Cq); HRMS calcd for C23H33N6O2SSi [M+H]
+
 485.2149, found 
485.2136. 
7-Methyl-N-(pyridin-2-yl)-6-((triisopropylsilyl)ethynyl)-7H-purin-2-amine (149) 
 
The title compound was synthesised following general procedure I using 2-iodo-7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purine 106 (500 mg, 1.17 mmol), 2-
aminopyridine 117 (118 mg, 1.25 mmol), K2CO3 (314 mg, 2.27 mmol), Pd(dba)2 (20 mg, 
0.02 mmol) and XPhos (11 mg, 0.02 mmol). The crude product was purified by MPC on 
silica (DCM: MeOH 19: 1) to give the product 149 as a yellow oil (200 mg, 0.49 mmol, 
43%). 
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Rf 0.30 (DCM: MeOH 9: 1); UV λmax (EtOH) 276 nm; IR (cm
-1
) 3376, 3246, 1680, 1497, 
1305, 1193; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.15-1.22 (21H, m, H-3’ and H-4’), 
4.05 (3H, s, NCH3), 6.96 (1H, ddd, J = 7.3, 4.9 and 1.0 Hz, H-3’’), 7.75 (1H, ddd, J = 8.6, 
7.3 and 1.9 Hz, H-4’’), 8.26 (1H, m, H-2’’), 8.36 (1H, d, J = 8.6 Hz, H-5’’), 8.51 (1H, s, 
H-8), 9.71 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 10.6 (C-3’), 18.4 (C-4’), 
32.8 (CH3), 98.7 (C-1’), 101.0 (C-2’), 107.9 (C-2’’), 111.7 (C-5’’), 111.9 (Cq), 136.9 (C-
4’’), 137.6 (C-3’’), 147.7 (Cq), 147.9 (Cq), 150.7 (Cq), 153.3 (C8), 159.7 (Cq); HRMS 
calcd for C22H31N6Si [M+H]
+
 407.2374, found 407.2365. 
2-(4-((6-Ethynyl-7-methyl-7H-purin-2-yl)amino)phenyl)acetamide (150) 
 
The title compound was synthesised following general procedure A using 2-(4-((7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-yl)amino)phenyl)acetamide 143 (90 mg, 
0.19 mmol) and TBAF (1M in THF, 0.19 mL, 0.19 mmol). The crude product was 
purified by MPC on silica (DCM: MeOH 9: 1) to give the product 150 as a yellow solid 
(28 mg, 0.09 mmol, 47%). 
Rf 0.40 (DCM: MeOH 9: 1); Mp = no melt, degradation; UV λmax (EtOH) 275 nm; IR 
(cm
-1
) 3341, 3231, 3128, 2110, 1677, 1598, 1556, 1495, 1387, 1302; 
1
H NMR (500 MHz, 
DMSO-d6) (ppm) δ 3.31 (2H, s, H-5’’), 4.00 (3H, s, NCH3), 4.99 (1H, s, H-2’), 6.83 (1H, 
br s, NH2), 7.17 (2H, d, J = 8.5 Hz, H-3’’), 7.38 (1H, br s, NH2), 7.72 (2H, d, J = 8.5 Hz, 
H-2’’), 8.45 (1H, s, H-8), 9.55 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 
32.8 (NCH3), 41.7 (C-5’’), 78.2 (C-1’), 87.5 (C-2’), 118.0 (C-3’’), 120.3 (Cq), 128.8 (Cq), 
129.0 (C-2’’), 133.3 (Cq), 139.3 (Cq), 150.2 (C-8), 156.5 (Cq), 162.4 (Cq), 172.6 (CO); 
HRMS calcd for C16H15N6O [M+H]
+
 307.1302, found 307.1307. 
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2-(3-((6-Ethynyl-7-methyl-7H-purin-2-yl)amino)phenyl)-N,N-dimethyl acetamide 
(151) 
 
The title compound was synthesised following general procedure A using N,N-
dimethyl-2-(3-((7-methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-yl)amino)phenyl) 
acetamide 144 (100 mg, 0.20 mmol) and TBAF (1M in THF, 0.20 mL, 0.20 mmol). The 
crude product was purified by MPC on silica (DCM: MeOH 19: 1) to give the product 
151 as a yellow solid (21 mg, 0.06 mmol, 31%). 
Rf 0.38 (DCM: MeOH 9: 1); Mp = no melt, degradation; UV λmax (EtOH) 272 nm; IR 
(cm
-1
) 3200, 3094, 2108 2110, 1640, 1565, 1493, 1467, 1385; 
1
H NMR (500 MHz, 
DMSO-d6) (ppm) δ 2.86 (3H, s, H-9’’), 3.05 (3H, s, H-9’’), 3.66 (2H, s, C-7’’), 4.01 (3H, 
s, NCH3), 5.00 (1H, s, H-2’), 6.77 (1H, d, J = 7.9 Hz, H-4’’), 7.21 (1H, dd, J = 7.9 and 
7.9 Hz, H-3’’), 7.63 (1H, s, H-6’’), 7.71 (1H, d, J = 7.9 Hz, H-2’’), 8.45 (1H, s, H-8); 13C 
NMR (125 MHz, DMSO-d6) (ppm) δ 32.8 (CH3), 35.0 (C-9’’), 37.2 (C-9’’), 40.1 (C-7’’), 
78.2 (C-1’), 87.5 (C-2’), 116.2 (C-2’’), 118.6 (C-6’’), 120.4 (Cq), 121.5 (C-4’’), 128.3 (C-
3’’), 133.1 (Cq), 136.0 (Cq), 141.0 (Cq), 150.3 (C-8), 156.5 (Cq), 162.6 (Cq), 170.2 (CO); 
HRMS calcd for C18H19N6O [M+H]
+
 335.1615, found 335.1618. 
2-(3-((6-Ethynyl-7-methyl-7H-purin-2-yl)amino)phenyl)-N-(2,2,2-trifluoro 
ethyl)acetamide (152) 
 
The title compound was synthesised following general procedure A using 2-(3-((7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-yl)amino)phenyl)-N-(2,2,2-trifluoro 
ethyl)acetamide 145 (150 mg, 0.28 mmol) and TBAF (1M in THF, 0.29 mL, 0.29 mmol). 
The crude product was purified by MPC on silica (DCM: MeOH 19: 1) to give the 
product 152 as a yellow solid (78 mg, 0.20 mmol, 73%). 
Rf 0.23 (DCM: MeOH 9: 1); Mp = no melt, degradation; UV λmax (EtOH) 273 nm; IR 
(cm
-1
) 3313, 3214, 3066, 2112, 1685, 1598, 1496, 1469, 1386, 1305; 
1
H NMR (500 MHz, 
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DMSO-d6) (ppm) δ 3.49 (2H, s, H-7’’), 3.89-3.96 (2H, m, H-9’’), 4.01 (3H, s, NCH3), 
5.00 (1H, s, H-2’), 6.83 (1H, d, J = 7.9 Hz, H-4’’), 7.22 (1H, dd, J = 7.9 and 7.9 Hz, H-
3’’), 7.63 (1H, s, H-6’’), 7.75 (1H, d, J = 7.9 Hz, H-2’’), 8.45 (1H, s, H-8), 8.76 (1H, t, J 
= 6.3 Hz, NH), 9.59 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 32.8 (NCH3), 
39.9 (q, J = 20.7 Hz, C-9’’), 42.1 (C-7’’), 78.2 (C-1’), 87.5 (C-2’), 116.4 (C-2’’), 118.9 
(C-6’’), 120.3 (Cq), 121.5 (C-4’’), 124.0 (q, J = 280.3 Hz, CF3), 128.3 (C-3’’), 133.2 (Cq), 
135.9 (Cq), 140.9 (Cq), 150.2 (C-8), 156.4 (Cq), 162.4 (Cq), 170.9 (CO); 
19
F NMR (470 
MHz, DMSO-d6) (ppm) δ -70.7; HRMS calcd for C18H16F3N6O [M+H]
+
 389.1332, found 
389.1326. 
3-(3-((6-Ethynyl-7-methyl-7H-purin-2-yl)amino)phenyl)propanamide (153) 
 
The title compound was synthesised following general procedure A using 3-(3-((7-
methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-yl)amino)phenyl)propanamide 146 (160 
mg, 0.34 mmol) and TBAF (1M in THF, 0.34 mL, 0.34 mmol). The crude product was 
purified by MPC on silica (DCM: MeOH 9: 1) to give the product 153 as a yellow solid 
(30 mg, 0.10 mmol, 28%). 
Rf 0.25 (DCM: MeOH 9: 1); Mp = 147-150 °C; UV λmax (EtOH) 272 nm; IR (cm
-1
) 3301, 
3194, 3074, 2110, 1660, 1595, 1556, 1482, 1390, 1288; 
1
H NMR (500 MHz, DMSO-d6) 
(ppm) δ 2.34-2.37 (2H, m, H-7’’), 2.76-2.79 (2H, m, H-8’’), 4.01 (3H, s, NCH3), 5.00 
(1H, s, H-2’), 6.78 (1H, d, J = 7.8 Hz, H-4’’), 6.79 (1H, br s, NH2), 7.19 (1H, dd, J = 7.9 
and 7.9 Hz, H-3’’), 7.32 (1H, br s, NH2), 7.58 (1H, s, H-6’’), 7.72 (1H, d, J = 7.8 Hz, H-
2’’), 8.45 (1H, s, H-8), 9.54 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 31.3 
(C-8’’), 32.8 (CH3), 36.8 (C-7’’), 78.2 (C-1’), 87.5 (C-2’), 115.8 (C-2’’), 118.0 (C-6’’), 
120.3 (Cq), 120.7 (C-4’’), 128.3 (C-3’’), 133.1 (Cq), 141.0 (Cq), 141.6 (Cq), 150.2 (C-8), 
156.5 (Cq), 162.5 (Cq), 173.4 (CO); HRMS calcd for C17H17N6O [M+H]
+
 321.1458, 
found 321.1763. 
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N-(2-acetamidoethyl)-2-(3-((6-ethynyl-7-methyl-7H-purin-2-yl)amino)phenyl) 
acetamide (154) 
 
The title compound was synthesised following general procedure A using N-(2-
acetamidoethyl)-2-(3-((7-methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-yl) amino) 
phenyl)acetamide 147 (100 mg, 0.19 mmol) and TBAF (1M in THF, 0.19 mL, 0.19 
mmol). The crude product was purified by MPC on silica (DCM: MeOH 9: 1) to give the 
product 154 as a yellow solid (46 mg, 0.12 mmol, 64%). 
Rf 0.29 (DCM: MeOH 9: 1); Mp = no melt, degradation; UV λmax (EtOH) 273 nm; IR 
(cm
-1
) 3293, 3246, 3068, 2113, 1639, 1568, 1542, 1475, 1303, 1276; 
1
H NMR (500 MHz, 
DMSO-d6) (ppm) δ 1.79 (3H, s, H-12’’), 3.11 (4H, m, H-9’’ and H-10’’), 3.38 (2H, s, H-
7’’), 4.01 (3H, s, NCH3), 5.00 (1H, s, H-2’), 6.83 (1H, d, J = 7.8 Hz, H-4’’), 7.21 (1H, dd, 
J = 7.8 and 7.8 Hz, H-3’’), 7.61 (1H, s, H-6’’), 7.75 (1H, d, J = 7.8 Hz, H-2’’), 7.89 (1H, 
br s, NH), 8.09 (1H, br s, NH), 8.45 (1H, s, H-8), 9.57 (1H, s, NH); 
13
C NMR (125 MHz, 
DMSO-d6) (ppm) δ 22.6 (C-12’”), 32.8 (CH3), 38.4 (C-10’’), 38.5 (C-9’’), 42.7 (C-7’’), 
78.2 (C-1’), 87.5 (C-2’), 116.3 (C-2’’), 118.8 (C-6’’), 120.3 (Cq), 121.6 (C-4’’), 128.2 (C-
3’’), 133.2 (Cq), 136.5 (Cq), 140.9 (Cq), 150.2 (C-8), 156.5 (Cq), 162.4 (Cq), 169.3 (CO), 
170.3 (CO); HRMS calcd for C20H22N7O2 [M+H]
+
 392.1829, found 392.1829. 
4-((6-Ethynyl-7-methyl-7H-purin-2-yl)amino)benzenesulfonamide (155) 
 
4-((7-Methyl-6-((triisopropylsilyl)ethynyl)-7H-purin-2-yl)amino)benzene sulfonamide 
148 (80 mg, 0.17 mmol) was solubilised in 5 mL of anhydrous MeOH. Fluoride on 
polymer support (100 mg) was added and the reaction was agitated with a shaker for 2 h. 
Beads were removed and the solvent was removed in vacuo to give the product 155 as an 
orange solid (20 mg, 0.06 mmol, 37%). 
Rf 0.19 (DCM: MeOH 9: 1); Mp = no melt, degradation; UV λmax (EtOH) 281 nm; IR 
(cm
-1
) 3253, 3080, 2953, 2113, 1596, 1561, 1493, 1466, 1309, 1149; 
1
H NMR (500 MHz, 
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DMSO-d6) (ppm) δ 4.03 (3H, s, NCH3), 5.07 (1H, s, H-2’), 7.17 (2H, s, NH2), 7.74 (2H, 
d, J = 8.9 Hz, H-2’’), 7.97 (2H, d, J = 8.9 Hz, H-3’’), 8.53 (1H, s, H-8), 10.10 (1H, s, 
NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 32.9 (NCH3), 78.0 (C-1’), 88.0 (C-2’), 
116.9 (C-3’’), 120.9 (Cq), 126.5 (C-2’’), 133.3 (Cq), 135.5 (Cq), 144.1 (Cq), 150.7 (C-8), 
155.7 (Cq), 162.3 (Cq); HRMS calcd for C14H13N6O2S [M+H]
+
 329.0815, found 329.082. 
6-Ethynyl-7-methyl-N-(pyridin-2-yl)-7H-purin-2-amine (156) 
 
7-Methyl-N-(pyridin-2-yl)-6-((triisopropylsilyl)ethynyl)-7H-purin-2-amine 149 (200 mg, 
0.49 mmol) was solubilised in dry THF (10 mL). The solution was stirred for 10 min at -
78 
0
C and TBAF (1M in THF, 0.54 mL, 0.54 mmol) was slowly added. The reaction was 
stirred for 5 min at -78 
0
C, until completion. The crude product was purified by MPC on 
silica (DCM: MeOH 19: 1) to give the product 156 as an orange solid (55 mg, 0.22 mmol, 
45%). 
Rf 0.23 (DCM: MeOH 9: 1); Mp = no melt, degradation; UV λmax (EtOH) 273 nm; IR 
(cm
-1
) 3344, 3178, 3021, 2103, 1601, 1579, 1423, 1390; 
1
H NMR (500 MHz, DMSO-d6) 
(ppm) δ 4.03 (3H, s, NCH3), 5.05 (1H, s, H-2’), 6.97 (1H, ddd, J = 7.3, 4.9 and 1.0 Hz, 
H-3’’), 7.78 (1H, ddd, J = 8.6, 7.3 and 1.9 Hz, H-4’’), 8.26 (1H, ddd, J = 4.9, 1.9 and 1.0 
Hz, H-2’’), 8.35 (1H, d, J = 8.6 Hz, H-5’’), 8.52 (1H, s, H-8), 9.68 (1H, s, NH); 13C NMR 
(125 MHz, DMSO-d6) (ppm) δ 32.9 (NCH3), 78.2 (C-1’), 88.1 (C-2’), 111.9 (C-5’’), 
117.0 (C-3’’), 121.0 (Cq), 128.3 (Cq), 133.1 (Cq), 137.6 (C-4’’), 147.9 (C-2’’), 150.6 (C-
8), 153.3 (Cq), 155.2 (Cq); HRMS calcd for C13H11N6 [M+H]
+
 251.1040, found 251.1043. 
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(E)-methyl 2-acetamido-3-((2-(2-((3-(2-amino-2-oxoethyl)phenyl)amino)-9H-purin-
6-yl)vinyl)thio)propanoate (158) 
 
2-(3-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)acetamide 42 (50 mg, 0.17 mmol), N-
acetylcysteine methyl ester 157 (151 mg, 0.85 mmol) and DABCO (10 mg, 0.09 mmol) 
were solubilised in anhydrous DMF (8 mL). The resulting solution was stirred at r.t. for 
16 h. The solvent was then removed in vacuo. The crude product was purified by MPC 
on silica (EtOAc: MeOH 9: 1) to give the product 158 as a yellow solid (41 mg, 0.09 
mmol, 51 %). 
Rf 0.55 (EtOAc: MeOH 9: 1); Mp = 269-272
 o
C; UV λmax (EtOH) 273 nm; 
1
H NMR (500 
MHz, DMSO-d6) (ppm) δ 1.88 (3H, s, H-‘’), 3.27 (1H, dd, J = 13.5 and 7.8 Hz, H-3’’), 
3.35 (2H, s, H-7’), 3.42 (1H, dd, J = 13.5 and 7.8 Hz, H-3’’), 3.68 (3H, s, H-5’’), 4.60 - 
4.64 (1H, m, H-4’’), 6.79 (1H, d, J = 15.5 Hz, H-1’’), 6.83 (1H, d, J = 7.8 Hz, H-4’), 6.86 
(1H, br s, NH2), 7.20 (1H, dd, J = 7.8 Hz, H-3’), 7.43 (1H, br s, NH2), 7.69 (1H, d, J = 
7.8 Hz, H-2’), 7.74 (1H, s, H-6’), 8.17 (1H, s, H-8), 8.29 (1H, d, J = 15.5 Hz, H-2’’), 8.57 
(1H, d, J = 7.8 Hz, NH), 9.32 (1H, s, NH), 12.89 (1H, br s, N
9
H); 
13
C NMR (125 MHz, 
DMSO-d6) (ppm) δ 22.3 (C-6’’), 33.0 (C-3’’), 42.6 (C-7’), 51.6 (C-4’’), 52.3 (C-5’’), 
116.5 (C-2’), 119.1 (C-6’), 120.2 (C-1’’), 121.4 (C-4’), 123.8 (Cq), 128.1 (C-3’), 136.5 
(Cq), 138.8 (C-2’’), 141.1 (Cq), 141.4 (C-8), 151.4 (Cq), 153.8 (Cq), 156.1 (Cq), 169.6 
(CO), 170.7 (CO), 172.3 (CO); HRMS calcd for C21H24N7O4S [M+H]
+
 470.1605, found 
470.1602. 
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6-(Cyclohexylmethoxy)-N-(4-(prop-1-en-2-ylsulfonyl)phenyl)-9H-purin-2-amine 
(162) 
 
6-(Cyclohexylmethoxy)-N-(4-((1-(pyrrolidin-1-yl)propan-2-yl)thio)phenyl)-9H-purin-2-
amine 181 (65 mg, 0.14 mmol) was solubilised in dry DCM (5 mL). m-CPBA (84 mg, 
0.49 mmol) was then added to the solution and the reaction was stirred at reflux for 3 h. 
The solvent was removed in vacuo. The product was purified by prep-TLC (DCM: 
MeOH 9: 1) to give the product 162 as a pale orange oil (20 mg, 0.05 mmol, 33%). 
Rf 0.19 (DCM: MeOH 9: 1); UV λmax (EtOH) 314 nm; IR (cm
-1
) 2931, 2842, 1572, 1421, 
1025; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.06-1.12 (2H, m, H-cyclo), 1.18-1.20 
(1H, m, H-cyclo), 1.23-1.32 (2H, m, H-cyclo), 1.66 (1H, m, H-cyclo), 1.72-1.75 (2H, m, 
H-cyclo), 1.84-1.87 (3H, m, H-cyclo, H-2’’), 1.91 (3H, s, H-6’), 4.33 (2H, d, J = 6.3 Hz, 
H-1’’), 5.82 (1H, d, J = 1.6 Hz, H-7’), 6.06 (2H, d, J = 1.6 Hz, H-7’), 7.66 (2H, d, J = 8.8 
Hz, H-2’), 7.68 (1H, s, NH), 7.79 (1H, s, H-8), 8.10 (2H, d, J = 8.8 Hz, H-3’), 9.56 (1H, s, 
N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 15.6 (C-6’), 25.2 (2 x C-cyclo), 26.0 (C-
cyclo), 29.2 (2 x C-cyclo), 36.9 (C-2’’), 71.1 (C-1’’), 117.1 (C-3’), 123.3 (C-7’), 125.9 
(Cq), 127.2 (Cq), 129.0 (C-2’), 134.5 (Cq), 146.4 (C-8), 146.6 (Cq), 153.2 (Cq), 159.1 (Cq); 
HRMS calcd for C21H26N5O3S [M+H]
+
 428.1751, found 428.1751. 
N-(4-(But-1-en-2-ylsulfonyl)phenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine (163) 
 
The title compound was synthesised following general procedure N using 6-
(cyclohexylmethoxy)-N-(4-((1-(pyrrolidin-1-yl)butan-2-yl)sulfonyl)phenyl)-9H-purin-2-
amine 230 (180 mg, 0.35 mmol), m-CPBA (90 mg, 0.39 mmol) and Cs2CO3 (280 mg, 
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0.88 mmol). The product was purified by MPC (DCM: MeOH 19: 1) to give the product 
163 as a yellow oil (36 mg, 0.08 mmol, 23%). 
Rf 0.48 (DCM: MeOH 19: 1); UV λmax (EtOH) 317 nm; IR (cm
-1
) 2924, 2851, 1594, 1451, 
1384, 1295, 1128; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.00 (3H, t, J = 7.2 Hz, H-7’), 
1.06-1.14 (2H, m, H-cyclo), 1.18-1.21 (1H, m, H-cyclo), 1.24-1.31 (2H, m, H-cyclo), 
1.66-1.68 (1H, m, H-cyclo), 1.72-1.75 (2H, m, H-cyclo), 1.84-1.86 (5H, m, H-cyclo, H-
2’’), 22.21 (2H, q, J = 7.2 Hz, H-7’), 4.37 (2H, d, J = 6.3 Hz, H-1’’), 5.84 (1H, s, H-8’), 
6.19 (1H, s, H-8’), 7.72 (2H, d, J = 8.7 Hz, H-2’), 8.05-8.07 (3H, m, H-8 and H-3’), 9.97 
(1H, br s, NH), 12.97 (1H, br s, N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 12.0 (C-
7’), 22.0 (C-6’), 25.2 (2 x C-cyclo), 26.0 (C-cyclo), 29.2 (2 x C-cyclo), 36.8 (C-2’’), 71.4 
(C-1’’), 115.5 (Cq), 117.6 (C-3’), 121.6 (C-8’), 128.6 (Cq), 129.0 (C-2’), 139.7 (C-8), 
146.1 (Cq), 152.1 (Cq), 153.8 (Cq), 154.4 (Cq), 160.2 (Cq); HRMS calcd for C22H27N5O3S 
[M+H]
+
 442.1907, found 442.1904. 
6-(Cyclohexylmethoxy)-N-(4-((3-methylbut-1-en-2-yl)sulfonyl)phenyl)-9H-purin-2-
amine (164) 
 
The title compound was synthesised following general procedure N using 6-
(cyclohexylmethoxy)-N-(4-((3-methyl-1-(pyrrolidin-1-yl)butan-2-yl)sulfonyl)phenyl)-9H 
-purin-2-amine 231 (70 mg, 0.13 mmol), m-CPBA (34 mg, 0.15 mmol) and Cs2CO3 (108 
mg, 0.33 mmol). The product was purified by MPC (DCM: MeOH 19: 1) to give the 
product 164 as a yellow oil (36 mg, 0.08 mmol, 23%). 
Rf 0.34 (DCM: MeOH 19: 1); UV λmax (EtOH) 317 nm; IR (cm
-1
) 3348, 2926, 2852, 1593, 
1532, 1450, 1389, 1291, 1123; 
1
H NMR (500 MHz, CDCl3) (ppm) δ 1.07-1.09 (6H, d, J 
= 6.8 Hz, H-7’), 1.11-1.16 (2H, m, H-cyclo), 1.21-1.24 (1H, m, H-cyclo), 1.26-1.31 (2H, 
m, H-cyclo), 1.70-1.73 (1H, m, H-cyclo), 1.77-1.79 (2H, m, H-cyclo), 1.91-1.93 (3H, m, 
H-cyclo, H-2’’), 2.67-2.72 (1H, m, H-6’), 4.37 (2H, d, J = 5.7 Hz, H-1’’), 5.78 (1H, s, H-
8’), 6.36 (1H, s, H-8’), 7.81 (2H, d, J = 8.1 Hz, H-2’), 7.88-7.95 (3H, m, H-3’ and H-8). 
13
C NMR (125 MHz, CDCl3) (ppm) δ 12.0 (C-7’), 22.0 (C-6’), 25.2 (2 x C-cyclo), 26.0 
(C-cyclo), 29.2 (2 x C-cyclo), 36.8 (C-2’’), 71.4 (C-1’’), 115.5 (Cq), 117.6 (C-3’), 121.6 
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(C-8’), 128.6 (Cq), 129.0 (C-2’), 139.7 (C-8), 146.1 (Cq), 152.1 (Cq), 153.8 (Cq), 154.4 
(Cq), 160.2 (Cq); HRMS calcd for C23H30N5O3S [M+H]
+
 456.2064, found 456.2069. 
6-(Cyclohexylmethoxy)-N-(4-((1-phenylvinyl)sulfonyl)phenyl)-9H-purin-2-amine 
(165) 
 
The title compound was synthesised following general procedure N using 6-
(cyclohexylmethoxy)-N-(4-((1-phenyl-2-(pyrrolidin-1-yl)ethyl)sulfonyl)phenyl)-9H-
purin-2-amine 232 (180 mg, 0.32 mmol), m-CPBA (82 mg, 0.35 mmol) and Cs2CO3 (261 
mg, 0.80 mmol). The product was purified by MPC (DCM: MeOH 19: 1) to give the 
product 165 as an orange oil (45 mg, 0.09 mmol, 29%). 
Rf 0.51 (DCM: MeOH 19: 1); UV λmax (EtOH) 320 nm; IR (cm
-1
) 2923, 2850, 1593, 1495, 
1450, 1384, 1298, 1138; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.05-1.12 (2H, m, H-
cyclo), 1.18-1.20 (1H, m, H-cyclo), 1.23-1.31 (2H, m, H-cyclo), 1.66-1.68 (1H, m, H-
cyclo), 1.72-1.74 (2H, m, H-cyclo), 1.81-1.87 (3H, m, H-cyclo, H-2’’), 4.35 (2H, d, J = 
6.3 Hz, H-1’’), 6.18 (1H, s, H-10’), 6.47 (1H, s, H-10’), 7.34-7.38 (5H, m, H-ar), 7.56 
(2H, d, J = 8.9 Hz, H-2’), 7.95 (2H, d, J = 8.9 Hz, H-3’), 8.06 (1H, s, H-8), 9.93 (1H, s, 
NH), 12.95 (1H, s, N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 25.2 (2 x C-cyclo), 
26.0 (C-cyclo), 29.2 (2 x C-cyclo), 36.8 (C-2’’), 71.4 (C-1’’), 115.5 (Cq), 117.0 (Cq), 
117.3 (C-3’), 125.6 (C-10’), 128.3 (2 x C-ar), 128.5 (2 x C-ar), 129.0 (C-2’), 129.2 (C-ar), 
139.7 (C-8), 146.1 (Cq), 150.3 (Cq), 153.7 (Cq), 154.4 (Cq), 160.1 (Cq); HRMS calcd for 
C26H28N5O3S [M+H]
+
 490.1907, found 490.1910. 
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6-(Cyclohexylmethoxy)-N-(4-((3,3-dimethylbut-1-en-2-yl)sulfonyl)phenyl)-9H-purin-
2-amine (166) 
 
The title compound was synthesised following general procedure P using 2-((4-((6-
(cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)-3,3-dimethylbutan-1-ol 254 
(27 mg, 0.06 mmol), Et3N (6.0 μL, 0.07 mmol) and MsCl (5.0 μL, 0.07 mmol). After 1 h, 
DBU (0.10 mL, 0.69 mmol) was added and the reaction was stirred at r.t. for 1 h. The 
solvent was removed in vacuo. The product was purified by MPC (EtOAc: MeOH 19: 1) 
to give the product 166 as a pale yellow oil (18 mg, 0.04 mmol, 69%). 
Rf 0.19 (100 EtOAc); UV λmax (EtOH) 317 nm; IR (cm
-1
) 3260, 2925, 2852, 1592, 1450, 
1317, 1114; 
1H NMR (500 MHz, MeOD) (ppm) δ 1.10-1.17 (2H, m, H-cyclo), 1.22-1.25 
(10H, m, H-cyclo and H-7’), 1.28-1.36 (2H, m, H-cyclo), 1.70-1.72 (1H, m, H-cyclo), 
1.77-1.79 (2H, m, H-cyclo), 1.90-1.92 (3H, m, H-cyclo and H-2’’), 4.35 (2H, d, J = 6.1 
Hz, H-1’’), 6.00 (1H, d, J = 1.5 Hz, H-8’), 6.19 (1H, d, J = 1.5 Hz, H-8’), 7.72 (2H, d, J = 
8.9 Hz, H-3’), 8.01-8.04 (3H, m, H-2’ and H-8); 13C NMR (125 MHz, MeOD) (ppm) δ 
24.7 (2 x C-cyclo), 25.4 (C-cyclo), 28.6 (2 x C-cyclo), 28.7 (C-7’), 35.3 (C-6’), 36.4 (C-
2’’), 71.1 (C-1’’), 116.6 (C-2’), 127.8 (C-8’), 131.0 (C-3’), 138.9 (C-8), 145.1 (Cq), 154.2 
(Cq), 154.4 (Cq), 159.3 (Cq); HRMS calcd for C24H32N5O3S [M+H]
+
 470.2220, found 
470.2210. 
Note: Three quaternary carbons were not visible on 
13
C NMR spectrum 
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N-(4-((1-Chlorovinyl)sulfonyl)phenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine 
(167) 
 
The title compound was synthesised following general procedure P using 2-chloro-2-
((4-((6-(cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)ethanol 268 (90.0 mg, 
0.19 mmol), Et3N (0.03 mL, 0.20 mmol) and MsCl (16.0 μL, 0.20 mmol). The crude 
product was purified by MPC on silica (petrol: EtOAc 4: 1) to give the product 167 as a 
colourless oil (19 mg, 0.04 mmol, 22%). 
Rf 0.35 (EtOAc 100); UV λmax (EtOH) 322 nm; IR (cm
-1
) 2922, 2850, 1591, 1449, 1309, 
1150; 
1
H NMR (500 MHz, MeOD) (ppm) δ 1.16-1.22 (2H, m, H-cyclo), 1.26-1.29 (1H, 
m, H-cyclo), 1.32-1.40 (2H, m, H-cyclo), 1.73-1.75 (2H, m, H-cyclo), 1.73-1.75 (1H, m, 
H-cyclo), 180-1.82 (2H, m, H-cyclo), 1.94-1.96 (3H, m, H-cyclo and H-2’’), 4.40 (2H, d, 
J = 6.2 Hz, H-1’’), 6.17 (1H, d, J = 3.1 Hz, H-6’), 6.67 (1H, d, J = 3.1 Hz, H-6’), 7.83 
(2H, d, J = 9.0 Hz, H-3’), 8.04 (1H, br s, H-8), 8.11 (2H, d, J = 9.0 Hz, H-2’); 13C NMR 
(125 MHz, MeOD) (ppm) δ 26.9 (2 x C-cyclo), 27.5 (C-cyclo), 30.8 (2 x C-cyclo), 38.7 
(C-2’’), 73.3 (C-1’’), 118.9 (C-2’), 124.1 (C-6’), 127.8 (Cq), 131.4 (C-3’), 140.5 (C-8), 
142.4 (Cq), 148.6 (Cq), 156.6 (Cq); HRMS calcd for C20H23ClN5O3S [M+H]
+
 448.1205, 
found 448.1202. 
Note: Three quaternary carbons were not visible on the 
13
C NMR spectrum 
6-(Cyclohexylmethoxy)-N-(4-((1-fluorovinyl)sulfonyl)phenyl)-9H-purin-2-amine 
(168) 
 
The title compound was synthesised following general procedure P using 2-((4-((6-
(cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)-2-fluoroethanol 272 (155 
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mg, 0.35 mmol), Et3N (0.05 mL, 0.38 mmol) and MsCl (30.0 μL, 0.38 mmol). The crude 
product was purified by MPC on silica (petrol: EtOAc 2: 3) to give the product 168 as a 
colourless oil (26 mg, 0.06 mmol, 10%). 
Rf 0.17 (petrol: EtOAc 1: 1); UV λmax (EtOH) 321 nm; IR (cm
-1
) 3134, 2927, 2853, 1595, 
1509, 1453, 1331, 1145; 
1
H NMR (500 MHz, MeOD) (ppm) δ 1.14-1.21 (2H, m, H-
cyclo), 1.25-1.27 (1H, m, H-cyclo), 1.29-1.40 (2H, m, H-cyclo), 1.73-1.75 (1H, m, H-
cyclo), 1.80-1.83 (2H, m, H-cyclo), 1.94-1.98 (3H, m, H-cyclo and H-2’’), 4.40 (2H, d, J 
= 6.1 Hz, H-1’’), 5.54 (1H, dd, J = 4.7 and 13.3 Hz, H-6’), 5.85 (1H, dd, J = 4.7 and 43.3 
Hz, H-6’), 7.83 (2H, d, J = 8.8 Hz, H-3’), 8.03 (1H, s, H-8), 8.12 (2H, d, J = 8.8Hz, H-2’); 
13
C NMR (125 MHz, MeOD) (ppm) δ 26.9 (2 x C-cyclo), 27.6 (C-cyclo), 30.8 (2 x C-
cyclo), 38.7 (C-2’’), 73.3 (C-1’’), 100.3 (d, J = 9.9 Hz, C-6’), 119.1 (C-2’), 128.1 (Cq), 
131.0 (C-3’), 148.8 (C-8), 156.6 (Cq), 161.7 (Cq), 164.0 (Cq); 
19
F NMR (470 MHz, 
MeOD) (ppm) δ -117.7; HRMS calcd for C20H23FN5O3S [M+H]
+
 432.1500, found 
432.1494. 
Note: Three quaternary carbons were not visible on the 
13
C NMR spectrum 
6-(Cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine (171) 
 
The title compound was synthesised following general procedure G using 6-
(cyclohexylmethoxy)-9-(4-methoxybenzyl)-9H-purin-2-amine 172 (344 mg, 0.94 mmol), 
CH2I2 (0.38 mL, 4.70 mmol), Cu(I)I (269 mg, 1.40 mmol) and isoamyl nitrite (0.38 mL, 
2.80 mmol). The crude product was purified by medium pressure chromatography on 
silica (petrol: EtOAc 2: 3) to give the product 171 as yellow oil (300 mg, 0.63 mmol, 
67%). 
Rf 0.63 (petrol: EtOAc 1: 1); UV λmax (EtOH) 245 nm; IR (cm 
-1
) 2926, 2853, 1585, 1514, 
1414, 1358, 1252; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.00-1.08 (2H, m, H-3’’ and 
H-7’’), 1.16-1.30 (3H, m, H-5’’, H-4’’ and H-6’’), 1.65-1.67 (1H, m, H-5’’), 1.70-1.73 
(2H, m, H-4’’ and H-6’’), 1.79-1.81 (3H, m, H-2’’, H-3’’ and H-7’’), 3.73 (3H, s, OCH3), 
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4.31 (2H, d, J = 6.2 Hz, H-1’’), 5.34 (2H, s, H-1’), 6.92 (2H, d, J = 8.7 Hz, H-3’), 7.27 
(2H, d, J = 8.7 Hz, H-4’), 8.39 (1H, s, H-8); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 
25.1 (C-4’’ and C-6’’), 25.8 (C-5’’), 28.9 (C-3’’ and C-7’’), 36.7 (C-2’’), 46.2 (C-1’), 
55.0 (OCH3), 72.2 (C-1’’), 114.1 (C-3’), 118.3 (Cq), 120.4 (Cq), 128.2 (Cq), 129.0 (C-4’), 
143.5 (C-8), 152.8 (Cq), 159.0 (Cq), 159.8 (Cq); HRMS calcd for C20H24IN4O2 [M+H]
+
 
479.0938, found 479.0929. 
6-(Cyclohexylmethoxy)-9-(4-methoxybenzyl)-9H-purin-2-amine (172) 
 
NaH (62 mg, 2.59 mmol) was added to a stirred solution of cyclohexylmethanol (0.32 mL, 
2.59 mmol) in anhydrous THF (10 mL) under N2. The resulting suspension was stirred 
for 1 h at r.t. then 6-chloro-9-(4-methoxybenzyl)-9H-purin-2-amine 80 (500 mg, 1.72 
mmol) was added, and the reaction was stirred at r.t. for 16 h. Water was added (20 mL) 
and the organic phase was extacted with EtOAc (3 x 30 mL). The organic phases were 
combined, dried over MgSO4 and the solvent was removed in vacuo. The crude product 
was purified by MPC on silica (petrol: EtOAc 2: 3) to give the product 172 as a white 
solid (445 mg, 1.21 mmol, 70%). 
Rf 0.56 (petrol: EtOAc 2: 3); Mp = 147-149 °C; UV λmax (EtOH) 263 nm; IR (cm 
-1
) 3355, 
2925, 2853, 1606, 1580, 1514, 1445, 1410, 1260; 
1
H NMR (500 MHz, DMSO-d6) (ppm) 
δ 1.00-1.08 (2H, m, H-3’’ and H-7’’), 1.16-1.30 (3H, m, H-5’’, H-4’’ and H-6’’), 1.65-
1.67 (1H, m, H-5’’), 1.70-1.73 (2H, m, H-4’’ and H-6’’), 1.79-1.81 (3H, m, H-2’’, H-3’’ 
and’H-7’’), 3.72 (3H, s, OCH3), 4.22 (2H, d, J = 6.2 Hz, H-1’’), 5.16 (2H, s, H-1’), 6.39 
(2H, s, NH2), 6.90 (2H, d, J = 8.7 Hz, H-3’), 7.22 (2H, d, J = 8.7 Hz, H-4’), 7.91 (1H, s, 
H-8); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 25.2 (C-4’’ and C-6’’), 26.0 (C-5’’), 29.2 
(C-3’’ and C-7’’), 36.8 (C-2’’), 45.2 (C-1’), 55.1 (OCH3), 70.6 (C-1’’), 113.6 (Cq), 114.0 
(C-3’), 128.6 (C-4’), 129.2 (Cq), 139.5 (C-8), 154.1 (Cq), 158.7 (Cq), 159.9 (Cq), 160.6 
(Cq); HRMS calcd for C20H26N5O2 [M+H]
+
 368.2081, found 368.2085.  
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Ethyl 2-((4-nitrophenyl)thio)propanoate (175)
262
 
 
The title compound was synthesised following general procedure J using methyl 2-
bromopropionate 174 (0.80 mL, 7.10 mmol), 4-nitrothiophenol 173 (1.00 g, 6.46 mmol) 
and Et3N (1.00 mL, 7.10 mmol). The crude product was purified by MPC on silica (petrol: 
EtOAc 9: 1) to give the products 175 as a yellow oil (1.56 g, 6.14 mmol, 94%). 
Rf 0.35 (petrol: EtOAc 4: 1); UV λmax (EtOH) 331 nm; IR (cm
-1
) 2983, 2937, 1728, 1512, 
1337, 1157; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.12 (3H, t, J = 7.1 Hz, H-8’), 1.49 
(3H, t, J = 7.1 Hz, H-6’), 4.04-4.14 (2H, m, H-7’), 4.44 (1H, q, J = 7.1 Hz, H-5’), 7.62 
(2H, d, J = 8.9 Hz, H-3’), 8.18 (2H, d, J = 8.9 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) 
(ppm) δ 13.8 (C-8’), 17.0 (C-6’), 42.4 (C-5’), 61.2 (C-7’), 123.9 (C-2’), 128.6 (C-3’), 
144.5 (C-4’), 145.4 (C-1’), 171.3 (CO); HRMS calcd for C11H14NO4S [M+H]
+
 256.0638, 
found 256.0639. 
2-((4-Nitrophenyl)thio)propanoic acid (176) 
 
The title compound was synthesised following general procedure K using ethyl 2-((4-
nitrophenyl)thio)propanoate 175 (1.23 g, 4.82 mmol) and LiOH (2M in THF, 26.6 mL). 
The product 176 was obtained without further purification as a yellow oil (962 mg, 4.24 
mmol, 88%). 
Rf 0.19 (petrol: EtOAc 4: 1); UV λmax (EtOH) 332 nm; IR (cm
-1
) 3120, 2932, 2828, 1704, 
1577, 1503, 1338, 1197; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.48 (3H, t, J = 7.1 Hz, 
H-6’), 4.33 (1H, q, J = 7.1 Hz, H-5’), 7.60 (2H, d, J = 8.9 Hz, H-3’), 8.18 (2H, d, J = 8.9 
Hz, H-2’), 13.08 (1H, br s, OH); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 17.2 (C-6’), 
42.5 (C-5’), 123.9 (C-2’), 127.8 (C-3’), 145.0 (C-4’), 145.5 (C-1’), 172.8 (CO); HRMS 
calcd for C9H8NO4S [M-H]
-
 226.0180, found 226.0174. 
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2-((4-Nitrophenyl)thio)propan-1-ol (177) 
 
The title compound was synthesised following general procedure L using 2-((4-
nitrophenyl)thio)propanoic acid 176 (880 mg, 3.88 mmol) and 1M Borane in complex 
with THF (19.4 mL, 19.40 mmol). The crude product was purified by MPC on silica 
(petrol: EtOAc 3: 2) to give the products 177 as a yellow oil (640 mg, 2.95 mmol, 76%). 
Rf 0.35 (petrol: EtOAc 4: 1); UV λmax (EtOH) 339 nm; IR (cm
-1
) 3375, 2927, 2870, 1576, 
1505, 1332, 1027; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.32 (3H, d, J = 6.8 Hz, H-6’), 
3.44-3.49 (1H, m, H-7’), 3.55-3.59 (1H, m, H-7’), 3.63-3.69 (1H, m, H-5’), 5.16 (1H, t, J 
= 5.6 Hz, OH), 7.54 (2H, d, J = 8.9 Hz, H-3’), 8.14 (2H, d, J = 8.9 Hz, H-2’); 13C NMR 
(125 MHz, DMSO-d6) (ppm) δ 17.3 (C-6’), 42.7 (C-5’), 64.7 (C-7’), 123.9 (C-2’), 127.2 
(C-3’), 144.4 (C-4’), 147.1 (C-1’); HRMS calcd for C9H12NO3S [M+H]
+
 214.0532, found 
214.0535. 
2-((4-Nitrophenyl)thio)propanal (178) 
 
2-((4-Nitrophenyl)thio)propan-1-ol 177 (600 mg, 2.82 mmol) was solubilised in dry 
DCM (30 mL) under N2. 0.3M Dess-Martin periodinane solution in DCM (10.4 mL, 
3.10mmol) was added dropwise to the solution. The resulting reaction was stirred at r.t. 
for 2 h. Sodium thiosulfate was then added dropwise at 0 
o
C to quench the reaction until 
reaching pH 7. The mixture was then extracted with DCM (3 x 50 mL). The organic layer 
was dried over MgSO4 and the solvent was removed in vacuo. The crude product was 
purified by MPC on silica (petrol: EtOAc 4: 1) to give the product 178 as a yellow oil 
(530 mg, 2.51 mmol, 89%). 
Rf 0.47 (petrol: EtOAc 4: 1); UV λmax (EtOH) 332 nm; IR (cm
-1
) 2924, 2827, 1724, 1696, 
1596, 1512, 1339; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.42 (3H, d, J = 7.1 Hz, H-6’), 
4.38-4.43 (1H, m, H-5’), 7.61 (2H, d, J = 8.8 Hz, H-3’), 8.18 (2H, d, J = 8.8 Hz, H-2’), 
9.46 (1H, d, J = 2.5 Hz, H-7’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 13.2 (C-6’), 
48.5 (C-5’), 124.0 (C-2’), 128.8 (C-3’), 143.3 (C-4’), 145.5 (C-1’), 196.2 (CO); HRMS 
calcd for C9H10NO3S [M+H]
+
 212.0378, found 212.0376. 
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1-(2-((4-Nitrophenyl)thio)propyl)pyrrolidine (179) 
 
2-((4-Nitrophenyl)thio)propanal 178 (530 mg, 2.51 mmol) was dissolved in anhydrous 
toluene (15 mL) under N2. Acetic acid (0.80 mL, 14.01 mmol) and MgSO4 (1,04 g, 8.73 
mmol) were added to the reaction. Then pyrrolidine (0.84 mL, 10.09 mmol) was added 
and the reaction was stirred at r.t. for 2 h. Sodium triacetoxyborohydride (240 mg, 6.16 
mmol) was added and the reaction was stirred at r.t. for 16 h. The reaction mixture was 
quenched with aqueous NaHCO3 until reaching pH 7. The solution was then extracted 
with EtOAc (3 x 30 mL). The organic layer was dried over MgSO4 and the solvent was 
removed in vacuo. The crude product was purified by MPC on silica (DCM: MeOH 9: 1) 
to give the products 179 as an orange oil (568 mg, 3.13 mmol, 85%). 
Rf 0.47 (DCM: MeOH 9: 1); UV λmax (EtOH) 339 nm; IR (cm
-1
) 2970, 2792, 1509, 1337; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.32 (3H, d, J = 6.6 Hz, H-6’), 1.68-1.70 (4H, m, 
H-pyr), 2.50-2.52 (4H, m, H-pyr), 2.60 (2H, dd, J = 3.5 and 6.6 Hz, H-7’), 3.80 (1H, h, J 
= 6.6 Hz, H-5’), 7.56 (2H, d, J = 9.0 Hz, H-3’), 8.14 (2H, d, J = 9.0 Hz, H-2’); 13C NMR 
(125 MHz, DMSO-d6) (ppm) δ 19.0 (C-6’), 23.2 (2 x C-pyr), 39.9 (C-5’), 50.0 (2 x C-
pyr), 60.9 (C-7’), 123.7 (C-2’), 127.7 (C-3’), 144.4 (C-4’), 146.8 (C-1’). 
Note: LRMS and HRMS were not available because the compound did not ionise. 
4-((1-(Pyrrolidin-1-yl)propan-2-yl)thio)aniline (180) 
 
The title compound was synthesised following general procedure H using 1-(2-((4-
nitrophenyl)thio)propyl)pyrrolidine 179 (690 mg, 2.59 mmol) and zinc powder (1.68 g, 
25.94 mmol). The crude product was purified by MPC on silica (DCM: MeOH 9: 1) to 
give the product 180 as a yellow oil (600 mg, 2.54 mmol, 98%). 
Rf 0.22 (DCM: MeOH 9: 1); UV λmax (EtOH) 254 nm; IR (cm
-1
) 3342, 2968, 2837, 1595, 
1496, 1396, 1277; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.12 (3H, d, J = 7.1 Hz, H-6’), 
1.64-1.67 (4H, m, H-pyr), 2.36-2.35 (2H, m, H-pyr), 2.40 (2H, d, J = 7.1 Hz, H-7’), 2.42-
2.44 (2H, m, H-pyr), 2.98 (1H, m, H-5’), 5.28 (2H, br s, NH2), 6.52 (2H, d, J = 8.5 Hz, 
H-2’), 7.10 (2H, d, J = 8.5 Hz, H-3’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 19.3 (H-
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6’), 23.1 (2 x C-pyr), 42.6 (C-5’), 55.6 (2 x C-pyr), 61.7 (H-7’), 114.1 (C-3’), 116.8 (C-
4’), 135.8 (C-2’), 148.8 (C-1’); HRMS calcd for C13H21N2S [M+H]
+
 237.1420, found 
237.1423. 
6-(Cyclohexylmethoxy)-N-(4-((1-(pyrrolidin-1-yl)propan-2-yl)thio)phenyl)-9H-purin 
-2-amine (181) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (460 mg, 0.96 mmol), 
4-((1-(pyrrolidin-1-yl)propan-2-yl)thio)aniline 180 (250 mg, 1.06 mmol), K2CO3 (267 mg, 
1.92 mmol), Pd(dba)2 (18 mg, 0.02 mmol) and XPhos (18 mg, 0.02 mmol). The crude 
mixture was then filtered through Celite and the solvent was removed in vacuo. The 
crude mixture was then solubilised in TFA (15 mL). The resulting solution was heated at 
70 °C for 5 h. Then the solvent was removed in vacuo. The product was purified by MPC 
on alumina (DCM: MeOH 19: 1) to give the product 181 as a pale orange oil (280 mg, 
0.60 mmol, 62%). 
Rf 0.22 (DCM: MeOH 9: 1); UV λmax (EtOH) 300 nm; IR (cm
-1
) 3383, 2926, 2851, 1672, 
1594, 1495, 1394, 1179, 1127; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.06-1.12 (2H, m, 
H-cyclo), 1.18-1.20 (1H, m, H-cyclo), 1.24-1.31 (2H, m, H-cyclo), 1.26 (3H, d, J = 6.7 
Hz, H-6’), 1.67 (1H, d, J = 11.7 Hz, H-cyclo), 1.73 (2H, d, J = 12.8 Hz, H-cyclo), 1.85 
(2H, m, H-cyclo), 1.87-1.93 (3H, m, H-pyr and H-2’’), 1.97-2.02 (2H, m, H-pyr), 2.96-
3.02 (1H, m, H-pyr), 3.08-3.12 (1H, m, H-pyr), 3.18-3.21 (1H, m, H-7’), 3.27-3.32 (1H, 
m, H-7’), 3.40-3.45 (1H, m, H-5’), 3.60-3.64 (2H, m, H-pyr), 4.35 (2H, d, J = 6.3 Hz, H-
1’’), 7.45 (2H, d, J = 8.8 Hz, H-2’), 7.90 (2H, d, J = 8.8 Hz, H-3’), 8.10 (1H, s, H-8), 9.56 
(1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 18.3 (C-6’), 22.4 (C-pyr), 22.5 (C-
pyr), 25.2 (2 x C-cyclo), 26.0 (C-cyclo), 29.2 (2 x C-cyclo), 36.8 (C-5’), 40.0 (C-2’’), 
53.9 (C-pyr), 54.0 (C-pyr), 58.7 (C-7’), 71.2 (C-1’’), 118.6 (C-3’), 120.7 (Cq), 135.1 (C-
2’), 140.1 (C-8), 141.9 (Cq), 155.0 (Cq), 157.9 (Cq), 158.1 (Cq), 159.5 (Cq); HRMS calcd 
for C25H35N6OS [M+H]
+
 467.2587, found 467.2582.  
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2-((4-Nitrophenyl)sulfonyl)propan-1-ol (182) 
 
The title compound was synthesised following general procedure M using 2-((4-
nitrophenyl)thio)propan-1-ol 177 (1.12 g, 5.26 mmol) and m-CPBA (2.68 g, 11.6 mmol). 
The crude product was purified by MPC on silica (petrol: EtOAc 1: 1) to give the product 
182 as a yellow solid (930 mg, 3.80 mmol, 72%). 
Rf 0.22 (petrol: EtOAc 7: 3); Mp = 95-97 
o
C; UV λmax (EtOH) 251 nm; IR (cm
-1
) 3554, 
2981, 2893, 1535, 1350, 1292, 1137; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.23 (3H, 
d, J = 6.7 Hz, H-6’), 3.53-3.60 (2H, m, H-5’ and H-7’), 3.67-3.72 (1H, m, H-7’), 5.01 
(1H, t, J = 5.4 Hz, OH), 8.15 (2H, d, J = 8.7 Hz, H-3’), 8.45 (2H, d, J = 8.7 Hz, H-2’); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 10.4 (C-6’), 59.7 (C-7’), 61.0 (C-5’), 124.3 (C-
2’), 130.3 (C-3’), 143.9 (C-4’), 150.5 (C-1’); HRMS calcd for C9H12NO5S [M+H]
+
 
246.0431, found 246.0431.  
2-((4-Aminophenyl)sulfonyl)propan-1-ol (183) 
 
The title compound was synthesised following general procedure H using 2-((4-
nitrophenyl)sulfonyl)propan-1-ol 182 (300 mg, 1.22 mmol) and zinc powder (796 mg, 
12.2 mmol). The crude product was purified by MPC on silica (DCM: MeOH 19: 1) to 
give the product 183 as a pale orange oil (240 mg, 1.12 mmol, 91 %). 
Rf 0.67 (DCM: MeOH 19: 1); UV λmax (EtOH) 270 nm; IR (cm
-1
) 3464, 3370, 2973, 2893, 
1596, 1263, 1126; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.16 (3H, d, J = 6.9 Hz, H-6’), 
3.07-3.10 (1H, m, H-5’), 3.27-3.32 (1H, m, H-7’), 3.70-3.74 (1H, m, H-7’), 4.87 (1H, t, J 
= 5.8 Hz, OH), 6.15 (2H, br s, NH2), 6.65 (2H, d, J = 8.7 Hz, H-3’), 7.42 (2H, d, J = 8.7 
Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 11.1 (C-6’), 59.9 (C-7’), 61.2 (C-5’), 
112.6 (C-3’), 121.9 (C-4’), 130.3 (C-2’), 153.6 (C-1’); HRMS calcd for C9H14NO3S 
[M+H]
+
 216.0689, found 216.0687.  
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2-((4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)propan-1-ol 
(184) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (171 mg, 0.36 mmol), 
2-((4-aminophenyl)sulfonyl)propan-1-ol 183 (120 mg, 0.56 mmol), K2CO3 (100 mg, 0.72 
mmol), Pd(dba)2 (7 mg, 0.01 mmol) and XPhos (3 mg, 0.01 mmol). The crude mixture 
was then filtered through Celite and the solvent was removed in vacuo. The crude 
mixture was then solubilised in TFA (10 mL). The resulting solution was heated at 70 °C 
for 2 h and the solvent was removed in vacuo. The product was purified by medium 
pressure chromatography (EtOAc: MeOH 95: 5) to give the product 184 as a pale orange 
oil (70 mg, 0.16 mmol, 44%). 
Rf 0.36 (EtOAc: MeOH 95: 5); UV λmax (EtOH) 313 nm; IR (cm
-1
) 3117, 2926, 2852, 
1596, 1535, 1392, 1205, 1132; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.08-1.14 (2H, m, 
H-cyclo), 1.16-1.20 (1H, m, H-cyclo), 1.21-1.22 (3H, d, J = 6.9 Hz, H-6’), 1.23-1.31 (2H, 
m, H-cyclo), 1.66-1.69 (1H, m, H-cyclo), 1.73-1.75 (2H, m, H-cyclo), 1.85-1.87 (3H, m, 
H-cyclo and H-2’’), 3.22-3.27 (1H, m, H-5’), 3.37-3.40 (1H, m, H-7’), 3.73-3.75 (1H, m, 
H-7’), 4.37 (2H, d, J = 6.3 Hz, H-1’’), 4.94 (1H, br s, OH), 7.72 (2H, d, J = 8.8 Hz, H-3’), 
8.07 (2H, d, J = 8.8 Hz, H-2’), 8.10 (1H, br s, H-8), 9.94 (1H, s, NH), 13.00 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 10.9 (C-6’), 25.2 (2 x C-cyclo), 26.0 (C-cyclo), 
29.2 (2 x C-cyclo), 36.8 (C-2’’), 59.9 (C-7’), 61.1 (C-5’), 71.4 (C-1’’), 117.2 (C-2’), 
128.1 (Cq), 129.5 (C-3’), 130.3 (Cq), 146.0 (C-8), 154.5 (Cq); HRMS calcd for 
C21H28N5O4S [M+H]
+
 446.1857, found 446.1848. 
Note: 3 quaternary carbons were not visible on the 
13
C NMR spectrum.  
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Ethyl 2-((4-nitrophenyl)thio)butanoate (188) 
 
The title compound was synthesised following general procedure J using ethyl 2-
bromobutyrate 185 (1.04 mL, 7.10 mmol), 4-nitrothiophenol 173 (1.00 g, 6.46 mmol) and 
Et3N (1.00 mL, 7.10 mmol). The crude product was purified by MPC on silica (petrol: 
EtOAc 9: 1) to give the product 188 as a yellow oil (1.57 g, 5.83 mmol, 90%). 
Rf 0.42 (petrol: EtOAc 4: 1); UV λmax (EtOH) 330 nm; IR (cm
-1
) 2972, 2880, 1729, 1577, 
1337, 1261, 1155; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.00 (3H, t, J = 7.3 Hz, H-7’), 
1.13 (3H, t, J = 7.1 Hz, H-9’), 1.77-1.85 (1H, m, H-6’), 1.86-1.93 (1H, m, H-6’), 4.08-
4.15 (2H, m, H-8’), 4.26 (1H, t, J = 6.8 Hz, H-5’), 7.62 (2H, d, J = 9.0 Hz, H-3’), 8.17 
(2H, d, J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 11.1 (C-7’), 14.1 (C-
9’), 24.6 (C-6’), 49.0 (C-5’), 61.4 (C-8’), 124.0 (C-2’), 128.3 (C-3’), 144.4 (C-4’), 145.5 
(C-1’), 171.0 (CO); HRMS calcd for C12H16NO4S [M+H]
+
 270.0795, found 270.0794. 
Ethyl 3-methyl-2-((4-nitrophenyl)thio)butanoate (189) 
 
The title compound was synthesised following general procedure J using ethyl 2-
bromoisovalurate 186 (1.16 mL, 7.10 mmol), 4-nitrothiophenol 173 (1.00 g, 6.46 mmol) 
and Et3N (1.00 mL, 7.10 mmol). The crude product was purified by MPC on silica (petrol: 
EtOAc 4: 1) to give the product 189 as a yellow oil (920 mg, 3.25 mmol, 46%). 
Rf 0.39 (petrol: EtOAc 4: 1); UV λmax (EtOH) 328 nm; IR (cm
-1
) 2967, 1727, 1577, 1512, 
1336, 1148; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.04 (3H, t, J = 6.6 Hz, H-7’), 1.09 
(3H, t, J = 6.6 Hz, H-7’), 1.14 (3H, t, J = 7.1 Hz, H-9’), 2.12-2.19 (1H, m, H-6’), 4.10-
4.14 (3H, m, H-5’ and H-8’), 7.62 (2H, d, J = 9.0 Hz, H-3’), 8.17 (2H, d, J = 9.0 Hz, H-
2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 13.9 (C-9’), 19.7 (C-7’), 19.9 (C-7’), 30.3 
(C-6’), 54.9 (C-5’), 61.0 (C-8’), 123.9 (C-2’), 128.3 (C-3’), 145.1 (C-4’), 145.3 (C-1’), 
170.6 (CO); HRMS calcd for C13H16NO4S [M-H]
-
 282.0806, found 282.0796.  
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Ethyl 2-((4-nitrophenyl)thio)-2-phenylacetate (190) 
 
The title compound was synthesised following general procedure J using ethyl α-
chlorophenylacetate 187 (1.22 mL, 7.10 mmol), 4-nitrothiophenol 173 (1.00 g, 6.46 
mmol) and Et3N (1.00 mL, 7.10 mmol). The crude product was purified by MPC on silica 
(petrol: EtOAc 9: 1) to give the product 190 as a yellow oil (1.35 g, 4.26 mmol, 66%). 
Rf 0.51 (petrol: EtOAc 4: 1); UV λmax (EtOH) 334 nm; IR (cm
-1
) 2967, 2853, 1707, 1578, 
1506, 1333, 1233; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.11 (3H, t, J = 7.1 Hz, H-
11’), 4.08-4.19 (2H, m, H-10’), 5.82 (1H, s, H-5’), 7.34-7.37 (1H, m, H-9’), 7.40 (2H, dd, 
J = 7.2 Hz, H-8’), 7.54 (2H, d, J = 7.2 Hz, H-7’), 7.59 (2H, d, J = 9.0 Hz, H-3’), 8.15 (2H, 
d, J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 13.7 (C-11’), 52.2 (C-10’), 
61.9 (C-5’), 123.9 (C-2’), 128.1 (C-3’), 128.4 (C-7’), 128.6 (C-9’), 128.9 (C-8’), 134.7 
(C-6’), 144.6 (C-4’), 145.3 (C-1’), 169.3 (CO); HRMS calcd for C16H14NO4S [M-H]
-
 
316.0649, found 316.0638. 
2-((4-Nitrophenyl)thio)butanoic acid (191) 
 
The title compound was synthesised following general procedure K using ethyl 2-((4-
nitrophenyl)thio)butanoate 188 (790 mg, 2.94 mmol) and LiOH (2M in THF, 16.2 mL). 
The product 191 was obtained without further purification as a yellow oil (630 mg, 2.61 
mmol, 89%). 
Rf 0.25 (petrol: EtOAc 4: 1); UV λmax (EtOH) 333 nm; IR (cm
-1
) 3096, 2985, 2871, 1704, 
1578, 1506, 1336, 1274; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.01 (3H, t, J = 7.3 Hz, 
H-7’), 1.78-1.84 (1H, m, H-6’), 1.85-1.93 (1H, m, H-6’), 4.15 (1H, t, J = 6.9 Hz, H-5’), 
7.62 (2H, d, J = 8.9 Hz, H-3’), 8.16 (2H, d, J = 8.9 Hz, H-2’), 13.1 (1H, br s, OH); 13C 
NMR (125 MHz, DMSO-d6) (ppm) δ 11.1 (C-7’), 24.5 (C-6’), 49.2 (C-5’), 124.0 (C-2’), 
128.0 (C-3’), 145.0 (C-4’), 145.5 (C-1’), 172.4 (CO); HRMS calcd for C10H10NO4S 
[M-H]
-
 240.0336, found 240.0328. 
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3-Methyl-2-((4-nitrophenyl)thio)butanoic acid (192) 
 
The title compound was synthesised following general procedure K using ethyl 3-
methyl-2-((4-nitrophenyl)thio)butanoate 189 (725 mg, 2.56 mmol) and LiOH (2M in 
THF, 12.8 mL). The product 192 was obtained without further purification as a yellow oil 
(610 mg, 2.39 mmol, 93%). 
Rf 0.19 (petrol: EtOAc 4: 1); UV λmax (EtOH) 330 nm; IR (cm
-1
) 2963, 2847, 1703, 1579, 
1511, 1336, 1294; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.06 (3H, t, J = 6.7 Hz, H-7’), 
1.09 (3H, t, J = 6.7 Hz, H-7’), 2.12-2.18 (1H, m, H-6’), 3.99 (1H, d, J = 7.6 Hz, H-5’), 
7.61 (2H, d, J = 9.0 Hz, H-3’), 8.16 (2H, d, J = 9.0 Hz, H-2’); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 19.7 (C-7’), 20.0 (C-7’), 30.1 (C-6’), 55.3 (C-5’), 123.9 (C-2’), 127.8 
(C-3’), 145.0 (C-4’), 145.9 (C-1’), 172.1 (CO); HRMS calcd for C11H12NO4S [M-H]
-
 
254.0493, found 254.0485. 
2-((4-Nitrophenyl)thio)-2-phenylacetic acid (193) 
 
The title compound was synthesised following general procedure K using ethyl 2-((4-
nitrophenyl)thio)-2-phenylacetate 190 (1.35 g, 4.26 mmol) and LiOH (2M in THF, 21.3 
mL). The product 193 was obtained without further purification as a yellow oil (1.19 g, 
4.12 mmol, 96%). 
Rf 0.43 (petrol: EtOAc 3: 2); UV λmax (EtOH) 332 nm; IR (cm
-1
) 2832, 1700, 1574, 1509, 
1452, 1334; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 5.67 (1H, s, H-5’), 7.32-7.35 (1H, 
m, H-9’), 7.39 (2H, dd, J = 7.1 Hz, H-8’), 7.55-7.57 (4H, m, H-7’ and H-3’), 8.13 (2H, d, 
J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 52.7 (C-5’), 123.9 (C-2’), 
127.7 (C-3’), 128.4 (C-7’), 128.5 (C-9’), 128.8 (C-8’), 135.4 (C-6’), 145.1 (C-4’), 145.3 
(C-1’), 170.7 (CO); LRMS calcd for C14H10NO4S [M-H]
-
 288.0, found 288.2.  
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2-((4-Nitrophenyl)thio)butan-1-ol (194) 
 
The title compound was synthesised following general procedure L using 2-((4-
nitrophenyl)thio)butanoic acid 191 (630 mg, 2.61 mmol) and 1M Borane in complex with 
THF (13.1 mL, 13.1 mmol). The crude product was purified by MPC on silica (petrol: 
EtOAc 3: 2) to give the product 194 as a yellow oil (438 mg, 1.93 mmol, 74%). 
Rf 0.37 (petrol: EtOAc 4: 1); UV λmax (EtOH) 339 nm; IR (cm
-1
) 3377, 2964, 2929, 1578, 
1507, 1334; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.01 (3H, t, J = 7.3 Hz, H-7’), 1.51-
1.59 (1H, m, H-6’), 1.86-1.92 (1H, m, H-6’), 3.46-3.50 (1H, m, H-5’), 3.51-3.55 (1H, m, 
H-8’), 3.59-3.63 (1H, m, H-8’), 5.10 (1H, t, J = 5.7 Hz, OH), 7.55 (2H, d, J = 9.0 Hz, H-
3’), 8.13 (2H, d, J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 11.2 (C-7’), 
23.6 (C-6’), 50.0 (C-5’), 62.8 (C-8’), 123.9 (C-2’), 127.2 (C-3’), 144.3 (C-4’), 147.7 (C-
1’); HRMS calcd for C10H14NO3S [M+H]
+
 228.0689, found 228.0692. 
3-Methyl-2-((4-nitrophenyl)thio)butan-1-ol (195) 
 
The title compound was synthesised following general procedure L using 3-methyl-2-
((4-nitrophenyl)thio)butanoic acid 192 (610 mg, 2.39 mmol) and 1M Borane in complex 
with THF (12.0 mL, 12.0 mmol). The crude product was purified by MPC on silica 
(petrol: EtOAc 3: 2) to give the product 195 as a yellow oil (485 mg, 2.01 mmol, 84%). 
Rf 0.41 (petrol: EtOAc 4: 1); UV λmax (EtOH) 338 nm; IR (cm
-1
) 3384, 2960, 2873, 1576, 
1506, 1336, 1085; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 0.96 (3H, t, J = 6.8 Hz, H-7’), 
1.05 (3H, t, J = 6.8 Hz, H-7’), 2.22-2.28 (1H, m, H-6’), 3.45-3.49 (1H, m, H-5’), 3.55-
3.65 (2H, m, H-8’), 5.08 (1H, t, J = 5.5 Hz, OH), 7.58 (2H, d, J = 9.0 Hz, H-3’), 8.13 (2H, 
d, J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 17.9 (C-7’), 20.4 (C-7’), 
27.9 (C-6’), 55.2 (C-5’), 61.8 (C-8’), 123.9 (C-2’), 127.4 (C-3’), 144.4 (C-4’), 147.8 (C-
1’); HRMS calcd for C11H16NO3S [M+H]
+
 242.0845, found 242.0850.  
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2-((4-Nitrophenyl)thio)-2-phenylethanol (196)
263
 
 
The title compound was synthesised following general procedure L using 2-((4-
nitrophenyl)thio)-2-phenylacetic acid 193 (1.23 g, 4.26 mmol) and 1M Borane in 
complex with THF (12.8 mL, 12.8 mmol). The crude product was purified by MPC on 
silica (petrol: EtOAc 7: 3) to give the product 196 as a yellow oil (720 mg, 2.62 mmol, 
62%). 
Rf 0.39 (petrol: EtOAc 4: 1); UV λmax (EtOH) 337 nm; IR (cm
-1
) 3374, 2926, 2870, 1576, 
1506, 1333, 1088, 852; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.76-3.81 (1H, m, H-
10’), 3.84-3.89 (1H, m, H-10’), 4.81 (1H, t, J = 6.5 Hz, H-5’), 5.31 (1H, t, J = 5.6 Hz, 
OH), 7.26 (1H, t, J = 7.8 Hz, H-9’), 7.34 (2H, dd, J = 7.8 Hz, H-8’), 7.49 (2H, d, J = 7.8 
Hz, H-7’), 7.54 (2H, d, J = 9.0 Hz, H-3’), 8.08 (2H, d, J = 9.0 Hz, H-2’); 13C NMR (125 
MHz, DMSO-d6) (ppm) δ 52.2 (C-5’), 64.8 (C-10’), 123.8 (C-2’), 127.4 (C-3’), 127.5 (C-
7’), 128.2 (C-9’), 128.8 (C-8’), 139.0 (C-6’), 144.6 (C-4’), 146.6 (C-1’); HRMS calcd for 
C14H14NO3S [M+H]
+
 276.0689, found 276.0694. 
3-Methyl-2-((4-nitrophenyl)thio)butanal (198) 
 
Dry DMSO (0.45 mL, 6.28 mmol) was added to a solution of oxalyl chloride (0.41 mL, 
4.79 mmol) in dry DCM (35 mL) at -78 
o
C, under N2. The solution was stirred at -78 °C 
for 30 min. 3-Methyl-2-((4-nitrophenyl)thio)butan-1-ol 195 (550 mg, 2.28 mmol) in 
solution in dry DCM (35 mL) was added dropwise to the reaction at -78 
o
C. The reaction 
was stirred at -78 °C for a further 1 h. Et3N (1.93 mL, 13.69 mmol) was then added and 
the reaction was allowed to warm to r.t. The solution was stirred for a additional 30 min 
at r.t. Brine (50 mL) was added and the solution was extracted with DCM (3 x 50 mL). 
The organic layer was dried over MgSO4 and the solvent was removed in vacuo. The 
crude product was purified by MPC on silica (petrol: EtOAc 9: 1) to give the product 198 
as a yellow oil (360 mg, 1.51 mmol, 66%). 
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Rf 0.62 (petrol: EtOAc 4: 1); UV λmax (EtOH) 326 nm; IR (cm
-1
) 2964, 2839, 1714, 1577, 
1510, 1336, 1089; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.06 (3H, t, J = 6.8 Hz, H-7’), 
1.09 (3H, t, J = 6.8 Hz, H-7’), 2.23-2.30 (1H, m, H-6’), 4.11 (1H, dd, J = 4.3 and 7.5 Hz, 
H-5’), 7.60 (2H, d, J = 8.9 Hz, H-3’), 8.15 (2H, d, J = 8.9 Hz, H-2’), 9.41 (1H, d, J = 4.3 
Hz, H-8’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 19.3 (C-7’), 20.2 (C-7’), 27.3 (C-6’), 
60.5 (C-5’), 123.9 (C-2’), 128.4 (C-3’), 143.9 (C-4’), 145.3 (C-1’), 196.0 (CO); HRMS 
calcd for C11H14NO3S [M+H]
+
 240.0689, found 240.0686. 
2-((4-Aminophenyl)thio)butan-1-ol (207) 
 
The title compound was synthesised following general procedure H using 2-((4-
nitrophenyl)thio)butan-1-ol 194 (569 mg, 2.51 mmol) and zinc powder (1.6 g, 25.1 
mmol). The crude product was purified by MPC on silica (DCM: MeOH 19: 1) to give 
the product 207 as a colourless oil (380 mg, 1.93 mmol, 77%). 
Rf 0.35 (DCM: MeOH 19: 1); UV λmax (EtOH) 263 nm; IR (cm
-1
) 3345, 3230, 2961, 2930, 
1596, 1494, 1278, 1049; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 0.99 (3H, t, J = 7.3 Hz, 
H-7’), 1.24-1.33 (1H, m, H-6’), 1.68-1.75 (1H, m, H-6’), 2.61-2.66 (1H, m, H-5’), 3.24-
3.28 (1H, m, H-8’), 3.47-3.50 (1H, m, H-8’), 4.69 (1H, br s, OH), 5.27 (2H, br s, NH2), 
6.51 (2H, d, J = 8.2 Hz, H-2’), 7.10 (2H, d, J = 8.2 Hz, H-3’); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 11.2 (C-7’), 23.2 (C-6’), 53.6 (C-5’), 63.2 (C-8’), 114.2 (C-2’), 117.0 
(C-4’), 135.7 (C-3’), 148.8 (C-1’); HRMS calcd for C10H14NOS [M-H]
-
 196.0802, found 
196.0801. 
2-((4-Aminophenyl)thio)-3-methylbutan-1-ol (208) 
 
The title compound was synthesised following general procedure H using 3-methyl-2-
((4-nitrophenyl)thio)butan-1-ol 194 (537 mg, 2.23 mmol) and zinc powder (1.45 g, 22.3 
mmol). The crude product was purified by MPC on silica (DCM: MeOH 19: 1) to give 
the product 208 as a colourless solid (572 mg, 2.71 mmol, 79%). 
Rf 0.58 (DCM: MeOH 9: 1); UV λmax (EtOH) 338 nm; IR (cm
-1
) 3351, 3229, 2958, 2872, 
1597, 1494, 1176; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 0.88 (3H, t, J = 6.8 Hz, H-7’), 
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1.06 (3H, t, J = 6.8 Hz, H-7’), 2.09-2.15 (1H, m, H-6’), 2.67-2.70 (1H, m, H-5’), 3.42-
3.50 (2H, m, H-8’), 4.68 (1H, br s, OH), 5.26 (2H, br s, NH2), 6.51 (2H, d, J = 8.5 Hz, H-
2’), 7.11 (2H, d, J = 8.5 Hz, H-3’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 17.5 (C-7’), 
21.0 (C-7’), 27.2 (C-6’), 60.2 (C-5’), 61.7 (C-8’), 114.3 (C-2’), 118.8 (C-4’), 135.0 (C-3’), 
148.5 (C-1’); HRMS calcd for C11H18NOS [M+H]
+
 212.1104, found 212.1103. 
2-((4-Aminophenyl)thio)-2-phenylethanol (209) 
 
The title compound was synthesised following general procedure H using 2-((4-
nitrophenyl)thio)-2-phenylethanol 196 (565 mg, 2.05 mmol) and zinc powder (1.3 g, 20.6 
mmol). The crude product was purified by MPC on silica (DCM: MeOH 19: 1) to give 
the product 209 as a colourless oil (430 mg, 1.76 mmol, 85%). 
Rf 0.62 (DCM: MeOH 9: 1); UV λmax (EtOH) 265 nm; IR (cm
-1
) 3379, 3308, 2940, 2896, 
1595, 1491, 1263; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.72-3.74 (2H, m, H-10’), 
3.98-4.01 (1H, m, H-5’), 4.84 (1H, br s, OH), 5.29 (2H, br s, NH2), 6.46 (2H, d, J = 8.4 
Hz, H-2’), 7.03 (2H, d, J = 8.4 Hz, H-3’), 7.21-7.29 (5H, m, H-ar); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 55.9 (C-5’), 63.9 (C-10’), 114.1 (C-2’), 117.3 (Cq), 126.8 (2 x C-ar), 
128.0 (Cq), 128.2 (2 x C-ar), 135.5 (C-3’), 140.5 (Cq), 140.9 (Cq); HRMS calcd for 
C14H16NOS [M+H]
+
 246.0947, found 246.0952. 
2-((4-((6-(Cyclohexylmethoxy)-9-(4-methoxybenzyl)-9H-purin-2-yl)amino)phenyl) 
thio)butan-1-ol (210) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (500 mg, 1.05 mmol), 
2-((4-aminophenyl)thio)butan-1-ol 207 (247 mg, 1.26 mmol), K2CO3 (289 mg, 2.09 
mmol), Pd(dba)2 (19 mg, 0.02 mmol) and XPhos (10 mg, 0.02 mmol). The crude mixture 
was then filtered through Celite and the solvent was removed in vacuo. The crude 
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mixture was then solubilised in TFA (15 mL). The resulting solution was heated at 70 °C 
for 2 h. Then the solvent was removed in vacuo. The product was purified by MPC 
(EtOAc: MeOH 19: 1) to give the product 210 as an orange oil (283 mg, 0.66 mmol, 
63%). 
Rf 0.27 (EtOAc: MeOH 19: 1); UV λmax (EtOH) 278 nm; IR (cm
-1
) 3285, 2926, 2852, 
1636, 1540, 1429, 1202, 1336; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 0.82 (3H, t, J = 
7.3 Hz, H-7’), 1.06-1.12 (2H, m, H-cyclo), 1.18-1.21 (1H, m, H-cyclo), 1.24-1.29 (2H, m, 
H-cyclo), 1.33-1.41 (1H, m, H-6’), 1.59-1.63 (1H, m, H-6’), 1.66-1.68 (1H, m, H-cyclo), 
1.72-1.75 (2H, m, H-cyclo), 1.84-1.86 (3H, m, H-cyclo and H-2’’), 2.89 (2H, dd, J = 5.8 
and 2.9 Hz, H-8’), 3.44-3.50 (1H, m, H-5’), 4.35 (2H, d, J = 6.3 Hz, H-1’’), 4.80 (1H, d, J 
= 5.8 Hz, OH), 7.32 (2H, d, J = 8.8 Hz, H-2’), 7.78 (2H, d, J = 8.8 Hz, H-3’), 7.98 (1H, s, 
H-8), 9.37 (1H, s, NH), 12.80 (1H, s, N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 
10.3 (C-7’), 25.2 (2 x C-cyclo), 25.9 (C-cyclo), 26.0 (C-6’), 29.1 (2 x C-cyclo), 36.8 (C-
2’’), 41.3 (C-8’), 70.2 (C-5’), 71.2 (C-1’’), 114.8 (Cq), 119.0 (C-3’), 126.9 (Cq), 130.3 (C-
2’), 138.9 (Cq), 139.6 (C-8), 154.1 (Cq), 155.2 (Cq), 160.1 (Cq); HRMS calcd for 
C22H30N5O2S [M+H]
+
 428.2115, found 428.2107. 
2-((4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)thio)-3-methylbutan-1-
ol (211) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (500 mg, 1.05 mmol), 
2-((4-aminophenyl)thio)-3-methylbutan-1-ol 208 (265 mg, 1.26 mmol), K2CO3 (289 mg, 
2.09 mmol), Pd(dba)2 (19 mg, 0.02 mmol) and XPhos (10 mg, 0.02 mmol). The crude 
mixture was then filtered through Celite and the solvent was removed in vacuo. The 
crude mixture was then solubilised in TFA (15 mL). The resulting solution was heated at 
70 °C for 2 h. Then the solvent was removed in vacuo. The product was purified by MPC 
(EtOAc 100) to give the product 211 as a pale orange oil (127 mg, 0.29 mmol, 28%). 
Rf 0.36 (EtOAc 100); UV λmax (EtOH) 316 nm; IR (cm
-1
) 3353, 3107, 2927, 2849, 1597, 
1494, 1394, 1306, 1119; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 0.83 (3H, t, J = 6.8 Hz, 
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H-7’), 0.86 (3H, t, J = 6.8 Hz, H-7’), 1.05-1.12 (2H, m, H-cyclo), 1.16-1.21 (1H, m, H-
cyclo), 1.24-1.31 (2H, m, H-cyclo), 1.66-1.68 (1H, m, H-cyclo), 1.72-1.76 (3H, m, H-
cyclo and H-6’), 1.83-1.85 (2H, m, H-cyclo), 1.90-1.91 (1H, m, H-2’’), 2.85 (1H, dd, J = 
7.5 and 13.1 Hz, H-8’), 2.95 (1H, dd, J = 4.8 and 13.1 Hz, H-8’), 3.36 (1H, m, H-5’), 
4.34 (2H, d, J = 6.2 Hz, H-1’’), 4.75 (1H, s, OH), 7.30 (2H, d, J = 8.7 Hz, H-2’), 7.77 (2H, 
d, J = 8.7 Hz, H-3’), 7.98 (1H, s, H-8), 9.37 (1H, s, NH), 12.80 (1H, s, N9H); 13C NMR 
(125 MHz, DMSO-d6) (ppm) δ 16.6 (C-7’), 19.2 (C-7’), 25.2 (2 x C-cyclo), 26.0 (C-
cyclo), 29.2 (2 x C-cyclo), 32.0 (C-6’), 36.8 (C-2’’), 40.0 (C-8’), 71.0 (C-1’’), 73.3 (C-5’), 
118.9 (C-3’), 127.1 (Cq), 130.3 (C-2’), 138.9 (Cq), 139.6 (Cq), 141.9 (Cq), 154.1 (Cq), 
155.2 (Cq), 160.1 (Cq); HRMS calcd for C23H32N5O2S [M+H]
+
 442.2271, found 442.2266. 
2-((4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)thio)-2-phenylethanol 
(212) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (500 mg, 1.05 mmol), 
2-((4-aminophenyl)thio)-2-phenylethanol 209 (308 mg, 1.26 mmol), K2CO3 (289 mg, 
2.09 mmol), Pd(dba)2 (19 mg, 0.02 mmol) and XPhos (10 mg, 0.02 mmol). The crude 
mixture was then filtered through Celite and the solvent was removed in vacuo. The 
crude mixture was then solubilised in TFA (15 mL). The resulting solution was heated at 
70 °C for 2 h. Then the solvent was removed in vacuo. The product was purified by MPC 
(EtOAc: MeOH 19: 1) to give the product 212 as an orange oil (130 mg, 0.27 mmol, 
26%). 
Rf 0.31 (EtOAc: MeOH 19: 1); UV λmax (EtOH) 281 nm; IR (cm
-1
) 3279, 2926, 2852, 
1598, 1529, 1494, 1394, 1306; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.05-1.13 (2H, m, 
H-cyclo), 1.17-1.19 (1H, m, H-cyclo), 1.24-1.32 (2H, m, H-cyclo), 1.65-1.68 (1H, m, H-
cyclo), 1.72-1.75 (2H, m, H-cyclo), 1.84-1.86 (3H, m, H-cyclo and H-2’’), 3.16 (2H, d, J 
= 7.4 Hz, H-8’), 3.46 (1H, br s, OH), 4.35 (2H, d, J = 6.3 Hz, H-1’’), 4.86-4.91 (1H, m, 
H-5’), 7.24-7.29 (3H, m, H-ar), 7.31-7.34 (4H, m, H-ar and H-2’), 7.81 (2H, d, J = 8.7 Hz, 
H-3’), 8.08 (1H, s, H-8), 8.44 (1H, s, NH), 9.43 (1H, s, N9H) ; 13C NMR (125 MHz, 
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DMSO-d6) (ppm) δ 25.4 (2 x C-cyclo), 26.1 (C-cyclo), 29.1 (2 x C-cyclo), 36.9 (C-2’’), 
40.6 (C-8’), 51.7 (C-5’), 71.3 (C-1’’), 118.9 (C-3’), 121.5 (Cq), 125.6 (Cq), 126.7 (2 x C-
ar), 127.1 (C-ar), 128.3 (2 x C-ar), 129.6 (Cq), 131.1 (C-2’), 140.2 (Cq), 142.0 (C-8), 
153.3 (Cq), 157.3 (Cq), 162.7 (Cq); HRMS calcd for C26H33N6O2S [M+H+MeCN]
+
 
517.2380, found 517.2383. 
2-((4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)butan-1-ol (213) 
 
The title compound was synthesised following general procedure M using 2-((4-((6-
(cyclohexylmethoxy)-9-(4-methoxybenzyl)-9H-purin-2-yl)amino)phenyl)thio) butan-1-ol 
210 (280 mg, 0.66 mmol) and m-CPBA (305 mg, 1.31 mmol). The crude product was 
purified by MPC on silica (EtOAc: MeOH 9: 1) to give the product 213 as a yellow oil 
(85 mg, 0.18 mmol, 28%). 
Rf 0.33 (EtOAc: MeOH 19: 1); UV λmax (EtOH) 311 nm; IR (cm
-1
) 3285, 2926, 2855, 
1596, 1361, 1224, 1138; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 0.75 (3H, t, J = 7.3 Hz, 
H-7’), 1.07-1.14 (2H, m, H-cyclo), 1.19-1.21 (1H, m, H-cyclo), 1.25-1.30 (2H, m, H-
cyclo), 1.35-1.40 (1H, m, H-6’), 1.50-1.56 (1H, m, H-6’), 1.66-1.69 (1H, m, H-cyclo), 
1.74-1.76 (2H, m, H-cyclo), 1.84-1.87 (3H, m, H-cyclo and H-2’’), 3.28 (2H, dd, J = 5.8 
and 3.0 Hz, H-8’), 3.75-3.81 (1H, m, H-5’), 4.38 (2H, d, J = 6.3 Hz, H-1’’), 4.81 (1H, d, J 
= 5.8 Hz, OH), 7.76 (2H, d, J = 8.9 Hz, H-3’), 8.05 (2H, d, J = 8.9 Hz, H-2’), 8.07 (1H, s, 
H-8), 9.92 (1H, br s, NH), 12.97 (1H, br s, N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) 
δ 9.4 (C-7’), 25.2 (2 x C-cyclo), 26.0 (C-cyclo), 29.2 (2 x C-cyclo), 29.6 (C-6’), 36.8 (C-
2’’), 62.0 (C-8’), 66.5 (C-5’), 71.3 (C-1’’), 115.5 (Cq), 117.2 (C-2’), 128.7 (C-3’), 130.9 
(Cq), 139.6 (C-8), 145.7 (Cq), 153.9 (Cq), 154.6 (Cq), 160.2 (Cq); HRMS calcd for 
C22H30N5O4S [M+H]
+
 460.2013, found 460.2004. 
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2-((4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)-3-methyl 
butan-1-ol (214) 
 
The title compound was synthesised following general procedure M using 2-((4-((6-
(cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)thio)-3-methylbutan-1-ol 211 (127 
mg, 0.29 mmol) and m-CPBA (141 mg, 0.61 mmol). The crude product was purified by 
MPC on silica (DCM: MeOH 19: 1) to give the product 214 as a colourless oil (50.0 mg, 
0.11 mmol, 36%). 
Rf 0.37 (DCM: MeOH 9: 1); UV λmax (EtOH) 318 nm; IR (cm
-1
) 3261, 3101, 2925, 2851, 
1595, 1535, 1386, 1135; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 0.76 (3H, d, J = 6.8 Hz, 
H-7’), 0.80 (3H, d, J = 6.8 Hz, H-7’), 1.07-1.14 (2H, m, H-cyclo), 1.18-1.21 (1H, m, H-
cyclo), 1.24-1.32 (2H, m, H-cyclo), 1.59-1.64 (1H, m, H-6’), 1.66-1.69 (1H, m, H-cyclo), 
1.73-1.76 (2H, m, H-cyclo), 1.85-1.91 (3H, m, H-cyclo, H-2’’), 3.21 (1H, dd, J = 3.0 and 
14.6 Hz, H-8’), 3.29 (1H, dd, J = 8.1 and 14.6 Hz, H-8’), 3.69-3.74 (1H, m, H-5’), 4.37 
(2H, d, J = 6.3 Hz, H-1’’), 4.76 (1H, d, J = 5.8 Hz, OH), 7.77 (2H, d, J = 8.9 Hz, H-3’), 
8.04 (2H, d, J = 8.9 Hz, H-2’), 8.07 (1H, s, H-8), 9.91 (1H, s, NH), 12.96 (1H, s, N9H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 16.4 (C-7’), 18.4 (C-7’), 25.2 (2 x C-cyclo), 
26.0 (C-cyclo), 29.2 (2 x C-cyclo), 33.2 (C-6’), 36.8 (C-2’’), 60.2 (C-8’), 69.5 (C-5’), 
71.3 (C-1’’), 115.4 (Cq), 117.2 (C-2’), 128.7 (C-3’), 131.0 (Cq), 139.6 (C-8), 145.7 (Cq), 
153.9 (Cq), 154.5 (Cq), 160.2 (Cq); HRMS calcd for C23H32N5O4S [M+H]
+
 474.2170, 
found 474.2161. 
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2-((4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)-2-phenyl 
ethanol (215) 
 
The title compound was synthesised following general procedure M using 2-((4-((6-
(cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)thio)-2-phenylethanol 212 (130 mg, 
0.27 mmol) and m-CPBA (127 mg, 0.55 mmol). The crude product was purified by MPC 
on silica (EtOAc: MeOH 9: 1) to give the product 215 as a yellow oil (78 mg, 0.15 mmol, 
56%). 
Rf 0.40 (EtOAc: MeOH 19: 1); UV λmax (EtOH) 313 nm; IR (cm
-1
) 3296, 2926, 2850, 
1596, 1534, 1453, 1395, 1298, 1138; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.08-1.14 
(2H, m, H-cyclo), 1.19-1.22 (1H, m, H-cyclo), 1.25-1.33 (2H, m, H-cyclo), 1.66-1.69 (1H, 
m, H-cyclo), 1.73-1.76 (2H, m, H-cyclo), 1.85-1.88 (3H, m, H-cyclo and H-2’’), 3.18 (2H, 
d, J = 5.0 Hz, H-8’), 4.11 (1H, m, OH), 4.38 (2H, d, J = 6.3 Hz, H-1’’), 5.20 (1H, m, H-
5’), 7.21-7.24 (3H, m, H-ar), 7.28-7.31 (2H, m, H-ar), 7.72 (2H, d, J = 8.8 Hz, H-3’), 
8.05 (2H, d, J = 8.8 Hz, H-2’), 8.07 (1H, s, H-8), 9.95 (1H, br s, NH), 12.98 (1H, br s, 
N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 25.1 (2 x C-cyclo), 26.1 (C-cyclo), 29.2 
(2 x C-cyclo), 36.8 (C-2’’), 51.5 (C-5’), 51.8 (C-8’), 71.1 (C-1’’), 118.9 (C-2’), 125.6 
(Cq), 126.7 (2 x C-ar), 127.1 (Cq), 128.3 (2 x C-ar), 129.4 (Cq), 131.1 (C-3’), 140.1 (Cq), 
142.0 (C-8), 155.3 (Cq), 157.3 (Cq), 162.7 (Cq), 168.5 (Cq); HRMS calcd for 
C28H33N6O4S [M+MeCN+H]
+
 549.2279, found 549.2273. 
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2-((4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)butyl acetate 
(217) 
 
2-((4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)butan-1-ol 213 (58 
mg, 0.13 mmol) was solubilised in dry DCM (3 mL) under N2. Et3N (0.02 mL, 0.14 
mmol), DMAP (1.5 mg, 0.01 mmol) and acetic anhydride (0.01 mL, 0.14 mmol) were 
added and the resukting solution was stirred at r.t. for 2 h. Na2CO3 was added and the 
reaction was extracted with DCM (3 x 10 mL). The organic layer was dried over MgSO4 
and the solvent was removed in vacuo. The crude product was purified by MPC on silica 
(DCM: MeOH 9: 1) to give the product 217 as a yellow oil (38 mg, 0.08 mmol, 60%). 
Rf 0.18 (DCM: MeOH 19: 1); UV λmax (EtOH) 313 nm; IR (cm
-1
) 2928, 2873, 1717, 1575, 
1347, 1216, 1137; 
1
H NMR (500 MHz, MeOD) (ppm) δ 0.88 (3H, t, J = 7.4 Hz, H-7’), 
1.15-1.21 (2H, m, H-cyclo), 1.25-1.29 (1H, m, H-cyclo), 1.32-1.40 (2H, m, H-cyclo), 
1.48-1.56 (1H, m, H-6’), 1.60-1.67 (1H, m, H-6’), 1.73-1.76 (1H, m, H-cyclo), 1.81-1.83 
(2H, m, H-cyclo), 1.95-1.97 (3H, m, H-cyclo and H-2’’), 2.11 (3H, s, H-9’), 3.34-3.35 
(1H, m, H-8’), 3.39-3.44 (1H, m, H-8’), 4.17-4.22 (1H, m, H-5’), 4.40 (2H, d, J = 6.1 Hz, 
H-1’’), 7.79 (2H, d, J = 8.9 Hz, H-3’), 8.05 (1H, s, H-8), 8.08 (2H, d, J = 8.9 Hz, H-2’); 
13
C NMR (125 MHz, MeOD) (ppm) δ 10.3 (C-7’), 26.9 (2 x C-cyclo), 27.6 (C-cyclo), 
29.1 (C-6’), 30.9 (2 x C-cyclo), 38.8 (C-2’’), 48.0 (C-5’), 49.9 (C-9’), 60.1 (C-8’); 73.3 
(C-1’’), 118.8 (C-2’), 129.4 (Cq), 130.2 (Cq), 130.3 (C-3’), 130.9 (Cq), 131.4 (Cq), 139.2 
(Cq), 147.7 (C-8), 156.8 (Cq), 172.7 (CO); HRMS calcd for C24H30N5O5S [M-H]
-
 
499.1884, found 499.2122. 
2-((4-Aminophenyl)sulfonyl)butan-1-ol (218) 
 
The title compound was synthesised following general procedure M using 2-((4-
aminophenyl)thio)butan-1-ol 194 (1.00 g, 4.41 mmol) and m-CPBA (2.15 g, 9.25 mmol). 
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The crude product was purified by MPC on silica (petrol: EtOAc 3: 2) to give the product 
218 as a yellow oil (1.11 g, 4.28 mmol, 97%). 
Rf 0.33 (petrol: EtOAc 3: 2); UV λmax (EtOH) 251 nm; IR (cm
-1
) 3575, 2978, 2891, 1531, 
1347, 1297, 1134; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 0.99 (3H, t, J = 7.5 Hz, H-7’), 
1.61-1.70 (1H, m, H-6’), 1.78-1.86 (1H, m, H-6’), 3.33-3.37 (1H, m, H-5’), 3.69-3.73 
(1H, m, H-8’), 3.76-3.80 (1H, m, H-8’), 4.92 (1H, t, J = 5.3 Hz, OH), 8.15 (2H, d, J = 9.0 
Hz, H-3’), 8.43 (2H, d, J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 11.0 
(C-7’), 17.8 (C-6’), 57.3 (C-8’), 67.0 (C-5’), 124.2 (C-2’), 130.3 (C-3’), 144.7 (C-4’), 
150.3 (C-1’). 
Note: LRMS and HRMS were not available because the compound did not ionise. 
3-Methyl-2-((4-nitrophenyl)sulfonyl)butan-1-ol (219) 
 
The title compound was synthesised following general procedure M using 3-methyl-2-
((4-nitrophenyl)thio)butan-1-ol 195 (373 mg, 1.55 mmol) and m-CPBA (755 mg, 3.25 
mmol). The crude product was purified by MPC on silica (petrol: EtOAc 3: 2) to give the 
product 219 as a yellow oil (287 mg, 1.05 mmol, 68%). 
Rf 0.49 (petrol: EtOAc 1: 1); UV λmax (EtOH) 253 nm; IR (cm
-1
) 3512, 2968, 2879, 1528, 
1349, 1297, 1145; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.04 (3H, t, J = 7.0 Hz, H-7’), 
1.10 (3H, t, J = 7.0 Hz, H-7’), 2.47-2.50 (1H, m, H-6’), 3.39-3.42 (1H, m, H-5’), 3.75-
3.83 (2H, m, H-8’), 4.81 (1H, t, J = 5.0 Hz, OH), 8.17 (2H, d, J = 8.8 Hz, H-3’), 8.42 (2H, 
d, J = 8.8 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 18.0 (C-7’), 21.3 (C-7’), 
25.3 (C-6’), 56.3 (C-8’), 70.3 (C-5’), 124.1 (C-2’), 129.8 (C-3’), 146.3 (C-4’), 150.2 (C-
1’); HRMS calcd for C11H16NO5S [M+H]
+
 274.0744, found 274.0741. 
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2-((4-Nitrophenyl)sulfonyl)-2-phenylethanol (220) 
 
The title compound was synthesised following general procedure M using 2-((4-
nitrophenyl)thio)-2-phenylethanol 196 (1.52 g, 4.79 mmol) and m-CPBA (2.34 g, 10.1 
mmol). The crude product was purified by MPC on silica (petrol: EtOAc 1: 1) to give the 
product 220 as a yellow oil (1.11 g, 3.18 mmol, 66%). 
Rf 0.58 (petrol: EtOAc 1: 1); UV λmax (EtOH) 253 nm; IR (cm
-1
) 3508, 2924, 2878, 1529, 
1346, 1277, 1142, 1064; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 4.01-4.06 (1H, m, H-
10’), 4.16-4.21 (1H, m, H-10’), 4.85 (1H, t, J = 5.9 Hz, H-5’), 5.17 (1H, t, J = 5.4 Hz, 
OH), 7.34 (5H, s, H-ar), 7.99 (2H, d, J = 8.8 Hz, H-3’), 8.37 (2H, d, J = 8.8 Hz, H-2’); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 59.3 (C-10’), 70.8 (C-5’), 124.1 (C-2’), 128.3 
(2 x C-ar), 128.8 (C-6’), 130.2 (2 x C-ar), 130.3 (C-3’), 130.8 (C-ar), 144.3 (C-4’), 150.3 
(C-1’); HRMS calcd for C14H12NO5S [M-H]
-
 306.0442, found 306.0437. 
1-(2-((4-Nitrophenyl)sulfonyl)butyl)pyrrolidine (221) 
 
The title compound was synthesised following general procedure Q using 2-((4-
aminophenyl)sulfonyl)butan-1-ol 218 (1.00 g, 3.86 mmol), Et3N (1.07 mL, 7.72 mmol), 
benzenesulfonyl chloride (0.98 mL, 7.72 mmol) and pyrrolidine (1.61 mL, 19.3 mmol). 
The crude product was purified by MPC on silica (petrol: EtOAc 7: 3) to give the product 
221 as a yellow oil (900 mg, 2.88 mmol, 75%). 
Rf 0.20 (petrol: EtOAc 3: 2); UV λmax (EtOH) 249 nm; IR (cm
-1
) 2965, 2877, 1529, 1349, 
1297, 1144; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.05 (3H, t, J = 7.5 Hz, H-7’), 1.25-
1.31 (2H, m, H-pyr), 1.34-1.41 (2H, m, H-pyr), 1.65-1.72 (1H, m, H-6’), 1.92-2.00 (1H, 
m, H-6’), 2.16-2.20 (4H, m, H-pyr), 2.56 (1H, dd, J = 13.0 and 5.5 Hz, H-8’), 2.80 (1H, 
dd, J = 13.0 and 8.3 Hz, H-8’), 3.59-3.64 (1H, m, H-5’), 8.16 (2H, d, J = 8.9 Hz, H-3’), 
8.40 (2H, d, J = 8.9 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 11.0 (C-7’), 
19.1 (C-6’), 22.9 (2 x C-pyr), 52.8 (2 x C-pyr), 53.4 (C-8’), 62.8 (C-5’), 123.8 (C-2’), 
 280 
129.5 (C-3’), 146.1 (C-4’), 150.0 (C-1’); HRMS calcd for C14H21N2O4S [M+H]
+
 
312.1217, found 312.1214. 
1-(3-Methyl-2-((4-nitrophenyl)sulfonyl)butyl)pyrrolidine (222) 
 
The title compound was synthesised following general procedure Q using 3-methyl-2-
((4-nitrophenyl)sulfonyl)butan-1-ol 219 (287 mg, 1.05 mmol), Et3N (0.22 mL, 1.58 
mmol), benzenesulfonyl chloride (0.20 mL, 1.58 mmol) and pyrrolidine (0.44 mL, 5.26 
mmol). The crude product was purified by MPC on silica (petrol: EtOAc 3: 2) to give the 
product 222 as a yellow oil (223 mg, 0.68 mmol, 65%). 
Rf 0.52 (petrol: EtOAc 3: 2); UV λmax (EtOH) 228 nm; IR (cm
-1
) 2965, 2875, 1528, 1345, 
1305; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.04 (3H, t, J = 7.0 Hz, H-7’), 1.10 (3H, t, 
J = 7.0 Hz, H-7’), 1.13-1.17 (2H, m, H-pyr), 1.26-1.32 (2H, m, H-pyr), 2.10-2.12 (4H, m, 
H-pyr), 2.53-2.55 (1H, m, H-8’), 2.65-2.70 (1H, m, H-6’), 3.01 (1H, dd, J = 13.3 and 10.2 
Hz, H-8’), 3.61-3.63 (1H, m, H-5’), 8.15 (2H, d, J = 8.9 Hz, H-3’), 8.37 (2H, d, J = 8.9 
Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 17.3 (C-7’), 21.1 (C-7’), 22.8 (2 x 
C-pyr), 25.2 (C-6’), 49.8 (C-8’), 52.3 (2 x C-pyr), 65.8 (C-5’), 123.8 (C-2’), 129.1 (C-3’), 
147.7 (C-4’), 149.7 (C-1’); HRMS calcd for C15H23N2O4S [M+H]
+
 327.1373, found 
327.1367. 
1-(2-((4-Nitrophenyl)sulfonyl)-2-phenylethyl)pyrrolidine (223) 
 
The title compound was synthesised following general procedure Q using 2-((4-
nitrophenyl)sulfonyl)-2-phenylethanol 220 (1.11 g, 3.18 mmol), Et3N (0.66 mL, 4.77 
mmol), benzenesulfonyl chloride (0.61 mL, 4.77 mmol) and pyrrolidine (1.33 mL, 15.9 
mmol). The crude product was purified by MPC on silica (petrol: EtOAc 3: 2) to give the 
product 223 as a yellow oil (780 mg, 1.94 mmol, 61%). 
Rf 0.27 (petrol: EtOAc 3: 2); UV λmax (EtOH) 251 nm; IR (cm
-1
) 2939, 2793, 1524, 1348, 
1295, 1138; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.34-1.43 (4H, m, H-pyr), 2.23-2.32 
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(4H, m, H-pyr), 3.03 (1H, dd, J = 12.7 and 7.4 Hz, H-10’), 3.31 (1H, dd, J = 12.7 and 7.4 
Hz, H-10’), 5.02 (1H, t, J = 7.4 Hz, H-5’),7.34-7.35 (3H, m, H-ar), 7.39-7.41 (2H, m, H-
ar), 8.05 (2H, d, J = 8.8 Hz, H-3’), 8.37 (2H, d, J = 8.8 Hz, H-2’); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 22.9 (C-pyr), 53.5 (C-pyr), 54.0 (C-10’), 67.5 (C-5’), 123.8 (C-2’), 
128.3 (2 x C-ar), 128.8 (C-6’), 129.8 (2 x C-ar), 130.2 (C-3’), 131.4 (C-ar), 145.0 (C-4’), 
150.1 (C-1’); HRMS calcd for C18H21N2O4S [M+H]
+
 361.1217, found 361.1209. 
4-((1-(Pyrrolidin-1-yl)butan-2-yl)sulfonyl)aniline (224) 
 
The title compound was synthesised following general procedure H using 1-(2-((4-
nitrophenyl)sulfonyl)butyl)pyrrolidine 221 (900 mg, 2.88 mmol) and zinc powder (1.87 g, 
28.9 mmol). The crude product was purified by MPC on silica (DCM: MeOH 9: 1) to 
give the product 224 as a colourless oil (606 mg, 2.15 mmol, 75%). 
Rf 0.17 (DCM: MeOH 9: 1); UV λmax (EtOH) 269 nm; IR (cm
-1
) 3466, 3375, 2964, 2935, 
1638, 1594, 1326, 1280, 1127; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 0.97 (3H, t, J = 
7.5 Hz, H-7’), 1.58-1.59 (4H, m, H-pyr), 1.64-1.70 (1H, m, H-6’), 1.73-1.79 (1H, m, H-
6’), 2.22-2.25 (2H, m, H-pyr), 2.37-2.39 (2H, m, H-pyr), 2.52 (1H, dd, J = 12.4 and 4.5 
Hz, H-8’), 2.60 (1H, dd, J = 12.4 and 9.0 Hz, H-8’), 3.02-3.07 (1H, m, H-5’), 6.11 (2H, s, 
NH2), 6.64 (2H, d, J = 8.7 Hz, H-3’), 7.44 (2H, d, J = 8.7 Hz, H-2’); 
13
C NMR (125 MHz, 
DMSO-d6) (ppm) δ 11.3 (C-7’), 20.2 (C-6’), 23.1 (2 x C-pyr), 53.5 (2 x C-pyr), 53.8 (C-
8’), 63.6 (C-5’), 112.5 (C-3’), 122.9 (C-4’), 130.2 (C-2’), 153.5 (C-1’); HRMS calcd for 
C14H23N2O2S [M+H]
+
 283.1475, found 283.1472. 
4-((3-Methyl-1-(pyrrolidin-1-yl)butan-2-yl)sulfonyl)aniline (225) 
 
The title compound was synthesised following general procedure H using 1-(3-methyl-
2-((4-nitrophenyl)sulfonyl)butyl)pyrrolidine 222 (220 mg, 0.67 mmol) and zinc powder 
(439 mg, 6.75 mmol). The crude product was purified by MPC on silica (DCM: MeOH 9: 
1) to give the product 225 as a colourless oil (150 mg, 0.51 mmol, 76%). 
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Rf 0.33 (DCM: MeOH 9: 1); UV λmax (EtOH) 270 nm; IR (cm
-1
) 3432, 1491, 1291; 
1
H 
NMR (500 MHz, DMSO d6) (ppm) δ 0.98 (3H, t, J = 7.0 Hz, H-7’), 1.05 (3H, t, J = 7.0 
Hz, H-7’), 1.52-1.54 (4H, m, H-pyr), 2.14-2.16 (2H, m, H-pyr), 2.27-2.29 (2H, m, H-pyr), 
2.44-2.48 (1H, m, H-6’), 2.61 (1H, dd, J = 13.0 and5.6 Hz, H-8’), 2.71 (1H, dd, J = 13.0 
and 8.4 Hz, H-8’), 3.08-3.10 (1H, m, H-5’), 6.06 (2H, s, NH2), 6.61 (2H, d, J = 8.7 Hz, 
H-3’), 7.45 (2H, d, J = 8.7 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 17.5 (C-
7’), 21.2 (C-7’), 23.0 (2 x C-pyr), 26.2 (C-6’), 50.7 (C-8’), 53.1 (2 x C-pyr), 66.4 (C-5’), 
112.3 (C-3’), 124.5 (C-4’), 128.3 (C-1’), 130.0 (C-2’); HRMS calcd for C15H25N2O2S 
[M+H]
+
 297.1631, found 297.1626. 
4-((1-Phenyl-2-(pyrrolidin-1-yl)ethyl)sulfonyl)aniline (226) 
 
The title compound was synthesised following general procedure H using 1-(2-((4-
nitrophenyl)sulfonyl)-2-phenylethyl)pyrrolidine 223 (780 mg, 1.94 mmol) and zinc 
powder (1.26 g, 19.4 mmol). The crude product was purified by MPC on silica (DCM: 
MeOH 9: 1) to give the product 226 as a pale orange oil (650 mg, 1.75 mmol, 90%). 
Rf 0.36 (DCM: MeOH 9: 1); UV λmax (EtOH) 274 nm; IR (cm
-1
) 3379, 2967, 2853, 1593, 
1282, 1137; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.50-1.52 (4H, m, H-pyr), 2.20-2.24 
(2H, m, H-pyr), 2.34-2.37 (2H, m, H-pyr), 3.00 (1H, dd, J = 12.3 and 3.8 Hz, H-10’), 
3.20 (1H, dd, J = 12.3 and 1.7 Hz, H-10’), 4.44 (1H, dd, J = 10.4 and 3.8 Hz, H-5’), 6.09 
(2H, s, NH2), 6.51 (2H, d, J = 8.7 Hz, H-3’), 7.20 (2H, d, J = 8.7 Hz, H-2’); 
13
C NMR 
(125 MHz, DMSO-d6) (ppm) δ 22.9 (2 x C-pyr), 53.5 (2 x C-pyr), 54.0 (C-10’), 68.9 (C-
5’), 112.3 (C-3’), 122.2 (C-6’), 127.8 (C-2’), 128.0 (C-ar), 129.9 (2 x C-ar), 130.4 (2 x C-
ar), 133.2 (C-4’), 153.5 (C-1’); HRMS calcd for C18H23N2O2S [M+H]
+
 331.1475, found 
331.1466. 
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(4-Nitrophenyl)(1-phenylvinyl)sulfane (229) 
 
2-((4-Nitrophenyl)thio)-2-phenylethanol 196 (100 mg, 0.32 mmol) was solubilised in dry 
DCM (5 mL) under N2. Et3N (0.05 mL, 0.35 mmol) and benzenesulfonyl chloride (0.05 
mL, 0.35 mmol) were added to the solution. The reaction was stirred at r.t. for 2 h. 
Pyrrolidine (0.13 mL, 1.58 mmol) was then added and the reaction was stirred for 30 min 
at r.t. The resulting mixture was washed with Brine (3 x 30 mL). The organic layer was 
dried over MgSO4 and the solvent was removed in vacuo. The crude product was purified 
by MPC on silica (petrol: EtOAc 9: 1) to give the product 229 as a yellow oil (70 mg, 
0.22 mmol, 74%). 
Rf 0.55 (petrol: EtOAc 9: 1); UV λmax (EtOH) 380 nm; IR (cm
-1
) 1675, 1577, 1506, 1334, 
1090; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 5.99 (1H, s, H-10’), 6.28 (1H, s, H-10’), 
7.33-7.38 (3H, m, H-ar), 7.42 (2H, d, J = 9.0 Hz, H-3’), 7.68 (2H, d, J = 6.6 Hz, H-ar), 
8.09 (2H, d, J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 124.1 (C-2’), 
125.3 (C-10’), 126.9 (2 x C-ar), 128.1 (C-3’), 128.7 (2 x C-ar), 129.0 (C-ar), 136.9 (Cq), 
138.7 (Cq), 144.9 (Cq), 145.3 (Cq); HRMS calcd for C14H12NO2S [M+H]
+
 258.0583, 
found 258.0583. 
6-(Cyclohexylmethoxy)-N-(4-((1-(pyrrolidin-1-yl)butan-2-yl)sulfonyl)phenyl)-9H-
purin-2-amine (230) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (406 mg, 1.28 mmol), 
4-((1-(pyrrolidin-1-yl)butan-2-yl)sulfonyl)aniline 224 (200 mg, 1.06 mmol), K2CO3 (195 
mg, 2.13 mmol), Pd(dba)2 (13 mg, 0.02 mmol) and XPhos (7 mg, 0.02 mmol). The crude 
mixture was then filtered through Celite and the solvent was removed in vacuo. The 
crude mixture was then solubilised in TFA (15 mL). The resulting solution was heated at 
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70 °C for 2 h. Then the solvent was removed in vacuo. The product was purified by MPC 
(DCM: MeOH 9: 1) to give the product 230 as a yellow oil (190 mg, 0.37 mmol, 35%). 
Rf 0.54 (DCM: MeOH 9: 1); UV λmax (EtOH) 315 nm; IR (cm
-1
) 2926, 2852, 1673, 1593, 
1450, 1386, 1128; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 0.96 (3H, t, J = 7.5 Hz, H-7’), 
1.07-1.15 (2H, m, H-cyclo), 1.19-1.21 (1H, m, H-cyclo), 1.24-1.32 (2H, m, H-cyclo), 
1.53-1.60 (1H, m, H-6’), 1.67-1.76 (4H, m, H-cyclo and H-6’), 1.85-1.91 (5H, m, H-
cyclo, H-pyr, H-2’’), 1.98-2.05 (2H, m, H-pyr), 2.97-3.03 (1H, m, H-pyr), 3.13-3.18 (1H, 
m, H-pyr), 3.48-3.52 (1H, m, H-8’), 3.58-3.61 (1H, m, H-8’), 3.68-3.74 (3H, m, H-pyr 
and H-5’), 4.38 (2H, d, J = 6.4 Hz, H-1’’), 7.83 (2H, d, J = 9.0 Hz, H-3’), 8.14 (2H, d, J = 
9.0 Hz, H-2’), 8.10 (1H, s, H-8), 9.48 (1H, br s, NH), 10.05 (1H, br s, N9H); 13C NMR 
(125 MHz, DMSO-d6) (ppm) δ 10.3 (C-7’), 21.0 (C-6’), 22.4 (2 x C-pyr), 25.2 (2 x C-
cyclo), 22.5 (C-pyr), 26.0 (C-cyclo), 29.2 (2 x C-cyclo), 36.8 (C-2’’), 51.5 (C-8’), 54.5 
(C-pyr), 54.6 (C-pyr), 60.9 (C-5’), 71.7 (C-1’’), 117.3 (C-2’), 126.1 (Cq), 129.9 (C-3’), 
146.8 (Cq), 154.3 (Cq); HRMS calcd for C26H37N6O3S [M+H]
+
 513.2642, found 513.2630. 
Note: Four quaternary carbons were not visible on the 
13
C NMR spectrum. 
6-(Cyclohexylmethoxy)-N-(4-((3-methyl-1-(pyrrolidin-1-yl)butan-2-yl)sulfonyl) 
phenyl)-9H-purin-2-amine (231) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (385 mg, 0.81 mmol), 
4-((3-methyl-1-(pyrrolidin-1-yl)butan-2-yl)sulfonyl)aniline 225 (200 mg, 0.68 mmol), 
K2CO3 (185 mg, 1.34 mmol), Pd(dba)2 (13 mg, 0.02 mmol) and XPhos (7 mg, 0.02 
mmol). The crude mixture was then filtered through Celite and the solvent was removed 
in vacuo. The crude mixture was then solubilised in TFA (15 mL). The resulting solution 
was heated at 70 °C for 2 h. Then the solvent was removed in vacuo. The product was 
purified by MPC (DCM: MeOH 9: 1) to give the product 231 as a brown oil (75 mg, 0.14 
mmol, 18%). 
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Rf 0.49 (DCM: MeOH 9: 1); UV λmax (EtOH) 316 nm; IR (cm
-1
) 3378, 2967, 2885, 1596, 
1495, 1248, 1124; 
1
H NMR (500 MHz, MeOD) (ppm) δ 0.00 (3H, t, J = 7.0 Hz, H-7’), 
0.05 (3H, t, J = 7.0 Hz, H-7’), 0.18-0.25 (2H, m, H-cyclo), 0.30-0.33 (1H, m, H-cyclo), 
0.35-0.42 (2H, m, H-cyclo), 0.75-0.78 (1H, m, H-cyclo), 0.83-0.85 (2H, m, H-cyclo), 
0.97-0.99 (3H, m, H-cyclo and H-2’’), 1.04-1.09 (1H, m, H-6’), 1.14-1.19 (2H, m, H-pyr), 
1.22-1.29 (2H, m, H-pyr), 2.17-2.21 (1H, m, H-pyr), 2.27-2.31 (1H, m, H-pyr), 2.58-2.59 
(1H, m, H-8’), 2.66-2.67 (1H, m, H-8’), 2.87-2.93 (1H, m, H-pyr), 2.97-3.05 (2H, m, H-
pyr and H-5’), 3.45 (2H, d, J = 6.1 Hz, H-1’’), 6.92 (2H, d, J = 9.0 Hz, H-3’), 7.18-7.21 
(3H, m, H-2’ and H-8); 13C NMR (125 MHz, MeOD) (ppm) δ 13.4 (C-7’), 18.4 (C-7’), 
21.2 (2 x C-pyr), 24.2 (2 x C-cyclo), 24.8 (C-cyclo), 26.0 (C-6’), 28.0 (2 x C-cyclo), 36.0 
(C-2’’), 48.6 (2 x C-pyr), 63.5 (C-8’), 65.1 (C-5’), 70.7 (C-1’’), 116.3 (C-2’), 125.2 (Cq), 
128.6 (C-3’), 134.6 (Cq), 135.4 (Cq), 136.4 (Cq), 145.9 (Cq), 154.0 (Cq), 158.6 (Cq); 
HRMS calcd for C27H39N6O3S [M+H]
+
 527.2799, found 527.2800. 
6-(Cyclohexylmethoxy)-N-(4-((1-phenyl-2-(pyrrolidin-1-yl)ethyl)sulfonyl) phenyl)-
9H-purin-2-amine (232) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (385 mg, 0.81 mmol), 
4-((1-phenyl-2-(pyrrolidin-1-yl)ethyl)sulfonyl)aniline 226 (250 mg, 0.67 mmol), K2CO3 
(185 mg, 1.34 mmol), Pd(dba)2 (13 mg, 0.02 mmol) and XPhos (7 mg, 0.02 mmol). The 
crude mixture was then filtered through Celite and the solvent was removed in vacuo. 
The crude mixture was then solubilised in TFA (15 mL). The resulting solution was 
heated at 70 °C for 2 h. Then the solvent was removed in vacuo. The product was 
purified by MPC (DCM: MeOH 9: 1) to give the product 232 as a brown oil (180 mg, 
0.32 mmol, 47%). 
Rf 0.60 (DCM: MeOH 9: 1); UV λmax (EtOH) 318 nm; IR (cm
-1
) 2926, 2851, 1671, 1594, 
1449, 1389, 1199; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.06-1.14 (2H, m, H-cyclo), 
1.18-1.22 (1H, m, H-cyclo), 1.24-1.33 (2H, m, H-cyclo), 1.67-1.70 (1H, m, H-cyclo), 
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1.73-1.79 (4H, m, H-cyclo and H-pyr), 1.83-1.89 (3H, m, H-cyclo and H-2’’), 1.94-2.01 
(2H, m, H-pyr), 3.00-3.04 (1H, m, H-pyr), 3.08-3.13 (1H, m, H-pyr), 3.36-3.41 (1H, m, 
H-pyr), 3.54-3.59 (1H, m, H-pyr), 4.02-4.06 (1H, m, H-10’), 4.13-4.18 (1H, m, H-10’), 
4.35 (2H, d, J = 6.3 Hz, H-1’’), 5.01-5.04 (1H, m, H-5’), 7.30 (2H, d, J = 7.1 Hz, H-ar), 
7.34-7.41 (5H, m, H-ar and H-3’), 7.95 (2H, d, J = 8.9 Hz, H-2’), 8.15 (1H, s, H-8), 9.47 
(1H, br s, NH), 9.98 (1H, br s, N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 22.2 (C-
pyr), 22.5 (C-pyr), 25.2 (2 x C-cyclo), 26.0 (C-cyclo), 29.2 (2 x C-cyclo), 36.8 (C-2’’), 
51.6 (C-10’), 52.5 (C-pyr), 54.0 (C-pyr), 65.9 (C-5’), 71.4 (C-1’’), 116.7 (C-2’), 125.6 
(Cq), 128.5 (C-3’), 128.8 (Cq), 129.4 (C-ar), 129.9 (2 x C-ar), 130.2 (2 x C-ar), 137.5 (C-
8), 141.1 (Cq), 145.2 (Cq), 146.3 (Cq), 153.2 (Cq), 154.9 (Cq); HRMS calcd for 
C30H37N6O3S [M+H]
+
 561.2642, found 561.2645. 
2-((4-Aminophenyl)sulfonyl)-3,3-dimethylbutan-1-ol (233) 
 
The title compound was synthesised following general procedure H using 3,3-dimethyl-
2-((4-nitrophenyl)sulfonyl)butan-1-ol 253 (130 mg, 0.45 mmol) and zinc powder (2.35, 
3.62 mmol). The crude product was purified by MPC on silica (petrol: EtOAC 3: 2) to 
give the product 233 as an orange oil (98 mg, 0.38 mmol, 84%). 
Rf 0.49 (petrol: EtOAc 1: 1); UV λmax (EtOH) 268 nm; IR (cm
-1
) 3494, 3450, 3353, 2966, 
2912, 1599, 1476, 1273, 1131; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.16 (9H, s, H-
7’), 2.87 (1H, dd, J = 4.5 and 4.5 Hz, H-5’), 3.65 (1H, ddd, J = 4.5, 4.5 and 7.9 Hz, H-8’), 
3.72 (1H, ddd, J = 4.5, 4.5 and 7.9 Hz, H-8’), 4.52 (1H, dd, J = 4.5 and 4.5 Hz, OH), 6.10 
(2H, s, NH2), 6.63 (2H, d, J = 8.6 Hz, H-3’), 7.45 (2H, d, J = 8.6 Hz, H-2’); 
13
C NMR 
(125 MHz, DMSO-d6) (ppm) δ 29.4 (C-7’), 34.8 (C-6’), 58.3 (C-8’), 75.0 (C-5’), 113.1 
(C-3’), 126.3 (C-4’), 130.4 (C-2’), 153.7 (C-1’); HRMS calcd for C12H18NO3S [M-H]
-
 
256.1013, found 256.1003. 
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Ethyl 2-((4-nitrophenyl)thio)acetate (236)
264
 
 
The title compound was synthesised following general procedure J using ethyl 
chloroacetate (1.51 mL, 14.2 mmol), 4-nitrothiophenol 173 (2.00 g, 12.9 mmol) and Et3N 
(1.97 mL, 14.2 mmol). The crude product was purified by MPC on silica (petrol: EtOAc 
4: 1) to give the product 236 as a yellow solid (2.95 g, 12.3 mmol, 95%). 
Rf 0.46 (petrol: EtOAc 4: 1); Mp = 48-50 °C (lit.,
265
 Mp = 46-47 °C); UV λmax (EtOH) 
340 nm; IR (cm
-1
) 1722, 1502, 1330, 1165; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.18 
(3H, t, J = 7.1 Hz, H-7’), 4.13 (2H, q, J = 7.1 Hz, H-6’), 4.16 (2H, s, H-5’), 7.53 (2H, d, J 
= 9.0 Hz, H-3’), 8.14 (2H, d, J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 
13.9 (C-7’), 33.3 (C-5’), 61.3 (C-6’), 123.9 (C-2’), 126.4 (C-3’), 144.8 (C-4’), 146.1 (C-
1’), 168.6 (CO); HRMS calcd for C10H10NO4S [M-H]
-
 240.0336, found 240.0336. 
Ethyl 2-((4-nitrophenyl)sulfonyl)acetate (237)
266
 
 
The title compound was synthesised following general procedure M using ethyl 2-((4-
nitrophenyl)thio)acetate 236 (2.90 g, 12.1 mmol) and m-CPBA (5.62 g, 24.2 mmol). The 
crude product was purified by MPC on silica (petrol: EtOAc 4: 1) to give the product 237 
as a pale yellow oil (2.84 g, 10.4 mmol, 86%). 
Rf 0.40 (petrol: EtOAc 4: 1); UV λmax (EtOH) 250 nm; IR (cm
-1
) 2910, 1738, 1534, 1300, 
1201, 1134; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.08 (3H, t, J = 7.1 Hz, H-7’), 4.06 
(2H, q, J = 7.1 Hz, H-6’), 4.88 (2H, s, H-5’), 8.22 (2H, d, J = 8.7 Hz, H-3’), 8.48 (2H, d, 
J = 8.7 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 13.7 (C-7’), 59.1 (C-5’), 61.7 
(C-6’), 124.4 (C-2’), 130.0 (C-3’), 144.2 (C-4’), 150.6 (C-1’), 162.4 (CO); HRMS calcd 
for C10H10NO6S [M-H]
-
 272.0234, found 272.0232. 
  
 288 
3,3-Dimethyl-2-oxobutyl benzoate (246b) 
 
To a solution of benzoic acid (1.00 g, 8.20 mmol) in dry DMF (50 mL), under N2, was 
added 1-chloropinacolone 247 (2.14 mL, 16.4 mmol) and diisopropylamine (7.12 mL, 
41.0 mmol). The reaction was stirred at r.t. for 2 h. Brine (100 mL) was added and the 
reaction mixture was extracted with EtOAc (3 x 100 mL). The organic layers were 
combined and dried over MgSO4. The solvent was removed in vacuo and the product was 
purified by MPC (petrol: EtOAc 9: 1) to give the product 246b as a white solid (1.20 g, 
5.45 mmol, 67%). 
Rf 0.63 (petrol: EtOAc 4: 1); Mp = 74-75 
o
C; UV λmax (EtOH) 273 nm; IR (cm
-1
) 2967, 
2846, 1714, 1598, 1256, 1062; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.18 (9H, s, 
t
Bu), 
5.29 (2H, s, H-2’), 7.57 (2H, dd, J = 7.8 and 8.2 Hz, H-ar), 7.70 (1H, dd, J = 8.2 and 8.2 
Hz, H-ar), 8.00 (2H, d, J = 7.8 Hz, H-ar); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 25.7 
(
t
Bu), 42.2 (C), 65.5 (C-2’), 128.8 (2 x C-ar), 129.2 (2 x C-ar), 133.5 (C-ar), 165.1 (CO), 
208.0 (C-1’); HRMS calcd for C13H17O3 [M+H]
+
 221.1172, found 221.1169. 
Note: One quaternary carbon was not visible on the 
13
C NMR spectrum. 
3,3-Dimethyl-2-((4-nitrophenyl)sulfonyl)butanoic acid (249) 
 
LHMDS (1M in THF, 2.33 mL, 2.33 mmol) was added to a stirred solution of 1-
(neopentylsulfonyl)-4-nitrobenzene 250 (500 mg, 1.95 mmol) in dry THF (10 mL) at -
78 °C, under N2. The solution was stirred at -78 °C for 1 h then dry ice was added. The 
solution was allowed to warm up to r.t. and the reaction was stirred for 30 min at r.t. 
Water (15 mL) and EtOAc (15 mL) were added and the organic phase was washed with 
water (3 x 20 mL). The aqueous phase was acidified to pH 1 with 2M HCl solution and 
the organic phase was extracted with EtOAc (3 x 40 mL). The organic layers were 
combined and dried over MgSO4 and the solvent was removed in vacuo to afford the 
product 249 as a pale yellow oil (290 mg, 0.10 mmol, 49%). No purification was 
performed.  
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Rf 0.45 (petrol: EtOAc 1: 4); UV λmax (EtOH) 252 nm; IR (cm
-1
) 3109, 2967, 2871, 1720, 
1530, 1334, 1148; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.21 (9H, s, H-7’), 4.42 (2H, 
s, H-5’), 8.17 (2H, d, J = 8.8 Hz, H-3’), 8.44 (2H, d, J = 8.8 Hz, H-2’), 13.30 (1 H, br s, 
OH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 28.4 (C-7’), 33.6 (C-6’), 77.3 (C-5’), 
124.4 (C-2’), 130.2 (C-3’), 145.2 (C-4’), 150.5 (C-1’), 165.5 (CO); HRMS calcd for 
C12H16NO6S [M+H]
+
 302.0693, found 302.0692. 
1-(Neopentylsulfonyl)-4-nitrobenzene (250) 
 
The title compound was synthesised following general procedure M using neopentyl(4-
nitrophenyl)sulfane 252 (1.14 g, 5.07 mmol) and m-CPBA (2.26 g, 10.13 mmol). The 
crude product was purified by MPC on silica (petrol: EtOAc 4: 1) to give the product 250 
as a white solid (1.12 g, 4.36 mmol, 86%). 
Rf 0.55 (petrol: EtOAc 7: 3); Mp = 124-126 
o
C; UV λmax (EtOH) 251 nm; IR (cm
-1
) 2964, 
2871, 1529, 1346, 1294; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.11 (9H, s, H-7’), 3.43 
(2H, s, H-5’), 8.21 (2H, d, J = 8.6 Hz, H-3’), 8.46 (2H, d, J = 8.6 Hz, H-2’); 13C NMR 
(125 MHz, DMSO-d6) (ppm) δ 29.4 (C-7’), 32.2 (C-6’), 64.9 (C-5’), 124.6 (C-2’), 129.0 
(C-3’), 146.8 (C-4’), 150.3 (C-1’); HRMS calcd for C11H14NO4S [M-H]
-
 256.0638, found 
256.0636. 
Neopentyl(4-nitrophenyl)sulfane (252) 
 
1-Iodo-2,2-dimethylpropane 251 (1.28 mL, 9.68 mmol) was added to a stirred solution of 
4-nitrothiophenol 173 (1.00 g, 6.45 mmol) and K2CO3 (1.34 g, 9.68 mmol) in anhydrous 
DMF (7 mL) under N2. The resulting solution was stirred at r.t. for 18 h. After 
completion, brine (20 mL) was added and the organic phase was extracted with EtOAc (3 
x 20 mL). The organic layers were combined and dried over MgSO4. The solvent was 
removed in vacuo and the crude product was purified by MPC on silica (petrol: EtOAc 19: 
1) to give the product 252 as a yellow oil (0.99 g, 4.40 mmol, 68%). 
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Rf 0.70 (petrol: EtOAc 9: 1); UV λmax (EtOH) 342 nm; IR (cm
-1
) 2958, 1573, 1503, 1330; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.04 (9H, s, H-7’), 3.08 (2H, s, H-5’), 7.55 (2H, 
d, J = 9.0 Hz, H-3’), 8.12 (2H, d, J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) 
(ppm) δ 28.6 (C-7’), 31.8 (C-6’), 44.7 (C-5’), 123.8 (C-2’), 126.4 (C-3’), 144.1 (C-4’), 
148.5 (C-1’); HRMS calcd for C11H16NO2S [M+H]
+
 226.0896, found 226.0892. 
3,3-Dimethyl-2-((4-nitrophenyl)sulfonyl)butan-1-ol (253) 
 
The title compound was synthesised following general procedure L using 3,3-dimethyl-
2-((4-nitrophenyl)sulfonyl)butanoic acid 249 (400 mg, 1.33 mmol) and 1M Borane in 
complex with THF (6.00 mL, 5.98 mmol). The crude product was purified by MPC on 
silica (petrol: EtOAc 7: 3) to give the product 253 as a yellow oil (525 mg, 1.83 mmol, 
73%). 
Rf 0.73 (petrol: EtOAc 1: 1); UV λmax (EtOH) 254 nm; IR (cm
-1
) 3513, 2966, 2880, 1532, 
1345, 1290, 1132; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.22 (9H, s, H-7’), 3.33-3.35 
(2H, m, H-5’), 3.70 (1H, ddd, J = 4.2, 4.2 and 8.1 Hz, H-8’), 3.76 (1H, ddd, J = 4.2, 4.2 
and 8.1 Hz, H-8’), 4.68 (1H, dd, J = 4.2 and 4.2 Hz, OH), 8.15 (2H, d, J = 8.7 Hz, H-3’), 
8.43 (2H, d, J = 8.7 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 29.3 (C-7’), 
35.3 (C-6’), 58.1 (C-8’), 74.8 (C-5’), 124.6 (C-2’), 130.2 (C-3’), 147.7 (C-4’), 150.5 (C-
1’); HRMS calcd for C12H16NO5S [M-H]
-
 286.0744, found 286.0742. 
2-((4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)-3,3-
dimethylbutan-1-ol (254) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (112 mg, 0.23 mmol), 
2-((4-aminophenyl)sulfonyl)-3,3-dimethylbutan-1-ol 233 (90 mg, 0.35 mmol), K2CO3 (65 
mg, 0.47 mmol), Pd(dba)2 (21 mg, 0.02 mmol) and XPhos (12 mg, 0.02 mmol). The 
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crude mixture was then filtered through Celite and the solvent was removed in vacuo. 
The crude mixture was then solubilised in TFA (7 mL). The resulting solution was heated 
at 70 °C for 2 h and the solvent was removed in vacuo. The product was purified by MPC 
(petrol: EtOAc 1: 9) to give the product 254 as a pale yellow oil (63 mg, 0.13 mmol, 
55%). 
Rf 0.20 (EtOAc 100); UV λmax (EtOH) 314 nm; IR (cm
-1
) 3309, 3169, 2925, 2852, 1575, 
1501, 1334, 1270, 1120; 
1H NMR (500 MHz, MeOD) (ppm) δ 1.14-1.21 (2H, m, H-
cyclo), 1.24-1.30 (10H, m, H-cyclo and H-7’), 1.32-1.39 (2H, m, H-cyclo), 1.73-1.75 (1H, 
m, H-cyclo), 1.80-1.83 (2H, m, H-cyclo), 1.94-1.96 (3H, m, H-cyclo and H-2’’), 3.09 (1H, 
dd, J = 4.0 and 4.0 Hz, H-5’), 3.89 (1H, dd, J = 4.0 and 12.9 Hz, H-8’), 3.99 (1H, dd, J = 
4.0 and 12.9 Hz, H-8’), 4.40 (2H, d, J = 6.0 Hz, H-1’’), 7.81 (2H, d, J = 8.6 Hz, H-3’), 
8.03-8.08 (3H, m, H-2’ and H-8); 13C NMR (125 MHz, MeOD) (ppm) δ 25.5 (2 x C-
cyclo), 26.2 (C-cyclo), 28.2 (C-7’), 29.4 (2 x C-cyclo), 34.5 (C-6’), 37.3 (C-2’’), 58.3 (C-
8’), 71.8 (C-1’’), 75.2 (C-5’), 117.2 (C-2’), 129.0 (C-3’), 131.9 (Cq), 139.9 (C-8), 146.0 
(Cq), 155.4 (Cq), 160.0 (Cq); HRMS calcd for C24H34N5O4S [M+H]
+
 488.2326, found 
488.2312. 
Note: Two quaternary carbons were not visible on the 
13
C NMR spectrum. 
2-((4-Nitrophenyl)thio)ethanol (255)
267
 
 
KOH (400 mg, 7.14 mmol) in water (2.6 mL) and 2-chloroethanol (1.00 mL, 15.0 mmol) 
were added to a stirred solution of 4-nitrothiophenol 173 (1.00 g, 6.45 mmol) in EtOH (2 
mL). The reaction was heated at reflux for 18 h. Brine (10 mL) was added and the 
organic phase was extracted with EtOAc (3 x 10 mL). The organic layers were combined 
and dried over MgSO4. The solvent was removed in vacuo. The product was purified by 
MPC (petrol: EtOAc 3: 2) to give the product 255 as a yellow solid (1.23 mg, 6.18 mmol, 
96%). 
Rf 0.40 (petrol: EtOAc 4: 1); Mp = 59-60 °C (lit.,
267
 Mp = 57 °C); UV λmax (EtOH) 377 
nm; IR (cm
-1
) 3541, 2914, 1575, 1505, 1325, 1056; 
1
H NMR (500 MHz, DMSO-d6) (ppm) 
δ 3.21 (2H, t, J = 6.5 Hz, H-5’), 3.65 (2H, td, J = 5.5 and 6.5 Hz, H-6’), 5.08 (1H, t, J = 
5.2 Hz, OH), 7.53 (2H, d, J = 9.0 Hz, H-3’), 8.13 (2H, d, J = 9.0 Hz, H-2’); 13C NMR 
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(125 MHz, DMSO-d6) (ppm) δ 33.8 (C-5’), 59.3 (C-6’), 126.2 (C-3’), 128.9 (C-2’), 144.3 
(C-4’), 147.8 (C-1’); HRMS calcd for C8H10NO3S [M+H]
+
 199.0376, found 199.1690. 
2-((4-Nitrophenyl)sulfonyl)ethanol (256) 
 
The title compound was synthesised following general procedure M using 2-((4-
nitrophenyl)thio)ethanol 255 (1.23 g, 6.18 mmol) and m-CPBA (3.12 g, 13.60 mmol). 
The crude product was purified by MPC on silica (petrol: EtOAc 1: 1) to give the product 
256 as a white crystalline solid (1.20 g, 5.19 mmol, 84%). 
Rf 0.19 (petrol: EtOAc 4: 1); Mp = 123-125 °C (lit.,
268
 Mp = 128 °C); UV λmax (EtOH) 
251 nm; IR (cm
-1
) 3526, 3111, 2926, 1532, 1347, 1283, 1135; 
1
H NMR (500 MHz, 
DMSO-d6) (ppm) δ 3.61 (2H, t, J = 5.9 Hz, H-5’), 3.73 (2H, td, J = 5.2 and 5.9 Hz, H-6’), 
4.91 (1H, t, J = 5.2 Hz, OH), 8.18 (2H, d, J = 8.9 Hz, H-3’), 8.44 (2H, d, J = 8.9 Hz, H-
2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 55.0 (C-6’), 57.4 (C-5’), 124.4 (C-2’), 
129.5 (C-3’), 145.6 (C-4’), 150.3 (C-1’); HRMS calcd for C8H10NO5S [M+H]
+
 232.0274, 
found 232.0275. 
1-(2-((4-Nitrophenyl)sulfonyl)ethyl)pyrrolidine (257) 
 
The title compound was synthesised following general procedure Q using 2-((4-
nitrophenyl)sulfonyl)ethanol 256 (1.20 mg, 5.19 mmol), Et3N (1.08 mL, 7.79 mmol), 
benzenesulfonyl chloride (1.00 mL, 7.79 mmol) and pyrrolidine (2.16 mL, 25.97 mmol). 
The crude product was purified by MPC on silica (petrol: EtOAc 1: 1) to give the product 
257 as a yellow crystalline solid (990 mg, 3.49 mmol, 67 %). 
Rf 0.33 (petrol: EtOAc 3: 2); Mp = 126-127 °C; UV λmax (EtOH) 249 nm; IR (cm
-1
) 2930, 
2806, 1530, 1344, 1286, 1149; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.44-1.47 (4H, m, 
H-pyr), 2.25-2.27 (4H, m, H-pyr), 2.72 (2H, t, J = 6.8 Hz, H-6’), 3.65 (2H, td, J = 5.2 and 
5.9 Hz, H-5’), 8.19 (2H, d, J = 8.9 Hz, H-3’), 8.43 (2H, d, J = 8.9 Hz, H-2’); 13C NMR 
(125 MHz, DMSO-d6) (ppm) δ 22.9 (2 x C-pyr), 48.4 (C-6’), 52.7 (2 x C-pyr), 53.4 (C-
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5’), 124.4 (C-2’), 129.4 (C-3’), 145.5 (C-4’), 150.3 (C-1’); HRMS calcd for C12H17N2O4S 
[M+H]
+
 285.0904, found 285.0899. 
tert-Butyl 2-((4-nitrophenyl)thio)acetate (260) 
 
The title compound was synthesised following general procedure J using tert-butyl 
chloroacetone (1.01 mL, 7.10 mmol), 4-nitrothiophenol 173 (1.00 g, 6.46 mmol) and 
Et3N (1.00 mL, 7.10 mmol). The crude product was purified by MPC on silica (petrol: 
EtOAc 9: 1) to give the product 260 as a yellow solid (1.56 g, 5.80 mmol, 90%). 
Rf 0.77 (petrol: EtOAc 4: 1); Mp = 53-54 °C (lit.,
265
 Mp = 47-49 °C); UV λmax (EtOH) 
330 nm; IR (cm
-1
) 2988, 1720, 1504, 1338, 1301, 1153; 
1
H NMR (500 MHz, DMSO-d6) 
(ppm) δ 1.39 (9H, s, H-7’), 4.04 (2H, s, H-5’), 7.53 (2H, d, J = 9.0 Hz, H-3’), 8.17 (2H, d, 
J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 27.5 (C-7’), 34.3 (C-5’), 81.7 
(C-6’), 123.8 (C-2’), 126.5 (C-3’), 144.7 (C-4’), 146.2 (C-1’), 167.6 (CO); HRMS calcd 
for C12H14NO4S [M-H]
-
 268.0649, found 268.0648. 
tert-Butyl 2-((4-nitrophenyl)sulfonyl)acetate (261) 
 
The title compound was synthesised following general procedure M using tert-butyl 2-
((4-nitrophenyl)thio)acetate 260 (1.55 g, 5.76 mmol) and m-CPBA (2.81 g, 12.1 mmol). 
The crude product was purified by MPC on silica (petrol: EtOAc 7: 3) to give the product 
261 as a white solid (1.64 g, 5.45 mmol, 95%). 
Rf 0.73 (petrol: EtOAc 1: 1); Mp = 85-86 °C; UV λmax (EtOH) 250 nm; IR (cm
-1
) 2964, 
2885, 1738, 1540, 1305, 1262, 1142; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.27 (9H, s, 
H-7’), 4.74 (2H, s, H-5’), 8.24 (2H, d, J = 8.9 Hz, H-3’), 8.50 (2H, d, J = 8.9 Hz, H-2’); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 27.2 (C-7’), 60.3 (C-5’), 82.6 (C-6’), 124.2 (C-
2’), 129.9 (C-3’), 144.4 (C-4’), 150.6 (C-1’), 161.4 (CO); HRMS calcd for C12H14NO6S 
[M-H]
-
 300.0547, found 300.0549.  
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tert-Butyl 2-chloro-2-((4-nitrophenyl)sulfonyl)acetate (262)
220
 
 
NaH (198 mg, 4.95 mmol) was added to a stirred solution of tert-butyl 2-((4-
nitrophenyl)sulfonyl)acetate 261 (1.49 g, 4.95 mmol) in dry THF (90 mL) under N2. The 
resulting mixture was stirred at r.t. for 30 min. N-Chlorosuccinimide (658 mg, 4.95 mmol) 
was then added and the solution was stirred at r.t. for 18 h. Brine (100 mL) was added 
and the reaction was extracted with EtOAc (3 x 50 mL). The organic layer was dried over 
MgSO4 and the solvent was removed in vacuo. The crude product was purified by MPC 
on silica (petrol: EtOAc 9: 1) to give the product 262 as a pale yellow solid (1.29 g, 3.85 
mmol, 78%). 
Rf 0.47 (petrol: EtOAc 9: 1); Mp = 93-95 °C; UV λmax (EtOH) 251 nm; IR (cm
-1
) 2974, 
1720, 1531, 1347, 1297, 1146; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.37 (9H, s, H-
7’), 6.71 (1H, s, H-5’), 8.25 (2H, d, J = 8.8 Hz, H-3’), 8.54 (2H, d, J = 8.8 Hz, H-2’); 13C 
NMR (125 MHz, DMSO-d6) (ppm) δ 27.1 (C-7’), 71.6 (C-5’), 85.5 (C-6’), 124.6 (C-2’), 
131.4 (C-3’), 140.7 (C-4’), 151.3 (C-1’), 159.9 (CO); HRMS calcd for C12H13ClNO6S 
[M-H]
-
 334.0158, found 334.0150. 
1-((Chloromethyl)sulfonyl)-4-nitrobenzene (264) 
 
tert-Butyl 2-chloro-2-((4-nitrophenyl)sulfonyl)acetate 262 (100 mg, 0.30 mmol) was 
solubilised in DCM (3 mL). TFA (0.3 mL, 4.03 mmol) was then added and the resulting 
solution was stirred at r.t. for 18 h. The precipitate formed was filtered to afford 264 as a 
white solid (68 mg, 0.29 mmol, 96%). 
OR 
The title compound was synthesised following general procedure K using ethyl 2-
chloro-2-((4-nitrophenyl)sulfonyl)acetate 265 (900 mg, 2.93 mmol) and LiOH (2M in 
THF, 14.6 mL). The product 264 was obtained without further purification as an orange 
oil (610 mg, 2.60 mmol, 88%). 
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Rf 0.53 (petrol: EtOAc 7: 3); Mp = 123-125 °C (lit.,
269
 Mp = 129-130 °C); UV λmax 
(EtOH) 250 nm; IR (cm
-1
) 2957, 1526, 1349, 1282, 1188; 
1
H NMR (500 MHz, DMSO-d6) 
(ppm) δ 5.52 (2H, s, H-5’), 8.24 (2H, d, J = 8.9 Hz, H-3’), 8.51 (2H, d, J = 8.9 Hz, H-2’); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 57.1 (C-5’), 124.6 (C-2’), 130.7 (C-3’), 141.1 
(C-4’), 151.0 (C-1’q); HRMS calcd for C7H5ClNO4S [M-H]
-
 233.9633, found 233.9632. 
Ethyl 2-chloro-2-((4-nitrophenyl)sulfonyl)acetate (265) 
 
NaH (417 mg, 10.44 mmol) was added to a stirred solution of ethyl 2-((4-
nitrophenyl)sulfonyl)acetate 237 (2.84 g, 10.4 mmol) in dry THF (100 mL) under N2. The 
resulting mixture was stirred at r.t. for 30 min. N-Chlorosuccinimide (1.38 g, 10.4 mmol) 
was then added and the solution was stirred at r.t. for 18 h. Brine (100 mL) was added 
and the reaction was extracted with EtOAc (3 x 50 mL). The organic layer was dried over 
MgSO4 and the solvent was removed in vacuo. The crude product was purified by MPC 
on silica (petrol: EtOAc 4: 1) to give the product 265 as a yellow oil (2.10 g, 6.84 mmol, 
66%). 
Rf 0.47 (petrol: EtOAc 4: 1); UV λmax (EtOH) 249 nm; IR (cm
-1
) 2966, 1738, 1532, 1346, 
1300, 1134; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.15 (3H, t, J = 7.1 Hz, H-7’), 4.22 
(2H, q, J = 7.1 Hz, H-6’), 6.84 (1H, s, H-5’), 8.23 (2H, d, J = 9.0 Hz, H-3’), 8.52 (2H, d, 
J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 13.6 (C-7’), 63.8 (C-6’), 70.5 
(C-5’), 124.5 (C-2’), 131.6 (C-3’), 140.2 (C-4’), 151.4 (C-1’), 161.2 (CO); HRMS calcd 
for C10H9ClNO6S [M-H]
-
 305.9845, found 305.9843. 
2-Chloro-2-((4-nitrophenyl)sulfonyl)ethanol (266) 
 
The title compound was synthesised following general procedure O using ethyl 2-
chloro-2-((4-nitrophenyl)sulfonyl)acetate 265 (2.1 g, 6.84 mmol) and DIBAL (1M in 
hexanes, 20.5 mL, 20.5 mmol). The crude product was purified by MPC on silica (petrol: 
EtOAc 3: 2) to give the product 266 as a yellow solid (1.20 g, 4.53 mmol, 66%). 
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Rf 0.43 (petrol: EtOAc 3: 2); Mp = 95-98 °C; UV λmax (EtOH) 249 nm; IR (cm
-1
) 3488, 
2943, 2877, 1530, 1304, 1136; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.39 (1H, m, H-
6’), 4.04 (1H, m, H-6’), 5.67 (1H, br s, OH), 5.76 (1H, dd, J = 4.2 and 6.1 Hz, H-5’), 8.23 
(2H, d, J = 9.0 Hz, H-3’), 8.48 (2H, d, J = 8.9 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) 
(ppm) δ 60.4 (C-6’), 74.3 (C-5’), 124.4 (C-2’), 131.3 (C-3’), 141.6 (C-4614’), 151.0 (C-
1’); HRMS calcd for C8H7ClNO5S [M-H]
-
 263.9739, found 263.9738. 
2-((4-Aminophenyl)sulfonyl)-2-chloroethanol (267) 
 
The title compound was synthesised following general procedure H using 2-chloro-2-
((4-nitrophenyl)sulfonyl)ethanol 266 (500 mg, 1.89 mmol) and zinc powder (1.23 g, 18.9 
mmol). The crude product was purified by MPC on silica (DCM: MeOH 9: 1) to give the 
product 267 as a pale orange oil (374 mg, 1.59 mmol, 84 %). 
Rf 0.57 (DCM: MeOH 9: 1); UV λmax (EtOH) 276 nm; IR (cm
-1
) 3335, 3215, 2928, 1592, 
1132; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.55-3.63 (1H, m, H-6’), 4.01-4.05 (1H, 
m, H-6’), 5.15 (1H, dd, J = 3.4 and 8.0 Hz, H-5’), 5.45 (1H, dd, J = 6.2 and 6.2 Hz, OH), 
6.34 (2H, br s, NH2), 6.66 (2H, d, J = 8.8 Hz, H-3’), 7.50 (2H, d, J = 8.8 Hz, H-2’); 
13
C 
NMR (125 MHz, DMSO-d6) (ppm) δ 61.2 (C-6’), 75.4 (C-5’), 112.4 (C-3’), 129.3 (C-4’), 
131.5 (C-2’), 139.1 (C-1’); HRMS calcd for C8H11ClNO3S [M+H]
+
 236.0143, found 
236.0143.  
2-Chloro-2-((4-((6-(cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl) 
sulfonyl)ethanol (268) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (176 mg, 0.37 mmol), 
2-((4-aminophenyl)sulfonyl)-2-chloroethanol 267 (130 mg, 0.55 mmol), K2CO3 (102 mg, 
0.74 mmol), Pd(dba)2 (7 mg, 0.01 mmol) and XPhos (4 mg, 0.01 mmol). The crude 
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mixture was then filtered through Celite and the solvent was removed in vacuo. The 
crude mixture was then solubilised in TFA (15 mL). The resulting solution was heated at 
70 °C for 2 h. Then the solvent was removed in vacuo and the product was purified by 
MPC (EtOAc 100) to give the product 268 as a yellow oil (56 mg, 0.12 mmol, 33%). 
Rf 0.30 (EtOAc 100); UV λmax (EtOH) 316 nm; IR (cm
-1
) 3259, 3106, 2924, 2850, 1592, 
1311; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.08-1.15 (2H, m, H-cyclo), 1.22-1.32 
(3H, m, H-cyclo), 1.66-1.69 (1H, m, H-cyclo), 1.73-1.76 (2H, m, H-cyclo), 1.85-1.90 (3H, 
m, H-cyclo and H-2’’), 3.66-3.70 (1H, m, H-6’), 4.06-4.08 (1H, m, H-6’), 4.38 (2H, d, J 
= 6.3 Hz, H-1’’), 5.37 (1H, dd, J = 3.5 and 7.5 Hz, H-5’), 5.54 (1H, br s, OH), 7.80 (2H, 
d, J = 8.8 Hz, H-3’), 8.09 (2H, d, J = 8.8 Hz, H-2’), 8.17 (1H, s, H-8), 10.04 (1H, br s, 
NH), 13.05 (1H, br s, N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 25.2 (2 x C-cyclo), 
26.0 (C-cyclo), 29.2 (2 x C-cyclo), 36.8 (C-2’’), 60.8 (C-6’), 71.4 (C-1’’), 75.1 (C-5’), 
117.1 (C-2’), 130.6 (C-3’), 146.9 (Cq), 154.3 (Cq), 160.3 (Cq); HRMS calcd for 
C20H23ClN5O4S [M-H]
-
 464.1165, found 464.1164. 
Note: Four quaternary carbons were not visible on the 
13
C NMR spectrum. 
Ethyl 2-fluoro-2-((4-nitrophenyl)sulfonyl)acetate (269) 
 
NaH (81 mg, 10.44 mmol) was added to a stirred solution of ethyl 2-((4-
nitrophenyl)sulfonyl)acetate 237 (500 mg, 1.84 mmol) in dry THF (20 mL) under N2. 
The resulting mixture was stirred at r.t. for 30 min. Then Selectfluor (1.30 g, 3.68 mmol) 
was added and the solution was stirred at r.t. for 2 h. Brine (20 mL) was added and the 
reaction was extracted with EtOAc (3 x 50 mL). The organic layer was dried over MgSO4 
and the solvent was removed in vacuo. The crude product was purified by MPC on silica 
(petrol: EtOAc 4: 1) to give the product 269 as a white solid (333 mg, 1.15 mmol, 62%). 
Rf 0.64 (petrol: EtOAc 7: 3); Mp = 97-98.5 
o
C; UV λmax (EtOH) 247 nm; IR (cm
-1
) 2966, 
1748, 1529, 1348, 1304, 1159; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.20 (3H, t, J = 
7.1 Hz, H-7’), 4.27 (2H, qd, J = 2.8 and 7.1 Hz, H-6’), 6.80 (1H, d, J = 45.1 Hz, H-5’), 
8.22 (2H, d, J = 8.9 Hz, H-3’), 8.53 (2H, d, J = 8.9 Hz, H-2’); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 13.7 (C-7’), 63.3 (C-6’), 96.0 (d, J = 226.8 Hz, C-5’), 124.9 (C-2’), 
131.3 (C-3’), 139.7 (C-4’), 151.6 (C-1’), 160.5 (d, J = 23.3 Hz, CO); 19F NMR (470 MHz, 
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DMSO-d6) (ppm) δ -183.2; HRMS calcd for C10H9FNO6S [M-H]
-
 290.0129, found 
290.0131. 
2-Fluoro-2-((4-nitrophenyl)sulfonyl)ethanol (270) 
 
The title compound was synthesised following general procedure O using ethyl 2-
fluoro-2-((4-nitrophenyl)sulfonyl)acetate 269 (300 mg, 1.03 mmol) and Dibal (1M in 
hexanes, 3.10 mL, 3.10 mmol). The crude product was purified by MPC on silica (petrol: 
EtOAc 7: 3) to give the product 270 as a white crystalline solid (175 mg, 0.70 mmol, 
68%). 
Rf 0.62 (petrol: EtOAc 7: 3); Mp = 95-97 °C; UV λmax (EtOH) 248 nm; IR (cm
-1
) 3097, 
2976, 2926, 1520, 1343, 1081, 1053; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.81-3.90 
(1H, m, H-6’), 4.02 (1H, dddd, J = 2.8, 6.0, 13.4 and 27.6 Hz, H-6’), 5.59 (1H, t, J = 6.0 
Hz, OH), 5.95 (1H, ddd, J = 2.8, 6.0 and 46.7 Hz, H-5’), 8.21 (2H, d, J = 8.9 Hz, H-3’), 
8.48 (2H, d, J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 57.7 (d, J = 20.0 
Hz, C-6’), 102.0 (d, J = 218.7 Hz, C-5’), 124.6 (C-2’), 131.0 (C-3’), 141.3 (C-4’), 151.2 
(C-1’); 19F NMR (470 MHz, DMSO-d6) (ppm) δ -186.5 (ddd, J = 24.2, 27.6 and 46.7 Hz); 
HRMS calcd for C8H9FNO5S [M+H]
+
 250.0180, found 250.0178. 
2-((4-Aminophenyl)sulfonyl)-2-fluoroethanol (271) 
 
The title compound was synthesised following general procedure H using 2-fluoro-2-
((4-nitrophenyl)sulfonyl)ethanol 270 (500 mg, 2.01 mmol) and zinc powder (1.30 g, 20.1 
mmol). The crude product was purified by MPC on silica (petrol: EtOAc 1: 4) to give the 
product 271 as an orange oil (270 mg, 1.23 mmol, 62 %). 
Rf 0.55 (DCM: MeOH 9: 1); UV λmax (EtOH) 277 nm; IR (cm
-1
) 3467, 3367, 1588, 1292, 
1071; 
1
H NMR (500 MHz, MeOD) (ppm) δ 3.68 (1H, ddd, J = 7.5, 13.2 and 19.0 Hz, H-
6’), 3.97 (1H, ddd, J = 2.6, 13.2 and 31.3 Hz, H-6’), 5.10 (1H, ddd, J = 2.6, 7.5 and 49.0 
Hz, H-5’), 6.63 (2H, d, J = 8.8 Hz, H-3’), 7.45 (2H, d, J = 8.8 Hz, H-2’); 13C NMR (125 
MHz, MeOD) (ppm) δ 60.2 (d, J = 20.8 Hz, C-6’), 103.9 (d, J = 218.1 Hz, C-5’), 114.3 
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(C-3’), 121.4 (C-4’), 132.5 (C-2’), 156.4 (C-1’); 19F NMR (470 MHz, MeOD) (ppm) δ -
186.9 (ddd, J = 19.0, 31.3 and 49.0 Hz); HRMS calcd for C8H9FNO3S [M-H]
-
 218.0293, 
found 218.0284. 
2-((4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)-2-fluoro 
ethanol (272) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (350 mg, 0.73 mmol), 
2-((4-aminophenyl)sulfonyl)-2-fluoroethanol 271 (240 mg, 1.10 mmol), K2CO3 (202 mg, 
1.46 mmol), Pd(dba)2 (13 mg, 0.01 mmol) and XPhos (7 mg, 0.01 mmol). The crude 
mixture was then filtered through Celite and the solvent was removed in vacuo. The 
crude mixture was then solubilised in TFA (15 mL). The resulting solution was heated at 
70 °C for 2 h. Then the solvent was removed in vacuo. The product was purified by MPC 
(EtOAc 100) to give the product 272 as a yellow oil (112 mg, 0.24 mmol, 33%). 
Rf 0.30 (EtOAc 100); UV λmax (EtOH) 316 nm; IR (cm
-1
) 3300, 3104, 2923, 2849, 1578, 
1386, 1137; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.08-1.14 (2H, m, H-cyclo), 1.17-
1.21 (1H, m, H-cyclo), 1.24-1.32 (2H, m, H-cyclo), 1.67-1.69 (1H, m, H-cyclo), 1.73-
1.76 (2H, m, H-cyclo), 1.85-1.91 (3H, m, H-cyclo and H-2’’), 3.66-3.74 (1H, m, H-6’), 
3.94-4.06 (1H, m, H-6’), 4.38 (2H, d, J = 6.3 Hz, H-1’’), 5.49 (1H, dd, J = 6.1 and 6.1 Hz, 
OH), 5.54-5.65 (1H, m, H-5’), 7.79 (2H, d, J = 8.9 Hz, H-3’), 8.09-8.14 (3H, m, H-2’ and 
H-8), 10.06 (1H, s, NH), 13.01 (1H, s, N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 
25.2 (2 x C-cyclo), 26.0 (C-cyclo), 29.2 (2 x C-cyclo), 36.8 (C-2’’), 58.2 (d, J = 20.1 Hz, 
C-6’), 71.4 (C-1’’), 102.0 (d, J = 217.1, C-5’), 115.6 (Cq), 117.4 (C-2’), 125.4 (Cq), 130.2 
(C-3’), 139.8 (C-8), 147.0 (Cq), 153.8 (Cq), 154.3 (Cq), 160.2 (Cq); 
19
F NMR (470 MHz, 
MeOD) (ppm) δ -185.60 (ddd, J = 20.2, 32.7 and 47.7 Hz); HRMS calcd for 
C20H23FN5O4S [M-H]
-
 448.1460, found 448.1446.  
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tert-Butyl(2-chloro-2-((4-nitrophenyl)sulfonyl)ethoxy)dimethylsilane (276) 
 
Imidazole (77 mg, 1.13 mmol) and tert-butyldimethylsilylchloride (63 mg, 0.42 mmol) 
were added at 0 
o
C to a solution of 2-chloro-2-((4-nitrophenyl) sulfonyl)ethanol 266 (100 
mg, 0.38 mmol) in dry DCM (75 mL) under N2. The reaction was stirred at 0 
o
C for 5 h. 
Then water (50 mL) was added to quench the reaction and the organic phase was 
extracted with DCM (3 x 50 mL) and dried over MgSO4. The solvent was removed in 
vacuo. The crude product was purified by MPC on silica (petrol: EtOAc 4: 1) to give the 
product 276 as a white soil (1.38 g, 3.64 mmol, 85%). 
Rf 0.77 (petrol: EtOAc 4: 1); Mp = 83-85 °C; UV λmax (EtOH) 251 nm; IR (cm
-1
) 2929, 
2857, 1529, 1345, 1254, 1131; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 0.00 (3H, s, H-
7’), 0.03 (3H, s, H-7’), 0.80 (9H, s, H-8’), 4.15 (1H, dd, J = 4.5 and 12.2 Hz, H-6’), 4.22 
(1H, dd, J = 4.5 and 12.2 Hz, H-6’), 5.94 (1H, dd, J = 4.5 and 4.5 Hz, H-5’), 8.25 (2H, d, 
J = 9.0 Hz, H-3’), 8.51 (2H, d, J = 8.9 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) 
δ -5.7 (C-7’), 17.9 (Cq), 25.5 (C-8’), 62.1 (C-6’), 73.7 (C-5’), 124.4 (C-2’), 131.3 (C-3’), 
141.9 (C-4’), 151.0 (C-1’); HRMS calcd for C14H23ClNO5SSi [M+H]
+
 380.0749, found 
380.0751. 
2-((4-Nitrophenyl)sulfonyl)oxirane (278) 
 
Cs2CO3 (92 mg, 0.28 mmol) was added to a stirred solution of 2-chloro-2-((4-
nitrophenyl)sulfonyl)ethanol 266 (50 mg, 0.19 mmol) in dry MeCN (1 mL) under N2. 
The reaction was stirred at r.t. for 2 h. The reaction mixture was filtered through Celite 
and the solvent was removed in vacuo. The crude product was purified by MPC on silica 
(DCM: MeOH 1: 1) to give the product 278 as a colourless oil (11 mg, 0.05 mmol, 25%). 
Rf 0.25 (DCM: MeOH 9: 1); UV λmax (EtOH) 306 nm; IR (cm
-1
) 1590, 1495, 1338, 1252, 
1110; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.85 (1H, dd, J = 2.5 and 8.7 Hz, H-5’), 
4.25 (1H, dd, J = 8.7 and 11.5 Hz, H-6’), 4.73 (1H, dd, J = 2.5 and 11.5 Hz, H-6’), 7.18 
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(2H, d, J = 9.3 Hz, H-3’), 8.21 (2H, d, J = 9.3 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) 
(ppm) δ 69.5 (C-6’), 77.2 (C-5’), 115.2 (C-3’), 125.9 (C-2’), 140.9 (C-4’), 163.7 (C-1’). 
Note: LRMS and HRMS were not available because the compound did not ionise. 
1-((2-(Benzyloxy)ethyl)sulfonyl)-4-nitrobenzene (282) 
 
To a stirred suspension of NaH (23 mg, 0.56 mmol) in dry DMF (2 mL), under N2, was 
added a solution of 2-((4-nitrophenyl)sulfonyl)ethanol 256 (100 mg, 0.43 mmol) in dry 
DMF (2 mL) at 0 
o
C. The resulting mixture was stirred at r.t. for 1 h. Benzyl bromide (88 
uL, 0.74 mmol) was slowly added to the solution. The reaction was stirred at r.t. fo a 
further 2 h. The reaction was quenched with a saturated aqueous solution of NH4Cl (5 
mL), diluted with EtOAc (10 mL) and washed with brine. The organic layer was dried 
over MgSO4 and the solvent was removed in vacuo. The crude product was purified by 
MPC on silica (petrol: EtOAc 1: 1) to give the product 282 as a yellow solid (82 mg, 0.26 
mmol, 59%). 
Rf 0.31 (petrol: EtOAc 7: 3); Mp = 155-156.5 
o
C; UV λmax (EtOH) 305 nm; IR (cm
-1
) 
2924, 1588, 1510, 1342, 1289, 1250, 1112, 1017; 
1
H NMR (500 MHz, DMSO-d6) (ppm) 
δ 3.63 (2H, t, J = 5.6 Hz, H-6’), 4.54 (2H, t, J = 5.6 Hz, H-5’), 4.60 (2H, s, H-7’), 7.25 
(2H, d, J = 9.2 Hz, H-3’), 7.42-7.44 (5H, m, H-ar), 8.25 (2H, d, J = 9.2 Hz, H-2’); 13C 
NMR (125 MHz, DMSO-d6) (ppm) δ 50.7 (C-6’), 59.5 (C-7’), 62.5 (C-5’), 115.2 (C-3’), 
126.0 (C-2’), 128.2 (Cq), 128.4 (C-ar), 128.5 (2 x C-ar), 131.2 (2 x C-ar), 141.3 (Cq), 
162.3 (Cq); HRMS calcd for C15H14NO5S [M-H]
-
 320.0598, found 320.0585. 
3-Hydroxy-3-methoxy-2-((4-nitrophenyl)sulfonyl)acrylonitrile (284) 
 
Methyl cyanoacetate 285 (0.79 mL, 9.00 mmol) and Cs2CO3 (2.94 g, 9.00 mmol) were 
stirred in dry MeCN (20 mL), under N2, with molecular seaves at 0 °C for 1 h. Then 4-
nitrobenzenesulfonyl chloride 242 (1.0 g, 4.50 mmol) was added and the reaction was 
stirred for 1 h at 0 °C. The solvent was removed in vacuo. The product was purified by 
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MPC on silica (DCM: MeOH 9:1) to give the product 284 as an orange oil (650 mg, 2.29 
mmol, 51%). 
Rf 0.17 (DCM: MeOH 9:1); UV λmax (EtOH) 248 nm; IR (cm
-1
) 3404, 2192, 1642, 1439, 
1347, 1192, 1090; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.36 (3H, s, H-7’), 8.00 (2H, 
d, J = 8.9 Hz, H-3’), 8.32 (2H, d, J = 8.9 Hz, H-2’), 8.84 (1H, br s, OH); 13C NMR (125 
MHz, DMSO-d6) (ppm) δ 49.5 (C-7’), 64.2 (C-5’), 119.9 (CN), 123.9 (C-2’), 127.3 (C-
3’), 148.5 (C-4’), 151.6 (C-1), 165.3 (C-6); HRMS calcd for C10H7N2O6S [M-H]
-
 
283.0030, found 283.0024. 
2-((4-Nitrophenyl)sulfonyl)acetonitrile (288) 
 
The title compound was synthesised following general procedure M using 2-((4-
nitrophenyl)thio)acetonitrile 290 (1.00 g, 5.15 mmol) and m-CPBA (2.30 g, 10.3 mmol). 
The crude product was purified by MPC on silica (petrol: EtOAc 1: 1) to give the product 
288 as a white powder (386 mg, 1.71 mmol, 33%). 
Rf 0.78 (petrol: EtOAc 3: 2); Mp = 151.5-153 
o
C; UV λmax (EtOH) 325 nm; IR (cm
-1
) 
2977, 2254, 1519, 1341, 1053; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 4.48 (1H, d, J = 
16.7 Hz, H-5’), 4.85 (1H, d, J = 16.7 Hz, H-5’), 8.04 (2H, d, J = 8.8 Hz, H-3’), 8.49 (2H, 
d, J = 8.8 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 43.3 (C-5’), 112.7 (CN), 
124.3 (C-2’), 126.1 (C-3’), 149.4 (C-4’), 149.6 (C-1’); HRMS calcd for C8H5N2O4S [M-
H]
-
 224.9976, found 224.9965. 
2-((4-Nitrophenyl)thio)acetonitrile (290)
270
 
 
The title compound was synthesised following general procedure J using 
iodoacetonitrile (0.51 mL, 7.10 mmol), 4-nitrothiophenol 173 (1.00 g, 6.45 mmol) and 
Et3N (1.08 mL, 7.75 mmol). The crude product was purified by MPC on silica (petrol: 
EtOAc 4: 1) to give the product 290 as a yellow solid (1.09 g, 5.62 mmol, 87%). 
Rf 0.78 (petrol: EtOAc 3: 2); Mp = 85-86 
o
C; UV λmax (EtOH) 314 nm; IR (cm
-1
) 2963, 
2254, 1574, 1506, 1337; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 4.50 (2H, s, H-5’), 7.68 
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(2H, d, J = 9.0 Hz, H-3’), 8.25 (2H, d, J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) 
(ppm) δ 16.8 (C-5’), 117.3 (CN), 124.2 (C-2’), 127.3 (C-3’), 143.2 (C-4’), 145.6 (C-1’); 
HRMS calcd for C8H5N2O2S [M-H]
-
 193.0077, found 193.0069. 
3,3,3-Trifluoropropane-1,2-diol (296)
226
 
 
Ethyl pyruvate 295 (0.95 mL, 5.88 mmol) was added dropwise to LiAlH4 (1M in THF, 
5.90 mL) at 0 °C, under N2. The mixture was then refluxed for 2 h. After completion, 2M 
HCl solution was added until obtaining a clear solution. Et2O was added (50 mL) and the 
organic layer was extracted. The organic phase was dried over MgSO4. The solvent was 
removed in vacuo at r.t.. The crude product was purified by distillation under vacuum 
using a Kügelrohr apparatus (60 °C, 4 mmbar) to give the product 296 as a colourless 
liquid (625 mg, 4.81 mmol, 82%). 
Rf 0.34 (petrol: EtOAc 4: 1); UV λmax (EtOH) 277 nm; IR (cm
-1
) 3343, 1271, 1112, 1029; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.46 (1H, dd, J = 6.7 and 11.4 Hz, H-2’), 3.58 
(1H, dd, J = 4.2 and 11.4 Hz, H-2’), 3.87-3.95 (1H, m, H-1’), 4.99 (1H, br s, OH), 6.20 
(1H, d, J = 6.3 Hz, OH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 60.2 (q, J = 2.0 Hz, C-
2’), 70.0 (q, J = 27.9 Hz, C-1’), 125.0 (q, J = 283 Hz, CF3); 
19
F NMR (470 MHz, DMSO-
d6) (ppm) δ -76.07. 
3-((tert-Butyldiphenylsilyl)oxy)-1,1,1-trifluoropropan-2-ol (297) 
 
Imidazole (157 mg, 2.31 mmol) and tert-butyldiphenylsilyl chloride (0.2 mL, 0.77 mmol) 
were added to a solution of 3,3,3-trifluoropropane-1,2-diol 296 (100 mg, 0.77 mmol) in 
dry DCM (5 mL) at 0 °C. The reaction was stirred for 1 h and water (10 mL) was added. 
The organic phase was extracted with DCM (3 x 10 mL) and dried over MgSO4. Then the 
solvent was removed in vacuo. The product was purified by MPC on silica (petrol: 
EtOAc 9:1) to give the product 297 as a colourless oil (211 mg, 0.57 mmol, 75%). 
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Rf 0.48 (petrol: EtOAc 9: 1); UV λmax (EtOH) 265 nm; IR (cm
-1
) 3512, 2933, 2859, 1143, 
1109; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.00 (9H, s, 
t
Bu), 3.72 (1H, dd, J = 5.5 
and 10.9 Hz, H-2’), 3.77 (1H, dd, J = 5.3 and 10.9 Hz, H-2’), 4.09-4.12 (1H, m, H-1’), 
6.40 (1H, d, J = 6.2 Hz, OH), 7.43-7.49 (6H, m, H-ar), 7.63-7.65 (4H, m, H-ar); 
13
C 
NMR (125 MHz, DMSO-d6) (ppm) δ 26.4 (
t
Bu), 62.7 (C-2’), 69.4 (q, J = 28.6 Hz, C-1’), 
124.5 (q, J = 283.8 Hz, CF3), 127.9 (C-ar), 130.0 (C-ar), 132.5 (C-ar), 135.1 (C-ar); 
19
F 
NMR (470 MHz, DMSO-d6) (ppm) δ -75.6; HRMS calcd for C19H22F3O2Si [M-H]
-
 
367.1347, found 367.1339. 
3-(Benzyloxy)-1,1,1-trifluoropropan-2-ol (304)
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3,3,3-Trifluoro-1,2-propenoxide 306 (1.50 mL, 17.9 mmol) was added to a stirred 
solution of benzyl acohol 305 (1.85 mL, 17.9 mmol) and boron trifluoride diethyletherate 
(44.00 μL, 0.36 mmol), under N2. The reaction mixture was then heated at 40 
o
C for 18 h. 
The reaction was diluted with DCM (50 mL) and washed with brine (2 x 50 mL). The 
organic phase was dried over MgSO4 and the solvent was removed in vacuo. The product 
was purified by MPC on silica (petrol: EtOAc 9: 1) to give the product 304 as a yellow 
liquid (3.11 g, 13.95 mmol, 85%). 
Rf 0.60 (petrol: EtOAc 4: 1); UV λmax (EtOH) 258 nm; IR (cm
-1
) 3425, 1453, 1270, 1121; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.55 (1H, dd, J = 6.5 and 10.5 Hz, H-2’), 3.65 
(1H, dd, J = 4.4 and 10.5 Hz, H-2’), 4.17-4.25 (1H, m, H-1’), 4.56 (2H, s, CH2), 6.43 (1H, 
d, J = 6.6 Hz, OH), 7.29-7.33 (1H, m, H-ar), 7.34-7.38 (4H, m, H-ar); 
13
C NMR (125 
MHz, DMSO-d6) (ppm) δ 68.00 (q, J = 29.0 Hz, C-1’), 68.5 (q, J = 1.8 Hz, C-2’), 72.4 
(CH2), 125.00 (q, J = 283.4 Hz, CF3), 127.5 (C-ar), 127.6 (2 x C-ar), 128.2 (2 x C-ar), 
137.9 (Cq); 
19
F NMR (470 MHz, DMSO-d6) (ppm) δ -72.2; HRMS calcd for C10H10F3O2 
[M-H]
-
 219.0627, found 219.1758. 
3-(Benzyloxy)-1,1,1-trifluoropropan-2-yl 4-methylbenzenesulfonate (308) 
 
Tosyl chloride (278 mg, 1.46 mmol) was added to a stirred solution of 3-(benzyloxy)-
1,1,1-trifluoropropan-2-ol 304 (200 mg, 0.97 mmol) and Et3N (0.20 mL, 1.46 mmol) in 
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dry DCM (5 mL) under N2. The resulting solution was stirred at r.t. for 1 h. The solvent 
was removed in vacuo. The product was purified by MPC on silica (petrol: EtOAc 9: 1) 
to give the product 308 as a colourless oil (219 mg, 0.59 mmol, 60%). 
Rf 0.69 (petrol: EtOAc 4: 1); UV λmax (EtOH) 263 nm; IR (cm
-1
) 2923, 1597 , 1453, 1274, 
1176, 1059; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 2.40 (3H, s, CH3), 3.68 (2H, s, 
CH2), 4.41 (1H, dd, J = 12.0 and 12.0 Hz, H-2’), 4.45 (1H, dd, J = 12.0 and 12.0 Hz, H-
2’), 5.50-5.56 (1H, m, H-1’), 7.20 (2H, d, J = 6.9 Hz, H-ar), 7.30-7.36 (3H, m, H-ar), 
7.44 (2H, d, J = 8.9 Hz, H-tosyl), 7.85 (2H, d, J = 8.9 Hz, H-tosyl); 
13
C NMR (125 MHz, 
DMSO-d6) (ppm) δ 21.1 (CH3), 65.6 (C-2’), 72.3 (CH2), 75.1 (q, J = 31.6 Hz, C-1’), 
122.00 (q, J = 281.9 Hz, CF3), 127.5 (2 x C-ar), 127.6 (C-ar), 127.8 (2 x C-tosyl), 128.2 
(2 x C-ar), 130.1 (2 x C-tosyl), 132.4 (Cq), 137.2 (Cq), 137.9 (Cq); 
19
F NMR (470 MHz, 
DMSO-d6) (ppm) δ -73.2; HRMS calcd for C17H16F3O4S [M-H]
-
 373.0716, found 
373.0717. 
1-Nitro-4-((2,2,2-trifluoroethyl)sulfonyl)benzene (313) 
 
The title compound was synthesised following general procedure M using (4-
nitrophenyl)(2,2,2-trifluoroethyl)sulfane 314 (1.10 g, 4.67 mmol) and m-CPBA (2.07 g, 
9.28 mmol). The crude product was purified by MPC on silica (petrol: EtOAc 17: 3) to 
give the product 313 as a pale yellow solid (0.79 g, 2.94 mmol, 63%). 
Rf 0.65 (petrol: EtOAc 17: 3); UV λmax (EtOH) 247 nm; Mp = 96-97 
o
C; IR (cm
-1
) 2995, 
1536, 1344, 1259; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 5.20 (2H, q, J = 10.1 Hz, H-
5’), 8.26 (2H, d, J = 8.9 Hz, H-3’), 8.52 (2H, d, J = 8.9 Hz, H-2’); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 55.7 (q, J = 29.9 Hz, C-5’), 124.5 (C-2’), 129.6 (C-3’), 131.0 (q, J = 
256.2 Hz, CF3), 143.8 (C-4’), 150.8 (C-1’); 
19
F NMR (470 MHz, DMSO-d6) (ppm) δ -
59.7 (t, J = 10.1 Hz); HRMS calcd for C8H7F3NO4S [M+H]
+
 270.0042, found 270.0037. 
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(4-Nitrophenyl)(2,2,2-trifluoroethyl)sulfane (314) 
 
1,1,1-Trifluoro-2-iodoethane (0.95 mL, 9.68 mmol) was added to a stirred solution of 4-
nitrothiophenol 173 (1.00 g, 6.45 mmol), K2CO3 (2.67 g, 19.4 mmol) and Rongalit (0.90 
g, 5.81 mmol) in anhydrous DMF (7 mL) under N2. The resulting solution was stirred at 
r.t. for 18 h. After completion, brine (20 mL) was added and the organic phase was 
extracted with EtOAc (3 x 20 mL). The organic layers were combined and dried over 
MgSO4. The solvent was removed in vacuo and the crude product was purified by MPC 
on silica (petrol: EtOAc 19: 1) to give the product 314 as a yellow oil (0.95 g, 4.01 mmol, 
62%). 
Rf 0.68 (petrol: EtOAc 9: 1); UV λmax (EtOH) 317 nm; IR (cm
-1
) 1512, 1338, 1070; 
1
H 
NMR (500 MHz, DMSO-d6) (ppm) δ 4.30 (2H, q, J = 10.3 Hz, H-5’), 7.73 (2H, d, J = 9.0 
Hz, H-3’), 8.19 (2H, d, J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 32.5 
(q, J = 32.2 Hz, C-5’), 124.0 (C-2’), 125.0 (q, J = 276.8 Hz, CF3), 127.6 (C-3’), 143.6 (C-
4’), 145.5 (C-1’); 19F NMR (470 MHz, DMSO-d6) (ppm) δ -64.7 (t, J = 10.3 Hz); HRMS 
calcd for C8H7F3NO2S [M+H]
+
 238.0144, found 238.0142. 
1-((4-Nitrophenyl)thio)propan-2-one (318)
272
 
 
The title compound was synthesised following general procedure J using chloroacetate 
317 (0.20 mL, 2.93 mmol), 4-nitrothiophenol 173 (500 mg, 3.23 mmol) and Et3N (0.50 
mL, 3.55 mmol). The crude product was purified by MPC on silica (DCM: MeOH 19: 1) 
to give the product 318 as a yellow solid (615 mg, 2.91 mmol, 98%). 
Rf 0.52 (EtOAc: petrol 2: 3); Mp = 65-67 
o
C (lit., 
263
 Mp = 68-69 °C); UV λmax (EtOH) 
334 nm; IR (cm
-1
) 2910, 2860, 1709, 1576, 1498, 1328; 
1
H NMR (500 MHz, DMSO-d6) 
(ppm) δ 2.27 (3H, s, H-7’), 4.30 (2H, s, H-5’), 7.46 (2H, d, J = 9.0 Hz, H-3’), 8.13 (2H, d, 
J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 28.6 (H-7’), 41.9 (H-5’), 
123.8 (C-2’), 126.3 (C-3’), 144.5 (C-4’), 146.6 (C-1’), 202.1 (CO); HRMS calcd for 
C9H8NO3S [M-H]
-
 210.0230, found 210.0227. 
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1-(1-((4-Nitrophenyl)thio)propan-2-yl)pyrrolidine (319) 
 
1-((4-Nitrophenyl)thio)propan-2-one 318 (615 mg, 2.91 mmol) was dissolved in 
anhydrous toluene (15 mL) under N2. Acetic acid (0.83 mL, 14.6 mmol) and MgSO4 
(1,04 g, 8.73 mmol) were added to the reaction, then pyrrolidine (0.87 mL, 10.5 mmol) 
and the reaction was stirred at r.t. for 2 h. Sodium triacetoxyborohydride (250 mg, 6.41 
mmol) was added and the reaction was stirred at r.t. overnight. The reaction mixture was 
quenched with aqueous NaHCO3 until reaching pH 7. The solution was then extracted 
with EtOAc (3 x 30 mL). The organic layer was dried over MgSO4 and the solvent was 
removed in vacuo. The crude product was purified by MPC on silica (DCM: MeOH 9: 1) 
to give the product 319 as an orange oil (443 mg, 1.67 mmol, 57%). 
Rf 0.38 (DCM: MeOH 9: 1); UV λmax (EtOH) 333 nm; IR (cm
-1
) 2966, 2792, 1576, 1508, 
1334; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.16 (3H, d, J = 6.4 Hz, H-7’), 1.67-1.70 
(4H, m, H-pyr), 2.53-2.58 (4H, m, H-pyr), 2.71-2.77 (1H, m, H-6’), 3.18 (1H, dd, J = 
11.9 and 4.3 Hz, H-5’), 3.30 (1H, dd, J = 11.9 and 5.7 Hz, H-5’), 7.50 (2H, d, J = 9.0 Hz, 
H-3’), 8.12 (2H, d, J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 17.1 (C-
7’), 23.2 (2 x C-pyr), 37.3 (C-5’), 50.0 (2 x C-pyr), 56.2 (C-6’), 123.8 (C-2’), 126.2 (C-
3’), 144.1 (C-4’), 148.8 (C-1’); HRMS calcd for C13H19N2O2S [M+H]
+
 267.1162, found 
267.1166. 
4-((2-(Pyrrolidin-1-yl)propyl)thio)aniline (320) 
 
The title compound was synthesised following general procedure H using 1-(1-((4-
nitrophenyl)thio)propan-2-yl)pyrrolidine 319 (440 mg, 1.66 mmol) and zinc powder 
(1.08 g, 16.6 mmol). The crude product was purified by MPC on silica (DCM: MeOH 9: 
1) to give the product 320 as a yellow oil (250 mg, 1.06 mmol, 64%). 
Rf 0.26 (DCM: MeOH 9: 1); UV λmax (EtOH) 254 nm; IR (cm
-1
) 3146, 2948, 1509, 1389, 
1248; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.12 (3H, d, J = 6.4 Hz, H-7’), 1.62-1.65 
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(4H, m, H-pyr), 2.44-2.49 (4H, m, H-pyr), 2.48-2.51 (1H, m, H-6’), 2.64 (1H, dd, J = 
12.7 and 8.2 Hz, H-5’), 2.98 (1H, dd, J = 12.7 and 3.4 Hz, H-5’), 5.20 (2H, br s, NH2), 
6.51 (2H, d, J = 8.6 Hz, H-2’), 7.09 (2H, d, J = 8.6 Hz, H-3’); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 17.0 (C-7’), 23.1 (2 x C-pyr), 41.6 (C-5’), 50.0 (2 x C-pyr), 57.4 (C-
6’), 114.4 (C-2’), 119.8 (C-4’), 133.2 (C-3’), 148.1 (C-1’); HRMS calcd for C13H21N2S 
[M+H]
+
 237.1420, found 237.1422. 
6-(Cyclohexylmethoxy)-N-(4-((2-(pyrrolidin-1-yl)propyl)thio)phenyl)-9H-purin-2-
amine (321) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (518 mg, 1.08 mmol), 
4-((2-(pyrrolidin-1-yl)propan-2-yl)thio)aniline 320 (280 mg, 1.19 mmol), K2CO3 (311 mg, 
2.17 mmol), Pd(dba)2 (20 mg, 0.02 mmol) and XPhos (10 mg, 0.02 mmol). The crude 
mixture was then filtered through Celite and the solvent was removed in vacuo. The 
crude mixture was then solubilised in TFA (15 mL). The resulting solution was heated at 
70 °C for 5 h. Then the solvent was removed in vacuo. The product was purified by MPC 
(DCM: MeOH 9: 1) to give the product 321 as an orange oil (255 mg, 0.55 mmol, 50%). 
Rf 0.33 (DCM: MeOH 9: 1); UV λmax (EtOH) 268 nm; IR (cm
-1
) 3152, 2926, 2853, 1668, 
1494, 1424, 1176, 1125; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.06-1.13 (2H, m, H-
cyclo), 1.17-1.21 (1H, m, H-cyclo), 1.24-1.29 (2H, m, H-cyclo), 1.36 (3H, d, J = 6.7 Hz, 
H-7’), 1.66-1.69 (1H, m, H-cyclo), 1.73-1.75 (2H, m, H-cyclo), 1.84-1.86 (5H, m, H-
cyclo, H-pyr and H-2’’), 1.95-2.00 (2H, m, H-pyr), 2.96-3.05 (2H, m, H-pyr and H-5’), 
3.10-3.14 (1H, m, H-pyr), 3.36-3.40 (1H, m, H-6’), 3.42-3.48 (2H, m, H-pyr and H-5’), 
3.54-3.58 (1H, m, H-pyr), 4.34 (2H, d, J = 6.3 Hz, H-1’’), 7.41 (2H, d, J = 8.8 Hz, H-2’), 
7.87 (2H, d, J = 8.8 Hz, H-3’), 8.14 (1H, s, H-8), 9.50 (1H, br s, NH), 9.82 (1H, br s, 
N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 14.8 (C-7’), 22.7 (C-pyr), 22.8 (C-pyr), 
25.2 (2 x C-cyclo), 26.0 (C-cyclo), 29.2 (2 x C-cyclo), 36.5 (C-5’), 36.8 (C-2’’), 50.5 (C-
pyr), 51.1 (C-pyr), 59.0 (C-6’), 71.2 (C-1’’), 118.9 (C-3’), 123.9 (Cq), 125.6 (Cq), 128.5 
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(Cq), 129.0 (Cq), 131.6 (C-2’), 140.8 (C-8), 142.8 (Cq), 155.2 (Cq); HRMS calcd for 
C25H35N6OS [M+H]
+
 467.2588, found 467.2582. 
6-(Cyclohexylmethoxy)-N-(4-((2-(pyrrolidin-1-yl)propyl)sulfonyl)phenyl)-9H-purin-
2-amine (322) 
 
6-(Cyclohexylmethoxy)-N-(4-((2-(pyrrolidin-1-yl)propyl)thio)phenyl)-9H-purin-2-amine 
321 (390 mg, 0.84 mmol) was solubilised in MeOH (10 mL). Oxone (642 mg, 2.09 mmol) 
in H2O (5 mL) was added at 0°C and the resulting solution was stirred at r.t. for 18 h. 
Brine (10 mL) was added and the reaction was extracted with DCM (3 x 20 mL). The 
organic layer was dried over MgSO4 and the solvent was removed in vacuo. The crude 
product was purified by MPC on silica (DCM: MeOH 9: 1) to give the product 322 as an 
orange oil (90 mg, 0.18 mmol, 38%). 
Rf 0.28 (DCM: MeOH 9: 1); UV λmax (EtOH) 314 nm; IR (cm
-1
) 3324, 2930, 1631, 1588, 
1404, 1143, 1088; 
1
H NMR (500 MHz, MeOD) (ppm) δ 1.16-1.21 (2H, m, H-cyclo), 
1.27-1.30 (1H, m, H-cyclo), 1.32-1.40 (2H, m, H-cyclo), 1.58 (3H, d, J = 6.7 Hz, H-7’), 
1.73-1.76 (1H, m, H-cyclo), 1.80-1.83 (2H, m, H-cyclo), 1.94-1.96 (3H, m, H-cyclo, H-
2’’), 2.07-2.09 (2H, m, H-pyr), 3.17-3.23 (2H, m, H-pyr), 3.57-3.60 (2H, m, H-pyr), 3.62-
3.67 (1H, m, H-5’), 3.83 (1H, dd, J = 14.6 Hz, J = 2.2 Hz, H-5’), 3.92-3.97 (1H, m, H-6’), 
4.40 (2H, d, J = 6.1 Hz, H-1’’), 7.88 (2H, d, J = 8.8 Hz, H-3’), 8.13 (2H, d, J = 8.8 Hz, H-
2’), 8.16 (1H, s, H-8); 13C NMR (125 MHz, MeOD) (ppm) δ 17.5 (C-7’), 24.2 (2 x C-
pyr), 26.9 (2 x C-cyclo), 27.5 (C-cyclo), 30.9 (2 x C-cyclo), 38.7 (C-2’’), 52.7 (2 x C-pyr), 
56.8 (C-6’), 58.3 (C-5’), 73.4 (C-1’’), 114.5 (Cq), 118.9 (C-2’), 130.4 (C-3’), 130.6 (Cq), 
131.4 (Cq), 141.5 (Cq), 148.4 (C-8), 156.7 (Cq), 161.2 (Cq); HRMS calcd for 
C25H35N6O3S [M+H]
+
 499.2485, found 499.2486. 
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(E)-6-(Cyclohexylmethoxy)-N-(4-(prop-1-en-1-ylsulfonyl)phenyl)-9H-purin-2-amine 
(323) 
 
The title compound was synthesised following general procedure N using 6-
(cyclohexylmethoxy)-N-(4-((2-(pyrrolidin-1-yl)propyl)sulfonyl)phenyl)-9H-purin-2-
amine 322 (80 mg, 0.16 mmol), m-CPBA (37 mg, 0.39 mmol) and Cs2CO3 (130 mg, 0.40 
mmol). The crude product was purified by MPC (DCM: MeOH 19: 1) to give the product 
323 as an orange oil (10 mg, 0.02 mmol, 15%). 
Rf 0.21 (DCM: MeOH 9: 1); UV λmax (EtOH) 314 nm; IR (cm
-1
) 3231, 2925, 2852, 1594, 
1451, 1387, 1136; 
1
H NMR (500 MHz, MeOD) (ppm) δ 1.01-1.09 (2H, m, H-cyclo), 
1.16-1.18 (1H, m, H-cyclo), 1.19-1.28 (2H, m, H-cyclo), 1.60-1.63 (1H, m, H-cyclo), 
1.68-1.70 (2H, m, H-cyclo), 1.81 (3H, d, J = 6.9 Hz, J = 1.7 Hz, H-7’), 1.82-1.84 (3H, m, 
H-cyclo, H-2’’), 4.27 (2H, d, J = 6.1 Hz, H-1’’), 6.44 (1H, dd, J = 14.9 Hz, J = 1.7 Hz, H-
5’), 6.77-6.84 (1H, m, H-6’), 7.63 (2H, d, J = 9.0 Hz, H-2’), 7.92 (1H, s, H-8), 7.93 (2H, 
d, J = 9.0 Hz, H-3’); 13C NMR (125 MHz, MeOD) (ppm) δ ppm 17.2 (C-7’), 26.9 (2 x C-
cyclo), 27.6 (C-cyclo), 30.8 (2 x C-cyclo), 38.7 (C-2’’), 73.2 (C-1’’), 119.0 (C-3’), 129.3 
(Cq), 129.6 (C-2’), 132.6 (Cq), 132.9 (Cq), 133.6 (C-5’), 140.4 (Cq), 142.7 (C-6’), 147.4 
(C-8), 156.8 (Cq), 162.1 (Cq); HRMS calcd for C21H26N5O3S [M+H]
+
 428.1751, found 
428.1757. 
1-((4-Nitrophenyl)sulfonyl)propan-2-one (324) 
 
The title compound was synthesised following general procedure M using 1-((4-
nitrophenyl)thio)propan-2-one 318 (1.47 g, 6.97 mmol) and m-CPBA (3.24 g, 13.93 
mmol). The crude product was purified by MPC on silica (petrol: EtOAc 3: 2) to give the 
product 324 as a white solid (1.24 g, 5.10 mmol, 73%). 
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Rf 0.42 (petrol: EtOAc 3: 2); Mp = 114-116 °C (lit.,
265
 Mp = 118 °C); UV λmax (EtOH) 
248 nm; IR (cm
-1
) 2965, 2919, 1717, 1521, 1346, 1295, 1144; 
1
H NMR (500 MHz, 
DMSO-d6) (ppm) δ 2.22 (3H, s, H-7’), 4.97 (2H, s, H-5’), 8.20 (2H, d, J = 8.9 Hz, H-3’), 
8.47 (2H, d, J = 8.9 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 31.0 (C-7’), 
65.1 (C-5’), 124.5 (C-2’), 129.9 (C-3’), 144.4 (C-4’), 150.6 (C-1’), 197.4 (CO); HRMS 
calcd for C9H8NO5S [M-H]
-
 242.0129, found 242.0127. 
1-((4-Nitrophenyl)sulfonyl)propan-2-ol (325) 
 
The title compound was synthesised following general procedure O using 1-((4-
nitrophenyl)sulfonyl)propan-2-one 326 (1.24 g, 5.10 mmol) and Dibal (1M in hexanes, 
7.7 mL). The crude product was purified by MPC on silica (petrol: EtOAc 3: 2) to give 
the product 325 as a pale yellow oil (1.15 g, 4.69 mmol, 92%). 
Rf 0.48 (petrol: EtOAc 1: 1); UV λmax (EtOH) 251 nm; IR (cm
-1
) 3390, 2977, 2928, 1529, 
1346, 1292, 1140, 1081; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.14 (3H, d, J = 6.3 Hz, 
H-7’), 3.51 (1H, dd, J = 4.4 and 14.6 Hz, H-5’), 3.56 (1H, dd, J = 7.5 and 14.6 Hz, H-5’), 
4.06-4.10 (1H, m, H-6’), 4.81 (1H, br s, OH), 8.18 (2H, d, J = 9.0 Hz, H-3’), 8.44 (2H, d, 
J = 9.0 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 23.3 (C-7’), 61.8 (C-6’), 62.4 
(C-5’), 124.2 (C-2’), 129.5 (C-3’), 146.1 (C-4’), 150.2 (C-1’); HRMS calcd for 
C9H10NO5S [M-H]
-
 244.0285, found 244.0285. 
1-((4-Aminophenyl)sulfonyl)propan-2-ol (326) 
 
The title compound was synthesised following general procedure H using 1-((4-
nitrophenyl)sulfonyl)propan-2-ol 325 (1.15 g, 4.69 mmol) and zinc powder (3.05 g, 46.9 
mmol). The crude product was purified by MPC on amine silica (DCM: MeOH 19: 1) to 
give the product 326 as a pale orange solid (845 mg, 3.93 mmol, 84%). 
Rf 0.67 (DCM: MeOH 9: 1); Mp = 110-112 
o
C; UV λmax (EtOH) 271 nm; IR (cm
-1
) 3481, 
3376, 2967, 2924, 1627, 1594, 1274, 1121; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.12 
(3H, d, J = 6.3 Hz, H-7’), 3.13 (1H, dd, J = 6.1 and 14.1 Hz, H-5’), 3.19 (1H, dd, J = 5.7 
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and 14.1 Hz, H-5’), 3.89-3.96 (1H, m, H-6’), 4.82 (1H, br s, OH), 6.11 (2H, br s, NH2), 
6.64 (2H, d, J = 8.8 Hz, H-3’), 7.48 (2H, d, J = 8.8 Hz, H-2’); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 23.4 (C-7’), 61.7 (C-6’), 63.8 (C-5’), 112.6 (C-2’), 124.7 (C-4’), 
129.5 (C-3’), 153.5 (C-1’); HRMS calcd for C9H14NO3S [M+H]
+
 216.0689, found 
216.0688. 
1-((4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)propan-2-ol 
(327) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (300 mg, 0.63 mmol), 
1-((4-aminophenyl)sulfonyl)propan-2-ol 326 (202 mg, 0.94 mmol), K2CO3 (173 mg, 1.26 
mmol), Pd(dba)2 (12 mg, 0.01 mmol) and XPhos (6 mg, 0.01 mmol). The crude mixture 
was then filtered through Celite and the solvent was removed in vacuo. The crude 
mixture was then solubilised in TFA (15 mL). The resulting solution was heated at 70 °C 
for 2 h. Then the solvent was removed in vacuo. The product was purified by MPC on 
silica (EtOAc 100) to give the product 327 as a pale yellow oil (86 mg, 0.19 mmol, 31%). 
Rf 0.37 (EtOAc 100); UV λmax (EtOH) 313 nm; IR (cm
-1
) 3280, 3112, 2925, 2851, 1594, 
1391, 1292, 1130; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.07-1.12 (2H, m, H-cyclo), 
1.14 (3H, d, J = 6.3 Hz, H-7’), 1.19-1.21 (1H, m, H-cyclo), 1.24-1.32 (2H, m, H-cyclo), 
1.66-1.69 (1H, m, H-cyclo), 1.73-1.76 (2H, m, H-cyclo), 1.84-1.90 (3H, m, H-cyclo and 
H-2’’), 3.27 (1H, dd, J = 5.6 and 14.3 Hz, H-5’), 3.31 (1H, dd, J = 8.3 and 14.3 Hz, H-5’), 
3.97-4.02 (1H, m, H-6’), 4.37 (2H, d, J = 6.3 Hz, H-1’’), 4.88 (1H, d, J = 5.3 Hz, OH), 
7.77 (2H, d, J = 8.8 Hz, H-3’), 8.05 (2H, d, J = 8.8 Hz, H-2’), 8.07 (1H, br s, H-8), 9.93 
(1H, br s, NH), 12.98 (1H, br s, N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 23.4 (C-
7’), 25.2 (2 x C-cyclo), 26.0 (C-cyclo), 29.2 (2 x C-cyclo), 36.8 (C-2’’), 61.7 (C-6’), 63.4 
(C-5’), 71.3 (C-1’’), 115.5 (Cq), 117.3 (C-2’), 128.7 (C-3’), 130.8 (Cq), 139.7 (Cq), 145.8 
(Cq), 153.9 (Cq), 154.5 (Cq), 160.2 (Cq); HRMS calcd for C21H28N5O4S [M+H]
+
 446.1857, 
found 446.1854.  
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3-((4-Nitrophenyl)thio)butan-2-one (328) 
 
The title compound was synthesised following general procedure J using 3-chloro-2-
butanone (2.14 mL, 21.3 mmol), 4-nitrothiophenol 173 (3.00 g, 19.4 mmol) and Et3N 
(2.96 mL, 21.3 mmol). The crude product was purified by MPC on silica (petrol: EtOAc 
9: 1) to give the product 328 as a yellow oil (3.86 g, 17.23 mmol, 89%). 
Rf 0.48 (petrol: EtOAc 9: 1); UV λmax (EtOH) 330 nm; IR (cm
-1
) 2979, 2925, 1710, 1576, 
1509, 1334; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.43 (3H, d, J = 7.1 Hz, H-6’), 2.26 
(3H, s, H-7’), 4.46 (1H, q, J = 7.1 Hz, H-5’), 7.55 (2H, d, J = 8.6 Hz, H-3’), 8.15 (2H, d, 
J = 8.6 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 16.0 (C-6’), 26.6 (C-7’), 49.7 
(C-5’), 124.0 (C-2’), 128.5 (C-3’), 144.5 (C-4’), 145.4 (C-1’), 204.9 (CO); HRMS calcd 
for C10H10NO3S [M-H]
-
 224.0387, found 224.0388. 
3-((4-Nitrophenyl)sulfonyl)butan-2-one (329) 
 
The title compound was synthesised following general procedure M using 3-((4-
nitrophenyl)thio)butan-2-one 328 (3.86 g, 17.3 mmol) and m-CPBA (8.00 g, 34.5 mmol). 
The crude product was purified by MPC on silica (petrol: EtOAc 7: 3) to give the product 
329 as a pale yellow solid (4.07 g, 15.9 mmol, 92%). 
Rf 0.36 (petrol: EtOAc 7: 3); Mp = 144-145 °C (lit.,
265
 Mp = 47-49 °C); UV λmax (EtOH) 
248 nm; IR (cm
-1
) 2932, 1715, 1527, 1532, 1304, 1232, 1167; 
1
H NMR (500 MHz, 
CDCl3) (ppm) δ 1.45 (3H, d, J = 7.1 Hz, H-6’), 2.47 (3H, s, H-7’), 4.24 (1H, q, J = 7.1 Hz, 
H-5’), 8.00 (2H, d, J = 8.9 Hz, H-3’), 8.40 (2H, d, J = 8.9 Hz, H-2’); 13C NMR (125 MHz, 
CDCl3) (ppm) δ 11.9 (C-6’), 31.0 (C-7’), 70.6 (C-5’), 124.2 (C-2’), 131.0 (C-3’), 141.5 
(C-4’), 151.2 (C-1’), 199.8 (CO); HRMS calcd for C10H10NO5S [M-H]
-
 256.0285, found 
256.0284.  
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3-((4-Nitrophenyl)sulfonyl)butan-2-ol (330) 
 
The title compound was synthesised following general procedure O using 3-((4-
nitrophenyl)sulfonyl)butan-2-one 329 (2.00 g, 7.81 mmol) and DIBAL (1M in hexanes, 
11.72 mL). The crude product was purified by MPC on silica (petrol: EtOAc 7: 3) to give 
the product 330 as a pale yellow oil (2.02 g, 7.80 mmol, 99%). 
Rf 0.23 (petrol: EtOAc 7: 3); UV λmax (EtOH) 252 nm; IR (cm
-1
) 3510, 2981, 2939, 1527, 
1349, 1293, 1143; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.10 (0.75H, d, J = 6.5 Hz, 
H-8’), 1.13 (2.25H, d, J = 6.5 Hz, H-8’), 1.18 (0.75H, d, J = 7.1 Hz, H-6’), 1.20 (2.25H, d, 
J = 7.1 Hz, H-6’), 3.39 (0.25H, qd, J = 2.3 and 7.1 Hz, H-5’), 3.50 (0.75H, qd, J = 5.4 
and 7.1 Hz, H-5’), 4.02 (0.75H, m, H-7’), 4.33 (0.25H, m, H-7’), 4.96 (1H, br s, OH), 
8.14 (2H, d, J = 8.9 Hz, H-3’), 8.43 (2H, d, J = 8.9 Hz, H-2’); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 7.3 (C-8’), 7.9 (C-8’), 19.3 (C-6’), 21.6 (C-6’), 63.0 (C-7’), 64.3 (C-
7’), 64.5 (C-5’), 65.1 (C-5’), 124.0 (C-2’), 124.3 (C-2’), 129.9 (C-3’), 130.7 (C-3’), 144.0 
(C-4’), 145.2 (C-4’), 150.3 (C-1’), 150.4 (C-1’); HRMS calcd for C10H12NO5S [M-H]
-
 
258.0431, found 258.0443. 
Note: A mixture of diastereoisomers was obtained with a ratio of 3:1. 
3-((4-Aminophenyl)sulfonyl)butan-2-ol (331) 
 
The title compound was synthesised following general procedure H using 3-((4-
nitrophenyl)sulfonyl)butan-2-ol 330 (2.02 g, 7.72 mmol) and zinc powder (5.01 g, 77.2 
mmol). The crude product was purified by MPC on silica (DCM: MeOH 19: 1) to give 
the product 331 as an orange solid (1.39 g, 6.07 mmol, 78%). 
Rf 0.75 (DCM: MeOH 9: 1); UV λmax (EtOH) 270 nm; IR (cm
-1
) 3446, 3336, 2979, 1590, 
1269, 1116; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.05 (3H, d, J = 6.4 Hz, H-8’), 1.09 
(3H, d, J = 7.1 Hz, H-6’), 2.94 (0.2H, qd, J = 2.9 and 7.1 Hz, H-5’), 3.11 (0.8H, qd, J = 
3.4 and 7.1 Hz, H-5’), 4.03-4.08 (0.8H, m, H-7’), 4.13-4.18 (0.2H, m, H-7’), 4.54 (0.8H, 
d, J = 5.6 Hz, OH), 4.86 (0.2H, q, J = 4.7 Hz, OH), 6.08 (0.4H, s, NH2), 6.14 (1.6H, s, 
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NH2), 6.62 (0.4H, d, J = 8.8 Hz, H-3’), 6.65 (1.6H, d, J = 8.8 Hz, H-3’), 7.42 (2H, d, J = 
8.8 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 7.1 (C-8’), 7.8 (C-8’), 17.8 (C-
6’), 22.2 (C-6’), 63.1 (C-7’), 63.3 (C-7’), 64.4 (C-5’), 65.0 (C-5’), 112.5 (C-3’), 112.7 (C-
3’), 122.6 (C-4’), 122.7 (C-4’), 130.1 (C-2’), 130.5 (C-2’), 153.4 (C-1’), 153.6 (C-1’); 
HRMS calcd for C10H16NO3S [M+H]
+
 230.0845, found 230.0843. 
Note: A mixture of diastereoisomers was obtained with a ratio of 4:1. 
3-((4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)butan-2-ol (332) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (500 mg, 1.05 mmol), 
3-((4-aminophenyl)sulfonyl)butan-2-ol 331 (360 mg, 1.57 mmol), K2CO3 (289 mg, 2.09 
mmol), Pd(dba)2 (19 mg, 0.02 mmol) and XPhos (10 mg, 0.02 mmol). The crude mixture 
was then filtered through Celite and the solvent was removed in vacuo. The crude 
mixture was then solubilised in TFA (15 mL). The resulting solution was heated at 70 °C 
for 2 h and the solvent was removed in vacuo. The product was purified by MPC on silica 
(EtOAc 100) to give the product 332 as a yellow oil (442 mg, 0.96 mmol, 46%). 
Rf 0.40 (DCM: MeOH 9: 1); UV λmax (EtOH) 313 nm; IR (cm
-1
) 3264, 3101, 2923, 1594, 
1449, 1276, 1131; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.09 (3H, d, J = 6.4 Hz, H-8’), 
1.14 (3H, d, J = 7.1 Hz, H-6’), 1.10-1.12 (2H, m, H-cyclo), 1.18-1.20 (1H, m, H-cyclo), 
1.23-1.31 (2H, m, H-cyclo), 1.65-1.67 (1H, m, H-cyclo), 1.72-1.74 (2H, m, H-cyclo), 
1.83-1.88 (3H, m, H-cyclo and H-2’’), 3.09 (0.1H, qd, J = 2.7 and 7.1 Hz, H-5’), 3.26 
(0.9H, qd, J = 3.6 and 7.1 Hz, H-5’), 4.06-4.09 (0.9H, m, H-7’), 4.21-4.25 (0.1H, m, H-
7’), 4.36 (2H, d, J = 6.3 Hz, H-1’’), 4.66 (0.1H, d, J = 5.7 Hz, OH), 4.93 (0.9H, d, J = 4.9 
Hz, OH), 7.72 (1.8H, d, J = 8.9 Hz, H-3’), 8.02 (0.2H, d, J = 8.9 Hz, H-3’), 8.04 (2.7H, m, 
H-2’ and H-8), 8.10 (0.2H, d, J = 8.9 Hz, H-2’), 8.31 (0.1H, s, H-8), 9.91 (0.1H, s, NH), 
9.95 (0.9H, s, NH), 12.97 (0.9H, br s, N
9
H), 13.20 (0.1H, br s, N
9
H); 
13
C NMR (125 MHz, 
DMSO-d6) (ppm) δ 7.2 (C-8’), 7.6 (C-8’), 18.0 (C-6’), 22.1 (C-6’), 25.2 (2 x C-cyclo), 
26.0 (C-cyclo), 29.2 (2 x C-cyclo), 36.8 (C-2’’), 63.1 (C-7’), 63.4 (C-7’), 64.3 (C-5’), 
65.0 (C-5’), 71.4 (C-1’’), 115.5 (C-2’), 117.2 (C-2’), 128.8 (Cq), 129.3 (C-3’), 129.7 (C-
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3’), 139.7 (C-8), 146.0 (Cq), 153.9 (Cq), 154.4 (Cq), 160.2 (Cq); HRMS calcd for 
C22H30N5O4S [M+H]
+
 460.2013, found 460.2004. 
Note: A mixture of diastereoisomers was obtained with a ratio of 1:9. 1 quaternary carbon 
was not visible on the 
13
C NMR spectrum. 
N-(4-(But-2-en-2-ylsulfonyl)phenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine (333) 
 
The title compound was synthesised following general procedure P using 3-((4-((6-
(cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)butan-2-ol 332 (126 mg, 
0.27 mmol), Et3N (42.00 μL, 0.30 mmol) and MsCl (24.00 μL, 0.30 mmol). The crude 
product was purified by reverse phase (MeCN + 0.1% HCOOH: water + 0.1% HCOOH 
60: 40) to give the product 333 as a colourless oil (20 mg, 0.05 mmol, 17%). 
Rf 0.20 (MeCN + 0.1% HCOOH: water + 0.1% HCOOH 60: 40); UV λmax (EtOH) 316 
nm; IR (cm
-1
) 3258, 2923, 1579, 1385, 1286, 1124; 
1
H NMR (500 MHz, MeOD) (ppm) δ 
1.13-1.20 (2H, m, H-cyclo), 1.26-1.28 (1H, m, H-cyclo), 1.31-1.38 (2H, m, H-cyclo), 
1.72-1.74 (1H, m, H-cyclo), 1.79-1.82 (2H, m, H-cyclo), 1.83-1.84 (2H, m, H-6’), 1.85-
1.86 (2H, m, H-8’), 1.93-1.94 (2H, m, H-cyclo), 1.95-1.96 (2H, m, H-2’’ and H-6’), 2.12 
(1H, qd, J = 2.9 and 7.5 Hz, H-8’), 4.39 (2H, d, J = 6.2 Hz, H-1’’), 6.20 (0.33H, m, H-7’), 
6.88-6.92 (0.66H, m, H-7’), 7.71 (1.33H, d, J = 8.9 Hz, H-3’), 7.77 (0.66H, d, J = 8.9 Hz, 
H-3’), 8.03-8.06 (3H, m, H-2’, H-2’, H-8 and H-8); 13C NMR (125 MHz, MeOD) (ppm) 
δ 11.20 (C-6’), 14.0 (C-, 14.9 (C-8’), 20.2 (C-6’), 26.9 (2 x C-cyclo), 27.6 (C-cyclo), 30.9 
(2 x C-cyclo), 38.8 (C-2’’), 73.3 (C-1’’), 119.0 (C-2’), 129.4 (C-3’), 130.1 (C-3’), 130.8 
(Cq), 130.9 (C-2’), 132.8 (Cq), 133.5 (Cq), 135.5 (Cq), 136.5 (Cq), 138.1 (Cq), 139.5 (Cq), 
147.4 (Cq), 156.8 (Cq); HRMS calcd for C22H28N5O3S [M+H]
+
 442.1907, found 442.1902. 
Note: A mixture of isomers was obtained with a ratio of 1:2 for Z: E.   
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1-Chloro-1-((4-nitrophenyl)sulfonyl)propan-2-ol (336) 
  
LHMDS (1M in THF, 4.55 mL, 4.55 mmol) was added dropwise to a stirred solution of 
1-((chloromethyl)sulfonyl)-4-nitrobenzene 264 (712 mg, 3.03 mmol) and EtOAc (0.74 
mL, 7.58 mmol) in dry THF (14 mL) at -78 
o
C under N2. The reaction was stirred at -78 
o
C for 1 h and HCl (2M in H2O, 10 mL) was added. The reaction was warmed up to r.t. 
and extracted with EtOAc (3 x 15 mL). The organic phases were combined and dried 
over MgSO4. The solvent was removed in vacuo to give 334 without further purification. 
Under N2, ZnCl2 (1.0 g, 5.5 mol) was solubilised in dry Et2O (10 mL) and the solution 
was reflux for 1.5 h. The solution was allowed to cool to r.t. The supernatant was added 
to a stirred suspension of NaBH4 (400 mg, 10.5 mol) in dry Et2O (30 mL). The resulting 
suspension was stirred at r.t. for 2 days. The supernatant was collected to afford a 
solution of Zn(BH4)2 in Et2O at 0.18M. 
Zn(BH4)2 in Et2O (0.18M, 9.2 mL, 1.66 mmol) was added to a stirred solution of 1-
chloro-1-((4-nitrophenyl)sulfonyl)propan-2-one 334 (383 mg, 1.38 mmol) in dry THF (6 
mL) under N2. The resulting solution was stirred at r.t. for 2 h. MeOH (3 mL) was added 
to quench the residual reductive agent. The solvent was removed in vacuo and the 
product was purified by MPC (petrol: EtOAc 3: 2) to give the product 336 as a yellow oil 
(280 mg, 1.00 mmol, 73%). 
Rf 0.27 (petrol: EtOAc 4: 1); UV λmax (EtOH) 251 nm; IR (cm
-1
) 3511, 3503, 3101, 2871, 
1525, 1305, 1152; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.19 (2H, d, J = 6.3 Hz, H-7’), 
1.29 (1H, d, J = 6.3 Hz, H-7’), 4.35-4.36 (0.33 H, m, H-6’), 4.58-4.61 (0.66 H, m, H-6’), 
5.36 (0.66 H, d, J = 6.1 Hz, OH), 5.62 (0.33 H, d, J = 6.1 Hz, OH), 5.68-5.70 (1H, m, H-5’ 
and H-5’), 8.20 (1.33 H, d, J = 8.8 Hz, H-3’), 8.24 (0.66 H, d, J = 8.8 Hz, H-3’), 8.46 
(1.33 H, d, J = 8.8 Hz, H-2’), 8.46 (0.66 H, d, J = 8.8 Hz, H-2’); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 19.8 (C-7’), 21.3 (C-7’), 64.3 (C-6’), 65.5 (C-6’), 78.2 (C-5’), 79.7 
(C-5’), 124.4 (C-2’), 124.9 (C-2’), 131.4 (C-3’), 132.2 (C-3’), 142.8 (C-4’), 143.1 (C-4’), 
151.0 (C-1’), 151.3 (C-1’); HRMS calcd for C9H9ClNO5S [M
35
Cl-H]
-
 277.9895, found 
277.9883, [M
37
Cl-H]
-
 279.9864, found 279.9852. 
Note: A mixture of diastereoisomers was obtained with a ratio of 2: 1. 
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1-((4-Aminophenyl)sulfonyl)-1-chloropropan-2-ol (337) 
 
The title compound was synthesised following general procedure H using 1-chloro-1-
((4-nitrophenyl)sulfonyl)propan-2-ol 336 (280 mg, 1.00 mmol) and zinc powder (8.03 
mmol). The crude product was purified by MPC on amine silica (petrol: EtOAC 1: 1) to 
give the product 337 as an orange oil (178 mg, 0.71 mmol, 71%). 
Rf 0.47 (petrol: EtOAc 1: 1); UV λmax (EtOH) 275 nm; IR (cm
-1
) 3465, 3369, 2979, 2937, 
1591, 1298, 1127; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.17 (2H, d, J = 6.4 Hz, H-7’), 
1.19 (1H, d, J = 6.2 Hz, H-7’), 4.34 (0.33 H, qd, J = 2.7 and 6.2 Hz, H-6’), 4.41 (0.66 H, 
qd, J = 2.1 and 6.4 Hz, H-6’), 5.09 (0.33 H, d, J = 2.7 Hz, H-5’), 5.13 (0.66 H, d, J = 2.1 
Hz, H-5’), 5.15 (1H, br s, OH and OH), 6.12 (2H, br s, NH2 and NH2), 6.63 (1.33 H, d, J 
= 8.8 Hz, H-3’), 6.66 (0.66 H, d, J = 8.8 Hz, H-3’), 7.49 (1.33 H, d, J = 8.8 Hz, H-2’), 
7.51 (0.66 H, d, J = 8.8 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 18.4 (C-7’), 
21.6 (C-7’), 64.5 (C-6’), 64.6 (C-6’), 80.1 (C-5’), 80.2 (C-5’), 112.8 (C-3’), 113.1 (C-3’), 
120.5 (C-4’), 121.1 (C-4’), 131.7 (C-2’), 132.2 (C-2’), 154.7 (C-1’), 155.0 (C-1’); HRMS 
calcd for C9H13ClNO3S [M
35
Cl +H]
+
 250.0299, found 250.0298, [M
37
Cl+H]
+
 252.0268, 
found 252.0266. 
Note: A mixture of diastereoisomers was obtained with a ratio of 2: 1. 
1-Chloro-1-((4-((6-(cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl) sulfonyl) 
propan-2-ol (338) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (220 mg, 0.48 mmol), 
1-((4-aminophenyl)sulfonyl)-1-chloropropan-2-ol 337 (178 mg, 0.71 mmol), K2CO3 (133 
mg, 0.96 mmol), Pd(dba)2 (28 mg, 0.05 mmol) and XPhos (23 mg, 0.05 mmol). The 
crude mixture was then filtered through Celite and the solvent was removed in vacuo. 
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The crude mixture was then solubilised in TFA (15 mL). The resulting solution was 
heated at 70 °C for 2 h. Then the solvent was removed in vacuo. The product was 
purified by MPC (petrol: EtOAc 1: 4) to give the product 338 as a colourless oil (38 mg, 
0.08 mmol, 17%). 
Rf 0.40 (petrol: EtOAc 1: 4); UV λmax (EtOH) 315 nm; IR (cm
-1
) 3259, 3106, 1592, 1131; 
1
H NMR (500 MHz, MeOD) (ppm) δ 1.17-1.24 (2H, m, H-cyclo), 1.32-1.42 (3H, m, H-
cyclo), 1.37 (2H, d, J = 6.4 Hz, H-7’), 1.42 (1H, d, J = 6.4 Hz, H-7’), 1.75-1.78 (1H, m, 
H-cyclo), 1.83-1.86 (2H, m, H-cyclo), 1.97-1.99 (3H, m, H-cyclo and H-2’’), 4.44 (2H, d, 
J = 6.2 Hz, H-1’’), 4.57 (0.33 H, qd, J = 3.5 and 6.4 Hz, H-6’), 4.74 (0.66 H, qd, J = 2.0 
and 6.4 Hz, H-6’), 5.07 (0.66 H, d, J = 2.0 Hz, H-5’), 5.08 (0.33 H, d, J = 3.5 Hz, H-5’), 
7.87 (0.66 H, d, J = 8.9 Hz, H-3’), 7.89 (1.33 H, d, J = 8.9 Hz, H-3’), 8.10 (1.33 H, d, J = 
8.9 Hz, H-2’), 8.13 (0.66 H, d, J = 8.9 Hz, H-2’), 8.14 (1H, s, H-8); 13C NMR (125 MHz, 
MeOD) (ppm) δ 17.4 (C-7’), 19.8 (C-7’), 25.5 (2 x C-cyclo), 26.2 (C-cyclo), 29.2 (2 x C-
cyclo), 37.2 (C-2’’), 64.6 (C-6’), 65.3 (C-6’), 71.9 (C-1’’), 79.0 (C-5’), 79.2 (C-5’), 117.0 
(C-2’), 117.3 (C-2’), 126.9 (Cq), 127.0 (Cq), 130.4 (C-3’), 130.8 (C-3’), 139.9 (C-8), 
146.8 (Cq), 147.0 (Cq), 155.0 (Cq), 153.3 (Cq), 155.4 (Cq), 159.9 (Cq); HRMS calcd for 
C21H27ClN5O4S [M
35
Cl +H]
+
 480.1467, found 480.1454, [M
37
Cl+H]
+
 482.1437, found 
482.1423. 
Note: A mixture of diastereoisomers was obtained with a ratio of 2: 1. 
N-(4-((1-Chloroprop-1-en-1-yl)sulfonyl)phenyl)-6-(cyclohexylmethoxy)-9H-purin-2-
amine (339) 
 
The title compound was synthesised following general procedure P using 1-chloro-1-
((4-((6-(cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl) propan-2-ol 338 (33 
mg, 0.07 mmol), Et3N (20.0 μL, 0.14 mmol) and MsCl (10.0 μL, 0.14 mmol). After 1 h, 
DBU (0.10 mL, 0.69 mmol) was added and the reaction was stirred at r.t. for 1 h. The 
solvent was removed in vacuo. The product was purified by MPC (petrol: EtOAc 1: 4) to 
give the product 339 as a yellow oil (16 mg, 0.03 mmol, 50%). 
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Rf 0.10 (petrol: EtOAc 1: 1); UV λmax (EtOH) 320 nm; IR (cm
-1
) 3262, 2923, 2851, 1580, 
1386, 1313, 1147; 
1
H NMR (500 MHz, CDCl3) (ppm) δ 1.04-1.12 (2H, m, H-cyclo), 
1.18-1.23 (1H, m, H-cyclo), 1.26-1.31 (2H, m, H-cyclo), 1.68-1.71 (1H, m, H-cyclo), 
1.74-1.76 (2H, m, H-cyclo), 1.86-1.89 (3H, m, H-cyclo and H-2’’), 1.97 (3H, d, J = 7.1 
Hz, H-7’), 4.35 (2H, d, J = 6.2 Hz, H-1’’), 7.26 (1 H, q, J = 7.1 Hz, H-6’), 7.85 (2 H, d, J 
= 9.3 Hz, H-3’), 7.89 (2 H, d, J = 9.3 Hz, H-2’), 8.06 (1H, s, H-8); 13C NMR (125 MHz, 
CDCl3) (ppm) δ 14.5 (C-7’), 25.7 (2 x C-cyclo), 26.3 (C-cyclo), 29.8 (2 x C-cyclo), 37.2 
(C-2’’), 72.8 (C-1’’), 117.6 (C-2’), 117.8 (Cq), 128.7 (Cq), 130.4 (C-3’), 134.2 (Cq), 134.8 
(C-6’), 138.4 (C-8), 145.2 (Cq), 145.3 (Cq), 154.7 (Cq), 160.7 (Cq); HRMS calcd for 
C21H25ClN5O3S [M
35
Cl+H]
+
 462.1361, found 462.1353, [M
37
Cl+H]
+
 464.1331, found 
464.1321. 
2-((4-Nitrophenyl)thio)cyclohexanol (racemic, 341)
273
 
 
4-Nitrothiophenol 173 (1.00 g, 6.45 mmol) was added to a solution of cyclohexene oxide 
340 (0.65 mL, 6.45 mmol) and DIPEA (2.24 mL, 12.9 mmol) in dry DCM (15 mL) under 
N2. The resulting solution was stirred at r.t. for 16 h. Water (15 mL) was added and the 
organic phase was extracted with DCM (3 x 15 mL). The organic layers were combined, 
dried over MgSO4 and the solvent was removed in vacuo. The product was purified by 
MPC (petrol: EtOAc 4: 1) to give the product 341 as a yellow solid (980 mg, 3.87 mmol, 
60%). 
Rf 0.40 (petrol: EtOAc 4: 1); Mp = 91-92 °C; UV λmax (EtOH) 346 nm; IR (cm
-1
) 3357, 
2924, 2856, 1578, 1507, 1338; 
1
H NMR (500 MHz, DMSO-d6) ppm 1.28-1.42 (4H, m H-
cyclo’) 1.58-1.60 (1H, m, H-cyclo’), 1.67-1.69 (1H, m, H-cyclo’), 1.92-1.95 (1H, m, H-
cyclo’), 2.07-2.09 (1H, m, H-cyclo’), 3.34-3.43 (2H, m, H-5’ and H-6’), 5.12 (1H, d, J = 
5.0 Hz, OH), 7.57 (2H, d, J = 8.9 Hz, H-3’), 8.12 (2H, d, J = 8.9 Hz, H-2’); 13C NMR 
(125 MHz, DMSO-d6) ppm 23.7 (C-cyclo’), 24.7 (C-cyclo’), 31.1 (C-cyclo’), 34.7 (C-
cyclo’), 51.4 (C-5’), 71.4 (C-6’), 123.7 (C-2’), 127.5 (C-3’), 144.3 (C-4’), 147.9 (C-1’); 
LRMS calcd for C12H16NO3S [M+H]
+
 254.1, found 254.3.  
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2-((4-Nitrophenyl)sulfonyl)cyclohexanol (racemic, 342) 
 
The title compound was synthesised following general procedure M using 2-((4-
nitrophenyl)thio)cyclohexanol 341 (1.21 g, 4.77 mmol) and m-CPBA (2.44 g, 2.20 mmol). 
The crude product was purified by MPC on silica (petrol: EtOAc 3: 2) to give the product 
342 as a pale orange solid (1.25 g, 4.39 mmol, 92%). 
Rf 0.33 (petrol: EtOAc 7: 3); Mp = 125-126 °C; UV λmax (EtOH) 235 nm; IR (cm
-1
) 3423, 
2930, 2860, 1523, 1348, 1296; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.18-1.24 (3H, m 
H-cyclo’) 1.34-1.42 (1H, m, H-cyclo’), 1.62-1.64 (1H, m, H-cyclo’), 1.76-1.82 (2H, m, 
H-cyclo’), 2.17-2.19 (1H, m, H-cyclo’), 3.34-3.39 (1H, m, H-5’), 3.59-3.65 (1H, m, H-6’), 
4.87 (1H, d, J = 5.7 Hz, OH), 8.17 (2H, d, J = 8.9 Hz, H-3’), 8.40 (2H, d, J = 8.9 Hz, H-
2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 23.3 (C-cyclo’), 23.4 (C-cyclo’), 24.0 (C-
cyclo’), 34.9 (C-cyclo’), 67.8 (C-5’), 68.5 (C-6’), 123.8 (C-2’), 129.8 (C-3’), 147.3 (C-4’), 
149.9 (C-1’); HRMS calcd for C12H16NO5S [M+H]
+
 286.0744, found 286.0747. 
2-((4-Aminophenyl)sulfonyl)cyclohexanol (racemic, 346) 
 
The title compound was synthesised following general procedure H using 2-((4-
nitrophenyl)sulfonyl)cyclohexanol 342 (720 mg, 2.53 mmol) and zinc powder (1.60 g, 
25.3 mmol). The crude product was purified by MPC on silica (DCM: MeOH 9: 1) to 
give the product 346 as a colourless solid (590 mg, 2.31 mmol, 92 %). 
Rf 0.51 (DCM: MeOH 9: 1); Mp = 158-160 °C; UV λmax (EtOH) 270 nm; IR (cm
-1
) 3449, 
3348, 2930, 2861, 1593, 1267, 1126; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.12-1.20 
(2H, m H-cyclo’), 1.22-1.29 (2H, m H-cyclo’), 1.57-1.59 (1H, m, H-cyclo’), 1.64-1.65 
(1H, m, H-cyclo’), 1.82-1.85 (1H, m, H-cyclo’), 1.90-1.92 (1H, m, H-cyclo’), 2.88-2.93 
(1H, m, H-5’), 3.52-3.58 (1H, m, H-6’), 4.68 (1H, d, J = 4.8 Hz, OH), 6.10 (2H, s, NH2), 
6.63 (2H, d, J = 8.7 Hz, H-3’), 7.45 (2H, d, J = 8.7 Hz, H-2’); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 23.0 (C-cyclo’), 23.7 (C-cyclo’), 24.7 (C-cyclo’), 34.2 (C-cyclo’), 
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67.7 (C-5’), 67.9 (C-6’), 112.4 (C-3’), 123.7 (C-4’), 130.5 (C-2’), 153.5 (C-5’); HRMS 
calcd for C12H18NO3S [M+H]
+
 256.1002, found 256.1004. 
2-((4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl) cyclohexanol 
(racemic, 347) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (500 mg, 1.05 mmol), 
2-((4-aminophenyl)sulfonyl)cyclohexanol 346 (400 mg, 1.57 mmol), K2CO3 (290 mg, 
2.09 mmol), Pd(dba)2 (20 mg, 0.02 mmol) and XPhos (10 mg, 0.02 mmol). The crude 
mixture was then filtered through Celite and the solvent was removed in vacuo. The 
crude mixture was then solubilised in TFA (15 mL). The resulting solution was heated at 
70 °C for 3 h. Then the solvent was removed in vacuo. The product was purified by MPC 
(EtOAc: MeOH 9: 1) to give the product 347 as a colourless oil (290 mg, 0.60 mmol, 
57%). 
Rf 0.45 (EtOAc: MeOH 9: 1); UV λmax (EtOH) 312 nm; IR (cm
-1
) 3498, 3111, 2927, 2855, 
1595, 1392, 1277, 1131; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.07-1.15 (2H, m H-
cyclo) 1.17-1.21 (4H, m, 3 x H-cyclo’ and H-cyclo), 1.23-1.32 (3H, m, H-cyclo’ and 2 x 
H-cyclo), 1.58-1.61 (1H, m, H-cyclo’), 1.67-1.69 (2H, m, H-cyclo and H-cyclo’), 1.73-
1.76 (2H, m, H-cyclo), 1.83-1.87 (4H, m, 2 x H-cyclo, H-cyclo’ and H-2’’), 2.00-2.02 
(1H, m, H-cyclo’), 3.03-3.08 (1H, m, H-cyclo’), 3.60 (1H, td, J = 9.3 and 4.4 Hz, H-
cyclo’), 4.37 (2H, d, J = 6.3 Hz, H-1’’), 4.77 (1H, br s, OH), 7.73 (2H, d, J = 8.9 Hz, H-
3’), 8.02 (2H, d, J = 8.9 Hz, H-2’), 8.14 (1H, s, H-8), 9.89 (1H, s, NH) , 13.00 (1H, br s, 
N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 23.3 (C-cyclo’), 23.8 (C-cyclo’), 24.5 
(C-cyclo’), 25.2 (2 x C-cyclo), 26.0 (C-cyclo), 29.2 (2 x C-cyclo), 34.6 (C-cyclo’), 36.8 
(C-2’’), 67.9 (C-cyclo’), 68.0 (C-cyclo’), 71.4 (C-1’’), 117.0 (C-2’), 129.5 (C-3’), 130.2 
(Cq), 140.6 (Cq), 145.6 (Cq), 147.0 (Cq), 154.5 (Cq); HRMS calcd for C24H32N5O4S 
[M+H]
+
 486.2170, found 486.2160. 
Note: Two quaternary carbons were not visible on the 
13
C NMR spectrum. 
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N-(4-(Cyclohex-1-en-1-ylsulfonyl)phenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine 
(349) 
 
The title compound was synthesised following general procedure P using 2-((4-((6-
(cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)cyclohexanol 347 (290 mg, 
0.60 mmol), Et3N (0.13 mL, 0.90 mmol) and MsCl (0.07 mL, 0.90 mmol). After 1 h, 
DBU (0.45 mL, 2.99 mmol) was added and the solution was stirred at r.t. for 3 h. Brine (5 
mL) was added and the organic phase was extracted with DCM (3 x 5 mL). The organic 
phases were combined, dried over MgSO4 and the solvent was removed in vacuo. The 
product was purified by MPC (DCM: MeOH 9: 1) to give the product 349 as a colourless 
oil (65 mg, 0.14 mmol, 23%). 
Rf 0.75 (DCM: MeOH 9: 1); UV λmax (EtOH) 317 nm; IR (cm
-1
) 3105, 2926, 2853, 1582, 
1534, 1450, 1286, 1138; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.09-1.13 (2H, m H-
cyclo) 1.18-1.21 (1H, m, H-cyclo), 1.24-1.29 (2H, m, H-cyclo), 1.48-1.51 (2H, m, H-
cyclo’), 1.55-1.58 (2H, m, H-cyclo’), 1.63-1.66 (1H, m, H-cyclo), 1.73-1.75 (2H, m, H-
cyclo), 1.84-1.87 (3H, m, H-cyclo and H-2’’), 2.08-2.09 (2H, m, H-cyclo’), 2.21-2.24 
(2H, m, H-cyclo’), 4.37 (2H, d, J = 6.3 Hz, H-1’’), 6.88-6.91 (1H, m, H-6’), 7.68 (2H, d, 
J = 8.8 Hz, H-2’), 8.04 (2H, d, J = 8.9 Hz, H-3’), 8.07 (1H, s, H-8), 9.93 (1H, s, NH) , 
12.96 (1H, br s, N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 20.4 (C-cyclo’), 21.4 (C-
cyclo’), 22.4 (C-cyclo’), 24.8 (C-cyclo’), 25.2 (2 x C-cyclo), 26.0 (C-cyclo), 29.2 (2 x C-
cyclo), 36.8 (C-2’’), 71.4 (C-1’’), 117.6 (C-3’), 128.6 (C-2’), 129.3 (Cq), 137.0 (C-6’), 
139.7 (Cq), 139.8 (C-8), 145.8 (Cq), 153.9 (Cq), 154.5 (Cq), 160.2 (Cq), 174.6 (Cq); 
HRMS calcd for C24H30N5O3S [M+H]
+
 468.2064, found 468.2054. 
  
 324 
4-((6-(Cyclohexylmethoxy)-9-(4-methoxybenzyl)-9H-purin-2-yl)amino) 
benzenesulfonamide (351) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (400 mg, 0.84 mmol), 
sulfanilamide 350 (173 mg, 1.00 mmol), K2CO3 (231 mg, 1.67 mmol), Pd(dba)2 (15 mg, 
0.02 mmol) and XPhos (8 mg, 0.02 mmol). The crude product was purified by MPC 
(DCM: MeOH 19: 1) to give the product 351 as an orange oil (98 mg, 0.18 mmol, 21%). 
Rf 0.54 (DCM: MeOH 9: 1); UV λmax (EtOH) 270 nm; IR (cm
-1
) 3425, 2935, 2847, 1525, 
1474, 1398, 1286; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 0.97-1.04 (2H, m, H-cyclo), 
1.18-1.28 (3H, m, H-cyclo), 1.60-1.66 (1H, m, H-cyclo), 1.69-1.73 (2H, m, H-cyclo), 
1.76-1.82 (3H, m, H-2’’, H-cyclo), 3.73 (3H, s, H-4’’’), 4.18 (2H, d, J = 6.4 Hz, H-1’’), 
5.20 (2H, s, H-1’’’), 6.02 (2H, s, NH2), 6.56 (2H, d, J = 8.8 Hz, H-3’’’), 6.88 (2H, d, J = 
8.7 Hz, H-2’), 7.29 (2H, d, J = 8.7 Hz, H-3’), 7.63 (2H, d, J = 8.8 Hz, H-2’’’), 8.20 (1H, s, 
H-8), 11.10 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 25.1 (2 x C-cyclo), 
25.9 (C-cyclo), 29.0 (2 x C-cyclo), 36.6 (C-2’’), 45.9 (C-1’’’), 55.1 (C-4’’’), 71.5 (C-1’’), 
112.2 (C-3’’’), 112.4 (Cq), 114.0 (C-3’), 125.5 (Cq), 127.4 (Cq), 128.7 (Cq), 129.1 (Cq), 
129.3 (C-2’), 129.4 (C-2’’’), 152.0 (Cq), 152.9 (Cq), 158.9 (Cq), 160.2 (Cq); HRMS calcd 
for C26H31N6O4S [M+H]
+
 523.2122, found 523.2115. 
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N-Acryloyl-N-((4-((6-(cyclohexylmethoxy)-9-(4-methoxybenzyl)-9H-purin-2-yl) 
amino)phenyl)sulfonyl)acrylamide (352) 
 
4-((6-(Cyclohexylmethoxy)-9-(4-methoxybenzyl)-9H-purin-2-yl)amino)benzene 
sulfonamide 351 (92 mg, 0.18 mmol) was solubilised in dry DCM (5 mL) under N2. 
DIPEA (0.07 mL, 0.36 mmol) and acryloyl chloride (0.03 mL, 0.36 mmol) were added to 
the solution. The reaction was stirred at r.t. for 1 h. The solution was washed with brine 
(3 x 5 mL) and the organic layer was dried with MgSO4. Then the solvent was removed 
in vacuo. The product was purified by MPC (petrol: EtOAc 4: 1) to give the product 352 
as a pale orange oil (33 mg, 0.05 mmol, 29%). 
Rf 0.49 (petrol: EtOAc 4: 1); UV λmax (EtOH) 282 nm; IR (cm
-1
) 3348, 2927, 2852, 1697, 
1590, 1514, 1405, 1358, 1241, 1163; 
1
H NMR (500 MHz, CDCl3) (ppm) δ 1.08-1.16 (2H, 
m, H-cyclo), 1.21-1.32 (3H, m, H-cyclo), 1.65-1.71 (1H, m, H-cyclo), 1.76-1.79 (2H, m, 
H-cyclo), 1.90-1.96 (3H, m, H-2’’, H-cyclo), 3.81 (3H, s, H-4’’’), 4.41 (2H, d, J = 6.4 Hz, 
H-1’’), 5.36 (2H, s, H-1’’’), 5.63 (1H, dd, J = 10.4 and 1.4 Hz, H-6’), 5.78 (1H, dd, J = 
16.6 and 10.4 Hz, H-5’), 5.86 (1H, dd, J = 10.3 and 1.0 Hz, H-8’), 6.31 (1H, dd, J = 16.8 
and 10.3 Hz, H-7’), 6.42 (1H, dd, J = 16.6 and 1.4 Hz, H-6’), 6.50 (1H, dd, J = 16.8 and 
1.0 Hz, H-8’), 6.91 (2H, d, J = 8.7 Hz, H-3’’’), 7.31 (2H, d, J = 8.7 Hz, H-2’’’), 7.82 (2H, 
d, J = 8.9 Hz, H-2’), 7.93 (1H, s, NH), 8.00 (1H, s, H-8), 8.21 (2H, d, J = 8.9 Hz, H-3’); 
13
C NMR (125 MHz, CDCl3) (ppm) δ 25.7 (2 x C-cyclo), 26.3 (C-cyclo), 29.7 (2 x C-
cyclo), 37.2 (C-2’’), 47.6 (C-1’’’), 55.4 (C-4’’’), 73.4 (C-1’’), 114.6 (C-3’’’), 119.0 (C-
3’), 121.2 (Cq), 126.7 (Cq), 127.8 (C-5’), 129.2 (C-8’), 129.7 (C-2’’’), 130.7 (C-7’), 130.8 
(C-2’), 131.8 (C-6’), 143.1 (Cq), 143.5 (C-8), 149.3 (Cq), 153.0 (Cq), 159.9 (Cq), 161.9 
(Cq), 163.8 (CO), 163.9 (CO); HRMS calcd for C32H35N6O6S [M+H]
+
 631.2333, found 
631.2338. 
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N-((4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl) acrylamide 
(353) 
 
N-Acryloyl-N-((4-((6-(cyclohexylmethoxy)-9-(4-methoxybenzyl)-9H-purin-2-yl) amino) 
phenyl)sulfonyl)acrylamide 352 (33 mg, 0.05 mmol) was solubilised in TFA (2 mL). The 
resulting solution was heated at 70 °C for 3 h. Then the solvent was removed in vacuo. 
The product was purified by MPC (DCM: MeOH 9: 1) to give the product 353 as a 
colourless oil (12 mg, 0.03 mmol, 53%). 
Rf: 0.46 (DCM: MeOH 9: 1); UV λmax (EtOH) 273 nm; IR (cm
-1
) 3316, 2927, 2852, 1627, 
1593, 1438, 1333, 1276, 1146, 1090; 
1
H NMR (500 MHz, MeOD) (ppm) δ 1.03-1.10 (2H, 
m, H-cyclo), 1.23-1.26 (1H, m, H-cyclo), 1.27-1.32 (2H, m, H-cyclo), 1.69-1.72 (1H, m, 
H-cyclo), 1.75-1.78 (2H, m, H-cyclo), 1.82-1.85 (3H, m, H-2’’, H-cyclo), 4.17 (2H, d, J 
= 6.2 Hz, H-1’’), 5.83 (1H, dd, J = 9.0 and 3.0 Hz, H-6’), 6.42-6.44 (2H, m, H-5’ and H-
6’), 7.86 (2H, d, J = 8.4 Hz, H-2’), 8.04 (2H, d, J = 8.4 Hz, H-3’), 8.16 (1H, s, H-8); 13C 
NMR (125 MHz, MeOD) (ppm) δ 26.8 (2 x C-cyclo), 27.5 (C-cyclo), 30.7 (2 x C-cyclo), 
38.6 (C-2’’), 73.6 (C-1’’), 120.4 (C-3’), 128.1 (Cq), 128.8 (C-6’), 129.2 (Cq), 130.1 (C-2’), 
132.1 (C-5’), 135.7 (Cq), 136.8 (Cq), 144.3 (C-8), 148.3 (Cq), 153.7 (Cq), 166.3 (CO); 
HRMS calcd for C21H25N6O4S [M+H]
+
 457.1653, found 457.1657. 
tert-Butyl-(4-aminophenyl)carbamate (357)
274
 
 
Boc2O (2.02 g, 9.26 mmol) was added to a solution of p-phenylenediamine 356 (1.00 g, 
9.26 mmol) and Et3N (1.29 mL, 9.26 mmol) in dry DMF (5 mL) under N2. The reaction 
was stirred at r.t. for 3 h. The solution was then diluted with EtOAc (20 mL) and washed 
with brine (2 x 30 mL) and water (1 x 30 mL) and the organic layer was dried with 
MgSO4. The product was purified by MPC (petrol: EtOAc 1: 1) to give the product 357 
as a pale orange oil (1.62 g, 7.79 mmol, 84%). 
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Rf 0.36 (petrol: EtOAc 1: 1); UV λmax (EtOH) 250 nm; IR (cm
-1
) 3665, 2985, 1693, 1515, 
1428, 1234, 1158; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.45 (9H, s, (CH3)3), 4.73 
(2H, s, NH2), 6.45 (2H, d, J = 8.7 Hz, H-3’), 7.07 (2H, d, J = 8.7 Hz, H-2’), 8.78 (1H, s, 
NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 28.3 (3 x CH3), 78.0 (C), 113.8 (C-3’), 
120.2 (C-2’), 143.3 (C-1’), 153.0 (C-4’), 170.5 (CO); HRMS calcd for C11H17N2O2 
[M+H]
+
 209.1285, found 209.1284. 
tert-Butyl (4-(vinylsulfonamido)phenyl)carbamate (358) 
 
tert-Butyl (4-aminophenyl)carbamate 357 (624 mg, 3.00 mmol) was solubilised in dry 
DCM (2 mL) under N2. DIPEA (1.05 mL, 6.00 mmol) and 2-chloroethanesulfonyl 
chloride (0.32 mL, 3.00 mL) were added. The reaction was stirred at r.t. for 2 h. The 
solvent was removed in vacuo. The product was purified by MPC (petrol: EtOAc 2: 3) to 
give the product 358 as a colourless oil (320 mg, 1.07 mmol, 36%). 
Rf 0.48 (petrol: EtOAc 1: 1); UV λmax (EtOH) 248 nm; IR (cm
-1
) 3375, 3265, 2982, 1704, 
1519, 1325, 1142; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.47 (9H, s, (CH3)3), 5.98 
(1H, d, J = 10.1 Hz, H-6’), 6.02 (1H, d, J = 16.5 Hz, H-6’), 6.71 (1H, dd, J = 10.1 and 
16.5 Hz, H-5’), 7.04 (2H, d, J = 8.8 Hz, H-3’), 7.37 (2H, d, J = 8.8 Hz, H-2’), 9.29 (1H, s, 
NH), 9.69 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 28.1 (3 x CH3), 78.8 
(C), 118.9 (C-2’), 121.6 (C-3’), 127.2 (C-6’), 131.5 (C-1’), 136.3 (C-5’), 152.7 (C-4’), 
168.9 (CO); HRMS calcd for C13H17N2O4S [M-H]
-
 297.0915, found 297.0904. 
tert-Butyl-(4-(2-(pyrrolidin-1-yl)ethylsulfonamido)phenyl)carbamate (359) 
 
Pyrrolidine (0.36 mL, 4.30 mmol) was added to a stirred solution of tert-butyl (4-
(vinylsulfonamido)phenyl)carbamate 358 (320 mg, 1.07 mmol) in dry DCM (10 mL) 
under N2. The reaction for stirred for 30 min at r.t. The solution was then diluted with 
DCM (20 mL) and washed with brine (2 x 30 mL) and water (1 x 30 mL) and the organic 
layer was dried with MgSO4. The product was purified by MPC (EtOAc: MeOH 9: 1) to 
give the product 359 as a colourless solid (237 mg, 0.64 mmol, 60%). 
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Rf 0.17 (EtOAc 100); Mp = 75-77 °C; UV λmax (EtOH) 249 nm; IR (cm
-1
) 2973, 2807, 
1704, 1515, 1313, 1146; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.47 (9H, s, (CH3)3), 
1.60-1.65 (4H, m, H-pyr), 2.35-2.38 (4H, m, H-pyr), 2.75 (2H, t, J = 7.6 Hz, H-6’), 3.16 
(2H, t, J = 7.6 Hz, H-5’), 7.21 (2H, d, J = 8.8 Hz, H-3’), 7.39 (2H, d, J = 8.8 Hz, H-2’), 
9.31 (1H, s, NH), 9.52 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 22.9 (2 x 
C-pyr), 28.1 (3 x CH3), 49.2 (C-5’ and C-6’), 53.3 (2 x C-pyr), 78.3 (C), 118.9 (C-2’), 
121.3 (C-3’), 132.3 (C-1’), 136.1 (C-4’), 170.2 (CO); HRMS calcd for C17H28N3O4S 
[M+H]
+
 370.1795, found 370.1795. 
N-(4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)-2-(pyrrolidin-1-
yl)ethanesulfonamide (361) 
 
6-(Cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (350 mg, 0.73 
mmol), tert-butyl (4-(2-(pyrrolidin-1-yl)ethylsulfonamido)phenyl)carbamate 359 (540 mg, 
1.46 mmol), Cs2CO3 (476 mg, 1.46 mmol) and 2-thiophenecarboxylic acid (28 mg, 0.22 
mmol) were solubilised in dry DMSO (2 mL) under N2. The solution was degased with 
N2 for 15 min then Cu(I)I (14 mg, 0.07 mmol) was added. The resulting solution was 
stirred at 60 °C for 18 h. EtOAc was added (10 mL) and the organic phase was washed 
with brine (3 x 10 mL). The organic layer was dried with MgSO4 and the solvent was 
removed in vacuo. The crude product was solubilised in TFA (10 mL) and the resulting 
solution was heated under MW at 110 °C for 45 min. The solvent was removed in vacuo 
and the crude mixture was resuspensed in DCM (10 mL). The oganic phase was washed 
with brine (2 x 30 mL) and water (1 x 30 mL) and the organic layer was dried with 
MgSO4. The crude compound was then solubilised in MeOH. NaBH4 (200 mg, 5.40 
mmol) was added and the solution was stirred at r.t. for 1 h. Then the solvent was 
removed in vacuo. The product was purified by MPC (DCM: MeOH 9: 1) to give the 
product 361 as a yellow oil (125 mg, 0.25 mmol, 34%). 
Rf 0.36 (DCM: MeOH 9: 1); UV λmax (EtOH) 255 nm; IR (cm
-1
) 3368, 3218, 2926, 2851, 
1590, 1513, 1360, 1270; 
1
H NMR (500 MHz, MeOD) (ppm) δ 0.96-1.02 (2H, m H-cyclo) 
1.18-1.29 (3H, m, H-cyclo), 1.66-1.68 (1H, m, H-cyclo), 1.71-1.75 (5H, m, 4 x H-cyclo 
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and H-2’’), 1.79-1.81 (4H, m, H-pyr), 2.60-2.62 (4H, m, H-pyr), 3.03-3.06 (2H, m, H-6’), 
4.15-4.17 (2H, m, H-5’), 4.19 (2H, d, J = 6.7 Hz, H-1’’), 6.72 (2H, d, J = 8.6 Hz, H-3’), 
7.06 (2H, d, J = 8.6 Hz, H-2’), 8.12 (1H, s, H-8); 13C NMR (125 MHz, MeOD) (ppm) δ 
24.4 (2 x C-pyr), 26.8 (2 x C-cyclo), 27.5 (C-cyclo), 30.6 (2 x C-cyclo), 38.4 (C-2’’), 
50.7 (C-6’), 53.9 (C-5’), 55.0 (2 x C-pyr), 73.7 (C-1’’), 116.1 (C-3’), 122.4 (Cq), 129.3 
(Cq), 132.3 (C-2’), 132.6 (Cq), 143.0 (C-8), 149.7 (Cq), 156.5 (Cq), 160.8 (Cq); HRMS 
calcd for C24H34N7O3S [M+H]
+
 500.2438, found 500.2431. 
N-(4-((6-(cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)ethene sulfonamide (362) 
 
N
1
-(6-(Cyclohexylmethoxy)-9H-purin-2-yl)benzene-1,4-diamine 364 (330 mg, 0.98 
mmol) was solubilised in dry DCM (5 mL) under N2. DIPEA (0.34 mL, 1.95 mmol) and 
2-chloroethanesulfonyl chloride (0.10 mL, 0.98 mL) were added. The reaction was stirred 
at r.t. for 2 h. The solvent was removed in vacuo. The product was purified by MPC on 
neutral alumina (DCM: MeOH 9: 1) and by semi-prep HPLC (0.1% Formic Acid in H2O: 
MeCN 2: 3) to give the product 362 as a colourless oil (13 mg, 0.03 mmol, 3%). 
Rf 0.37 (DCM: MeOH 19: 1); UV λmax (EtOH) 299 nm; IR (cm
-1
) 3261, 2923, 2849, 1586, 
1507, 1449, 1212, 1146; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.06-1.12 (2H, m, H-
cyclo), 1.15-1.20 (1H, m, H-cyclo), 1.23-1.31 (2H, m, H-cyclo), 1.66-1.68 (1H, m, H-
cyclo), 1.72-1.75 (2H, m, H-cyclo), 1.82-1.88 (3H, m, H-cyclo, H-2’’), 4.32 (2H, d, J = 
5.8 Hz, H-1’’), 6.00 (2H, dd, J = 9.8 and 16.3 Hz, H-6’), 6.74 (2H, dd, J = 9.8 and 16.3 
Hz, H-6’), 7.07 (2H, d, J = 8.4 Hz, H-3’), 7.72 (2H, d, J = 8.4 Hz, H-2’), 8.25 (1H, br s, 
H-8), 9.27 (1H, br s, NH), 9.63 (1H, br s, N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 
25.2 (2 x C-cyclo), 26.0 (C-cyclo), 29.2 (2 x C-cyclo), 36.8 (C-2’’), 71.0 (C-1’’), 119.1 
(C-2’), 121.9 (C-3’), 127.2 (C-6’), 133.6 (C-5’); HRMS calcd for C20H25N6O3S [M+H]
+
 
429.1703, found 429.1702. 
Note: Seven quaternary carbons were not visible on the 
13
C NMR spectrum. 
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N-(4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)-2-(pyrrolidin-1-
yl)ethanesulfonamide (363) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (500 mg, 1.05 mmol), 
4-nitroaniline 3524 (217 mg, 1.57 mmol), K2CO3 (290 mg, 2.09 mmol), Pd(dba)2 (20 mg, 
0.02 mmol) and XPhos (10 mg, 0.02 mmol). The crude mixture was then filtered through 
Celite and the solvent was removed in vacuo. The crude mixture was then solubilised in 
TFA (15 mL). The resulting solution was heated at 70 °C for 3 h. Then the solvent was 
removed in vacuo. The product was purified by MPC (petrol: EtOAc 1: 1) to give the 
product 363 as a yellow solid (160 mg, 0.43 mmol, 42%). 
Rf 0.48 (petrol: EtOAc 1: 1); Mp = 190-191 °C; UV λmax (EtOH) 370 nm; IR (cm
-1
) 2926, 
2853, 1595, 1497, 1318, 1300, 1110; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.08-1.15 
(2H, m H-cyclo) 1.18-1.22 (1H, m, H-cyclo), 1.24-1.32 (2H, m, H-cyclo), 1.67-1.69 (1H, 
m, H-cyclo), 1.73-1.76 (2H, m, H-cyclo), 1.85-1.88 (3H, m, H-cyclo and H-2’’), 4.38 (2H, 
d, J = 6.3 Hz, H-1’’), 8.07 (2H, d, J = 9.4 Hz, H-2’), 8.18 (1H, s, H-8), 8.20 (2H, d, J = 
9.4 Hz, H-3’), 10.21 (1H, s, NH) , 13.10 (1H, s, N9H); 13C NMR (125 MHz, DMSO-d6) 
(ppm) δ 25.2 (2 x C-cyclo), 26.0 (C-cyclo), 29.2 (2 x C-cyclo), 36.8 (C-2’’), 71.5 (C-1’’), 
117.0 (C-2’), 125.0 (C-3’), 135.8 (Cq), 139.8 (Cq), 140.8 (Cq), 147.7 (Cq), 149.6 (Cq), 
149.8 (Cq), 154.1 (Cq); HRMS calcd for C18H20N6O3 [M+H]
+
 369.1670, found 369.1671. 
N-(6-(Cyclohexylmethoxy)-9H-purin-2-yl)benzene-1,4-diamine (364) 
 
N-(4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)-2-(pyrrolidin-1-yl) ethane 
sulfonamide 363 (290 mg, 0.79 mmol) in MeOH (16 mL) was subjected to palladium 
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catalysed hydrogenation using an H-Cube reactor and a 10% Pd/C CatCart. The 
reaction was conducted at 40 °C for 2 h. The solvent was removed in vacuo to give 364 
as a brown oil (260 mg, 0.77 mmol, 97%). 
Rf 0.77 (DCM: MeOH 9: 1); UV λmax (EtOH) 276 nm; IR (cm
-1
) 3435, 2925, 2853, 1617, 
1584, 1451, 1407, 1142; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.03-1.10 (2H, m H-
cyclo) 1.18-1.20 (1H, m, H-cyclo), 1.23-1.28 (2H, m, H-cyclo), 1.65-1.68 (1H, m, H-
cyclo), 1.72-1.74 (2H, m, H-cyclo), 1.82-1.85 (3H, m, H-cyclo and H-2’’), 4.28 (2H, d, J 
= 6.3 Hz, H-1’’), 5.14 (2H, br s, NH2), 6.55 (2H, d, J = 8.6 Hz, H-3’), 7.40 (2H, d, J = 8.6 
Hz, H-2’), 7.91 (1H, s, H-8), 8.77 (1H, s, NH), 12.61 (1H, br s, NH); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 25.2 (2 x C-cyclo), 26.0 (C-cyclo), 29.2 (2 x C-cyclo), 36.8 (C-2’’), 
70.7 (C-1’’), 113.6 (Cq), 114.4 (C-3’), 120.8 (C-2’), 128.6 (Cq), 131.0 (Cq), 138.4 (Cq), 
142.1 (C-8), 156.2 (Cq), 159.7 (Cq); HRMS calcd for C18H22N6O [M+H]
+
 339.1928, 
found 339.1928. 
1-((4-Aminophenyl)sulfonyl)propan-2-one (365) 
 
The title compound was synthesised following general procedure H using 1-((4-
aminophenyl)sulfonyl)propan-2-one 324 (550 mg, 2.26 mmol) and zinc powder (1.47 mg, 
22.6 mmol). The crude product was purified by MPC on silica (DCM: MeOH 49: 1) to 
give the product 365 as an orange oil (370 mg, 1.74 mmol, 77 %). 
Rf 0.58 (DCM: MeOH 19: 1); Mp = 114-116 
o
C; UV λmax (EtOH) 274 nm; IR (cm
-1
) 
3370, 2919, 1719, 1594, 1284, 1131; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 2.19 (3H, s, 
H-7’), 4.40 (2H, s, H-5’), 6.24 (2H, br s, NH2), 6.63 (2H, d, J = 8.7 Hz, H-3’), 7.47 (2H, 
d, J = 8.7 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 31.1 (C-7’), 67.4 (C-5’), 
112.6 (C-3’), 129.8 (C-2’), 140.2 (C-4’), 154.0 (C-1’), 190.9 (CO); HRMS calcd for 
C9H10NO3S [M-H]
-
 212.0387, found 212.0391.   
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1-((4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)sulfonyl)propan-2-one 
(366) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (300 mg, 0.63 mmol), 
1-((4-aminophenyl)sulfonyl)propan-2-one 365 (200 mg, 0.94 mmol), K2CO3 (173 mg, 
1.26 mmol), Pd(dba)2 (12 mg, 0.01 mmol) and XPhos (6 mg, 0.01 mmol). The crude 
mixture was then filtered through Celite and the solvent was removed in vacuo. The 
crude mixture was then solubilised in TFA (15 mL). The resulting solution was heated at 
70 °C for 2 h. Then the solvent was removed in vacuo. The product was purified by MPC 
(petrol: EtOAc 1: 4) to give the product 366 as a pale yellow oil (125 mg, 0.28 mmol, 
45%). 
Rf 0.28 (petrol: EtOAc 1: 4); UV λmax (EtOH) 313 nm; IR (cm
-1
) 3199, 2919, 2844, 1710, 
1576, 1302, 1136; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.08-1.14 (2H, m, H-cyclo), 
1.20-1.22 (1H, m, H-cyclo), 1.25-1.33 (2H, m, H-cyclo), 1.67-1.69 (1H, m, H-cyclo), 
1.73-1.76 (2H, m, H-cyclo), 1.85-1.92 (3H, m, H-cyclo and H-2’’), 2.23 (3H, s, H-7’), 
4.38 (2H, d, J = 6.3 Hz, H-1’’), 4.58 (2H, s, H-5’), 7.77 (2H, d, J = 8.8 Hz, H-3’), 8.06 
(2H, d, J = 8.8 Hz, H-2’), 8.08 (1H, s, H-8), 9.98 (1H, br s, NH), 12.99 (1H, br s, N9H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 25.2 (2 x C-cyclo), 26.0 (C-cyclo), 29.2 (2 x C-
cyclo), 31.2 (C-7’), 36.8 (C-2’’), 66.8 (C-5’), 71.4 (C-1’’), 115.5 (Cq), 117.3 (C-2’), 
128.9 (C-3’), 129.7 (Cq), 138.7 (C-8), 146.2 (Cq), 153.8 (Cq), 154.4 (Cq), 160.2 (Cq), 
197.3 (CO); HRMS calcd for C21H24N5O4S [M-H]
-
 442.1554, found 442.1553. 
4-((Chloromethyl)sulfonyl)aniline (367) 
 
The title compound was synthesised following general procedure H using 1-
((chloromethyl)sulfonyl)-4-nitrobenzene 264 (300 mg, 1.28 mmol) and zinc powder (664 
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mg, 10.2 mmol). The crude product was purified by MPC on silica (petrol: EtOAc 3: 2) 
to give the product 367 as an orange oil (184 mg, 0.90 mmol, 70%). 
Rf 0.47 (petrol: EtOAc 1: 1); UV λmax (EtOH) 274 nm; IR (cm
-1
) 3490, 3388, 3014, 2946, 
1592, 1298; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 5.02 (2H, s, H-5’), 6.32 (2H, br s, 
NH2), 6.66 (2H, d, J = 8.8 Hz, H-3’), 7.51 (2H, d, J = 8.8 Hz, H-2’); 
13
C NMR (125 MHz, 
DMSO-d6) (ppm) δ 58.8 (C-5’), 113.3 (C-3’), 120.2 (C-4’), 131.4 (C-2’), 154.9 (C-1’); 
HRMS calcd for C7H7ClNO2S [M-H]
-
 203.9892, found 203.9883. 
N-(4-((Chloromethyl)sulfonyl)phenyl)-6-(cyclohexylmethoxy)-9H-purin-2-amine 
(368) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (200 mg, 0.42 mmol), 
4-((chloromethyl)sulfonyl)aniline 367 (127 mg, 0.63 mmol), K2CO3 (115 mg, 0.84 
mmol), Pd(dba)2 (19 mg, 0.02 mmol) and XPhos (10 mg, 0.02 mmol). The crude mixture 
was then filtered through Celite and the solvent was removed in vacuo. The crude 
mixture was then solubilised in TFA (10 mL). The resulting solution was heated at 70 °C 
for 2 h. Then the solvent was removed in vacuo. The product was purified by MPC 
(petrol: EtOAc 1: 4) to give the product 368 as a yellow oil (77 mg, 0.18 mmol, 47%). 
Rf 0.35 (petrol: EtOAc 1: 4); UV λmax (EtOH) 315 nm; IR (cm
-1
) 3256, 2924, 2851, 1593, 
1310, 1145; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.07-1.14 (2H, m, H-cyclo), 1.16-
1.21 (1H, m, H-cyclo), 1.24-1.32 (2H, m, H-cyclo), 1.66-1.68 (1H, m, H-cyclo), 1.73-
1.75 (2H, m, H-cyclo), 1.85-1.87 (3H, m, H-cyclo and H-2’’), 4.38 (2H, d, J = 6.3 Hz, H-
1’’), 5.20 (2H, s, H-5’), 7.81 (2H, d, J = 8.9 Hz, H-3’), 8.10 (2H, d, J = 8.9 Hz, H-2’), 
8.19 (1H, s, H-8), 10.05 (1H, br s, NH), 13.07 (1H, br s, N
9
H); 
13
C NMR (125 MHz, 
DMSO-d6) (ppm) δ 25.7 (2 x C-cyclo), 26.5 (C-cyclo), 29.7 (2 x C-cyclo), 37.3 (C-2’’), 
58.4 (C-5’), 71.9 (C-1’’), 117.8 (C-2’), 126.4 (Cq), 130.4 (C-3’), 147.3 (Cq), 154.9 (Cq); 
HRMS calcd for C19H23ClN5O3S [M
35
Cl-H]
-
 436.1205, found 436.1204, [M
37
Cl-H]
-
 
438.1174, found 438.1173. 
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Note: Four quaternary carbons were not visible on the 
13
C NMR spectrum. The reaction 
was heated under microwaves at 100 
o
C for 30 min. 
1-((Fluoromethyl)sulfonyl)-4-nitrobenzene (370) 
 
The title compound was synthesised following general procedure K using ethyl 2-
fluoro-2-((4-nitrophenyl)sulfonyl)acetate 269 (566 mg, 1.95 mmol) and LiOH (2M in 
THF, 9.8 mL). After work-up, the residue obtained was solubilised in dry MeCN (5 mL) 
and the resulting solution was heated under MW at 180 
o
C, 8 bars for 1 h. The solvent 
was removed in vacuo and the product 370 was obtained without further purification as 
an orange oil (336 mg, 3.61 mmol, 79%). 
Rf 0.55 (petrol: EtOAc 7: 3); UV λmax (EtOH) 246 nm; IR (cm
-1
) 2938, 2868, 1525, 1337, 
1154; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 5.80 (2H, d, J = 45.6 Hz, H-5’), 8.23 (2H, 
d, J = 8.8 Hz, H-3’), 8.52 (2H, d, J = 8.8 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) 
(ppm) δ 92.0 (d, J = 212.2 Hz, C-5’), 125.3 (C-2’), 131.0 (C-3’), 141.7 (C-4’), 151.7 (C-
1’); 19F NMR (470 MHz, DMSO- d6) (ppm) δ -214.04 (t, J = 45.6 Hz); HRMS calcd for 
C7H5FNO4S [M-H]
-
 217.9929, found 217.9919. 
4-((Fluoromethyl)sulfonyl)aniline (371) 
 
The title compound was synthesised following general procedure H using 1-
((fluoromethyl)sulfonyl)-4-nitrobenzene 370 (366 mg, 1.67 mmol) and zinc powder (870 
mg, 13.37 mmol). The crude product was purified by MPC on silica (petrol: EtOAc 3: 2) 
to give the product 371 as an orange oil (245 mg, 1.30 mmol, 78%). 
Rf 0.45 (petrol: EtOAc 1: 1); UV λmax (EtOH) 273 nm; IR (cm
-1
) 3477, 3370, 2939, 1633, 
1588, 1290, 1130; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 5.45 (2H, d, J = 46.3 Hz, H-
5’), 6.35 (2H, br s, NH2), 6.68 (2H, d, J = 8.8 Hz, H-3’), 7.50 (2H, d, J = 8.8 Hz, H-2’); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 92.0 (d, J = 210.3 Hz, C-5’), 113.3 (C-3’), 
120.0 (C-4’), 131.2 (C-2’), 155.1 (C-1’); 19F NMR (470 MHz, DMSO- d6) (ppm) δ -
212.30 (t, J = 46.3 Hz); HRMS calcd for C7H7FNO2S [M-H]
-
 188.0187, found 188.0189. 
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6-(Cyclohexylmethoxy)-N-(4-((fluoromethyl)sulfonyl)phenyl)-9H-purin-2-amine 
(372) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (200 mg, 0.42 mmol), 
4-((fluoromethyl)sulfonyl)aniline 371 (119 mg, 0.63 mmol), K2CO3 (115 mg, 0.84 mmol), 
Pd(dba)2 (19 mg, 0.02 mmol) and XPhos (10 mg, 0.02 mmol). The crude mixture was 
then filtered through Celite and the solvent was removed in vacuo. The crude mixture 
was then solubilised in TFA (10 mL). The resulting solution was heated at 70 °C for 2 h. 
Then the solvent was removed in vacuo. The product was purified by MPC (petrol: 
EtOAc 1: 9) to give the product 372 as a colourless oil (40 mg, 0.10 mmol, 23%). 
Rf 0.30 (petrol: EtOAc 1: 4); UV λmax (EtOH) 315 nm; IR (cm
-1
) 3254, 2923, 2849, 1592, 
1307, 1140; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.07-1.14 (2H, m, H-cyclo), 1.16-
1.21 (1H, m, H-cyclo), 1.23-1.32 (2H, m, H-cyclo), 1.66-1.68 (1H, m, H-cyclo), 1.73-
1.75 (2H, m, H-cyclo), 1.85-1.87 (3H, m, H-cyclo and H-2’’), 4.38 (2H, d, J = 6.3 Hz, H-
1’’), 5.60 (2H, d, J = 46.0 Hz, H-5’), 7.81 (2H, d, J = 8.9 Hz, H-3’), 8.12 (2H, d, J = 8.9 
Hz, H-2’), 8.18 (1H, s, H-8), 10.07 (1H, br s, NH), 12.95 (1H, br s, N9H); 13C NMR (125 
MHz, DMSO-d6) (ppm) δ 25.7 (2 x C-cyclo), 26.5 (C-cyclo), 29.6 (2 x C-cyclo), 37.3 (C-
2’’), 71.9 (C-1’’), 92.0 (d, J = 210.9 Hz, C-5’), 118.0 (C-2’), 126.3 (Cq), 130.3 (C-3’), 
141.1 (C-8), 147.5 (Cq), 154.8 (Cq), 160.0 (Cq); HRMS calcd for C19H23FN5O3S [M+H]
+
 
420.1500, found 420.1499. 
Note: Two quaternary carbons were not visible on the 
13
C NMR spectrum. The reaction 
was heated under microwaves at 100 
o
C for 30 min. 
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4-((2,2,2-Trifluoroethyl)thio)aniline (373) 
 
The title compound was synthesised following general procedure H using (4-
nitrophenyl)(2,2,2-trifluoroethyl)sulfane 314 (820 mg, 3.46 mmol) and zinc powder (1.80 
g, 27.7 mmol). The crude product was purified by MPC on silica (petrol: EtOAc 3: 2) to 
give the product 373 as an orange oil (610 mg, 2.95 mmol, 85 %). 
Rf 0.48 (petrol: EtOAc 7: 3); UV λmax (EtOH) 262 nm; IR (cm
-1
) 3375, 1613, 1595, 1495, 
1235; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.59 (2H, q, J = 10.7 Hz, H-5’), 6.53 (2H, 
d, J = 8.8 Hz, H-3’), 7.20 (2H, d, J = 8.8 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) 
(ppm) δ 38.5 (q, J = 30.0 Hz, C-5’), 114.8 (C-3’), 116.8 (C-4’), 126.0 (q, J = 276.5 Hz, 
CF3), 135.2 (C-2’), 150.0 (C-1’); 
19
F NMR (470 MHz, DMSO-d6) (ppm) δ -64.7 (t, J = 
10.7 Hz); HRMS calcd for C8H9F3NS [M+H]
+
 208.0402, found 208.0397. 
6-(Cyclohexylmethoxy)-N-(4-((2,2,2-trifluoroethyl)thio)phenyl)-9H-purin-2-amine 
(374) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (400 mg, 0.84 mmol), 
4-((2,2,2-trifluoroethyl)thio)aniline 373 (260 mg, 1.26 mmol), K2CO3 (231 mg, 1.67 
mmol), Pd(dba)2 (38 mg, 0.04 mmol) and XPhos (20 mg, 0.04 mmol). The crude mixture 
was then filtered through Celite and the solvent was removed in vacuo. The crude 
mixture was then solubilised in TFA (15 mL). The resulting solution was heated at 70 °C 
for 2 h. Then the solvent was removed in vacuo. The product was purified by MPC 
(petrol: EtOAc 2: 3) to give the product 374 as a brown oil (157 mg, 0.36 mmol, 43%). 
Rf 0.29 (petrol: EtOAc 1: 1); UV λmax (EtOH) 308 nm; IR (cm
-1
) 3286, 2927, 2853, 1630, 
1193, 1123; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.05-1.12 (2H, m, H-cyclo), 1.16-
1.21 (1H, m, H-cyclo), 1.24-1.32 (2H, m, H-cyclo), 1.66-1.68 (1H, m, H-cyclo), 1.72-
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1.75 (2H, m, H-cyclo), 1.83-1.86 (3H, m, H-cyclo and H-2’’), 3.84 (2H, q, J = 10.4 Hz, 
H-5’), 4.34 (2H, d, J = 6.3 Hz, H-1’’), 7.45 (2H, d, J = 8.7 Hz, H-3’), 7.83 (2H, d, J = 8.7 
Hz, H-2’), 8.12 (1H, s, H-8), 9.52 (1H, br s, NH), 13.05 (1H, br s, N9H); 13C NMR (125 
MHz, DMSO-d6) (ppm) δ 25.7 (2 x C-cyclo), 26.5 (C-cyclo), 29.7 (2 x C-cyclo), 37.0 (q, 
J = 31.2 Hz, C-5’), 37.3 (C-2’’), 71.7 (C-1’’), 119.3 (C-2’), 123.8 (Cq), 126.0 (q, J = 
276.5 Hz, CF3), 131.7 (Cq), 132.8 (C-3’), 140.3 (C-8), 141.6 (Cq), 152.0 (Cq), 155.6 (Cq); 
19
F NMR (470 MHz, DMSO-d6) (ppm) δ -64.7 (t, J = 10.4 Hz); HRMS calcd for 
C20H21F3N5OS [M-H]
-
 436.1424, found 436.1421. 
Note: The reaction was heated under microwaves at 100 
o
C for 30 min. 
6-(Cyclohexylmethoxy)-N-(4-((2,2,2-trifluoroethyl)sulfonyl)phenyl)-9H-purin-2-
amine (375) 
 
The title compound was synthesised following general procedure M using 6-
(cyclohexylmethoxy)-N-(4-((2,2,2-trifluoroethyl)thio)phenyl)-9H-purin-2-amine 374 
(150 mg, 0.38 mmol) and m-CPBA (180 mg, 0.76 mmol). The crude product was purified 
by MPC on silica (petrol: EtOAc 3: 7) to give the product 375 as a yellow oil (72 mg, 
0.15 mmol, 40%). 
Rf 0.25 (petrol: EtOAc 1: 4); UV λmax (EtOH) 315 nm; IR (cm
-1
) 3260, 2925, 2851, 1594, 
1310, 1242, 1145; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.07-1.14 (2H, m, H-cyclo), 
1.16-1.21 (1H, m, H-cyclo), 1.23-1.32 (2H, m, H-cyclo), 1.66-1.69 (1H, m, H-cyclo), 
1.73-1.75 (2H, m, H-cyclo), 1.85-1.87 (3H, m, H-cyclo and H-2’’), 4.37 (2H, d, J = 6.3 
Hz, H-1’’), 4.82 (2H, q, J = 9.9 Hz, H-5’), 7.82 (2H, d, J = 9.0 Hz, H-3’), 8.08-8.10 (3H, 
m, H-2’ and H-8), 10.05 (1H, br s, NH), 13.01 (1H, br s, N9H); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 25.7 (2 x C-cyclo), 26.5 (C-cyclo), 29.7 (2 x C-cyclo), 37.3 (C-2’’), 
56.7 (q, J = 29.1 Hz, C-5’), 71.9 (C-1’’), 117.7 (C-2’), 122.0 (q, J = 277.5 Hz, CF3), 
129.6 (C-3’), 129.7 (Cq), 140.2 (C-8), 147.2 (Cq), 154.8 (Cq), 160.7 (Cq); 
19
F NMR (470 
MHz, DMSO-d6) (ppm) δ -60.0. (t, J = 9.9 Hz); HRMS calcd for C20H23F3N5O3S [M-H]
-
 
470.1468, found 470.1463. 
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Note: Two quaternary carbons were not visible on the 
13
C NMR spectrum. 
Methyl 3-hydroxy-3-(4-nitrophenyl)propanoate (377) 
 
NaBH4 (481 mg, 12.7 mmol) was added dropwise to a stirred solution of ethyl 4-
nitrobenzoylacetate 376 (1.00 g, 4.22 mmol) in MeOH (10.5 mL). The reaction was 
stirred at r.t. for 1 h. The reaction mixture was partitioned with brine (20 mL) and EtOAc 
(30 mL) and the organic phase was extracted with EtOAc (3 x 30 mL). The organic layer 
was dried over MgSO4 and the solvent was removed in vacuo. The crude product was 
purified by MPC on silica (petrol: EtOAc 7: 3) to give the product 377 as a yellow oil 
(603 mg, 2.68 mmol, 64%). 
Rf 0.43 (petrol: EtOAc 7: 3); UV λmax (EtOH) 270 nm; IR (cm
-1
) 3420, 2957, 2852, 1709, 
1510, 1347, 1173; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 2.62 (1H, dd, J = 8.9, 15.1 
Hz, H-6’), 2.74 (1H, dd, J = 4.6, 15.1 Hz, H-6’), 3.60 (3H, s, OCH3), 5.11 (1H, ddd, J = 
4.6, 4.9, 8.9 Hz, H-5’), 5.86 (1H, d, J = 4.9 Hz, OH), 7.67 (2H, d, J = 8.8 Hz, H-3’), 8.20 
(2H, d, J = 8.8 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 44.1 (C-6’), 51.9 
(OCH3), 69.1 (C-5’), 123.8 (C-2’), 127.6 (C-3’), 147.1 (C-4’), 152.9 (C-1’), 171.2 (CO); 
HRMS calcd for C10H10NO5 [M-H]
-
 224.0564, found 224.0555. 
1-(4-Nitrophenyl)propane-1,3-diol (378) 
 
The title compound was synthesised following general procedure O using methyl 3-
hydroxy-3-(4-nitrophenyl)propanoate 377 (603 mg, 2.68 mmol) and DIBAL (1M in 
hexanes, 8.00 mL). The crude product was purified by MPC on silica (petrol: EtOAc 1: 1) 
to give the product 378 as a yellow oil (410 mg, 2.08 mmol, 78%). 
Rf 0.18 (petrol: EtOAc 1: 1); UV λmax (EtOH) 274 nm; IR (cm
-1
) 3317, 2943, 2885, 1512, 
1341, 1045; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.70-1.80 (2H, m, H-7’), 3.41-3.47 
(1H, m, H-6’), 3.52-3.58 (1H, m, H-6’), 4.50 (1H, t, J = 5.1 Hz, OH), 4.80-4.84 (1H, m, 
H-5’), 5.48 (1H, d, J = 4.7 Hz, OH), 7.60 (2H, d, J = 8.7 Hz, H-3’), 8.20 (2H, d, J = 8.7 
Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 42.7 (C-7’), 58.0 (C-6’), 69.3 (C-5’), 
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123.8 (C-2’), 127.3 (C-3’), 146.8 (C-4’), 155.0 (C-1’); HRMS calcd for C9H15N2O4 
[M+NH4]
+
 215.1026, found 215.1025. 
3-((tert-Butyldiphenylsilyl)oxy)-1-(4-nitrophenyl)propan-1-ol (379) 
 
Imidazole (722 mg, 10.6 mmol) and TBDPSCl (0.92 mL, 3.54 mmol) were added to a 
stirred solution of 1-(4-nitrophenyl)propane-1,3-diol 378 (630 mg, 3.54 mmol) in dry 
DCM (25 mL) at 0 
o
C, under N2. The reaction was stirred at 0 
o
C for 1 h. Water (30 mL) 
was added and the organic phase was extracted with DCM (3 x 30 mL). The organic layer 
was dried over MgSO4 and the solvent was removed in vacuo. The crude product was 
purified by MPC on silica (petrol: EtOAc 9: 1) to give the product 379 as a yellow oil 
(672 mg, 1.54 mmol, 44%). 
Rf 0.24 (petrol: EtOAc 9: 1); 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 0.99 (9H, s, 
t
Bu), 
1.88 (2H, dd, J = 6.4, 6.4 Hz, H-7’), 3.64-3.69 (1H, m, H-6’), 3.81-3.86 (1H, m, H-6’), 
4.88-4.91 (1H, m, H-5’), 5.56 (1H, d, J = 4.7 Hz, OH), 7.41-7.47 (6H, m, H-ar), 7.56 (2H, 
d, J = 8.7 Hz, H-3’), 7.59-7.61 (4H, m, H-ar), 8.18 (2H, d, J = 8.7 Hz, H-2’); 13C NMR 
(125 MHz, DMSO-d6) (ppm) δ 19.2 (
t
Bu), 27.1 (
t
Bu), 42.2 (C-7’), 60.8 (C-6’), 69.0 (C-
5’), 123.8 (C-2’), 127.3 (C-3’), 128.3 (C-ar), 130.3 (C-ar), 133.7 (Cq), 135.5 (C-ar), 
146.8 (C-4’), 154.6 (C-1’). 
3-((tert-Butyldiphenylsilyl)oxy)-1-(4-nitrophenyl)propan-1-one (380) 
 
Dess-martin periodinane (0.3 M in DCM, 5.66 mL) was added dropwise to a stirred 
solution of 3-((tert-butyldiphenylsilyl)oxy)-1-(4-nitrophenyl)propan-1-ol 379 (672 mg, 
1.54 mmol) in dry DCM (17 mL) under N2. The resulting solution was stirred at r.t. for 2 
h. A saturated aqueous solution of Na2S2O3 (15 mL) was added dropwise at 0 
o
C and the 
organic phase was extracted with DM (3 x 15 mL). The organic layer was dried over 
MgSO4 and the solvent was removed in vacuo. The crude product was purified by MPC 
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on silica (petrol: EtOAc 19: 1) to give the product 380 as a yellow oil (570 mg, 1.32 
mmol, 85%). 
Rf 0.48 (petrol: EtOAc 9: 1); UV λmax (EtOH) 264 nm; IR (cm
-1
) 2972, 2882, 1658, 1534; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 0.93 (9H, s, 
t
Bu), 3.39 (2H, t, J = 6.1 Hz, H-7’), 
4.03 (2H, t, J = 6.1 Hz, H-6’), 7.40-7.48 (4H, m, H-ar), 7.46-7.48 (2H, m, H-ar), 7.57-
7.59 (4H, m, H-ar), 8.20 (2H, d, J = 8.8 Hz, H-3’), 8.35 (2H, d, J = 8.8 Hz, H-2’); 13C 
NMR (125 MHz, DMSO-d6) (ppm) δ 19.2 (
t
Bu), 27.0 (
t
Bu), 42.0 (C-7’), 60.3 (C-6’), 
124.3 (C-2’), 128.3 (C-ar), 130.0 (C-3’), 130.3 (C-ar), 133.3 (Cq), 135.5 (C-ar), 141.9 (C-
4’), 150.4 (C-1’), 198.7 (CO); HRMS calcd for C25H28NO4Si [M+H]
+
 434.1782, found 
434.1786. 
1-(4-Nitrophenyl)prop-2-en-1-one (383) 
 
Tributyl(vinyl)tin was added to a solution of 4-nitrobenzoyl chloride 382 (300 mg, 1.61 
mmol) and Pd(PPh3)4 (1 mg, 0.005 mmol) in dry THF (1.5 mL) under N2. The reaction 
was degased with N2 and heated at 65 
o
C for 1 h. The reaction was cooled to r.t. and 
EtOAc (5 mL) was added. The organic phase was washed with a saturated aqueous 
solution of KF (3 x 5 mL). The organic layer was dried over MgSO4 and the solvent was 
removed in vacuo. The crude product was purified by MPC on silica (petrol: EtOAc 9: 1) 
to give the product 383 as a pale yellow solid (99 mg, 0.56 mmol, 35%). 
Rf 0.62 (petrol: EtOAc 7: 3); Mp = 87-89 
o
C; UV λmax (EtOH) 259 nm; IR (cm
-1
) 2923, 
2856, 1665, 1596, 1519, 1341; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 6.12 (1H, d, J = 
10.5 Hz, H-7’), 6.40 (1H, d, J = 17.0 Hz, H-7’), 7.40 (1H, dd, J = 10.5, 17.0 Hz, H-6’), 
8.21 (2H, d, J = 8.8 Hz, H-3’), 8.37 (2H, d, J = 8.8 Hz, H-2’); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 124.4 (C-2’), 130.4 (C-3’), 132.5 (C-7’), 132.8 (C-6’), 142.0 (C-4’), 
150.4 (C-1’), 189.9 (CO); HRMS calcd for C9H6NO3 [M-H]
-
 176.0342, found 176.0362. 
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1-(4-Nitrophenyl)-3-(pyrrolidin-1-yl)propan-1-one (384) 
 
Pyrrolidine (0.37 mL, 4.46 mmol) was added to a stirred solution of 1-(4-
nitrophenyl)prop-2-en-1-one 383 (79 mg, 0.45 mmol) in dry DCM (3 mL) under N2. The 
resulting solution was stirred at r.t. for 2 h. Brine (5 mL) was added and the organic phase 
was extracted with DCM (3 x 5 mL). The organic layer was dried over MgSO4 and the 
solvent was removed in vacuo. The crude product was purified by MPC on silica (DCM: 
MeOH 9: 1) to give the product 384 as a yellow oil (56 mg, 0.23 mmol, 51%). 
Rf 0.28 (DCM: MeOH 19: 1); UV λmax (EtOH) 263 nm; IR (cm
-1
) 2967, 2876, 1520, 1342; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.65-1.68 (4H, m, H-pyr), 2.44-2.47 (4H, m, H-
pyr), 2.78 (2H, t, J = 7.1 Hz, H-7’), 3.28 (2H, t, J = 7.1 Hz, H-6’), 8.20 (2H, d, J = 8.9 Hz, 
H-3’), 8.34 (2H, d, J = 8.9 Hz, H-2’); 13C NMR (125 MHz, DMSO-d6) (ppm) δ 23.6 (C-
pyr), 38.8 (C-7’), 50.8 (C-6’), 54.0 (C-pyr), 124.3 (C-2’), 129.8 (C-3’), 141.8 (C-4’), 
150.3 (C-1’), 199.0 (CO); HRMS calcd for C13H17N2O3 [M+H]
+
 249.1234, found 
249.1237. 
Methyl 4-((6-(cyclohexylmethoxy)-9H-purin-2-yl)amino)benzoate (387) 
 
The title compound was synthesised following general procedure I using 6-
(cyclohexylmethoxy)-2-iodo-9-(4-methoxybenzyl)-9H-purine 171 (500 mg, 1.05 mmol), 
methyl 4-aminobenzoate 386 (237 mg, 1.57 mmol), K2CO3 (289 mg, 2.09 mmol), 
Pd(dba)2 (60 mg, 0.10 mmol) and XPhos (50 mg, 0.10 mmol). The crude mixture was 
then filtered through Celite and the solvent was removed in vacuo. The crude mixture 
was then solubilised in TFA (20 mL). The resulting solution was heated at 70 °C for 2 h. 
Then the solvent was removed in vacuo. The product was purified by MPC (petrol: 
EtOAc 1: 4) to give the product 387 as a pale yellow solid (222 mg, 0.58 mmol, 55%). 
Rf 0.46 (petrol: EtOAc 1: 4); Mp = 224-226 
o
C; UV λmax (EtOH) 321 nm; IR (cm
-1
) 3280, 
2924, 2851, 1704, 1596, 1395, 1266, 1171; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 
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1.07-1.14 (2H, m, H-cyclo), 1.18-1.21 (1H, m, H-cyclo), 1.25-1.32 (2H, m, H-cyclo), 
1.66-1.69 (1H, m, H-cyclo), 1.73-1.75 (2H, m, H-cyclo), 1.85-1.87 (3H, m, H-cyclo and 
H-2’’), 3.82 (3H, s, H-5’), 4.37 (2H, d, J = 6.3 Hz, H-1’’), 7.88 (2H, d, J = 8.8 Hz, H-2’), 
7.97 (2H, d, J = 8.8 Hz, H-3’), 8.19 (1H, s, H-8), 9.84 (1H, br s, NH), 12.81 (1H, br s, 
N
9
H); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 25.7 (2 x C-cyclo), 26.5 (C-cyclo), 29.7 
(2 x C-cyclo), 37.3 (C-2’’), 52.1 (C-5’), 71.9 (C-1’’), 117.9 (C-3’), 121.6 (Cq), 130.6 (C-
2’), 146.2 (Cq), 155.3 (Cq), 166.5 (CO); HRMS calcd for C20H24N5O3 [M+H] 382.1874, 
found 382.1876. 
Note: Four quaternary carbons were not visible on the 
13
C NMR spectrum. The reaction 
was heated under microwaves at 100 
o
C for 30 min. 
4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)-N-methoxy-N-methyl benzamide 
(388) 
 
Isopropylmagnesium chloride (2M in THF, 1.08 mL) was added to a stirred solution of 
methyl 4-((6-(cyclohexylmethoxy)-9H-purin-2-yl)amino)benzoate 387 (164 mg, 0.43 
mmol) and N,O-dimethyl hydroxylamine (125 mg, 1.29 mmol) in dry THF (3.5 mL) at 0 
o
C, under N2. The resulting solution was stirred at 0 
o
C for 1.5 h. Isopropylmagnesium 
chloride (2 M in THF, 0.54 mL) was added to the reaction and the solution was stirred for 
0.5 h at 0 
o
C. A saturated aqueous solution of NH4Cl (10 mL) was added and the organic 
phase was extracted with EtOAc (3 x 10 mL). The organic layer was dried over MgSO4 
and the solvent was removed in vacuo. The crude product was purified by MPC on silica 
(petrol: EtOAc 1: 9) to give the product 388 as a colourless oil (171 mg, 0.42 mmol, 
97%). 
Rf 0.48 (EtOAc 100); UV λmax (EtOH) 315 nm; IR (cm
-1
) 3263, 2923, 2849, 1734, 1596, 
1351, 1117; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.06-1.13 (2H, m, H-cyclo), 1.17-
1.20 (1H, m, H-cyclo), 1.23-1.32 (2H, m, H-cyclo), 1.66-1.68 (1H, m, H-cyclo), 1.73-
1.76 (2H, m, H-cyclo), 1.84-1.91 (3H, m, H-cyclo and H-2’’), 3.25 (3H, s, H-5’), 3.58 
(3H, s, H-6’), 4.36 (2H, d, J = 6.4 Hz, H-1’’), 7.60 (2H, d, J = 8.8 Hz, H-2’), 7.90 (2H, d, 
J = 8.8 Hz, H-3’), 8.04 (1H, s, H-8), 9.62 (1H, br s, NH), 12.90 (1H, br s, N9H); 13C NMR 
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(125 MHz, DMSO-d6) (ppm) δ 25.7 (2 x C-cyclo), 26.5 (C-cyclo), 29.7 (2 x C-cyclo), 
34.0 (C-5’), 37.3 (C-2’’), 61.0 (C-6’), 71.7 (C-1’’), 117.4 (C-3’), 126.0 (Cq), 129.5 (C-2’), 
140.0 (Cq), 144.0 (Cq), 155.4 (Cq), 169.4 (CO); HRMS calcd for C21H25N6O3 [M-H]
-
 
409.1994, found 409.2000. 
Note: Four quaternary carbons were not visible on the 
13
C NMR spectrum. 
1-(4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)prop-2-en-1-one (389) 
 
A solution of vinylmagnesium chloride (1.6M in THF, 0.36 mL) was added to a stirred 
solution of 4-((6-(cyclohexylmethoxy)-9H-purin-2-yl)amino)-N-methoxy-N-methyl 
benzamide 388 (53 mg, 0.13 mmol) in dry THF (1.2 mL) at 0 
o
C, under N2. The reaction 
was stirred for 1 h at 0 
o
C and vinylmagnesium chloride (1.6M in THF, 0.10 mL) was 
added. The reaction was stirred for a further 1 h and a saturated aqueous solution of 
NH4Cl (3 mL) was added. The organic phase was extracted with EtOAc (3 x 5 mL). The 
organic layer was dried over MgSO4 and the solvent was removed in vacuo. The crude 
product was purified by MPC on silica (petrol: EtOAc 3: 7) to give the product 389 as a 
yellow oil (18 mg, 0.05 mmol, 36%). 
Rf 0.42 (EtOAc 100); UV λmax (EtOH) 335 nm; IR (cm
-1
) 3263, 2923, 2850, 1662, 1594, 
1529, 1392, 1177; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.07-1.12 (2H, m, H-cyclo), 
1.16-1.22 (1H, m, H-cyclo), 1.24-1.33 (2H, m, H-cyclo), 1.67-1.69 (1H, m, H-cyclo), 
1.73-1.77 (2H, m, H-cyclo), 1.85-1.89 (3H, m, H-cyclo and H-2’’), 4.38 (2H, d, J = 6.4 
Hz, H-1’’), 5.91 (1H, dd, J = 2.1 and 10.4 Hz, H-6’), 6.32 (1H, dd, J = 2.1 and 16.9 Hz, 
H-6’), 7.46 (1H, dd, J = 10.4 and 16.9 Hz, H-5’), 7.99 (2H, d, J = 9.0 Hz, H-2’), 8.01 (2H, 
d, J = 9.0 Hz, H-3’), 8.09 (1H, s, H-8), 9.87 (1H, br s, NH), 13.00 (1H, br s, N9H); 13C 
NMR (125 MHz, DMSO-d6) (ppm) δ 25.7 (2 x C-cyclo), 26.5 (C-cyclo), 29.7 (2 x C-
cyclo), 37.3 (C-2’’), 71.8 (C-1’’), 117.7 (C-3’), 129.2 (C-6’), 130.4 (C-2’), 132.7 (C-5’), 
143.2 (Cq), 146.6 (Cq), 155.0 (Cq), 188.0 (CO); HRMS calcd for C21H24N5O2 [M+H]
+
 
378.1925, found 378.1928. 
Note: Four quaternary carbons were not visible on the 
13
C NMR spectrum.  
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1-(4-((6-(Cyclohexylmethoxy)-9H-purin-2-yl)amino)phenyl)prop-2-yn-1-one (390) 
 
A solution of ethynylmagnesium bromide (0.5M in THF, 1.30 mL) was added to a stirred 
solution of 4-((6-(cyclohexylmethoxy)-9H-purin-2-yl)amino)-N-methoxy-N-methyl 
benzamide 388 (89 mg, 0.22 mmol) in dry THF (2.0 mL) at 0 
o
C, under N2. The reaction 
was stirred for 1 h at 0 
o
C and for 18 h at r.t.. A saturated aqueous solution of NH4Cl (5 
mL) was added and the organic phase was extracted with EtOAc (3 x 5 mL). The organic 
layer was dried over MgSO4 and the solvent was removed in vacuo. The crude product 
was purified by MPC on silica (petrol: EtOAc 3: 7) to give the product 390 as an orange 
oil (21 mg, 0.06 mmol, 25%). 
Rf 0.43 (EtOAc 100); UV λmax (EtOH) 367 nm; IR (cm
-1
) 3251, 2922, 2850, 1664, 1591, 
1528, 1382, 1168; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.07-1.14 (2H, m, H-cyclo), 
1.17-1.21 (1H, m, H-cyclo), 1.24-1.30 (2H, m, H-cyclo), 1.66-1.69 (1H, m, H-cyclo), 
1.73-1.76 (2H, m, H-cyclo), 1.85-1.90 (3H, m, H-cyclo and H-2’’), 4.38 (2H, d, J = 6.4 
Hz, H-1’’), 4.93 (1H, s, H-6’), 8.01 (2H, d, J = 9.0 Hz, H-2’), 8.04 (2H, d, J = 9.0 Hz, H-
3’), 8.12 (1H, s, H-8), 10.04 (1H, br s, NH), 12.99 (1H, br s, N9H); 13C NMR (125 MHz, 
DMSO-d6) (ppm) δ 25.7 (2 x C-cyclo), 26.5 (C-cyclo), 29.7 (2 x C-cyclo), 37.3 (C-2’’), 
71.9 (C-1’’), 81.1 (C-5’), 84.5 (C-6’), 117.6 (C-3’), 118.9 (Cq), 128.8 (Cq), 131.2 (C-2’), 
147.9 (Cq), 154.8 (Cq), 175.6 (CO); HRMS calcd for C21H22N5O2 [M+H]
+
 376.1768, 
found 376.1772. 
Note: Three quaternary carbons were not visible on the 
13
C NMR spectrum.  
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4-(2,6-Dichlorobenzamido)-N-(1-(vinylsulfonyl)piperidin-4-yl)-1H-pyrazole-3-
carboxamide (395) 
 
2-Chloroethanesulfonyl chloride (0.03 mL, 0.26 mmol) and DIPEA (0.09 mL, 0.52 mmol) 
were added to a stirred suspension of 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-1H-
pyrazole-3-carboxamide 401 (100 mg, 0.26 mmol) in dry DCM (2.5 mL) under N2. The 
resulting solution was stirred at r.t. for 1 h. Water (5 mL) was added and the organic 
phase was extracted with DCM (3 x 5 mL) and dried over MgSO4. The solvent was 
removed in vacuo and the crude product was purified by MPC on silica (petrol: EtOAc 2: 
3) to give the product 395 as a colourless oil (42 mg, 0.09 mmol, 34%). 
Rf 0.76 (petrol: EtOAc 1: 4); UV λmax (EtOH) 266 nm; IR (cm
-1
) 3206, 2930, 1676, 1635, 
1545, 1426; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.66-1.73 (2H, m, H-pip), 1.80-1.83 
(2H, m, H-pip), 2.66-2.71 (2H, m, H-pip), 3.52-3.54 (2H, m, H-pip), 3.82-3.88 (1H, m, 
H-pip), 6.14 (1H, dd, J = 0.9 and 16.5 Hz, H-vinyl), 6.16 (1H, dd, J = 0.9 and 10.0 Hz, H-
vinyl), 6.80 (1H, dd, J = 10.0 and 16.5 Hz, H-vinyl), 7.53 (1H, dd, J = 6.9 and 9.2 Hz, H-
ar), 7.58 (1H, d, J = 9.2 Hz, H-ar), 7.60 (1H, d, J = 6.9 Hz, H-ar), 8.36 (1H, s, H-5), 8.46 
(1H, d, J = 8.6 Hz, NH), 10.15 (1H, s, NH), 13.43 (1H, br s, NH); 
13
C NMR (125 MHz, 
DMSO-d6) (ppm) δ 30.9 (2 x C-pip), 45.2 (2 x C-pip), 45.6 (C-pip), 121.2 (C-5), 122.0 
(Cq), 128.9 (2 x C-ar), 129.3 (C-vinyl), 131.7 (C-ar), 132.4 (Cq), 133.6 (C-vinyl), 135.9 
(Cq), 160.8 (CO), 163.2 (CO); HRMS calcd for C18H18Cl2N5O4S [M
35
Cl-H]
-
 470.0462, 
found 470.0469, [M
37
Cl-H]
-
 472.0432, found 472.0434, [M
39
Cl-H]
-
 474.0402, found 
474.0398. 
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N-(1-Acryloylpiperidin-4-yl)-4-(2,6-dichlorobenzamido)-1H-pyrazole-3-
carboxamide (396) 
 
Acryloyl chloride (0.02 mL, 0.26 mmol) was added to a stirred suspension of 4-(2,6-
dichlorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide 401 (100 mg, 0.26 
mmol) and DIPEA (0.05 mL, 0.29 mmol) in dry THF (2.5 mL) at 0 
o
C, under N2. The 
resulting solution was stirred at 0 
o
C for 1 h. Water (5 mL) was added and the organic 
phase was extracted with DCM (3 x 5 mL), dried over MgSO4. The solvent was removed 
in vacuo and the crude product was purified by MPC on silica (petrol: EtOAc 1: 9) to 
give the product 396 as a white solid (61 mg, 0.14 mmol, 53%). 
Rf 0.21 (petrol: EtOAc 2: 3); Mp = 152-154 
o
C; UV λmax (EtOH) 265 nm; IR (cm
-1
) 3283, 
2952, 1646, 1550, 1454; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.49-1.54 (2H, m, H-
pip), 1.75-1.79 (2H, m, H-pip), 2.66-2.71 (1H, m, H-pip), 3.07-3.12 (1H, m, H-pip), 3.98-
4.08 (2H, m, H-pip), 4.40-4.43 (1H, m, H-pip), 5.67 (1H, dd, J = 2.4 and 10.4 Hz, H-
vinyl), 6.10 (1H, dd, J = 2.4 and 16.7 Hz, H-ar), 6.82 (1H, dd, J = 10.4 and 16.7 Hz, H-
vinyl), 7.53 (1H, dd, J = 6.9 and 9.1 Hz, H-ar), 7.59 (1H, d, J = 9.1 Hz, H-ar), 7.60 (1H, d, 
J = 6.9 Hz, H-ar), 8.36 (1H, s, H-5), 8.42 (1H, d, J = 8.0 Hz, NH), 10.17 (1H, s, NH), 
13.41 (1H, s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 31.4 (C-pip), 32.4 (C-pip), 
41.2 (C-pip), 44.7 (C-pip), 46.4 (C-pip), 121.2 (C-5), 122.0 (Cq), 127.6 (C-vinyl), 128.9 
(2 x C-ar), 129.0 (C-vinyl), 131.7 (2 x Cq), 132.4 (C-ar), 133.4 (Cq), 135.9 (Cq), 160.8 
(CO), 163.1 (CO), 164.6 (CO); HRMS calcd for C19H18Cl2N5O3 [M
35
Cl-H]
-
 343.0797, 
found 434.0799, [M
37
Cl-H]
-
 436.0763, found 436.0765, [M
39
Cl-H]
-
 438.0734, found 
438.0732.  
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tert-Butyl 4-(4-amino-1H-pyrazole-3-carboxamido)piperidine-1-carboxylate (399)
84
 
 
4-Aminopiperidine N1-boc 397 (4.20 g, 21.0 mmol), EDCI.HCl (4.40 g, 23.0 mmol) and 
HOAt (3.10 g, 23.0 mmol) were added to a stirred solution of 4-nitro-1H-pyrazole-3-
carboxylic acid (3.00 g, 19.1 mmol) in dry DMF (40 mL) under N2. The reaction was 
stirred at r.t. for 16 h. The solvent was removed in vacuo. The residue was triturated with 
water to form a beige solid which was collected by filtration. The crude material was 
solubilised in EtOH (250 mL) and DMF (40 mL) and was subjected to palladium 
catalyzed hydrogenation using an H-Cube reactor and a 10% Pd/C CatCart. The 
reaction was conducted at 40 °C for 16 h. The solvent was removed in vacuo and the 
residue was resuspended in DCM (50 mL). The organic phase was washed with brine (3 
x 50 mL), dried over MgSO4 and the solvent was removed in vacuo. The crude product 
was purified by MPC on silica (EtOAc: MeOH 19: 1) to give the product 399 as a brown 
foam (2.10 g, 6.80 mmol, 36%). 
Rf 0.47 (EtOAc 100); UV λmax (EtOH) 287 nm; IR (cm
-1
) 3323, 3270, 2957, 1669, 1648, 
1526, 1428, 1146; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 1.41 (9H, s, 
t
Bu), 1.45-1.49 
(2H, m, H-pip), 1.70-1.72 (2H, m, H-pip), 2.74-2.89 (2H, m, H-pip), 3.88-3.94 (3H, m, 
H-pip), 4.58 (2H, br s, NH2), 7.10 (1H, s, H-5), 7.68 (1H, d, J = 8.3 Hz, NH), 12.50 (1H, 
s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 28.6 (3 x CH3), 31.9 (2 x C-pip), 40.6 
(C-pip), 45.7 (2 x C-pip), 79.1 (Cq), 115.4 (C-5), 132.2 (Cq), 133.4 (Cq), 154.6 (CO), 
162.8 (CO); HRMS calcd for C14H22N5O3 [M-H]
-
 308.1728, found 308.1735.  
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tert-Butyl-4-(4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamido) piperidine-1-
carboxylate (400)
84
 
 
2,6-Dichlorobenzoic acid (1.34 g, 6.99 mmol) was added to a stirred solution of tert-butyl 
4-(4-amino-1H-pyrazole-3-carboxamido)piperidine-1-carboxylate 399 (1.96 g, 6.36 
mmol), EDCI.HCl (1.46 g, 7.63 mmol) and HOAt (1.03 g, 7.63 mmol) in dry DMF (100 
mL). The resulting solution was stirred at r.t. for 72 h. The solvent was removed in vacuo 
and the residue was resuspended in DCM (50 mL). The organic phase was washed with 
brine (3 x 50 mL), dried over MgSO4 and the solvent was removed in vacuo. The crude 
product was purified by MPC on silica (petrol: EtOAc 2: 3) to give the product 400 as an 
off-white solid (1.90 g, 3.94 mmol, 62%). 
Rf 0.46 (petrol: EtOAc 1: 1); Mp = 197-199 
o
C; UV λmax (EtOH) 263 nm; IR (cm
-1
) 3364, 
3200, 2995, 2868, 1672, 1649, 1574, 1542, 1430, 1143; 
1
H NMR (500 MHz, DMSO-d6) 
(ppm) δ 1.40 (9H, s, tBu), 1.46-1.54 (2H, m, H-pip), 1.68-1.71 (2H, m, H-pip), 2.70-2.80 
(2H, m, H-pip), 3.88-3.94 (3H, m, H-pip), 7.53 (1H, dd, J = 6.9 and 9.2 Hz, H-ar), 7.58 
(1H, d, J = 9.2 Hz, H-ar), 7.60 (1H, d, J = 6.9 Hz, H-ar), 8.36 (1H, d, J = 1.3 Hz, H-5), 
8.40 (1H, d, J = 8.4 Hz, NH), 10.17 (1H, s, NH), 13.43 (1H, s, NH); 
13
C NMR (125 MHz, 
DMSO-d6) (ppm) δ 28.6 (3 x CH3), 31.5 (2 x C-pip), 40.6 (C-pip), 46.3 (2 x C-pip), 79.1 
(Cq), 121.2 (Cq), 122.0 (C-5), 128.9 (C-ar), 129.1 (C-ar), 131.7 (Cq), 132.4 (C-ar), 133.4 
(Cq), 134.4 (Cq), 135.8 (Cq), 154.4 (CO), 160.7 (CO), 163.1 (CO); HRMS calcd for 
C21H24Cl2N5O4 [M
35
Cl-H]
-
 480.1211, found 480.1216, [M
37
Cl-H]
-
 482.1182, found 
482.1183, [M
39
Cl-H]
-
 484.1153, found 484.1150. 
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4-(2,6-Dichlorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide (401)
84
 
 
tert-Butyl 4-(4-(2,6-dichlorobenzamido)-1H-pyrazole-3-carboxamido)piperidine-1-carbo 
xylate 400 (1.90 g, 3.94 mmol) was solubilised in TFE (40 mL) and the reaction mixture 
was sealed. The reaction was heated under MW at 160 
o
C, 12 bars, for 4 h. The solvent 
was removed in vacuo and the crude product was purified by MPC on amine silica (DCM: 
MeOH 49: 1) to give the product 401 as a beige solid (918 mg, 2.41 mmol, 61%). 
Rf 0.37 (DCM: MeOH 9: 1); Mp = 270-273 
o
C; UV λmax (EtOH) 266 nm; IR (cm
-1
) 3409, 
3312, 2942, 2828, 1654, 1574, 1537, 1423; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 
1.42-1.50 (2H, m, H-pip), 1.64-1.66 (2H, m, H-pip), 2.41-2.47 (2H, m, H-pip), 2.91-2.93 
(2H, m, H-pip), 3.30 (1H, br s, NH), 3.73-3.79 (1H, m, H-pip), 7.53 (1H, dd, J = 6.9 and 
9.1 Hz, H-ar), 7.58 (1H, d, J = 9.1 Hz, H-ar), 7.60 (1H, d, J = 6.9 Hz, H-ar), 8.25 (1H, d, 
J = 7.9 Hz, NH), 8.33 (1H, s, H-5), 10.19 (1H, br s, NH), 13.44 (1H, s, NH); 
13
C NMR 
(125 MHz, DMSO-d6) (ppm) δ 29.5 (C-pip), 33.2 (C-pip), 41.4 (C-pip), 45.8 (C-pip), 
47.2 (C-pip), 121.9 (C-5), 128.9(2 x C-ar), 131.7 (2 x Cq), 132.3 (C-ar), 133.3 (Cq), 135.9 
(Cq), 146.0 (Cq), 160.8 (CO), 162.7 (CO); HRMS calcd for C16H16Cl2N5O2 [M
35
Cl-H]
-
 
380.0687, found 380.0691, [M
37
Cl-H]
-
 382.0657, found 382.0657, [M
39
Cl-H]
-
 384.0628, 
found 384.0624.  
Methyl 2-mercaptobenzoate (405)
275
 
 
Concentrated H2SO4 (0.25 mL) was added slowly to a stirred solution of 2-
mercaptobenzoic acid 404 (2.00 g, 13.0 mmol) in MeOH (10 mL). The reaction was 
refluxed for 48 h. The reaction was then cooled to 0 
o
C and a saturated aqueous solution 
of NaHCO3 (15 mL) was added. The organic phase was extracted with EtOAc (3 x 20 
mL), the phases were combined, dried over MgSO4 and the solvent was removed in 
vacuo to give the product 405 as a yellow oil (1.94 g, 11.6 mmol, 89%). 
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Rf 0.80 (petrol: EtOAc 7: 3); UV λmax (EtOH) 331 nm; IR (cm
-1
) 2949, 1701, 1588, 1432, 
1250, 1062; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.85 (3H, s, OCH3), 5.33 (1H, s, 
SH), 7.23 (1H, dd, J = 1.0 and 7.9 Hz, H-4), 7.43 (1H, dd, J = 1.5 and 7.9 Hz, H-5), 7.57 
(1H, d, J = 7.9 Hz, H-6), 7.92 (1H, d, J = 7.9 Hz, H-3); 
13
C NMR (125 MHz, DMSO-d6) 
(ppm) δ 52.6 (CH3), 125.2 (C-4), 126.1 (C-1), 131.5 (C-6), 131.6 (C-3), 133.2 (C-5), 
138.6 (C-2), 166.6 (CO); HRMS calcd for C8H7O2S [M-H]
-
 167.0172, found 167.0173. 
Methyl 2-((2-carbamoylphenyl)thio)acetate (407) 
 
Formamide (0.36 mL, 8.93 mmol) was added to a stirred solution of methyl 2-
mercaptobenzoate 405 (500 mg, 2.98 mmol) in dry DMF (21 mL) under N2. The solution 
was heated at 70 
o
C for 5 min and NaOMe (25% wt/wt solution in MeOH, 1.57 mL, 6.85 
mmol) was added. The mixture was then heated at 120 
o
C for 2 h. The reaction was 
cooled to r.t. and the solvent was removed in vacuo. The crude product was suspended in 
dry MeCN (12 mL) under N2, and K2CO3 (451 mg, 3.27 mmol) and ethyl chloroacetate 
(0.35 mL, 3.27 mmol) were added. The reaction was stirred at r.t. for 1 h and then MeOH 
(10 mL) was added and the suspension was filtered through Celite. The solvent was 
removed in vacuo and the crude product was purified by MPC on silica (petrol: EtOAc 3: 
7) to give the product 407 as a white solid (86 mg, 0.38 mmol, 13%). 
Rf 0.15 (petrol: EtOAc 7: 3); Mp = 96-98 
o
C; UV λmax (EtOH) 270 nm; IR (cm
-1
) 3356, 
3175, 2955, 1729, 1614, 1548, 1398, 1277; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.64 
(3H, s, OCH3), 3.87 (2H, s, H-7), 7.21-7.24 (1H, m, H-4), 7.37-7.39 (1H, m, H-5), 7.39-
7.42 (1H, m, H-6), 7.43 (1H, br s, NH2), 7.50 (1H, dd, J = 1.2 and 7.6 Hz, H-3), 7.84 (1H, 
br s, NH2); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 35.0 (C-7), 52.7 (CH3), 125.5 (C-4), 
127.8 (C-5), 128.3 (C-3), 129.8 (C-1), 130.7 (C-6), 131.6 (C-2), 161.9 (CO), 170.5 (CO); 
HRMS calcd for C10H12NO3S [M+H]
+
 226.0532, found 226.0534.  
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Methyl 2-((2-carbamoylphenyl)sulfonyl)acetate (408) 
 
The title compound was synthesised following general procedure M using methyl 2-((2-
carbamoylphenyl)thio)acetate 407 (85 mg, 0.38 mmol) and m-CPBA (136 mg, 0.79 
mmol). The crude product was purified by MPC on silica (EtOAc 100) to give the 
product 408 as a colourless oil (72 mg, 0.28 mmol, 73%). 
Rf 0.30 (EtOAc 100); UV λmax (EtOH) 256 nm; IR (cm
-1
) 3424, 3346, 2954, 1738, 1665, 
1611, 1317, 1279; 
1
H NMR (500 MHz, DMSO-d6) (ppm) δ 3.61 (3H, s, OCH3), 4.90 (2H, 
s, H-7), 7.62 (1H, dd, J = 1.2 and 7.5 Hz, H-3), 7.70 (1H, ddd, J = 1.2, 7.5 and 7.5 Hz, H-
5), 7.74 (1H, br s, NH2), 7.81 (1H, ddd, J = 1.2, 7.5 and 7.5 Hz, H-4), 7.94 (1H, dd, J = 
1.2 and 7.5 Hz, H-6), 8.17 (1H, br s, NH2); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 53.0 
(CH3), 61.4 (C-7), 129.3 (C-3), 130.1 (C-5), 131.1 (C-6), 134.7 (C-4), 136.7 (C-2), 138.4 
(C-1), 163.7 (CO), 170.0 (CO); HRMS calcd for C10H12NO5S [M+H]
+
 258.0431, found 
258.0431.  
4-Ethyl-1H-pyrazol-3-amine (412)
276
 
 
LiHMDS (1M in THF, 12.5 mL, 12.5 mmol) was added dropwise to a stirred solution of 
butyronitrile 410 (1.09 mL, 12.5 mmol) in dry THF (25 mL), under N2, at -78 
o
C and the 
resulting solution was stirred at -78 
o
C for 1 h. A solution of ethylformate (0.50 mL, 6.25 
mmol) in dry THF (0.8 mL) was added dropwise to the solution. The mixture was stirred 
at -78 
o
C for 30 min. A solution of saturated NH4Cl (10 mL) was added at -78 oC to 
quench the reaction and stirred until reaching r.t. The organic phase was then extracted 
with EtOAc (3 x 15 mL). The organic phases were combine, dried over MgSO4 and the 
solvent was removed in vacuo to give a yellow oil. The crude product was dissolved in 
EtOH (8.5 mL) and hydrazine (0.61 mL, 12.5 mmol) followed by AcOH (0.14 mL, 2.5 
mmol) were added. The reaction was carried out in a MW vial so the reaction was sealed 
and heated at 80 
o
C for 40 h. The reaction was then cooled to r.t. and brine (30 mL) was 
added. The organic phase was extracted with EtOAc (8 x 40 mL). The organic phases 
were combined, dried over MgSO4 and the solvent was removed in vacuo. The crude 
 352 
product was purified by MPC on silica (EtOAc: MeOH 19: 5) to give the product 412 as 
a pale yellow solid (372 mg, 3.35 mmol, 54%). 
Rf 0.27 (EtOAc 100); Mp = 49-50 
o
C; UV λmax (EtOH) 256 nm; IR (cm
-1
) 3318, 3167, 
2960, 1492; 
1
H NMR (500 MHz, DMSO-d6) (ppm) 1.07 (3H, t, J = 7.6 Hz, H-2’), 2.24 
(2H, q, J = 7.6 Hz, H-1’), 4.26 (1H, br s, NH2), 7.11 (1H, s, H-5), 11.14 (1H, br s, NH); 
13
C NMR (125 MHz, DMSO-d6) (ppm) δ 15.0 (C-2’), 16.1 (C-1’), 126.4 (C-5); HRMS 
calcd for C5H10N3 [M+H]
+
 112.0869, found 112.0867.  
Note: Two quaternary carbons were not visible on the 
13
C NMR spectrum. 
3-Ethyl-7-hydroxypyrazolo[1,5-a]pyrimidin-5(4H)-one (413)
276
 
 
Dimethylmalonate (0.60 mL, 5.30 mmol) and NaOMe (25% wt/wt in MeOH, 3.00 mL, 
14.4 mmol) were added to a stirred solution of 4-ethyl-1H-pyrazol-3-amine 412 (327 mg, 
2.95 mmol) in dry MeOH (5 mL), under N2. The resulting mixture was heated at reflux 
for 16 h. After completion, the reaction was cooled to r.t. and Celite (0.35 g) and water 
(3.6 mL) were added. The mixture was stirred for 10 min and filtered to remove the solid. 
The filtrate was adjusted to pH ~ 3 with aqueous HCl to effect precipitation. The 
precipitate was filtered and washed with water. The solid was dried to give the product 
413 as a pale beige solid (393 mg, 2.20 mmol, 74%). 
Rf 0.17 (EtOAc 100); Mp = degradation; UV λmax (EtOH) 254 nm; IR (cm
-1
) 3443, 3208, 
1659, 1621, 1584; 
1
H NMR (500 MHz, DMSO-d6) (ppm) 1.40 (3H, t, J = 7.5 Hz, H-2’), 
2.46 (2H, q, J = 7.5 Hz, H-1’), 3.14 (1H, br s, H-3’), 3.80 (1H, br s, OH), 7.65 (1H, s, H-
5), 11.14 (1H, br s, NH); LRMS calcd for C8H8N3O2 [M-H]
-
 178.1, found 178.0.  
Note: The 
1
H NMR was recorded at 100 
o
C because of the keto-enol tautomerism. For the 
same reason, the 
13
C NMR was not recorded.   
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Appendices 
 Kinetic Studies 
2-(3-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)acetamide (42) 
 
2-(3-((6-Ethynyl-9H-purin-2-yl)amino)phenyl)acetamide (42) (690 µL from stock 
solution DMSO-d6, 1.23 mg, 4.2 µmol) was treated according to general procedure R. 
Disappearance of the singlet at 4.71-4.91 ppm was monitored as a function of time using 
the 
1
H qNMR method outlined. Each spectrum was recorded every 10 min using 8 scans 
per experiment. 
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Experiment 1 (R
2
 =
 
1.00; kapp = 2.50 × 10
-4
 s
-1
; t1/2 = 2773 s) 
Time (s) 
Baseline 
corrected integral 
Concentration 
(mM) 
Ln(Csm/C0) 
0 1.00 6.00 0.00 
744 0.62 3.74 -0.47 
1344 0.53 3.16 -0.64 
1944 0.44 2.65 -0.82 
2544 0.41 2.43 -0.90 
3144 0.33 1.98 -1.11 
3744 0.28 1.69 -1.27 
4344 0.24 1.46 -1.41 
4944 0.21 1.27 -1.56 
5544 0.18 1.08 -1.71 
6144 0.16 0.95 -1.85 
6744 0.13 0.79 -2.02 
7344 0.11 0.68 -2.17 
7944 0.10 0.59 -2.31 
8544 0.09 0.51 -2.47 
9144 0.08 0.48 -2.52 
9744 0.07 0.43 -2.63 
Experiment 2 (R
2
 =
 
0.99; kapp = 2.43 × 10
-4
 s
-1
; t1/2 = 2852 s) 
Time (s) 
Baseline 
corrected integral 
Concentration 
(mM) 
Ln(Csm/C0) 
0 1.00 6.00 0.00 
698 0.64 3.83 -0.45 
1298 0.55 3.30 -0.60 
1898 0.48 2.85 -0.74 
2498 0.44 2.61 -0.83 
3098 0.37 2.21 -1.00 
3698 0.33 1.97 -1.11 
4298 0.30 1.77 -1.22 
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4898 0.26 1.54 -1.36 
5498 0.23 1.36 -1.48 
6098 0.19 1.12 -1.68 
6698 0.15 0.89 -1.91 
7298 0.13 0.77 -2.06 
7898 0.11 0.67 -2.19 
8498 0.09 0.55 -2.40 
9098 0.08 0.50 -2.48 
9698 0.08 0.47 -2.54 
Experiment 3 (R
2
 =
 
0.99; kapp = 2.40 × 10
-4
 s
-1
; t1/2 = 2888 s) 
Time (s) 
Baseline 
corrected integral 
Concentration 
(mM) 
Ln(Csm/C0) 
0 1.00 6.00 0.00 
768 0.63 3.78 -0.46 
1368 0.57 3.39 -0.57 
1968 0.50 2.98 -0.70 
2568 0.45 2.68 -0.81 
3168 0.40 2.38 -0.93 
3768 0.36 2.13 -1.04 
4368 0.32 1.93 -1.13 
4968 0.27 1.61 -1.32 
5568 0.24 1.41 -1.45 
6168 0.20 1.21 -1.60 
6768 0.16 0.93 -1.86 
7368 0.13 0.77 -2.05 
7968 0.12 0.71 -2.13 
8568 0.11 0.63 -2.25 
9168 0.09 0.53 -2.42 
9768 0.08 0.47 -2.55 
 
6-Ethynyl-9-methyl-N-phenyl-9H-purin-2-amine (61) 
 
6-Ethynyl-9-methyl-N-phenyl-9H-purin-2-amine (61) (690 µL from stock solution 
DMSO-d6, 1.05 mg, 4.2 µmol) was treated according to general procedure R. 
Disappearance of the singlet at 4.75-4.95 ppm was monitored as a function of time using 
the 
1
H qNMR method outlined. Each spectrum was recorded every 10 min using 8 scans 
per experiment. 
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Experiment 1 (R
2
 = 1.00, kapp = 3.87.10
-4
 s
-1
; t1/2 = 1829 s) 
Time (s) 
Baseline 
corrected integral 
Concentration 
(mM) 
Ln(Csm/C0) 
0 1 6 -5.12 
887 0.61 3.66 -5.61 
1487 0.48 2.88 -5.85 
2087 0.36 2.16 -6.14 
2687 0.28 1.68 -6.39 
3287 0.23 1.38 -6.59 
3887 0.18 1.08 -6.83 
4487 0.14 0.84 -7.08 
5087 0.12 0.72 -7.24 
5687 0.10 0.60 -7.42 
6287 0.07 0.42 -7.78 
6887 0.06 0.36 -7.93 
7487 0.05 0.30 -8.11 
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Experiment 2 (R
2
 = 0.99, kapp = 3.86.10
-4
 s
-1
; t1/2 = 1773 s) 
Time (s) 
Baseline 
corrected integral 
Concentration 
(mM) 
Ln(Csm/C0) 
0 1 6 -5.12 
842 0.59 3.54 -5.64 
1442 0.46 2.76 -5.89 
2042 0.35 2.10 -6.17 
2642 0.28 1.68 -6.39 
3242 0.21 1.26 -6.68 
3842 0.17 1.02 -6.89 
4442 0.12 0.72 -7.24 
5042 0.11 0.66 -7.32 
5642 0.09 0.54 -7.52 
6242 0.07 0.42 -7.78 
6842 0.06 0.36 -7.93 
7442 0.04 0.24 -8.33 
Experiment 3 (R
2
 = 0.99, kapp = 3.01.10
-4
 s
-1
; t1/2 = 2303 s) 
Time (s) 
Baseline 
corrected integral 
Concentration 
(mM) 
Ln(Csm/C0) 
0 1 6 -5.12 
878 0.62 3.72 -5.59 
1478 0.48 2.88 -5.85 
2078 0.38 2.28 -6.08 
2678 0.30 1.80 -6.32 
3278 0.23 1.38 -6.59 
3878 0.19 1.14 -6.78 
4478 0.15 0.90 -7.01 
5078 0.13 0.78 -7.16 
5678 0.10 0.60 -7.42 
6278 0.08 0.48 -7.64 
6878 0.06 0.36 -7.93 
 
6-Ethynyl-7-methyl-N-phenyl-7H-purin-2-amine (62) 
 
6-Ethynyl-7-methyl-N-phenyl-7H-purin-2-amine (62) (690 µL from stock solution 
DMSO-d6, 1.05 mg, 4.2 µmol) was treated according to general procedure R. 
Disappearance of the singlet at 4.90-5.10 ppm was monitored as a function of time using 
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the 
1
H qNMR method outlined. Each spectrum was recorded every 10 min using 8 scans 
per experiment. 
 
Experiment 1 (R
2
 = 1.00, kapp = 28.57.10
-4
 s
-1
; t1/2 = 243 s) 
Time (s) 
Baseline 
corrected integral 
Concentration 
(mM) 
Ln(Csm/C0) 
0 1 6 -5.12 
549 0.23 1.38 -6.59 
729 0.14 0.84 -7.08 
909 0.09 0.54 -7.52 
1089 0.05 0.30 -8.11 
1269 0.03 0.18 -8.62 
1449 0.02 0.12 -9.03 
1626 0.01 0.06 -9.72 
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Experiment 2 (R
2
 = 0.99, kapp = 27.77.10
-4
 s
-1
; t1/2 = 250 s) 
Time (s) 
Baseline 
corrected integral 
Concentration 
(mM) 
Ln(Csm/C0) 
0 1 6 -5.12 
710 0.13 0.78 -7.16 
890 0.08 0.48 -7.64 
1070 0.05 0.30 -8.11 
1250 0.03 0.18 -8.62 
1430 0.02 0.12 -9.03 
1610 0.01 0.06 -9.72 
Experiment 3 (R
2
 = 0.99, kapp = 27.77.10
-4
 s
-1
; t1/2 = 250 s) 
Time (s) 
Baseline 
corrected integral 
Concentration 
(mM) 
Ln(Csm/C0) 
0 1 6 -5.12 
530 0.22 1.32 -6.63 
710 0.13 0.78 -7.16 
890 0.08 0.48 -7.64 
1070 0.04 0.24 -8.33 
1250 0.03 0.18 -8.62 
1430 0.02 0.12 -9.03 
1610 0.01 0.06 -9.72 
 
2-(3-((6-Ethynyl-9-methyl-9H-purin-2-yl)amino)phenyl)acetamide (63) 
 
2-(3-((6-Ethynyl-9-methyl-9H-purin-2-yl)amino)phenyl)acetamide (63) (690 µL from 
stock solution DMSO-d6, 1.29 mg, 4.2 µmol) was treated according to general procedure 
R. Disappearance of the singlet at 4.74-4.94 ppm was monitored as a function of time 
using the 
1
H qNMR method outlined. Each spectrum was recorded every 10 min using 8 
scans per experiment. 
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Experiment 1 (R
2
 = 0.99, kapp = 2.87.10
-4
 s
-1
; t1/2 = 2415 s) 
Time (s) 
Baseline 
corrected integral 
Concentration 
(mM) 
Ln(Csm/C0) 
0 1.00 6.00 0.00 
1097 0.47 2.79 -0.77 
1697 0.35 2.08 -1.06 
2297 0.30 1.81 -1.20 
2897 0.26 1.54 -1.36 
3497 0.20 1.22 -1.59 
4097 0.19 1.11 -1.69 
4697 0.15 0.89 -1.90 
5297 0.13 0.79 -2.02 
5897 0.11 0.67 -2.19 
6497 0.09 0.55 -2.40 
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Experiment 2 (R
2
 = 0.99, kapp = 3.11.10
-4
 s
-1
; t1/2 = 2229 s) 
Time (s) 
Baseline 
corrected integral 
Concentration 
(mM) 
Ln(Csm/C0) 
0 1.00 6.00 0.00 
620 0.62 3.74 -0.47 
1220 0.43 2.59 -0.84 
1820 0.37 2.24 -0.98 
2420 0.29 1.72 -1.25 
3020 0.24 1.45 -1.42 
3620 0.20 1.22 -1.59 
4220 0.17 1.04 -1.75 
4820 0.14 0.86 -1.94 
5420 0.12 0.73 -2.11 
6020 0.11 0.65 -2.23 
6620 0.09 0.52 -2.45 
Experiment 3 (R
2
 = 0.99, kapp = 3.01.10
-4
 s
-1
; t1/2 = 2303 s) 
Time (s) 
Baseline 
corrected integral 
Concentration 
(mM) 
Ln(Csm/C0) 
0 1.00 6.00 0.00 
728 0.61 3.65 -0.50 
1328 0.50 2.98 -0.70 
1928 0.38 2.26 -0.98 
2528 0.30 1.81 -1.20 
3128 0.24 1.45 -1.42 
3728 0.22 1.31 -1.52 
4328 0.19 1.16 -1.65 
4928 0.15 0.91 -1.89 
5528 0.14 0.85 -1.96 
6128 0.12 0.71 -2.14 
6728 0.09 0.54 -2.41 
 
2-(3-((6-Ethynyl-7-methyl-7H-purin-2-yl)amino)phenyl)acetamide (64) 
 
2-(3-((6-Ethynyl-7-methyl-7H-purin-2-yl)amino)phenyl)acetamide (64) (690 µL from 
stock solution DMSO-d6, 1.29 mg, 4.2 µmol) was treated according to general procedure 
R. Disappearance of the singlet at 4.90-5.10 ppm was monitored as a function of time 
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using the 
1
H qNMR method outlined. Each spectrum was recorded every 3 min using 4 
scans per experiment. 
 
Experiment 1 (R
2
 = 0.99, kapp = 14.62.10
-4
 s
-1
; t1/2 = 474 s) 
Time (s) 
Baseline 
corrected integral 
Concentration 
(mM) 
Ln(Csm/C0) 
0 1.00 6.00 0.00 
577 0.17 1.04 -1.75 
757 0.13 0.76 -2.07 
937 0.09 0.55 -2.40 
1117 0.07 0.39 -2.73 
1297 0.05 0.29 -3.04 
1477 0.04 0.22 -3.32 
1657 0.03 0.18 -3.51 
1837 0.03 0.15 -3.69 
2017 0.02 0.12 -3.91 
2197 0.02 0.10 -4.14 
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Experiment 2 (R
2
 = 1.00, kapp = 15.19.10
-4
 s
-1
; t1/2 = 468 s) 
Time (s) 
Baseline 
corrected integral 
Concentration 
(mM) 
Ln(Csm/C0) 
0 1.00 6.00 0.00 
534 0.18 1.08 -1.71 
714 0.13 0.78 -2.04 
894 0.11 0.65 -2.23 
1074 0.09 0.52 -2.44 
1254 0.06 0.35 -2.85 
1434 0.05 0.27 -3.10 
1614 0.04 0.22 -3.32 
1794 0.03 0.17 -3.58 
1974 0.02 0.12 -3.91 
2154 0.02 0.09 -4.20 
Experiment 3 (R
2
 = 1.00, kapp = 14.83.10
-4
 s
-1
; t1/2 = 467 s) 
Time (s) 
Baseline 
corrected integral 
Concentration 
(mM) 
Ln(Csm/C0) 
0 1.00 6.00 0.00 
528 0.19 1.13 -1.67 
708 0.15 0.88 -1.92 
888 0.12 0.70 -2.15 
1068 0.09 0.54 -2.41 
1248 0.07 0.44 -2.62 
1428 0.05 0.32 -2.94 
1608 0.04 0.24 -3.22 
1788 0.03 0.19 -3.47 
1968 0.02 0.14 -3.78 
2148 0.02 0.10 -4.07 
 
 Small molecule X-ray Crystallography Data 
2-Iodopurine 101 
Table 24 - Crystal data and structure refinement for 101 
Identification code rjg12 
Chemical formula (moiety) C13H17IN4O 
Chemical formula (total) C13H17IN4O 
Formula weight 372.21 
Temperature 150(2) K 
Radiation, wavelength MoK, 0.71073 Å 
Crystal system, space group monoclinic, P121/c1 
Unit cell parameters a = 20.6041(14) Å      = 90° 
b = 10.2213(6) Å        = 90.370(7)° 
c = 6.8832(5) Å           = 90° 
Cell volume 1449.58(17) Å
3
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Z 4 
Calculated density 1.705 g/cm
3
 
Absorption coefficient  2.208 mm1 
F(000) 736 
Crystal colour and size colourless, 0.30  0.10  0.02 mm3 
Reflections for cell refinement 2746 ( range 2.8 to 28.5°) 
Data collection method Xcalibur, Atlas, Gemini ultra thick-slice  
scans 
 range for data collection 2.8 to 26.0° 
Index ranges h 25 to 25, k 12 to 12, l 7 to 8 
Completeness to  = 26.0° 97.4 % 
Reflections collected 2784 
Independent reflections 2784 (Rint = 0.0000) 
Reflections with F
2
>2 2450 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.5572 and 0.9572 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0458, 7.7247 
Data / restraints / parameters 2784 / 0 / 173 
Final R indices [F
2
>2] R1 = 0.0428, wR2 = 0.1064 
R indices (all data) R1 = 0.0500, wR2 = 0.1115 
Goodness-of-fit on F
2
 1.064 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 1.66 and 0.67 e Å3 
Table 25 - Atomic coordinates and equivalent isotropic displacement parameters (Å
2
) for 101. 
Ueq is defined as one third of the trace of the orthogonalised U
ij
 tensor. 
 x y z Ueq 
I 0.21039(2) 0.12326(3) 0.36754(7) 0.03328(16) 
O 0.22906(16) 0.3834(3) 0.4345(6) 0.0180(8) 
N(1) 0.08634(19) 0.4141(4) 0.3291(6) 0.0147(9) 
N(2) 0.0243(2) 0.2366(5) 0.2696(6) 0.0204(10) 
N(3) 0.1075(2) 0.0724(4) 0.3211(6) 0.0179(9) 
N(4) 0.21187(19) 0.1611(4) 0.4056(6) 0.0141(8) 
C(1) 0.1043(2) 0.5508(5) 0.3523(9) 0.0206(11) 
C(2) 0.0272(3) 0.3658(6) 0.2795(8) 0.0229(12) 
C(3) 0.0857(2) 0.1983(5) 0.3170(7) 0.0170(10) 
C(4) 0.1687(2) 0.0659(5) 0.3635(7) 0.0153(10) 
C(5) 0.1902(2) 0.2830(5) 0.3982(7) 0.0119(10) 
C(6) 0.1249(2) 0.3055(5) 0.3533(7) 0.0135(10) 
C(7) 0.2968(2) 0.3587(5) 0.4761(9) 0.0220(12) 
C(8) 0.3386(2) 0.4332(5) 0.3344(8) 0.0144(10) 
C(9) 0.4094(2) 0.3923(6) 0.3628(11) 0.0316(14) 
C(10) 0.4542(3) 0.4665(7) 0.2284(11) 0.0393(17) 
C(11) 0.4466(3) 0.6126(6) 0.2540(11) 0.0344(15) 
C(12) 0.3765(3) 0.6557(7) 0.2254(10) 0.0349(15) 
C(13) 0.3314(2) 0.5791(5) 0.3557(9) 0.0209(11) 
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Table 26 - Bond lengths [Å] and angles [°] for 101 
I–C(4) 2.116(5) O–C(5) 1.324(6) 
O–C(7) 1.445(6) N(1)–C(1) 1.453(7) 
N(1)–C(2) 1.357(7) N(1)–C(6) 1.375(6) 
N(2)–C(2) 1.323(8) N(2)–C(3) 1.362(7) 
N(3)–C(3) 1.364(7) N(3)–C(4) 1.295(7) 
N(4)–C(4) 1.348(6) N(4)–C(5) 1.325(6) 
C(1)–H(1A) 0.980 C(1)–H(1B) 0.980 
C(1)–H(1C) 0.980 C(2)–H(2A) 0.950 
C(3)–C(6) 1.382(7) C(5)–C(6) 1.397(6) 
C(7)–H(7A) 0.990 C(7)–H(7B) 0.990 
C(7)–C(8) 1.511(7) C(8)–H(8A) 1.000 
C(8)–C(9) 1.529(6) C(8)–C(13) 1.506(7) 
C(9)–H(9A) 0.990 C(9)–H(9B) 0.990 
C(9)–C(10) 1.515(9) C(10)–H(10A) 0.990 
C(10)–H(10B) 0.990 C(10)–C(11) 1.512(9) 
C(11)–H(11A) 0.990 C(11)–H(11B) 0.990 
C(11)–C(12) 1.522(9) C(12)–H(12A) 0.990 
C(12)–H(12B) 0.990 C(12)–C(13) 1.513(8) 
C(13)–H(13A) 0.990 C(13)–H(13B) 0.990 
C(5)–O–C(7) 119.0(4) C(1)–N(1)–C(2) 127.2(4) 
C(1)–N(1)–C(6) 128.1(4) C(2)–N(1)–C(6) 104.7(4) 
C(2)–N(2)–C(3) 103.5(4) C(3)–N(3)–C(4) 111.9(4) 
C(4)–N(4)–C(5) 116.7(4) N(1)–C(1)–H(1A) 109.5 
N(1)–C(1)–H(1B) 109.5 N(1)–C(1)–H(1C) 109.5 
H(1A)–C(1)–H(1B) 109.5 H(1A)–C(1)–H(1C) 109.5 
H(1B)–C(1)–H(1C) 109.5 N(1)–C(2)–N(2) 114.6(5) 
N(1)–C(2)–H(2A) 122.7 N(2)–C(2)–H(2A) 122.7 
N(2)–C(3)–N(3) 125.5(5) N(2)–C(3)–C(6) 110.8(5) 
N(3)–C(3)–C(6) 123.6(4) I–C(4)–N(3) 116.4(4) 
I–C(4)–N(4) 113.0(3) N(3)–C(4)–N(4) 130.7(5) 
O–C(5)–N(4) 121.2(4) O–C(5)–C(6) 119.7(4) 
N(4)–C(5)–C(6) 119.1(4) N(1)–C(6)–C(3) 106.4(4) 
N(1)–C(6)–C(5) 135.6(5) C(3)–C(6)–C(5) 118.0(4) 
O–C(7)–H(7A) 109.7 O–C(7)–H(7B) 109.7 
O–C(7)–C(8) 109.8(4) H(7A)–C(7)–H(7B) 108.2 
H(7A)–C(7)–C(8) 109.7 H(7B)–C(7)–C(8) 109.7 
C(7)–C(8)–H(8A) 108.2 C(7)–C(8)–C(9) 109.1(4) 
C(7)–C(8)–C(13) 112.3(4) H(8A)–C(8)–C(9) 108.2 
H(8A)–C(8)–C(13) 108.2 C(9)–C(8)–C(13) 110.6(4) 
C(8)–C(9)–H(9A) 109.3 C(8)–C(9)–H(9B) 109.3 
C(8)–C(9)–C(10) 111.7(5) H(9A)–C(9)–H(9B) 107.9 
H(9A)–C(9)–C(10) 109.3 H(9B)–C(9)–C(10) 109.3 
C(9)–C(10)–H(10A) 109.4 C(9)–C(10)–H(10B) 109.4 
C(9)–C(10)–C(11) 111.1(5) H(10A)–C(10)–H(10B) 108.0 
H(10A)–C(10)–C(11) 109.4 H(10B)–C(10)–C(11) 109.4 
C(10)–C(11)–H(11A) 109.3 C(10)–C(11)–H(11B) 109.3 
C(10)–C(11)–C(12) 111.7(5) H(11A)–C(11)–H(11B) 107.9 
H(11A)–C(11)–C(12) 109.3 H(11B)–C(11)–C(12) 109.3 
C(11)–C(12)–H(12A) 109.4 C(11)–C(12)–H(12B) 109.4 
C(11)–C(12)–C(13) 111.1(5) H(12A)–C(12)–H(12B) 108.0 
H(12A)–C(12)–C(13) 109.4 H(12B)–C(12)–C(13) 109.4 
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C(8)–C(13)–C(12) 113.2(5) C(8)–C(13)–H(13A) 108.9 
C(8)–C(13)–H(13B) 108.9 C(12)–C(13)–H(13A) 108.9 
C(12)–C(13)–H(13B) 108.9 H(13A)–C(13)–H(13B) 107.8 
Table 27 - Anisotropic displacement parameters (Å
2
) for 101. The anisotropic displacement 
factor exponent takes the form: 22[h2a*2U11 + ...+ 2hka*b*U12] 
 U
11
 U
22
 U
33
 U
23
 U
13
 U
12
 
I 0.0448(3) 0.0198(2) 
0.0353(2
) 
0.00089(17) 0.00130(19) 0.00403(17) 
O 0.0092(16) 0.0121(17) 0.033(2) 0.0038(16) 0.0034(15) 0.0010(13) 
N(1) 0.0085(18) 0.020(2) 0.016(2) 0.0026(18) 0.0008(16) 0.0017(16) 
N(2) 0.0107(19) 0.033(3) 0.018(2) 0.002(2) 0.0017(17) 0.0053(19) 
N(3) 0.022(2) 0.018(2) 0.014(2) 0.0005(18) 0.0008(18) 0.0061(18) 
N(4) 0.0110(18) 0.017(2) 0.015(2) 0.0013(17) 0.0013(17) 0.0001(17) 
C(1) 0.016(2) 0.018(3) 0.027(3) 0.003(2) 0.000(2) 0.004(2) 
C(2) 0.011(2) 0.038(3) 0.019(3) 0.002(3) 0.005(2) 0.000(2) 
C(3) 0.018(2) 0.022(3) 0.011(2) 0.001(2) 0.0010(19) 0.004(2) 
C(4) 0.022(2) 0.012(2) 0.012(2) 0.001(2) 0.003(2) 0.000(2) 
C(5) 0.009(2) 0.014(2) 0.012(2) 0.001(2) 0.0011(18) 0.0025(18) 
C(6) 0.014(2) 0.016(2) 0.010(2) 0.002(2) 0.0025(19) 0.0001(19) 
C(7) 0.008(2) 0.023(3) 0.035(3) 0.010(2) 0.008(2) 0.000(2) 
C(8) 0.006(2) 0.017(2) 0.021(3) 0.004(2) 0.0003(19) 0.0001(18) 
C(9) 0.010(2) 0.024(3) 0.060(4) 0.008(3) 0.005(3) 0.006(2) 
C(10) 0.017(3) 0.045(4) 0.056(4) 0.003(4) 0.012(3) 0.001(3) 
C(11) 0.022(3) 0.036(4) 0.045(4) 0.011(3) 0.008(3) 0.008(3) 
C(12) 0.032(3) 0.032(3) 0.041(4) 0.018(3) 0.003(3) 0.009(3) 
C(13) 0.016(2) 0.012(2) 0.034(3) 0.001(2) 0.001(2) 0.003(2) 
Table 28 - Hydrogen coordinates and isotropic displacement parameters (Å
2
) for 101. 
 x y z U 
H(1A) 0.0665 0.6062 0.3245 0.031 
H(1B) 0.1191 0.5660 0.4860 0.031 
H(1C) 0.1393 0.5723 0.2621 0.031 
H(2A) 0.0092 0.4202 0.2539 0.028 
H(7A) 0.3071 0.3867 0.6105 0.026 
H(7B) 0.3058 0.2639 0.4654 0.026 
H(8A) 0.3249 0.4085 0.1997 0.017 
H(9A) 0.4136 0.2973 0.3376 0.038 
H(9B) 0.4226 0.4087 0.4992 0.038 
H(10A) 0.4443 0.4427 0.0920 0.047 
H(10B) 0.4998 0.4414 0.2561 0.047 
H(11A) 0.4614 0.6376 0.3860 0.041 
H(11B) 0.4744 0.6585 0.1590 0.041 
H(12A) 0.3636 0.6423 0.0881 0.042 
H(12B) 0.3727 0.7501 0.2550 0.042 
H(13A) 0.2860 0.6037 0.3251 0.025 
H(13B) 0.3402 0.6035 0.4926 0.025 
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Table 29 - Torsion angles [°] for 101. 
C(3)–N(2)–C(2)–N(1) 0.3(6) C(1)–N(1)–C(2)–N(2) 179.7(5) 
C(6)–N(1)–C(2)–N(2) 0.0(6) C(2)–N(2)–C(3)–N(3) 177.9(5) 
C(2)–N(2)–C(3)–C(6) 0.5(6) C(4)–N(3)–C(3)–N(2) 177.3(5) 
C(4)–N(3)–C(3)–C(6) 0.3(7) C(3)–N(3)–C(4)–I 178.3(3) 
C(3)–N(3)–C(4)–N(4) 1.2(8) C(5)–N(4)–C(4)–I 177.3(3) 
C(5)–N(4)–C(4)–N(3) 2.3(8) C(7)–O–C(5)–N(4) 2.2(7) 
C(7)–O–C(5)–C(6) 178.5(5) C(4)–N(4)–C(5)–O 179.0(4) 
C(4)–N(4)–C(5)–C(6) 1.7(7) C(1)–N(1)–C(6)–C(3) 179.4(5) 
C(1)–N(1)–C(6)–C(5) 2.5(9) C(2)–N(1)–C(6)–C(3) 0.3(5) 
C(2)–N(1)–C(6)–C(5) 177.9(6) N(2)–C(3)–C(6)–N(1) 0.5(5) 
N(2)–C(3)–C(6)–C(5) 178.0(4) N(3)–C(3)–C(6)–N(1) 177.9(4) 
N(3)–C(3)–C(6)–C(5) 0.6(7) O–C(5)–C(6)–N(1) 2.3(9) 
O–C(5)–C(6)–C(3) 179.8(4) N(4)–C(5)–C(6)–N(1) 178.4(5) 
N(4)–C(5)–C(6)–C(3) 0.4(7) C(5)–O–C(7)–C(8) 123.3(5) 
O–C(7)–C(8)–C(9) 172.6(5) O–C(7)–C(8)–C(13) 64.4(6) 
C(7)–C(8)–C(9)–C(10) 178.4(5) C(13)–C(8)–C(9)–C(10) 54.4(7) 
C(8)–C(9)–C(10)–C(11) 
55.8(8) 
C(9)–C(10)–C(11)–
C(12) 
55.5(8) 
C(10)–C(11)–C(12)–
C(13) 
53.9(8) 
C(7)–C(8)–C(13)–C(12) 
175.8(5) 
C(9)–C(8)–C(13)–C(12) 
53.6(7) 
C(11)–C(12)–C(13)–
C(8) 
53.6(7) 
 
N
7
-methylpurine 64 
Table 30 - Crystal data and structure refinement for 64. 
Identification code rjg12 
Chemical formula (moiety) C16H14N6O·0.5CH4O 
Chemical formula (total) C16.50H16N6O1.50 
Formula weight 322.35 
Temperature 150(2) K 
Radiation, wavelength MoK, 0.71073 Å 
Crystal system, space group monoclinic, P121/n1 
Unit cell parameters a = 15.3730(7) Å       = 90°  
b = 14.1912(4) Å       = 117.831(6)° 
c = 16.2612(7) Å       = 90° 
Cell volume 3137.2(2) Å
3
 
Z 8 
Calculated density 1.365 g/cm
3
 
Absorption coefficient  0.093 mm1 
F(000) 1352 
Crystal colour and size yellow, 0.30  0.30  0.20 mm3 
Reflections for cell refinement 10793 ( range 2.9 to 28.6°) 
Data collection method Xcalibur, Atlas, Gemini ultra thick-slice  
scans 
 range for data collection 2.9 to 28.6° 
Index ranges h 20 to 20, k 19 to 16, l 20 to 21 
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Completeness to  = 25.0° 99.9 % 
Reflections collected 22860 
Independent reflections 6971 (Rint = 0.0256) 
Reflections with F
2
>2 5642 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.9725 and 0.9816 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0480, 1.5888 
Data / restraints / parameters 6971 / 0 / 473 
Final R indices [F
2
>2] R1 = 0.0436, wR2 = 0.1046 
R indices (all data) R1 = 0.0569, wR2 = 0.1134 
Goodness-of-fit on F
2
 1.026 
Extinction coefficient 0.0017(4) 
Largest and mean shift/su 0.001 and 0.000 
Largest diff. peak and hole 0.33 and 0.24 e Å3 
Table 31 - Atomic coordinates and equivalent isotropic displacement parameters (Å
2
) for 64. Ueq 
is defined as one third of the trace of the orthogonalised U
ij
 tensor. 
 x y z Ueq 
O(2) 0.13596(7) 0.25524(7) 0.70862(7) 0.0240(2) 
O(3) 0.71384(9) 0.17655(10) 0.98258(8) 0.0363(3) 
N(7) 0.01532(10) 0.24940(10) 0.58691(9) 0.0236(3) 
N(8) 0.27744(9) 0.59808(9) 0.85838(8) 0.0220(3) 
N(9) 0.29180(9) 0.50266(9) 0.98140(8) 0.0212(3) 
N(10) 0.33164(9) 0.41005(9) 1.11897(8) 0.0238(3) 
N(11) 0.48848(9) 0.45793(9) 1.20213(8) 0.0218(3) 
N(12) 0.42367(9) 0.60228(8) 0.99107(8) 0.0202(3) 
C(17) 0.04899(10) 0.28165(10) 0.66964(9) 0.0188(3) 
C(18) 0.01292(11) 0.35635(10) 0.71346(10) 0.0218(3) 
C(19) 0.05864(10) 0.45025(10) 0.71062(10) 0.0205(3) 
C(20) 0.02102(11) 0.50168(11) 0.62872(10) 0.0264(3) 
C(21) 0.06845(12) 0.58365(12) 0.62517(11) 0.0301(4) 
C(22) 0.15238(12) 0.61362(11) 0.70174(10) 0.0261(3) 
C(23) 0.18995(10) 0.56326(10) 0.78503(9) 0.0203(3) 
C(24) 0.14184(10) 0.48172(10) 0.78908(10) 0.0204(3) 
C(25) 0.33163(10) 0.56447(10) 0.94696(9) 0.0193(3) 
C(26) 0.35389(10) 0.47345(10) 1.06740(10) 0.0202(3) 
C(27) 0.41451(11) 0.40366(11) 1.19796(10) 0.0238(3) 
C(28) 0.45079(10) 0.50463(10) 1.11784(9) 0.0196(3) 
C(29) 0.48389(10) 0.57240(10) 1.07751(9) 0.0189(3) 
C(30) 0.58090(11) 0.61239(10) 1.12422(10) 0.0216(3) 
C(31) 0.66149(12) 0.64286(11) 1.16572(11) 0.0264(3) 
C(32) 0.58664(12) 0.46424(12) 1.28115(10) 0.0292(3) 
C(33) 0.78699(13) 0.23375(13) 1.05222(12) 0.0361(4) 
O(1) 0.98227(9) 0.51798(10) 0.88206(9) 0.0411(3) 
N(1) 0.87278(12) 0.47099(12) 0.92939(11) 0.0372(4) 
N(2) 0.82862(12) 0.12140(10) 0.88083(10) 0.0325(3) 
N(3) 0.90670(10) 0.02332(9) 0.89151(9) 0.0257(3) 
N(4) 0.96400(11) 0.18354(10) 0.90586(10) 0.0346(3) 
N(5) 0.88375(12) 0.24145(10) 0.98052(11) 0.0385(4) 
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N(6) 0.79939(10) 0.00537(9) 0.96008(9) 0.0260(3) 
C(1) 0.90370(12) 0.48062(12) 0.86584(12) 0.0305(4) 
C(2) 0.83883(13) 0.43812(12) 0.77196(12) 0.0337(4) 
C(3) 0.86585(13) 0.33539(12) 0.77555(11) 0.0321(4) 
C(4) 0.93098(18) 0.30517(14) 0.74402(15) 0.0497(5) 
C(5) 0.9621(2) 0.21241(14) 0.75707(18) 0.0620(7) 
C(6) 0.93045(18) 0.14785(13) 0.80162(16) 0.0503(6) 
C(7) 0.86499(13) 0.17786(12) 0.83303(11) 0.0311 (4) 
C(8) 0.83304(13) 0.27071(12) 0.81896(11) 0.0305(4) 
C(9) 0.84830(11) 0.03044(11) 0.91181(10) 0.0252(3) 
C(10) 0. 91210(11) 0.11254(11) 0.92037(10) 0.0262(3) 
C(11) 0.94415(15) 0.25809(13) 0.94264(14) 0.0417(4) 
C(12) 0.86169(12) 0.14690(11) 0.96682(11) 0.0279(3) 
C(13) 0.80502(11) 0.08454(11) 0.98726(10) 0.0260(3) 
C(14) 0.75129(12) 0.10995(12) 1.03626(11) 0.0312(4) 
C(15) 0.70815(15) 0.13116(16) 1.07719(14) 0.0442(5) 
C(16) 0.8461(2) 0.31088(15) 1.0224(2) 0.0633(7) 
Table 32 - Bond lengths [Å] and angles [°] for 64. 
O(2)–C(17) 1.2404(17) O(3)–C(33) 1.420(2) 
O(3)–H(3) 0.94(3) N(7)–C(17) 1.3247(19) 
N(7)–H(7A) 0.880(19) N(7)–H(7B) 0.835(19) 
N(8)–C(23) 1.4064(18) N(8)–C(25) 1.3697(18) 
N(8)–H(8) 0.831(19) N(9)–C(25) 1.3335(18) 
N(9)–C(26) 1.3388(18) N(10)–C(26) 1.3776(19) 
N(10)–C(27) 1.324(2) N(11)–C(27) 1.349(2) 
N(11)–C(28) 1.3828(18) N(11)–C(32) 1.4580(19) 
N(12)–C(25) 1.3626(18) N(12)–C(29) 1.3408(18) 
C(17)–C(18) 1.519(2) C(18)–H(18A) 0.990 
C(18)–H(18B) 0.990 C(18)–C(19) 1.517(2) 
C(19)–C(20) 1.386(2) C(19)–C(24) 1.393(2) 
C(20)–H(20A) 0.950 C(20)–C(21) 1.388(2) 
C(21)–H(21A) 0.950 C(21)–C(22) 1.377(2) 
C(22)–H(22A) 0.950 C(22)–C(23) 1.396(2) 
C(23)–C(24) 1.391(2) C(24)–H(24A) 0.950 
C(26)–C(28) 1.395(2) C(27)–H(27A) 0.950 
C(28)–C(29) 1.388(2) C(29)–C(30) 1.437(2) 
C(30)–C(31) 1.182(2) C(31)–H(31) 0.92(2) 
C(32)–H(32A) 0.980 C(32)–H(32B) 0.980 
C(32)–H(32C) 0.980 C(33)–H(33A) 0.980 
C(33)–H(33B) 0.980 C(33)–H(33C) 0.980 
O(1)–C(1) 1.230(2) N(1)–C(1) 1.331(2) 
N(1)–H(1A) 1.00(3) N(1)–H(1B) 0.97(2) 
N(2)–C(7) 1.402(2) N(2)–C(9) 1.367(2) 
N(2)–H(2) 0.90(2) N(3)–C(9) 1.332(2) 
N(3)–C(10) 1.339(2) N(4)–C(10) 1.372(2) 
N(4)–C(11) 1.319(2) N(5)–C(11) 1.353(2) 
N(5)–C(12) 1.376(2) N(5)–C(16) 1.462(2) 
N(6)–C(9) 1.3637(19) N(6)–C(13) 1.340(2) 
C(1)–C(2) 1.506(2) C(2)–H(2A) 0.990 
C(2)–H(2B) 0.990 C(2)–C(3) 1.509(2) 
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C(3)–C(4) 1.389(3) C(3)–C(8) 1.388(2) 
C(4)–H(4A) 0.950 C(4)–C(5) 1.383(3) 
C(5)–H(5A) 0.950 C(5)–C(6) 1.389(3) 
C(6)–H(6A) 0.950 C(6)–C(7) 1.391(2) 
C(7)–C(8) 1.387(2) C(8)–H(8A) 0.950 
C(10)–C(12) 1.398(2) C(11)–H(11A) 0.950 
C(12)–C(13) 1.387(2) C(13)–C(14) 1.436(2) 
C(14)–C(15) 1.177(2) C(15)–H(15) 0.92(2) 
C(16)–H(16A) 0.980 C(16)–H(16B) 0.980 
C(16)–H(16C) 0.980   
C(33)–O(3)–H(3) 109.2(18) C(17)–N(7)–H(7A) 117.9(12) 
C(17)–N(7)–H(7B) 118.1(12) H(7A)–N(7)–H(7B) 123.9(17) 
C(23)–N(8)–C(25) 129.86(13) C(23)–N(8)–H(8) 114.8(12) 
C(25)–N(8)–H(8) 114.9(12) C(25)–N(9)–C(26) 113.52(12) 
C(26)–N(10)–C(27) 103.61(12) C(27)–N(11)–C(28) 105.70(12) 
C(27)–N(11)–C(32) 125.51(13) C(28)–N(11)–C(32) 128.79(13) 
C(25)–N(12)–C(29) 117.80(12) O(2)–C(17)–N(7) 122.00(13) 
O(2)–C(17)–C(18) 120.90(12) N(7)–C(17)–C(18) 117.04(13) 
C(17)–C(18)–H(18A) 109.9 C(17)–C(18)–H(18B) 109.9 
C(17)–C(18)–C(19) 108.84(11) H(18A)–C(18)–H(18B) 108.3 
H(18A)–C(18)–C(19) 109.9 H(18B)–C(18)–C(19) 109.9 
C(18)–C(19)–C(20) 120.01(13) C(18)–C(19)–C(24) 119.61(13) 
C(20)–C(19)–C(24) 120.27(14) C(19)–C(20)–H(20A) 120.3 
C(19)–C(20)–C(21) 119.30(14) H(20A)–C(20)–C(21) 120.3 
C(20)–C(21)–H(21A) 119.7 C(20)–C(21)–C(22) 120.65(14) 
H(21A)–C(21)–C(22) 119.7 C(21)–C(22)–H(22A) 119.7 
C(21)–C(22)–C(23) 120.52(14) H(22A)–C(22)–C(23) 119.7 
N(8)–C(23)–C(22) 116.21(13) N(8)–C(23)–C(24) 124.83(13) 
C(22)–C(23)–C(24) 118.91(13) C(19)–C(24)–C(23) 120.30(13) 
C(19)–C(24)–H(24A) 119.9 C(23)–C(24)–H(24A) 119.9 
N(8)–C(25)–N(9) 119.84(13) N(8)–C(25)–N(12) 112.88(12) 
N(9)–C(25)–N(12) 127.27(13) N(9)–C(26)–N(10) 125.42(13) 
N(9)–C(26)–C(28) 124.11(13) N(10)–C(26)–C(28) 110.47(12) 
N(10)–C(27)–N(11) 114.61(13) N(10)–C(27)–H(27A) 122.7 
N(11)–C(27)–H(27A) 122.7 N(11)–C(28)–C(26) 105.61(12) 
N(11)–C(28)–C(29) 136.40(14) C(26)–C(28)–C(29) 117.93(13) 
N(12)–C(29)–C(28) 119.24(13) N(12)–C(29)–C(30) 117.87(13) 
C(28)–C(29)–C(30) 122.89(13) C(29)–C(30)–C(31) 177.23(16) 
C(30)–C(31)–H(31) 179.7(13) N(11)–C(32)–H(32A) 109.5 
N(11)–C(32)–H(32B) 109.5 N(11)–C(32)–H(32C) 109.5 
H(32A)–C(32)–H(32B) 109.5 H(32A)–C(32)–H(32C) 109.5 
H(32B)–C(32)–H(32C) 109.5 O(3)–C(33)–H(33A) 109.5 
O(3)–C(33)–H(33B) 109.5 O(3)–C(33)–H(33C) 109.5 
H(33A)–C(33)–H(33B) 109.5 H(33A)–C(33)–H(33C) 109.5 
H(33B)–C(33)–H(33C) 109.5 C(1)–N(1)–H(1A) 118.0(14) 
C(1)–N(1)–H(1B) 120.7(13) H(1A)–N(1)–H(1B) 119.5(19) 
C(7)–N(2)–C(9) 131.84(15) C(7)–N(2)–H(2) 114.0(14) 
C(9)–N(2)–H(2) 114.1(14) C(9)–N(3)–C(10) 113.17(13) 
C(10)–N(4)–C(11) 103.58(14) C(11)–N(5)–C(12) 105.43(14) 
C(11)–N(5)–C(16) 126.81(16) C(12)–N(5)–C(16) 127.69(15) 
C(9)–N(6)–C(13) 118.06(13) O(1)–C(1)–N(1) 123.29(17) 
O(1)–C(1)–C(2) 120.63(15) N(1)–C(1)–C(2) 116.01(15) 
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C(1)–C(2)–H(2A) 110.1 C(1)–C(2)–H(2B) 110.1 
C(1)–C(2)–C(3) 107.91(14) H(2A)–C(2)–H(2B) 108.4 
H(2A)–C(2)–C(3) 110.1 H(2B)–C(2)–C(3) 110.1 
C(2)–C(3)–C(4) 121.12(15) C(2)–C(3)–C(8) 119.97(15) 
C(4)–C(3)–C(8) 118.63(16) C(3)–C(4)–H(4A) 120.2 
C(3)–C(4)–C(5) 119.64(17) H(4A)–C(4)–C(5) 120.2 
C(4)–C(5)–H(5A) 119.1 C(4)–C(5)–C(6) 121.87(18) 
H(5A)–C(5)–C(6) 119.1 C(5)–C(6)–H(6A) 120.7 
C(5)–C(6)–C(7) 118.61(18) H(6A)–C(6)–C(7) 120.7 
N(2)–C(7)–C(6) 124.95(16) N(2)–C(7)–C(8) 115.61(15) 
C(6)–C(7)–C(8) 119.43(15) C(3)–C(8)–C(7) 121.81(16) 
C(3)–C(8)–H(8A) 119.1 C(7)–C(8)–H(8A) 119.1 
N(2)–C(9)–N(3) 120.56(14) N(2)–C(9)–N(6) 111.82(14) 
N(3)–C(9)–N(6) 127.58(14) N(3)–C(10)–N(4) 125.44(14) 
N(3)–C(10)–C(12) 124.02(14) N(4)–C(10)–C(12) 110.50(14) 
N(4)–C(11)–N(5) 114.80(16) N(4)–C(11)–H(11A) 122.6 
N(5)–C(11)–H(11A) 122.6 N(5)–C(12)–C(10) 105.69(14) 
N(5)–C(12)–C(13) 135.90(15) C(10)–C(12)–C(13) 118.40(15) 
N(6)–C(13)–C(12) 118.66(14) N(6)–C(13)–C(14) 117.19(14) 
C(12)–C(13)–C(14) 124.15(15) C(13)–C(14)–C(15) 179.3(2) 
C(14)–C(15)–H(15) 179.9(17) N(5)–C(16)–H(16A) 109.5 
N(5)–C(16)–H(16B) 109.5 N(5)–C(16)–H(16C) 109.5 
H(16A)–C(16)–H(16B) 109.5 H(16A)–C(16)–H(16C) 109.5 
H(16B)–C(16)–H(16C) 109.5   
Table 33 - Anisotropic displacement parameters (Å
2
) for 64. The anisotropic displacement factor 
exponent takes the form: 22[h2a*2U11 + 2hka*b*U12] 
 U
11
 U
22
 U
33
 U
23
 U
13
 U
12
 
O(2) 0.0172(5) 0.0277(6) 0.0236(5) 0.0010(4) 0.0067(4) 0.0004(4) 
O(3) 0.0273(6) 0.0376(7) 0.0374(6) 0.0044(5) 0.0096(5) 0.0070(5) 
N(7) 0.0176(7) 0.0268(7) 0.0232(6) 0.0037(5) 0.0069(5) 0.0021(5) 
N(8) 0.0209(6) 0.0214(6) 0.0206(6) 0.0015(5) 0.0071(5) 0.0045(5) 
N(9) 0.0206(6) 0.0236(6) 0.0198(6) 0.0018(5) 0.0099(5) 0.0028(5) 
N(10) 0.0267(7) 0.0247(7) 0.0229(6) 0.0002(5) 0.0141(5) 0.0018(5) 
N(11) 0.0240(6) 0.0219(6) 0.0191(6) 0.0001(5) 0.0098(5) 0.0014(5) 
N(12) 0.0198(6) 0.0195(6) 0.0211(6) 0.0023(5) 0.0096(5) 0.0011(5) 
C(17) 0.0192(7) 0.0182(7) 0. 0196(6) 0.0022(5) 0.0096(6) 0.0033(6) 
C(18) 0.0187(7) 0.0257(8) 0.0218(7) 0.0039(6) 0.0101(6) 0.0030(6) 
C(19) 0.0192(7) 0.0220(7) 0.0216(7) 0.0034(6) 0.0106(6) 0.0016(6) 
C(20) 0.0236(8) 0.0283(8) 0.0193(7) 0.0033(6) 0.0033(6) 0.0002(6) 
C(21) 0.0348(9) 0.0277(8) 0.0207(7) 0.0044(6) 0.0070(7) 0.0022(7) 
C(22) 0. 0294(8) 0.0215(8) 0.0252(7) 0.0015(6) 0.0108(6) 0.0026(6) 
C(23) 0.0196(7) 0.0210(7) 0.0196(7) 0.0023(5) 0.0087(6) 0.0016(6) 
C(24) 0.0202(7) 0.0216(7) 0.0187(6) 0.0003(6) 0.0086(6) 0.0012(6) 
C(25) 0.0197(7) 0.0184(7) 0.0198(7) 0.0032(5) 0.0091(6) 0.0000(6) 
C(26) 0.0221(7) 0.0197(7) 0.0207(7) 0.0032(6) 0.0117(6) 0.0009(6) 
C(27) 0.0294(8) 0.0230(8) 0.0216(7) 0.0006(6) 0.0143(6) 0.0004(6) 
C(28) 0.0213(7) 0.0195(7) 0.0179(6) 0.0022(5) 0.0091(6) 0.0016(6) 
C(29) 0.0188(7) 0.0186(7) 0.0197(6) 0.0042(5) 0.0093(6) 0.0002(6) 
C(30) 0.0235(8) 0.0207(7) 0.0217(7) 0.0003(6) 0.0115(6) 0.0017(6) 
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C(31) 0.0221(8) 0.0240(8) 0.0307(8) 0.0012(6) 0.0103(7) 0.0013(7) 
C(32) 0.0265(8) 0.0329(9) 0.0216(7) 0.0020(6) 0.0057(6) 0.0022(7) 
C(33) 0.0345(9) 0.0388(10) 0.0292(8) 0.0023(7) 0.0102(7) 0.0067(8) 
O(1) 0.0376(7) 0.0469(8) 0.0419(7) 0.0045(6) 0.0211(6) 0.0092(6) 
N(1) 0.0320(8) 0.0425(9) 0.0415(9) 0.0083(7) 0.0209(7) 0.0045(7) 
N(2) 0.0482(9) 0.0239(7) 0.0393(8) 0.0002(6) 0.0322(7) 0.0011(6) 
N(3) 0.0287(7) 0.0262(7) 0.0242(6) 0.0015(5) 0.0139(6) 0.0020(6) 
N(4) 0.0390(8) 0.0309(8) 0.0408(8) 0.0066(6) 0.0245(7) 0.0079(6) 
N(5) 0.0501(9) 0.0279(8) 0.0497(9) 0.0077(7) 0.0336(8) 0.0047(7) 
N(6) 0.0308(7) 0.0261(7) 0.0245(6) 0.0020(5) 0.0159(6) 0.0027(6) 
C(1) 0.0300(9) 0.0237(8) 0.0382(9) 0.0018(7) 0.0164(7) 0.0026(7) 
C(2) 0.0337(9) 0.0320(9) 0.0320(8) 0.0075(7) 0.0124(7) 0.0007(7) 
C(3) 0.0422(10) 0.0288(9) 0.0261(8) 0.0006(7) 0.0167(7) 0.0048(7) 
C(4) 0.0860(16) 0.0314(10) 0.0600(12) 0.0035(9) 0.0577(13) 0.0097(10) 
C(5) 0.108(2) 0.0327(10) 0.0955(18) 0.0081(11) 0.0900(17) 0.0055(12) 
C(6) 0.0876(16) 0.0241(9) 0.0726(14) 0.0054(9) 0.0655(13) 0.0022(10) 
C(7) 0.0451(10) 0.0256(8) 0.0316(8) 0.0034(7) 0.0254(8) 0.0054(7) 
C(8) 0.0367(9) 0.0298(9) 0.0288(8) 0.0004(7) 0.0185(7) 0.0012(7) 
C(9) 0.0296(8) 0.0248(8) 0.0222(7) 0.0044(6) 0.0130(6) 0.0058(6) 
C(10) 0.0259(8) 0.0288(8) 0.0237(7) 0.0003(6) 0.0115(6) 0.0001(6) 
C(11) 0.0507(11) 0.0327(10) 0.0529(11) 0.0087(8) 0.0336(10) 0.0113(8) 
C(12) 0.0314(8) 0.0254(8) 0.0288(8) 0.0016(6) 0.0156(7) 0.0009(7) 
C(13) 0.0265(8) 0.0288(8) 0.0226(7) 0.0017(6) 0.0113(6) 0.0042(7) 
C(14) 0.0334(9) 0.0319(9) 0.0295(8) 0.0010(7) 0.0157(7) 0.0019(7) 
C(15) 0.0428(11) 0.0574(13) 0.0424(10) 0.0069(9) 0.0283(9) 0.0040(9) 
C(16) 0.0969(19) 0.0305(11) 0.1005(19) 0.0185(11) 0.0779(17) 0.0084(11) 
Table 34 - Hydrogen coordinates and isotropic displacement parameters (Å
2
) for 64. 
 x y z U 
H(18A) 0.0597 0.3609 0.6789 0.026 
H(18B) 0.0318 0.3391 0.7786 0.026 
H(20A) 0.0366 0.4811 0.5756 0.032 
H(21A) 0.0428 0.6194 0.5694 0.036 
H(22A) 0.1850 0.6690 0.6979 0.031 
H(24A) 0.1659 0.4474 0.8456 0.024 
H(27A) 0.4213 0.3640 1.2477 0.029 
H(32A) 0.5874 0.4322 1.3349 0.044 
H(32B) 0.6043 0.5306 1.2965 0.044 
H(32C) 0.6342 0.4341 1.2652 0.044 
H(33A) 0.8507 0.2215 1.0543 0.054 
H(33B) 0.7697 0.3003 1.0376 0.054 
H(33C) 0.7910 0.2189 1.1128 0.054 
H(2A) 0.7688 0.4444 0.7569 0.040 
H(2B) 0.8489 0.4710 0.7234 0.040 
H(4A) 0.9540 0.3480 0.7137 0.060 
H(5A) 1.0063 0.1923 0.7349 0.074 
H(6A) 0.9531 0.0845 0.8105 0.060 
H(8A) 0.7875 0.2906 0.8396 0.037 
H(11A) 0.9702 0.3188 0.9426 0.050 
H(16A) 0.8832 0.3697 1.0331 0.095 
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H(16B) 0.8536 0.2867 1.0818 0.095 
H(16C) 0.7764 0.3228 0.9804 0.095 
H(8) 0.3036(13) 0.6418(13) 0.8439(12) 0.025(4) 
H(7A) 0.0048(13) 0.2063(13) 0.5606(12) 0.029(5) 
H(7B) 0.0733(14) 0.2686(13) 0.5644(12) 0.027(5) 
H(1A) 0.9218(18) 0.4795(17) 0.9960(18) 0.064(7) 
H(2) 0.7873(16) 0.1519(16) 0.8972(15) 0.049(6) 
H(1B) 0.8101(17) 0.4415(16) 0.9136(15) 0.056(6) 
H(3) 0.735(2) 0.113(2) 0.992(2) 0.086(9) 
H(31) 0.7242(15) 0.6663(14) 1.1980(14) 0.041(5) 
H(15) 0.6743(17) 0.1477(18) 1.1093(17) 0.065(7) 
Table 35 - Torsion angles [°] for 64. 
O(2)–C(17)–C(18)–C(19) 69.15(16) N(7)–C(17)–C(18)–C(19) 108.14(14) 
C(17)–C(18)–C(19)–C(20) 78.40(16) C(17)–C(18)–C(19)–C(24) 97.94(15) 
C(18)–C(19)–C(20)–C(21) 174.85(14) C(24)–C(19)–C(20)–C(21) 1.5(2) 
C(19)–C(20)–C(21)–C(22) 0.4(2) C(20)–C(21)–C(22)–C(23) 1.5(2) 
C(21)–C(22)–C(23)–N(8) 178.28(14) C(21)–C(22)–C(23)–C(24) 0.7(2) 
C(25)–N(8)–C(23)–C(22) 179.67(14) C(25)–N(8)–C(23)–C(24) 2.3(2) 
N(8)–C(23)–C(24)–C(19) 176.17(13) C(22)–C(23)–C(24)–C(19) 1.2(2) 
C(18)–C(19)–C(24)–C(23) 174.06(13) C(20)–C(19)–C(24)–C(23) 2.3(2) 
C(26)–N(9)–C(25)–N(8) 177.92(12) C(26)–N(9)–C(25)–N(12) 3.5(2) 
C(29)–N(12)–C(25)–N(8) 178.36(12) C(29)–N(12)–C(25)–N(9) 2.9(2) 
C(23)–N(8)–C(25)–N(9) 16.4(2) C(23)–N(8)–C(25)–N(12) 164.80(13) 
C(25)–N(9)–C(26)–N(10) 179.89(13) C(25)–N(9)–C(26)–C(28) 0.8(2) 
C(27)–N(10)–C(26)–N(9) 179.76(14) C(27)–N(10)–C(26)–C(28) 0.53(16) 
C(26)–N(10)–C(27)–N(11) 0.30(17) C(28)–N(11)–C(27)–N(10) 0.03(17) 
C(32)–N(11)–C(27)–N(10) 179.63(14) C(27)–N(11)–C(28)–C(26) 0.36(15) 
C(27)–N(11)–C(28)–C(29) 176.62(16) C(32)–N(11)–C(28)–C(26) 179.93(14) 
C(32)–N(11)–C(28)–C(29) 3.0(3) N(9)–C(26)–C(28)–N(11) 179.81(13) 
N(9)–C(26)–C(28)–C(29) 2.2(2) N(10)–C(26)–C(28)–N(11) 0.56(16) 
N(10)–C(26)–C(28)–C(29) 177.08(12) C(25)–N(12)–C(29)–C(28) 0.44(19) 
C(25)–N(12)–C(29)–C(30) 179.83(12) N(11)–C(28)–C(29)–N(12) 179.42(15) 
N(11)–C(28)–C(29)–C(30) 0.9(3) C(26)–C(28)–C(29)–N(12) 2.7(2) 
C(26)–C(28)–C(29)–C(30) 177.56(13) N(12)–C(29)–C(30)–C(31) 178(100) 
C(28)–C(29)–C(30)–C(31) 2(3) O(1)–C(1)–C(2)–C(3) 91.86(19) 
N(1)–C(1)–C(2)–C(3) 85.14(19) C(1)–C(2)–C(3)–C(4) 96.3(2) 
C(1)–C(2)–C(3)–C(8) 77.5(2) C(2)–C(3)–C(4)–C(5) 173.3(2) 
C(8)–C(3)–C(4)–C(5) 0.5(3) C(3)–C(4)–C(5)–C(6) 0.4(4) 
C(4)–C(5)–C(6)–C(7) 0.6(4) C(5)–C(6)–C(7)–N(2) 178.5(2) 
C(5)–C(6)–C(7)–C(8) 0.1(3) C(9)–N(2)–C(7)–C(6) 3.4(3) 
C(9)–N(2)–C(7)–C(8) 175.29(17) N(2)–C(7)–C(8)–C(3) 177.69(16) 
C(6)–C(7)–C(8)–C(3) 1.1(3) C(2)–C(3)–C(8)–C(7) 172.66(16) 
C(4)–C(3)–C(8)–C(7) 1.2(3) C(10)–N(3)–C(9)–N(2) 174.84(14) 
C(10)–N(3)–C(9)–N(6) 2.9(2) C(13)–N(6)–C(9)–N(2) 174.11(14) 
C(13)–N(6)–C(9)–N(3) 3.8(2) C(7)–N(2)–C(9)–N(3) 5.4(3) 
C(7)–N(2)–C(9)–N(6) 176.58(16) C(9)–N(3)–C(10)–N(4) 177.61(15) 
C(9)–N(3)–C(10)–C(12) 0.2(2) C(11)–N(4)–C(10)–N(3) 177.41(17) 
C(11)–N(4)–C(10)–C(12) 0.26(19) C(10)–N(4)–C(11)–N(5) 0.3(2) 
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C(12)–N(5)–C(11)–N(4) 0.2(2) C(16)–N(5)–C(11)–N(4) 177.3(2) 
C(11)–N(5)–C(12)–C(10) 0.07(19) C(11)–N(5)–C(12)–C(13) 179.7(2) 
C(16)–N(5)–C(12)–C(10) 177.1(2) C(16)–N(5)–C(12)–C(13) 2.7(4) 
N(3)–C(10)–C(12)–N(5) 177.59(15) N(3)–C(10)–C(12)–C(13) 2.2(2) 
N(4)–C(10)–C(12)–N(5) 0.12(19) N(4)–C(10)–C(12)–C(13) 179.93(14) 
C(9)–N(6)–C(13)–C(12) 1.3(2) C(9)–N(6)–C(13)–C(14) 178.70(14) 
N(5)–C(12)–C(13)–N(6) 178.43(18) N(5)–C(12)–C(13)–C(14) 1.6(3) 
C(10)–C(12)–C(13)–N(6) 1.3(2) C(10)–C(12)–C(13)–C(14) 178.64(15) 
N(6)–C(13)–C(14)–C(15) 126(18) C(12)–C(13)–C(14)–C(15) 54(18) 
Table 36 - Hydrogen bonds for 64 [Å and °]. 
D–H...A d(D–H) d(H...A) d(D...A) <(DHA) 
N(8)–H(8)...O(2A) 0.831(19) 2.220(19) 3.0476(17) 175(2) 
N(7)–H(7A)...N(12B) 0.880(19) 2.23(2) 3.1018(18) 172(2) 
N(7)–H(7B)...O(3A) 0.835(19) 2.08(2) 2.9112(18) 175(2) 
N(1)–H(1A)...O(1C) 1.00(3) 1.84(3) 2.830(2) 174(2) 
N(2)–H(2)...O(3) 0.90(2) 2.19(2) 3.0314(19) 155(2) 
N(1)–H(1B)...N(10D) 0.97(2) 2.04(2) 2.989(2) 167(2) 
O(3)–H(3)...N(6) 0.94(3) 2.03(3) 2.8660(18) 148(2) 
 
Symmetry operations for equivalent atoms: A x+1/2,y+1/2,z+3/2; B x+1/2, y1/2, 
z+3/2; C x+2, y1, z+2; D x+1, y, z+2. 
 
N
9
-methylpurine 63 
Table 37 - Crystal data and structure refinement for 63. 
Identification code rjg120010 
Chemical formula (moiety) C16H14N6O 
Chemical formula (total) C16H14N6O 
Formula weight 306.33 
Temperature 150(2) K 
Radiation, wavelength synchroton, 0.68890 Å 
Crystal system, space group monoclinic, P21/c 
Unit cell parameters a = 20.880(7) Å      = 90° 
b = 4.7912(15) Å    = 105.544(3)° 
c = 14.900(5) Å      = 90° 
Cell volume 1436.1(8) Å
3
 
Z 4 
Calculated density 1.417 g/cm
3
 
Absorption coefficient  0.095 mm1 
F(000) 640 
Crystal colour and size yellow, 0.10  0.10  0.00 mm3 
Reflections for cell refinement 8029 ( range 2.7 to 27.3°) 
Data collection method Crystal Logic diffractometer and Rigaku 
Saturn 724+ CCD thick-slice  scans 
 range for data collection 1.0 to 27.4° 
Index ranges h 27 to 27, k 6 to 3, l 19 to 19 
Completeness to  = 27.4° 94.9 % 
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Reflections collected 13223 
Independent reflections 3389 (Rint = 0.0380) 
Reflections with F
2
>2 2884 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.9905 and 0.9999 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F
2
 
Weighting parameters a, b 0.0529, 0.5159 
Data / restraints / parameters 3389 / 0 / 226 
Final R indices [F
2
>2] R1 = 0.0441, wR2 = 0.1174 
R indices (all data) R1 = 0.0512, wR2 = 0.1215 
Goodness-of-fit on F
2
 1.118 
Extinction coefficient 0.044(16) 
Largest and mean shift/su 0.000 and 0.000 
Largest diff. peak and hole 0.28 and 0.22 e Å3 
Table 38 - Atomic coordinates and equivalent isotropic displacement parameters (Å
2
) for 63. Ueq 
is defined as one third of the trace of the orthogonalised U
ij
 tensor. 
 x y z Ueq 
O 0.16661(6) 0.5043(2) 0.70303(7) 0.0336(3) 
N(1) 0.21534(7) 0.0828(3) 0.72648(9) 0.0337(3) 
N(2) 0.20548(5) 0.8195(3) 0.39794(7) 0.0260(3) 
N(3) 0.28640(5) 0.7663(2) 0.53946(7) 0.0241(3) 
N(4) 0.29791(5) 1.0968(2) 0.42101(7) 0.0233(3) 
N(5) 0.38238(5) 0.7561(3) 0.67265(7) 0.0245(3) 
N(6) 0.44645(5) 1.0803(3) 0.62783(7) 0.0261(3) 
C(1) 0.16895(7) 0.2581(3) 0.67855(9) 0.0266(3) 
C(2) 0.11864(7) 0.1431(3) 0.59360(10) 0.0320(3) 
C(3) 0.11001(6) 0.3208(3) 0.50677(9) 0.0267(3) 
C(4) 0.04911(7) 0.3281(4) 0.43937(11) 0.0354(4) 
C(5) 0.04231(7) 0.4864(4) 0.35916(11) 0.0400(4) 
C(6) 0.09471(7) 0.6430(4) 0.34632(10) 0.0327(3) 
C(7) 0.15574(6) 0.6430(3) 0.41455(8) 0.0242(3) 
C(8) 0.16319(6) 0.4749(3) 0.49320(9) 0.0252(3) 
C(9) 0.26525(6) 0.8939(3) 0.45605(8) 0.0226(3) 
C(10) 0.34625(6) 0.8528(3) 0.58740(8) 0.0224(3) 
C(11) 0.38579(6) 1.0527(3) 0.56028(8) 0.0226(3) 
C(12) 0.35826(6) 1.1760(3) 0.47317(8) 0.0229(3) 
C(13) 0.44149(6) 0.9000(3) 0.69226(9) 0.0265(3) 
C(14) 0.36037(7) 0.5481(3) 0.72919(9) 0.0287(3) 
C(15) 0.39490(6) 1.3870(3) 0.43913(9) 0.0257(3) 
C(16) 0.43154(7) 1.5552(4) 0.42143(10) 0.0313(3) 
Table 39 - Bond lengths [Å] and angles [°] for 63. 
O–C(1) 1.2394(18) N(1)–H(1A) 0.92(2) 
N(1)–H(1B) 0.90(2) N(1)–C(1) 1.335(2) 
N(2)–H(2) 0.91(2) N(2)–C(7) 1.4114(17) 
N(2)–C(9) 1.3620(16) N(3)–C(9) 1.3488(16) 
N(3)–C(10) 1.3287(16) N(4)–C(9) 1.3686(17) 
N(4)–C(12) 1.3456(16) N(5)–C(10) 1.3725(16) 
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N(5)–C(13) 1.3752(17) N(5)–C(14) 1.4566(18) 
N(6)–C(11) 1.3970(16) N(6)–C(13) 1.3159(18) 
C(1)–C(2) 1.5155(19) C(2)–H(2A) 0.990 
C(2)–H(2B) 0.990 C(2)–C(3) 1.519(2) 
C(3)–C(4) 1.3935(19) C(3)–C(8) 1.3925(19) 
C(4)–H(4A) 0.950 C(4)–C(5) 1.390(2) 
C(5)–H(5A) 0.950 C(5)–C(6) 1.382(2) 
C(6)–H(6A) 0.950 C(6)–C(7) 1.4012(17) 
C(7)–C(8) 1.3961(19) C(8)–H(8A) 0.950 
C(10)–C(11) 1.3930(18) C(11)–C(12) 1. 4015(18) 
C(12)–C(15) 1.4398(19) C(13)–H(13A) 0.950 
C(14)–H(14A) 0.980 C(14)–H(14B) 0.980 
C(14)–H(14C) 0.980 C(15)–C(16) 1.188(2) 
C(16)–H(1) 0.93(2)   
H(1A)–N(1)–H(1B) 120.2(18) H(1A)–N(1)–C(1) 116.8(13) 
H(1B)–N(1)–C(1) 119.1(13) H(2)–N(2)–C(7) 114.9(12) 
H(2)–N(2)–C(9) 115.1(12) C(7)–N(2)–C(9) 129.58(11) 
C(9)–N(3)–C(10) 112.50(11) C(9)–N(4)–C(12) 117.72(11) 
C(10)–N(5)–C(13) 105.46(11) C(10)–N(5)–C(14) 125.87(11) 
C(13)–N(5)–C(14) 128.66(11) C(11)–N(6)–C(13) 103.30(11) 
O–C(1)–N(1) 121.42(13) O–C(1)–C(2) 121.25(13) 
N(1)–C(1)–C(2) 117.32(14) C(1)–C(2)–H(2A) 108.8 
C(1)–C(2)–H(2B) 108.8 C(1)–C(2)–C(3) 113.90(12) 
H(2A)–C(2)–H(2B) 107.7 H(2A)–C(2)–C(3) 108.8 
H(2B)–C(2)–C(3) 108.8 C(2)–C(3)–C(4) 120.34(13) 
C(2)–C(3)–C(8) 120.24(12) C(4)–C(3)–C(8) 119.41(13) 
C(3)–C(4)–H(4A) 120.1 C(3)–C(4)–C(5) 119.78(13) 
H(4A)–C(4)–C(5) 120.1 C(4)–C(5)–H(5A) 119.6 
C(4)–C(5)–C(6) 120.86(13) H(5A)–C(5)–C(6) 119.6 
C(5)–C(6)–H(6A) 120.0 C(5)–C(6)–C(7) 119.98(14) 
H(6A)–C(6)–C(7) 120.0 N(2)–C(7)–C(6) 116.21(12) 
N(2)–C(7)–C(8) 124.84(11) C(6)–C(7)–C(8) 118.95(12) 
C(3)–C(8)–C(7) 120.93(12) C(3)–C(8)–H(8A) 119.5 
C(7)–C(8)–H(8A) 119.5 N(2)–C(9)–N(3) 119.02(12) 
N(2)–C(9)–N(4) 114.13(11) N(3)–C(9)–N(4) 126.85(11) 
N(3)–C(10)–N(5) 126.63(12) N(3)–C(10)–C(11) 127.12(12) 
N(5)–C(10)–C(11) 106.21(11) N(6)–C(11)–C(10) 110.45(11) 
N(6)–C(11)–C(12) 134.03(12) C(10)–C(11)–C(12) 115.50(11) 
N(4)–C(12)–C(11) 120.28(12) N(4)–C(12)–C(15) 119.89(11) 
C(11)–C(12)–C(15) 119.83(11) N(5)–C(13)–N(6) 114.57(11) 
N(5)–C(13)–H(13A) 122.7 N(6)–C(13)–H(13A) 122.7 
N(5)–C(14)–H(14A) 109.5 N(5)–C(14)–H(14B) 109.5 
N(5)–C(14)–H(14C) 109.5 H(14A)–C(14)–H(14B) 109.5 
H(14A)–C(14)–
H(14C) 
109.5 H(14B)–C(14)–H(14C) 109.5 
C(12)–C(15)–C(16) 171.43(14) C(15)–C(16)–H(1) 178.3(13) 
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Table 40 - Anisotropic displacement parameters (Å
2
) for 63. The anisotropic displacement factor 
exponent takes the form: 22[h2a*2U11 + 2hka*b*U12]. 
 U
11
 U
22
 U
33
 U
23
 U
13
 U
12
 
O 0.0479(6) 0.0248(6) 0.0251(5) 0.0024(4) 0.0048(4) 0.0011(4) 
N(1) 0.0395(7) 0.0265(8) 0.0331(6) 0.0007(5) 0.0061(5) 0.0007(5) 
N(2) 0.0242(5) 0.0319(7) 0.0185(5) 0.0031(4) 0.0001(4) 0.0055(5) 
N(3) 0.0227(5) 0.0287(7) 0.0191(5) 0.0008(4) 0.0024(4) 0.0041(4) 
N(4) 0.0240(5) 0.0260(7) 0.0194(5) 0.0004(4) 0.0045(4) 0.0020(4) 
N(5) 0.0231(5) 0.0281(7) 0.0198(5) 0.0032(4) 0.0015(4) 0.0026(4) 
N(6) 0.0225(5) 0.0308(7) 0.0223(5) 0.0009(4) 0.0016(4) 0.0036(4) 
C(1) 0.0331(7) 0.0259(8) 0.0225(6) 0.0008(5) 0.0102(5) 0.0055(5) 
C(2) 0.0373(7) 0.0293(8) 0.0285(7) 0.0028(6) 0.0072(6) 0.0123(6) 
C(3) 0.0291(6) 0.0263(8) 0.0243(6) 0.0052(5) 0.0066(5) 0.0053(5) 
C(4) 0.0264(7) 0.0414(10) 0.0362(7) 0.0011(7) 0.0046(6) 0.0118(6) 
C(5) 0.0255(7) 0.0502(11) 0.0368(8) 0.0025(7) 0.0046(6) 0.0091(7) 
C(6) 0.0277(7) 0.0390(9) 0.0266(6) 0.0038(6) 0.0013(5) 0.0038(6) 
C(7) 0.0229(6) 0.0269(8) 0.0216(6) 0.0039(5) 0.0037(5) 0.0030(5) 
C(8) 0.0238(6) 0.0281(8) 0.0215(6) 0.0027(5) 0.0025(5) 0.0037(5) 
C(9) 0.0221(6) 0.0263(8) 0.0186(5) 0.0006(5) 0.0041(4) 0.0012(5) 
C(10) 0.0228(6) 0.0250(7) 0.0182(5) 0.0003(5) 0.0034(4) 0.0010(5) 
C(11) 0.0220(6) 0.0240(7) 0.0205(6) 0.0011(5) 0.0036(4) 0.0028(5) 
C(12) 0.0238(6) 0.0250(7) 0.0201(5) 0.0014(5) 0.0062(4) 0.0007(5) 
C(13) 0.0222(6) 0.0317(8) 0.0229(6) 0.0014(5) 0.0014(5) 0.0026(5) 
C(14) 0.0301(6) 0.0316(8) 0.0224(6) 0.0058(5) 0.0034(5) 0.0037(6) 
C(15) 0.0250(6) 0.0296(8) 0.0208(6) 0.0008(5) 0.0030(5) 0.0007(5) 
C(16) 0.0297(7) 0.0365(9) 0.0265(6) 0.0052(6) 0.0055(5) 0.0053(6) 
Table 41 - Hydrogen coordinates and isotropic displacement parameters (Å
2
) for 63. 
 x y z U 
H(1A) 0.2410(9) 0.144(4) 0.7833(14) 0.045(5) 
H(1B) 0.2109(9) 0.101(5) 0.7142(14) 0.049(6) 
H(2) 0.1937(9) 0.913(4) 0.3427(14) 0.046(5) 
H(2A) 0.0751 0.1261 0.6078 0.038 
H(2B) 0.1327 0.0466 0.5806 0.038 
H(4A) 0.0124 0.2253 0.4482 0.043 
H(5A) 0.0011 0.4869 0.3126 0.048 
H(6A) 0.0894 0.7506 0.2912 0.039 
H(8A) 0.2051 0.4654 0.5381 0.030 
H(13A) 0.4760 0.8716 0.7478 0.032 
H(14A) 0.3337 0.4059 0.6885 0.043 
H(14B) 0.3334 0.6386 0.7655 0.043 
H(14C) 0.3992 0.4598 0.7716 0.043 
H(1) 0.4610(9) 1.684(4) 0.4091(14) 0.049(5) 
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Table 42 - Torsion angles [°] for 63. 
O–C(1)–C(2)–C(3) 50.41(18) N(1)–C(1)–C(2)–C(3) 130.34(14) 
C(1)–C(2)–C(3)–C(4) 149.87(14) C(1)–C(2)–C(3)–C(8) 31.0(2) 
C(2)–C(3)–C(4)–C(5) 178.47(15) C(8)–C(3)–C(4)–C(5) 0.6(2) 
C(3)–C(4)–C(5)–C(6) 1.7(3) C(4)–C(5)–C(6)–C(7) 0.1(3) 
C(5)–C(6)–C(7)–N(2) 176.93(14) C(5)–C(6)–C(7)–C(8) 2.5(2) 
C(9)–N(2)–C(7)–C(6) 169.61(14) C(9)–N(2)–C(7)–C(8) 9.7(2) 
C(2)–C(3)–C(8)–C(7) 178.88(13) C(4)–C(3)–C(8)–C(7) 2.0(2) 
N(2)–C(7)–C(8)–C(3) 175.77(13) C(6)–C(7)–C(8)–C(3) 3.6(2) 
C(10)–N(3)–C(9)–N(2) 177.95(12) C(10)–N(3)–C(9)–N(4) 1.8(2) 
C(7)–N(2)–C(9)–N(3) 7.9(2) C(7)–N(2)–C(9)–N(4) 172.31(13) 
C(12)–N(4)–C(9)–N(2) 178.09(11) C(12)–N(4)–C(9)–N(3) 1.7(2) 
C(9)–N(3)–C(10)–N(5) 177.30(13) C(9)–N(3)–C(10)–C(11) 0.5(2) 
C(13)–N(5)–C(10)–N(3) 177.86(13) C(13)–N(5)–C(10)–C(11) 0.30(15) 
C(14)–N(5)–C(10)–N(3) 3.2(2) C(14)–N(5)–C(10)–C(11) 178.59(12) 
N(3)–C(10)–C(11)–N(6) 177.89(13) N(3)–C(10)–C(11)–C(12) 0.8(2) 
N(5)–C(10)–C(11)–N(6) 0.26(15) N(5)–C(10)–C(11)–C(12) 178.96(12) 
C(13)–N(6)–C(11)–C(10) 0.10(15) C(13)–N(6)–C(11)–C(12) 178.47(15) 
C(9)–N(4)–C(12)–C(11) 0.11(19) C(9)–N(4)–C(12)–C(15) 179.50(12) 
N(6)–C(11)–C(12)–N(4) 177.33(14) N(6)–C(11)–C(12)–C(15) 2.3(2) 
C(10)–C(11)–C(12)–N(4) 0.98(19) C(10)–C(11)–C(12)–C(15) 179.41(12) 
C(11)–N(6)–C(13)–N(5) 0.10(16) C(10)–N(5)–C(13)–N(6) 0.26(16) 
C(14)–N(5)–C(13)–N(6) 178.59(13) N(4)–C(12)–C(15)–C(16) 177.5(10) 
C(11)–C(12)–C(15)–
C(16) 
2.1(11)   
Table 43 - Hydrogen bonds for 63 [Å and °]. 
D–H...A d(D–H) d(H...A) d(D...A) <(DHA) 
N(1)–H(1A)...N(4A) 0.92(2) 2.42(2) 3.3246(19) 167(2) 
N(1)–H(1B)...OB 0.90(2) 2.09(2) 2.941(2) 157(2) 
N(2)–H(2)...OC 0.91(2) 2.04(2) 2.9227(17) 162(2) 
 
Symmetry operations for equivalent atoms: A x, y+3/2, z+1/2; B x, y1, z; C x, y+3/2, 
z1/2. 
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 Results of Dundee Screen  
Table 44 – Results of the Dundee screen of compounds 61-64 tested at 1.0 μM 
Compound 61 62 63 64 
 
IC50 
(μM)1 SD2 
IC50 
(μM) SD 
IC50 
(μM) SD 
IC50 
(μM) SD 
MKK1 93 5 91 10 77 11 83 9 
MKK2 94 10 89 5 97 1 101 12 
MKK6 93 4 78 3 100 6 91 15 
ERK1 83 1 80 12 94 3 96 12 
ERK2 93 11 86 14 105 10 99 5 
JNK1 81 6 81 14 86 10 88 14 
JNK2 82 5 91 13 90 6 85 9 
JNK3 95 12 89 3 101 3 93 2 
p38a MAPK 93 4 77 3 84 4 89 0 
p38b MAPK 95 10 95 2 103 11 103 12 
p38g MAPK 104 8 98 4 98 7 108 8 
p38d MAPK 112 21 91 12 99 1 125 18 
ERK8 84 4 88 1 94 9 107 9 
RSK1 81 3 77 19 90 7 94 7 
RSK2 93 11 72 3 95 10 82 16 
PDK1 101 0 92 7 93 4 103 12 
PKBa 90 8 84 4 84 13 103 7 
PKBb 87 2 63 9 80 14 67 5 
SGK1 109 7 104 11 97 13 106 2 
S6K1 84 4 91 6 98 3 92 1 
PKA 103 12 100 0 103 3 99 2 
ROCK 2 95 2 91 10 93 10 90 5 
PRK2 82 1 70 2 81 8 85 12 
PKCa 102 7 109 2 99 0 96 1 
PKCγ 90 3 85 18 102 7 93 2 
PKCz 110 14 99 2 113 2 107 17 
PKD1 87 2 74 11 93 1 93 1 
STK33 91 7 78 7 82 11 92 1 
MSK1 89 1 85 1 92 5 97 1 
MNK1 99 9 90 10 106 28 110 19 
MNK2 99 14 87 12 98 2 102 6 
MAPKAP-K2  109 1 90 5 99 4 103 13 
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MAPKAP-K3 76 11 75 5 80 12 84 3 
PRAK 86 1 82 7 104 6 102 10 
CAMKKb 103 7 99 11 96 3 103 1 
CAMK1 95 7 82 9 106 9 92 8 
SmMLCK 91 2 69 0 90 9 77 1 
PHK 94 6 108 4 97 14 114 3 
DAPK1 92 6 80 3 100 6 78 7 
CHK1 96 2 95 12 93 11 113 5 
CHK2 77 4 74 6 87 18 89 8 
GSK3b 84 6 79 3 76 3 104 6 
CDK2-cyclin A 90 5 92 5 89 1 94 3 
CDK9-cyclin T1 100 9 82 3 107 6 86 1 
PLK1 100 27 90 2 95 11 105 4 
Aurora A 99 1 106 8 96 11 122 9 
Aurora B 49 5 48 2 49 7 63 13 
TLK1 108 10 118 10 100 5 111 4 
LKB1 83 7 97 5 82 1 90 1 
AMPK 91 12 90 3 92 6 98 13 
MARK1 89 2 88 7 86 5 95 3 
MARK2 85 11 90 3 91 1 107 14 
MARK3 81 7 78 3 81 4 83 6 
MARK4 92 3 79 16 88 3 87 16 
BRSK1 97 2 96 11 108 5 103 10 
BRSK2 97 10 88 6 95 15 101 3 
MELK 99 5 97 14 90 19 110 11 
NUAK1 88 11 79 7 86 8 85 16 
SIK2 96 10 95 0 90 7 108 9 
SIK3 92 12 78 1 80 6 80 7 
TSSK1 98 4 87 21 101 0 99 1 
CK1γ2 92 5 87 0 84 5 102 5 
CK1δ 88 5 83 5 94 8 96 3 
CK2 99 6 100 1 99 2 119 14 
TTBK1 89 6 84 2 92 8 95 10 
DYRK1A 93 4 81 1 92 12 96 5 
DYRK2 95 3 82 7 87 2 87 10 
DYRK3 91 1 93 2 97 2 112 5 
NEK2a 85 1 85 13 79 7 94 16 
 381 
NEK6 111 4 89 6 107 6 94 3 
IKKb 81 6 79 10 89 3 97 14 
IKKe 85 9 84 0 75 4 91 3 
TBK1 105 9 90 12 98 8 89 3 
PIM1 89 2 85 0 96 0 93 1 
PIM2 97 1 100 6 100 3 108 7 
PIM3 85 4 95 11 101 0 100 9 
SRPK1 90 4 72 0 80 1 84 10 
EF2K 90 2 75 4 101 2 104 2 
EIF2AK3 97 4 88 1 102 5 97 11 
HIPK1 97 9 99 1 112 2 109 2 
HIPK2 95 4 88 5 100 8 105 10 
HIPK3 124 17 114 24 122 5 97 4 
CLK2 94 10 90 5 80 5 95 4 
PAK2 82 4 85 4 90 8 98 12 
PAK4 86 13 74 14 80 2 91 23 
PAK5 85 1 88 4 93 5 88 1 
PAK6 100 4 90 2 102 3 92 16 
MST2 89 2 79 3 81 9 85 1 
MST3 76 9 80 17 109 32 92 16 
MST4 96 13 82 1 79 7 96 6 
GCK 91 1 91 5 86 3 95 18 
MINK1 70 0 68 3 74 6 73 2 
MEKK1 99 2 81 4 87 10 88 1 
MLK1 90 1 77 4 85 2 82 0 
MLK3 80 5 67 1 75 3 89 8 
TESK1 110 6 76 4 91 8 88 1 
TAO1 102 8 94 3 97 3 98 5 
ASK1 115 0 99 8 92 11 117 11 
TAK1 89 4 79 10 88 2 94 2 
IRAK1 107 4 110 13 101 1 113 7 
IRAK4 84 17 86 18 86 4 97 9 
RIPK2 82 0 77 5 98 4 89 6 
OSR1 99 16 101 6 118 9 100 0 
TTK 106 20 97 25 100 24 113 25 
MPSK1 98 1 98 9 101 2 97 6 
WNK1 96 2 100 0 108 3 96 2 
 382 
Src 81 2 70 1 88 6 83 0 
Lck 102 4 85 7 101 3 103 11 
CSK 66 6 62 4 85 11 81 8 
YES1 109 8 104 12 113 5 111 6 
ABL 101 3 92 3 104 0 95 2 
BTK 71 2 54 0 119 48 71 4 
JAK2 92 8 93 14 99 5 86 3 
SYK 98 4 107 6 104 17 101 3 
ZAP70 107 19 92 1 89 5 104 33 
TIE2 81 6 79 5 109 3 96 2 
BRK 94 25 109 1 100 9 132 6 
EPH-A2 107 3 82 2 79 4 109 1 
EPH-A4 107 8 90 2 127 3 100 4 
EPH-B1 94 6 96 9 91 5 94 1 
EPH-B2 128 3 143 49 110 4 161 26 
EPH-B3 107 7 102 10 119 9 122 1 
EPH-B4 95 2 90 4 95 12 132 3 
FGF-R1 89 7 78 13 82 3 91 12 
HER4 100 1 85 12 109 2 81 11 
IGF-1R 102 16 104 7 84 5 116 20 
IR 71 10 61 4 67 8 75 1 
IRR 89 3 88 7 92 3 97 8 
TrkA 101 4 107 10 102 6 101 9 
DDR2 105 3 95 15 102 26 109 12 
VEG-FR 70 11 75 4 82 13 87 1 
1
 Compounds screened in duplicate – average value of n =2 given. 2 Standard deviation. 
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